Ringschluss-Alkin-Metathese, Semihydrierung von Eninen: Totalsynthesen von Leiodermatolide und Mandelalide A by Willwacher, Jens
  
 
Max-Planck-Institut 
für Kohlenforschung 
 
 
Ringschluss-Alkin-Metathese / 
Semihydrierung von Eninen: 
Totalsynthesen von  
Leiodermatolide und Mandelalide A 
 
 
Dissertation 
 
zur Erlangung des akademischen Grades eines  
Doktors der Naturwissenschaften 
(Dr. rer. nat.) 
des Fachbereiches Chemie der Technischen Universität Dortmund 
 
 
 
vorgelegt von 
Jens Willwacher 
geboren am 11.09.1986 
in Leverkusen 
 
 
Mülheim an der Ruhr, 2015
   
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hiermit versichere ich, dass ich die eingereichte Dissertation sebstständig verfasst und keine 
anderen als die angegebenen Quellen und Hilfsmittel benutzt, sowie Zitate kenntlich gemacht 
habe. 
 
 
Mülheim an der Ruhr, 22.01.2015       _______________________ 
(Ort, Datum)          (Unterschrift) 
  
   
  
 
1. Berichterstatter:  Prof. Dr. Alois Fürstner 
2. Berichterstatter: Prof. Dr. Norbert Krause 
 
 
Die vorliegende Arbeit entstand unter Anleitung von Prof. Dr. Alois Fürstner in der Zeit von 
Oktober 2011 bis Januar 2015 am Max-Planck-Institut für Kohlenforschung in 
Mülheim/Ruhr. Teile dieser Arbeit wurden bereits in folgenden Beiträgen veröffentlicht: 
 
"Divergent Total Synthesis of the Antimitotic Agent Leiodermatolide"  
J. Willwacher, N. Kausch-Busies, A. Fürstner, Angew. Chem. Int. Ed. 2012, 51, 12041. 
 
"Catalysis-based Total Synthesis of Putative Mandelalide A" 
J. Willwacher, A. Fürstner, Angew. Chem. Int. Ed. 2014, 53, 4217. 
 
"Synthesis, Molecular Editing, and Biological Assessment of the Potent Cytotoxin Leiodermatolide" 
D. Mailhol, J. Willwacher, N. Kausch-Busies, E. E. Rubitski, Z. Sobol, M. Schuler, M.-H. Lam, S. 
Musto, F. Loganzo, A. Maderna, A. Fürstner, J. Am. Chem. Soc. 2014, 136, 15719. 
 
 
Die Arbeiten erfolgten zum Teil in enger Zusammenarbeit mit Dr. Nina Kausch-Busies und 
Dr. Damien Mailhol (Kapitel 2); sowie Dipl. Ing. Berit Heggen und M. Sc. Katharina 
Holthusen (Kapitel 3). Um eine umfassende Beschreibung der Ergebnisse zu ermöglichen, 
wurden deren Ergebnisse in die Diskussion aufgenommen. Die von diesen Mitarbeitern 
erzielten Ergebnisse sind an den entsprechenden Stellen gekennzeichnet. 
 
 
  
   
Danksagung 
Mein herzlichster Dank geht an Herrn Prof. Dr. Alois Fürstner für die Aufnahme in seinen 
Arbeitskreis, die spannende und herausfordernde Themenstellung sowie das entgegengebrachte 
Vertrauen. Die hilfreichen Diskussionen sowie die mir gewährte Freiheit habe ich stets sehr geschätzt. 
Für die Übernahme des Zweitgutachtens danke ich Herrn Prof. Dr. Norbert Krause von der 
Technischen Universität Dortmund. 
Ich möchte mich herzlich bei Dr. Nina Kausch-Busies und Dr. Damien Mailhol für die exzellente 
Zusammenarbeit auf dem Leiodermatolide-Projekt; sowie bei Dipl. Ing. Berit Heggen und M. Sc. 
Katharina Holthusen für die Kooperation während des Mandelalide A Projekts bedanken. 
Allen technischen Angestellten aus dem Arbeitskreis Fürstner – Karin Radkowski, Helga Krause, 
Saskia Schulthoff, Günter Seidel und Daniel Laurich– danke ich für ihre Geduld, Hilfsbereitschaft und 
den Erhalt eines funktionierenden Labors. Frau Monika Lickfeld danke ich für ihre freundliche 
Unterstützung bei organisatorischen Problemen. 
Zu tiefstem Dank verpflichtet bin ich allen Mitarbeitern der analytischen Abteilungen für die Messung 
und Analyse zahlreicher Proben. Herausheben möchte ich Conny Wirtz und Frau Gabor aus der NMR-
Abteilung für die detaillierten Zuordnungen von komplexen NMR-Spektren und für die dabei 
aufgekommenen Diskussionen. Frau Rosenthal und Herr Klein sei für die Aufnahme der 
Massenspektren gedankt. 
Laura Hoffmeister, Konrad Gebauer, Aaron Lackner und Damien Mailhol danke ich für das 
sorgfältige Korrekturlesen der Arbeit. Für die gute Atmosphäre im Labor und die inspirierenden 
Diskussionen sei allen aktuellen und ehemaligen Mitarbeitern gedankt; insbesondere möchte ich mich 
bei meinen langjährigen Box- und Bürokollegen Dr. Pep Llaveria, Dr. Michael Fuchs, Dr. Gaelle 
Valot, Karin Radkowski (+Azubis) und Jakub Flasz bedanken. 
Für all den Spaß und die gute Zeit außerhalb des Labors, die jede Menge tolle Erinnerungen 
hervorgebracht hat, bedanke ich mich bei allen Beteiligten und verbeuge mich vor Marina Ilg, Laura 
Hoffmeister, Konrad Gebauer, Andreas Ahlers, Dr. Alexander Arlt, Dr. Lennart Brewitz, Dr. Alicia 
Casitas, Minh Dao, Dr. Michael Fuchs, Dr. Teresa de Haro, Dr. Johannes Heppekausen, Dr. Aaron 
Lackner, Dr. Rudy Lhermet, Dr. Pep Llaveria, Dr. Peter Persich, Johannes Preindl, Heiko Sommer und 
Dr. Henrik Teller. 
Auch bei der Stiftung Stipendien-Fonds des Verbandes der chemischen Industrie, die meine 
Promotion mit einem Kekulé-Stipendium finanziell unterstützt hat, möchte ich mich herzlich 
bedanken! 
Den größten Dank verdienen meine Familie und Marina, die mich immerzu unterstützt haben und mir 
stets liebevoll zur Seite standen. Ihnen sei diese Arbeit gewidmet. 
 
Danke 
 
 Inhalt 
Konjugierte Alkene sind allgegenwärtige Motive in Naturstoffen marinen Ursprungs, die die 
pharmazeutische Industrie auch weiterhin mit Leitstrukturen für die Entwicklung von neuen 
Arzneimitteln versorgen. Solche mehrfach-ungesättigten Doppelbindungen in einem 
makrozyklischen Gerüst stellen den synthetischen Chemiker vor eine große Herausforderung, 
da der selektive Zugang per Alkenmetathese bis dato nicht möglich ist. 
Die Ringschluss-Alkinmetathese (RCAM) bietet eine nunmehr unverzichtbare Alternative, da 
sie nicht nur eine Vielzahl funktioneller Gruppen toleriert, sondern auch strikt zwischen 
Alkinen und Alkenen zu unterscheiden vermag. Im Rahmen dieser Arbeit wurde die RCAM 
mit der syn-selektiven Semihydrierung kombiniert, was als Schlüsselsequenz für die Synthese 
der makrozyklischen Naturstoffe Leiodermatolide und Mandelalide A diente. 
Leiodermatolide, ein Naturstoff aus dem Tiefseeschwamm Leiodermatium, zeigte in ersten 
Studien hohe antimitotische Aktivität ohne mit isoliertem Tubulin zu wechselwirken, was 
einen neuen Wirkmechanismus verspricht. Obwohl die Struktur von Leiodermatolide nicht 
vollständig aufgeklärt war, wurde eine Totalsynthese initiiert.  
 
Der Naturstoff konnte im Rahmen dieser Arbeit erfolgreich synthesiert werden; ebenso gelang 
die Strukturzuordnung. Eine überarbeitete Synthese wurde anschließend entwickelt um die 
verbleibenden Schwachstellen der ersten Generation auszumerzen. Mit dieser verbesserten 
Route konnten sowohl signifikante Mengen des Naturstoffs als auch einige Analoga 
hergestellt werden, die für eine eingehende biologische Untersuchung genutzt wurden. Die 
bisher erhaltenen Ergebnisse sprechen für einen neuartigen Wirkmechanismus via 
"centrosome declustering". 
 Im Anschluss wurde die Synthese des Naturstoffs Mandelalide A verfolgt. Neben der noch 
komplexeren Struktur war die vermeintlich hohe biologische Aktivität erneut ein 
ausschlaggebendes Auswahlkriterium.  
 
Nach der erfolgreichen Synthese aller benötigten Fragmente und deren Kupplung konnte, zum 
ersten Mal im Rahmen einer Naturstoffsynthese, ein terminales Alkin in der RCAM 
erfolgreich umgesetzt werden, vorausgesetzt das Molybdän-Alkylidin C1 wurde als 
Katalysator eingesetzt. Das gebildete zyklische Enin wurde im Anschluss semi-reduziert und 
weiter in die angestrebte Struktur umgewandelt. Es stellte sich heraus, dass die Struktur des 
Naturstoffs falsch zugeordnet worden war; durch die Synthese des Isomers mit invertiertem 
Nordfragment konnte die korrekte Stereochemie aufgeklärt werden. Leider konnte die 
biologische Aktivität mit dem synthetischen Material nicht bestätigt werden. Trotzdem wurde 
das Projekt um die Synthese des verwandten Naturstoffs Mandelalide C erweitert.  
 Abstract 
Conjugated olefins are common motifs in natural products of marine origin, which continue to 
serve the pharmaceutical industry as lead structures for the development of novel drugs. 
Polyunsaturated sites within a macrocyclic framework pose a considerable challenge to 
synthetic organic chemists, since their selective assembly is not possible via the well-
established olefin metathesis reaction. 
Ring-closing alkyne metathesis (RCAM) offers an indispensable alternative, as it tolerates a 
variety of polar functional groups and the catalysts display unmet selectivity for alkynes over 
olefins. To further elaborate the scope of this transformation, RCAM was combined with syn-
selective semi-hydrogenation to achieve the synthesis of the cyclodienes found in 
leiodermatolide and mandelalide A. 
Leiodermatolide, a natural product derived from a deep-sea sponge, was chosen as a target as 
it displayed high antimitotic acitivity against a variety of differenct cancer cell lines without 
interfering with purified tubulin, thus indicating a novel mode of action. Moreover, the 
structure could not be fully secured by the isolation team and led us to consider two possible 
diastereomers.  
 
In the event, the natural product could be successfully synthesized and its structure assigned 
based on subtle differences in the NMR spectra of two diastereomeric compounds. A second 
generation synthesis was in turn developed that addressed the remaining bottlenecks of the 
initial approach and features a catalytic asymmetric propargylation of a highly enolizable -
keto lactone. Substantial amounts of material and a set of analogues were thus synthesized to 
 allow for a deeper biological investigation. Until now, the acquired data points to centrosome 
declustering as the potential mode of action. 
An even more challenging enyne-yne metathesis was pursued within the total synthesis of 
mandelalide A, a natural product isolated from a marine ascidian along with three related 
macrolides. Mandelalide A was chosen as the primary target for a synthetic endeavor as the 
most active member of the family. 
 
After fragment synthesis and assembly, the RCAM reaction now engaged an enyne with a 
terminal alkyne, a structural motif that had been long beyond reach due to significant 
polymerization side-reactions. This was enabled by the use of the recently developed 
molybdenum alkylidynes bearing silanolate ligands. The resulting cycloenyne was 
subsequently semireduced and further transformed into the target molecule. However, the 
natural product had been misassigned by the isolation team, but was reassigned by inverting 
the whole northern fragment. Unfortunately, the promising biological activity could not be 
confirmed. Nevertheless, the project was extended to approach the closely related natural 
product mandelalide C.  
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1  Introduction 
Secondary metabolites are natural products produced by living organisms and are meant to 
undergo an interaction with an enzyme or a specific receptor protein.
[1]
 The structures of such 
compounds can be interpreted as the result of an evolutionary process and display the 
outcome of a long optimization period. Therefore, these natural products often exhibit a 
remarkable biological activity,
[2]
 even in completely remote contexts and are ideal starting 
points for drug discovery programs in the pharmaceutical industry.
[3]
 The plethora of 
successfully developed and approved drugs derived from such metabolites maintains the high 
interest of both industrial and academic research. At the end of a discovery process, the 
natural product is not necessarily the most potent drug candidate, but rather a derivative 
thereof.
[4]
 This is demonstrated by the textbook example of halichondrin B,
[5]
 which was 
replaced during clinical evaluation by the truncated but more active synthetic congener 
eribulin (scheme 1.1a).
[6]
 
 
Scheme 1.1: a) Naturally occurring halichondrin B; approved synthetic drug eribulin. 
                   b) Selected macrocyclic polyketides with important biological activity. 
The material supply from the natural sources, especially when dealing with those of marine 
origin, is frequently unreliable and only minute amounts of the target compound can be 
accessed. A modern total synthesis route should therefore be robust, scalable and hence 
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enable a steady supply of the target molecule to allow further evaluation of biological 
properties and record of structure activity relationships.
[7]
  
The challenging structural motifs found in natural compounds have ever since inspired 
synthetic chemists toward the development of novel reactions and will likely continue to do 
so. Moreover, total synthesis serves as the ultimate setting for the testing and application of 
novel methodologies. The numerous polar functional groups and complex architecture found 
in natural products offer a tremendous challenge to most catalysts. 
Finally, it is worth mentioning that, even in the age of ever more sophisticated spectroscopic 
methods, structure misassignments regularly come about.
[8]
 In most cases, total synthesis has 
served as the ultimate tool to prove a proposed structure or to reassign the stereochemistry or 
even connectivity of a natural product. 
Macrocyclic polyketides are an important class of natural products since they often display 
impressive biological activity.
[9]
 Prominent examples are the anticancer agent epothilone (see 
chapter 2.10, scheme 2.52),
[10]
 the approved antibiotic drug erythromycin,
[11]
 the antifungal 
drug amphotericin B
[12]
 and the insecticide and antihelmithic agent avermectin (see scheme 
1.1b).
[13]
 
Conjugated double bonds are common motifs of such macrocyclic compounds and occur with 
greater frequency than isolated double bonds for ring sizes between 16 and 24.
[14]
 The 
selective assembly of these polyene units poses a considerable challenge for ring-closing 
olefin metathesis (RCM) reaction, which has become the method of choice for the synthesis 
of cycloolefins due to the high functional group tolerance, easy handling and reliability of 
Grubbs' ruthenium alkylidene complexes.
[15]
 However, one considerable drawback of this 
approach is the lack of stereocontrol over the constructed double bond, especially during the 
formation of medium-
[16]
 or macrocyclic rings (scheme 1.2).
[17]
 
 
Scheme 1.2: General drawback of ring-closing olefin metathesis (RCM). 
In general, the (E)-isomer is thermodynamically more stable and prevails in the product 
mixture over the corresponding (Z)-double bond;
[18]
 yet, the product distribution can be 
influenced by the constraints of the macrocycle and is difficult to predict. At the outset of this 
thesis, (Z)-selective olefin metathesis was immature and far from being applicable to the 
synthesis of complex natural products.
[19]
 During the course of this investigation, impressive 
progress has been made;
[20]
 however, it still remains doubtful that this strategy would 
currently be applicable to the ring closing diene metathesis as needed within the natural 
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product syntheses addressed herein.
[21]
 Moreover, (E)-selective olefin metathesis catalysts are 
not known to date and the metatheses of unhindered, non-polarized sites likely produce 
mixtures of isomers. 
A second drawback comes into play, when one considers the construction of diene motifs. 
Not only does the olefin geometry need to be controlled, the catalyst must further differentiate 
between the different unsaturated sites to impede undesired ring-contraction reactions that are 
generally observed for such systems. Nevertheless, few successful outcomes of diene 
metathesis within the context of complex natural product synthesis are known.
[22]
 For 
example, introducing a silyl substituent on the inner olefin of the diene was shown to enable 
selective diene-ene metathesis and produces selectively the (E,Z)-diene after 
protodesilylation.
[23]
 
 
Scheme 1.3: General drawback of ring-closing olefin metathesis with dienes. 
Recourse to alkyne metathesis allows these problems to be easily fixed.
[17, 24]
 With the advent 
of the latest generation of alkyne metathesis catalysts such as C1 and C2 that combine user-
friendliness, high activity and exceptional functional group tolerance, a competitive 
alternative to olefin metathesis has been established.
[25]
 Like most metal alkylidyne 
complexes, these catalysts were shown to chemoselectively activate carbon-carbon triple 
bonds in the presence of olefins and enabled the construction of isolated and conjugated 
cycloalkyne units of highly functionalized products.
[26]
  
 
Scheme 1.4: Recently developed alkyne metathesis catalyst.
[25]
 
After successful ring-closing alkyne metathesis (RCAM), cycloenynes were shown to be 
selectively transformed into cyclodienes with complete control over the double bond 
geometry.
[27]
 Previously, this approach was elegantly adopted to construct the macrocyclic 
frameworks of lactimidomycin
[28]
 and latrunculin A;
[29]
 yet, further applications were deemed 
desirable. 
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Scheme 1.5: Selective construction of diene motifs within a macrocyclic framework by RCAM / semireduction. 
The application of ring closing alkyne metathesis followed by semi-hydrogenation for the 
selective generation of diene motifs within a macrocyclic polyketidic natural product will be 
described in the following chapters. In particular, employment of this strategy should produce 
the (Z,Z)- or (Z,E)-dienyl units within the total syntheses of leiodermatolide (scheme 1.5, 
blue) and mandelalide A (red), respectively. The results obtained during these synthetic 
endeavors are disclosed below. 
 
2  Total synthesis of leiodermatolide 
Remark: This project was initiated by postdoctoral researcher Dr. Nina Kausch-Busies and 
parts of this research were carried out in close collaboration. After completion of the first 
generation synthesis, the synthesis of leiodermatolide analogues and the development of a 
second generation synthesis was carried out in close collaboration with postdoctoral 
researcher Dr. Damien Mailhol. Their contributions are gratefully acknowledged and are 
indicated by references 42, 55 and 57. 
2.1 Isolation, structural discussion and biological activity 
Leiodermatolide (1) was first detected in a Leiodermatium sp. off Wemyss Bight, Bahamas at 
a depth of 618 m. After further exploration, it was found in about 10-fold higher concentration 
in a Leiodermatium sp. at a depth of 401 m on the Miami Terrace, off Ft. Lauderdale.
[30]
 
Extraction of the collected sponge (1037 g) and chromatographic purifications along with 
bioassay-guided fractionation allowed 11.8 mg of the pure sample to be obtained as an 
amorphous white solid, which corresponds to 0.0011% wet weight. 
[30]
 
The structure was elucidated by careful analysis of the 2D-NMR spectra in combination with 
theoretical considerations (comparative DFT GIAO NMR shift calculations) and molecular 
modeling.
[31]
 This ensured the assignment of the relative configuration of the macrocyclic 
portion (scheme 2.1, red) as well as the -lactone fragment (blue). Nevertheless, the 
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segregation of these two parts through a pentadienyl spacer (black) prohibited their 
stereochemical correlation. Therefore, two possible diastereomers of leiodermatolide had to 
be considered as the actual structure (1 and 2). Moreover, the absolute configuration was 
uncertain, tracing the structure of the natural compound back to four possible stereoisomers.  
Overall, leiodermatolide possesses nine stereogenic centers, six of which are contained within 
the macrocyclic skeleton, while the remaining three can be found within the -lactone. The 
only quaternary stereogenic center of the molecule is a tertiary alcohol at C.21 that connects 
the -lactone with the (E,E)-configured dienyl linker. The pseudo-axial attachment at C.21 is 
quite unusual and has been questioned in the past.
[32]
 
 
Scheme 2.1: The four possible structures of leiodermatolide. 
Within the 16-membered macrocycle lies a (Z,Z)-diene between C.10 and C.13 along with an 
isolated (E)-configured trisubstituted double bond between C.4 and C.5. Three protic 
functional groups are found on the carbon skeleton of 1; noteworthy is the carbamate at C.9, 
which is in close proximity to the secondary alcohol at C.7 but remote from the tertiary 
alcohol at C.21.  
An initial bioassay revealed that leiodermatolide acts as an antimitotic agent and is strongly 
cytotoxic against several cancer cell lines. The tested cell lines along with the obtained IC50 
values are depicted in table 2.1. The reduced cytotoxicity towards Vero monkey kidney cells 
(entry 6) was interpreted as an indication of selectivity for malignant over healthy tissue. 
Moreover, cell cycle analysis of the A549 and PANC-1 cell lines showed an arrest at the 
G2/M transition, which is a common effect of several known tubulin poisons.
[31]
 Whereas no 
changes with interphase cells were observed, leiodermatolide caused abnormal spindle 
formation in mitotic cells at low two-digit nanomolar concentrations.  
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Table 2.1: Cytotoxicity of leiodermatolide as reported by the isolation team.
[30-31]
 
entry cell line IC50 /nM 
1 A549 lung adenocarcinoma 3.3 
2 PANC-1 pancreatic carcinoma 5.0 
3 DLD-1 colorectal carcinoma 8.3 
4 NCI/ADR-Res ovarian adenocarcinoma 233 
5 P388 murine leukemia 3.3 
6 Vero monkey kidney 211 
 
However, no noteworthy effect on purified tubulin could be detected in vitro, even at 
concentrations as high as 20 µM.
[31]
 This observation is remarkable since all approved drugs 
interfere with microtubule assembly upon contact with the target protein; the ultimate 
consequence is cell-cycle arrest, which eventually causes cell death. It was concluded that 1 
acts through a distinct mechanism when compared to well-established antimitotic agents such 
as the taxanes, the vinca alkaloids vincristine, vinblastine and vindesine, the epothilones and 
discodermolide (see chapter 2.10).
[33]
 The severe side-effects of these compounds and the 
development of drug resistances are the reasons for the need of alternative drugs that are ever 
more selective and effective.
[34]
 
With this in mind, leiodermatolide (1) appeared to be an ideal target since a divergent total 
synthesis based on ring-closing alkyne metathesis would  
(1) allow both stereoisomers of leiodermatolide to be synthesized and the structure of the 
natural product to be assigned, 
(2) open a sustainable and reliable path to significant amounts of material required for 
additional biological tests, and 
(3) provide a challenging setting for the application of a RCAM for the synthesis of the 
(Z,Z)-diene within the macrocyclic segment of 1. 
 
2.2 Previous synthetic approaches by other groups 
Due to the interesting structural and biological features, leiodermatolide attracted the interest 
of several research groups. At the outset of this thesis, the groups of Prof. Maier and Prof. 
Paterson had already published their results describing synthetic studies towards a total 
synthesis of 1. Their strategies as well as the lessons learned from these reports are outlined 
below. 
The initial publication from Maier and co-workers
[32]
 features fragment syntheses for the 
macrocycle and the -lactone region. Since only the flat structure of leiodermatolide was 
depicted in the isolation patents,
[30]
 the relative stereoinformation was obtained from the 
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webpage of the isolation team. However, this structure (scheme 2.2) was later corrected to be 
as drawn in scheme 2.1.
[31]
 
 
Scheme 2.2: Maier's initial strategy for the synthesis of a leiodermatolide isomer.
[32]
  
Their key disconnection relied on a ring closing alkene-metathesis (RCM) reaction of the 
trisubstituted alkene at C.4 / C.5 for the closure of the macrocycle and a Sonogashira coupling 
between C.12 and C.13 to join the two fragments 4 and 5 (scheme 2.2). Although it was later 
shown that the two fragments could be fused and semi-reduced to give the (Z,Z)-diene, the 
RCM failed under a variety of conditions.
[35]
 The synthesis of the -lactone 6 was envisioned 
to proceed via an intramolecular Reformatsky reaction, which, in the event, yielded only the 
wrong diastereomer with the side chain attached in the pseudo-equatorial position at C.21. 
Moreover, the sulfone failed to undergo the projected Julia-Kocienski olefination for the 
creation of the required dienyl linker, even with simple aldehydes.
[36]
  
A second approach by Maier et al. based on a Stille fragment coupling and Yamaguchi 
macrolactonization allowed the macrocyclic segment 7 to be synthesized in 26 steps along the 
longest linear sequence.
[37]
 Yet, no attempt was made to install the missing carbamate 
functionality or to attach the -lactone fragment 6. 
 
Scheme 2.3: Second generation approach by Maier culminating in a synthesis of the macrocyclic core of 3.
[37]
 
A similar strategy based on Stille fragment coupling and Yamaguchi macrolactonization was 
independently pursued by the group of Paterson.
[38]
 The stereogenic centers of the macrolide 
sector were mainly created by boron-mediated aldol reactions (scheme 2.4). Although no 
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attempt was made to prepare the -lactone fragment of 1, the synthesis served as a 
confirmation of the predicted stereochemistry within the macrocycle.
[31]
  
 
Scheme 2.4: Key disconnections of the synthetic strategy by the Paterson group.
[38]
 
A result of paramount importance for the strategic considerations in the Fürstner group was 
the attempted carbamoylation of the unprotected macrocyclic 1,3-diol 10. Even when 
performed at −78 °C, no preference for the allylic alcohol at C.9 (11) was observed; rather, 
the alcohol at C.7 (3:2 ratio of 11:12, scheme 2.5) was favorably transformed into the 
corresponding carbamate.
[38]
 Additionally, the observation that reactions at the C.10/C.11 
double bond were difficult as long as the allylic alcohol was protected as its silyl ether turned 
out to be a precious hint for the synthetic adventures described below. 
 
Scheme 2.5: Carbamoylation.Conditions: a) Cl3(CO)NCO, CH2Cl2, −78 °C; then Al2O3, 35% 11, 52% 12. 
Only after the completion and publication of the total synthesis by our group in 2012,
[39]
 the 
Paterson group achieved the total synthesis of 1 in early 2014 with similar key steps as 
outlined in scheme 2.4.
[40]
 Though finally successful, their strategy required 24 steps in the 
longest linear sequence and produced only 0.6 mg of the natural product. 
Besides the above mentioned groups, Roush and co-workers are currently addressing a total 
synthesis of 1, although no details of their strategy have been made available.
[41]
  
 
2.3 Objectives 
None of the synthetic studies described above addressed the problem of assigning the 
stereochemistry of the macrocycle in relation to the -lactone. Furthermore, the fascinating 
biological profile and the low, as well as fluctuating, natural abundance of leiodermatolide 
served as reasonable arguments to engage in a total synthesis program. The resulting synthetic 
plan should be short, efficient and flexible in order to allow both antipodal -lactone segments 
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to be attached to the macrocycle. After structure assignment and confirmation of the 
biological activity, such a divergent strategy would further allow the facile synthesis of 
analogues of the parent natural product. In light of these challenging goals, a robust and 
scalable synthesis was required in order to provide sufficient material for the synthesis of the 
natural product itself and analogues thereof. 
The (Z,Z)-diene within the macrocyclic core of leiodermatolide was deemed as an ideal 
setting not only to apply the previously developed latest generation of ring closing alkyne 
metathesis catalysts, but to expand their known limits with an intriguingly challenging 
substrate. 
 
2.4 Retrosynthetic Analysis 
The retrosynthetic considerations were based on the desire to apply a ring closing alkyne 
metathesis reaction to access the macrocyclic framework. This specific transformation had 
proven reliable when dealing with complex natural product precursors and brings several 
advantages over its more famous relative, the olefin metathesis reaction. This is particularly 
true when a specific olefin geometry is required in the presence of other sites of unsaturation 
(see chapter 1). The (Z,Z)-dienyl unit was chosen as the key retrosynthetic disconnection, 
since this motif was impossible to generate by metathesis otherwise at the outset of this 
investigation. The disconnection between C.17 and C.18 would allow a late-stage Suzuki 
coupling of two advanced fragments, the -lactone fragment B and its macrocyclic 
counterpart A.  
 
Scheme 2.6: Retrosynthetic analysis with key disconnection between C.12 and C.13. 
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The two olefins of the diene between C.10 and C.13 allowed for two distinct approaches. 
Disconnection between C.12 and C.13 (scheme 2.6, red) was initially targeted, since the 
resulting alkyne metathesis reaction between an enyne bearing a protected allylic alcohol C 
and an internal alkyne found in D, which is branched in the propargylic position, was deemed 
more feasible. The steric bulk around both alkynes was believed to be rather small and should 
therefore not pose a significant challenge for the latest generation of alkyne metathesis 
catalysts. Although enynes tend to be less reactive than unconjugated alkynes, their successful 
engagement in RCAM boded well.
[28a]
 These promises outweighed the concern of having two 
fragments of different size, which clearly diminished the convergence of the route.  
Alternatively, disassembly of the olefin between C.10 and C.11 (scheme 2.7, red) led to 
metathesis precursors bearing a protected propargylic alcohol on one side (E) and an enyne on 
the other side (F).  
 
Scheme 2.7: Alternative retrosynthetic analysis with key disconnection between C.10 and C.11. 
In this scenario, the alkyne metathesis would not only suffer from lower reactivity of the 
enyne, but the protected propargylic alcohol puts a severe steric and electronic demand on the 
alkyne metathesis reaction, since it deactivates the alkyne through -electron withdrawal. The 
propargylic alcohol could further provide a potential pathway for unwanted side reactions, 
since it could serve as a leaving group next to a nucleophilic Schrock alkylidyne unit that is 
necessarily generated during the metathesis reaction. Furthermore, it was unclear at the outset 
of the study whether the potentially reactive vinyl iodide unit would be tolerated during the 
alkyne metathesis. 
Both approaches rely on an esterification of an alcohol fragment with an acid fragment to set 
the stage for the RCAM reaction. What is more, the difficulty to selectively carbamoylate the 
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allylic alcohol at C.9 (see chapter 2.2) over the secondary alcohol at C.7 was thought to be 
addressed by using two orthogonal protecting groups. In the event, the deprotection of PG
1
 
must proceed without interference of PG
2
. Carbamoylation of the umasked allylic alcohol at 
C.9 followed by deprotection of PG
2
 should then release the natural product 1.  
 
2.5 The C.12 / C.13 disconnection approach[42] 
All experiments described in this chapter were carried out by Dr. Nina Kausch-Busies.  
2.5.1 Attempted Synthesis of the acid fragment C 
The initial approach targeted acid fragment C since it was believed to result in a more reliable 
RCAM. The carboxylate moiety of C would derive from an Ireland-Claisen rearrangement
[43]
 
of a tertiary allylic alcohol, which after acetylation and rearrangement as reported by 
Overman
[44]
 would create both, the carbonyl functionality and the unsaturation in ,-position 
(scheme 2.8). This is traced back to ketone intermediate G, which could be accessed from 
enyne H by desilylation or from allylic alcohol I by ozonolysis and subsequent Julia-
Kocienski reaction.
[45]
 The stereotetrad of the acid fragment could be built up by two Evans 
syn-aldol reactions followed by an anti-selective Evans-Saksena reduction.
[46]
 In case of H, 
this would require the starting materials 13, 14 and 15, whereas in case of I, aldehyde 15 
would be exchanged for its more stable analogue 16.  
 
Scheme 2.8: Retrosynthetic analysis of acid fragment C. 
The use of aldehyde 17 would avoid further functional group conversions, but this compound 
is reported to be unstable; the isomerization of the (Z)-double bond to the more stable (E)-
form occurs at temperatures above −78 °C due to conjugation to both alkyne and aldehyde.[47] 
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In order to explore the route via H, propargylic alcohol 18 was subjected to 
hydroalumination/iodination of the triple bond.
[48]
 After Negishi cross-coupling to the desired 
enyne 19,
[49]
 the route via H was quickly abandoned since it was realized that oxidation of the 
corresponding alcohol precursor even under mild conditions (MnO2, rt) led to substantial 
amounts of the isomerized aldehyde (Z)-15.  
 
Scheme 2.9:  Attempted synthesis of aldehyde 15. Conditions: a) DIBAl-H, Et2O, reflux; then I2, −78 °C, 81%; 
b) propynyl lithium, ZnBr2, Pd(PPh3)4 (8 mol%), THF, 0 °C, quant.; c) MnO2, Et2O, rt, E/Z = 
1:1.
[42]
 
The path via dimethylacrolein (16) seemed more promising. The syn-aldol reaction of 
oxazolidinone 13 with propanal (14) proceeded as expected with high yield and selectivity. 
Subsequent Parikh-Doering oxidation
[50]
 gave the literature known ketone 21, which was 
engaged in a second syn-aldol reaction mediated by a combination of Sn(OTf)2 and 
triethylamine.
[51]
 After some optimization, the anti-reduction under Evans-Saksena conditions 
employing Me4NBH(OAc)3 proceeded smoothly and with high diastereoselectivity to install 
the fourth stereogenic center found on the rim of the macrocycle.
[46]
  
 
Scheme 2.10:  Synthesis of diol 22. Conditions: a) propanal (14), (n-Bu)2BOTf, NEt3, CH2Cl2, −78 °C to 0 °C, 
88%; b) SO3·Pyr, DMSO, CH2Cl2, 0 °C, 85%; c) dimethylacrolein, Sn(OTf)2, NEt3, CH2Cl2, 
−20 °C, 72-87%; d) Me4NBH(OAc)3, AcOH, MeCN, −50 to 0 °C, 89% (92:8 d.r.).
[42]
 
Attempted Evans-Tishchenko reactions
[52]
 that would simultaneously discriminate between 
the two secondary alcohols failed under a variety of conditions due to retro-aldol side 
reactions. However, the crucial discrimination could be achieved by selective silylation of the 
allylic alcohol of diol 22 at low temperatures. After elaboration into the corresponding 
Weinreb amide, the remaining secondary alcohol was masked as its MOM ether to give 24. 
The subsequent ozonolysis proceeded without complication and gave aldehyde 25.  
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Scheme 2.11:  Attempted synthesis of enyne 26. Conditions: a) TBSOTf, NEt3, CH2Cl2, −78 °C, 84%; b) AlMe3, 
MeONHMe·HCl, THF, 0 °C to rt, 62%; c) MOMCl, DIPEA, DMF, 50 °C, 83%; d) O3, CH2Cl2, 
−78 °C; then Me2S, rt, quant.
[42]
 
Somewhat unexpectedly, the Julia-Kocienski reaction of sulfone R1 with 25 failed under a 
variety of conditions to give the desired product 26 with acceptable yields or selectivity.
[42]
 
This was the main reason why the C.12 / C.13 disconnection approach was abandoned. 
 
2.5.2 Synthesis of the alcohol fragment D[42] 
In parallel to the findings described in the previous chapter, an approach to the alcohol 
fragment D had been developed. As outlined in scheme 2.12, the key disconnection was a 
Marshall reaction of aldehyde 27 and allene 28 in order to set the two stereogenic centers. 
Compound 28 was proposed to derive from propargylic alcohol 29, whereas aldehyde 27 is 
literature known.
[53]
 
 
Scheme 2.12: Retrosynthetic Analysis of the alcohol fragment D.
[42]
 
In the forward direction, methyl methacrylate (30) served as the starting material for the 
synthesis of compound 27. A sequence of dibromination and base-mediated elimination 
followed by reduction and oxidation gave aldehyde 27 in good yield.
[22a]
 The initial studies 
were carried out with racemic alcohol 29, which was transformed into allene 28 upon 
treatment of the corresponding mesylate with LiSnBu3 in the presence of copper bromide. 
Although not fully optimized, the key Marshall reaction gave either the anti- or syn-product 
31 depending on the Lewis acid employed.
[54]
 The obtained yields were rather moderate, 
mainly due to low diastereoselectivity and formation of an allenic addition product (32). 
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Scheme 2.13:  Synthesis of alcohol fragment D. Conditions: a) Br2, NEt3, CH2Cl2, 0 °C; then DBU, reflux, 92%; 
b) DIBAl-H, CH2Cl2, −78 °C, 60%; c) MnO2, Et2O, rt, 62%; d) MsCl, NEt3, CH2Cl2, −78 °C; e) 
LDA, (n-Bu)3SnH, CuBr2·SMe2, THF, −78 °C, 79% over 2 steps; f) SnCl4, CH2Cl2, −78 °C, 31: 
60% (d.r. 9:1 anti/syn) + 32: 30%; g) BF3·Et2O, CH2Cl2, −78 °C, 31: 75% (d.r. 4:1 syn/anti)  + 32: 
10%.
[42]
 
A short and convenient route to the alcohol fragment D was thus developed, although it was 
not fully optimized. The C.12 / C.13 disconnection approach was eventually abandoned 
because of the above mentioned problems faced during the synthesis of the acid 
fragment C.
[42]
 
 
2.6 The C.10 / C.11 disconnection approach (first generation) 
2.6.1 Synthesis of the acid fragment E 
Since the synthesis of key fragments of the C.12 / C.13 disconnection approach turned out to 
be a formidable obstacle, our efforts were focused on the C.10 / C.11 disconnection. 
For this purpose, compound 24 was used as a model system in order to evaluate the remaining 
steps required for the introduction of the C.1 – C.5 framework. With this in mind, 24 was 
treated subsequently with methylmagnesium chloride and vinylmagnesium bromide to give 
the tertiary alcohol 33 (scheme 2.14).
[42]
  
 
Scheme 2.14:  Model system for the synthesis of the acid fragment. Conditions: a) MeMgCl, Et2O, 0 °C, 93%; b) 
vinylMgBr, THF, −78 °C; 52%; c) PBr3, pyridine, Et2O; d) EtOAc, LDA, CuI, THF, −110 to 
−30 °C, 40-60% over 2 steps; e) TMSOK, Et2O, rt, 90%.
[42]
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The formation of the tertiary acetate 34 required for the projected Ireland-Claisen 
rearrangement failed under a variety of conditions, including classical Steglich conditions, in 
situ acetylation after Grignard reaction and Yamamoto's Lewis acid catalysis. However, an 
alternative two-step process consisting of allylic displacement by bromide and subsequent 
alkylation allowed for the clean transformation into ethyl ester 36.
[42]
 Finally, hydrolysis of 
the ethyl ester under mild conditions using TMSOK at ambient temperature furnished the 
desired acid 37; the reaction was slow, but efficient.
[42]
 
With optimized conditions in hand, the synthesis of acid fragment E terminating in a methyl-
capped alkyne was addressed. Compound 21 was thus treated with freshly prepared 2-butynal 
(38) to produce the desired aldol product in moderate yield, with the remaining mass balance 
consisting of reisolated starting material.
[55]
 Later studies by Dr. Damien Mailhol showed that 
the yield could be dramatically improved by using rigorously dry Sn(OTf)2. Subsequent 1,3-
anti reduction completed the stereotetrad with high selectivity and yield. Selective silylation 
of the propargylic alcohol and conversion into the corresponding Weinreb amide 40 preceded 
the protection of the secondary alcohol with MOMCl. 
In light of previous experiences in the group, in which difficulties in cleaving methoxymethyl 
ethers from highly functionalized substrates were encountered, several alternatives were 
investigated at this stage. However, the secondary alcohol could not be converted into the 
corresponding PMB ether regardless of the conditions employed. Moreover, this alcohol 
failed to undergo silylation with TBDPSCl or TBDPSOTf. Although it could be transformed 
under forcing conditions (50 °C) into the triisopropylsilyl ether, the yield of this reaction was 
unsatisfactory (49%). Therefore, the synthesis was continued with the MOM group in place. 
 
Scheme 2.15:  Synthesis of the acid fragment E. Conditions: a) Sn(OTf)2, NEt3, CH2Cl2, −20 °C, 55% (88% 
brsm); b) Me4NBH(OAc)3, HOAc, MeCN, −50 °C, 98%; c) TBSOTF, NEt3, CH2Cl2, −78 to 0 °C, 
89%; d) (MeO)NHMeHCl, AlMe3, THF, 0 °C to rt, 90%; e) MOMCl, (i-Pr)2NEt, DMF, 50 °C, 
89%; f) MeMgCl, Et2O, 0 °C, 97%; g) vinylMgBr, THF, −78 °C to rt, 87% 2:1 d.r.; h) PBr3, 
pyridine, Et2O, 0 °C; i) EtOAc, LDA, CuI, −110 to −30 °C, 63% over 2 steps; j) TMSOK, Et2O, rt, 
quant.
[55]
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Two Grignard additions as described above for the model system gave the tertiary alcohol 41 
as an inconsequential mixture of diastereomers. The allylic alcohol 41 was then treated with 
PBr3 to furnish the rather unstable allylic bromide, which was immediately added to the 
lithium enolate of ethyl acetate in the presence of CuI resulting in a clean alkylation. Again, 
the saponification of ethyl ester 42 was achieved with TMSOK to give the desired acid 43 in 
high yield. The acid segment E was thus produced in 12 steps in the longest linear 
sequence.
[55]
 During the first generation synthesis, batches of 347 mg and 415 mg of acid 43 
were produced, highlighting the robustness and scalability of this fragment synthesis. 
 
2.6.2 Synthesis of the alcohol fragment F 
The retrosynthetic analysis of the alcohol fragment F centered on a Julia-Kocienski reaction 
for the construction of the required (Z)-enyne. Aldehyde 44 was thought to originate from an 
anti-selective aldol reaction of either propanal (14) or an ester or amide of type 45 with 
aldehyde 46 to enable the creation of the anti-scaffold of the two stereogenic centers. 
 
Scheme 2.16: Retrosynthetic analysis of the alcohol fragment F. 
The literature known aldehyde 46 was synthesized in 4 steps from commercially available 
diethyl methylmalonate (47).
[56]
 After deprotonation with sodium hydride and alkylation with 
iodoform, the diiodoalkyl species 48 was obtained in excellent yield. Treatment with 
potassium hydroxide in aqueous ethanol led to the saponification of both esters, 
decarboxylation of one of the two carboxylates, and elimination of iodide to afford 3-
iodomethacrolein (49) in good yield. The acid was reduced with lithium aluminum hydride to 
give a primary alcohol that was oxidized on demand with manganese dioxide to yield the 
rather unstable aldehyde 46.  
 
Scheme 2.17:  Synthesis of aldehyde 46. Conditions: a) NaH, CHI3, Et2O, 0 °C to reflux, 99%; b) KOH, 
EtOH/H2O, reflux, 72%; c) LiAlH4, Et2O, 0 °C to rt, 49%; d) MnO2 (10 eq.), CH2Cl2, rt, 98%; e), 
BH3·THF, THF, −30 °C to rt, f) [Cu(MeCN)4]OTf (5 mol%), bipyridine (5 mol%), TEMPO 
(5 mol%), NMI (10 mol%), air, MeCN, 55% over 2 steps. 
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More reproducible results were later obtained by replacing LiAlH4 with BH3·THF.
[57]
 
Moreover, a copper catalyzed air oxidation
[58]
 was found to be more practical than the use of 
excess MnO2 during a second generation synthesis.
[57]
 
Aldehyde 46 and its brominated congener 27 were first subjected to Evans anti-aldol 
conditions employing MgCl2,
[59]
 but only traces of the desired adducts 50 and 51 were 
detected by mass spectrometry after workup. On the other hand, resorting to ester 40,
[60]
 
derived from norephedrine
[61]
 according to Masamune and Abiko, secured good yields and 
stereoselectivity as previously reported.
[62]
 Since the outcome with iodo-aldehyde 46 was 
superior when compared to the bromo-aldehyde 27, the former was used for scale-up and the 
synthesis continued with the vinyl iodide in place. 
 
Scheme 2.18:  Attempted anti-aldol reactions. Conditions: a) 27 or 46 (1.2 eq), NEt3, TMSCl, MgCl2 (20 mol%), 
EtOAc, rt; b) 27, NEt3, TMSCl, MgCl2 (10 mol%), NaSbF6 (30 mol%), EtOAc, rt; c) 27 or 46, 
Cy2B(OTf), NEt3, CH2Cl2, −78 °C, 53 (X=Br): 58% (10:1 d.r.), 54 (X=I): 76% (12:1 d.r.).  
The secondary alcohol was converted into the corresponding TBS-ether and the auxiliary 
reductively cleaved by using DIBAl-H. Aldehyde 44 was then obtained by oxidation of the 
primary alcohol with Dess-Martin periodinane
[63]
 and immediately submitted to the Julia-
Kocienski reaction.
[45]
 In the initial experiments, substantial isomerization at C.14 was 
observed, although the (E/Z)-selectivity was high. 
 
Scheme 2.19:  Completion of the synthesis of the alcohol fragment F. Conditions: a) TBSOTf, 2,6-lutidine, 
CH2Cl2, −10 °C; b) DIBAl-H, toluene, −78 °C, 83% over 2 steps; c) DMP, CH2Cl2, 0 °C; d) R1, 
KHMDS, THF, −55 °C, 56% over 2 steps, (E/Z > 24:1); e) TBAF, THF, 0 °C, 99%. 
This problem could be circumvented by stirring sulfone R1
[28a]
 with KHMDS for 30 min 
before the deprotonated sulfone was transferred to a cooled solution of aldehyde 44 via 
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canula. A longer reaction time for the deprotonation did not improve the outcome of the 
reaction further. Finally, removal of the silyl group occurred readily with TBAF to give 
alcohol 57 in excellent yield. 
Attempts to shorten the synthesis of alcohol fragment F by performing the reactions without 
silyl protecting group failed (scheme 2.20). Upon treatment of 54 with DIBAl-H, only traces 
of the reduced product 58 were obtained, mainly due to retro-aldol side reactions. Likewise, 
the attempted shortcut on the way to 57 via a proline-catalyzed cross-aldol reaction
[64]
 
between propanal (14) and aldehyde 46 was unsuccessful.
[57]
 Instead of the cross-aldol 
product 59, only homocoupling of propanal (14) was observed.  
 
Scheme 2.20:  Attempted shortcuts. Conditions: a) DIBAl-H, toluene, −78 °C to rt; b) (L)-proline (10 mol%), 
DMF, 4 °C. 
Overall, synthetic access to alcohol fragment F was established with 10 steps in the longest 
linear sequence starting from commercially available malonyl diester 47. 
 
2.6.3 Synthesis of the -lactone fragment B 
The -lactone fragment of leiodermatolide (1) is unique for its three contiguous stereogenic 
centers, one of which is a tertiary alcohol. The allylic substituent of this site connects to the 
macrolide segment, segregated through a pentadienyl linker.  
Several strategies based on the cyclic -keto ester 61 as a key intermediate were investigated 
and will be discussed in this chapter. The initial strategy was based on a nucleophilic opening 
of the exocyclic epoxide 60 with an ethynyl or vinyl metal reagent followed by cross 
metathesis with a vinyl boronate or hydroboration, respectively. Epoxide 60 should be 
accessed either directly from 61 via a Corey-Chaykovsky reaction or by a two-step sequence 
involving methylenation and epoxidation. The cyclic -keto ester 61 is literature known and 
can be assembled through an intramolecular Claisen condensation of the acetylated anti-aldol 
product of ent-13 with propanal (14).
[65]
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Scheme 2.21: Retrosynthetic analysis of -lactone fragment B. 
In the event, the synthesis of 61 proceeded as reported and furnished the desired compound on 
gram scale.
[65]
 The aldol reaction with two equivalents of dibutylboron triflate as described by 
Heathcock led to the anti-product 62 with acceptable selectivity (11:1 d.r.).
[66]
 Acetylation 
with acetic anhydride set the stage for a Dieckmann-type condensation, which, when 
mediated by LiHMDS at low temperatures, gave the desired product in 83% yield. 
 
Scheme 2.22:  Synthesis of key -keto ester 61 and attempted epoxidation. Conditions: a) (n-Bu)2BOTf, NEt3, 
Et2O, −78 °C, 74% (11:1 d.r.); b) Ac2O, NEt3, DMAP (cat.), CH2Cl2, 0 °C, 82%; c) LiHMDS, 
THF, −78 °C, 83%; d) KHMDS, R2, THF, 0 °C; e) NaH, R3, THF, 0 °C. 
The projected Corey-Chaykovsky epoxidation with sulfonium salt R2 or sulfoxonium salt R3 
failed due to the high acidity of the -protons of 61.[67] Although no starting material could be 
detected by TLC analysis during the reaction, it reappeared after a slightly acidic workup. 
These initial results already indicated the major problem that had to be overcome with 61. 
Comparison of literature known pKA values for Meldrum's acid or other cyclic -dicarbonyl 
compounds allowed for an estimation of the pKA value of 61 (scheme 2.23).
[68]
 With a 
forecasted pKA value of slightly less than 11, the acidity of 61 is similar to protonated amines 
(Et3NH
+
 pKA = 9.1; BnNH3
+
 pKA = 10.2; n-BuNH3
+
 pKA = 11.1, all values for DMSO).
[69]
 It 
is interesting to note that the acidities of cyclic -dicarbonyl compounds are significantly 
lower than those of their acyclic counterparts. 
  
Scheme 2.23: Comparison of pKA values of several -dicarbonyl compounds.
[68]
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This was attributed to preferred orbital overlap of the *C-H with the *C-O of an adjacent 
carbonyl that is maximized in cyclic systems according to calculations.
[70]
 This lowers the 
overall energy of the *C-H LUMO and facilitates the overlap with a lone-pair of a base. NMR 
analysis of 61 revealed that the keto form is the only observed species in CDCl3 and [D6]-
benzene, whereas the enol form dominates in [D6]-DMSO.  
 
Scheme 2.24: Attempted methylenation of 61; observed products 64 and 65. 
As the direct epoxidation of 61 had failed, a two-step sequence was envisioned. 
Methylenation should precede the epoxidation of the generated exocyclic double bond. 
Although the former transformation proceeded readily with the expected regioselectivity for 
the ketone using the Tebbe reagent at low temperatures, the exocyclic double bond of 63 
isomerized quickly into conjugation with the ester upon contact with either H2O, SiO2 or, over 
time, in CH2Cl2 solution. At temperatures above 0 °C, the methylenation of the ester carbonyl 
took place preferentially and product 65 was detected. Resorting to other mild methylenating 
agents did not help to overcome this hurdle. No reaction occurred with the Lombardo reagent 
generated in situ from Zn, CH2Br2 and TiCl4,
[71]
, whereas the Nystedt
[72]
 reagent reacted 
slowly, but only the isomerized product 64 with an endocyclic double bond was observed 
after workup. A different retrosynthetic analysis was therefore mandatory.  
 
Scheme 2.25: Revised retrosynthetic analysis of the -lactone segment B.  
It was envisioned that the alcohol functionality could be introduced by a nucleophilic 
epoxidation of an unsaturated lactone of type 66 followed by radical epoxide opening. The 
precursor was thought to be derived from vinyl triflate 67, which should be readily accessible 
from 61. 
Indeed, trapping of the enol form of 61 with triflic anhydride occurred without difficulty to 
give the stable vinyl triflate 67. The envisioned palladium catalyzed cross-coupling was only 
tried with propargylic pinacolborolane R5 and furnished either allene 69 or the conjugated 
alkyne 68 as the major product depending on the reaction temperature.  
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Scheme 2.26:  Attempted cross-coupling approach. Conditions: a) Tf2O, NEt3, CH2Cl2, −78 °C, 91%; b) R4, 
[Pd(dppf)Cl2]·CH2Cl2, Cs2CO3, THF/H2O 10:1, for 68: reflux, HCl workup, 33%, for 69: rt, 
neutral workup: 60%, 18:1 d.r.; c) n-BuLi, THF, then MgCl2, (pin)B(OiPr), −40 °C, 83%. 
The formation of alkyne 68 is noteworthy and it remains unclear, whether the forcing 
conditions led to a Hiyama coupling of R5 with concurrent protodeborylation or if it was the 
result of an isomerization process. At this stage, the more promising Stille coupling with an 
allyl or propargyl tin reagent was not investigated,
[73]
 since an alternative strategy was 
explored simultaneously and was found to be much more efficient in terms of step count. 
 
Scheme 2.27: Retrosynthetic analysis of -lactone segment B based on direct allylation or propargylation.  
This strategy was based on the direct propargylation (scheme 2.27, blue) or allylation (red) of 
the previously described -keto ester 61. It was inspired by the report of Hinterding, who had 
shown that a hydride could be delivered with high selectivity from the face syn to the adjacent 
methyl group (scheme 2.28).
[65]
 If this outcome could be translated to a carbon nucleophile in 
a propargylation or allylation reaction, this strategy would allow the -lactone with the axial 
C-branch to be synthesized in only five steps from commercial material. 
 
Scheme 2.28:  Reported reduction of -keto lactone ent-61.[65] Conditions: a) t-BuNH2·BH3, citric acid, MeOH, 
H2O, 0 °C, 73%. 
Due to the high acidity of the -protons, a reactive but non-basic nucleophile had to be 
employed. Therefore, a variety of conditions were screened for the identification of suitable 
reagents.
[74]
 The propargylation of compound 61 was initially tried with an organocerium 
compound
[75]
 generated from 1-trimethylsilyl-1-propyne (R4) and the organozinc reagent 
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generated from R5.
[76]
 In both cases, no addition occurred due to the pronounced enolization 
of 61 and the starting material was reisolated (scheme 2.29).  
 
Scheme 2.29:  Attempted propargylation of 61. Conditions: a) R4, n-BuLi, CeCl3, THF, −78 to 0 °C; b) R5, 
Et2Zn, THF, −78 °C to rt. 
An early result proved that an allylindium reagent generated in situ from allyl bromide and 
elemental indium
[77]
 could afford the allylated compound 70 when the reaction was carried 
out in water (table 2.2, entry 2).
[78]
 However, the analysis of the NOESY spectra did not allow 
for a stereochemical assignment of the newly created stereogenic center. 
Fortunately, crystals of the major isomer suitable for X-ray analysis were obtained by slowly 
cooling a saturated CH2Cl2/hexane solution 
to −40 °C. The crystal structure revealed 
that the allyl group was attached in the 
pseudo-equatorial position and the product 
was assigned to epi-70 (figure 2.1). This 
meant that the allylation took place from the 
bottom face anti to the adjacent methyl 
group at C.22 and therefore mainly 
delivered the undesired diastereomer.  
A short solvent screen revealed THF to be beneficial in terms of both conversion and 
diastereoselectivity, but the stereochemical outcome could not be inverted (entry 3). No 
reaction was observed with the solvent employed for the reduction that consisted of a mixture 
of aqueous citric acid and methanol as solvent (entry 4).
[65]
 
In order to invert the facial selectivity, several chiral ligands and additives were screened. 
None of these modifiers was able to cause a switch in diastereoselection. For instance, (+)-L1 
improved the rate and diastereomeric ratio of the products, but the enantiomeric ligand (‒)-L1 
was not able to override the substrate bias (entry 5).
[79]
 At best, an almost 1:1 mixture of 
diastereomers was obtained with moderate yield when the PyBOX ligand L2 was employed 
(entry 6). 
Figure 2.1: Crystal structure of epi-70 
21 
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Other metal mediated allylations including allyltin (entries 7 – 9),[80] allylsamarium (entry 
10)
[81]
 and allylboron reagents (entries 11 – 14)[82] under Lewis acid catalysis were screened, 
but none of these was fruitful. 
Table 2.2: Selected results towards the allylation of 61. 
 
entry conditions conv.
1)
 (yield) 70 : epi-70 
1)
 
1 allylbromide, In, DMF, rt to 50 °C complex mixture - 
2 allylbromide, In, H2O, 50 °C 65 (42%) 1:6 
3 allylbromide, In, THF, rt 79 1:1.9 
4 allylbromide, In, MeOH, citric acid, rt no reaction - 
5 allylbromide, In, L1, THF, rt (+): 95 (−): 69 (+): 1:10; (−): 1:3.5 
6 allylbromide, In, Sc(OTf)3, (S,S)-L2 64 1:1.3 
7 allylbromide, Sn, NaBF4, H2O, rt 18 1:3.9 
8 Sn(allyl)4, Ti(OiPr)4, BINOL, i-PrOH/CH2Cl2, rt (R): 23 (S): 15 (R): 1:12; (S): 1:10 
9 Bu3Sn(allyl), InBr3, BINOL, CH2Cl2, 4 Å MS, rt to 40 °C (S): 56 (R): - (S): 1:5.3; (R): - 
10 allylbromide, Sm, I2 (cat.), THF, 40 °C 26 1:7.8 
11 (pin)B(allyl), PCy3, Cu(OAc), L3, THF, 50 °C no reaction - 
12 (pin)B(allyl), CuF2, L4, La(Oi-Pr)3, DMF, rt no reaction - 
13 (Ipc)2B(allyl), Et2O, 0 °C complex mixture - 
14 R6, w/o BF3·Et2O, CH2Cl2, rt no reaction - 
15 9-allyl-9-BBN, THF, 0 °C 78 (72%) 1 : 1.9 
16 (1S)-R7, CH2Cl2, −78 °C 100 (88%) 1:7.5 
17 (1R)-R7 (1.1 eq.), CH2Cl2, 0 °C to rt 100 (58%) 4.1:1 
18 (1R)-R7 (1.1 eq.), CH2Cl2, 0 °C (inverse order of add.) 100 (86%; 73% 70) 5.5:1 
 
1) in %; determined by 1H NMR analysis of a crude sample. 
 
Even though several reactions with allylboron reagents failed, the allylboration with 9-allyl-9-
BBN
[83]
 was quite clean and yielded the allylated product as a 1:1.9 mixture of diastereomers 
(entry 15). For this reason, the chiral reagent R7 reported by Soderquist was synthesized and 
explored (entries 16 – 18).[84] Fortunately, the (1R)-isomer was able to override the parent 
substrate control and furnished the allylated product with a diastereomeric ratio of 4.1:1 
favoring the desired isomer 70. 
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After a short optimization process, best results were 
obtained by using a slight excess of (1R)-R7 and 
reversing the order of addition when compared to the 
originally reported conditions; dropwise addition of the 
reagent to a chilled solution of 61 ensured a rather low 
local concentration of (1R)-R7 and suppressed the 
otherwise observed double and triple allylation 
products. This protocol allowed the reaction to be 
performed at 0 °C and increased the diastereomeric 
ratio to 5.5:1. Repeated column chromatography on fine 
silica gel allowed the desired isomer 70 to be separated 
from its counterpart epi-70 and to be isolated with a 
yield of 73% (86% combined yield).
[85]
 With an 
efficient and reliable protocol developed, the allylation was similarly performed on ent-61 
with the enantiomeric reagent (1S)-R7 that allowed a crystal structure of ent-70 to be grown. 
The crystal structure depicted in figure 2.2 highlights the rather unusual pseudo-axial 
attachment of the allyl moiety at C.21.  
The synthesis of R7 was performed as described in scheme 2.30 and is based on the insertion 
of the benzylic carbene generated from 75 into the C−B bond of 9-methoxy-9-BBN.[84] The 
diazo species 75 is literature known and was previously synthesized from the corresponding 
tosylhydrazone by vacuum pyrolysis.
[86]
 A more convenient synthesis was chosen in the 
present case, since the handling of a potentially dangerous diazo compound at temperatures 
above 220 °C seemed hazardous.  
As it turned out, simple oxidation of benzaldehyde hydrazone (74) with MnO2
[87]
 worked well 
in the presence of molecular sieves to trap the generated water.
[88]
 This oxidation proceeded at 
room temperature and delivered a solution of the diazo compound 75 after filtration, which 
was immediately used for the insertion step. No high-temperature operations were thus 
required, although the yield over the two steps was significantly lower than reported, most 
likely due to inefficient trapping of water during the diazo formation and side reactions with 
the ethereal solvent.
[89]
 
Figure 2: Crystal structure of ent-70 
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Scheme 2.30:  Synthesis of chiral allylboron reagent R7. Conditions: a) H2NNH2·H2O, 100 °C, sealed tube, 
quant.; b) MnO2 (5 eq.), Et2O, 4 Å MS, rt; c) 9-MeO-9-BBN, pentane, 0 °C to rt, 37% over 2 steps; 
d) (S,S)-L5, pentane reflux, (1S)-77: 26%; then (R,R)-L5, pentane, reflux, (1R)-R7: 22%; e) 
allylMgBr, Et2O, −78 °C to rt, 92%. 
The racemic insertion product 76 was then resolved by fractional crystallization with the 
pseudoephedrine derivative L5 to give the enantiopure adducts 77. The order of 
crystallizations was reversed once it was shown that (1R)-R7 gave the desired isomer 70. 
Treatment with allyl magnesium bromide gave the desired allylboron compound R7 after 
precipitation and filtration of the magnesium salt of L5. 
Since the challenging construction of the quaternary stereogenic center was now 
accomplished, a functionalization at C.18 for the Suzuki coupling was required. Olefin cross-
metathesis was initially explored with vinyl pinacolboronates, but the product suffered from 
rapid hydrolysis of the pinacol ester during workup and chromatography. Replacement by the 
more stable MIDA boronate ester readily solved this problem.
[90]
 The cross metathesis 
catalyzed by Grubbs 2
nd
 generation catalyst (C3) afforded the desired (E)-olefin in good yield 
and high selectivity (>19:1).
[91]
 In contrast to the corresponding pinacol ester, product 78 was 
stable during flash chromatography and upon storage. 
 
Scheme 2.31:  Cross metathesis reaction. Conditions: a) R8, C3 (5 mol%), CH2Cl2, reflux, 81% (E/Z>19:1). 
A short five-step synthesis of the structurally challenging -lactone fragment B was 
successfully established. Although the allylation required the use of stoichiometric amounts of 
R7, the developed route was deemed satisfactory for a first generation synthesis. For further 
improvements, see chapter 2.9.  
26 Total synthesis of leiodermatolide 
 
2.6.4 Fragment assembly, macrocyclization, endgame and structure assignment 
With all three fragments in hand, the focus shifted to their assembly. The envisioned 
esterification of alcohol 57 with acid 43 proceeded efficiently when mediated by EDCI and 
DMAP. The stage was now set for the anticipated ring closure by alkyne metathesis (table 
2.3). Surprisingly though, the highly active alkyne metathesis catalyst C1 based on 
molybdenum bearing silanolate ligands
[25]
 failed, giving exclusively an open dimer (entry 
1).
[42]
 On the basis of 
1
H NMR analysis and comparison with the spectra of diyne precursor 
79, the triple bond next to the silyl ether seemed to be inert to the catalyst and was not 
engaged in a metathesis reaction. This outcome was independent on the reaction temperature 
as similar results were obtained at 23 °C and 120 °C. Moreover, ring-closure was not 
achieved with either the ate-complex C2 or with complex C4 bearing supposedly smaller tert-
butyldimethylsilanolate ligands. 
Table 2.3: Optimization of the RCAM. Conditions: a) EDCI·HCl, DMAP, CH2Cl2, 0 °C to rt, 89%. 
 
entry cat conditions result 
1 C1 (15 mol%) toluene, 5 Å MS, rt or reflux acyclic dimer (~80%) 
2 C2 (15 mol%) toluene, 5 Å MS, reflux acyclic dimer (~80%) 
3 C4 (50 mol%) toluene, 5 Å MS, reflux acyclic dimer (45%) 
4 C5 (50 mol%) p-nitrophenol, toluene, 100 °C no reaction 
5 C6 (50 mol%) CH2Cl2, toluene, 100 °C, 0.006 M 58% 80 + open & closed dimer 
6 C6 (40 mol%) CH2Cl2, toluene, 100 °C, 0.0015 M 72% 80 + traces dimer & s.m. 
7 C6 (4 x 10 mol%) CH2Cl2, toluene, 100 °C, 0.0015 M 68% 80 + traces dimer & s.m. 
 
Substitution of the bulky silanolate ligands for sterically less demanding ligands on the 
molybdenum center was therefore evaluated. The catalyst derived in situ from C5 and p-
nitrophenol according to the protocol by Moore
[92]
 did not induce any reaction. On the other 
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hand, the species generated in situ from Cummins precatalyst
[93]
 C6 and CH2Cl2 effected the 
desired transformation.
[94]
  
In the initial experiment, stoichiometric amounts of C6 were used due to the small scale;
[42]
 
on larger scale, a catalyst loading of 40 mol% was still required to obtain macrocyclic enyne 
80 in a reproducible manner. Close inspection of the reaction progress by TLC and HPLC-MS 
revealed that a dimeric species was initially formed, which was then converted into 
monomeric cycloenyne 80. The catalytic systems C1 and C6/CH2Cl2 therefore seem to differ 
in their ability to activate the alkyne next to the propargylic silylether of this dimeric species. 
The long reaction time and the high catalyst loading can be explained by considering the ring 
strain of the polyunsaturated macrocycle, the immense steric demand of the propargylic site 
and the slight electronic deactivation of the enyne. These individual factors combine to result 
in an extremely challenging overall transformation that required harsh conditions in order to 
proceed. As expected, the chemoselectivity was excellent and all other unsaturated sites of the 
molecule including the vinyl iodide survived the metathesis reaction unaltered.
[95]
 
This functionality defined the order of the subsequent steps. Model studies with compound 56 
showed that the vinyl iodide was not compatible with semihydrogenation conditions 
employing activated Zn (scheme 2.32).
[42]
 Under the conditions reported by Boland
[96]
 or 
Rieke
[97]
 the deiodination was as fast as or faster than the semireduction and only product 
mixtures of the desired compound 81 and deiodinated products 82 and 83 were detected by 
GC-MS, ESI-MS, and 
1
H NMR. Activated Zn as described by Brandsma
[98]
 failed to react 
with 56; most likely, the activation of Zn was not achieved on the rather small scale. Upon 
Lindlar hydrogenation,
[99]
 the vinyl iodide unit stayed intact,
[100]
 but the reaction suffered 
from overreduction and resulted in a mixture of 81 and several other products.
[42]
 Therefore, it 
was concluded that the Suzuki coupling of macrocycle 63 with -lactone 61 had to precede 
the semireduction of the enyne to consume the vinyl iodide. 
 
Scheme 2.32:  Attempted semihydrogenation and detected products.
[42]
 Conditions: a) Zn(Cu/Ag), 
THF/H2O/MeOH 1:1:1, 45 °C, mixture obtained; b) ZnBr2, K, THF/H2O/MeOH 1:1:1, 50 °C, 
mixture obtained; c) Zn, (H2BrC)2, CuBr, LiBr, EtOH/THF 1:1, 50 °C, no reaction; d) Pd/CaCo3, 
H2 (1 atm), pentane, rt, 81 + overreduced products. 
Again, compound 56 served as a model system for the Suzuki cross coupling with epi-78 
(scheme 2.33). Despite its excellent functional group tolerance and the host of successful 
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Suzuki couplings in the context of total synthesis,
[101]
 this specific case turned out to be very 
demanding. The MIDA boronate ester required the use of an aqueous solvent mixture to allow 
the in situ release of the boronic acid.
[102]
 Although the product was detected in trace amounts 
under classical conditions during an intensive screening process,
[103]
 only the use of a thallium 
base
[104]
 allowed the coupled product 84 to be isolated in 15% yield despite a high catalyst 
loading. Analysis of the crude reaction mixture by mass spectrometry enabled the 
identification of ring-opened diol 85 as a side-product.  
 
Scheme 2.33:  Suzuki cross-coupling model studies. Conditions: a) [Pd(PPh3)4] (20 mol%), Tl(OEt), THF/H2O 
9:1, 50 °C, 84: 15% 85 detected in the crude mixture; b) [Pd(PPh3)4] (20 mol%), Tl(OEt), 
THF/H2O 3:1, rt; then MTBE/0.5 M HCl, rt, 81%. 
It seems likely that the rather basic conditions employed for the cross-coupling not only 
hydrolyzed the boronate ester but also the -lactone. The crude product was therefore treated 
overnight with diluted aqueous HCl to close the partially opened -lactone. This workup 
procedure significantly improved the yield (81%) without causing isomerization of the 
conjugated olefins or alcohol deprotection. 
Application of these conditions to the macrocyclic vinyl iodide 80 gave the desired adduct 86 
after a similar acidic workup in 49-56% yield. Although the outcome was only moderate, this 
reaction was reliable and served well for the material supply of a first generation synthesis. 
Nevertheless, it was kept in mind that a higher yielding alternative would be desirable for a 
later upscaling process. 
 
Scheme 2.34:  Suzuki cross-coupling. Conditions: a) [Pd(PPh3)4] (20 mol%), Tl(OEt), THF/H2O 3:1, rt; then 
MTBE/0.5 M HCl, rt, 49-56%. 
The semihydrogenation was now explored on a macrocyclic system. Initial experiments with 
model compounds 87 and 88
[105]
 bearing a truncated side chain revealed that only the 
deprotected propargylic alcohol 88 was successfully reduced with either Zn(Cu/Ag) as 
described by Boland
[96]
 or activated zinc obtained by the Rieke method,
[97]
 whereas the triple 
bond of silylether 87 was inert under identical conditions. As discussed above, this is likely 
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due to the steric hindrance imposed by the bulky tert-butyldimethylsilyl protecting group. 
Furthermore, White had previously described an activating effect of alcohol groups in 
proximity to the alkyne.
[97c]
 It was speculated that the alcohol assists the coordination of the 
substrate to the heterogeneous metal surface. 
 
Scheme 2.35:  Model for the semihydrogenation. Conditions: a) R9, [Pd(PPh3)4], Tl(OEt), THF/H2O 3:1, rt, 56%; 
b) TBAF, THF, 0 °C, 96%; c) Zn(Cu/Ag), MeOH/H2O 1:1, 50 °C, 91%; d) ZnBr2, K, 
THF/MeOH/H2O, reflux, 85%. 
These promising results were translated to the actual system (scheme 2.36). Thus, the 
propargylic silyl ether 86 was deprotected using TBAF in the presence of 4 Å MS to ensure 
short reaction times. Since the isolated yield was low when 90 was purified by column 
chromatography on silica gel, all chromatographic operations after this point were carried out 
on less acidic Florisil
®
. The stage was set for the semihydrogenation of the propargylic 
alcohol 90.  
 
Scheme 2.36:  Semihydrogenation and selective carbamoylation. Conditions: a) TBAF, THF, 4 Å MS, 0 °C, 
85%; b) Zn(Cu/Ag), THF, H2O/MeOH, 50 °C, 89%, c) Cl3C(O)NCO, CH2Cl2, −78 °C, then Al2O3, 
84%. 
After treatment with freshly prepared Zn(Cu/Ag) at elevated temperature, the targeted (Z,Z)-
diene 91 was isolated as a single olefin isomer in high yields. Although the reaction times 
fluctuated from batch to batch, the reaction always proceeded to full conversion. With an 
efficient and highly selective entry for the diene unit of the macrocycle in hand, the allylic 
alcohol at C.9 was carbamoylated with trichloroacetyl isocyanate in the presence of the more 
shielded tertiary alcohol at C.21. The primary adduct was hydrolyzed by prolonged contact 
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with basic alumina to release the desired allylic carbamate 92 in good yield.
[106]
 Although the 
isolation team had reported that the tertiary alcohol easily undergoes esterification reactions 
during Mosher ester formation, the carbamoylation was completely selective for the 
secondary alcohol.
[31]
 During this first generation synthesis, 38 mg of MOM-protected 
leiodermatolide were prepared in a single batch. 
The cleavage of the MOM group as the last step of the synthesis posed another considerable 
hurdle. As can be seen from table 2.4, the reaction with a host of Brønsted (entry 1)
[107]
 or 
Lewis acids
[108]
 formed complex mixtures. Due to the small scale and the manifold by-
products, the compounds could not be isolated from the crude mixture, which was hence 
analyzed by ESI-MS analysis. All detected side-products are depicted in scheme 2.37. Since 
no NMR data was available, the structures are only tentative. As eliminated species like 95 - 
98 were often detected during this process, it was postulated that a conjugated and therefore 
stabilized carbocation was initially formed, which likely loses a proton to form elimination 
products. Indeed, when the reaction was carried out in the presence of a nucleophile like n-
butylthiol, the adducts 94 were detected by ESI-MS in the crude mixture (entry 4). Treatment 
with B-bromocatechol borane
[109]
 (entry 5) led, for the first time, to the detection of the 
desired signal in the crude ESI-MS sample. 
Table 2.4: Optimization of final MOM-deprotection. For structures of the by-products, see scheme 2.37. 
 
entry reagent conditions result 
1)
 
1 AcCl, EtOH CH2Cl2, 0 °C mix of 95, 97, 98, 100 
2 TMSCl, n-Bu4NBr CH2Cl2, 0 °C complex mixture  
3 Ph3CBF4 w/o 2,6-di(t-Bu)pyridine, CH2Cl2, −20 °C mix of 99, 95, 96 
4 ZnBr2, n-BuSH CH2Cl2, 0 to 10 °C mix of 94a, 94b, 98, 96 
5 (catechol)BBr w/o i-Pr2NEt, CH2Cl2, −78 to −35 °C mix of 1 (traces), 95, 96 
6 (catechol)BCl CH2Cl2, −78 to −35 °C 95, 92, unidentified product 
7 9-I-9-BBN w/o i-Pr2NEt, CH2Cl2, −78 °C mix of 97, 1, 100, 96, 92 
8 Me2BBr CH2Cl2, −90 to −78 °C clean reaction, 61% 1 isolated 
 
1) determined by ESI-MS of a crude sample. 
Based on this finding, several boron-based Lewis acids were screened in order to identify a 
reagent that would cleave the MOM group without causing undesired elimination. In some 
cases, these Lewis acids were combined with bulky bases to quench any Brønsted acid 
(entries 5, 7), but no effect was noticed.  
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Scheme 2.37: Putative structures of the by-products detected in the crude mixtures by ESI-MS.  
Although the MOM group was cleaved on some occasions, as can be concluded from the 
formation of 94a, 96 and 98, the reactions were often accompanied by a substantial amount of 
elimination side reactions. Fortunately, the use of the slim but highly Lewis acidic 
Me2BBr
[110]
 as a last resort enabled the clean deprotection of 92 and allowed the isolation of 1 
in 61% isolated yield after preparative TLC.  
Due to its high volatility (bp. 29 °C) and violent reaction with moisture, dimethylboron 
bromide is no longer commercially available and was freshly prepared prior to use from 
tetramethyltin and borontribromide for optimal results. This practical drawback 
notwithstanding, this reagent accomplished its task reliably by first transforming the MOM 
ether into the corresponding bromo-acetal 101 either directly by nucleophilic attack as 
outlined (scheme 2.38) or via the corresponding oxonium ion as proposed by Guindon and co-
workers.
[111]
 Upon aqueous NaHCO3 workup, this intermediate is converted into the hemi-
acetal 102, which collapses to give the targeted compound 1. Quite surprisingly, the hemi-
acetal 102 was stable enough to be detected by mass spectrometry after purification by 
preparative TLC. 
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Scheme 2.38:  Proposed mechanism and detected hemi-acetal. Conditions: a) Me2BBr, CH2Cl2, −90 to −78 °C.  
The diastereomeric compound 2 bearing the antipodal -lactone fragment was synthesized 
analogously (scheme 2.39) in order to allow for a stereochemical assignment of the natural 
product. Hence, the enantiomeric -lactone ent-78 was engaged in the Suzuki coupling with 
80 to give 103. As described before, fluoride-induced desilylation preceded the 
semihydrogenation, which yielded allylic alcohol 105. Selective introduction of the yet 
missing carbamate and deprotection of the MOM-acetal under the previously established 
conditions afforded the targeted compound 2. The low yield of 18% is likely a consequence of 
the preparative HPLC purification that was necessary with this isomer after the MOM 
deprotection. It can be assumed that a significant amount of product got lost during the 
purification process due to the small scale. 
 
Scheme 2.39:  Total synthesis of diastereomeric compound 2. Conditions: a) [Pd(PPh3)4], Tl(OEt), THF/H2O 3:1, 
rt, 56% b) TBAF, THF, 4 Å MS, 0 °C, 76%; c) Zn(Cu/Ag), THF, H2O/MeOH, 50 °C, 81%, d) 
Cl3C(O)NCO, CH2Cl2, −78 °C, then Al2O3, 63%, e) Me2BBr, CH2Cl2, −90 to −78 °C, 18%. 
Nevertheless, the isolated material allowed for a direct comparison of both 
1
H and 
13
C NMR 
data of the two compounds with those of the natural product (see appendix for full spectra). 
The recorded 
13
C NMR spectra of the two diastereomers were almost identical, and 
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juxtaposition with the spectrum of the natural product (see figure 2.3) did not allow for a 
conclusive assignment. In both cases, marginal deviations from the peaks of the natural 
product were observed that were within the experimental error of 0.1 – 0.2 ppm. To exclude 
concentration effects, the spectra of 1 were recorded at different molarities, though no 
significant differences were observed. 
 
Figure 2.3: Differences in 
13
C shifts () of 1 (red) and 2 (blue) with the natural product. 
A similar situation was encountered for the 
1
H NMR spectra, which were indistinguishable 
except for the region between 2.20 and 2.50 ppm. The subtle differences found within this 
region were characteristic and did not change upon lowering the concentration of the sample 
solution. Therefore, it was used for the comparison with the natural product. The pattern of 1 
(figure 2.4, red) was essentially identical with the spectrum of the natural product (black, 
extracted from the isolation paper
[31]
), whereas the spectrum of 2 showed a subtle but distinct 
dissimilarity. 
The comparison of the recorded optical rotation of 1 (
24][ D  = –74.3, c = 0.41, MeOH) and 2  
(
24][ D = –58, c = 0.09, MeOH) with the one reported for the natural product (
24][ D  = –84.2, c 
= 0.34, MeOH)
[31]
 indicated that the absolute configuration of the synthetic material was 
identical to that of natural leiodermatolide. As a consequence, the structure of leiodermatolide 
is correctly represented by formula 1. This assignment was later independently confirmed by 
the total synthesis of the Paterson group
[40]
 and by the biological tests summarized in chapter 
2.10. 
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Figure 2.4: Extract from the 
1
H NMR spectra of 1 (red), natural leiodermatolide (black) and 2 (blue). All spectra 
were recorded in CD2Cl2 on a 600 MHz spectrometer. The full spectra can be found in the appendix. 
As outlined in this chapter, the first total synthesis of the scarce marine natural product 
leiodermatolide was achieved in 19 steps along the longest linear sequence. The synthesis of 
both possible isomers allowed the structure to be assigned based on subtle differences in the 
1
H NMR spectra.
[39]
 This short and flexible route delivered approximately 13 mg of the 
natural product and enabled a detailed biological investigation (see chapter 2.10). A 
significantly larger amount of the natural product was later prepared during a second 
generation synthesis (for details, see chapter 2.9). 
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2.7 Structural considerations 
During the deprotection of the MOM-protected precursor 92 to give 1, a perspicuous change 
in the 
1
H NMR spectra was noticed. Specifically, the spectra of all MOM-protected precursors 
of 1 show a significant line broadening for the atoms on the periphery of the macrocycle, 
regardless of the solvent (CDCl3, CD2Cl2, C6D6) or concentration. This line broadening 
vanishes once the MOM group has been removed. It is postulated that the unmasking of the 
hydroxyl group at C.7 enables the formation of a hydrogen bond with the carbamate moiety at 
C.9. Due to this stabilizing effect, it is believed that the conformational freedom is reduced 
and the signals on the macrocycle become better resolved. Figure 2.6 illustrates this spectral 
feature and shows a juxtaposition of the spectra of 92 and 1. Both spectra were recorded on a 
600 MHz spectrometer with CD2Cl2 as the solvent.  
Although the isolation team had described leiodermatolide as an amorphous white solid, a 
crystal structure could be obtained by slowly evaporating a CH2Cl2/Et2O solution of 
leiodermatolide (1).
[57]
 The collected single crystals turned out to be the monohydrate of 1, 
which crystallized in the P212121 space group. The structure of 1 in the solid state as 
represented in figure 2.5 reveals several characteristic structural features of the macrocycle.  
 
Figure 2.5: Crystal structure of leiodermatolide (1).  
Hydrogen atoms and the co-crystallized water molecule are omitted for clarity. 
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Figure 2.6: Comparison of the 
1
H NMR spectra (600 MHz, CD2Cl2) of 1 (top) and 92 (bottom). Signals that resolve after deprotection are highlighted in red. 
Total synthesis of leiodermatolide 37 
 
For instance, the (Z,Z)-diene is almost orthogonal to the macrocyclic framework; a feature that 
was previously observed during the iejimalide project.
[112]
 The proximity of the carbamate 
moiety at C.9 and the alcohol functionality at C.7 confirms the previously proposed stabilizing 
hydrogen bond. Although the bridging proton could not be localized in a differential Fourier 
map, the calculation puts it only 2.116 Å away from the carbonyl group. Moreover, the relative 
configuration of both groups is deemed indicative, since they point into the very same 
direction, which is sterically and electronically disfavored otherwise. 
The olefins of the pentadienyl spacer are in parallel orientation for maximal orbital overlap and 
populate the energetically favored s-trans configuration. Therefore, the -lactone side chain is 
spatially remote from the macrocycle, which is in line with the observation that these two 
substructures could not be correlated by spectroscopic means and the diastereomeric 
counterparts 1 and 2 show only minimally distinct spectral signatures. 
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2.8 Synthesis of leiodermatolide analogues 
2.8.1 Motivation 
The promising biological profile inspired the pursuit of several leiodermatolide analogues to 
shed light on the pharmacophore of leiodermatolide, which was unknown at the outset of this 
study. Specifically, the -lactone side chain was systematically varied to disclose whether this 
rather unusual motif is required for biological activity. In addition to the previously synthesized 
compound 2 bearing an antipodal head group, several modifications with respect to the 
structure of the natural product were targeted (scheme 2.40). Thus, the -lactone was replaced 
by a cyclohexanol ring (as in 107) to maintain the tertiary alcohol while simultaneously lacking 
the hydrolysis-prone lactone, or by a linear methyl ester group (as in 108), which retained only 
the ester carbonyl group. Both compounds preserved the pentadienyl linker that keeps this 
functional handle at distance to the macrocycle. As a less profound variation, compound 109 
lacks one site of saturation within the spacer and should thus provide more structural flexibility.  
The replacement of the carbamate moiety allows to evaluate whether the postulated hydrogen 
bond is necessary for biological activity. Thus, an acetate group (110) was envisioned to take 
its place as a slightly less potent hydrogen bond acceptor. Furthermore, the free diol 111 was an 
interesting target, since a possible engagement in hydrogen bonding would from a six- instead 
of an eight-membered ring. The MOM-protected compound 92 was further submitted to the 
assay, since all functional groups were present except for the hydrogen bond donor at C.7. 
 
Scheme 2.40: Targeted derivatives of 1: carbamate modification (blue) and -lactone side chain variations (red). 
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2.8.2 Modifications of the side chain 
Remark: All experiments described in this chapter were carried out by Dr. Damien Mailhol; 
details can be found elsewhere.
[113]
 Although the transformations leading to analogues 107, 108 
and 109 were not fully optimized, sufficient material for a preliminary cytotoxicity evaluation 
was obtained. 
 
The analogues bearing different side chains were synthesized according to the same logic as 
outlined above. The cyclohexanol derivative 113 was prepared by allylation of cyclohexanone 
(112)
[114]
 and ensuing cross-metathesis with vinyl MIDA boronate ester (R8). The endgame 
according to the sequence described for the natural product delivered the target compound 107, 
albeit in slightly reduced yield since the carbamoylation was no longer selective for the 
secondary allylic alcohol. 
 
Scheme 2.41:  Preparation of cyclohexanol analogue 107. Conditions: a) (allyl)B(pin), In
0
 (3 mol%), H2O, rt, 90%; 
b) vinylB(MIDA) (R8), C3 (10 mol%), CH2Cl2, 40 °C, 69% (E/Z > 20:1).
[57]
 
Hydroboration of commercial methyl 5-hexynoate (115) followed by copper-catalyzed boron-
tin exchange
[115]
 set the stage for the Stille coupling envisioned for the introduction of the 
methyl ester side chain of analogue 108. The coupling proceeded in 80% yield and enabled the 
rapid access to this derivative after carrying out the sequence of semihydrogenation, 
carbamoylation and protecting group manipulations. 
 
Scheme 2.42:  Synthesis of methyl ester analogue 108. Conditions: a) Cy2BH, THF, 0 °C, then aq. NaOH, rt, then 
Cu(acac)2 (5 mol%), (n-Bu)3SnCl, −15 °C to rt, 28% (d.r. > 20:1).
[57]
 
Lastly, the -lactone side chain 70 was TMS protected before being subjected to a sequence of 
hydroboration, alkyl Suzuki coupling and oxidation of the partially reduced lactone. Although 
the yields were rather moderate and the subsequent silyl deprotection was plagued by 
elimination of the trimethylsilyl ether, enough material of analogue 109 could be secured for a 
first biological assessment. 
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Scheme 2.43:  Preparation of side chain analogue 109. Conditions: a) imidazole, TMSCl, DMAP, CH2Cl2, 0 °C to 
rt, 76%; b) 9-BBN, THF, 50 °C, then KOMe, rt, 2h, then 80, Pd(dppf)Cl2·CH2Cl2 (20 mol%), AsPh3 
(50 mol%), 70 °C; then PCC, CH2Cl2, rt, 47% over 2 steps.
[57]
 
 
2.8.3 Modifications on the macrocycle 
The synthesis of analogues bearing modifications of the carbamate moiety started from the 
macrocyclic diene 91. In line with the result of the carbamoylation, the acetylation of 
compound 91 occurred preferentially at C.9, although formation of the bis-acetylated 
compound (27%, not shown) could not be avoided, most likely due to the higher reaction 
temperatures required for the acetylation (0 °C vs. −78 °C). Nevertheless, acetate 118 was 
isolated in sufficient amounts and was subsequently deprotected using the conditions developed 
for the natural product. The reaction required multiple additions of dimethylboron bromide, but 
afforded the targeted analogue 110 in moderate yield. 
 
Scheme 2.44:  Synthesis of acetate analogue 110. Conditions: a) Ac2O, NEt3, DMAP, CH2Cl2, 0 °C to rt, 54%; b) 
Me2BBr, CH2Cl2, −90 to −78 °C, 54%. 
It was originally planned to access diol 111 from the very same intermediate 91 by direct 
deprotection of the MOM group. In the event, the desired product could not be detected in the 
complex crude mixture. Rather, the formation of cyclic acetal 119 was observed, which could 
be isolated in 18% yield by preparative TLC. Its formation can be explained by intramolecular 
trapping of the oxonium ion generated from the MOM-ether at C.7 by the alcohol at C.9. The 
more rigid 1,3-dioxane derivative itself was deemed structurally interesting, since the hydrogen 
bonding array of 1 was replaced by a more rigid covalently bridged acetal. Further experiments 
to obtain diol 111 were therefore not carried out. 
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Scheme 2.45:  Attempted synthesis of analogue 111. Conditions: a) Me2BBr, CH2Cl2, −90 to −78 °C, 20%. 
Studies to optimize the yields for compounds 110 or 119 were not performed since it was 
unclear at the time how these compounds would perform in the biological assays. 
 
2.9 Development of a second generation synthesis 
2.9.1 Motivation 
After the successful first generation synthesis, which permitted the structure assignment and 
delivered sufficient material for more thorough biological testing, a continuing and reliable 
material supply of this otherwise scarce natural product was deemed necessary. Therefore, the 
bottlenecks of the first generation were to be replaced by more efficient steps. Three 
problematic transformations were identified for which more practical and more reliable 
operations had to be found: 
(i) The allylation of -keto ester 61 was performed with stoichiometric amounts of the 
chiral allylating agent R7. Since the preparation of this reagent was inconvenient 
and required the generation and use of diazo compounds as well as isolation by 
fractional crystallization, a more efficient catalytic alternative was desirable.  
(ii) With an isolated yield of no more than 55%, the Suzuki coupling of the macrocycle 
80 with the -lactone fragment 78 was arguably the major bottleneck of the first 
generation synthesis. Since no starting material could be reisolated, every coupling 
reaction resulted in loss of half of the precious material. Furthermore, the rather 
acidic conditions required for closure of the partially opened -lactone had to be 
carefully controlled, since further material loss was suspected from prolonged 
exposure. 
(iii) The RCAM required the handling of the extremely sensitive precatalyst C6, which 
entailed that all solvents had to be rigorously dried and degassed prior to use. 
Furthermore, t-butyl-dimethylaniline, resulting from hydrolysis of the amido ligand, 
was always isolated along with the desired product and could only be removed by 
applying high vacuum at 60 °C. The more convenient and user-friendly catalyst C1 
was unable to mediate ring-closure. A more detailed analysis of this reaction was 
therefore intended to shed light on the reasons for the failure of C1. 
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Slight modifications were also required during the scale-up syntheses of the alcohol fragment F 
and the acid fragment E. Since these modifications were only minor, they have been already 
mentioned in chapter 2.6. 
 
2.9.2 Catalytic installation of the C.21 stereogenic center 
After a long screening process, the stereogenic center of the -lactone moiety at C.21 was 
installed by a reagent controlled allylation of cyclic -keto ester 61. Although the reaction itself 
was reliable and successfully repeated with up to 180 mg of 61, the tedious and low-yielding 
preparation of the reagent R7 stimulated the search for a more convenient catalytic alternative. 
It was speculated that allylboronates would exhibit similar reactivity and may therefore be 
applicable to the challenging substrate 61. Although allylboronates were originally decorated 
with bidentate ligands in a stoichiometric manner,
[116]
 Schaus later showed that catalytic 
amounts of 2,2'-binaphthol ligands work well for the asymmetric allylation of ketones.
[117]
 
Furthermore, a single example of a successfully allylated acyclic -keto ester was reported. 
During the screening of conditions for the first generation synthesis, a promising result was 
obtained by combining allyl-donor R10 with catalytic amounts of 3,3'-dibromo 2,2'-binaphthol 
(L5) in the presence of t-BuOH. Although the conversion reached only 44%, the preference for 
the desired adduct 70 over the epimer epi-70 suggested that optimization of the reaction 
conditions might eventually result in a satisfactory outcome (table 2.5, entry 2).  
Table 2.5: Optimization of the catalytic asymmetric allylation of 61. 
 
entry 
catalyst 
(10 mol%) 
conditions 
yield [%] 
(conv.)
1)
 
70 : epi-70 
1)
 
1 (S)-L5 t-BuOH, toluene, rt (39) 1:10 
2 (R)-L5 t-BuOH, toluene, rt (10-44) 4:1 
3 (R)-L5 t-BuOH, H2O, toluene, rt (6) 4:1 
4 (R)-L5 t-BuOH, rt (neat) (5) 4:1 
5
[57]
 (R)-L5 t-BuOH, toluene, microwave, 130 °C 84 6.1 
6
[57]
 (R)-L5 toluene, microwave, 130 °C 95 6:1 
7
[57]
 (S)-L5 t-BuOH, toluene, microwave, 130 °C 88 1:9 
 
1) Determined by 1H NMR analysis of a crude sample. 
However, all attempts to reproduce or improve this result failed for unknown reasons. Various 
experiments with modified reaction parameters such as solvent or water content led to no more 
than 15% conversion (entries 2, 3, 4). 
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After an extensive literature survey, it was found that microwave irradiation at 130 °C
[118]
 
ensured reliable conversion of 61 into the allylated product 70.
[57]
 Surprisingly, the 
diastereomeric ratio was improved despite the high reaction temperature. The addition of t-
BuOH was found to be irrelevant and its omission simplified the experimental procedure.  
In order to replace the Suzuki coupling with a Stille coupling that had proven quite efficient 
during the synthesis of analogue 108, the propargylation of 61 with allenylboronate R11 under 
otherwise identical condition was explored.
[118]
 The selectivity of this reaction was even better 
and provided the desired homopropargylic alcohol 71 with a diastereomeric ratio of 7.6:1 and 
excellent yield. The stereochemical outcome was confirmed by X-ray diffraction of the minor 
isomer epi-71.
[57]
 Moreover, the control experiment with (S)-L5 indicated that the addition is 
catalyst- rather than substrate-controlled.  
 
Scheme 2.46:  Synthesis of homopropargylic alcohol 71. Conditions: a) R11, (R)-L5 (10 mol%), toluene, 
microwave, 130 °C, 94% (7.6:1 d.r.); b) R11, (S)-L5 (10 mol%), toluene, microwave, 130 °C, 87%, 
(1:15 d.r.).
[57]
  
According to the calculated transition state structure by Goodman,
[119]
 the boronate undergoes 
full ligand exchange with L5, releasing 1,3-propanediol. This was supported by the fact that t-
BuOH was neither necessary nor beneficial for the reaction. The substrate resides in the chiral 
pocket formed by the binaphthol derivative through coordination of the ketone carbonyl to the 
Lewis acidic boron center (scheme 2.46). To avoid steric repulsion with the bulky -systems of 
the ligand, the substituents on the six-membered ring are oriented towards the open quadrant in 
the back. This prepositioning of the substrate explains the high selectivity encountered during 
the allylation and propargylation process, placing the newly introduced substituent in a pseudo-
axial position. 
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Scheme 2.47:  Preparation of the modified -lactone fragment 120. Conditions: a) n-Bu3SnH (added over 15 min), 
Pd2(dba)3 (1 mol%), PCy3HBF4 (4 mol%), i-PrNEt2 (8 mol%), CH2Cl2, rt, 120: 72%, 121: 15%.
[57]
 
The subsequent hydrostannation was achieved with Pd2(dba)3 as the precatalyst, PCy3 as the 
ligand and dropwise addition of tin hydride to ensure full conversion.
[120]
 Small amounts of the 
undesired regioisomer 121 were removed by column chromatography.
[57]
 
 
2.9.3 Stille cross coupling reaction[57] 
Next, the modified coupling partner 120 was engaged in a Stille-Migita coupling with vinyl 
iodide 80. Under conditions previously developed in the group, the reaction was clean and the 
formation of 86 was complete after 1 min, thus minimizing the contact time of the sensitive 
compounds with transition metals.
[121]
 The virtually neutral reaction conditions allowed the 
desired adduct 86 to be isolated in excellent 93% yield, which could be reproduced on a 
100 mg scale.
[57]
 
 
Scheme 2.48:  Stille cross coupling reaction. Conditions: a) [Pd(PPh3)4] (5 mol%), CuTC, [NBu4][Ph2PO2], DMF, 
rt, 93%.
[57]
 
Although 1.4 equivalents of vinyl stannane 111 had to be engaged due to competing proto-
destannylation, the low-yielding Suzuki coupling from the first generation synthesis was 
replaced by a very efficient Stille coupling, allowing for a significantly higher material 
throughput. 
 
2.9.4 Further investigation of the RCAM reaction 
The RCAM of 79 proceeded only under forcing conditions with C6 activated by CH2Cl2 as 
catalyst. At the time, it was speculated that the failure to activate the alkyne was due to the 
steric demand of the flanking propargylic silyl ether. The results obtained during the 
semihydrogenation, which occurred only once the silyl ether was cleaved, further indicated a 
pronounced steric shielding of the alkyne by the bulky silyl ether.  
Based on these observations, the TBS group of 79 was cleaved with the aid of TBAF and the 
resulting product 122 engaged in the RCAM reaction. Since it was well known that the 
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extremely sensitive system C6/CH2Cl2 would not tolerate an alcohol group, the silanolate 
bearing molybdenum catalyst C1 was examined again. Under the conditions previously used 
for the protected congener 79, the ring closure of 122 now occurred with only trace amounts of 
dimeric species detectable in the reaction mixture (entry 1). It was soon realized that the 
catalyst loading could be lowered to 15 mol% (entries 2, 3) and the reaction was similarly 
effective even at ambient temperature (entry 3) when carried out in the presence of 5 Å MS to 
sequester the released 2-butyne. Finally, adjustment of the concentration minimized the 
formation of dimeric species and allowed cycloenyne 123 to be isolated in 61% yield with 
15 mol% of C1 (entry 4). 
Table 2.6: Further investigation of the RCAM. Conditions: a) TBAF, THF, 0 °C to rt, 85%. 
 
entry catalyst conc. conditions result 
1 C1 (30 mol%) 0.003 M toluene, 100 °C,  65% 
2 C1 (10 mol%) 0.003 M toluene, 100 °C,  s.m.:prod 1:4
1)
 
3 C1 (15 mol%) 0.003 M toluene, 5 Å MS, rt 52% + 18% dimer 
4 C1 (15 mol%) 0.0016 M toluene, 5 Å MS, rt 61% 
 
1) determined by 1H NMR analysis of a crude sample. 
 
The tolerance of a propargylic alcohol during an alkyne metathesis reaction was largely 
unprecedented, and only simultaneously were successful examples reported by our group.
[122]
 
On one hand, such substrates can simply coordinate to the Lewis acidic molybdenum center 
through the oxygen lone-pair. This ligation might either tune down the catalytic activity of the 
molybdenum catalyst or could eventually end up in carbon-oxygen bond cleavage of the 
substrate under formation of a stabilized propargylic cation (scheme 2.49, left).
[122a]
 On the 
other hand, the alkylidyne formed from a propargylic alcohol and the metal catalyst possesses 
highly nucleophilic character at the -carbon and is likely to induce elimination of the alcohol. 
(scheme 2.49, right).
[122a]
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Scheme 2.49:  Possible side reactions of propargylic alcohols and molybdenum alkylidynes. 
It is for these reasons that alkyne metathesis with substrates bearing functional groups in the 
propargylic position remained largely unexplored and was enabled only by the introduction of 
the latest generation of alkyne metathesis catalysts.
[25]
 The findings described herein will likely 
encourage further applications of this strategy in sterically demanding cases.
[122b]
 
With an alternative procedure for the crucial ring-closure established, the optimized Stille 
cross-coupling reaction was executed with the macrocyclic vinyl iodide 123 bearing a free 
propargylic alcohol.
[57]
 As expected, the additional protic functionality did not interfere with 
this protocol and the cross-coupled product 90 was obtained without incident while converging 
with the route described for the first generation synthesis. 
 
Scheme 2.50:  Interception of the first generation synthesis by Stille cross-coupling. Conditions: a) [Pd(PPh3)4] 
(5 mol%), CuTC, [NBu4][Ph2PO2], DMF, rt, 90%.
[57]
 
In conclusion, all supply-limiting steps of the first generation synthesis were replaced by more 
efficient and convenient synthetic manipulations. The revised synthesis of the -lactone 
features a catalytic asymmetric propargylation of a highly enolizable substrate. The low-
yielding Suzuki coupling was replaced by a more efficient Stille coupling that ensured 
excellent yields for this critical fragment-assembling step. Finally, a closer investigation of the 
RCAM opened an alternative pathway to achieve the generation of the macrocyclic framework.  
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2.10 Investigation of the biological properties 
The results described in this chapter were obtained in collaboration with Pfizer Drug Safety 
Research and Development, Pfizer Oncology and Pfizer Oncology Medicinal Chemistry. The 
contributions of Xingzhi Tan, Weidong Ding, Elizabeth E. Rubitski, Zhanna Sobol, Maik 
Schuler, My-Hanh Lam, Sylvia Musto, Frank Loganzo and Andreas Maderna are gratefully 
acknowledged. 
2.10.1 Cytotoxicity 
In order to confirm the biological activity reported by the isolation team, synthetic 
leiodermatolide (1) was tested against seven different human cancer cell lines. In all cases, GI50 
values in the low single-digit nanomolar scale were obtained (table 2.7) after an incubation 
period of four days. Impressively, this high antiproliferative activity was maintained when 
HEL92.1.7 leukemia cells were treated with leiodermatolide (entry 4). This human 
erythroleukemia cell line is known to express the permeability glycoprotein (Pgp) efflux 
transporter, also known as multidrug resistance protein 1, which is often believed to be the 
main reason for the development of resistances of leukemia cells against the treatment with 
chemotherapeutic agents.
[123]
 It acts by pumping the cytotoxic agent out of the cell and 
therefore lowers its bioavailability.
[124]
 This process is believed to be an evolutionary adaption 
to the threat imposed upon cells by potentially toxic substances.
[125]
 It seemed reasonable to 
assume that leiodermatolide (1) is therefore not an effective efflux substrate, although more 
evidence has to be acquired in the future. 
Table 2.7: Cytotoxic effect of synthetic leiodermatolide on a select panel of cancer cells. 
entry cell line histotype GI50 [nM] 
1 HL60 leukemia 1.0 
2 NB4 leukemia 0.4 
3 Raji leukemia 1.0 
4 HEL92.1.7 leukemia 0.9 
5 N87 gastric 2.4 
6 MDA-MB-361-DYT2 breast 3.5 
7 HT29 colon 2.5 
 
As a second step, the set of synthesized analogues (see overview in scheme 2.51) was tested for 
antiproliferative activity against the same panel of cancer cell lines. 
All compounds underwent a prescreening to select those with a detectable proliferative activity 
at concentrations below 1 µM. During this prescreening process, the analogue 119 containing a 
rigid cyclic acetal and compound 108, in which the -lactone was replaced by a simple methyl 
ester were excluded from further testing. Apart from these, some synthetic intermediates en 
route to the natural product (91) or to its derivatives as well as a variety of -lactone isomers 
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(70, epi-70, ent-70, ent,epi-70) did not meet the generous cutoff of 1 µM. Nevertheless, six 
compounds made it into the next round and were tested on the very same cell lines as the 
natural product (table 2.8). 
 
Scheme 2.51:  Selected leiodermatolide analogues submitted to the biological evaluation. 
Not surprisingly, the natural product itself was the most potent of the tested compounds. The 
immediate MOM-protected precursor 92 was rather inactive, except for two cell lines, where 
the potency is roughly tenfold reduced. However, acetate derivative 110 is only slightly less 
cytotoxic towards the indicated cancer cell lines than 1.  
Table 2.8: Cytotoxic effect of leiodermatolide analogues on cancer cells (96 h incubation, GI50 in nM). 
 HL60 NB4 Raji HEL92.1.7 N87 MDA-361 HT29 
1 1.0 0.4 1.0 0.9 2.4 3.5 2.5 
92 >100 >100 >100 >100 50.4 44.6 >100 
110 13.0 17.5 67.9 1.4 8.0 >10 5.9 
2 n.d. n.d. n.d. n.d. 144.9 306.5 199.3 
109 35.8 14.8 66.5 51.0 41.1 52.6 40.6 
107 n.d. n.d. n.d. n.d. 288.6 422.3 480.2 
 
Taken together, these data indicate that a hydrogen bond between C.7 OH and the proximal 
carbonyl is not only of structural but also of functional relevance. Nevertheless, these initial 
results suggest that the carbamate is not essential and therefore interchangeable. This might 
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gain importance when considering the opportunity of using this position as a possible 
anchoring site for attaching a monoclonal antibody. Antibody-drug conjugates are receiving 
massive attention in light of the possibility to further increase the selectivity of anticancer drugs 
by attaching them to selective carrier proteins.
[126]
 
Compound 2 bearing the enantiomeric -lactone side chain was less active by a factor of more 
than 50. Although the spectral differences of the diastereomeric compounds 1 and 2 were only 
subtle, they can be clearly distinguished by their biological activity. As a consequence, these 
biological results served as an ultimate proof of the original structure assignment. Since both 
ends of the molecule tend to have a strong influence on the activity, they are deemed crucial for 
obtaining high activity. The supposedly more flexible derivative 109 bearing only one olefin 
within the linking unit showed slightly reduced potency, although it remained reasonably 
active. 
In light of these findings, the retained activity of compound 107 for some of the cancer cell 
lines is remarkable, although it is significantly reduced when compared to the parent molecule 
1. Bearing only a truncated cyclohexanol moiety, structural stability and hydrophobic 
interactions seem to be the predominant structural feature for high activity, whereas the 
necessity to have an ester moiety as hydrogen bond acceptor appears non-critical. In line with 
this analysis, compound 108 was ruled out during the prescreening. 
 
2.10.2 Investigation of the mode of action 
For a better understanding of the cell cycle analysis carried out with leiodermatolide, it is 
essential to recall the general function of the cell cycle and the terms used for its 
description.
[127]
 In general, the cell cycle describes the process of cell division, in which a cell 
replicates into two identical daughter cells. It can be split into three individual phases, namely 
the interphase, the mitotic phase and the cytokinesis phase. The interphase is further divided 
into three parts, Gap1 (G1) phase, Synthesis (S) phase, and Gap2 (G2) phase. The first stage of 
the interphase (G1) is responsible for increasing the amount of centrioles, which are mainly 
composed of tubulin. After the G1 phase, the cell can either reversibly enter the G0 phase, 
which is an inactive idling or move on into the S phase. During the S phase, the replication of 
the genetic material in the form of DNA occurs until all chromosomes have been duplicated. In 
the subsequent G2 phase, the enzymes involved in cell duplication are produced.
[127]
 
The cell then enters the mitosis phase, which can further be partitioned into prophase, 
metaphase, anaphase and telophase.  
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i) During the prophase, all chromosomes assemble in pairs which are held together at the 
centromere. The centrioles then occupy positions at opposite poles of the cell and 
simultaneously install a network of microtubules, which is also known as the spindle 
apparatus. 
ii) At the end of this stage, the centromeres connect via their proteins to the end of the 
microtubules thereby causing an alignment at the equator of the cell; this is called the 
metaphase.  
iii) The anaphase starts with the degradation of the protein, which holds the sister 
chromatids together, causing them to migrate to opposite poles.  
iv) During the telophase, the stretching of the cell continues due to the ongoing lengthening 
of microtubules. A new membrane forms around the now separated chromosomes from 
the former cell membrane, although the final cell division takes place only during 
cytokinesis and involves vesicles from the Golgi apparatus.
[127]
 
The microtubules involved in this process are dynamic species, which are formed by 
polymerization of a heterodimeric species consisting of - and -tubulin.[128] Although their 
dynamics differ throughout the cell cycle, they are key proteins involved in the process of 
mitosis. This has made them an attractive target for cancer therapy. Two different concepts to 
interfere with tubulin dynamics are known:  
(1) destabilizing the microtubules causing depolymerization, as in the case of the vinca 
alkaloids
[129]
 or 
(2) stabilizing the microtubules by co-polymerization, as in the case of paclitaxel, 
discodermolide and the epothilones.
[130]
 
 
Scheme 2.52: Structures of selected previously reported antimitotic agents. 
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For both cases, the target binding pockets have been identified by co-crystallization in the 
past.
[131]
 Although the underlying mechanisms are different, the most potent effect of both 
cancer agent groups is the suppression of microtubule dynamics.
[132]
 
As described above, the exact mode of 
action of leiodermatolide was unknown 
at the outset of the project. Therefore, 
high content imaging analysis was 
performed in order to obtain 
information on cell cycle distribution, 
micronucleus induction, centrosome 
enumeration and interaction with 
tubulin.
[133]
 For the present study, 
human U2OS cells from a 15-year old 
female patient suffering from bone 
cancer were used for the image analysis. 
The cell cycle analysis was carried out 
by measuring the DNA content of 
DAPI-stained U2OS cells after 
exposure to leiodermatolide for 24 h. 
Figure 2.7 shows the relative changes 
in cell cycle population after treatment 
with 1 in direct comparison with cells 
treated only with DMSO as the 
negative control. The population of the subG1 phase, which accommodated less than two pairs 
of chromosomes, increased steadily between 0.9 and 4 nM, but decreased prior to the 
commencement of the G2/M phase. Strangely, the raise of subG1 population did not show a 
correlation to the cytotoxicity either; this was indicated by the fact that small cells were 
identified during the image analysis rather than the expected debris (figure 2.8). The G0/G1 
population started to decrease at concentrations above 8 nM, which can be interpreted as a 
reduction of the overall cell cycle activity. The same concentration caused a shift to high 
population of the S phase, which decreased upon increasing concentrations. Cells in G2/M 
phase were accumulated at concentrations of and above 18 nM in a dose-dependent way. 
  
Figure 2.7: Cell cycle distribution of treated cells compared 
to control after 24 h incubation. 
Figure 2.8: Representative images during cell cycle 
analysis. Arrows indicate cells in subG1 (<2N DNA). 
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Another indication for tubulin 
disruption is the measure of 
micronuclei that form upon treatment 
with a chemical substance. 
Micronuclei can form throughout the 
anaphase of mitosis; they are 
characteristic for chemicals that 
damage DNA strands or disrupt the 
mitosis process in general. Between 
4 nM and 8 nM concentrations, 1 
commenced to initiate the formation 
of micronuclei. It reached a maximum at concentrations of 37 nM with fivefold more 
micronucleated cells being observed when compared to the negative control. The absolute 
value is comparable to the positive control nocodazole. Even higher concentrations did not lead 
to a continuing rise in micronuclei formation, most likely due to increasing toxicity, which 
ultimately led to apoptosis.  
Furthermore, the effect on centrosome 
amplification was measured. Centrosome 
amplification can occur when the 
replication process is stimulated and thus 
decoupled from the cell cycle.
[134]
 The 
duplication sequence usually occurs during 
S phase, but can continue during the 
subsequent steps, when stimulated by 
chemical agents. Moreover, significant 
levels of centrosome amplification have 
been observed with untreated cancer 
cells.
[135]
 These stand in sharp contrast to healthy human cells, which generally do not exhibit 
agglomeration of centrosomes. Thus, healthy tissue is far less sensitive than malignant cells to 
therapeutics acting by centrosome declustering. 
Figure 2.10 details the concentration-dependent occurrence of amplified centrosomes, which is 
the percentage of cells containing more than two centrosomes. Unexpectedly, treatment of 
U2OS cells with leiodermatolide at levels below any observed toxicity induced a slight 
regression of amplified centrosomes when compared to the negative control. The maximum 
Figure 2.10: Centrosome amplification after 24 h. 
incubation. 
Figure 2.9: Micronuclei induction after 24 h incubation  
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effect was seen at 4 nM, for which the amount of amplified centrosomes was halved. In 
contrast, at concentrations above 8 nM, a significant concentration-dependent accumulation 
was noticed culminating in similar levels as the positive control nocodazole, which showed the 
highest concentration as evaluated during this study. 
Finally, immunofluorescence imaging was carried out with an antibody specific to -tubulin. 
Intriguingly, leiodermatolide caused abnormal spindle formation only above 8 nM 
concentration. Below this level, the recorded images do not show any effect on morphology 
with respect to -tubulin or on the shape and size of cell nuclei. Furthermore, the 
supernumerary occurrence of centrosomes (green, figure 2.11) confirms the observations made 
before.  
Taken together, all acquired data resemble the mode of action of a typical tubulin poison for 
concentrations above 8 nM. The observed effects induced by 1 at high concentrations are 
consistent with those observed for well-established tubulin-interfering drugs like nocodazole, 
colchicine, vinblastine and paclitaxel.  
 
 
 
In this context, it is of particular importance to note that leiodermatolide did not cause any 
effect on purified tubulin. Thus, the previously reported outcome of the tubulin polymerization 
assay,
[31]
 which showed no evidence for tubulin binding, was confirmed. Likewise, other 
biophysical assays like size exclusion chromatography (SEC LC-MS), tubulin-tryptophan 
quenching, an indicative test for the colchicine and vinca binding sites,
[136]
 and isothermal 
titration calorimetry
[137]
 did not indicate any interaction with purified tubulin. Since none of 
Figure 2.11: Fluorescence imaging of tubulin disruption (-tubulin: red, nuclei: blue, centrosomes: green). 
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these studies indicated a direct contact between tubulin and leiodermatolide, initially designed 
co-crystallization experiments were not carried out.  
In order to establish a possible alternative target, a broad panel screen with 50 different kinases 
was performed (figure 2.12). However, no significant inhibition was observed for the 
investigated kinases, even at 1 µM concentration of the natural product. The direct binding 
target of leiodermatolide therefore remains unknown. 
 
Figure 2.12: Kinase panel screen (c = 1 µM). green: 0% inhibition; yellow: 50% inhibition 
 
However, the behavior at concentrations below the 8 nM limit is unprecedented for an 
antimitotic agent and likely represents a novel mode of action. At these concentrations, no 
detectable toxicity for the employed cell line was observed. Nevertheless, leiodermatolide 
caused a significant drop of centrosome amplified cells compared to control. Similarly, the very 
same concentration caused an accumulation of subG1 cells with less than 2N DNA content. 
Taken together, the recorded data are suggestive of an arrest of the cell cycle prior to S phase 
but after completion of mitosis. Additionally, the replicated cells lack the full array of 
chromosomes and hypodiploidy was often recognized. The careful analysis of the samples 
obtained during the imaging studies showed that these cells are not debris and were correctly 
considered as small cells. 
The data acquired so far point at centrosome declustering as leiodermatolide's potential mode 
of action. The observed spindle dysfunctioning leading to mitotic arrest followed by a peak in 
the subG1 cell population are common features of previously described centrosome 
declustering drugs.
[138]
 Nevertheless, additional experiments including the staining for -tubulin 
and centrin2 as well as the measurement of phosphorylation of TACC3 as an indication for 
centrosome disruption in the subG1 population
[139]
 should be performed to obtain more insight. 
If this mode of action is confirmed in future studies, it seems likely that the enormous potential 
offered by this specific mechanism offers will encourage more research with this unique natural 
product.
[140]
 It should display a very high selectivity for tumor over healthy cells and may 
therefore reduce the side-effects commonly encountered with established anticancer agents. 
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3 Total synthesis of mandelalide A 
3.1 Isolation, structural discussion and biological activity 
Mandelalide A (124) was isolated along with three congeners, namely the mandelalides B, C, 
and D, from a Lissoclinum species found off the South African coast near Algoa Bay. The 
ascidian was collected by hand at a depth of 18 m from a white sand reef. After extraction of 
the raw material (15.1 g), bioassay-guided fractionation by reversed phase HPLC enabled the 
isolation of four novel natural products: mandelalides A (0.8 mg), B (0.5 mg), C (0.8 mg) and 
D (0.6 mg).
[141]
 Their structures (scheme 3.1) were proposed based on the analysis of 2D-NMR 
data. The relative configuration was established by analyzing the ROESY as well as 
homonuclear (
3
JH,H) and heteronuclear (
2
JC,H) coupling constants. The absolute configuration 
could be assigned after acidic cleavage of the sugar moiety and co-injection of the bis-silylated 
methanolysis product with both enantiomeric glycosides of known configuration. 
   
Scheme 3.1: Structures of mandelalides A – D as proposed by the isolation team. [141] 
Bridging oxygen atoms lead to the occurrence of an all-cis substituted THF as well as an all-cis 
substituted THP ring within the macrocyclic framework and reduce the actual ring size of 
mandelalide A to 21. Mandelalide A possesses 14 stereogenic centers, nine of which decorate 
the macrocyclic scaffold; additional five reside on the sugar moiety. Within the macrocycle lies 
a diene of (E,Z)-configuration and an ,-unsaturated ester. The carbon-carbon bond between 
C.24 and C.2 distinguishes mandelalides B, C and D (125, 126 and 127) from mandelalide A 
(124), and installs a supplementary -lactone characteristic for these compounds. Furthermore, 
the former double bond between C.2 and C.3 is now oxidized to a diol motif. The all-syn 
configuration of the four contiguous stereogenic centers between C.23 and C.3 found in 
mandelalides C and D is noteworthy and was anticipated to pose a serious synthetic challenge. 
Remarkably, the mandelalides A (124) and B (125) differ in their sugar moiety, which is a 2-
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methoxy L-rhamnosyl unit in 124, whereas 125 contains the epimeric C.4' sugar unit derived 
from 6-dehydro L-talose. 
In contrast, mandelalides C and D lack this glycosidic site and terminate in a free alcohol at 
C.7. Both compounds bear an additional stereogenic center at C.24 and differ only in the 
substitution pattern at this functional site. Moreover, 127 was found to degrad over the course 
of 12 months to deacylmandelalide D (128) by hydrolysis of the two butyrates. 
 
Scheme 3.2: Degradation product of mandelalide D and related madeirolides A and B. 
The structures of the mandelalide family are reminiscent of the equally scarce natural products 
madeirolides A (129) and B (130).
[142]
 Surprisingly, these compounds were isolated from a 
lithistid Leiodermatium sponge but contain the enantiomeric northern THF fragment.
[143]
 
However, the similarities of the southern THP fragment and the diene moiety clearly link the 
structures of these two compound classes. The different origins suggest an underlying 
biosynthetic pathway, perhaps by a common microbial symbiont. 
As the organic extract of the isolation showed promising cytotoxicity against three different 
cancer cell lines, mandelalides A and B were also tested. The pure compounds showed a half 
maximum inhibitory concentration (IC50) in the two-digit nanomolar range with mandelalide A 
being twice as active as its counterpart mandelalide B.  
Somewhat surprising, the related madeirolides exhibited no significant proliferative activity 
against pancreatic cancer cell lines, but are potent growth inhibitors against Candida albicans, 
thus displaying antifungal rather than antitumor properties.  
Table 3.1: Cytotoxicity of mandelalide A and B as reported by the isolation team. 
 IC50 
entry cell line
1)
 organic extract 124 125 
1 NCI-H460 0.7 µg/mL 12 nM 29 nM 
2 Neuro-2A 5.6 µg/mL  44 nM 84 nM 
3 MDA-MB-231 22.1 µg/mL  - - 
 
1) NCI-H460: human lung cancer cells; Neuro-2A: mouse neuroblastoma cancer cells; 
MDA-MB-231:human breast carcinoma. 
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These preliminary results clearly demanded a more systematic investigation of the biological 
activity. The rare natural occurrence rendered a reliable and robust access by total synthesis 
indispensable. Moreover, the challenging structural features as outlined above made the 
mandelalide family an attractive target. Being the biologically most active family member, 
mandelalide A was chosen as the primary objective for our synthetic endeavor. The (E,Z)-diene 
scaffold within the macrocycle offered an excellent opportunity to implement RCAM followed 
by semihydrogenation of the enyne as the key sequence of the total synthesis.  
 
3.2 Previous synthetic studies 
At the outset of this study, neither a completed total synthesis nor any synthetic studies towards 
a member of the mandelalide family had been described. However, shortly after the initiation of 
the project, the group of Paterson described the synthesis of the C.1 to C.11 fragment of the 
related madeirolide A.
[143]
 Their retrosynthetic strategy is outlined in scheme 3.3, which 
highlights the key reactions of the fragment synthesis. 
 
Scheme 3.3: Retrosynthetic analysis of the C.1 to C.11 fragment of madeirolide A by Paterson.
[143]
 
The macrocyclic framework was envisioned to be built up by a Yamaguchi macrolactonization, 
whereas the two fragments should be coupled by Stille cross-coupling. Vinyl iodide 131 was 
assembled by a Takai olefination and the cinerulose motif was attached by a glycosidation 
reaction. The all-cis configured THP ring was installed by an acid-mediated oxa-Michael 
addition on the ,-unsatured thioester of 132, which was constructed with a Horner-
Wadsworth-Emmons olefination reaction using 134. The stereogenic center at C.5 was 
introduced by a boron-mediated, asymmetric syn-aldol reaction of 133 and 135. Although the 
obtained fragment 131 showed good spectral overlap with the reported data for the natural 
product and thus confirmed the assignment made for this region, the synthesis required 18 steps 
in the longest linear sequence. A significantly shorter route was thus desired and addressed for 
the synthesis of the southern mandelalide fragment during the course of this investigation. 
Only after the total synthesis of the proposed structure of mandelalide A as a result of this 
thesis was published,
[144]
 a total synthesis of the proposed aglycone of mandelalide A was 
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described by Ghosh and co-workers.
[145]
 Furthermore, the group of Ye reported the successful 
synthesis and structure reassignment of mandelalide A
[146]
 shortly after identical results had 
been disclosed in our group.
[147]
 Consequently, these studies did not influence the retrosynthetic 
considerations nor any of the reactions carried out during the research outlined below and are 
therefore not discussed further. In contrast to our strategy, both approaches relied on a key 
cross-coupling between C.12 and C.13 and a Horner-Wadsworth-Emmons reaction to install 
the enoate motif at C.2 / C.3 (see Scheme 3.4 for numbering). 
 
3.3 Objectives 
Due to the seemingly promising biological profile, mandelalide A (124) was chosen as a target 
for total synthesis. The developed synthetic route was not only thought to confirm the structural 
assignment made by the isolation team, but also enable access to reasonable amounts of 
material to allow for a more detailed investigation of the biological properties. In view of these 
requirements, the overall strategy should be robust and scalable, and should rely on transition 
metal catalyzed reactions for C-C bond forming steps to establish an efficient pathway to the 
required material. 
As in the leiodermatolide case, the synthetic sequence should depend on RCAM followed by 
semihydrogenation as the key operations for the selective formation of the macrocycle. In order 
to expand the limits of alkyne metathesis, the metathesis reaction envisioned for ring-closure 
was supposed to involve a terminal alkyne, a structural motif that was previously beyond reach 
due to significant polymerization on contact with a metal alkylidyne. Therefore, terminal 
acetylenes have never been metathesized in the context of a complex natural product 
synthesis.
[148]
 The maturity of this recently developed method should therefore be challenged 
by the inevitable presence of a variety of polar functional groups in the mandelalide precursor. 
The chosen strategy should further traverse an advanced intermediate that allows access to 
mandelalides B, C and D. Thus, the attachment of the sugar moiety should take place after the 
framework of the macrocycle is built up in order to clear the way for the synthesis of family 
members by deviation from the original route. 
 
3.4 Retrosynthetic analysis 
The first disconnection removes the mono-methylated rhamnosyl unit from the macrocycle. As 
outlined above, this late introduction of the sugar unit should allow the diversification of a 
common macrocyclic intermediate and could, if successful, give access to all mandelalide 
family members. This strategic consideration further dictated the choice of protecting groups. 
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Since the primary alcohol at C.24 might be easily differentiated from its sterically more 
shielded secondary relatives, the two secondary alcohols at C.7 and C.21 had to be adorned 
with orthogonally cleavable protecting groups. They were chosen in a way that selective 
deprotection of the alcoholic functionalities at either C.7 or C.24 could be achieved. 
 
Scheme 3.4: Retrosynthetic analysis of mandelalide A: Late-stage introduction of the sugar moiety. 
As previously outlined, the (E,Z)-diene scaffold of the macrocycle was envisioned to be the site 
of ring-closure for the synthesis of mandelalide A (124). Two possible disconnections of 
macrocycle A were thus analyzed: The retrosynthetic cut between C.12 and C.13 seemed 
attractive (red, scheme 3.5), since a direct trans-hydrogenation of alkynes was recently 
developed in the group.
[149]
  
 
Scheme 3.5: Retrosynthetic analysis of the aglycone of mandelalide A. 
However, enynes could not yet be successfully engaged in this transformation and suffer from 
low or no conversions. This direct transformation is unmet in terms of efficacy, yet substitutes 
are well established and include the hydrosilylation/protodesilylation sequence.
[27, 150]
 Although 
this multistep alternative has already been fruitfully applied in natural product synthesis,
[28, 95e]
 
the cut between C.14 and C.15 seemed more viable since the direct (Z)-selective 
60 Total synthesis of mandelalide A 
 
semihydrogenation of an (E)-cycloenyne would furnish the desired (E,Z)-dienyl motif without 
detours. 
Thus, this approach was chosen and the macrocycle was retrosynthetically disconnected at the 
indicated site between C.14 and C.15 (blue, scheme 3.5). The key reaction sequence should 
involve the metathesis of the terminal acetylene subunit of D and would ultimately challenge 
the recently developed fusion of terminal and internal alkynes.
[148h]
 In analogy to the 
leiodermatolide case, an esterification reaction should connect the northern alcohol fragment D 
with southern acid fragment E. 
 
3.5 Synthesis of the southern acid fragment 
Within the southern fragment E, the enyne lies next to a methyl-bearing stereogenic center in 
the allylic position, which is fused to an all-cis substituted THP ring via a methylene linker. 
The pseudo-symmetric nature of the THP ring with all substituents in equatorial positions 
further led to the decision to construct this moiety first and introduce the functionalities on the 
side chains later. 
Thus, the enyne moiety was thought to be introduced by an (E)-selective olefination reaction, 
whereas the ,-unsaturated ester was envisioned to derive from an alkene cross metathesis 
reaction. The stereogenic center at C.11 was supposed to originate from a diastereoselective 
alkylation reaction using a chiral auxiliary. This led back to the THP ring G decorated with a 
primary alkyl halide, which was to be built up by a halo-etherification reaction. This 
transformation could be carried out with the C2-symmetric diol 136, which is literature known 
and can be prepared conveniently in one step from commercial 1,3-propanediol (137) by 
bidirectional iridium-catalyzed allylation as reported by the group of Krische.
[151]
  
 
Scheme 3.6: Retrosynthetic analysis of the southern acid fragment E. 
In the forward direction, the procedure of Krische et al. was reproducible even on multigram-
scale and afforded the desired diol 136 in good yield and diastereoselectivity.
[152]
 In order to 
determine the enantiomeric excess, it had to be converted into bis-(4-nitrobenzoate) 138 to 
attach a UV chromophore for HPLC analysis on a chiral stationary phase, which revealed an 
Total synthesis of mandelalide A 61 
 
excellent enantiomeric enrichment of >99%. However, the high cost of the (S)-BIPHEP ligand 
L6 might limit a further scale-up exercise. When cheaper (S)-BINAP was used as a substitute 
under otherwise identical conditions, similar levels of enantio- and diastereoselectivity were 
observed; unfortunately, the yield dropped to 37%. Additional experiments were carried out to 
reduce the catalyst loading or to recover the catalyst; yet, these efforts were not met with 
success and therefore abandoned. 
 
Scheme 3.7:  Bidirectional allylation of propanediol. Conditions: a) allyl acetate (10 eq.), [Ir(cod)Cl]2 (5 mol%), 
L1 (10 mol%), 3-nitro-4-chlorobenzoic acid (20 mol%), Cs2CO3, 1,4-dioxane, 90 °C, 71% (d.r. ≥ 
29:1, 99% ee); b) 4-nitrobenzoyl chloride, DMAP (5 mol%), pyridine, CH2Cl2, rt, 94%. 
With diol 136 in hand, the desymmetrizing iodo-etherification was investigated. From a 
mechanistic understanding, this reaction should proceed through a cyclic chair-like transition-
state TS1, in which all substituents populate pseudo-equatorial positions. The all-cis isomer 
139 should therefore be favored over the 9-epi isomer 140.  
Table 3.2: Selected results of the haloetherification. . Conditions: a) Zn, I2 (cat.) DMA, 80 °C, 80%. 
 
entry conditions 
comb. yield, 
(pure 139) [%] 
139:140
1)
 
1 I2, NaHCO3, MeCN, −20 °C 65 4.3:1 
2 NIS, CH2Cl2, 0 °C 44 3.8:1 
3 (sym-collidine)2I
+
PF6
-
, MeCN, 0 °C to rt - - 
4 Hg(OAc)2, toluene, 0 °C; then I2 - - 
5 I2, KOt-Bu, THF, −78 °C to rt - - 
6 I2, MeCN, −35 °C 48 3.5:1 
7 I2, NaHCO3, hexanes or CH2Cl2, −78 to 0 °C < 10 - 
8 I2, NaHCO3, THF, −78 °C 65 5:1 
9 I2, NaHCO3, MeCN, −40 °C 81 (65) 5:1 
 
1) determined by integration of 1H NMR signals. 
This reaction had been previously described by Krische on a substrate bearing additional 
methyl groups at C.4, C.6 and C.8 and resulted in the formation of a single diastereomer.
[152]
 
For the present substrate however, identical reaction conditions led to a slight preference for 
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139 of 4.3:1 (table 3.2, entry 1) with rather moderate yield. In order to improve this outcome, 
several electrophilic reagents known to induce such a cyclization were tested on diol 136 
(entries 2-4), yet no improvement was reached.
[153]
 
The use of molecular iodine was inevitable and the accompanying base as well as the solvent 
was next varied (entries 5-7).
[154]
 Optimal results were obtained in THF at −78 °C (entry 8) or 
in MeCN at −40 °C (entry 9) with an acceptable diastereomeric ratio of 5:1 and good yields. 
The two diastereomeric compounds were fully separated after three consecutive 
chromatographic purifications.  
The iodoetherification was further attempted with a mono-silylated variant of 136 to increase 
the steric bulk in the equatorial position at C.7, but a reduced diastereoselectivity of 2:1 in favor 
of the all-cis substituted product was observed.
[155]
 To ensure recovery of the valuable material, 
especially in view of the high costs of the bis-allylation, the undesired diastereomer was 
converted back to diol 136 upon treatment with activated Zn in DMA at elevated 
temperature;
[155, 156]
 the use of t-BuLi gave far inferior results. 
Since different stereochemical outcomes of iodo-etherification reactions during THP syntheses 
had previously been reported,
[157]
 the major product was carefully assigned by analysis of the 
NOESY spectrum after silylation (figure 3.1). Although no direct NOE signals were observed 
between the axial protons at C.5, C.7 and C.9 (which were detected on later intermediates), the 
other contacts around the six-membered ring clearly support the assignment. Additionally, the 
pseudo-symmetric nature of the signals is suggestive of an all-cis substituted THP ring. Further 
evidence was gained from the coupling constants recorded for 141 in deutero-benzene. The 
large 
3
J of H.8ax (1.10 ppm, ddd, J = 12.2, 11.1, 11.0 Hz) are indicative of one geminal and two 
axial vicinal couplings; whereas for H.8eq (1.74 ppm, dddd, J = 12.3, 4.4, 2.3, 2.3 Hz) one 
geminal and two equatorial vicinal coupling constants were observed. The coupling constants 
of H.9 (2.93 ppm, dddd, J = 11.2, 6.6, 4.6, 2.0 Hz) can be linked to H.8ax (11.2 Hz), H.10a 
(6.6 Hz), H.10b (4.6 Hz) and H.8eq (2.0 Hz) and are in full agreement with the stereochemical 
assignment. 
 
Figure 3.1: Observed NOE contacts for the major etherification isomer after silylation (141, C6D6, 400 MHz). 
Next, the introduction of the stereogenic center at C.11 was addressed after converting the 
secondary alcohol into the corresponding TBS-ether 141. Initial experiments had shown that 
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the enolate of the Evans oxazolidinone 13 failed to undergo the desired alkylation.
[158]
 This is 
likely caused by the stereoelectronic bias of alkyl iodide 141. The proximal oxygen lone pairs 
of the ether along with the steric demand imposed by the -branched substitution pattern render 
139 a particularly challenging electrophile.  
 
Scheme 3.8:  Asymmetric alkylation with alkyl iodide 141. Conditions: a) TBSOTf, 2,6-lutidine, CH2Cl2, 0 °C, 
96%; b) R11, LDA, HMPA, THF, 0 °C; then 141, 74%; c) 1N aq. HCl, 100 °C, 44%; d) R12, LDA, 
LiCl, THF; then 141, 76%; e) LDA, BH3·NH3, THF, 0 °C to rt, 96% (97:3 d.r.). 
On this basis, the more reactive dianionic enolates of R11 and R12 were investigated. The 
prolinol-derived amide R11
[159]
 was deprotonated with LDA and treated with alkyl iodide 141 
in the presence of HMPA. The desired adduct 142 was formed and could be isolated in 
reasonable yields; however, the conditions for the cleavage of the auxiliary required 1N HCl at 
reflux temperature and simultaneously cleaved the silyl ether at C.7. The use of the Myers 
pseudoephedrine-derived amide R12 was more promising:
[160]
 Although somewhat forcing 
conditions (48 h at 45 °C) were needed to achieve reasonable rates and full conversion, the 
alkylated adduct 144 was isolated in 76% yield.
[161]
 Even more importantly, the subsequent 
reduction was achieved under mild conditions using LiNH2·BH3 and furnished the desired 
primary alcohol 145 with excellent yield and diastereoselectivity.
[160]
 
The stage was set for the envisioned alkene cross-metathesis reaction with methyl acrylate,
[91]
 
which proceeded at ambient temperature when catalyzed by the Hoveyda-Grubbs 2
nd
 
generation catalyst C7. The ,-unsaturated ester 146 was formed in 83% yield after separation 
from minor amounts of the (Z)-isomer. The primary alcohol was then oxidized with Dess-
Martin periodinane to give aldehyde 147 for the olefination reaction.  
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Scheme 3.9:  Preparation of aldehyde 147. Conditions: a) methyl acrylate (5 eq.), C1 (3 mol%), CH2Cl2, rt, 83% 
(+7% Z-isomer); b) DMP, CH2Cl2, 0 °C to rt, 77%. 
Exposure of aldehyde 147 to the lithium enolate of R13 gave the desired product 148 as an 
inseparable mixture of (E)- and (Z)-isomers (table 3.3, entry 1). The yield was moderate, 
ranging between 41% and 54%, and could not be improved despite considerable 
experimentation. Change of the counterion (entry 2) or inversion of the addition protocol did 
not improve the outcome (entry 3). The detection of the water-soluble by-product 149 by ESI-
MS and 
1
H NMR serves as an explanation for this disappointing result: after successful 
installation of the (E)-enyne, the enolate of the phosphonate reacts further with the ,-
unsaturated ester, thus diminishing the isolated yield.  
Table 3.3:  Selected conditions for the olefination of 147. 
 
 
 
entry reagent conditions addition type yield [%] E / Z
 1)
 
1 R13 LiHMDS, THF, −78 °C Barbier
2)
 41-54 7 : 1 
2 R13 KOt-Bu, THF, −78 °C  Barbier
2)
 51 1 : 1 
3 R13 LiHMDS, THF, −78 °C  preformed enolate 42 4 : 1 
4 R14 LiHMDS, THF, −78 °C  preformed enolate 23 8 : 1 
5 R15 n-BuLi, THF, −78 °C preformed enolate 12 7 : 1 
6 R16 PhLi, KOt-Bu, t-BuOH, THF, 0 °C preformed enolate - - 
 
1) determined by integration of olefinic 1H NMR signals. 2) Barbier: the base was added to a premixed solution of 
aldehyde and reagent at the indicated temperature. 
 
In the following, the methyl groups of the phosphonate were replaced by more bulky isopropyl 
groups (R14, entry 4), but the yield remained disappointingly low. The use of lithiated 
trimethylpropargylphosphonium bromide (R15, entry 5) also furnished the desired product with 
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acceptable selectivity; yet, only trace amounts could be isolated. Use of the 
triphenylpropargylphosphonium bromide R16 (entry 6) under Schlosser conditions resulted in 
the formation of a complex mixture, which was not further analyzed.  
A more reliable, two-step alternative was developed, which commenced with an (E)-selective 
Takai olefination to give vinyl iodide 150.
[162]
 Initially, low yields were obtained due to 
problems associated with the removal of the chromium waste; however, this issue could be 
solved by quenching the reaction mixture with an aq. serine solution. Serine is thought to 
sequester the excess amount of chromium salts and its addition ensured an easy workup 
procedure.
[163]
 Furthermore, the desired (E)-isomer 150 was easily separated from the undesired 
(Z)-isomer by column chromatography and subsequently subjected to a modified Suzuki 
propynylation protocol developed in the Fürstner group.
[164]
 This protocol allowed the enyne to 
be obtained in 58% yield over two steps as a single olefin isomer.  
 
Scheme 3.10:  Two-step alternative for the installation of the enyne. Conditions: a) CHI3, CrCl2·THF, THF, −8 °C, 
aq. serine workup, 72% (+8% (Z)-isomer); b) sodium propyne, (MeO)3B, [Pd(dppf)Cl2]·CH2Cl2 
(10 mol%), THF, 70 °C, 81%; c) TMSOK, Et2O, rt, 151: 80% 152: 7%. 
Lastly, the ester was saponified with TMSOK at ambient temperature to give the desired acid 
151 along with minute amounts of product 152, in which the double bond isomerized out of 
conjugation. Both compounds could be separated by flash chromatography; as it turned out 
however, this deconjugation could not be avoided during the subsequent esterification step (see 
chapter 3.8). As a consequence, the two compounds were used as a mixture upon scale-up in 
order to simplify the purification process. 
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3.6 Synthesis of the northern alcohol fragment 
The northern alcohol fragment bears an all-cis substituted THF ring, the terminal alkyne for the 
envisioned ring-closure and three alcohol functionalities, two of which had to be protected to 
ensure a selective esterification of the secondary alcohol at C.23 with the southern fragment. 
TBDPS groups were chosen in order to allow the TBS group of the southern fragment to be 
selectively released under acidic conditions. The alkyne was thought to be assembled last 
during the fragment synthesis (scheme 3.11). The all-cis substituted five-membered ring of H 
was supposed to be built up by an electrophile-induced cyclization of an alcohol at C.17 onto 
an alkene in a formal 5-endo mode. The adjacent stereogenic center at C.21 was envisioned to 
derive from an Evans-Tishchenko reaction that would simultaneously differentiate the two 
secondary alcohols at C.21 and C.23. The -hydroxy ketone J displayed a common 
intermediate of two different approaches that will be discussed separately in the following.  
   
Scheme 3.11: Retrosynthetic analysis of the northern alcohol fragment D for the installation of the THF ring. 
 
3.6.1 1
st
 generation strategy: Meyer-Schuster rearrangement 
Initially, enone J was meant to be constructed by a Meyer-Schuster rearrangement of the 
propargylic acetate K (scheme 3.12). This was designed to derive from addition of a lithiated 
alkyne M into aldehyde 152. The terminal alkyne was further disassembled into epoxide 155, 
which should be opened by TMS-acetylene 154. Aldehyde 152 on the other hand could be 
derived from the corresponding alkene by ozonolysis, which in turn was deemed to be 
composed from aldehyde 153 by an asymmetric syn-crotylation reaction. 
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Scheme 3.12: Retrosynthetic strategy for enone J. 
Aldehyde 153 was easily prepared by copper-catalyzed TEMPO/air oxidation of the 
commercially available mono-benzylated 1,3-propanediol (156) as reported by Stahl and co-
workers,
[58]
 which was significantly more convenient than the well-established Swern reaction. 
The subsequent syn-crotylation was first tested with the crotylboron reagent generated from 
(−)-Ipc2BOMe and the potassium salt of cis-but-2-ene as reported by Brown;
[165]
 however, the 
enantiomeric excess was unsatisfactory (84% ee) and the product isolation difficult (29% 
yield).  
 
Scheme 3.13:  Synthesis of aldehyde 152 using a syn-crotylation protocol. Conditions: a) [Cu(MeCN)4]BF4 
(5 mol%), 2,2'-bipyridine (5 mol%), TEMPO (5 mol%), NMI (10 mol%), MeCN, air, 94%; b) (R,R)-
R17, Sc(OTf)3 (5 mol%), CH2Cl2, −78 to 0 °C, 82% (d.r. 98:2, 94% ee); c) TBSOTf, 2,6-lutidine, 
CH2Cl2, 0 °C, 96%; d) O3, CH2Cl2, −78 °C; then PPh3, rt, 152: 91%, 159: 4%. 
The chiral crotyl silane described by Leighton and co-workers proved to be more effective.
[166]
 
The synthesis of the chiral diamine ligand was straightforward and was carried out on a 40 g 
scale. The reagent R17 failed to crystallize as described,
[167]
 but was judged pure on the basis of 
NMR analysis and used as solution in the crotylation reaction. After slight modification of the 
protocol that involved the addition of Sc(OTf)3 at −78 °C, a reproducible process was 
established, which afforded the crotylated product 157 in good yield and enantioselectivity 
(94% ee). After routine silylation of the secondary alcohol, ozonolysis furnished 152, which 
was accompanied by over-oxidized aldehyde 159. This side reaction could be almost 
completely suppressed by lowering the temperature to −78 °C allowing aldehyde 152 to be 
isolated in excellent yield after reductive workup.  
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For the synthesis of the alkyne fragment, commercial (S)-glycidol (155) was converted into 
silyl ether 160. The epoxide opening with lithiated trimethylsilylacetylene in the presence of 
BF3·Et2O proceeded without incident and gave alcohol 161 in high yield on a 15 g scale. 
Although the subsequent silyl cleavage off the alkyne is literature known and reported to afford 
162 in 99% yield,
[168]
 the reaction suffered from 1,2-silyl migration and a mixture of the desired 
compound 162 and primary alcohol 163 was obtained.
[169]
 Exposure of this mixture to classical 
silylation conditions at low temperature masked selectively the primary alcohol and allowed for 
the facile purification of 162.  
Compound 162 was then decorated with different protecting groups to allow for the systematic 
investigation of the Meyer-Schuster rearrangement. Thus, triethylsilyl ether 164, benzoate 165, 
and nitrobenzoate 166 were prepared. 
 
 
Scheme 3.14:  Synthesis of several protected alkynes of type M. Conditions: a) TBDPSCl, imidazole, CH2Cl2, 0 °C 
to rt, 94%; b) 154, n-BuLi, BF3·Et2O, THF, −78 °C, 91%; c) K2CO3, MeOH, 0 °C, 97% (162/163 
8:1); d) TESCl (0.15 eq.), NEt3, DMAP, CH2Cl2, −78 °C, 76%; e) TESCl, NEt3, DMAP, CH2Cl2, 
0 °C, 164: 87%; f) benzoyl chloride, NEt3, DMAP, CH2Cl2, 0 °C, 165: 79%; g) 4-nitrobenzoyl 
chloride, NEt3, DMAP, CH2Cl2, 0 °C, 166: 87%. 
The alkyne fragments were joined with aldehyde 152 en route to the propargylic acetate as the 
Meyer-Schuster precursor. The alkynyl lithium species was generated by treatment with either 
n-BuLi (for 162 and 164) or LDA (for 165 and 166), followed by the addition of aldehyde 152 
at low temperature. In case of the triethylsilyl ether 164, the reaction mixture was quenched 
with acetyl chloride to yield propargylic acetate 167 immediately, albeit in low yield. In all 
other cases, the propargylic alcohols were isolated in moderate yields and separately treated 
with acetic anhydride to yield a diverse set of substrates for the Au-catalyzed rearrangement. 
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Scheme 3.15:  Synthesis of rearrangement precursors 167-170. Conditions: a) n-BuLi (2 eq.), THF, −78 °C; then 
152, 60%; b) Ac2O, NEt3, DMAP, CH2Cl2, 0 °C, 168: 84%, 169: 60%; 170: 76%; c) n-BuLi, THF, 
−78 °C; then 152, −78 to 0 °C; then AcCl, 0 °C to rt, 35%; d) LDA, THF, -78 °C; then 165 or 166, 
−78 to 0 °C, R=Bz: 58%; R=4-NO2-Bz: 40%. 
Next, the envisioned gold-catalyzed Meyer-Schuster rearrangement was investigated. 
Regardless of the gold source, solvent or temperature,
[170]
 the silyl ether 167 led to the 
formation of a complex mixture (scheme 3.18) and the desired compound 171 could never be 
isolated in pure form. Two major components were identified by 
1
H NMR analysis as well as 
mass spectrometry, to which structures 172 and 173 were assigned. This result indicated that 
the silyl ether interfered by attacking either the transitionally activated alkyne prior to 
rearrangement or the allene after rearrangement. From a mechanistic point of view, it cannot be 
ruled out that the silyl ether is first cleaved and the released secondary alcohol reacts with the 
activated alkyne.  
 
Scheme 3.16: Attempted Meyer-Schuster rearrangement of 167 and observed by-products. 
Although it remained unclear at which stage the triethylsilyl ether was cleaved,
[171]
 it was 
speculated that the use of electron-withdrawing protecting groups like acetate or benzoate 
would diminish the nucleophilicity of the oxygen atom at C.23 and thus the formation of 
unwanted side-products. Indeed, this was the case with substrates 168, 169 and 170; the Meyer-
Schuster rearrangement proceeded cleanly in the presence of cationic NHC-Au(I) complexes in 
wet THF.
[172]
 As a consequence, the targeted enones 174, 175 and 176 could be isolated in 
good yields and high purity after silica gel chromatography. 
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Scheme 3.17:  Succesfull Meyer-Schuster rearrangements. Conditions: a) [(IPr)AuCl] (6 mol%), AgSbF6 (6 mol%), 
THF/H2O 39:1, 60 °C, 174: 79%; 175: 73%; 176: 73%; b) K2CO3, MeOH, 0 °C to rt, 84% (177/178 
8:1). 
Next, the ester protecting group had to be hydrolyzed. Even under mild conditions, scrambling 
of the silyl group occurred and a mixture of the desired secondary alcohol 177 and the primary 
alcohol 178 was obtained that could not be separated by chromatographic means.
[169]
 Since 
reductive methods would also reduce the ketone, it became apparent that only an entirely 
different strategy would pave a reliable route to the key enone intermediate. Furthermore, the 
sequence described above was deemed too long to ensure reasonable material supply for the 
subsequent steps and the endgame. A shorter approach with fewer protecting group operations 
was thus drafted and developed as disclosed below.  
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3.6.2 Revised strategy: olefin cross metathesis 
The revised retrosynthetic analysis is based on an olefin cross-metathesis reaction that should 
selectively built up the thermodynamically favored (E)-enone. This idea led to compound 157, 
which had already been synthesized during the first generation approach, and enone 179, which 
was accessible by addition of a vinyl magnesium species onto amide 180. The latter compound 
was thought to derive from a carbonylative epoxide opening in the presence of a morpholine 
species that would trap the intermediate acyl metal species.  
 
Scheme 3.18: Revised retrosynthetic analysis of enone J. 
In the forward direction, epoxide 160 was subjected to carbon monoxide (1 atm), N-
(trimethylsilyl)morpholine and catalytic amounts of dicobalt octacarbonyl as reported by the 
Jacobsen group.
[173]
 This reaction mandates the solvent and the silylated morpholine to be 
rigorously dry; otherwise, a significant drop in yield was observed. Moreover, reproducible 
results were only obtained when the reaction mixture was concentrated and directly loaded onto 
silica gel without hydrolysis of the secondary TMS group, which was cleaved in the subsequent 
step anyway.  
The addition of vinyl magnesium bromide was troublesome since the released morpholine 
underwent an aza-Michael addition to the produced enone 179 upon workup.
[174]
 In order to 
reduce the electrophilicity of the 1,4--acceptor, a propenyl Grignard reagent was used instead. 
Moreover, the reaction mixture was cooled to −78 °C before being poured via canula into 
diluted hydrochloric acid, which ensured protonation of the amine and therefore inhibited the 
aza-Michael addition process. Enone 181 was obtained in high yield (83%) as an 
inconsequential mixture of (E/Z)-isomers in readiness for the envisioned cross metathesis. 
 
Scheme 3.19:  Synthesis of enones 179 and 181. Conditions: a) [Co2(CO)8] (8 mol%), N-(trimethyl-
silyl)morpholine, CO (1 atm), EtOAc, 74%; b) vinylmagnesium chloride, THF, −78 to 0 °C, 179: 
41%; c) propenylmagnesium bromide, THF, −25 °C; then −78 °C, 0.75 M HCl, 181: 83% (E/Z = 
2:1).  
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After routine silylation of alcohol 157, the stage was set for the fragment coupling via cross 
metathesis. Intriguingly, the Hoveyda-Grubbs 2
nd
 generation catalyst C7 reacted only with the 
sterically more accessible (Z)-isomer of 181, whereas (E)-181 was reisolated. Resort to the 
slightly more active Zhan-1B catalyst C8 allowed this problem to be solved and cleanly 
generated the desired enone with high (E)-selectivity (>19:1). To retain a high catalytic activity 
over the course of the reaction, the metal alkylidene was added in three portions. The key enone 
183 was thus produced in only 4 steps in the longest linear sequence, which compares 
favorably to the first generation strategy (8 steps l.l.s.). 
 
Scheme 3.20:  Fragment coupling via cross metathesis. Conditions: a) TESCl, NEt3, DMAP, CH2Cl2, 0 °C, 90%; b) 
C7 (4+2+2 mol%), CH2Cl2, reflux, 79%. 
The anti-configured 1,3-diol was subsequently introduced by an Evans-Tishchenko reaction 
with excess isobutanal.
[52]
 To this end, SmI2 was freshly synthesized from Sm and 
diiodoethane, since the reaction with commercial SmI2 solution led to prolonged reaction times 
and substantial decomposition.
[175]
 Not only was the stereogenic center of 184 formed with 
excellent stereoselectivity, but the alcohol at C.23 was simultaneously masked as an ester that 
provided the crucial discrimination of the two secondary alcohols. The alcohol at C.21 was 
elaborated into the corresponding TBDPS ether and the triethylsilyl group removed under 
moderately acidic conditions to give the secondary alcohol 185. 
 
Scheme 3.21:  Installation of the 1,3 anti-diol motif. Conditions: a) i-PrCHO, SmI2 (35 mol%), THF, −50 °C, 78% 
(d.r. > 19:1); b) TBDPSCl, imidazole, CH2Cl2, 0 °C to rt, 87%; c) CSA (30 mol%), CH2Cl2/MeOH 
2:1, 0 °C, 97%. 
Inspired by the reports from Lipshutz
[176]
 and Mihelich,
[177]
 the homoallylic alcohol 185 was 
treated with phenylselenyl chloride (table 3.4, entry 1), which was expected to induce the 
highest selectivity. However, a disappointing 2:1 mixture of diastereoisomers was produced 
without reaching full consumption of the substrate. As alternatives, N-phenylselenophtalimide 
(N-PSP, entry 5) and phenylselenyl bromide (entry 2) were employed, causing an increase of 
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diastereoselectivity; yet, the reaction stopped at half conversion and several by-products began 
to form. It was speculated that the generated acid accounts for this observation and basic 
additives were therefore investigated. Surprisingly, the reactivity was completely shut down by 
addition of either homogeneous (entry 3) or heterogeneous bases (entry 4).
[178]
 Iodine as an 
electrophilic mediator led to a stereorandom cyclization,
[179]
 and the commitment of a C.17 
OH-silylated cyclization precursor was also not fruitful.
[180]
  
Table 3.4:  Representative results of the cyclization of 185 for the construction of the THF ring. 
 
entry reagent conditions 
conv.
1)
  
(yield) [%] 
186 / 187
2)
 
1 PhSeCl MeCN, −40 °C to rt 30 2 : 1 
2 PhSeBr MeCN, −40 °C to rt 54 4.4 : 1 
3 " 2,6-di(t-Bu)pyridine, MeCN, rt - - 
4 " K2CO3, MeCN, rt - - 
5 N-PSP PPTS, CH2Cl2, rt 53 4.3 : 1 
6 " TFA, Ph3P=S, CH2Cl2, rt 100 (76) 7.4 : 1 
7 " TFA, Ph3P=S, CH2Cl2, −40 to −20 °C 100 (84) 14 : 1 
 
1) determined by analysis of the crude 1H NMR; 2) determined by HPLC analysis of a crude 
sample. 
Fortunately, activation of N-PSP with catalytic amounts of Lewis basic 
triphenylphosphinesulfide in the presence of a Brønsted acid, as reported by Denmark, resulted 
in the selective formation of 186, provided that the transformation was carried out at low 
temperatures (entry 7).
[181]
 Under optimized conditions, the crucial cyclization was successfully 
performed on a gram-scale. 
The careful analysis of the NOESY spectra of both compounds allowed for a stereochemical 
assignment. As depicted in figure 3.2, the major isomer 186 showed NOE correlations of H.20 
with H.17 and H.18, whereas these contacts were missing in the minor isomer 187. 
Furthermore, the NOE contacts of the minor isomer implied spatial proximity of H.20 and the 
methyl group at C.18. Another indication for this assignment was gained by comparison of the 
chemical shifts of H.19 next to the selenyl moiety. In compound 186, this proton has two syn-
alkyl neighbors, which cause an upfield shift ( = 2.93 ppm) as opposed to the very same 
proton of compound 187 flanked by only one syn-alkyl group ( = 3.69 ppm). Comparison with 
literature values in similar systems are in full agreement with these conclusions.
[177, 182]
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Figure 3.2:  Key NOE contacts of the THF region of both isomers and chemical shifts of H.19 leading to the 
structure assignment (CDCl3, 600 MHz). 
Next, the simultaneous removal of the selenyl- and benzyl-moieties was investigated. However, 
when 186 was treated with Raney nickel under hydrogen atmosphere, the cleavage of both 
functionalities occurred, yet it was accompanied by reduction of one phenyl ring of the silyl 
protecting groups in varying amounts. As a consequence, the phenylselenyl entity was first 
removed under free-radical conditions using AIBN and tributyltin hydride followed by the 
reductive cleavage of the benzyl group over Pearlman's catalyst. 
 
Scheme 3.22:  Synthesis of primary alcohol 189. Conditions: a) n-Bu3SnH, AIBN, toluene, 80 °C, 93%; b) 
Pd(OH)2/C (cat.), H2 (1 atm), EtOH/EtOAc (9:1), 88%. 
Oxidation of the primary alcohol occurred readily upon contact with Dess-Martin periodinane. 
Treatment of aldehyde 190 with diazophosphonate R18 under standard Ohira-Bestmann 
conditions (K2CO3, MeOH) resulted in the formation of the desired alkyne 191;
[183]
 however, 
the compound was obtained as a 2.3:1 diastereomeric mixture at C.17. This epimerization 
likely occurred via a retro-oxa-Michael/Michael process. This erosion of stereochemical 
information could be impeded by preforming the reactive anionic phosponate with 
stoichiometric amounts of NaOMe at −78 °C prior to addition of aldehyde 190.[184] Once the 
reaction mixture was warmed to −55 °C, a heavy gas evolution indicated that the reaction took 
place. Under these conditions, the terminal alkyne 191 was isolated virtually as a single isomer. 
 
Scheme 3.23:  Construction of terminal alkyne 191. Conditions: a) DMP, CH2Cl2, 0 °C to rt, b) R18, NaOMe, 
THF, −78 °C; then 190, −78 to −50 °C, 93% (d.r. ≥ 98:2). 
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At this stage, elaboration into the methyl-capped alkyne was investigated in case the alkyne 
metathesis with the terminal alkyne would fail. Therefore, the methylation of the alkyne was 
validated with compound 191. After deprotonation with LDA and quenching with methyl 
iodide, only trace amounts of the alkylated product were observed by mass spectrometry. The 
addition of HMPA significantly increased the conversion and led to the isolation of a mixture 
of mono- and bis-methylated products. As evident from the 
1
H NMR spectrum, the majority of 
methylation occurred at the acidic -position of the ester protecting group. The similar pKA 
values of the alkyne and the ester proton prohibited a selective deprotonation and rendered a 
selective mono-methylation impossible. The carcinogenic properties of HMPA encouraged the 
search for a less toxic alternative. The complete bis-methylation with excess base and methyl 
iodide was tried, but always gave mixtures of mono- and bis-methylated species 192 and 193. It 
was therefore decided to skip further experiments regarding the methylation and first 
investigate the terminal alkyne metathesis, which seemed attractive in terms of stepcount and 
with respect to the novelty of the envisioned cyclization.  
 
Scheme 3.24:  Attempted methylation of 191. Conditions: a) LDA, MeI, HMPA, THF, −78 to 0 °C. 
To complete the northern alcohol fragment, the isobutylester of 191 was cleaved under 
reductive conditions (DIBAl-H) rather than by hydrolysis to avoid scrambling of the silyl 
groups as previously observed (scheme 3.16). The alcohol fragment 194 was thus synthesized 
in a longest linear sequence of 13 steps starting from commercial material. 
 
Scheme 3.25:  Completion of the alcohol fragment. Conditions: a) DIBAl-H, toluene, −78 °C, 97%. 
 
3.7 Synthesis of the sugar fragment 
Two different strategies were explored in parallel and will be discussed successively. The 
results described in chapter 3.7.1 were obtained in collaboration with Ms. Katharina Holthusen 
during a six week research stay in our laboratory. 
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3.7.1 Selective bis-acetal approach 
The presence of a methoxy group at the C.2' position required several protecting group 
manipulations on commercial rhamnose. The strategy followed in here was based on the 
selective formation of a bis-acetal engaging the two equatorial alcohols at C.3' and C.4' as 
originally developed by Ley and co-workers. This functionalization would allow for the 
selective methylation of the remaining alcohol at C.2'. The overall retrosynthetic strategy is 
outlined in scheme 3.26. 
 
Scheme 3.26: Retrosynthetic analysis of the rhamnosyl donor B. 
As an entry point, L-rhamnose (195) was treated with allyl alcohol in acidic media to install the 
allyl glycoside. Alternatively, a benzyl group was implemented, but slightly lower yields were 
obtained in the following steps. 
The two equatorial alcohols were then transformed into the bis-acetal 197 upon treatment with 
butane-2,3-dione in acidic medium.
[185]
 The alternative bis-acetal from 1,2-cyclohexadione 
gave inferior results and was not further heeded.
[186]
 The subsequent methylation occurred 
without incident after deprotonation of the remaining alcohol with sodium hydride and 
furnished 198 in moderate yield. The bis-acetal was exchanged for more labile acetate groups 
in a two-step process to ensure mild deprotection conditions during the endgame of the 
mandelalide A synthesis. 
 
Scheme 3.27:  Selective introduction of the methyl group. Conditions: a) allyl alcohol, H2SO4 (cat.), reflux, 78%; 
b) butane-2,3-dione, MeC(OMe)3, pTsOH·H2O (cat.), MeOH, reflux, 72%; c) NaH, MeI, DMF, 0 °C 
to rt, 64%; d) TFA/H2O 20:1; e) Ac2O, DMAP, NEt3, CH2Cl2, 0 °C to rt, 68% over 2 steps. 
Suitable reaction conditions for the removal of the allyl group were found after a short 
screening. The best result was obtained with SeO2,
[187]
 which presumably causes an allylic 
oxidation; the generated hemiacetal spontaneously collapses to release the deprotected 
rhamnosyl donor as an inconsequential mixture of anomers. Finally, the trichloracetimidate 
moiety was introduced in the presence of trichloroacetonitrile in excellent yield and a single 
isomer of 201 was generated.  
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Scheme 3.28:  Synthesis of the trichloroacetimidate 201. Conditions: a) SeO2, HOAc, 1,4-dioxane, reflux, 86%; b) 
Cl3CCN, Cs2CO3, CH2Cl2, 98%. 
 
3.7.2 Selective acetylation approach 
Simultaneously, a different strategy was explored that relied on the selective acetylation of the 
equatorial alcohol at C.3' in the presence of the neighboring alcohol at C.2'. The retrosynthetic 
scheme 3.32 shows that once two acetates are installed, the methylation of Q should give the 
appropriately functionalized rhamnosyl donor 201. Compound Q was thought to be assembled 
from R by selective acetylation of the equatorial alcohol at C.3'. Diol R was further traced back 
to the acetal S, which should preferentially be formed with the two alcohols in syn-relationship 
at C.2'/C.3' as opposed to the anti-configured diol at C.3'/C.4'.  
 
Scheme 3.29: Alternative retrosynthetic analysis of the sugar fragment. 
Again, the allyl group was selected as a suitable aglycone. Compound 196 was treated with 2,2-
dimethoxypropane under acidic conditions to form the acetal moiety with the syn-diol. The 
crude mixture was subjected to the acetylation reaction to install the first acetate at C.4' in 73% 
yield over the two steps. Treatment of 203 with aqueous acetic acid at elevated temperatures 
cleaved the acetal and unmasked diol 204. 
 
Scheme 3.30:  Synthesis of diol 204. Conditions: a) 2,2-dimethoxypropane, pTsOH·H2O, DMF, rt; b) AcCl, 
pyridine, DMF, 0 °C to rt, 73% over two steps; c) 90% aq. AcOH, 110 °C, 97%. 
Although literature evidence suggested that the following acetylation might be selective for the 
C.3' position,
[188]
 the experiment under standard conditions (AcCl, pyridine, DMAP) resulted in 
a rather moderate regioselectivity of 4:1, even when carried out at −78 °C. The application of 
preformed dialkylstannylene intermediates was inferior in terms of regioselectivity and yield. 
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However, with the recently developed method by Taylor and co-workers using the 
ethanolamine ester of diphenylborinic acid as catalyst,
[189]
 a synthetically useful selectivity of 
10:1 for the C.3' position was obtained. The separation of the two regioisomers proved to be 
difficult and was achieved only after several subsequent flash chromatographic purifications. 
 
Scheme 3.31:  Regioselective acetylation and methylation. Conditions: a) Ph2B(OCH2CH2NH2), i-Pr2NEt, AcCl, 
MeCN, rt, 97% (10:1 r.r.); b) TMSCHN2 (24 eq.), aq. HBF4, CH2Cl2, 0 °C, 71%. 
The methylation of the remaining alcohol at C.2' was plagued by 1,2-acyl shift under the basic 
conditions usually employed for methylation reactions (e.g. with NaH, MeI or Ag2O, MeI). 
Fortunately, resort to trimethylsilyl diazomethane as methylating agent in the presence of aq. 
HBF4 allowed this problem to be solved.
[190]
 A large excess of the diazo compound was 
required to achieve full conversion, yet permitted the isolation of 199, which intercepts the 
route described above. 
Overall, the synthesis of the sugar fragment was achieved in seven (bis-acetal approach) or 
eight steps (selective acetylation approach) respectively. In practice, the bis-acetal route is not 
only one step shorter, but also more convenient in terms of product purification. 
 
3.8 Fragment assembly, macrocyclization and endgame 
With all required fragments in hand, the assembly stage began with the esterification of alcohol 
194 with acid 151. Despite the numerous methods available in the literature, this transformation 
turned out to be a fundamental challenge. As can be seen from table 3.5, application of the 
reaction conditions employed during the leiodermatolide synthesis (EDCI·HCl, DMAP) failed 
and led to full recovery of the starting alcohol (entry 1). With 2,4,6-trichlorobenzoyl chloride as 
the activator for acid 151 according to Yamaguchi,
[191]
 the desired product was detected for the 
first time, although the yield remained disappointingly low (entry 2). Moreover, the product 
consisted of an inseparable mixture of ,- and ,-isomers, both of which mostly as the (E)-
isomer (>19:1). The more reactive 2-methyl-6-nitrobenzoic anhydride was evaluated (entry 3), 
but no improvement was achieved.
[192]
 In these cases, the alcohol could be recovered, whereas 
the acid was fully consumed. Likewise, the use of a 2-chloropyridinium salt as described by 
Mukaiyama suffered from poor conversion (entry 4),
[193]
 whereas the Lewis acidic conditions 
reported by Yamamoto caused decomposition (entry 5).
[194]
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Table 3.5:  Optimization of the esterification of 151 and 194. Conditions: a) (COCl)2, DMF, CH2Cl2, quant. 
 
entry substrate conditions result 207/208 
1)
 
1 151 EDCI·HCl, DMAP, CH2Cl2 (0.1 M), rt to reflux rec. 194 - 
2 " 2,4,6-trichlorobenzoylchloride, NEt3, DMAP, toluene, 100 °C 33% 1.5 : 1 
3 " 2-methyl-6-nitro-benzoicanhydride NEt3, DMAP, toluene, rt 18% 1.4 : 1 
4 " 2-chloro-N-methylpyridinium iodide, NEt3, CH2Cl2, rt 9% 0 : 1 
5 " 4-NO2-benzoicanhydride, Sc(OTf)3 cat., MeCN, rt decomp. - 
6 " DCC (2.2 eq), DMAP (5 eq), CH2Cl2(1.0 M), rt 64% 1.5 : 1  
7 206 NEt3, CH2Cl2, rt decomp. - 
8 " 194, n-BuLi; 206, THF, −78 °C to rt 8% 1 : 0 
 
1) determined by integration of olefinic signals in the crude 1H NMR. 
Preactivation of the acid as acyl chloride was next investigated. Although the acyl chloride 206 
could be readily synthesized in quantitative yield by treatment with oxalyl chloride, only 
decomposition occurred in the presence of NEt3 (entry 7), whereas the lithium salt of 194 
reacted sluggishly with acyl chloride 206 (entry 8). Fortunately, the use of excess DCC and 
DMAP at high concentration yielded the desired ester in 64% yield, although the isomerization 
of the double bond out of conjugation could not be suppressed (entry 6). Variations of the 
nucleophilic catalyst (NMI or PBu3)
[195]
 or addition of acidic proton sources (CSA or 
DMAP·HCl) under otherwise identical conditions gave inferior results.
[196]
 
Control experiments with acid 151 and ester 207 implied that neither DMAP nor NEt3 is able to 
isomerize the -double bond out of conjugation. It seems likely that an activated intermediate 
of type I1 with more acidic -protons can be deprotonated by a second molecule of DMAP to 
form a ketene I2, which is attacked by the alcohol and produces the isomeric product 208 
(scheme 3.35, red pathway). The desired product 194 can be formed by attack of the alcohol on 
the active intermediate I1 following the generally accepted mechanism of Steglich 
esterifications (blue). Model studies, in which 194 was replaced by menthol, resulted in 
80 Total synthesis of mandelalide A 
 
significantly reduced isomerization, indicating that the steric bulk around the secondary alcohol 
in 194 retards the reaction with I1. 
 
Scheme 3.32: Mechanistic rationale for the observed isomerization during the esterification reaction. 
Since this deconjugation process could not be avoided, the product mixture was treated with 
catalytic amounts of DBU in MeCN at elevated temperature, which initiated the migration of 
the double bond of 208 back into conjugation. Trace amounts of the generated (Z)-isomer 
(~3%) were separated by flash chromatography, affording the desired adduct 207 in 91% as a 
single isomer. The stage was set for the alkyne metathesis comprising an internal as well as a 
terminal alkyne within the substrate.  
Upon exposure of diyne 207 to the undoubtedly most active and functional-group tolerant 
catalyst C1,
[25]
 the desired macrocycle 209 formed readily even at ambient temperature. A 
catalyst loading of 10 mol% of the molybdenum alkylidyne was necessary to achieve full 
conversion and allowed the isolation of cycloalkyne 209 in 72% yield. The presence of 4 Å and 
5 Å molecular sieves ensured that the reaction medium was rigorously dry and sequestered the 
released propyne. No dimeric or oligomeric species were detected by mass-spectrometric 
analysis when the reaction was carried out at high dilution (2 µM).  
 
Scheme 3.33:  Ring-closing alkyne metathesis of 207. Conditions: a) DBU (25 mol%), MeCN, 50 °C, 91%; b) C1 
(10 mol%), 4 Å MS, 5 Å MS, toluene, 72%. 
In light of the side reactions previously encountered with terminal acetylenes such as 
polymerization
[148c-f]
 and catalyst deactivation,
[148b, 148h]
 the result of this transformation is 
remarkable and enabling at the same time. Moreover, it represents the first successful example 
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of a metathesized terminal alkyne in the context of natural product synthesis and likely 
encourages further applications in the future.
[197]
 
The subsequent semihydrogenation was initially attempted with poisoned palladium catalysts 
under hydrogen atmosphere. These Lindlar reductions resulted in the formation of the desired 
cyclodiene 210 along with ~20% of an overreduced product that was not further characterized. 
Based on the experience gained during the total synthesis of leiodermatolide, it was found that 
an activated Zn(Cu/Ag) couple as the reducing agent enabled the clean formation of the desired 
(E,Z)-diene, which was the only isomer formed under these conditions.
[96]
 Although some 
reactivity was noticed at ambient temperature, the reaction was carried out at 45 °C for the sake 
of reproducibility. With the diene installed, the TBS-ether was cleaved upon treatment with p-
toluenesulfonic acid to unmask the alcohol functionality at C.7 without touching the more 
robust TBDPS groups within the northern fragment. 
 
Scheme 3.34:  Semihydrogenation and selective deprotection. Conditions: a) Zn(Cu/Ag), THF/MeOH/H2O 1:1:1, 
45 °C, 88%; b) pTsOH·H2O (30 mol%), CH2Cl2/MeOH 2:1, 90%. 
As expected, the glycosidation reaction of 211 with rhamnosyl donor 201 attached the sugar 
moiety to the parent macrocycle with high yield and high selectivity (d.r. > 16:1) even without 
neighboring group participation.
[188]
 Of the tested Lewis acids, TESOTf produced compound 
212 with the highest yield and allowed the temperature to be lowered to −50 °C, thus ensuring 
a clean reaction. The acetate groups of the rhamnosyl fragment were then carefully saponified 
under mild conditions (K2CO3, MeOH) without opening of the macrocyclic lactone. 
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Scheme 3.35:  Attachment of the rhamnosyl fragment. Conditions: a) 201, TESOTf, CH2Cl2, 4 Å MS, −50 °C, 
89%; b) K2CO3, MeOH, 0 °C, 80%. 
For the final desilylation, compound 213 as the immediate precursor was subjected to typical 
conditions previously used for the global deprotection of macrocyclic compounds (table 3.6). 
Under almost all conditions tried, the primary TBDPS ether at C.24 was cleaved readily to give 
intermediate 214 with the secondary TBDPS-ether intact. The steric impediment around this 
site retarded the oxygen-silicon bond cleavage. The reaction was plagued by slow conversion 
and 1,2-acyl shift of the macrocyclic lactone, which led to the ring-expanded product 215. This 
side reaction could easily occur under the basic conditions using fluoride sources, but could 
also be triggered by Brønsted acid catalysis. To bypass this undesired pathway, the 
deprotection was carried out under buffered conditions.  
When TBAF was buffered with AcOH, the reaction stopped after deprotection of the primary 
alcohol (entry 1), whereas the use of TASF in different solvent mixtures failed to suppress the 
ring expansion (entries 2, 3). The use of mildly acidic aqueous hydrogen fluoride allowed the 
desired product to be isolated for the first time, however the reaction was rather messy and 
suffered from partial decomposition (entry 4). When the pyridine adduct of HF (Olah's reagent) 
was used, a slight improvement in yield was noticed; yet, the obtained reaction mixture 
contained several unidentified compounds (entry 5). Buffering the reaction mixture with excess 
pyridine slowed down the conversion and only traces of the desired product were detected 
(entry 6). 
Finally, the combination of HF·pyridine and pyridine as the co-solvent allowed the reaction to 
proceed cleanly and allowed full conversion into 92 to be reached after 28 h (entry 7). Under 
these conditions, the globally deprotected compound 124 was isolated in 80% yield along with 
traces of its ring-expanded congener 215 (8%). This reaction was successfully performed with 
42 mg of 213 as the single largest batch, allowing for the isolation of 19 mg of 124. 
  
Total synthesis of mandelalide A 83 
 
Table 3.6:  Optimization of the final deprotection.  
 
entry conditions 214 : 124 : 215 
1)
 
yield of 
124 [%] 
1 TBAF, AcOH, rt 90 : 7 : 3 - 
2 TASF, MeCN, DMF 2:1, rt 8 : 20 : 72 - 
3 TASF, H2O, THF, rt 10 : 40 : 50 - 
4 aq. HF, MeCN, 0 °C to rt 10 : 60 : 30 25 
5 HF·pyridine (50 eq), THF, rt 3 : 73 : 24 41 
6 HF·pyridine (50 eq), pyridine (100 eq), THF, rt 85 : 10 : 5 - 
7 HF·pyridine, pyridine, THF (1:1:1), 0 °C to rt 0 : 91 : 9 80 
 
1) determined by HPLC analysis of a crude sample. 
Overall, more than 25 mg of 124 were prepared by the developed route, which, for the first 
time, opened a concise (21 steps l.l.s.) and flexible entry into the mandelalide family. 
However, the 
1
H as well as 
13
C NMR spectra of both 124 and 215 did not comply with those 
reported for the natural product (for the full NMR spectra, see appendix). The 
1
H NMR 
spectrum was clearly distinct from the one reported by the isolation team
[141]
 and small 
deviations were observed throughout the relevant ppm range. As the concentration, at which 
the NMR spectrum was recorded by the isolation team, remained unknown, a concentration 
series was filed with the synthetic material. However, the spectral signature did not change for 
both the 
1
H and 
13
C nuclei and only the signals of two hydroxyl groups shifted observably. 
On the other hand, the spectral data for synthetic 124 left no doubt about its constitution or 
stereochemistry. Thus, it was concluded that the structure of mandelalide A must have been 
misassigned by the isolation team and the putative structure of the natural product had been 
synthesized in the first instance. 
  
84 Total synthesis of mandelalide A 
 
3.9 Structure reassignment of mandelalide A 
The direct comparison of the 
13
C NMR data (figure 3.3) should help to identify a possible site 
of misassignment. The largest deviations were observed at the stereogenic center at C.11 ( = 
+1.4 ppm) and the adjacent C.25 methyl group ( = −1.8 ppm). Moreover the coupling 
constant recorded for H.11 and H.12 (
3
J11,12 = 7.6 Hz) did not match the one of the natural 
product (
3
J11,12 = 9.6 Hz). This stereogenic center had previously been assigned by analysis of 
the homo- and heteronuclear coupling constants.
[141]
 Since a handheld model of the macrocycle 
was rather flexible, the NMR data likely reflects an average of more than a single conformation 
and hence renders the correct interpretation difficult, if not impossible. The observed 
differences were interpreted as an indication that the chiral center at C.11 might have 
previously been misassigned. A crafted ball-and-stick model with inverted C.11 
stereochemistry suggested that this isomer might be able to adopt a confirmation which would 
be in agreement with the reported ROESY data and coupling constants. 
 
Figure 3.3:  Observed 
13
C NMR differences (in ppm) between synthetic 124 (CDCl3, 600 MHz) and the natural 
product (CDCl3, 700 MHz). 
To corroborate this assumption, the epimer 11-epi-1 was targeted. The modified synthesis is 
depicted in scheme 3.39 and starts with the alkylation of alkyl iodide 141 with the enantiomeric 
Myers auxiliary ent-R12. To exclude that the stereochemical information already contained in 
141 overwrote that of the auxiliary R12, a detailed Mosher ester analysis was carried out after 
cross metathesis with methyl acrylate. The primary alcohols 146 and 11-epi-146 were reacted 
with both (R)- and (S)-acylchloride R19 and gave the Mosher esters 217a, 217b, 218a and 
218b.
[198]
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Scheme 3.36:  Synthesis of the epimeric southern fragment and Mosher esters 217 and 218. Conditions: a) ent-R12, 
LDA, LiCl, THF, 0 °C to 45 °C, 84% (d.r. 98:2); b) LDA, NH3·BH3, THF, 0 °C to rt, 87%; c) 
methylacrylate, C7 (3 mol%), CH2Cl2, rt, 91%; d) DMP, NaHCO3, CH2Cl2, 0 °C to rt, 76%; e) CHI3, 
CrCl2·THF, THF, −8 °C; aq. serine workup, 61%; f) sodium propyne, (MeO)3B, 
[PdCl2(dppf)]·CH2Cl2 (10 mol%), THF, 70 °C, 76%; g) KOTMS, Et2O, rt, 88%; h) (R)- or (S)-R19, 
pyridine, CH2Cl2, 0 °C to rt, 217a: 88%; 217b: 91%, 218a: 89%, 218b: 93%. 
Figure 3.4 displays the characteristic region of their 
1
H NMR spectra between 4.45 and 
3.95 ppm, showing the two geminal protons at C.12. According to literature precedence,
[199]
 the 
distance between the two inner lines of the two doublets of dublet is characteristic for each 
isomer. A large difference indicates either an (R,R)- or (S,S)-configuration.
[200]
  
Indeed, the  of the protons at C.12 is bigger for the (R)-Mosher Ester of the (11R)-isomer 
217a, whereas it increased in case of the (S)-Mosher Ester for the (11S)-isomer 218a. Based on 
this evidence, the stereogenic center at C.11 is clearly controlled by the chiral Myers auxiliary 
employed in the reaction and not by the chiral alkyl iodide. 
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Figure 3.4:  Mosher esters of compounds 146 and 11-epi-146. (
1
H NMR, CDCl3, 400 MHz, 4.45 – 3.95 ppm). 
The remaining steps en route to the epimeric southern fragment are analogous to those of the 
original synthesis and afforded 11-epi-151 after oxidation of the primary alcohol, Takai 
olefination, alkynylation and ester hydrolysis. 
The endgame was similarly straightforward. After esterification, the macrocyclization 
proceeded readily upon contact with molybdenum alkylidyne C1 and set the stage for the 
semihydrogenation, which afforded 11-epi-211 cleanly. Selective removal of the TBS group, 
glycosidation, and global deprotection under previously optimized conditions afforded the 
targeted C.11 epimer. Remarkably, no ring-expanded isomer was detected during the 
deprotection in the 11-epi series. 
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Scheme 3.37:  Synthesis of the C.11 epimer of putative mandelalide A. Conditions: a) DCC, DMAP, CH2Cl2, rt, 
71% (,/, = 1.5:1); b) DBU (25 mol%), MeCN, 50 °C, 92%; c) C1 (10 mol%), toluene 
(0.002 M), rt, 64%; d) Zn(Cu/Ag), THF/MeOH/H2O 1:1:1, 45 °C, 86%; e) pTsOH·H2O (30 mol%), 
CH2Cl2/MeOH 2:1, rt, 89%; f) 201, TESOTf (30 mol%), CH2Cl2, 4 Å MS, −40 °C, 87%; g) K2CO3, 
MeOH, 0 °C, 88%; h) HF·pyridine, pyridine, THF, 0 °C to rt, 85%. 
Unfortunately, both 
1
H and 
13
C NMR spectra of 11-epi-124 again showed significant 
differences when compared to the data of natural mandelalide A (see appendix for full spectra). 
Figure 3.5 reveals the deviations in the
 13
C NMR with its peak being found at the methyl group 
of C.25 ( = 3.7 ppm). Interestingly though, the coupling constant between the protons at 
C.11 and C.12 (
3
J11,12 = 9.7 Hz) is in agreement with the reported data.  
 
Figure 3.5:  Observed 
13
C NMR differences (in ppm) between synthetic 11-epi-124 (CDCl3, 600 MHz) and the 
natural product (CDCl3, 700 MHz). 
It was concluded that the error made during the assignment was more profound and may well 
be located in more than one position. Inspired by structural similarities with the madeirolides, 
likely candidates bore the enantiomeric northern fragment (see compounds 219 and 11-epi-219, 
figure 3.6). However, the presence of no less than nine stereogenic centers around the 
macrocyclic fragment led to the initiation of a cooperation with Ms. Berit Heggen from the 
group of Prof. Dr. Walter Thiel.
[201]
 The calculations performed during this collaboration were 
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supposed to forecast the correct structure of mandelalide A with the aid of NMR prediction via 
the DP4 probability method developed by Goodman
[202]
 and therefore minimize the number of 
isomers that had to be synthesized in order to find the correct structure of the natural product. 
Over 20 diastereomers with configurational inversion of the whole northern fragment or 
alternatively at C.11, C.20 and C.21 were taken into account; for clarity aspects, only four 
diastereomers are discussed in the following (see figure 3.6). For all compounds, a conformer 
sampling using a molecular mechanics conformational search was performed with the 
CHARMM general force field (CGenFF). All gas-phase conformers at 298.15 K within a range 
of 10 kJ/mol were considered and subjected to either single-point DFT calculations or manual 
geometry optimizations to determine the calculated energies and the shielding constants in the 
gas phase. After averaging the shielding constants over the Boltzmann distribution, the NMR 
shifts relative to tetramethylsilane were calculated according to the GIAO method.
[203]
 The 
calculated shifts were subsequently correlated to the experimental data and the DP4 probability 
was obtained, which indicates the probability that the computed structure matches the 
experimental data.
[202]
 The advantage of this methodology is that it takes several conformers 
into account, weighs them according to their relative energies and should therefore be 
applicable to flexible macrocyclic compounds like in the present scenario. 
Table 3.8:  Conformer energies (in kcal/mol) of the diastereomers considered in the NMR prediction.
[201]
  
entry 124 11-epi-124 219 11-epi-219 
1 4.05 19.55 11.20 5.84 
2 0.00 19.55 7.33 0.00 
3 2.76 0.00 0.00  
4 11.56 6.98 0.95  
5 8.30 13.08 11.65  
6  10.27 3.91  
7  8.23   
8  16.52   
 
The conformers, which correspond to the global energy minimum are depicted in figure 3.6 and 
reveal interesting structural features. Thus, compound 124 is the only isomer, in which the 
northern fragment is bent over the southern fragment and forms a U-shape with the methyl 
group of C.26 pointing into the semi-circle (figure 3.7a). This forces the (E,Z)-configured diene 
to adopt a conformation that is twisted with an angle of 38° around the C.13 and C.14 bond, 
which in turn decreases the efficacy of orbital overlap between the two -systems (figure 3.7b). 
The proximity of the primary alcohol at C.24 and the neighboring carbonyl group at C.1 
suggests a stabilizing hydrogen bond for 124 (figure 3.7c), which is clearly less pronounced for 
all other calculated structures that fail to adjust the alcohol and the carbonyl group in co-
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planarity. Remarkably, the lowest lying energy conformers of all other structures adopt an ideal 
s-trans configuration of the diene and do not show the above mentioned bending. 
 
 
 
Figure 3.6: Lowest lying energy conformers calculated for the four most likely mandelalide isomers.
[201]
 
 
a)           b)      c) 
 
 
 
 
 
 
 
Figure 3.7: Lowest lying energy conformer of 124 from different perspectives: a) U-shape of the macrocycle; b) 
projection along the diene single bond between C.13 and C.14; c) postulated hydrogen bond.
[201]
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The calculated DP4 probabilities (table 3.9) however were contradictory in themselves and did 
not facilitate the search for actual mandelalide A. Of the calculated probabilities obtained for 
the four considered diastereomers, only structure 219 offers potential hits. Intriguingly, the DP4 
probability for the calculated 
13
C shifts of 219 shows a perfect match with all three available 
experimental datasets, whereas the predicted 
1
H shifts cannot be assigned to any of the isomers. 
The different absolute overall values can be explained by the fact that they are not obtained 
from the 
1
H and 
13
C probability products displayed in the table, but are the result of an 
algorithm, which multiplies each probability value of a 
1
H nuclei with the corresponding 
13
C 
probality value.
[201]
 
Table 3.9:  Calculated DP4 probabilities of four calculated mandelalide A isomers.
[201]
  
 NMR 124 (theor) 
11-epi-124 
(theor) 
219 (theor) 
11-epi-219 
(theor) 
natural 
product 
13
C
 
 0 0 1.00 0 
(experimental) 
1
H 0 0 0 0 
 overall 0 0 0.24 0 
124 
13
C 0 0 1.00 0 
(experimental) 
1
H 0 0 0 0 
 overall 0 0 0.90 0 
11-epi-124 
 
13
C
 
 0 0 1.00 0 
(experimental) 
1
H 0 0 0 0 
 overall 0 0 0 0 
 
The best entire overlap was obtained for the calculated NMR shifts of 219 with the 
experimental data of compound 124, which had already proven to be false by synthesis. 
Moreover, the expected matches of the calculated isomers 124 and 11-epi-124 with the 
appropriate experimental data obtained during this study were not found and clearly indicated 
that this particular NMR prediction method had failed in the mandelalide case. 
With this result, total synthesis remained the ultimate tool to shed light on the actual structure 
of mandelalide A. Based on biochemical reasoning and the similarity to the madeirolides, the 
most likely candidates consisted of compounds 219 and 11-epi-219 with fully inverted 
stereochemistry within the northern fragment. As a consequence, these compounds were 
synthesized by using the corresponding enantiomeric building blocks. At the same time, this 
opportunity was used to scale up the synthesis of ent-194 by a factor of three. The strategy and 
the synthetic operations were not changed and enabled reliable access to more than 700 mg of 
the required alcohol ent-194 (scheme 3.38).  
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Scheme 3.38:  Synthesis of the enantiomeric alcohol fragment. Conditions: a) TBDPSCl, imidazole, CH2Cl2, 0 °C 
to rt, 95%; b) Co2(CO)8 (8 mol%), N-TMS morpholine, CO (1 atm), EtOAc, rt, 74%; c) propenyl-
magnesium bromide, THF, −25 °C; then −78 °C, aq. HCl workup, 79%; d) (S,S)-R17, Sc(OTf)3 
(5 mol%), CH2Cl2, −78 to 0 °C, 80% (94.6% ee); e) TESCl, NEt3, DMAP, CH2Cl2, 0 °C to rt, 91%; 
f) C8 (4+2+2 mol%), CH2Cl2, reflux, 73%; g) i-PrCHO (5 eq.), SmI2 (35 mol%), THF, −50 °C, 74% 
(>19:1 d.r.); h) TBDPSCl, imidazole, CH2Cl2, 0 °C to rt, 82%; i) CSA (30 mol%), CH2Cl2/MeOH 
2:1, 0 °C, 99%; j) N-PSP, TFA, Ph3P=S (12 mol%), CH2Cl2, −40 to −20 °C 82% (14:1 d.r.); k) 
n-Bu3SnH, AIBN, toluene, 80 °C, 97%; l) Pd(OH)2/C (cat.), H2 (1 atm), EtOAc/EtOH 1:9, rt, 82%; 
m) DMP, CH2Cl2, 0 °C to rt, 94%; n) R18, NaOMe, THF, −78 °C; then ent-190, to −50 °C, 96%; o) 
DIBAl-H, toluene, −78 °C, 97%. 
With the enantiomeric alcohol fragment in hand, the endgame was carried out with both 
previously synthesized acid fragments. Remarkably, the alkyne metathesis reaction to produce 
221 under the previously employed conditions gave a diminished yield of only 45% (scheme 
3.39).  
 
Scheme 3.39:  Fragment assembly and RCAM with the enantiomeric northern fragment. Conditions: a) DCC, 
DMAP, CH2Cl2, rt, 52% (,/, 1.5:1); b) DBU (25 mol%), MeCN, 50 °C, 85%; c) C1 (10 mol%), 
toluene (0.002 M), 4 Å MS, 5 Å MS, rt, 45%; d) C1 (10 mol%), toluene (0.002 M), 4 Å MS, 5 Å MS, 
85 °C, 74%. 
This problem could be overcome by increasing the reaction temperature to 85 °C, which 
significantly speeded up the reaction and allowed the desired cycloenyne 221 to be isolated in 
74% yield. One may speculate that the diyne precursor adopts a conformation that does not 
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favor ring-closure and elevated temperatures are required to bring the two alkyne units in 
proximity. The reaction was significantly slower when carried out at ambient temperature and 
competing oligo- or polymerization pathways were believed to take over. To exclude an 
experimental error, several control reactions were performed in parallel at ambient and at 
elevated temperature with the same stock solution of catalyst and the same batch of substrate. 
The remaining steps held no surprise and furnished the targeted compound 219 with good 
yields along the whole sequence (scheme 3.40).  
 
Scheme 3.40:  Completion of the synthesis of 219. Conditions: a) Zn(Cu/Ag), THF/MeOH/H2O 1:1:1, 45 °C, 91%; 
b) pTsOH·H2O (30 mol%), CH2Cl2/MeOH 2:1, rt, 86%; c) 201, TESOTf (30 mol%), CH2Cl2, 4 Å 
MS, −40 °C, 83%; d) K2CO3, MeOH, 0 °C, 96%; e) HF·pyridine, pyridine, THF, 0 °C to rt, 71%. 
The epimeric compound 11-epi-219 was prepared analogously. Notably, the RCAM to produce 
11-epi-221 proceeded readily at ambient temperature as previously observed and furnished the 
desired product in 83% isolated yield (scheme 3.44).  
The C.11 stereogenic center seems to be, at least to a certain extent, responsible for retarding 
the ring-closure by dictating an unfavorable conformation. Again, the following steps worked 
reliably and produced the targeted compound 11-epi-219 after semihydrogenation, 
glycosidation and global deprotection. 
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Scheme 3.41:  Completion of the synthesis of 11-epi-219. Conditions: a) DCC, DMAP, CH2Cl2, rt, 53% (,/, 
1.5:1); b) DBU (25 mol%), MeCN, 50 °C, 93%; c) C1 (10 mol%), toluene (0.002 M), 4 Å MS, 5 Å 
MS, rt, 83%; d) Zn(Cu/Ag), THF/MeOH/H2O 1:1:1, 45 °C, 83%; e) pTsOH·H2O (30 mol%), 
CH2Cl2/MeOH 2:1, rt, 90%; f) 201, TESOTf (30 mol%), CH2Cl2, 4 Å MS, −40 °C, 80%; g) K2CO3, 
MeOH, 0 °C, 92%; h) HF·pyridine, pyridine, THF, 0 °C to rt, 68%. 
The 
1
H and 
13
C NMR spectra of the two compounds 219 and 11-epi-219 were again compared 
with those of the natural product. The recorded 
1
H and 
13
C spectra of 219 in CDCl3 and d
5
-
pyridine show a perfect match and are identical in all respects, whereas those of 11-epi-219 are 
clearly distinct (figure 3.8).  
 
Figure 3.8: Observed 
13
C NMR differences (in ppm) between synthetic 219 (orange) and 11-epi-219 (violet) 
(both: CDCl3, 600 MHz) with the natural product (CDCl3, 700 MHz). 
In consequence, mandelalide A was reassigned and is correctly depicted by structure 219. Thus, 
the stereogenic center at C.11 was properlyy assigned by the isolation team; however, the 
stereochemistry of the whole northern fragment is inverted.  
The recorded optical rotation of 219 ([∝]𝐷
23 = 29 (c=0.25, MeOH)) is higher than the one 
reported for natural mandelalide A ([∝]𝐷
23 = 9 (c=0.25, MeOH)) but its sign indicates the 
correct absolute configuration. It is unclear whether the differences are caused by an 
experimental error or by traces of highly optically active impurities in one of the samples. 
However, the group of Ye later reported an optical rotation for synthetic mandelalide A  
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([∝]𝐷
20 = 34.6 (c=0.25, MeOH)),[146] which is in reasonable agreement with the data found for 
the synthetic material in this study. 
 
3.10 Studies towards the total synthesis of mandelalides C and D 
3.10.1 Retrosynthetic analysis 
Since the developed route was deemed robust and scalable, the project was extended to access 
other family members from a common macrocyclic intermediate. The mandelalides C (126) 
and D (127) were chosen as primary targets to evaluate this strategy, as these compounds lack 
the glycosidic unit and were believed to be more readily accessible. Since the stereochemistry 
of the northern fragment of mandelalide A had turned out to be misassigned, it was 
hypothesized that the northern stereocluster of 126 and 127 suffered from the very same 
structural incorrectness. Although the stereogenic centers were assigned by interpretation of the 
ROESY contacts and coupling constants,
[141]
 it seemed likely that the stereogenic centers at 
C.2, C.3 and C.24 of 126 and 127 also needed to be inverted.  
 
Scheme 3.42: Newly proposed structures for 126 and 127 based on the structural reassignment of mandelalide A. 
This was based on the consideration that the stereogenic centers in question are in direct 
neighborhood to a previously fixed stereogenic center at C.23 from the northern fragment, 
whereas the assignment with regard to the southern fragment involved a rather flexible 
methylene unit at C.4, which renders a correlation difficult. As depicted in scheme 3.42, the 
targeted structures have all stereogenic centers of the northern and eastern part of the molecule 
inverted when compared to the originally proposed structures.
[141]
 
The retrosynthetic analysis shown in scheme 3.43 highlights the key disconnection. The oxygen 
functionalities at C.2 and C.3 were supposed to be introduced via dihydroxylation directed by 
the alcohol at C.24 or via directed epoxidation reaction depending on the double bond 
configuration of the allylic alcohol precursor 226. The carbon-carbon bond between C.24 and 
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C.2 distinguishes the macrocyclic core of the targeted compounds from mandelalide A and was 
thought to derive from an intramolecular Morita-Baylis-Hillman (MBH) reaction of aldehyde 
227. The just mentioned aldehyde was thought to be accessible by oxidation of the 
corresponding primary alcohol, which would be obtained after selective deprotection of the 
previously synthesized macrolactone 210. 
 
Scheme 3.43: Retrosynthetic analysis of mandelalides C and D leading back to previously synthesized 210. 
Since all four mandelalides were isolated from the same species, one might be tempted to 
speculate about the biomimetic pathway. The proposed synthesis via a late stage MBH reaction 
would indeed explain the occurrence of all four mandelalide species within the same ascidian. 
However, it was previously stated that "the MBH reaction does not occur in nature."
[204]
 
Simultaneously, the same authors have reported that certain carrier proteins were able to 
catalyze MBH reactions of simple model substrates; yet, these results were interpreted as 
unnatural enzymatic promiscuity.
[204, 205]
 In this light, the alternative pathway involving classic 
aldol processes for the construction of the C.24/C.2 bond followed by redox and elimination 
processes seems more reasonable. Although it remains unknown whether this bond formation 
occurs before or after construction of the macrocycle, it was reasonable to assume that the 
macrocyclic framework exerts a certain degree of control over the forming stereogenic center at 
C.24. 
The envisioned sequence with an intramolecular MBH reaction followed by directed oxidation 
seemed fascinating and synthetically challenging alike, and ensured motivation to pursue this 
approach. Before the synthetic endeavor with the macrocyclic system was initiated, the key 
MBH reaction was investigated on a simple model. 
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3.10.2 Model studies for the Morita-Baylis-Hillman reaction and directed 
dihydroxylation 
A model compound was synthesized to explore the feasibility of the envisioned intramolecular 
MBH reaction. This transformation was deemed particularly challenging for three reasons: 
i) -substituted Michael acceptors are rarely employed in MBH reactions since they 
suffer from low reactivity towards the nucleophilic mediator due to steric shielding 
of the electrophilic 4-position of the Michael acceptor,
[206]
  
ii) the anticipated reaction formally displays a 5-(enolendo)-exo-trig cyclization, which 
is classified as "disfavored" by the Baldwin rules,
[207]
 and 
iii) the MBH precursor contains an -acetoxy aldehyde motif, which is known to 
rearrange under basic conditions to the corresponding -acetoxy ketone (scheme 
3.47).
[208]
 This transformation likely occurs through enolization, 1,2-acyl shift and 
keto-enol tautomerism. 
 
Scheme 3.44: Base-catalyzed rearrangement of -acetoxy aldehydes. 
The presence of a single literature report of an intramolecular MBH reaction producing a five-
membered ring emboldened the desire to find suitable conditions applicable to the mandelalide 
case.
[209]
 However, the group of Krishna used a more reactive -unsubstituted Michael acceptor 
228 as can be seen in scheme 3.45.  
 
Scheme 3.45: Literature evidence for a 5-(enolendo)-exo-trig MBH cyclization. Conditions: a) DABCO 
(50 mol%), CH2Cl2, rt, 62%.
[209]
 
Moreover, the produced -lactone 229 bears the hydroxyl and the alkyl substituent in an anti-
relationship as opposed to the syn-motif in the mandelalide family. However, it was speculated 
that the conformation of the macrocycle as well as the chiral environment of the substrate could 
dictate the stereochemical outcome and override the inherent stereoselectivity of this reaction. 
The synthesis of a suitable model substrate started with the copper-catalyzed epoxide opening 
of 160 with n-decyl Grignard, which was chosen to decrease the volatility of the subsequent 
products. The crude product 230 was engaged into the esterification reaction with trans-
crotonic acid to furnish ester 231. The silyl group on the masked primary alcohol was removed 
Total synthesis of mandelalide A 97 
 
with TBAF in the presence of acetic acid to reduce the amount of 1,2-acyl shift. Oxidation of 
alcohol 232 with DMP under buffered conditions gave aldehyde 233 in acceptable yields and 
set the stage for the exploration of the MBH reaction. 
 
Scheme 3.46: Synthesis of MBH model substrate 233. Conditions: a) C10H21MgBr, CuCN (2 mol%), Et2O/THF, 
−15 °C, 98%; b) (E)-crotonic acid, DCC, DMAP, CH2Cl2, rt, 81%; c) TBAF, AcOH, THF, 0 °C to 
rt, 89%; d) DMP, NaHCO3, CH2Cl2, 0 °C to rt, 55%. 
Aldehyde 233 was first subjected to the conditions reported by the group of Krishna, which 
employed DABCO to achieve the cyclization.
[209]
 However, the additional methyl substituent 
shut down the reactivity of the Michael acceptor and no reaction was observed at ambient 
temperature, whereas clean conversion to the rearranged product 235 was detected at 50 °C 
(table 3.10, entry 1). Other amine-based nucleophiles were subsequently employed but none of 
these were able to promote the desired reaction; they either led to the formation of 235 
(entries 2, 3)
[210]
 or to rather complex mixtures (entry 4).
[211]
  
Table 3.10:  Selected attempts towards a MBH cyclization with model system 233. 
 
entry conditions
1)
 result
2)
 
1 DABCO (50 mol%), CH2Cl2, rt to 50 °C no reaction; then 95% 235 
2 Quinuclidine (1 eq.), MeOH (1.5 eq), rt 97% 235 
3 DBU (50 mol%), MeCN, 0 °C to rt 80% 235 
4 DMAP, DMAP·HCl, EtOH, reflux complex mixture 
5 NMI-oxide (5 eq.), neat, rt s.m., trace 235 
6 Ph3P=S, DMF, 90 °C s.m. 
7 Et3P=O, DMF, 90 °C s.m. 
8 Et2AlI, CH2Cl2/toluene, −78 to −20 °C complex mixture 
9 PhSCH2CH2OH or Me2S, TiCl4, CH2Cl2, 0 °C complex mixture 
10 N(CH2CH2NMe)3P=S, TiCl4, CH2Cl2, 0 °C to rt s.m.; complex mixture 
11 MgBr2, TMEDA, DMAP, MeOH 20% 235, complex mixture 
12 n-BuSeLi, THF, −78 °C; H2O2 workup trace 234, complex mixture 
13 PhSeMgBr, THF, −78 °C to rt two unidentified products 
14 n-BuTeLi, THF, 0 °C complex mixture 
1) Unless stated otherwise, 1 eq. of MBH mediator was employed. 2) determined by 1H NMR. 
The use of other Lewis basic mediators like NMI-oxide,
[212]
 phosphine sulfides or phosphine 
oxides failed and the starting material was recovered in these cases along with traces of the 
rearranged product 235 (entries 5 – 7). When Lewis acids combined with thiols, amines or 
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other Lewis bases were employed, complex mixtures caused by unknown decomposition 
pathways were obtained (entries 8 – 11).[210b, 213] The use of lithiated selenols or tellurols 
seemed more promising as they were reported to tolerate -substition of the unsaturated ester in 
intermolecular settings, although the subsequent elimination might require an additional 
step.
[214]
 However, application of these conditions to model substrate 233 led to the formation 
of several unidentified products that were difficult to purifiy (entries 12 - 14).  
As a last resort, phosphines were thought to be appropriate catalysts for the MBH reaction.
[215]
 
Indeed, trimethylphosphine was able to cataylze the desired cyclization in CH2Cl2 when carried 
out at high dilution, but the dehydrated product 236 was isolated (table 3.11, entry 1). 
Nevertheless, the formation of the desired carbon-carbon bond was observed and encouraged a 
closer inspection of different phosphines. 
As the more bulky tributylphosphine did not affect any cyclization, the reaction seems sensitive 
to both sterics and to the basicity of the phosphine. It was further hypothesized that a less basic, 
but slim phosphine might similarly induce the cyclization without triggering the elimination of 
the allylic hydroxyl group formed. Therefore, dimethylphenylphosphine was engaged in the 
reaction;
[216]
 however the reaction in CH2Cl2 at ambient temperature afforded only reisolated 
starting material (entry 2). Increasing the solvent polarity (DMF) as well as the temperature 
allowed the cyclization to occur, yet it was again plagued by elimination of water (entry 3). 
Remarkably, the use of methyldiphenylphosphine as the catalyst enabled the isolation of the 
desired -lactone 234 after 2.5 days at 90 °C in 65% overall yield (entry 4). 
Table 3.11:  Phosphine-catalyzed MBH reaction. 
 
entry conditions
1)
 
result 
(234:235:236)
2)
 
yield of 234  
(E/Z)
3)
 
1 PMe3, CH2Cl2, rt (0 : 11 : 78) - 
2 Me2PPh, CH2Cl2, rt mainly s.m. - 
3 Me2PPh, DMF, 90 °C (4 : 9 : 73) - 
4 MePPh2, DMF, 90 °C, 60 h (70 : 6 : 8)  65% (7:1) 
5 MePPh2, DMF, 120 °C, 24 h (72 : 3 : 12) 67% (5:1) 
6 PPh3, DMF, 90 °C no reaction - 
7 P(2-furyl)3, DMF, 90 °C no reaction - 
8 P(4-MeO-Ph)3, DMF, 90 °C no reaction - 
 
1) Unless stated otherwise, 30 mol% of phosphine was employed. 2) determined by 
GC-MS analysis. Since several minor by-products were also formed, the products do 
not add up to 100. 3) determined by 1H NMR. 
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The careful analysis of the crude reaction mixture revealed that 234 was formed as the trans-
isomer with high diastereoselectivity (> 18:1) as previously described, whereas the double bond 
was produced as an (E/Z)-mixture of 7:1. The syn/trans assignment was based on NOE contacts 
and coupling constants; moreover, the chemical shift of the protons at C.3 supported the NOE 
assignment of the double bond geometry: the proton at C.3 of (E)-234 is shifted downfield as 
compared to the (Z)-isomer due to the magnetic anisotropy of the carbonyl group. The double 
bond isomers were separated by careful chromatography on silica gel. 
The reaction time could be decreased to 24 h, when the reaction was performed at 120 °C in 
DMF, although the (E/Z)-ratio was slightly lower (entry 5). Electron neutral and rich triaryl 
phosphines were subsequently employed (entries 6-8);
[217]
 however, they failed to mediate the 
MBH reaction and starting material could be recovered in all cases. Furthermore, variation of 
the solvent, catalyst loading, temperature, pressure and additives were explored in more than 25 
additional experiments, but the original result with mere methyldiphenylphosphine could not be 
outperformed. 
In parallel, two stepwise approaches to the -lactone were followed on model substrates. On the 
one hand, the primary alcohol 232 was converted into the corresponding primary alkyl bromide 
237 and subjected to MBH alkylation reaction conditions. Neither phosphine-catalysis,
[218]
 nor 
thioethanol in the presence of Cs2CO3
[219]
 nor the use of strong organic bases like DBU 
promoted the transformation to 238; rather, the starting material remained mainly untouched. 
As the following allylic oxidation was also expected to be troublesome, this sequence was 
quickly abandoned. 
 
Scheme 3.47: Attempted MBH alkylation. Conditions: a) PPh3, CBr4, CH2Cl2, 0 °C to rt, 62%. 
On the other hand, the unsaturated ester in 232 was -brominated by dibromination / 
elimination to produce 239. After oxidation, aldehyde 240 was exposed to SmI2, which was 
thought to induce a radical cyclization onto the carbonyl group. However, the desired product 
234 was not detected; rather, the deacetylated aldehyde and alcohol were observed by mass 
spectrometry. Somewhat unexpectedly, the *-orbital of the carbon oxygen bond in position 
of the aldehyde seems to be a better electron acceptor than the one of the carbon bromine bond 
next to the double bond. Similarly, -lactone 234 was not formed when 240 was exposed to 
chromium(II) chloride in the presence of catalytic amounts of nickel(II) chloride. Finally, 
insertion of activated zinc into the carbon-bromine bond occurred, but debrominated and 
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oligomeric species prevailed over the cyclized product, which was only detected in trace 
quantity. 
 
Scheme 3.48: Attempted two-step alternative. Conditions: a) Br2, CH2Cl2, 0 °C, then NEt3, Et2O, rt, 58%; b) DMP, 
NaHCO3, CH2Cl2, 0 °C to rt, 51%. 
Based on these results, the moderate yield of the phosphine-catalyzed MBH reaction remained 
the only hit. Next, the subsequent directed dihydroxylation reaction was modelled with (E)-
234. 
Despite the fact that several asymmetric variants are known, the directed dihydroxylation of 
allylic alcohols was only made possible by the research of the Donohoe group.
[220]
 This 
transformation relies on the addition of TMEDA to stoichiometric amounts of osmium 
tetroxide. As exemplified for the dihydroxylation of cyclohexenol (241), the diamine is 
believed to coordinate to the rather electrophilic metal center and in consequence increases the 
electron density at osmium.  
 
Scheme 3.49: Reported directed dihydroxylation and postulated mechanism. Conditions: a) TMEDA (1.10 eq.), 
OsO4 (1.05 eq.), CH2Cl2, −78 °C; aq. Na2SO3 workup, 98% (6:1 syn/anti).
[221]
 
At the same time, the back-bonding from the metal center to the oxo-ligands is increased and 
renders them potential hydrogen bond acceptors (TS2). Mechanistic studies have shown that 
the TMEDA ligand is chelated to the osmium center before and after the reaction with an 
alkene, indicating that the guidance occurs via hydrogen bonding with the oxo ligands rather 
than through interactions of the allylic alcohol with a free tertiary amine from a mono-
coordinated ligand. The rather stable osmate ester 242 was then cleaved upon treatment with 
HCl, ethylenediamine or aq. Na2SO3 to release triol 243.
[221]
 If TMEDA was omitted, the 
reaction would produce the anti-product for both cyclic and acyclic allylic alcohols as first 
recognized by Kishi.
[222]
  
When applied to the present model substrate 234, a single diastereoisomer of the intermediate 
osmate ester 244 was produced, which was later assigned to be the expected syn-addition 
product. The reaction was surprisingly fast and reached full conversion, even at −78 °C, 
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immediately after complete addition of osmiumtetroxide to a solution of substrate and 
TMEDA.  
Table 3.12:  Selected attempts to cleave osmate ester 244. Conditions: a) OsO4, TMEDA, CH2Cl2, −78 °C. 
 
entry Workup result 
1 conc. HCl, MeOH, 0 °C 41% (245); rather messy 
2 ethylenediamine, CH2Cl2, −78 °C to rt 246 (MS) 
3 THF, aq. Na2SO3, 70 °C no hydrolysis 
4 Mannitol, AcOH, HFIP, rt to 50 °C no hydrolysis 
5 EDTA or Na2EDTA, MeOH/HFIP, rt to 50 °C no hydrolysis 
6 THF, aq. NaHSO3, 70 °C 71% (245) 
7 THF, aq. NaHSO3, rt 74% (245) 
 
However, the cleavage of the resulting osmate ester 244 proved to be less facile. The 
previously described conditions were initially investigated. Of those, only the rather harsh 
acidic conditions (table 3.12, entry 1) afforded the desired product in modest yield. However, 
application of these conditions to the macrocyclic system of mandelalide would most certainly 
be incompatible with the variety of functional groups and potentially acid labile protecting 
groups.
[223]
 
With ethylendiamine, the osmate ester was cleaved after 48 h reaction time. However, the 
product could neither be detected nor isolated; rather, ESI-MS analysis suggested that 
ethylenediamine simultaneously opened the -lactone to give amide 246, which was not further 
characterized or purified due to the high polarity and good water solubility (entry 2). The 
seemingly mildest cleavage conditions were the treatment of the crude reaction mixture with an 
aqueous Na2SO3 solution. 
Surprisingly though, no reaction occurred and the osmate ester 244 was recovered unchanged 
even after prolonged exposure at 70 °C (entry 3). Initial attempts to release the diol by 
treatment with chelating agents such as mannitol
[224]
 or EDTA
[225]
 were unsuccessful and 
quickly abandoned (entries 4, 5). An extensive literature survey suggested the use of sodium 
bisulfite as a reducing agent for the osmate ester.
[226]
 In the event, the intermediate 244 could be 
cleanly elaborated into triol 245 with acceptable yields, regardless of the reaction temperature. 
These conditions were judged to be mild enough to be tried on the macrocyclic system during 
the envisaged synthesis of mandelalide C.  
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3.10.3 Application to the mandelalides: total synthesis of isomers of mandelalide C and 
deacylmandelalide D 
With suitable conditions for both key reactions developed, their application on the macrocyclic 
system needed to be explored. To this end, the primary TBDPS group at C.24 had to be cleaved 
in the presence of the two secondary silyl ethers. The selectivity issue was addressed with the 
11-epi-isomer of compound 210 as an appropriate model substrate. During the deprotection of 
mandelalide A, HF·pyridine cleanly deprotected the primary TBDPS first before touching the 
secondary silyl ether; however, these conditions could not be applied to 11-epi-210 as the 
secondary TBS group at C.7 was cleaved at similar rates as the primary TBDPS group. Another 
promising literature report described the use of equimolar amounts of TBAF and AcOH to 
selectively remove TBDPS groups in the presence of TBS groups.
[227]
 Unfortunately, in all 
circumstances and independent of the solvent or TBAF source, full conversion was not 
achieved and the secondary alcohol at C.21 was liberated along with the desired primary 
alcohol (entries 2, 3). 
Table 3.13:  Selected attempts to achieve the selective deprotection of macrocycle 11-epi-210. 
 
entry conditions 
conv. 
1)
 
(yield) [%] 
11-epi-247 /  
multiple deprot.
1,2)
 
1 HF·pyridine, pyridine, THF, 0 °C to rt 100 1 : 16 (2° TBS cleaved) 
2 TBAF (1.1 eq.), AcOH (1.1 eq.), DMF, rt 70 1 : 1 (2° TBDPS cleaved) 
3 TBAF·3H2O (1.1 eq), AcOH (1.1 eq.), THF, rt 93 1 : 2 (mixture) 
4 Al2O3, hexanes, rt 0 - 
5 NH4F (1.5 eq.), MeOH, rt to 55 °C 24 1 : 2 (2° TBS cleaved) 
6 NH4F (110 eq.), HFIP, 0 °C to rt 86 (67) 82 : 1 (2° TBDPS cleaved) 
 
1) determined by HPLC analysis. 2) multiple deprot. = sum of multiple deprotection products. The major by-
product is given in parenthesis. 
 
The protocol with dried aluminum oxide in aprotic solvent also failed to induce any O-Si bond 
cleavage (entry 4).
[228]
 Next, commercially available ammonium fluoride was employed: in 
methanol, a slight excess sufficed to induce accompanying cleavage of the TBS group at C.7 
(entry 5),
[229]
 whereas the use of hexafluoroisopropanol as solvent significantly improved the 
outcome of this reaction. Even when excess NH4F was utilized, the deprotection was selective 
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for the desired primary position and allowed the targeted primary alcohol 11-epi-247 to be 
isolated in 67% yield after 60 h reaction time (entry 6).
[230]
  
With suitable conditions for the crucial selective deprotection identified, Dess-Martin oxidation 
of the primary alcohol yielded aldehyde 11-epi-227 as the immediate precursor for the 
envisioned MBH reaction. However, upon treatment with methyldiphenylphosphine in DMF at 
elevated temperature, no cyclization product was detected in the crude mixture. Rather, the 
NMR analysis pointed at the formation of the ring-expanded ketone; though, the small scale 
prohibited the isolation of the rearranged product.  
 
Scheme 3.50: Attempted MBH reaction with the mandelalide macrocycle. Conditions: a) DMP, NaHCO3, CH2Cl2, 
0 °C to rt, 52%; b) MePPh2 (30 mol%), DMF, 90 to 120 °C, sealed tube. 
To exclude that the epimeric stereogenic center at C.11 prohibited the population of a reactive 
conformation, the original diastereomer 227 was synthesized by applying the exact same 
conditions. The deprotection of 210 furnished the corresponding primary alcohol reliably, 
which was immediately oxidized to aldehyde 227. Again, the envisioned MBH cyclization 
failed under the conditions previously developed, although the reasons remained unclear. 
 
Scheme 3.51: Attempted MBH reaction with the mandelalide macrocycle. Conditions: a) NH4F, HFIP, rt, 65%; b) 
DMP, NaHCO3, CH2Cl2, 0 °C to rt, 84%; c) MePPh2 (30 mol%), DMF, 90 to 120 °C, sealed tube. 
It was speculated that the macrocyclic scaffold might prevent population of the required s-trans 
configuration of the indicated ester carbon-oxygen single bond (figure 3.9). Again, 
computational methods were used to evaluate whether the adoption of such a conformation was 
feasible.
[201]
 To shorten the computing time, the silyl groups at C.7 and C.21 were omitted, 
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although the results might be influenced by these massive steric differences. After geometry 
optimization (Gaussian09 RevD.01, B3LYP/6-31G* level) of the truncated macrocycle 248, 
energy minima for both s-cis and s-trans conformations were discovered. The displayed 
diagram shows that the s-trans configuration, which is approximately 11 kcal/mol higher in 
energy than the corresponding s-cis isomer, can be reached via a transition state amounting to 
14 kcal/mol. As can be seen in the calculated structure of the s-trans isomer, the aldehyde and 
C.2 are closer and bond formation seems possible. Based on these encouraging results, which 
suggested that the adoption of a reactive conformation is not a mission impossible – at least for 
the truncated variant without protecting groups – further studies with the macrocyclic system 
were carried out. 
         
                                                                 
Figure 3.9: Calculated energy minima for s-cis and s-trans conformers of truncated macrocycle 248. 
In parallel, this hypothesis was tested on the open form, namely aldehyde 249, which was 
obtained by selective desilylation of 220 and subsequent oxidation. Since compound 249 did 
not have any macrocyclic rigidity it was thought to better resemble model substrate 233; it was 
expected to allow the translation of the developed conditions as it should be able to adopt the 
required s-trans configuration of the ester more readily. However, when exposed to catalytic 
amounts of methyldiphenylphosphine in DMF at 90 °C, only epimerization in the -position of 
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the aldehyde was observed. Further increase of the reaction temperature led to the formation of 
a complex mixture with several unidentified decomposition products. These results indicated 
that the constraints entailed by the macrocycle were not responsible for the failure of the 
envisioned cyclization. 
 
Scheme 3.52: Attempted MBH reaction with a linear mandelalide precursor. Conditions: a) NH4F, HFIP, rt, 70%; 
b) DMP, NaHCO3, CH2Cl2, 0 °C to rt, 83%; c) MePPh2 (30 mol%), DMF, 90 to 120 °C, sealed tube; 
d) Me2PPh (30 mol%), DMF, 90 to 120 °C, sealed tube, 38% (6:1 E/Z). 
It was then speculated that the steric bulk imposed by the branching THP ring at C.5 might be 
accountable. Eventually, replacement of methyldiphenylphosphine by the sterically less bulky 
dimethylphenylphosphine enabled the crucial carbon-carbon bond formation and allowed the 
isolation of a 6:1 (E/Z)-mixture of 250 as a single diastereomer at C.24 comprising the -
lactone along with minor amounts of the elimination product. Remarkably, the very same 
phosphine had given exclusively the dehydrated product with the model substrate. After 
detailed analysis of the NOESY spectrum and comparison of the coupling constants, the 
hydroxyl group of the newly formed stereogenic center at C.24 was found to be in an anti-
relationship to the alkyl group at C.23. Therefore, the stereogenic center at C.24 was (R)-
configured, whereas the reassigned natural products 224 and 225 bear the opposite (24S)-
configuration. 
As a consequence, aldehyde 227 was treated with dimethylphenylphosphine hoping to override 
the observed stereocontrol by the chiral environment of the macrocyclic scaffold. Although the 
complete inversion of stereochemistry was not achieved, -lactone 226 was produced as a 
1.6 : 1 mixture of diastereomers in favor of the undesired (24R)-isomer. The two diastereomers 
and the dehydrated by-product 251 could be easily separated by column chromatography. The 
olefin geometry was assigned to be (E)-configured based on NOE contacts between the protons 
at C.4 and C.24; this assignment is consistent with the downfield shift of the proton at C.3, 
which experiences the anisotropic field of the ester carbonyl group. The corresponding (Z)-
isomers were produced to only minor extents and were inadvertently removed during the 
purification process. 
106 Total synthesis of mandelalide A 
 
 
Scheme 3.53: MBH reaction with macrocyclic aldehyde 227. Conditions: a) Me2PPh (30 mol%), DMF, 90 °C, 
sealed tube, (24R)-226: 34%, (24S)-226: 19%, 251: 5%. 
The stereogenic center at C.24 was assigned based on NOE contacts of the protons H.22, H.23 
and H.24 as depicted in figure 3.10 and was supported by the measured coupling constants 
extracted from 1D-COSY experiments. The strong NOE contacts between the hydroxyl group 
at C.24 and H.23 for (24R)-226, as well as the strong NOE signal of the protons H.23 and H.24 
for (24S)-226 were deemed indicative. This original assignment was confirmed throughout the 
course of this investigation. 
 
Figure 3.10: NOESY data and coupling constants for both diastereomeric -lactones of 226 (CDCl3, 600 MHz). 
With both diastereomers in hand, the directed dihydroxylation was pursued. At first, the 
undesired isomer (24R)-226 was dihydroxylated with osmium tetroxide in the presence of 
TMEDA. After reductive cleavage of the intermediate osmate ester with sodium bisulfite, the 
desired triol 252 was obtained as a single diastereomer in 65% yield. Intriguingly, the 
dihydroxylation was fully selective for the ,-unsaturated double bond, although the diene 
offered potentially reactive sites. To prevent overoxidation, the reaction was performed with 
1.01 eq. of osmium tetroxide and stopped once the addition was complete. The stereochemical 
outcome was assured by NOESY experiments, which clearly suggested that the delivery of the 
two hydroxyl groups occurred syn to the hydroxyl group at C.24 (figure 3.11) as expected. 
Indicative is the observed NOE contact between the hydroxyl group at C.2 with H.23. 
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Scheme 3.54: Dihydroxylation and deprotection. Conditions: a) OsO4 (1.01 eq.), TMEDA (1.15 eq.), CH2Cl2, 
−78 °C; then THF, aq. NaHSO3, rt, 65%; b) HF·pyridine, pyridine, THF, 0 °C to rt, 72%. 
The two remaining silyl groups at C.21 and C.7 were removed upon treatment with buffered 
HF·pyridine and the expected pentaol 253 was isolated in good yield. As expected, the spectral 
signature of 253 showed small but distinct deviations from those of deacylmandelalide D as 
reported by the isolation team. Compound 253 possesses three inverted stereogenic centers 
when compared to the reassigned natural degradation product and represents most likely the 
2,3,24-epi-isomer of deacylmandelalide D . 
 
Figure 3.11: NOESY data for the -lactone region of 252 (CDCl3, 600 MHz). 
Likewise, (24S)-226 was subjected to the conditions of directed dihydroxylation followed by 
reductive workup to give triol 254 as a single diastereomer in 78% yield.  
 
Scheme 3.55: Dihydroxylation and deprotection. Conditions: a) OsO4 (1.01 eq.), TMEDA (1.15 eq.), CH2Cl2, 
−78 °C; then THF, aq. NaHSO3, rt, 78%; b) HF·pyridine, pyridine, THF, 0 °C to rt, 86%. 
Surprisingly though, the observed NOE contacts suggested that the dihydroxylation was not 
directed by the allylic alcohol but rather delivered the two oxygen functionalities from the 
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opposite site anti to the alcohol at C.24. As depicted in figure 3.12, the NOE contact of the OH 
group at C.2 with H.23 can only be explained by selective di-oxo delivery from the top face. 
Moreover, all other observed NOE contacts support this unexpected stereochemical outcome. 
This assignment was backed up by the fact that deprotection of 254 produced pentaol 255, 
which clearly did not represent deacylmandelalide D. Again, both 
1
H and 
13
C spectra deviated 
significantly from those previously reported in the literature (see appendix for all spectra). 
According to this assignment, compound 255 represents the 2,3-epi-isomer of reassigned 
deacylmandelalide D. 
 
Figure 3.12: NOESY data for the -lactone region of 254 (CDCl3, 600 MHz). 
The poor quality of the reported NMR spectra of deacylmandelalide D prohibited a detailed 
comparison with the synthetic material. To exclude any ambiguity, the butyrated variants 
mandelalide C and D were targeted. When triol 254 was subjected to the esterification reaction 
with 2.2 equivalents of butyric anhydride, the mono-butyrated compound 256 was selectively 
produced. Again, the NOESY data of 256 indicated the syn-relationship of the hydroxy group 
at C.2 and H.23 (figure 3.13) as was the case after deprotection with HF·pyridine, which 
enabled the isolation of 257 in good yield.  
 
Scheme 3.56: Synthesis of a mandelalide C isomer. Conditions: a) butyric anhydride (2.2 eq.), pyridine, DMAP, 
CH2Cl2, 0 °C to rt, 69%; b) HF·pyridine, pyridine, THF, 0 °C to rt, 78%. 
Again, the NMR spectra of the synthetic material were clearly distinct from those of the natural 
sample. Based on the assignment made above, the synthesized compound 257 likely equals the 
2,3-epi-isomer of the putative reassigned structure of mandelalide C (224). 
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Figure 3.13: NOESY data for the -lactone region of 256 and 257 (CDCl3, 600 MHz). 
To evaluate why the allylic alcohol of (24S)-226 was unable to direct the ligated osmium 
tetroxide, but still delivered a single diastereomer, an exhaustive conformational analysis was 
performed. The relevant NOESY cross-peaks are represented in figure 3.14 and served as a 
basis for a structural discussion. The observed NOE contact between the hydroxyl group at 
C.24 with H.11 for (24S)-226 indicates that the hydroxyl group is likely pointing into the cavity 
of the macrocyclic ring and is therefore not available for hydrogen bonding with the incoming 
osmium complex. This is supported by the spatial proximity of protons H.3 and H.5 which have 
to align in a virtually parallel manner. The NOE contacts for (24R)-226 were manifold and 
likely represent an average over more than a single conformation. 
 
Figure 3.14: Selected NOESY contacts for allylic alcohols (24S)-226 and (24R)-226 (CDCl3, 600 MHz). 
In order to obtain a more detailed three-dimensional impression of the -lactones produced in 
the MBH reaction, the NOESY data of both diastereomers (24S)-226 and (24R)-226 were used 
as a basis for a computational energy optimization using Gaussian09 RevD.01 with the 
B3LYP/6-31G* method in the gasphase.
[201]
 For simplification purposes, the silyl groups were 
replaced by tert-butyl groups, which are supposedly similar in size but easier to integrate in the 
calculation. The distance between each proton couple, for which a NOE contact was 
experimentally observed, was kept below 4 Å during the geometry optimization. 
For the (24S)-isomer, an energy minimum (24S)-258a was quickly found, which was in 
agreement with all observed NOESY data (figure 3.15). The hydroxyl group at C.23 points 
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inside the macrocyclic ring and comes into close proximity to the THF oxygen atom suggesting 
the presence of a transannular hydrogen bond. This arrangement forces the alkene between C.2 
and C.3 to be aligned orthogonally to the plane of the macrocycle, which in consequence 
shields the -face of the olefin syn to the hydroxyl group at C.23. Both effects likely combine 
and contribute to the observed outcome of the dihydroxylation reaction: since the hydroxyl 
group is engaged in a hydrogen bonding, it cannot undergo a second interaction with the 
incoming osmium species, which then reacts with the more accessible site of the -system that 
lies anti to the allylic alcohol. The second lowest energy conformation was significantly higher 
in energy (+4.0 kcal/mol) and did not align the protons H.3 andH.5 in parallel as expected from 
the observed NOE contacts. Nevertheless, the conformation (24S)-258b as depicted in figure 
3.15 renders it unlikely that the allylic alcohol directs the bulky osmium species due to the 
flanking THP ring and the methyl group at C.11, which point towards the trajectory of an 
incoming reactant. 
   
Figure 3.15: Computed energy minima of (24S)-258: a (±0 kcal/mol), b (+4.0 kcal/mol). 
For the (24R)-isomer, all observed NOE contacts could not be mapped onto a single conformer. 
Rather, three different conformations within a range of 2.0 kcal/mol were found that 
collectively reflect the experimentally observed NOE correlations. The two conformers of 
lowest energies, (24R)-258c and (24R)-258d (figure 3.16), engage the C.23 hydroxyl group in a 
hydrogen bond with the oxygen atoms at C.5/9 or C.21, but do not allow for a clear distinction, 
which face of the olefin is more accessible. However, the third conformer (24R)-258e shows 
neither steric hindrance around the hydroxyl group nor around the top face of the alkene and 
could represent the most reactive conformer, which may well account for the observed directed 
dihydroxylation. 
(24S)-258a (24S)-258b 
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Figure 3.16: Computed energy minima of (24R)-258: c (−1.7 kcal/mol), d (−0.6 kcal/mol), e (+0.3 kcal/mol). 
The regioselective attack of the osmium species on the electron deficient olefin of (24S)-226 in 
the presence of the undoubtedly more electron rich dienyl motif was surprising and demanded 
closer inspection. It is generally accepted that osmium-based dihydroxylation reactions occur 
favorably with electron-rich double bonds unless they are sterically encumbered.
[231]
 Indeed, a 
control experiment without TMEDA showed a decreased reaction rate and led to unselective 
dihydroxylation of the olefinic moieties of the diene. Since four isomers were possibly formed, 
product isolation was not attempted; however, the olefinic signal H.3 remained intact and 
integrated properly when compared to the integral of H.23.  
Although in case of diamine ligands, improved reactivity towards electron-poor double bonds 
was reported,
[232]
 the inversion of regioselectivity has never been reported for unbiased 
systems. However, several groups noted that the regiochemical outcome can be inversed, if the 
more electron rich double bond is sterically shielded.
[233]
 In the present case, both olefins of the 
macrocyclic diene were thought to be sterically more accessible and more electron rich than the 
reactive site at C.2/C.3. Thus, this new type of reactivity is intriguing and was further explored 
on a simple model system. 
In this regard, aldehyde 260 and -lactone 259 were fused by means of an aldol reaction and the 
generated alcohol in -position was eliminated after transformation into the corresponding 
mesylate. This in situ protocol allowed the envisioned model system 261 to be accessed in only 
one step from commercial material. It possesses a trisubstituted ,-unsaturated ester that has 
to compete with the isolated disubstituted olefin during the dihydroxylation reaction. When 
compared to the mandelalide case, it misses the allylic hydroxyl group within the -lactone 
scaffold. Osmium tetroxide was added to a solution of 261 in the presence of TMEDA at low 
(24R)-258c (24R)-258d (24R)-258e 
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temperature until all starting material was consumed. The analysis of the crude mixture by 
1
H 
NMR indicated that two compounds were formed in a ratio of 8:1, which could be assigned to 
the mono-dihydroxylated compound 262 and the bis-dihydroxylated tetraol 263 after reductive 
workup. After column chromatography, the major component 262 was isolated in 72% yield.  
 
Scheme 3.57: Model system for a regioselective dihydroxylation reaction. Conditions: a) LiHMDS, 259, THF, 
−78 °C; then 260; then MsCl, NEt3, −78 °C to rt; then DBU, 0 °C to rt, (E)-261: 58%; (Z)-261: 9%; 
b) OsO4 (1.01 eq.), TMEDA, CH2Cl2, −78 °C; then aq. NaHSO3/THF, rt, crude: 262/263 = 8:1, 262: 
72%.  
Together with the observations from the attempted mandelalide C synthesis, these results 
appear to be the first examples of selective dihydroxylation of the electron poor and sterically 
more hindered double bond in the presence of an electron rich, less hindered one. Two 
mechanistic scenarios may account for the observed selectivity: 
(i) The TMEDA ligand increases the electron density at osmium, which leads to an 
increase of electron back-donation from the metal centers to the oxo-ligands. This 
electron enrichment might favor an inverse electron demand [3+2] cycloaddition 
with the electron poor double bond of the ,-unsaturated ester. In unligated cases, 
the reaction likely proceeds via a 'normal' electron demand cycloaddition and 
therefore favors electron rich olefins.
[234]
 
(ii) Due to the electron enriched oxo-ligands, the initial [3+2] cycloaddition occurs 
stepwise rather than concerted and starts with an oxa-Michael addition to the ,-
unsaturated ester. The generated enolate then attacks a second oxo-ligand 
completing the formal cycloaddition reaction or reacts with the osmium center 
under formation of a four-membered ring, which could rearrange to the five-
membered metallacycle.
[235]
 
At present, it remains unclear, which of the two mechanistic scenarios is responsible for the 
observed selectivity.
[235]
  
 
Although the total synthesis of family members of mandelalide A was not achieved during the 
course of this investigation, the chosen strategy is unique and displays the immaturity of 
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seemingly well-established reactions. Thus, a novel intramolecular MBH reaction was 
developed involving a -substituted Michael acceptor. However, the envisioned directed 
dihydroxylation reaction failed dependent on the configuration of the generated allylic alcohol. 
Nevertheless, an interesting reactivity pattern was observed for osmium-mediated 
dihydroxylations in the presence of diamines that merits further investigation. The current 
enterprise highlights the notion that total synthesis serves as a valuable platform for the design 
of new transformations and for the serendipitous discovery of novel reactivity. 
 
3.11 Biological evaluation of mandelalide A and isomers of the mandelalide 
family 
The promising biological profile as reported by the isolation team
[141]
 demanded for a more 
detailed cytotoxicity investigation of the synthetic material. In cooperation with Pfizer Inc. 
under guidance of Dr. Andreas Maderna, synthetic mandelalide A (219) and all three 
synthesized isomers (124, 11-epi-124, 11-epi-219) were tested for their activity towards three 
representative cancer cell lines. Moreover, two ring-expanded by-products (215, 264) formed in 
the final deprotection step were engaged in this initial screening (scheme 3.61).  
Unexpectedly and contrary to the results from the isolation team, all compounds - including 
mandelalide A - were rather inactive and showed values in the three-digit nanomolar scale 
(table 3.14). Only the natural product reached a reasonable activity against one of the tested 
cancer cell lines, which was in the range of the IC50 values reported by the isolation team. 
Simultaneously, the publication of Ye appeared online and independently validated these 
disappointing findings. In their hands, mandelalide A showed no appreciable activity (IC50 < 1 
µM) towards ten different cancer cell lines.
[146]
 
 
Table 3.14:  Cytotoxicity evaluation of mandelalide A and isomers (GI50 are given in nM). 
entry compound N87
1)
 MDA-361
1)
 HT29
1)
 
1 219 206 41 >1000 
2 124 598 >1000 >1000 
3 11-epi-219 423 391 >1000 
4 11-epi-124 962 >1000 >1000 
5 215 873 >1000 >1000 
6 263 722 >1000 >1000 
 
1) N87: human stomach cancer cell line; MDA-MB-361-DYT2: human 
breast carcinoma cells; HT29: human colon cancer cells. 
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Scheme 3.58: Overview of compounds engaged in biological screenings. 
All mandelalide A diastereomers as well as compounds 253, 255, and 257 were further engaged 
in a biological assessment to determine their antifungal activity inspired by the reported activity 
of related madeirolides. This investigation is still ongoing at present in the laboratories of Prof. 
Dr. Rolf Müller (Helmholtz-Institute for Pharmaceutical Research Saarland) and will be 
reported elsewhere. 
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4 Conclusion 
During the course of this thesis, ring-closing enyne-yne metathesis reactions were 
investigated in combination with subsequent (Z)-selective semireduction in the context of the 
total syntheses of marine natural products bearing conjugated polyunsaturated systems. To 
date, the selective assembly of 1,3-diene motifs via ring-closing alkene metathesis is far from 
mature and cannot be used as a reliable tool in complex settings.
[17]
 It is shown that the use of 
alkyne metathesis allows this problem to be fixed and enables the access to such scaffolds that 
are otherwise difficult to prepare. 
As a demanding setting for the recently developed generation of alkyne metathesis 
catalysts,
[25]
 the total syntheses of leiodermatolide and mandelalide A were addressed. 
Isolated in 2008 from Wright et al. from a deep-water marine sponge, leiodermatolide (1) 
comprises not only intriguingly challenging structural features such as an unusually 
substituted -lactone and a highly unsaturated macrocycle, but also displayed a fascinating 
biological profile.
[30]
 It showed antimitotic activity at single-digit nanomaler concentrations 
against a select panel of human cancer cell lines without interacting with purified tubulin.
[31]
 
This stands in sharp contrast to other well-established anticancer agents, like the vinca 
alkaloids, the taxanes, the epothilones or discodermolide to name only the most prominent 
ones. However, the structure of leiodermatolide could not be fully assigned by the isolation 
team, which led us to consider two possible diastereomers as the correct structure of the 
natural product (1 and 2). The unprecendented mode of action, the challenging structural 
features and the low natural abundance prompted us to engage in a total synthesis program. 
 
Scheme 4.1: Two possible stereostructures of leiodermatolide and putative mandelalide A. 
Mandelalide A, isolated in 2012 from a new ascidian Lissoclinum species, presented an even 
more complex architecture along with a purported high activity in a first cytotoxicity 
assay.
[141]
 Again, the low natural abundance prohibited further investigation of the biological 
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profile and a more sustainable and reliable supply to this glycosylated polyketidic natural 
product by total synthesis was desirable. 
The retrosynthetic strategies to both molecules are depicted in scheme 4.1; they rely on the 
use of a sequence of ring-closing alkyne metathesis (RCAM) and semihydrogenation for the 
selective assembly of the dienyl motifs within the macrocyclic frameworks. Both 
retrosynthetic disconnections offer novel challenges for the alkyne metathesis catalyst. In the 
leiodermatolide case, the challenge arises collectively from the steric impediment of the 
propargylic silyl ether, the electronic deactivation of both alkynes and by the ring strain of the 
highly unsaturated macrocycle. In the mandelalide series, a terminal alkyne was to be engaged 
in the alkyne metathesis reaction, a structural motif that has not been amenable for a long time 
to synthetic applications due to its tendency to polymerize upon contact with metal 
alkylidynes. 
 
Scheme 4.2: Common strategy for the selective assembly of leiodermatolide and mandelalide A. 
A first generation synthesis of leiodermatolide was developed in cooperation with Dr. Nina 
Kausch-Bausies and started with the synthesis of the required acid and alcohol fragments, 
which were designed to be of similar size for maximal convergence. This strategy should 
eventually allow for the synthesis of both possible diastereomers of the natural product (1 and 
2). 
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The synthesis of acid fragment 43 started with the literature-known syn-aldol reaction of 13 
and subsequent Parikh-Doering oxidation, followed by a second aldol reaction and 1,3-anti 
reduction to install the stereotetrad. After the crucial orthogonal protection of the two 
secondary alcohols, the site of the auxiliary was further elaborated into the tertiary allylic 
alcohol 41. This moiety was transformed into the ,-unsaturated acid to complete the 12-step 
synthesis of this fragment with an overall yield of 17%. 
 
Scheme 4.3: Synthesis of acid fragment 43. 
The enyne fragment 57 was synthesized from the literature-known iodo-aldehyde 46, which 
can be prepared in 4 steps from commercial malonate 47.
[56]
 A Masamune-Abiko anti-aldol 
reaction set the two contiguous stereogenic centers.
[60]
 After TBS-protection, the auxiliary 
was reductively removed and the generated alcohol oxidized to aldehyde 44, which was 
immediately employed in the Julia-Kocienski olefination reaction with sulfone R1. Lastly, 
silyl group removal with TBAF furnished alcohol 57, which was obtained after 10 steps with 
an overall yield of 12%.  
 
Scheme 4.4: Synthesis of enyne fragment 57. 
The successful strategy for the synthesis of the -lactone fragment 78 started with an anti-
aldol reaction of ent-13 with propanal. The resulting alcohol was acetylated and the product 
engaged in a Dieckmann-type condensation reaction to give literature-known 61.
[65]
 After 
extensive screening of suitable reaction conditions, the reagent controlled allylation of the 
highly enolizable -keto lactone 61 was achieved with the chiral allyl boron reagent R7 
allowing the side chain to be attached in the unusual pseudo-axial position.
[84]
 Further 
functionalization of the terminal alkene was achieved via olefin cross metathesis and 
furnished access to vinyl MIDA boronate 78. This strategy allowed for the synthesis of the -
lactone fragment in only 5 steps from commercial material with 30% overall yield and 
compares favorably with other approaches to this fragment.
[32, 40]
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Scheme 4.5: First generation synthesis of the -lactone fragment 78. 
The fragment coupling was realized by esterification of 43 and 57 under mediation of EDCI 
and DMAP. Notably, the key RCAM failed when catalyzed by molybdenum alkylidyne C1 
endowed with silyloxy-based ligands, producing instead an open dimeric species.
[25]
 
However, the use of the Cummins precatalyst C6 in combination with CH2Cl2 allowed the 
ring-closure to proceed and afforded macrocyclic enyne 80 in 72% yield.
[94]
 Compound 80 
was next engaged in a Suzuki-coupling with -lactone fragment 78, which mandated the use 
of a thallium base. After acidic workup, the cross-coupled adduct was reliably isolated in up 
to 56% yield. 
 
Scheme 4.6: Completion of the first generation synthesis of leiodermatolide (1). 
The propargylic alcohol had to be unmasked prior to semihydrogenation with Zn(Cu/Ag) to 
install the isomerization-prone (Z,Z)-diene motif as a single isomer. Selective carbamoylation 
was readily achieved at low temperatures, whereas the cleavage of the MOM group required 
careful optimization of the reaction conditions. Finally, it was discovered that treatment with 
dimethylboron bromide allowed the targeted natural product to be isolated with a longest 
linear sequence of 19 steps and an average yield of 82% per step. The very same sequence 
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was carried out with the enantiomeric -lactone to yield the isomeric compound 2. The natural 
product was assigned based on subtle differences in the NMR spectra and recorded optical 
rotations, which are fully matched by compound 1.
[39]
 This assignment was independently 
confirmed by the biological activity of synthetic 1, which is approximately two orders of 
magnitude higher than that of 2. 
 
Scheme 4.7: Second generation synthesis of -lactone fragment 120. 
Because of the promising biology, a second generation synthesis was developed in 
collaboration with Dr. Damien Mailhol to obliterate the remaining synthetic bottlenecks.
[113]
 
In detail, the stoichiometric allylboration of -keto ester 61 was replaced by a catalytic 
version that relied on a commercial binol-derived ligand allowing the practicability, yield and 
diastereoselectivity of this transformation to be largely improved.
[118]
 The corresponding 
propargylation further enabled the replacement of the rather low-yielding Suzuki coupling for 
a high-yielding Stille coupling (93%). Inspired by observations during the first generation 
synthesis, the alkyne metathesis was carried out with the free propargylic alcohol. This 
adjustment enabled the use of the undoubtedly more user-friendly molybdenum alkylidyne 
C1, which catalyzed the reaction with significantly reduced loading even at ambient 
temperature.
[25]
 This result is remarkable in light of the potential side reactions of propargylic 
alcohols and represents one of the earliest examples, in which a free alcohol is tolerated 
during an alkyne metathesis reaction.
[122a, 122b]
  
 
Scheme 4.8: Revised alkyne metathesis and second generation synthesis of 1. 
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In summary, all throughput-limiting steps of the first generation synthesis were replaced by 
more convenient and more robust protocols to establish a reliable supply of appreciable 
amounts of this otherwise scarce natural product. 
Moreover, the sequence described herein enabled the synthesis of a first set of analogues, 
which was used to record structure activity relationships and shed light on the pharmacophore 
of leiodermatolide. Whereas the -lactone scaffold seems to be required for the remarkable 
potency of 1, the carbamate is an extraneous site and can be replaced by an acetate moiety 
without significant loss of biological activity. This result might enable the use of 
leiodermatolide as a payload for an antibody drug conjugate and deserves closer 
investigation.
[126]
 Furthermore, the biochemical mechanism of leiodermatolide was 
investigated in some detail. All acquired data, including cell cycle analysis, micronuclei 
formation, centrosome amplification and immunofluorescence imaging, point to centrosome 
declustering as the likely mode of action.
[113]
 If confirmed in further studies, this result is 
promising due to the fact that healthy cells generally do not suffer from amplified 
centrosomes and are significantly less susceptible towards centrosome declustering agents 
than tumor cells. 
 
An even more challenging enyne-yne metathesis/semihydrogenation tactic was employed for 
the total synthesis of mandelalide A (124). The northern alcohol fragment was assembled with 
a strategic olefin cross-metathesis reaction that fused the readily accessible building blocks 
181 and 182. Subsequently, a SmI2-catalyzed Evans-Tishchenko reaction installed the 1,3-anti 
diol motif and simultaneously allowed the differentiation of the two secondary alcohols. The 
all-cis substituted THF ring was constructed via cyclization of an alcohol onto the double 
bond, which was activated with an electrophilic selenyl species generated from N-PSP and 
catalytic amounts of a Lewis base.
[181b]
 Finally, the alkyne was introduced and the secondary 
alcohol at C.23 released to give the northern fragment 194 after 13 steps in the longest linear 
sequence with an overall yield of 17%. 
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Scheme 4.9: Synthesis of alcohol fragment 194 via olefin cross-metathesis. 
The synthesis of the southern fragment started with a bidirectional allylation of 1,3-
propanediol to give the literature-known C2-symmetric diol 136 that was desymmetrized 
upon iodo-etherification.
[151]
 The stereogenic center at C.11 was next introduced by an 
asymmetric alkylation reaction with the pseudoephedrine-derived auxiliary R12, which was 
reductively cleaved prior to installing the enoate moiety via cross-metathesis. The (E)-enyne 
was introduced in a multi-step sequence consisting of oxidation, Takai olefination and Suzuki 
coupling. Saponification of the ester completed the synthesis of the acid fragment, which was 
achieved with an overall yield of 11% over ten steps. 
 
Scheme 4.10: Synthesis of acid 151 fragment containing the (E)-enyne. 
The two fragments were combined in an esterification reaction setting the stage for the 
projected enyne-yne metathesis. The formation of the macrocycle via RCAM worked 
exceptionally well in the presence of molybdenum catalyst C1 and proceeded at ambient 
temperature. This reaction represents the first application of terminal acetylene metathesis in 
the context of complex natural product synthesis and will certainly encourage further 
applications of this emerging strategy in the future.
[148h, 236]
 The following semihydrogenation 
with Zn(Cu/Ag) produced the desired diene with full control over the double bond 
geometry.
[96]
 Protecting group manipulations and glycosidation with the trichloroacetimidate 
201, which could be prepared via two independent routes, completed the synthesis of putative 
mandelalide A (124). A largely catalysis-based route was thus developed that required 21 
steps along the longest linear sequence with an overall yield of 4% (average yield: 83%).
[144]
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Scheme 4.11: Completion of the total synthesis of mandelalide A enabled the structural reassignment. 
However, the recorded NMR spectra were not in agreement with those reported for the natural 
product. Thus, mandelalide A had been missasigned by the isolation team. During the course 
of this investigation, four stereoisomers that might constitute the true natural product were 
prepared following the same synthetic logic and allowed for a structural reassignment of 
mandelalide A, which is correctly represented by structure 219. This compound has all five 
stereogenic centers of the northern fragment inverted, which is reminiscent of the 
madeirorolides, a related family of polyketidic natural products. Unfortunately, the promising 
biological profile as suggested by the isolation team could not be confirmed with the synthetic 
material obtained in this study or by others.
[146]
 
Equipped with a robust scalable route and the correct structure, it was hypothesized that 
access to other members of the mandelalide family could be gained from subjecting a 
common intermediate to a modified endgame. For this purpose, a novel intramolecular 
Morita-Baylis-Hillman cyclization was developed that could eventually be performed on the 
macrocyclic system.  
The choice of phosphine was crucial and only dimethylphenylphospine allowed the 
unprecedented formation of the desired -lactone within the macrocyclic scaffold. The 
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generated allylic alcohol was intended to serve as a directing group for the consecutive 
dihydroxylation;
[220a, 221]
 however, this reaction occurred from the opposite face anti to the 
alcohol at C.24. The careful analysis of NOESY data in combination with computational 
geometry optimizations indicated that (24S)-226 likely adopts a conformation in which the 
allylic alcohol points into the cavity of the macrocycle and can no longer steer the incoming 
osmium tetroxide reagent. Moreover, one face of the alkene is shielded by the surrounding 
macrocycle, leaving only the -face anti to the hydroxyl group open to attack by the 
dihydroxylating agent. Intriguingly, the regioselectivity was unprecedented and could be 
generalized by translation to a simple model substrate. These results seem to represent the 
first examples of selective dihydroxylation of electron poor olefins in the presence of less 
hindered and more electron rich alkenes and deserve further investigation. Selective 
butanoylation and deprotection of the remaining silyl groups allowed the isolation of tetraol 
257, which most likely comprises the (2,3)-epimer of reassigned putative mandelalide C. 
 
Scheme 4.12: Attempted synthesis of "reassigned" mandelalide C. 
Although the challenging carbon framework of the mandelalide family could be prepared via 
the chosen strategy, the introduction of the oxygen functionalities via directed 
dihydroxylation failed to follow the expected stereochemical course. Future studies should 
therefore consider to carry out the dihydroxylation at an earlier stage of the synthesis or to 
redesign the synthesis of this fragment. 
 
In conclusion, the results obtained herein highlight the maturity of ring-closing alkyne 
metathesis, which can be reliably performed in the presence of various proximal, Lewis basic 
functional groups even within the challenging context of natural product synthesis. The 
synthetic applications clearly expanded the frontiers of alkyne metathesis with two inherently 
challenging substrates and proved that RCAM is an indispensable tool, even in cases where 
olefin metathesis is likely to find its limits. The combination with subsequent (Z)-selective 
semireduction allowed the stereoselective assembly of (Z,Z)- and (E,Z)-dienes within 
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macrocyclic frameworks as exemplified by the stereoselective total syntheses of 
leiodermatolide and mandelalide A. 
Both successful endeavors further highlight that total synthesis remains the ultimate tool for 
structure assignments, especially when dealing with segregated stereoclusters, which are 
difficult or impossible to assign via spectroscopic means. In the course of this thesis, the 
synthesis of two leiodermatolide isomers enabled the assignment of the previously unknown 
stereostructure of the natural compound. Furthermore, mandelalide A was originally 
misassigned by the isolation team and required four possible diastereomers to be synthesized, 
as an attempted computational prediction failed. Fortunately, one of the synthesized isomers 
correctly resembles the natural product and allowed the structure to be established. This 
encouraged us to pursue a close relative, mandelalide C, of which only a diastereomer could 
be accessed; yet, the unprecedented discoveries made during this specific synthetic approach 
are deemed intriguing. 
The results of this thesis, in particular the total synthesis and structure assignment of 
leiodermatolide along with the biological evaluation of the natural product and analogues 
thereof, as well as the total synthesis and structure reassignment of mandelalide A together 
with the methodology spin-off towards mandelalide C, demonstrate the importance of 
synthetic organic chemistry. 
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5. Experimental section 
5.1 General 
All reactions were carried out under Ar in flame-dried glassware unless H2O was used as a solvent or 
otherwise noted. The following solvents and organic bases were purified by distillation over the drying 
agents indicated and were transferred under Ar: THF, Et2O (Mg/anthracene); hexane, toluene (Na/K), 
DBU, diisopropylamine, DMSO, CH2Cl2, DMA, HMPA (CaH2); MeOH (Mg, stored over 3 Å MS), 
EtOH (3 Å MS), EtOAc (P2O5, filter through dry Al2O3, store over 4 Å MS). 1,4-Dioxane, DMF, 
MeCN , NEt3 and pyridine were dried by an adsorbtion solvent purification system based on molecular 
sieves. DBU (CaH2), diisopropylamine (CaH2), (n-Bu)2BOTf, allyl acetate, trimethylborate, acetyl 
chloride, acetic anhydride, N-trimethylsilyl morpholine, and isobutyraldehyde were distilled under Ar 
prior to use. All other commercially available compounds (Alfa Aesar, Aldrich, Fluka, Lancaster) 
were used as received. The following compounds were prepared according to the cited protocol by 
myself or within the department of Prof. Fürstner: C1,
[25a]
 C2,
[25a]
 C4,
[25b]
 C5,
[92]
 C6,
[93a]
 Soderquist 
reagent R7,
[84]
 Pd(PPh3)4,
[237]
 Me2BBr,
[238]
 R10,
[117b]
 R11,
[159a]
 R12,
[160]
 SmI2,
[175]
 Leighton reagent 
R17,
[167]
 TBDPSCl,
[239]
 Ohira-Bestmann reagent R18.
[183b]
 
Compounds 13, ent-13, 21, 38, 39, 40, 41, 42, 43 and their precursors were originally prepared by Dr. 
Nina Kausch-Busies; compounds 195, 196, 197, 198, 199, 200, and 201 were prepared by M. Sc. 
Katharina Holthusen. The procedures described herein are taken from their reports with only minor 
modifications. 
Thin layer chromatography (TLC) was performed on Macherey-Nagel precoated plates 
(POLYGRAM® SIL/UV254). Detection was achieved under UV light (254 nm) and by staining with 
either acidic p-anisaldehyde or basic KMnO4 solution.  
Flash chromatography was performed with Merck silica gel 60 (40-63 µm) using predistilled or HPLC 
grade solvents. In some cases, fine silica gel (15-40 µm pore size) had to be used and is indicated 
within the experimental procedure.  
Spectra were recorded on Bruker DPX 300, AMX 300, AV 400, AV 500 or AVIII 600 spectrometer in 
the solvents indicated; chemical shifts (δ) are given in ppm relative to TMS, coupling constants (J) in 
Hz. The solvent signals were used as references and the chemical shifts converted to the TMS scale 
(CDCl3: δH 7.24 ppm, δC 77.0 ppm; C6D6: δH7.16 ppm, δC128.0 ppm; CD2Cl2: δH5.32 ppm, 
δC53.8 ppm; [D6]-DMSO: δH2.50 ppm, δC39.52 ppm; pyridine-d
5
: δH8.74 ppm; δC 150.35 
ppm). Multiplets are indicated by the following abbreviations: s: singlet, d: doublet, t: triplet, q: 
quartet, quint: quintet; hept: heptet, m: multiplet. The abbreviation "br" indicates a broad signal. 
13
C 
NMR spectra were recorded [
1
H]-decoupled and the values of chemical shifts are rounded to one 
position after decimal point. All spectra from the 500 MHz and 600 MHz spectrometers were acquired 
by the NMR department under guidance of Dr. Christophe Farès at the Max-Planck-Institut für 
Kohlenforschung. 
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IR spectra were recorded on Spectrum One (Perkin-Elmer) spectrometer and Alpha Platinum ATR 
(Bruker) at room temperature, wavenumbers (̃) are given in cm1.  
Mass spectrometric samples were measured by the department for mass spectrometry at the Max-
Planck-Institut für Kohlenforschung. The following equipment was used: MS (EI): Finnigan MAT 
8200 (70 eV), ESI-MS: Bruker ESQ3000, accurate mass determinations: Bruker APEX III FT-MS (7 
T magnet) or Mat 95 (Finnigan). All values are given in  
Optical rotations were measured with a Perkin-Elmer Model 343 polarimeter at a wavelength of 
589 nm. They are given as specific optical rotation with exact temperature, concentration 
(c /(10 mg/mL)) and solvent. 
 
5.2 Total synthesis of leiodermatolide 
5.2.1 Synthesis of acid 43. 
(S)-4-Benzyl-3-((2S,3R)-3-hydroxy-2-methylpentanoyl)oxazolidin-2-one (20). (n-Bu)2BOTf (1 M in 
CH2Cl2, 49 mL, 49 mmol) was slowly added to a solution of oxazolidinone 13 (9.7 g, 
41.6 mmol) in CH2Cl2 (92 mL) at 0 °C. NEt3 (7.6 mL, 55 mmol) was then added at 
such a rate as to keep the internal temperature below 2 °C. Once the addition was 
complete, the mixture was cooled to −78 °C before freshly distilled propionaldehyde (4.4 mL, 
46.4 mmol) was introduced. The mixture was stirred for 30 min at –78 °C before the CO2/acetone bath 
was replaced by an ice bath. Stirring was continued for 1 h and the reaction quenched with aq. 
phosphate buffer (46 mL, pH 7) and MeOH (138 mL) (T < −6 °C). Next, a 1:2 mixture of MeOH and 
30% aqueous H2O2 (138 mL) was carefully added such that the internal temperature never rose above 
10 °C. The mixture was stirred for 1 h once the addition was complete. After concentration, Et2O 
(50 mL) was added to the slurry and the aqueous phase extracted with Et2O (3 x 50 mL). The 
combined extracts were washed with aq. sat. NaHCO3 (12 mL) and brine (12 mL) before being dried 
over MgSO4. Evaporation of the solvent and flash chromatography (hexanes/EtOAc, 3:1) of the 
residue, followed by recrystallization of the product from Et2O/hexanes afforded the title compound as 
a white solid (11.71 g, 97%). [∝]𝐷
20 = + 20.8 (c = 1.38, CHCl3), 
1
H NMR (300 MHz, CDCl3): δ = 7.36 
– 7.25 (m, 3H), 7.22 – 7.16 (m, 2H), 4.68 (ddq, J = 13.7, 6.9, 3.4 Hz, 1H), 4.27 – 4.12 (m, 2H), 3.89 – 
3.80 (m, 1H), 3.80 – 3.70 (m, 1H), 3.24 (dd, J = 13.4, 3.3 Hz, 1H), 2.76 (dd, J = 13.4, 9.5 Hz, 1H), 
1.88 (br s, 1H), 1.66 – 1.32 (m, 2H), 1.23 (d, J = 7.0 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H) ppm; 13C NMR 
(75 MHz, CDCl3): δ = 177.6, 153.0, 135.0, 129.4, 129.0, 127.4, 73.0, 66.2, 55.1, 41.7, 37.8, 26.7, 10.4, 
10.2 ppm; IR (film):  ̃ = 3466, 2969, 1778, 1696, 1455, 1385, 1210, 1113, 1030, 969, 762, 749, 702 
cm
−1
; MS (EI) m/z (%): 292 (7), 291 (30), 273 (9), 244 (46), 233 (30), 178 (42), 158 (100), 142 (12), 
134 (63), 133 (20), 117 (38), 116 (23), 115 (49), 97 (26), 91 (56), 86 (80), 77 (7), 69 (34), 57 (45), 42 
(15); HRMS (ESIpos): m/z: calcd for C16H21NO4Na: 314.1363, found 314.1364. The analytical and 
spectroscopic data are in agreement with those reported in the literature.
[240]
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(S)-1-((S)-4-Benzyl-2-oxo-oxazolidin-3-yl)-2-methylpentane-1,3-dione (21). The aldol product 
obtained in the previous step (5.70 g, 19.6 mmol) was dissolved in CH2Cl2 (92 mL) 
and DMSO (92 mL) and the solution cooled to −15 °C. NEt3 (8.20 ml, 58.8 mmol) 
was introduced, followed by slow addition of a solution of SO3·pyridine (9.40 g, 
58.8 mmol) in DMSO (92 mL) and the resulting mixture was stirred for 3 h. For workup, Et2O 
(400 mL) was added and the organic phase washed with aq. KHSO4 (1 M, 400 mL), sat. aq. NaHCO3 
(400 mL) and brine (400 mL). After drying of the organic layer over MgSO4 and concentration in 
vacuo, the residue was purified by flash chromatography (hexanes/EtOAc, 6:1 to 3:1) to give product 
21 as a white solid (4.96 g, 88%). m.p. = 71-72 °C (hexanes); [∝]𝐷
20= +137.4 (c = 0.91, CHCl3); 
1
H 
NMR (300 MHz, CDCl3): δ = 7.39 – 7.29 (m, 3H), 7.27 – 7.18 (m, 2H), 4.82 – 4.70 (m, 1H), 4.62 (q, 
J = 7.3 Hz, 1H), 4.31 – 4.09 (m, 2H), 3.33 (dd, J = 13.3, 3.3 Hz, 1H), 2.85 – 2.57 (m, 3H), 1.46 (d, J = 
7.3 Hz, 3H), 1.09 (t, J = 7.3 Hz, 3H) ppm; 
13
C NMR (100 MHz, CDCl3): δ = 208.2, 170.3, 153.8, 
135.1, 129.4, 129.0, 127.3, 66.5, 55.3, 52.7, 38.0, 34.0, 12.9, 7.5 ppm; IR (film):  ̃ = 2985, 1760, 
1718, 1702, 1455, 1390, 1360, 1250, 1213, 1125, 1082, 1082, 1051, 1010, 974, 763, 748, 703 cm
–1
; 
MS (EI) m/z (%): 289 (15) [M
+
], 260 (15), 233 (15), 178 (10), 142 (25), 117 (40), 91 (25), 65 (5), 57 
(100), 42 (5); HRMS (ESIpos): m/z: calcd for C16H19NO4Na: 312.1206, found 312.1204. The 
analytical and spectroscopic data are in agreement with those reported in the literature.
[241] 
 
But-2-ynal (38). But-2-ynol (5.0 mL, 66 mmol) was added to a vigorously stirred suspension of MnO2 
(activated, 65 g, 748 mmol) in Et2O (7 mL). Additional Et2O (17 mL) was then added and 
the mixture was stirred at ambient temperature overnight. After filtration through a pad of 
Celite
®
 and careful evaporation of the filtrate at  40 °C bath temperature, the residue was 
distilled (b.p. 75-80 °C) under Ar to give but-2-ynal as a pale yellow liquid (1.99 g, 44%), which must 
be stored at low temperature and used readily. 
1
H NMR (300 MHz, CDCl3):  = 9.13 (dd, J = 1.8, 0.9 
Hz, 1H), 2.05 (d, J = 1.0 Hz, 3H) ppm. The analytical and spectroscopic data are in agreement with 
those reported in the literature.
[242]
 
 
(2S,4R,5R)-1-((S)-4-Benzyl-2-oxo-oxazolidin-3-yl)-5-hydroxy-2,4-dimethyloct-6-yne-1,3-dione. 
NEt3 (0.78 mL, 5.66 mmol) was added dropwise to a solution of Sn(OTf)2 
(2.36 g, 5.66 mmol) in CH2Cl2 (27 mL). After cooling to −30 °C, a solution 
of 21 (1.56 g, 13.07 mmol) in CH2Cl2 (9 mL) was slowly introduced and the 
mixture was stirred for 1 h at this temperature before it was cooled to −78 °C and but-2-ynal (38) 
(1.8 ml, 29 mmol) was added dropwise. After an additional 45 min, the mixture was diluted with 
CH2Cl2 (30 mL) and added to a vigorously stirred aq. solution of NaHSO4 (1 M, 80 mL) at 0 °C. This 
slurry was stirred for 10 min before the aqueous phase was extracted with CH2Cl2 (4 x 80 mL). The 
combined extracts were washed with aq. sat. NaHCO3 (120 mL), dried over Na2SO4 and concentrated. 
Flash chromatography of the residue afforded the title compound as a white solid (1.05 g, 55%, 88% 
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brsm). [∝]𝐷
20= + 101.1 (c = 0.55, CHCl3); 
1
H NMR (400 MHz, CDCl3): δ = 7.35 – 7.25 (m, 3H), 7.23 
– 7.14 (m, 2H), 4.90 (q, J = 7.3 Hz, 1H), 4.78 – 4.68 (m, 1H), 4.60 (s, 1H), 4.31 – 4.21 (m, 1H), 4.17 
(dd, J = 9.1, 2.8 Hz, 1H), 3.28 (dd, J = 13.4, 3.2 Hz, 1H), 3.02 – 2.88 (m, 1H), 2.76 (dd, J = 13.3, 
9.6 Hz, 1H), 2.40 (s, 1H), 1.82 (d, J = 1.8 Hz, 3H), 1.47 (d, J = 7.2 Hz, 3H), 1.36  (d, J = 7.2 Hz, 3H) 
ppm; 
13
C NMR (100 MHz, CDCl3): δ = 209.3, 170.5, 153.7, 135.0, 129.3, 129.0, 127.4, 82.5, 78.0, 
66.4, 63.3, 55.2, 51.8, 50.3, 37.9, 12.7, 12.0, 3.4 ppm; IR (film):  ̃ = 3511, 2940, 1775, 1716, 1690, 
1454, 1357, 1212, 1117, 998, 913, 762, 735, 703 cm
−1
; MS (EI) m/z (%): 357 (2), 339 (2), 311 (2), 289 
(40), 260 (17), 233 (30), 204 (1), 178 (29), 159 (3), 156 (5), 142 (19), 134 (38), 125 (33), 117 (78), 
112 (100), 107 (26), 101 (16), 97 (3), 91 (74), 86 (73), 83 (25), 79 (24), 77 (13), 69 (32), 65 (19), 57 
(89), 42 (30), 39 (28), 29 (26); HRMS (ESIpos): m/z: calcd for C20H23NO5Na: 380.1468, found 
380.1470.  
 
(S)-4-Benzyl-3-((2S,3R,4S,5R)-3,5-dihydroxy-2,4-dimethyloct-6-ynoyl)oxazolidin-2-one (39). 
Me4NBH(OAc)3 (3.72 g, 14.2 mmol) was dissolved in MeCN (260 mL) and 
HOAc (160 mL) and the resulting mixture cooled to −50 °C. A solution of 
the ketone described above (1.01 g, 2.83 mmol) in MeCN (34 mL) was 
added and the mixture warmed to +10 °C overnight. The mixture was then poured into a pre-cooled 
(0 °C) mixture of sat. aq. solution of Rochelle salt (140 mL) and tert-butyl methyl ether (140 mL). 
Under vigorous stirring, sat. NaHCO3-solution and solid NaHCO3 were added in small portions until 
no further gas evolution could be observed. The phases were separated and the aqueous layer was 
extracted with tert-butyl methyl ether (4 x 100 mL). The combined extracts were washed with brine, 
dried over MgSO4 and concentrated to obtain the desired diol (1.00 g, 98%) as a mixture of 
diastereomers (2:92:4:1:0.5 as determined by HPLC: 50 mm Ultra HAT Pro 18, 120 A, 2 m,  3.0 
mm, MeOH/H2O = 60:40, 0.5 mL/min, 308 K, 27.4 MPa). [∝]𝐷
20= + 36.0 (c =1.1, CHCl3); 
1
H NMR 
(400 MHz, CDCl3): δ = 7.35 – 7.25 (m, 3H), 7.21 – 7.15 (m, 2H), 4.75 – 4.66 (m, 1H), 4.45 (s, 1H), 
4.27 – 4.15 (m, 3H), 4.14 – 4.01 (m, 1H), 3.89 – 3.76 (m, 2H), 3.22 (dd, J = 13.4, 3.4 Hz, 1H), 2.82 – 
2.73 (m, 1H), 2.06 – 1.93 (m, 1H), 1.84 (t, J = 3.6 Hz, 3H), 1.24 (dd, J = 13.8, 7.0 Hz, 3H), 0.91 – 0.83 
(m, 3H) ppm; 
13
C NMR (100 MHz, CDCl3): δ = 178.1, 152.7, 134.9, 129.4, 129.0, 127.5, 81.9, 78.3, 
73.7, 67.3, 66.2, 54.9, 39.7, 39.1, 37.8, 12.9, 9.7, 3.6 ppm; IR (film):  ̃ = 3417, 2974, 2921, 1778, 
1698, 1455, 1388, 1287, 978, 762, 702 cm
−1
; MS (EI) m/z (%): 359 (1), 341 (3), 308 (1), 273 (68), 262 
(7), 244 (3), 233 (38), 183 (3), 178 (50), 165 (14), 159 (4), 149 (4), 142 (12), 136 (11), 134 (29), 126 
(13), 117 (57), 109 (34), 103 (8), 96 (100), 91 (71), 86 (74), 80 (44), 77 (11), 69 (35), 67 (11), 65 (17), 
57 (51), 41 (32), 39 (18), 29 (23), 27 (9); HRMS (ESIpos): m/z: calcd for C20H25NO5Na: 382.1625, 
found 382.1620. 
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(S)-4-Benzyl-3-((2S,3R,4S,5R)-5-(tert-butyldimethylsilyloxy)-3-hydroxy-2,4-dimethyloct-6-
ynoyl)oxazolidin-2-one. NEt3 (0.97 mL, 4.2 mmol) and TBSOTf (0.78 mL, 5.6 mmol) were 
successively added to a solution of the above diol (1.00 g, 2.78 mmol) in 
CH2Cl2 (15 mL) at −78 °C. After stirring for 3 h, the reaction was quenched 
with sat. aq. NaHCO3 and the resulting mixture warmed to ambient 
temperature. The aqueous phase was extracted with CH2Cl2 (3 x 15 mL), and the combined extracts 
were washed with brine, dried over Na2SO4 and concentrated. The residue was purified by flash 
chromatography (hexanes/EtOAc, 9:1 to 7:1) to obtain the title compound as a colorless oil (1.17 g, 
89%). [∝]𝐷
20 = + 36.8 (c =1.64, CHCl3); 
1
H NMR (400 MHz, CDCl3): δ = 7.34 – 7.24 (m, 3H), 7.23 – 
7.17 (m, 2H), 4.73 – 4.62 (m, 2H), 4.26 – 4.05 (m, 3H), 3.91 (d, J = 2.0 Hz, 1H), 3.85 (qd, J = 6.9, 
2.4 Hz, 1H), 3.31 (dd, J = 13.3, 3.2 Hz, 1H), 2.74 (dt, J = 16.7, 8.4 Hz, 1H), 1.86 – 1.73 (m, 4H), 1.26 
– 1.18 (m, 3H), 0.95 (d, J = 7.0 Hz, 3H), 0.87 (s, 9H), 0.12 (s, 3H), 0.11 (s, 3H) ppm; 13C NMR (100 
MHz, CDCl3): δ = 176.5, 153.0, 135.4, 129.4, 128.9, 127.3, 82.1, 78.5, 72.6, 66.4, 66.1, 55.6, 41.8, 
40.3, 37.8, 25.8, 18.1, 11.7, 9.1, 3.5, −4.5, −5.4 ppm; IR (film):  ̃ = 3509, 2928, 1782, 1702, 1680, 
1455, 1387, 1360, 1285, 1242, 1209, 1104, 1050, 1019, 984, 938, 836, 777, 702, 678 cm
−1
; MS (EI) 
m/z (%): 473 (M+, 6), 416 (21), 398 (3), 348 (4), 341 (3), 337 (7), 336 (32), 324 (329, 318 (10), 306 
(14), 290 (5), 273 (8), 262 (4), 252 (44), 239 (14), 233 (14), 183 (100), 178 (41), 165 (5), 159 (42), 
147 (85), 143 (53), 136 (5), 133 (6), 127 (9), 119 (14), 117 (32), 115 (25), 109 (20), 97 (14), 91 (27), 
81 (8), 77 (6), 75 (72), 73 (49), 57 (11), 29 (5); HRMS (ESIpos): m/z: calcd for C26H39NO3SiNa: 
496.2490, found 496.2491.  
 
(2S,3R,4S,5R)-5-(tert-Butyldimethylsilyloxy)-3-hydroxy-N-methoxy-N,2,4-trimethyloct-6-yn 
amide (40). AlMe3 (2 M in heptane, 4.2 mL, 8.31 mmol) was carefully added (exothermic reaction) to 
a solution of N,O-dimethylhydroxylamine hydrochloride (0.811 g, 
8.31 mmol) in THF (7 mL) at 0 °C and the resulting suspension was stirred 
for 15 min at this temperature and for 75 min at room temperature. The mixture was then cooled to 
−70 °C before a solution of the above mentioned silyl ether (1.05 g, 2.22 mmol) in THF (10 mL) was 
slowly added. The mixture was warmed to −10 °C over 8 h before it was poured into a chilled (0 °C) 
sat. aq. Rochelle salt solution (300 mL). The resulting suspension was stirred for 45 min and then 
repeatedly extracted with CH2Cl2. The combined extracts were washed with brine, dried over Na2SO4 
and concentrated. The residue was purified by flash chromatography (hexanes/EtOAc, 6:1) to afford 
the title compound as a colorless oil that solidified in the fridge (715 mg, 90%). [∝]𝐷
20 = +46.5 (c = 
0.79, CHCl3); mp  13 °C; 
1
H NMR (400 MHz, CDCl3): δ = 4.86 – 4.82 (m, 1H), 4.05 (s, 1H), 3.75 
(dd, J = 9.2, 2.4 Hz, 1H), 3.69 (s, 3H), 3.18 (s, 3H), 3.06 – 2.92 (m, 1H), 1.80 (d, J = 2.2 Hz, 3H), 1.73 
– 1.63 (m, 1H), 1.11 (d, J = 7.1 Hz, 3H), 0.95 (d, J = 6.9 Hz, 3H), 0.86 (s, 9H), 0.11 (s, 3H), 0.08 (s, 
3H) ppm; 
13
C NMR (100 MHz, CDCl3): δ = 178.3, 80.5, 80.3, 71.7, 63.1, 61.4, 42.2, 36.0, 32.0, 25.8, 
18.1, 10.4, 9.5, 3.4, −4.6, −5.3 ppm; IR (film):  ̃ = 3458, 2956, 2932, 2857, 1639, 1462, 1416, 1388, 
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1361, 1292, 1251, 1178, 1146, 1113, 1056, 1016, 998, 863, 833, 776, 684 cm
−1
; MS (EI) m/z (%): 357 
(1), 326 (2), 302 (3), 300 (47), 297 (13), 241 (9), 232 (3), 225 (6), 220 (34), 217 (24), 208 (27), 183 
(100), 174 (7), 164 (16), 159 (8), 153 (16), 143 (24), 138 (7), 127 (7), 117 (30), 115 (42), 109 (17), 97 
(19), 87 (9), 85 (11), 81 (12), 75 (90), 73 (64), 62 (8), 61 (12), 59 (12), 45 (7), 41 (8), 29 (14); HRMS 
(ESIpos): m/z: calcd for C18H35NO4SiNa: 380.2228, found 380.2228. 
 
(2S,3R,4S,5R)-5-(tert-Butyldimethylsilyloxy)-N-methoxy-3-(methoxymethoxy)-N,2,4-trimethyl 
oct-6-ynamide. i-Pr2NEt (3.01 mL, 18.2 mmol) and MOMCl (0.691 mL, 9.10 mmol) were added to a 
solution of 16 (650 mg, 1.82 mmol) in DMF (5 mL) and the resulting 
slightly fuming mixture was stirred at 50 °C for 18 h. After cooling, tert-
butyl methyl ether (20 mL) and brine (30 mL) were introduced and the 
aqueous phase was extracted with tert-butyl methyl ether (3 x 15 mL). The combined extracts were 
dried over Na2SO4 and concentrated, and the residue was purified by flash chromatography 
(hexanes/EtOAc, 29:1 to 8:1) to furnish product 17 as a colorless oil (651 mg, 89%). 
1
H NMR (400 
MHz, CDCl3): δ = 4.64 – 4.43 (m, 3H), 3.97 (dd, J = 8.8, 2.7 Hz, 1H), 3.65 (s, 3H), 3.31 (s, 3H), 3.15 
(s, 3H), 2.96 (qd, J = 6.9, 2.7 Hz, 1H), 1.80 (d, J = 2.2 Hz, 3H), 1.78 – 1.68 (m, 1H), 1.09 (d, J = 
7.0 Hz, 3H), 0.98 (d, J = 6.9 Hz, 3H), 0.86 (s, 9H), 0.12 (s, 3H), 0.08 ppm (s, 3H); 
13
C NMR (100 
MHz, CDCl3): δ = 171.2, 98.1, 96.0, 80.9, 79.6, 62.7, 61.0, 56.3, 44.2, 38.1, 25.8, 18.2, 14.2, 10.9, 9.7, 
3.5, −3.9, −5.0 ppm; IR (film):  ̃ = 2931, 2890, 2857, 1672, 1463, 1408, 1377, 1250, 1168, 1143, 
1031, 1002, 940, 920, 834, 776, 673 cm
–1
; MS (EI) m/z (%): 370 (5), 357 (3), 356 (12), 344 (51), 341 
(10), 312 (6), 300 (5), 282(11), 274 (16), 271 (34), 260 (8), 253 (7), 239 (10), 234 (14), 227 (15), 223 
(18), 208 (32), 183 (62), 179 (25), 157 (19), 149 (12), 127 (12), 119 (15), 115 (28), 105 (16), 97 (28), 
89 (73), 73 (84), 59 (179, 45 (100), 29 (6) ; HRMS (ESIpos): m/z: calcd for C20H39NO5SiNa: 
424.2490, found 424.2489.  
 
(3S,4R,5S,6R)-6-(tert-Butyldimethylsilyloxy)-4-(methoxymethoxy)-3,5-dimethylnon-7-yn-2-one. 
MeMgCl (2.76 M in THF, 1.76 mL, 4.86 mmol) was added dropwise to a solution 
of compound 17 (650 mg, 1.62 mmol) in Et2O (15.0 mL) at 0 °C and the 
resulting mixture was stirred for 2 h. The reaction was quenched with brine 
(15 mL) and the aqueous phase was extracted with Et2O (3 x 10 mL). The combined extracts were 
dried over Na2SO4 and concentrated to give the desired ketone as a colorless oil which was used as 
such in the next step (562 mg, 97%, > 98% pure). An analytically pure sample was obtained by flash 
chromatography (hexanes/EtOAc, 29:1 to 8:1). [∝]𝐷
20= +64.1 (c = 0.88, hexanes); 
1
H NMR (300 MHz, 
CDCl3): δ = 4.65 – 4.43 (m, 3H), 4.03 (dd, J = 9.2, 1.9 Hz, 1H), 3.21 (s, 3H), 2.58 (qd, J = 6.9, 1.8 Hz, 
1H), 2.19 (s, 3H), 1.81 (d, J = 2.2 Hz, 3H), 1.79 – 1.70 (m, 1H), 1.05 (d, J = 6.9 Hz, 3H), 0.98 (d, J = 
6.9 Hz, 3H), 0.88 (s, 9H), 0.14 (s, 3H), 0.09 (s, 3H) ppm; 
13
C NMR (75 MHz, CDCl3): δ = 210.0, 97.9, 
81.4, 80.5, 79.9, 62.7, 55.9, 49.5, 44.1, 28.1, 25.9, 18.2, 11.0, 8.2, 3.5, −3.8, −4.5 ppm; IR (film):  ̃ = 
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2931, 2857, 1716, 1462, 1360, 1251, 1188, 1142, 1090, 1058, 1032, 918, 834, 777, 677 cm
−1
; MS (EI) 
m/z (%): 311 (1), 299 (1), 293 (3), 255 (4), 239 (12), 237 (99, 229 (59, 227 (9), 225 (4), 197 (27), 183 
(86), 163 (46), 159 (27), 157 (15), 153 (15), 119 (19), 115 (18), 97 (21), 89 (57), 75 (55), 74 (6), 59 
(17), 45 (100), 43 (46), 41 (8); HRMS (ESIpos): m/z: calcd for C19H36O5SiNa: 379.2275, found 
379.2273. 
 
(4S,5R,6S,7R)-7-(tert-Butyldimethylsilyloxy)-5-(methoxymethoxy)-3,4,6-trimethyldec-1-en-8-yn-
3-ol (41). Vinylmagnesium bromide (1.0 M in THF, 3.15 mL, 3.15 mmol) was slowly added at –78 °C 
to a solution of the ketone obtained in the previous step (562 mg, 1.58 mmol) in 
THF (15 mL). The mixture was slowly warmed to ambient temperature (2 h) and 
stirred for an additional 2 h. Sat. aq. NH4Cl (25 mL) was then introduced and the 
aqueous phase was extracted with Et2O (3 x 12 mL). The combined organic extracts were dried over 
Na2SO4 and concentrated. The residue was purified by flash chromatography (hexanes/EtOAc, 10:1 to 
8:1) to provide alcohol 18 as an incosequential mixture of isomers (2:1, 
1
H NMR) (530 mg, 87%). 
[∝]𝐷
20 = + 47.4 (c = 0.69, CHCl3); 
1
H NMR (300 MHz, CDCl3, data given for the major isomer): δ = 
5.92 – 5.68 (m, 1H), 5.39 – 5.16 (m, 1H), 5.12 – 4.95 (m, 1H), 4.79 – 4.59 (m, 2H), 4.56 – 4.44 (m, 
1H), 4.05 – 3.78 (m, 2H), 3.37 (s, 3H), 1.89 – 1.76 (m, 3H), 1.76 – 1.52 (m, 3H), 1.31 (s, 1H), 1.18 (d, 
J = 0.7 Hz, 2H), 1.03 – 1.01 (m, 2H), 0.95 – 0.90 (m, 3H), 0.89 – 0.83 (m, 9H), 0.16 – 0.05 (m, 6H) 
ppm; 
13
C NMR (75 MHz, CDCl3, data given for the major isomer): δ = 146.7, 111.5, 99.5, 82.7, 81.4, 
80.4, 75.9, 63.1, 55.8, 44.5, 41.9, 27.3, 25.9, 18.1, 11.2, 7.1, 3.5, −3.6, −5.0; IR (film):  ̃ = 3483, 2931, 
2857, 1462, 1380, 1361, 1250, 1209, 1143, 1032, 920, 833, 814, 776, 678 cm
−1
; MS (EI) m/z (%): 384, 
339, 253 (1), 215 (4), 185 (11), 183 (100), 157 (9), 143 (10), 127 (7), 119 (7), 115 (9), 97 (11), 89 
(22), 75 (24), 73 (37), 59 (6), 45 (34) ; HRMS (ESIpos): m/z: calcd for C21H40O4SiNa: 407.2588, 
found 407.2592.  
 
(5S,6S,7R)-5-((R,E)-5-Bromo-3-methylpent-3-en-2-yl)-6,9,9,10,10-pentamethyl-7-(prop-1-ynyl)-
2,4,8-trioxa-9-silaundecane. Pyridine (0.32 mL, 3.92 mmol) was added at 0 °C to a solution of 
alcohol 18 (502 mg, 1.31 mmol) in Et2O (6.1 mL), followed by dropwise 
addition of PBr3 (1.0 M in toluene, 3.13 mL, 3.13 mmol) over 10 min. The 
resulting mixture was stirred for 3 h at 0 °C before it was diluted with Et2O 
(20 mL). The reaction was carefully quenched with sat. aq. NaHCO3 (100 mL) and the aqueous phase 
was extracted with Et2O (3 x 20 mL). The combined extracts were dried over Na2SO4, filtered through 
a short pad of SiO2 and evaporated. The sensitive residue was immediately used in the next reaction 
(556 mg, 95%). 
1
H NMR (400 MHz, C6D6): δ = 5.49 – 5.42 (m, 1H), 4.95 (ddd, J = 4.8, 2.3, 2.3 Hz, 
1H), 4.60 (d, J = 6.6 Hz, 1H), 4.47 (d, J = 6.6 Hz, 1H), 3.75 (dd, J = 8.4, 2.7 Hz, 1H), 3.66 (dd, J = 
8.4, 2.1 Hz, 2H), 3.17 (s, 3H), 2.16 (dq, J = 6.8, 1.1 Hz, 1H), 2.04 – 1.96 (m, 1H), 1.55 (d, J = 1.0 Hz, 
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3H), 1.50 (d, J = 2.2 Hz, 3H), 1.13 (d, J = 6.8 Hz, 3H), 1.06 (s, 9H), 0.97 (d, J = 6.9 Hz, 3H), 0.36 (s, 
3H), 0.28 (s, 3H) ppm; HRMS (ESIpos): m/z: calcd for C21H39BrO3SiNa: 469.1744, found 469.1749. 
 
(6R,7S,8S,9R,E)-Ethyl 9-(tert-butyldimethylsilyloxy)-7-(methoxymethoxy)-5,6,8-tri-methyldodec-
4-en-10-ynoate (42). n-BuLi (1.6 M in hexanes, 14.6 mL, 23.4 mmol) was added to a solution of 
diisopropylamine (3.47 mL, 24.7 mmol) in THF (20 mL) at 0 °C and 
the resulting mixture stirred for 1 h.  
In parallel, CuI (8.9 g, 46.8 mmol) was suspended in THF (40 mL) 
and the suspension cooled to −110 °C (cooling bath: Et2O/CO2/N2). EtOAc (2.43 mL, 24.7 mmol) was 
added via syringe followed by dropwise addition of the freshly prepared LDA-solution via canula. The 
mixture was warmed over 3 h to −30 °C, causing a color change of the slurry from grey to yellow-
brown. A solution of allyl bromide 19 (580 mg, 1.30 mmol) in THF (5 mL) was then slowly 
introduced and the mixture stirred for 2.5 h. The suspension was cooled to −60 °C before the reaction 
was quenched with aq. NH4Cl/NH4OH (9:1; 63 g NH4Cl, 17.5 mL 30% aqueous NH4OH, filled up to 
350 mL with H2O). The aqueous phase was repeatedly extracted with tert-butyl methyl ether (5 x 
150 mL), the combined organic layers were washed with brine, dried over Na2SO4 and concentrated 
under reduced pressure. Flash chromatography of the residue (hexanes/EtOAc, 100:0 to 19:1) afforded 
the title compound as a pale yellow oil (369 mg, 62%). [∝]𝐷
20 = + 16.0 (c = 0.24, CHCl3); 
1
H NMR 
(300 MHz, CDCl3): δ = 5.17 (t, J = 6.3 Hz, 1H), 4.56 (ddd, J = 5.6, 2.1, 2.0 Hz, 1H), 4.52 (dd, J = 
6.3 Hz, 1H), 4.43 (d, J = 6.3 Hz, 1H), 4.11 (q, J = 7.1 Hz, 2H), 3.61 (dd, J = 7.8, 3.6 Hz, 1H), 3.32 (s, 
3H), 2.31 (m, 4H), 2.26 – 2.17 (m, 1H), 1.80 (d, J = 2.1 Hz, 3H), 1.78 – 1.71 (m, 1H), 1.64 (s, 3H), 
1.24 (t, J = 7.1 Hz, 3H), 0.96 (dd, J = 6.9, 4.7 Hz, 6H), 0.88 (s, 9H), 0.13 (s, 3H), 0.09 (s, 3H) ppm; 
13
C NMR (75 MHz, CDCl3): δ = 173.3, 138.98, 123.1, 98.0, 81.2, 80.6, 80.6, 63.2, 60.2, 55.9, 44.3, 
42.8, 34.2, 25.8, 23.6, 18.2, 15.8, 14.2, 12.5, 11.1, 3.4, −4.1, −5.1 ppm; IR (film):  ̃ = 2956, 2929, 
2857, 1727, 1462, 1374, 1249, 1143, 1116, 1093, 1033, 919, 835, 814, 777, 676 cm
−1
; MS (EI) m/z 
(%): 439, 397 (1), 365 (1), 329 (4), 283 (13), 253 (3), 211 (6), 183 (100), 169 (11), 157 (17), 115 (9), 
95 (17), 89 (17), 73 (29), 45 (31); HRMS (ESIpos): m/z: calcd for C25H46O5SiNa: 477.3007, found 
477.3009. 
 
(6R,7S,8S,9R,E)-9-(tert-Butyldimethylsilyloxy)-7-(methoxymethoxy)-5,6,8-trimethyl-dodec-4-en-
10-ynoic acid (43). TMSOK (521 mg, 4.06 mmol) was added to a solution of the ethyl ester described 
above (369 mg, 0.812 mmol) in Et2O (48 mL). The suspension was 
stirred for 48 h before being carefully neutralized with solid CO2 and 
sat. aq. NH4Cl solution (50 mL) containing 5 drops of 1 M HCl. The 
aqueous phase was extracted with EtOAc (5 x 25 mL) and the combined extracts were washed with 
brine (40 mL), dried over Na2SO4 and concentrated. The crude acid 20, obtained as a pale yellow oil, 
was judged pure and therefore used without further purification in the next step (347 mg, quant.). 
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[∝]𝐷
20= +44.7 (c = 0.75, CHCl3); 
1
H NMR (400 MHz, CDCl3): δ = 11.5 – 9.5 (br s, 1H), 5.16 (t, J = 
6.1 Hz, 1H), 4.56 – 4.53 (m, 1H), 4.52 (d, J = 6.3 Hz, 1H), 4.43 (d, J = 6.3 Hz, 1H), 3.60 (dd, J = 7.8, 
3.5 Hz, 1H), 3.32 (s, 3H), 2.42 – 2.29 (m, 4H), 2.28 – 2.20 (m, 1H), 1.80 (d, J = 2.7 Hz, 3H), 1.78 – 
1.71 (m, 1H), 1.64 (s, 3H), 0.97 (t, J = 7.2 Hz, 6H), 0.89 (s, 9H), 0.12 (s, 3H), 0.08 (s, 3H) ppm; 
13
C 
NMR (100 MHz, CDCl3): δ = 178.7 139.3, 122.8, 98.0, 81.2, 80.7, 80.6, 63.2, 55.9, 44.3, 42.8, 33.8, 
25.9, 23.4, 18.2, 15.8, 12.5, 11.1, 3.5, −4.1, −5.0 ppm; IR (film):  ̃ = 3095, 2929, 2857, 2333, 2171, 
1712, 1463, 1377, 1250, 1143, 1033, 923, 834, 777, 676 cm
−1
; MS (EI) m/z (%): 411, 337 (1), 307 (3), 
283 (12), 227 (6), 183 (100), 173 (8), 157 (16), 154 (14), 115 (9), 97 (8), 89 (14), 75 (16), 73 (30), 45 
(48); HRMS (ESIpos): m/z: calcd for C23H42O5SiNa: 449.2694, found 449.2695. 
 
5.2.2 Synthesis of alcohol 57. 
Diethyl 2-(diiodomethyl)-2-methylmalonate (48). A solution of diethyl methylmalonate (47) 
(9.81 mL, 57.0 mmol) in Et2O (20 mL) was added over 30 min to a suspension of 
NaH (1.65 g, 69.0 mmol) in Et2O (100 mL), causing the mixture to reach reflux 
temperature while vigorously evolving H2. Once the addition was complete, the 
mixture was stirred at reflux temperature for 1.5 h before solid CHI3 (22.6 g, 57.0 mmol) was added. 
Stirring was continued at reflux temperature for 12 h before the mixture was cooled to 0 °C and excess 
NaH was carefully quenched with aq. HCl (1 M, 100 mL). After stirring for 20 min, the layers were 
separated and the aqueous phase was extracted with Et2O (3 x 65 mL). The combined organic extracts 
were washed with brine (80 mL), dried over Na2SO4 and concentrated to give the title compound as a 
pale brown oil, which was used in the next without further purification (24.9 g, 99%). 
1
H NMR (400 
MHz, CDCl3): δ = 5.73 (br s, 1H), 4.18 (dq, J = 7.1 Hz, 1.4 Hz, 4H), 1.75 (s, 3H), 1.25 (t, J = 7.1 Hz, 
6H) ppm; 
13
C NMR (100 MHz, CDCl3): δ = 166.0, 62.6, 62.1, 20.3, 13.9, −26.0 ppm; IR (film):  ̃ = 
1731, 1447, 1380, 1366, 1261, 1207, 1162, 1093, 1074, 1015, 859 cm
−1
; MS (EI) m/z (%): 440 (12), 
313 (9), 241 (22), 213 (27), 195 (17), 167 (12), 113 (7), 85 (12), 41 (16), 39 (23), 29 (100), 27 (15); 
HRMS (ESI): m/z: calcd for C9H14O2I2Na: 462.8874, found 462.8871. The analytical and 
spectroscopic data are in agreement with those reported in the literature.
[56]
 
 
(E)-3-Iodo-2-methylacrylic acid (49). KOH (15.9 g, 283 mmol) and water (60 mL) were added to a 
solution of crude malonate 48 (24.8 g, 56.3 mmol) in EtOH (180 mL), and the resulting 
red solution was stirred at reflux temperature for 4 h. After cooling and evaporation of 
all volatile materials, the residue was dissolved in aq. K2CO3 (10%, 150 mL), which was then 
carefully acidified with conc. HCl at 0 °C. Extraction with CH2Cl2 (8 x 50 mL) was followed by 
drying of the combined organic layers over Na2SO4 and evaporation of the solvent. The residue was 
purified by flash chromatography (hexanes/EtOAc, 9:1 + 0.5% HOAc) to yield the title compound as a 
pale yellow solid (8.58 g, 72%). 
1
H NMR (400 MHz, CDCl3): δ = 12.28 (br s, 1H), 8.00 (q, J = 1.2 Hz, 
1H), 2.03 (d, J = 1.2 Hz, 3H) ppm; 
13
C NMR (100 MHz, CDCl3): δ = 169.3, 139.0, 102.1, 19.8 ppm; 
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IR (film):  ̃ = 3079, 2966, 2596, 1682, 1593, 1409, 1379, 1296, 1235, 1108, 991, 915, 838, 727, 685 
cm
−1
; MS (EI) m/z (%): 212 (56), 167 (6), 127 (6), 85 (75), 57 (12), 45 (14), 43 (11), 41 (28), 40 (16), 
39 (100), 38 (18), 37 (9), 29 (18); HRMS (EI): m/z: calcd for C4H5O2I: 211.9334, found 211.9336. The 
analytical and spectroscopic data are in agreement with those reported in the literature.
[62]
 
 
(E)-3-Iodo-2-methylprop-2-en-1-ol. A solution of acid 5 (8.4 g, 39.6 mmol) in Et2O (25 mL) was 
added over 20 min to a suspension of LiAlH4 (1.65 g, 43.6 mmol) in E2O (60 mL) at 0 °C. 
After additional 30 min at this temperature, the ice bath was removed and the mixture 
stirred at ambient temperature for 2.5 h. The excess LiAlH4 was carefully quenched with sat. aq. 
Na2SO4 (130 mL) and the mixture diluted with H2SO4 (2 M, 60 mL) and Et2O. The aqueous layer was 
extracted with Et2O (3 x 40 mL), the combined organic phases were washed with aq. K2CO3 (10%, 
50 mL), dried over Na2SO4 and concentrated under reduced pressure. Purification of the remaining oil 
by flash chromatography (pentane/Et2O, 4:1) gave the title compound as a colorless oil (3.6 g, 49%). 
1
H NMR (400 MHz, CDCl3): δ = 6.25 (m, 1H), 4.09 (d, J = 5.4 Hz, 2H), 1.85 – 1.81 (m, 4H) ppm; 
13
C 
NMR (100 MHz, CDCl3): δ = 147.2, 77.3, 67.1, 21.3 ppm; IR (film):  ̃ = 3295, 2912, 2851, 1620, 
1433, 1376, 1274, 1252, 1145, 1066, 1008, 942, 829, 771, 665 cm
−1
; MS (EI) m/z (%): 198 (75), 183 
(5), 127 (9), 71 (100), 53 (28), 43 (59), 31 (57), 39 (61), 38 (12), 31(34), 29(14), 27(26); HRMS (EI): 
m/z: calcd for C4H7IO: 197.9542, found 197.9541. The analytical and spectroscopic data are in 
agreement with those reported in the literature.
[56]
 
 
(E)-3-Iodo-2-methylacrylaldehyde (46). MnO2 (11.1 g, 127 mmol) was added in three portions to a 
vigorously stirred solution of (E)-3-iodo-2-methylprop-2-en-1-ol (2.52 g, 12.7 mmol) in 
CH2Cl2 (35 mL), causing a slightly exothermic reaction. After 3.5 h, the mixture was 
filtered through a pad of flame-dried Celite
®
, which was rinsed with CH2Cl2 (2 x 10 mL). The 
combined filtrates were evaporated and the residue was briefly dried in high vacuum to give the title 
compound as a pink oil (2.46 g, 98%). Due to the unstable nature of this compound, it was dissolved 
in CH2Cl2 (10 mL) containing 4 Å MS and immediately used in the next step. 
1
H NMR (300 MHz, 
CDCl3): δ = 9.52 (s, 1H), 7.8 (q, J = 1.2 Hz, 1H), 1.92 (d, J = 1.2 Hz, 3H) ppm; 
13
C NMR (75 MHz, 
CDCl3): δ = 189.4, 150.8, 109.4, 16.4 ppm; IR (film):  ̃ = 2921, 2842, 1691, 1591, 1294, 1099, 1027, 
1015, 798, 679 cm
−1
; MS (EI) m/z (%): 196 (99), 167 (14), 127 (8), 69 (86), 41 (59), 30 (11), 39 (100), 
38 (13), 29 (8); HRMS (EI): m/z: calcd for C4H5IO: 195.9385, found 195.9384. 
 
Masamune anti-aldol bromide 53. NEt3 (59.6 µl; 0.430 mmol) and (1R,2S)-2-(N-benzyl-2,4,6-
trimethylphenylsulfonamido)-1-phenylpropyl propionate (52)
[243]
 
(82.0 mg, 0.170 mmol) were dissolved in CH2Cl2 (2.4 mL) and the 
solution cooled to −78 °C. A solution of dicyclohexylboryl triflate (1.0 M 
in CH2Cl2, 0.43 mL, 0.43 mmol) was then added over 12 min to give a yellow suspension, which was 
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kept at this temperature for 5 h. A solution of freshly prepared aldehyde 46 (56.6 mg, 0.375 mmol) in 
CH2Cl2 (1 mL) was then added and stirring was continued for 1.5 h before the cooling bath was 
removed and the mixture allowed to reach room temperature. After 3 h, the reaction was quenched 
with pH 7 buffer (3 mL) and the mixture treated with MeOH (2 mL) and aq. H2O2 (35% w/w, 1.5 mL) 
overnight. The solvent was removed in vacuo, the residue was dissolved in CH2Cl2 (5 mL), and the 
organic phase was washed with H2O (6 mL). The aqueous phase was extracted with CH2Cl2 
(3 x 5 mL), the combined organic layers were dried over Na2SO4 and evaporated. 
1
H NMR analysis of 
the crude product showed a diastereomeric ratio of 13:1. Purification of the residue by flash 
chromatography (hexanes/EtOAc 9:1 to 6:1) yielded the title compound as a pale yellow oil (62.0 mg, 
58%, 13:1 d.r.). [∝]𝐷
20 = +38.3 (c = 0.87, CH2Cl2); 
1
H NMR (400 MHz, CDCl3): δ = 7.39 – 7.20 (m, 
8H), 6.93 (s, 2H), 6.92- 6.88 (m, 2H), 6.28 (d, J = 1.0 Hz, 1H), 5.90 (d, J = 3.8 Hz, 1H), 4.82 (d, J = 
16.6 Hz, 1H), 4.64 (d, J = 16.7 Hz, 1H), 4.24 (dd, J = 9.2, 3.7 Hz, 1H), 4.09 (qd, J = 6.9, 2.4 Hz, 1H), 
3.00 (d, J = 4.0 Hz, 1H), 2.68 (dq, J = 9.0, 7.3 Hz, 1H), 2.56 (s, 6H), 2.33 (s, 3H), 1.84 (d, J = 1.2 Hz, 
3H), 1.22 (d, J = 7.1 Hz, 3H), 1.00 (d, J = 7.2 Hz, 3H) ppm; 
13
C NMR (100 MHz, CDCl3): δ = 174.1, 
142.5, 140.8, 140.2, 138.7, 138.0, 133.2, 132.0, 128.3, 128.2, 127.9, 127.5, 127.0, 125.7, 107.4, 78.5, 
77.4, 56.8, 48.1, 43.2, 35.5, 22.9, 20.8, 17.2, 14.0, 13.5 ppm; IR (film):  ̃ = 3482, 1743, 1606, 1498, 
1381, 1321, 1211, 1152, 1117, 1010, 931, 859, 750, 731, 698 cm
−1
; MS (EI) m/z (%): 406 (2), 317 
(20), 316 (100), 183 (6), 149 (2), 119 (18), 91 (61). HRMS (ESIpos): m/z: calcd for 
C32H38NO5Br1S1Na: 650.1546, found 650.1540. 
 
 (2R,3S,E)-((1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl) 3-hydroxy-
5-iodo-2,4-dimethylpent-4-enoate (54). NEt3 (0.904 mL, 6.52 mmol) and (1R,2S)-2-(N-benzyl-2,4,6-
trimethylphenylsulfonamido)-1-phenylpropyl propionate (52)
[243]
 (2.61 
g, 5.43 mmol) were dissolved in CH2Cl2 (45 mL) and the solution cooled 
to −78 °C. A solution of dicyclohexylboryl triflate (2.13 g, 6.52 mmol) 
in pentane (12 mL) was then added over 12 min to give a yellow suspension, which was kept at this 
temperature for 5 h. A solution of freshly prepared aldehyde 6 (2.45 g, 12.5 mmol) in CH2Cl2 (10 mL) 
was then added and stirring continued for 1.5 h before the cooling bath was removed and the mixture 
allowed to reach room temperature. After 3 h, the reaction was quenched with pH 7 buffer (30 mL) 
and the mixture treated with MeOH (100 mL) and aq. H2O2 (35% w/w, 15 mL) overnight. The solvent 
was removed in vacuo, the residue was dissolved in CH2Cl2 (150 mL), and the organic phase was 
washed with H2O (60 mL). The aqueous phase was extracted with CH2Cl2 (3 x 50 mL), the combined 
organic layers were dried over Na2SO4 and evaporated. 
1
H NMR analysis of the crude product showed 
a diastereomeric ratio of 13:1. Purification of the residue by flash chromatography yielded the title 
compound as a white solid (2.79 g, 76%, single isomer). [∝]𝐷
20 = +45.0 (c = 0.95, CH2Cl2); 
1
H NMR 
(400 MHz, CDCl3): δ = 7.33 – 7.13 (m, 8H), 6.87 (s, 2H), 6.86- 6.82 (m, 2H), 6.28 (s, 1H), 5.83 (d, J 
= 4.0 Hz, 1H), 4.73 (d, J = 16.7 Hz, 1H), 4.54 (d, J = 16.7 Hz, 1H), 4.23 (dd, J = 8.9, 3.8 Hz, 1H), 4.09 
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(dq, J = 4.0, 7.0 Hz, 1H), 2.73 (d, J = 4.1 Hz, 1H), 2.64 – 2.52 (m, 1H), 2.48 (s, 6H), 2.26 (s, 3H), 1.80 
(d, J = 1.1 Hz, 3H), 1.15 (d, J = 7.0 Hz, 3H), 0.94 (d, J = 7.2 Hz, 3H) ppm; 
13
C NMR (100 MHz, 
CDCl3): δ = 174.0, 146.9, 142.6, 140.3, 138.5, 138.1, 133.4, 132.1, 128.5, 128.3, 128.0, 127.6, 127.2, 
125.9, 81.2, 78.6, 78.5, 56.8, 48.2, 43.3, 22.9, 20.9, 18.8, 14.1, 13.3 ppm; IR (film):  ̃ = 3496, 1741, 
1604, 1496, 1455, 1379, 1317, 1151, 1117, 1031, 1011, 929, 858, 752, 730, 698, 659 cm
−1
; MS (EI) 
m/z (%): 406 (1), 317 (20), 316 (100), 183 (5), 119 (17), 91 (60), 57 (3), 41 (3); HRMS (ESIpos): m/z: 
calcd for C32H38NO5ISNa: 698.1408, found 698.1411. The analytical and spectroscopic data are in 
agreement with those reported in the literature.
[62]
 
 
(2R,3S,E)-((1R,2S)-2-(N-Benzyl-2,4,6-trimethylphenylsulfonamido)-1-phenylpropyl) 3-(tert-
butyldimethylsilyloxy)-5-iodo-2,4-dimethylpent-4-enoate (55). 2,6-Lutidine (0.863 mL, 7.43 mmol) 
was added via syringe to a stirred solution of alcohol 54 (2.51 g, 
3.71 mmol). The mixture was cooled to 0 °C before TBSOTf (1.28 mL, 
5.57 mmol) was slowly added. After stirring for 2 h at 0 °C, the reaction 
was quenched with sat. aq. NH4Cl and the aqueous phase was extracted with CH2Cl2 (3 x 20 mL). The 
combined organic layers were washed with brine, dried over Na2SO4 and concentrated to give a white 
solid, which was used in the next step without further purification (2.89 g, 95%). An analytically pure 
sample was obtained by flash chromatography (hexanes/EtOAc, 9:1). [∝]𝐷
20 = +36.3 (c = 0.85, 
CHCl3); 
1
H NMR (400 MHz, CDCl3): δ = 7.38 (d, J = 7.3 Hz, 2H), 7.30 – 7.22 (m, 3H), 7.19 – 7.13 
(m, 1H), 7.07 (t, J = 7.5 Hz, 2H), 6.85 (s, 2H), 6.7 (d, J = 7.3 Hz, 2H), 6.18 (s, 1H), 5.67 (d, J = 
6.0 Hz, 1H), 4.85 (d, J = 16.1 Hz, 1H), 4.37 (d, J = 16.1 Hz, 1H), 4,29 (d, J = 9.3 Hz, 1H), 4.04 (dq, J 
= 6.6, 6.6 Hz, 1H), 2.61 (dq, J = 9.1, 7.3 Hz, 1H), 2.39 (s, 6H), 2.29 (s, 3H), 1.73 (d, J = 0.8 Hz, 3H), 
1.16 (d, J = 6.9 Hz, 3H), 0.80 (s, 9H), 0.74 (d, J = 7.2 Hz, 3H), −0.03 (s, 3H), −0.05 (s, 3H) ppm; 13C 
NMR (100 MHz, CDCl3): δ = 172.9, 147.5, 142.4, 140.4, 138.5, 138.0, 132.9, 132.1, 128.4, 128.4, 
128.2, 127.9, 127.4, 126.4, 80.6, 79.2, 77.7, 56.6, 48.1, 44.7, 25.7, 22.8, 20.9, 18.6, 18.1, 14.9, 13.8, 
−5.1, −5.1 ppm; IR (film):  ̃ = 2956, 2935, 2857, 1743, 1605, 1455, 1379, 1325, 1254, 1154, 1072, 
1030, 1011, 929, 857, 836, 777, 729, 698, 659. cm
−1
; MS (EI) m/z (%): 406 (23), 317 (21), 316 (100), 
183 (6), 132 (7), 119 (20), 91 (62), 73 (11); HRMS (ESIpos): m/z: calcd for C38H52NO5ISSiNa: 
812.2272, found 812.2280. 
 
(2S,3S,E)-3-(tert-Butyldimethylsilyloxy)-5-iodo-2,4-dimethylpent-4-en-1-ol. DIBAl-H (1 M in 
toluene, 9.38 mL, 9.38 mmol) was added over a period of 12 min to a solution of the 
above silyl ether (2.89 g, 95% pure, 3.48 mmol) in toluene (25 mL) at −78 °C. After 
stirring 2 h at this temperature, the excess DIBAl-H was carefully quenched with MeOH (2 mL). The 
mixture was diluted with tert-butyl methyl ether (20 mL) and aq. sat. Rochelle salt solution (30 mL). 
The resulting mixture was stirred overnight at ambient temperature before the aqueous layer was 
extracted with tert-butyl methyl ether (3 x 30 mL). The combined extracts were washed with brine 
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(25 mL), dried over Na2SO4 and concentrated. The residue was purified by flash chromatography 
(hexanes/EtOAc, 9:1) to give the title compound as a colorless oil (1.07 g, 83% over two steps). [∝]𝐷
20 
= −32.3 (c = 1.05, CHCl3); 
1
H NMR (400 MHz, CDCl3): δ = 6.18 (s, 1H), 4.00 (d, J = 8.0 Hz, 1H), 
3.61 (dd, J = 4.5, 0.7 Hz, 1H), 3.60 (d, J = 4.8 Hz, 1H), 2.44 (t, J = 5.68 Hz, 1H), 1.88 – 1.78 (m, 1H), 
1.76 (d, J = 1.0 Hz, 3H), 0.88 (s, 9H), 0.78 (d, J = 7.0 Hz, 3H), 0.06 (s, 3H), −0.02 (s, 3H) ppm; 13C 
NMR (100 MHz, CDCl3): δ = 148.8, 82.8, 79.3, 66.2, 38.7, 25.8, 19.5, 18.1, 14.0, −4.8, −5.3 ppm; IR 
(film):  ̃ = 339, 2956, 2928, 2884, 2857, 1615, 1471, 1462, 1376, 1361, 1252, 1140, 1064, 1037, 1004, 
982, 938, 834, 774, 672 cm
−1
; MS (EI) m/z (%): 313 (46), 311 (23), 271 (18), 185 (52), 171 (16), 115 
(6), 111 (9), 75 (100), 73 (44), 53 (6), 45 (5), 43 (5), 41 (6); HRMS (ESIpos): m/z: calcd for 
C13H27O2ISiNa: 393.0717, found 393.0715. 
 
(2R,3S,E)-3-(tert-Butyldimethylsilyloxy)-5-iodo-2,4-dimethylpent-4-enal (44). A solution of the 
above primary alcohol (600 mg, 1.62 mmol) in CH2Cl2 (6 mL) was added to a 
suspension of Dess-Martin periodinane (756 mg, 1.78 mmol) in CH2Cl2 (10 mL) at 
0 °C. After stirring for 15 min, the mixture was allowed to warm to room temperature and stirring 
continued for 2 h. The reaction was quenched with sat. Na2S2O3/Na2CO3 (1:1, 10 mL) and the aqueous 
phase extracted with CH2Cl2 (3 x 10 mL). The combined organic extracts were dried over Na2SO4 and 
evaporated. The residue was suspended in hexane/EtOAc (9:1) and the resulting suspension filtered 
through a short pad of SiO2. Concentration of the filtrate under reduced pressure gave the rather 
unstable aldehyde, which was immediately used in the next step (586 mg, 98%). 
1
H NMR (500 MHz, 
CDCl3): δ = 9.73 (d, J = 2.7 Hz, 1H), 6.28 (s, 1H), 4.27 (d, J = 8.4 Hz, 1H), 2.59 (dqd, J = 8.4, 7.1, 
2.5 Hz, 1H), 1.79 (d, J = 1.0 Hz, 3H), 0.88 (d, J = 7.1 Hz, 3H), 0.85 (s, 9H), 0.03 (s, 3H), −0.03 (s, 
3H) ppm; 
13
C NMR (125 MHz, CDCl3): δ = 203.8, 147.6, 80.1, 79.0, 50.1, 25.6, 19.0, 18.0, 10.8, −4.8, 
−5.4 ppm. 
 
tert-Butyl-((1E,3S,4S,5Z)-1-iodo-2,4-dimethylnona-1,5-dien-7-yn-3-yloxy)dimethylsilane (56). A 
precooled (−78 °C) solution of KHMDS (0.729 g, 3.66 mmol) in THF (6 mL) was 
added to a solution of sulfone R1 (1.00 g, 3.98 mmol) in THF (6 mL) at –55 °C, 
causing a color change to dark-red. After stirring for 30 min at this temperature, a 
precooled (−78 °C) solution of aldehyde 44 (586 mg, 1.59 mmol) in THF (3 mL) was 
added dropwise and the resulting mixture stirred for 13 h at −55 °C before it was poured into brine 
(15 mL) and warmed to ambient temperature. MTBE (20 mL) and H2O (5 mL) were added and the 
aqueous phase was extracted with MTBE (2 x 20 mL). The combined organic layers were dried over 
Na2SO4 and concentrated. Purification of the residue by flash chromatography yielded the title 
compound as a colorless oil (364 mg, 56%). [∝]𝐷
20 = +100.1 (c = 1.0, CHCl3); 
1
H NMR (400 MHz, 
CDCl3): δ = 6.09 (m, 1H), 5.61 (dd, J = 10.3, 10.0 Hz, 1H), 5.39 (dq, J = 10.8, 2.3 Hz, 1H), 3.98 (d, J 
= 5.4 Hz, 1H), 2.92 (ddq, J = 9.3, 6.5, 6.4 Hz, 1H), 1.94 (d, J = 2.4 Hz, 3H), 1.76 (d, J = 0.9 Hz, 3H), 
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0.91 (d, J = 6.9 Hz, 3H), 0.86 (s, 9H), 0.01 (s, 3H), −0.06 (s, 3H) ppm; 13C NMR (100 MHz, CDCl3): δ 
= 149.2, 143.7, 109.8, 89.4, 80.8, 78.0, 76.6, 39.5, 25.7, 20.6, 18.2, 17.1, 4.4, −4.9, −5.2 ppm; IR 
(film):  ̃ = 2956, 2928, 2885, 2856, 2332, 2330, 2324, 1615, 1471, 1462, 1361, 1252, 1081, 1019, 
1005, 938, 862, 833, 773, 749, 673 cm
−1
; MS (EI) m/z (%): 347 (6), 312 (16), 311 (100), 146 (7), 127 
(8), 115 (12), 91 (6), 75 (13), 73 (70), 59 (9), 53 (7); HRMS (ESIpos): m/z: calcd for C17H29OISiNa: 
427.0925, found 427.0926. 
 
(1E,3S,4S,5Z)-1-Iodo-2,4-dimethylnona-1,5-dien-7-yn-3-ol (57). TBAF (1 M in THF, 1.42 mL, 
1.42 mmol) was added to a solution of silyl ether 56 (230 mg, 0.568 mmol) in THF 
(5 mL) at 0 °C and the mixture stirred at this temperature for 3.5 h before the 
reaction was quenched with water (5 mL), sat. NH4Cl solution (2 mL) and tert-butyl 
methyl ether (10 mL). The aqueous phase was extracted with MTBE (3 x 10 mL), 
and the combined extracts were dried over Na2SO4 and concentrated under reduced pressure. The 
residue was purified by flash chromatography (hexanes/EtOAc, 9:1) to yield alcohol 57 as a colorless 
oil (163 mg, 99%). [∝]𝐷
20 = +24.0 (c = 0.50, CHCl3); 
1
H NMR (500 MHz, CDCl3): δ = 6.24 (s, 1H), 
5.64 (dd, J = 10.3 Hz, 10.1 Hz, 1H), 5.55 (dq, J = 10.7 Hz, 2.1 Hz, 1H), 3.91 (dd, J = 8.0 Hz, 3.1 Hz, 
1H), 2.97 (dqd, J = 9.2, 7.2, 7.1 Hz, 1H), 1.97 (d, J = 2.2 Hz, 3H), 1.88 (d, J = 3.3 Hz, 1H), 1.83 (d, J 
= 0.8 Hz, 3H), 0.90 (d, J = 6.9 Hz, 3H) ppm; 
13
C NMR (125 MHz, CDCl3): δ = 148.2, 142.9, 111.8, 
90.8, 80.7, 79.6, 76.0, 38.8, 19.4, 16.8, 4.4 ppm; IR (film):  ̃ = 3535, 3419, 2962, 2916, 2873, 2853, 
1615, 1454, 1399, 1377, 1271, 1143, 1117, 1072, 1005, 933, 753, 671 cm
−1
; MS (EI) m/z (%): 290 (1), 
197 (59), 163 (10), 95 (9), 94, (100), 93 (16), 91(26)79 (89), 77 (40), 60 (5), 65 (9), 53 (10), 51 (7), 43 
(12), 4 1 (6), 39 (25), 29 (5); HRMS (EI): m/z: calcd for C11H15OI: 290.0168, found 290.0166. 
 
5.2.3 Synthesis of -lactone fragment 57. 
(S)-4-Benzyl-3-((2R,3R)-3-hydroxy-2-methylpentanoyl)oxazolidin-2-one. According to the 
protocol of Heathcock,
[244]
 i-Pr2NEt (3.35 mL, 19.7 mmol) was added to a cooled 
(0 °C) solution of ent-13 (4.00 g, 17.1 mmol) and freshly destilled (n-Bu)2BOTf 
(7.38 mL, 34.2 mmol) in Et2O (40 mL). After stirring for 45 min at 0 °C, the yellow 
suspension was cooled to −78 °C before a precooled (−78 °C) solution of freshly destilled 
propionaldehyde (14) (1.62 mL, 22.2 mL) in Et2O (10 mL) was slowly introduced. After an additional 
30 min, the reaction was quenched by addition of solid tartaric acid (13 g) and the mixture stirred at 
ambient temperature for 2 h. The reaction was partitioned between ether and H2O, and the combined 
organic layers were washed with sat. aq. NaHCO3 solution (2 x 40 mL). A mixture of MeOH/30% 
H2O2 (3:1, 50 mL) was added under vigorous stirring at 0 °C and the resulting mixture stirred for 1 h 
at room temperature before the aqueous phase was extracted with Et2O (2 x 30 mL). The combined 
organic extracts were washed with sat. NaHCO3 solution and brine (30 mL each), dried over Na2SO4 
and concentrated. The crude material was purified by flash chromatography (hexanes/EtOAc, 3:1) to 
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give the title compound as an off-white solid (3.69 g, 74%, 11:1 dr.), along with additional 350 mg of 
mixed fractions. 
1
H NMR (400 MHz, CDCl3): δ = 7.34 – 7.29 (m, 2H), 7.28 – 7.25 (m, 1H), 7.23 – 
7.19 (m, 2H), 4.67 (ddd, J = 13.0, 6.8, 3.2 Hz, 1H), 4.21 – 4.12 (m, 2H), 3.90 (dq, J = 6.9, 6.9 Hz, 1H), 
3.65 (dddd, J = 8.3, 8.3, 7.4, 3.5 Hz, 1H), 3.31 (dd, J = 13.5, 3.4 Hz, 1H), 2.76 (dd, J = 13.4, 9.6 Hz, 
1H), 2.56 – 2.52 (m, 1H), 1.73 – 1.63 (m, 1H), 1.54 – 1.41 (m, 1H), 1.20 (d, J = 6.9 Hz, 3H), 1.00 (t, J 
= 7.4 Hz, 3H) ppm; 
13
C NMR (100 MHz, CDCl3): δ = 176.9, 153.6, 135.2, 129.4, 129.0, 127.3, 76.0, 
66.0, 55.6, 42.9, 37.9, 27.8, 14.6, 9.8 ppm; IR (film):  ̃ = 3516, 2967, 2936, 2879, 1775, 1695, 1455, 
1385, 1351, 1291, 1209, 1111, 1051, 1015, 969, 762, 749, 702 cm
−1
; MS (EI) m/z (%): 291 (10), 244 
(28), 233 (18), 178 (32), 158 (15), 142 (13), 134 (24), 133 (16), 118 (14), 117 (51), 116 (25), 115 (42), 
97 (27), 96 (11), 92 (39), 91 (100), 86 (87), 85 (25), 77 (11), 70 (13), 69 (37), 65 (29), 59 (57), 58 
(19), 57 (89), 56 (24), 45 (27), 43 (22), 42 (33), 41 (38), 39 (18), 31 (42), 30 (15), 29 (73), 28 (22), 27 
(33); HRMS (EI): m/z: calcd for C16H21NO4Na: 314.1363, found 314.1357. 
 
(R)-4-Benzyl-3-((2S,3S)-3-hydroxy-2-methylpentanoyl)oxazolidin-2-one. This enantiomer was 
obtained analogously from 13 (4.00 g, 17.1 mmol) as a white solid (3.50 g, 71%). 
 
 
 
(2R,3R)-1-((S)-4-Benzyl-2-oxooxazolidin-3-yl)-2-methyl-1-oxopentan-3-yl acetate (62). NEt3 
(2.20 mL, 15.8 mmol) and freshly distilled acetic anhydride (1.40 mL, 14.6 mmol) 
were successively added to a solution of the above alcohol (3.55 g, 12.1 mmol) in 
CH2Cl2 (36 mL). The mixture was cooled to 0 °C and DMAP (296 mg, 2.40 mmol) 
was introduced. After 30 min, the ice bath was removed and stirring was continued 
for 90 min before the reaction was quenched with sat. NH4Cl solution (20 mL). The aqueous phase 
was extracted with CH2Cl2 (2 x 25 mL), the combined organic layers were washed with brine (30 mL), 
dried over Na2SO4 and concentrated. The residue was purified by flash chromatography 
(hexanes/EtOAc, 4:1 to 3:1) to give the title compound as a white solid (single d.r., 3.26 g, 82%). 
1
H 
NMR (400 MHz, CDCl3): δ = 7.35 – 7.29 (m, 2H), 7.28 – 7.25 (m, 1H), 7.22 – 7.18 (m, 2H), 5.23 
(ddd, J = 8.1, 8.0, 3.6 Hz, 1H), 4.70 – 4.63 (m, 1H), 4.20 – 4.10 (m, 3H), 3.25 (dd, J = 13.1, 3.3 Hz, 
1H), 2.68 (dd, J = 13.3, 9.7 Hz, 1H), 2.00 (s, 3H), 1.88 – 1.78 (m, 1H), 1.63 – 1.52 (m, 1H), 1.17 (d, J 
= 7.1 Hz, 3H), 0.92 (t, J = 7.5 Hz, 3H) ppm; 
13
C NMR (100 MHz, CDCl3): δ = 174.6, 170.1, 153.0, 
135.1, 129.4, 129.0, 127.4, 75.7, 65.8, 55.3, 40.8, 37.8, 24.1, 21.0, 14.0, 8.8 ppm; IR (film):  ̃ = 3029, 
2978, 2944, 2883, 1782, 1737, 1699, 1491, 1455, 1378, 1349, 1291, 1208, 1111, 1098, 1049, 1016, 
962, 884, 840, 762, 741, 726, 698 cm
−1
; MS (EI) m/z (%): 273 (14), 244 (27), 178 (11), 157 (14), 117 
(19), 97 (86), 96 (18), 91 (32), 69 (23), 57 (10), 43 (100), 41 (16), 29 (13); HRMS (EI): m/z: calcd for 
C18H23NO5Na: 356.1468, found 356.1469. 
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(2S,3S)-1-((R)-4-Benzyl-2-oxooxazolidin-3-yl)-2-methyl-1-oxopentan-3-yl acetate (ent-62). This 
enantiomer was obtained analogously from (R)-4-benzyl-3-((2S,3S)-3-hydroxy-2-
methylpentanoyl)oxazolidin-2-one (3.50 g, 12.1 mmol) as a white solid (3.00 g, 
75%). 
 
 
(5S,6S)-6-Ethyl-5-methyldihydro-2H-pyran-2,4(3H)-dione (61). A pre-cooled solution (−78 °C) of 
LiHMDS (4.5 g, 27.0 mmol) in THF (50 mL) was added via canula to a solution of 
acetate 62 (3.00 g, 9.01 mmol) in THF (50 mL) at −78 °C. After 1 h, the mixture was 
poured into sat. NH4Cl/H2O/MeOH (1:1:1, 250 mL) and diluted with EtOAc (150 mL). 
The organic phase containing the chiral auxiliary was separated, which could be recovered by flash 
chromatography (hexanes/EtOAc, 1:1). The aqueous phase was acidified with HCl (1 M) to pH 2 and 
then extracted with CH2Cl2 (3 x 60 mL). The combined organic layers were dried over Na2SO4 and 
concentrated, and the residue was purified by flash chromatography (hexanes/EtOAc, 3:1 to 1:1) to 
yield the desired ß-keto ester as a white solid (1.17 g, 83%). [∝]𝐷
20 = +14.4 (c = 0.55, Et2O); 
1
H NMR 
(400 MHz, CDCl3): δ = 4.25 (ddd, J = 10.5, 7.6, 3.0 Hz, 1H), 3.53 (d, J = 19.1 Hz, 1H), 3.41 (d, J = 
19.2 Hz, 1H), 2.40 (dq, J = 10.4, 7.1 Hz, 1H), 1.93 (tdd, J = 14.8, 7.3, 3.0 Hz, 1H), 1.69 (qdd, J = 14.7, 
7.4, 7.3 Hz, 1H), 1.15 (d, J = 7.1 Hz, 3H), 1.08 (t, 3H, J = 7.3 Hz) ppm; 
13
C NMR (100 MHz, CDCl3): 
δ = 202.7, 167.2, 81.2, 46.3, 45.8, 25.4, 10.7, 8.5 ppm; IR (neat):  ̃ = 3205, 2969, 2928, 2763, 2346, 
1652, 1587, 1450, 1395, 1376, 1323, 1275, 1260, 1220, 1152, 1127, 1084, 1055, 1039, 991, 964, 903, 
872, 850, 823, 750, 697 cm
−1
; MS (EI) m/z (%): 156 (12), 127 (20), 98 (70), 97 (14), 85 (58), 70 (29), 
69 (16), 57 (35), 56 (100), 55 (34), 43 (12), 42 (41), 31 (18), 39 (13), 29 (35), 28 (25), 27 (20); HRMS 
(EI): m/z: calcd for C8H12O3: 156.0787, found 156.0787. 
 
(5R,6R)-6-Ethyl-5-methyldihydro-2H-pyran-2,4(3H)-dione (ent-61). This enantiomer was obtained 
analogously from ent-62 (2.90 g, 8.78 mmol) as a white solid (1.23 g, 79%). 
 
 
 
Vinyl triflate 67. A solution of -keto lactone 61 (300 mg, 1.921 mmol) in CH2Cl2 (12 mL) was 
cooled to −78 °C, before triethylamine (293 µL, 2.11 mmol) and triflic anhydride 
(348 µL, 2.08 mmol) were added dropwise via syringe. The reaction mixture was 
stirred at this temperature for 1 h before the reaction was quenched with water 
(10 mL). After warming to ambient temperature, the aqueous phase was extracted with CH2Cl2 (3 x 
10 mL). The combined organic extracts were dried over Na2SO4 and concentrated. The residue was 
purified by flash chromatography (hexanes/EtOAc 6:1) to give the desired product as a colorless oil 
(505 mg, 91%). 
1
H NMR (400 MHz, CDCl3)  = 6.03 (d, J = 1.1 Hz, 1H), 4.17 (dt, J = 6.3, 6.2 Hz, 
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1H), 2.74 (dqd, J = 7.0, 6.9, 1.0 Hz, 1H), 1.84 – 1.75 (m, 2H), 1.30 (d, J = 7.1 Hz, 3H), 1.04 (t, J = 
7.4 Hz, 3H) ppm; 
13
C NMR (100 MHz, CDCl3)  = 165.1, 162.3, 109.0, 83.5, 35.8, 26.0, 14.4, 9.4 
ppm; IR (film):  ̃ = 2979, 2944, 2886, 1729, 1656, 1459, 1427, 1378, 1348, 1315, 1246, 1207, 1133, 
1074, 1041, 1008, 903, 874, 833, 799, 761, 732 cm
−1
; MS (EI) m/z (%): 289 (1), 259 (47), 231 (8), 230 
(100), 109 (15), 81 (26), 69 (67), 53 (25), 41 (16), 29 (13); HRMS (EI): m/z: calcd for C9H11F3O5S1Na: 
311.0172, found 311.0175.  
 
Pinacolborolane R5. Trimethyl(prop-1yn-1-yl)silane (R4) (1.15 mL, 7.7 mmol) was dissolved in 
THF (10 mL) and the resulting solution cooled to −78 °C. A solution of n-BuLi 
(1.6 M in hexanes, 4.7 mL, 7.5 mmol) was then added via syringe and the 
resulting yellow solution stirred for 1 h. The mixture was then transferred via canula into a solution of 
triisopropyl pinacolborate (1.5 mL, 7.2 mmol) and MgCl2 (0.68 g, 7.2 mmol) in THF (10 mL) at 
−40 °C. The yellow solution was stirred for 2 h before being carefully quenched with aq. HCl (1 M, 
20 mL). The aqueous phase was extracted with Et2O (3 x 20 mL) and the combined organic extracts 
were washed with brine, dried over Na2SO4 and concentrated. The yellow residue was dried under 
high-vacuum and was judged pure on the basis of NMR and GC-MS analysis (1.43 g, 83%). 
1
H NMR 
(500 MHz, CDCl3)  = 1.85 (s, 2H), 1.14 (s, 12H), 0.00 (s, 9H) ppm; 
13
C NMR (100 MHz, C6D6)  = 
103.2, 84.0, 83.2, 24.7, 0.2 ppm; MS (EI) m/z (%): 238 (1), 223 (52), 167 (24), 138 (29), 123 (47), 107 
(35), 96 (21), 83 (100), 73 (33), 69 (11), 55 (22); HRMS (EI): m/z: calcd for C12H23BO2Si1Na: 
261.1458, found 261.1455. 
 
Alkyne 68. Vinyl triflate 67 (20.0 mg, 69.4 µmol) and borolane R5 (18.2 mg, 76.3 µmol) were 
dissolved in a degassed mixture of THF and water (10:1, 0.77 mL). Cs2CO3 
(67.7 mg, 20.8 µmol) and PdCl2(dppf)·CH2Cl2 (5.1 mg, 6.3 µmol) were added at 
ambient temperature and the resulting orange solution placed in a pre-heated oil 
bath at 80 °C and strirred for 17 h. After cooling to ambient temperature, the reaction was quenched by 
addition of aq. HCl (1 M, 5 mL) and the aqueous phase extracted with MTBE (3 x 6 mL). The 
combined organic extracts were dried over Na2SO4 and concentrated. The residue was purified by 
flash chromatography (hexanes/EtOAc 19:1 to 9:1) to give a white solid (4.2 mg, 33%). 
1
H NMR (400 
MHz, CD2Cl2): δ = 5.99 (dd, J = 1.9, 0.8 Hz, 1H), 4.03 (td, J = 7.7, 4.2 Hz, 1H), 2.41 (qd, J = 7.2, 
1.8 Hz, 1H), 2.07 (s, 3H), 1.78 – 1.67 (m, 2H), 1.22 (d, J = 7.2 Hz, 3H), 1.01 (t, J = 7.4 Hz, 3H) ppm; 
13
C NMR (100 MHz, CD2Cl2): δ = 164.1, 145.5, 122.5, 99.5, 84.5, 77.3, 36.5, 26.6, 16.2, 9.6, 5.1 ppm; 
IR (film):  ̃ = 2970, 2933, 2880, 2222, 1712, 1602, 1456, 1376, 1348, 1311, 1283, 1255, 1237, 1221, 
1135, 1111, 1059, 1024, 1008, 990, 971, 846 cm
−1
; MS (EI) m/z (%): 178 (11), 149 (42), 120 (100), 91 
(54), 77 (23), 65 (14), 51 (8). HRMS (ESIpos): m/z: calcd for C11H14O2Na: 178.0994, found 178.0991. 
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Allene 69. Vinyl triflate 67 (80.0 mg, 0.284 mmol) and borolane R5 (169 mg, 0.709 mmol) were 
dissolved in a degassed mixture of THF and water (10:1, 2.8 mL). Cs2CO3 
(277 mg, 0.851 mmol) and PdCl2(dppf)·CH2Cl2 (20.8 mg, 25.5 µmol) were added 
at ambient temperature and the resulting orange solution stirred for 15 h. The 
reaction was quenched by addition of water (5 mL) and extracted with Et2O (3 x 6 mL). The combined 
organic extracts were dried over Na2SO4 and concentrated. The residue was purified by flash 
chromatography (hexanes/EtOAc 9:1) to give a white solid (56.7 mg, 18:1 d.r., 60%). 
1
H NMR (400 
MHz, CDCl3): δ = 5.76 (t, J = 1.1 Hz, 1H), 4.76 (d, J = 1.2 Hz, 2H), 4.18 (ddd, J = 8.2, 6.1, 1.2 Hz, 
1H), 2.60 (qd, J = 7.0, 1.2 Hz, 1H), 1.85 – 1.73 (m, 1H), 1.58 – 1.46 (m, 1H), 1.21 (d, J = 7.1 Hz, 3H), 
0.95 (t, J = 7.5 Hz, 3H), 0.21 (s, 9H) ppm; 
13
C NMR (100 MHz, CDCl3): δ = 213.3, 163.8, 157.7, 
114.5, 98.6, 84.7, 72.4, 34.8, 26.7, 19.4, 10.3, −0.6 ppm; IR (film):  ̃ = 2980, 2945, 2867, 1712, 1461, 
1441, 1382, 1323, 1262, 1210, 1118, 1101, 1008, 987, 915, 705 cm
−1
; MS (EI) m/z (%): 250 (38), 160 
(11), 145 (12), 117 (14), 73 (100), 45 (12). HRMS (ESIpos): m/z: calcd. for C14H22O2Si1Na [M
+
+Na]: 
273.1281, found 273.1279. 
 
(4S,5S,6S)-4-Allyl-6-ethyl-4-hydroxy-5-methyltetrahydro-2H-pyran-2-one (70). A precooled 
(0 °C) solution of the freshly prepared Soderquist reagent (1R)-R7 (150 mg, 
0.596 mmol) in THF (2 mL + 0.5 mL rinse) was slowly added to a cold (0 °C) 
solution of ß-keto ester 22 (84.6 mg, 0.542 mmol) in THF (3.5 mL) via syringe. 
After stirring at 0 °C for 4 h, the mixture was diluted with hexanes (15 mL) and N,N-
dimethylethanolamine (53.0 mg, 0.596 mmol) was introduced. The resulting cloudy solution was 
stirred overnight under reflux. After cooling to ambient temperature, sat. NH4Cl solution (35 mL) was 
introduced and the aqueous layer was extracted with EtOAc (4 x 15 mL). The combined organic layers 
were dried over Na2SO4 and concentrated, and the residue was purified by flash chromatography 
(silica gel 60 (15 x 40 µm), hexanes/EtOAc, 2.5:1 to 2:1) to yield the desired isomer (77.3 mg, 72%) 
as white needles. [∝]𝐷
20= −1.8 (c = 0.56, CHCl3); 
1
H NMR (400 MHz, C6D6): δ = 5.70 (dddd, J = 17.1, 
10.1, 7.5, 7.1 Hz, 1H), 5.02 (dddd, J = 10.1, 1.9, 0.9, 0.8 Hz, 1H), 4.95 (ddd, J = 17.1, 3.3, 1.4 Hz, 
1H), 3.44 (ddd, J = 10.2, 7.4, 2.9 Hz, 1H), 2.57 (d, J = 16.4 Hz, 1H), 2.18 (dd, J = 16.5, 1.1 Hz, 1H), 
1.98 (ddq, J = 13.9, 6.8, 1.1 Hz, 1H), 1.90 (br s, 1H), 1.78 – 1.71 (m, 1H), 1.55 (dq, J = 10.1, 6.9 Hz, 
1H), 1.51 – 1.41 (m, 1H), 1.32 – 1.21 (m, 1H), 0.90 (t, J = 7.3 Hz, 3H), 0.57 (d, J = 6.9 Hz, 3H) ppm; 
13
C NMR (100 MHz, C6D6): δ = 168.4, 132.2, 120.2, 82.5, 71.0, 43.1, 42.9, 38.9, 27.0, 10.7, 9.1 ppm; 
IR (neat): ̃ = 3434, 3078, 2974, 2939, 1721, 1640, 1463, 1377, 1247, 1163, 1085, 1042, 1006, 919, 
838, 796 cm
−1
; MS (EI) m/z (%): 157 (25), 127 (9), 111 (9), 99 (45), 98 (11), 95 (37), 71 (100), 67 
(14), 57 (37), 55 (35), 53 (29), 43 (60), 42 (43), 41 (96), 40 (13), 39 (44), 29 (73), 27 (42); HRMS 
(EI): m/z: calcd for C11H18O3Na: 221.1148, found 221.1146. 
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(4R,5R,6R)-4-Allyl-6-ethyl-4-hydroxy-5-methyltetrahydro-2H-pyran-2-one (ent-70). This 
enantiomer was obtained analogously from ent-61 (40.5 mg, 0.161 mmol) as a white 
solid (22.3 mg, 70%). A crystal suitable for X-ray analysis was obtained by slowly 
cooling a concentrated solution of the compound in hexanes/CH2Cl2 (92:8) to 
−40 °C. 
 
(4S,5R,6R)-4-Allyl-6-ethyl-4-hydroxy-5-methyltetrahydro-2H-pyran-2-one (epi-70). Prepared 
analogously from -keto ester 61 (40.8 mg, 0.262 mmol) and (1S)-R7 as a white 
solid (45.6.3 mg, 88%). 
1
H NMR analysis of the crude product before flash 
chromatography indicated a diastereomeric ratio of 7.5:1 in favor of epi-70. A 
crystal suitable for X-ray analysis was obtained by slowly cooling a concentrated solution of the 
compound in hexanes/CH2Cl2 (92:8) to –40 °C. 
1
H NMR (500 MHz, C6D6): δ = 5.45 (dddd, J = 17.1, 
9.9, 7.3, 7.3 Hz, 1H), 4.94 (dddd, J = 10.1, 1.7, 0.7, 0.7 Hz, 1H), 4.88 (ddd, J = 17.0, 3.2, 1.3 Hz, 1H), 
4.21 (ddd, J = 10.5, 7.7, 2.8 Hz, 1H), 2.48 (d, J = 17.3 Hz, 1H), 2.38 (br s, 1H), 2.21 (d, J = 17.3 Hz, 
1H), 2.00 (dd, J = 13.7, 7.3 Hz, 1H), 1.90 (dd, J = 13.7, 7.6 Hz, 1H), 1.59 – 1.50 (m, 1H), 1.19 – 1.29 
(m, 2H), 0.91 (t, J = 7.3 Hz, 3H), 0.63 (d, J = 6.7 Hz, 3H) ppm; 
13
C NMR (100 MHz, CDCl3): δ = 
170.8, 131.6, 120.6, 82.3, 71.1, 44.4, 42.3, 38.9, 25.8, 9.6, 8.6 ppm; IR (film):  ̃ = 3429, 2978, 2935, 
1710, 1460, 1442, 1385, 1326, 1261, 1107, 1008, 987, 919, 702 cm
−1
; MS (EI) m/z (%): 157 (26), 127 
(9), 111 (9), 99 (45), 98 (12), 95 (37), 71 (100), 67 (16), 57 (37), 55 (30), 53 (29), 43 (60), 42 (43), 41 
(96), 40 (13), 39 (44), 29 (73), 27 (43); HRMS (ESIpos): m/z: calcd for C11H18O3Na: 221.1148, found 
221.1146. 
 
(−)-MIDA ester 78. A flame-dried Schlenk flask was charged with the ruthenium carbene complex 
C3 (25.8 mg, 30.4 µmol) and the vinylboronic acid derivative R8 
(116.6 mg, 0.637 mmol), evacuated and backfilled with Ar (3 cycles). A 
solution of the homoallylic alcohol 70 (120.4 mg, 0.607 mmol) in CH2Cl2 
(6 mL) was then introduced and the flask fitted with a reflux condenser and an Argon bubbler, 
allowing the generated ethane to evaporate. The reaction mixture was heated to 40 °C for 16 h. After 
cooling to room temperature, DMSO (300 µL) was added and the mixture stirred for 8 h. It was then 
concentrated under reduced pressure and the resulting residue purified by flash chromatography (tert-
butyl methyl ether/MeCN, 3:1) to yield the title compound as a white solid (174 mg, 81%). [∝]𝐷
20 = 
−4.4 (c = 0.88, MeCN); 1H NMR (400 MHz, [D6]-DMSO): δ = 6.05 (ddd, J = 17.7, 8.1, 5.6 Hz, 1H), 
5.44 (d, J = 17.7 Hz, 1H), 4.91 (s, 1H), 4.22 (d, J = 7.3 Hz, 1H), 4.17 (d, J = 7.4 Hz, 1H), 3.99 – 3.90 
(m, 3H), 2.75 (s, 3H), 2.61 (d, J = 16.3 Hz, 1H), 2.33 (dd, J = 14.0, 5.4 Hz, 1H), 2.25 (d, J =16.4 Hz, 
1H), 2.08 (dd, J = 13.9, 8.4 Hz, 1H), 1.81 – 1.69 (m, 2H), 1.57 – 1.47 (m, 1H), 0.93 (d, J = 6.8 Hz, 
3H), 0.92 (t, J = 7.6 Hz, 3H) ppm; 
13
C NMR (100 MHz, [D6]-DMSO): δ = 170.3, 169.2, 169.1, 139.3, 
130.4 (br), 82.8, 70.7, 61.3, 61.2, 46.7, 43.0, 42.4, 41.0, 26.2, 11.0, 9.0 ppm; IR (film): ̃ = 3504, 
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2953, 1745, 1716, 1639, 1464, 1375, 1286, 1247, 1223, 1118, 1029, 1001, 987, 958, 893, 859, 841, 
779, 723 cm
−1
; MS (ESI) m/z 376.2 [M
+
+Na]; HRMS (ESIpos): m/z: calcd for C16H24BNO7Na: 
376.1552, found 376.1543. 
 
(+)-MIDA ester ent-78. This enantiomer was obtained analogously from ent-70 (15 mg, 75.6 µmol) as 
a white solid (22.4 mg, 84%). 
 
 
 
5.2.4 Fragment assembly and endgame. 
(6R,7S,8S,9R,E)-((1E,3S,4S,5Z)-1-Iodo-2,4-dimethylnona-1,5-dien-7-yn-3-yl) 9-(tert-butyl-
dimethylsilyloxy)-7-(methoxymethoxy)-5,6,8-trimethyldodec-4-en-10-ynoate (79). EDCI·HCl 
(83.1 mg, 0.433 mmol) was added to a solution of alcohol 57 
(114 mg, 0.393 mmol) in CH2Cl2 (2.8 mL) and the resulting mixture 
cooled to 0 °C. Next, DMAP (52.9 mg, 0.433 mmol) was introduced 
in three portions and the mixture stirred for 10 min before a solution 
of acid 43 (185 mg, 0.433 mmol) in CH2Cl2 (2.5 mL) was slowly added. Stirring was continued for 30 
min at 0 °C before the ice bath was removed. After 5 h at ambient temperature, the mixture was 
poured into brine (10 mL) and diluted with CH2Cl2 (5 mL). The aqueous layer was extracted with 
CH2Cl2 (3 x 8 mL), the combined organic phases were dried over Na2SO4 and concentrated. The 
residue was purified by flash chromatography (hexanes/EtOAc, 29:1 to 19:1) to give the title 
compound as a colorless oil (244 mg, 89%). [∝]𝐷
20 = +80.9 (c = 1.0, CHCl3); 
1
H NMR (400 MHz, 
CDCl3): δ = 6.26 (s, 1H), 5.56 (dd, J = 10.1, 10.0 Hz, 1H), 5.43 (dq, J = 10.7, 2.2 Hz, 1H), 5.19 (d, J = 
7.4 Hz, 1H), 5.16 – 5.10 (br t, 1H), 4.56 – 4.52 (m, 1H), 4.51 (d, J = 6.3 Hz, 1H), 4.43 (d, J = 6.2 Hz, 
1H), 3.60 (dd, J = 7.7, 3.6 Hz, 1H), 3.32 (s, 3H), 3.12 (ddq, J = 9.3, 7.1, 7.1 Hz, 1H), 2.37 – 2.27 (m, 
4H), 2.27 – 2.19 (m, 1H), 1.96 (d, J = 2.2 Hz, 3H), 1.83 (d, J = 0.8 Hz, 3H), 1.80 (d, J = 2.1 Hz, 3H), 
1.79 – 1.73 (m, 1H), 1.63 (s, 3H), 0.97 (d, J = 6.8 Hz, 3H), 0.96 (d, J = 6.9 Hz, 3H), 0.92 (d, J = 
6.9 Hz, 3H), 0.87 (s, 9H), 0.12 (s, 3H), 0.08 (s, 3H) ppm; 
13
C NMR (100 MHz, CDCl3): δ = 172.2, 
144.6, 142.1, 139.0, 123.0, 111.0, 98.0, 90.3, 81.2, 80.8, 80.7, 80.4, 80.1, 76.1, 63.3, 56.0, 44.4, 42.8, 
37.1, 34.3, 25.9, 23.7, 20.5, 18.2, 16.8, 15.8, 12.5, 11.1, 4.4, 3.5, −4.0, −5.0 ppm; IR (film): ̃ = 2955, 
2928, 2856, 1738, 1618, 1461, 1376, 1248, 1142, 1117, 1091, 1075, 1061, 1031, 938, 920, 833, 775, 
675 cm
−1
; MS (EI) m/z (%): 458 (5), 283 (28), 185 (16), 184 (16), 183 (100), 174 (5), 169 (26), 163 
(5), 159 (6), 157 (15), 153 (12), 146 (40), 145 (17), 137 (11), 131(29), 115 (7), 97 (6), 93 (8), 91 (8), 
89 (16), 82 (8), 73 (29), 45 (39); HRMS (EI): m/z: calcd for C34H55IO5SiNa: 721.2756, found 
721.2755. 
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Cycloenyne 80. All glassware used for the ring closing alkyne metathesis reaction was flame-dried 
under vacuum and backfilled with Argon after cooling to room 
temperature (3 cycles). All employed solvents were freshly distilled 
(toluene from Na/K, CH2Cl2 from CaH2), stored over 4 Å MS and 
degassed by 4 freeze-pump-thaw cycles prior to use. A stock solution of 
activated catalyst was prepared as follows: CH2Cl2 (205 µL, 3.26 mmol) was added to a solution of 
complex C6 (80.0 mg, 0.128 mmol) in toluene (6.4 mL). The resulting brown solution was stirred for 
30 min to give a 0.194 M stock solution of the active catalyst. 
Diyne 79 (350 mg, 0.501 mmol) was azeotropically dried with toluene (3 x 3 mL). It was then 
transferred as a toluene solution to a two-necked round-bottom flask equipped with a reflux condenser 
and septum. Additional toluene was added to reach a total volume of 350 mL. The solution was heated 
to 100 °C and an aliquot of the activated catalyst solution (0.773 mL, 0.150 mmol) was introduced via 
syringe. The reaction was stirred at 100 °C for 7 h before a second aliquot of the catalyst solution 
(0.258 mL, 50.1 µmol) was added. Stirring was continued at 100 °C for further 12 h. After reaching 
ambient temperature, the mixture was diluted with Et2O (300 mL) to slowly form a brown precipitate, 
which was filtered off through a short pad of SiO2, eluting with Et2O (350 mL). The pale brown filtrate 
was evaporated and the residue purified by flash chromatography (hexanes/EtOAc, 39:1 to 19:1) to 
provide a mixture of N-tert-butyl-3,5-dimethylaniline and the desired product. The amine was 
removed at 60 °C under high vacuum overnight to leave the desired compound 80 as a pale yellow oil 
(232.6 mg, 72%). [∝]𝐷
20 = +83.0 (c = 0.57, hexanes); 
1
H NMR (400 MHz, CDCl3): δ = 6.34 (d, J = 
1.0 Hz, 1H), 5.63 (dd, J = 10.6, 9.6 Hz, 1H), 5.54 (dd, J = 10.6, 1.6 Hz, 1H), 5.36 – 5.30 (m, 1H), 5.24 
(d, J = 9.6 Hz, 1H); 4.73 (d, J = 6.8 Hz, 1H), 4.62 (d, J = 6.8 Hz, 1H), 4.37 (dd, J = 9.1, 1.1 Hz, 1H), 
3.43 (d, J = 9.2 Hz, 1H), 3.39 (s, 3H), 3.17 (dddd, J = 16.5, 9.7, 6.9, 6.8 Hz, 1H), 2.98 – 2.88 (m, 1H), 
2.45 – 2.36 (m, 1H), 2.35 – 2.19 (m, 3H), 2.07 (dddd, J = 15.5, 7.2, 7.2, 0.6 Hz, 1H), 1.83 (d, J = 
1.0 Hz, 3H), 1.48 (s, 3H), 1.07 (d, J = 7.1 Hz, 3H), 1.00 (d, J = 7.0 Hz, 3H), 0.89 (s, 9H), 0.82 (d, J = 
6.9 Hz, 3H), 0.11 (s, 3H), 0.07 (s, 3H) ppm; 
13
C NMR (100 MHz, CDCl3): δ = 171.9, 144.6, 144.3, 
137.4, 126.4, 110.3, 98.9, 96.9, 87.0, 82.5, 82.0, 80.6, 63.9, 56.0, 46.0, 42.0, 37.7, 34.6, 25.8, 22.5, 
19.5, 18.2, 17.4, 16.6, 16.3, 12.1, −4.5, −5.1 ppm; IR (film):  ̃ = 2957, 2929, 2856, 1732, 1617, 1462, 
1377, 1361, 1257, 1143, 1058, 1031, 990, 932, 858, 835, 801, 775, 753, 672 cm
−1
; MS (ESIpos) m/z 
(%): 683 (M+K, 30), 667 (M+Na, 100); HRMS (EI): m/z: calcd for C30H49IO5SiNa: 667.2286, found 
667.2290. 
 
  
146 Experimental section 
 
Suzuki coupling model compound 84. A flame-dried Schlenck flask was charged with solutions of 
MIDA-boronate epi-78 (5.0 mg, 14.2 µmol) and vinyl iodide 56 
(4.8 mg, 11.9 µmol) in CH2Cl2. The solvent was evaporated by 
application of an Ar flow and the flask subjected to high-vacuum/Ar 
cycles (3x). A degassed mixture of THF and water (3:1, 0.12 mL) was 
then introduced and the mixture stirred until all substrates were completely dissolved. [Pd(PPh3)4] 
(2.8 mg, 2.4 µmol) was then added as a solid, followed by Tl(OEt) (4.8 µL, 6.0 µmol) via syringe 
causing the precipitation of a yellow solid. After 105 min, the reaction was judged complete by TLC 
analysis and was quenched with aqueous HCl (0.5 M, 2 mL). The mixture was transferred to a round-
bottom flask (10 mL), rinsed with MTBE (2 mL) and stirred vigorously overnight. It was then diluted 
with H2O (5 mL) and extracted with EtOAc (3 x 5 mL). The combined organic extracts were dried 
over Na2SO4 and concentrated. The residue was purified by flash chromatography (hexanes/EtOAc 9:1 
to 4:1) to give the desired product as a pale-brown oil (4.6 mg, 81%). 
1
H-NMR (400 MHz, CD2Cl2)  
= 6.39 (ddt, J = 15.0, 10.9, 1.3 Hz, 1H), 5.95 (d, J = 10.9 Hz, 1H), 5.71 (t, J = 10.2 Hz, 1H), 5.56 (dt, J 
= 15.2, 7.7 Hz, 1H), 5.38 (dq, J = 10.6, 2.4 Hz, 1H), 4.26 (ddd, J = 10.3, 7.3, 2.9 Hz, 1H), 3.87 (d, J = 
5.8 Hz, 1H), 2.94 (dq, J = 8.9, 6.6 Hz, 1H), 2.53 (s, 2H), 2.36 (d, J = 7.7 Hz, 2H), 1.93 (d, J = 2.3 Hz, 
3H), 1.86 (dqd, J = 14.9, 7.4, 3.0 Hz, 1H), 1.74 – 1.71 (m, 4H), 1.68 (dd, J = 6.8, 3.7 Hz, 1H), 1.62 – 
1.56 (m, 1H), 1.04 – 0.95 (m, 6H), 0.91 (d, J = 7.0 Hz, 3H), 0.89 (s, 9H), 0.04 (s, 3H), −0.04 (s, 3H) 
ppm; 
13
C-NMR (100 MHz, CD2Cl2)  = 170.6, 145.6, 140.1, 132.2, 125.8, 125.7, 109.7, 89.7, 82.9, 
82.0, 77.2, 72.5, 44.1, 43.1, 40.2, 39.6, 26.6, 26.2, 18.7, 17.7, 13.3, 10.2, 9.1, 4.6, −4.3, −4.8 ppm; IR 
(film):  ̃ = 3425, 2956, 2929, 2856, 1714, 1471, 1461, 1387, 1323, 1250, 1119, 1071, 1007, 986, 971, 
937, 889, 859, 836, 775, 680 cm
−1
; MS (ESIpos) m/z (%): 497.3 (100); HRMS (EI): m/z: calcd. for 
C28H46O4Si1Na: 497.3058, found 497.3059. 
 
Compound 86. A solution of compound 80 (129 mg, 0.200 mmol) in THF/H2O (3:1, 2.4 mL, 
degassed by three freeze-pump-thaw cycles) was added 
to a degassed solution of MIDA ester (−)-ent-28 
(85.2 mg, 0.241 mmol) and Pd(PPh3)4 (46.5 mg, 
40.2 µmol) in degassed THF/H2O (3:1 1.0 mL). 
Thallium ethoxide (85.0 µL, 1.21 mmol) was added via syringe to the yellow mixture causing a yellow 
solid to precipitate from the reaction mixture, which was stirred for 2.5 h at room temperature. It was 
next diluted with tert-butyl methyl ether (10 mL) and transferred to a round-bottom flask equipped 
with a stirbar. Aqueous HCl (0.5 M, 11 mL) was introduced (pH ~ 2) and the mixture stirred for 2.5 h. 
H2O (10 mL) was added and the aqueous phase was extracted with tert-butyl methyl ether (4 x 
10 mL). The combined organic layers were washed with brine (15 mL), dried over Na2SO4 and 
evaporated. The residue was purified by flash chromatography (hexanes/EtOAc, 2.5:1 to 2:1) to give 
the title compound as a white solid (79 mg, 55%). [∝]𝐷
20= +117.3 (c = 0.88, CHCl3); 
1
H NMR (500 
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MHz, CDCl3): δ = 6.31 (dd, J = 15.0, 10.9 Hz, 1H), 6.01 (d, J = 11.0 Hz, 1H), 5.70 (ddd, J = 15.0, 
7.5, 7.5 Hz, 1H), 5.65 (dd, J = 10.3, 10.2 Hz, 1H), 5.52 (dd, J = 10.8, 0.9 Hz, 1H), 5.37 – 5.32 (m, 
1H), 5.07 (d, J = 9.8 Hz, 1H), 4.71 (d, J = 6.8 Hz, 1H), 4.61 (d, J = 6.8 Hz, 1H), 4.35 (d, J = 8.8 Hz, 
1H), 3.92 (ddd, J = 10.0, 7.3, 2.9 Hz, 1H), 3.41 (br d, J = 7.6 Hz, 1H), 3.38 (s, 3H), 3.24 – 3.13 (m, 
1H), 3.00 – 2.80 (br s, 1H), 2.77 (d, J = 16.7 Hz, 1H), 2.45 – 2.37 (m, 2H), 2.35 (d, J = 16.7 Hz, 1H), 
2.33 – 2.24 (m, 2H), 2.23 – 2.12 (m, 2H), 2.08 (ddd, J = 15.4, 7.6, 7.5 Hz, 1H), 1.90 (ddd, J = 16.8, 
6.9, 6.9 Hz, 1H), 1.83 (ddq, J = 14.7, 7.3, 2.8 Hz, 1H), 1.73 (s, 3H), 1.60 (ddq, , J = 14.7 Hz, 7.3, 
7.3 Hz, 1H), 1.45 (s, 3H), 1.06 (d, J = 7.1 Hz, 3H), 1.02 – 0.97 (m, 9H), 0.87 (s, 9H), 0.80 (d, J = 
6.9 Hz, 3H), 0.09 (s, 3H), 0.06 (s, 3H) ppm; 
13
C NMR (125 MHz, CDCl3): δ = 172.2, 170.2, 145.1, 
137.0, 134.0, 131.4, 128.9, 127.4, 126.7, 109.8, 98.9, 96.5, 87.2, 83.6, 82.5, 82.2, 71.5, 63.9, 56.0, 
46.1, 42.7, 42.6, 41.8, 37.8, 37.6, 34.6, 26.8, 25.7, 22.4, 18.1, 17.4, 16.8, 16.5, 12.1, 11.9, 11.2, 8.9, 
−4.5, −5.2 ppm; IR (film):  ̃ = 3448, 2961, 2930, 2857, 1724, 1462, 1377, 1248, 1144, 1058, 1032, 
1004, 983, 919, 858, 835, 750, 667 cm
−1
; MS (EI) m/z (%): 714 (5), 696 (4), 657 (4), 425 (5), 381 (13), 
357 (8), 325 (7), 299 (9), 267 (12), 249 (27), 222 (72), 173 (11), 171 (14), 169 (68), 159 (11), 157 
(16), 145 (13), 143 (11), 137 (18), 133 (18), 119 (17), 107 (16), 95 (25), 89 (36), 81 (20), 75 (41), 73 
(100), 72 (24); HRMS (EI): m/z: calcd for C41H66O8SiNa: 737.4412, found 737.4419. 
 
Isomeric cross-coupling adduct 103. This diastereomer was obtained analogously from vinyl iodide 
80 (54 mg, 83.8 µmol) as an off-white solid (30.3 mg, 
56%) using MIDA ester (+)-28. [∝]𝐷
20 = +206.5 (c = 
0.94, CHCl3); 
1
H NMR (500 MHz, CDCl3): 6.35 (dd, J 
= 15.1, 10.8 Hz, 1H), 6.04 (dd, J = 10.8, 0.8 Hz, 1H), 
5.70 (ddd, J = 15.4, 7.7, 7.7 Hz, 1H), 5.66 (dd, J = 10.5, 10.4, 1H), 5.53 (dd, J = 10.6, 1.5 Hz, 1H), 
5.37 (dd, J = 6.6, 3.9 Hz, 1H), 5.09 (d, J = 9.7 Hz, 1H), 4.73 (d, J = 6.9 Hz, 1H), 4.62 (d, J = 6.9 Hz, 
1H), 4.36 (dd, J = 9.3, 1.1 Hz, 1H), 3.93 (ddd, J = 10.2, 7.3, 3.0, 1H), 3.42 (br d, J = 7.8 Hz, 1H), 3.39 
(s, 3H), 3.20 (ddq, J = 10.1, 10.1, 6.8 Hz, 1H), 2.96 (br s, 1H), 2.78 (d, J = 16.8 Hz, 1H), 2.41 (dd, J = 
13.9, 6.9 Hz, 1H), 2.38 – 2.34 (m, 1H), 2.37 (d, J = 16.8 Hz, 1H), 2.33 – 2.23 (m, 2H), 2.22 – 2.16 (m, 
2H), 2.13 – 2.05 (m, 1H), 1.95 (br s, 1H), 1.92 (dq, J = 10.3, 6.9 Hz, 1H), 1.83 (ddq, J = 14.7, 7.3, 
3.0 Hz, 1H), 1.61 (ddq, J = 14.6, 7.3, 7.3 Hz, 1H), 1.46 (s, 3H), 1.08 (d, J = 7.1 Hz, 3H), 1.05 – 0.98 
(m, 3H), 1.02 (d, J = 6.9 Hz, 3H), 1.01 (t, J = 7.1 Hz, 3H), 0.89 (s, 9H), 0.82 (d, J = 6.8 Hz, 3H), 0.11 
(s, 3H), 0.07 (s, 3H) ppm; 
13
C NMR (125 MHz, CDCl3): 172.2, 170.1, 145.1, 137.2, 134.3, 131.7, 
128.8, 127.1, 126.7, 109.9, 99.0, 96.6, 87.2, 83.5, 82.6, 82.2, 71.5, 63.9, 56.0, 46.1, 42.8, 42.5, 41.9, 
37.8, 37.6, 34.7, 26.8, 25.8, 22.5, 18.2, 17.4, 16.8, 16.6, 12.1, 12.0, 11.1, 8.9, −4.5, −5.1 ppm; IR 
(film):  ̃ = 3465, 2960, 2930, 2857, 1727, 1463, 1389, 1332, 1250, 1144, 1060, 1035, 1005, 985, 918, 
859, 837, 776, 755, 733, 669 cm
−1
; MS (ESIpos) m/z (%): 737.5 (M+Na, 100); HRMS (EI): m/z: calcd 
for C41H66O8SiNa: 737.4412, found 737.4423.  
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Analogous cross-coupling product 87. A schlenck-flask was charged with trans-3-phenyl-1-propen-
1-ylboronic acid (R9) (2.4 mg, 15 µmol) and Pd(PPh3)4 
(1.7 mg, 1.5 µmol), sealed, evacuated and backfilled with 
Argon (3 cycles). A solution of macrocyclic vinyl iodide 80 
(3.8 mg, 5.9 µmol,) in THF/H2O (9:1, 0.2 mL, degassed by 
bubbling Ar through the solvent for 15 min) was added to the reaction mixture, followed by the 
addition of thallium ethoxide (2.1 µL, 29 µmol) via syringe. The resulting yellow suspension was 
stirred for 1 hour at room temperature before being diluted with EtOAc (2 mL). The mixture was 
filtered through Celite
®
 and concentrated. The red residue was purified by flash chromatography 
(Hex/Et2O=9:1) to give the title compound as a white solid (2.1 mg, 56% yield). 
1
H NMR (400 MHz, 
C6D6):  = 7.13 – 7.09 (m, 2H), 7.08 – 7.02 (m, 3H), 6.26 (ddt, J = 14.9, 10.9, 1.3 Hz, 1H), 6.12 (d, J = 
11.0 Hz, 1H), 5.72 (ddd, J = 14.7, 7.3, 7.2 Hz, 1H), 5.66 – 5.61 (m, 1H), 5.58 (dd, J = 10.4, 10.3 Hz, 
1H), 5.42 – 5.38 (m, 2H), 4.69 (d, J = 8.6 Hz, 1H), 4.61 (d, J = 6.6 Hz, 1H), 4.56 (d, J = 6.8 Hz, 1H), 
3.56 – 3.47 (m, 1H), 3.45 – 3.34 (m, 1H), 3.25 – 3.22 (m, 2H), 3.22 (s, 3H), 2.39 – 2.30 (m, 1H), 2.25 
– 2.10 (m, 5H), 1.82 (s, 3H), 1.43 (s, 3H), 1.27 (d, J = 7.1 Hz, 3H), 1.15 (d, J = 6.8 Hz, 3H), 1.04 (s, 
9H), 0.80 (d, J = 6.8 Hz, 3H), 0.28 (s, 3H), 0.19 (s, 3H) ppm. 
 
Propargylic alcohol 88. To a 0 °C solution of silylether 87 (1.4 mg, 2.2 µmol) was added a solution 
of TBAF (1.0 M in THF, 4.8 µL, 4.8 µmol) at 0 °C. The 
reaction mixture was stirred for 3 hours at 0 °C befored being 
quenched with sat. NH4Cl/H2O (1:1, 3 mL), extracted with 
MTBE (3 x 4 mL), dried over Na2SO4 and concentrated. The 
residue was purified by flash chromatography (Hex/EtOAc=4:1) to give the title compound as a white 
solid (1.1 mg, 96% yield). 
1
H NMR (400 MHz, CDCl3)  = 7.30 – 7.25 (m, 3H), 7.20 – 7.15 (m, 2H), 
6.26 (ddt, J = 14.9, 10.9, 1.3 Hz, 1H), 5.92 (dd, J = 10.8, 0.9 Hz, 1H), 5.79 (ddd, J = 14.8, 7.3, 7.2 Hz, 
1H), 5.65 (dd, J = 10.2, 9.5 Hz, 1H), 5.53 (d, J = 10.9 Hz, 1H), 5.33 (dd, J = 6.5, 5.6 Hz, 1H), 5.11 (d, 
J = 5.8 Hz, 1H), 4.95 – 4.91 (m, 1H), 4.69 (d, J = 6.8 Hz, 1H), 4.65 (d, J = 6.7 Hz, 1H), 3.47 – 3.41 
(m, 3H), 3.41 (s, 3H), 3.11 (d, J = 2.7 Hz, 1H), 3.07 – 2.98 (m, 1H), 2.56 (ddd, J = 15.9, 7.3, 7.2 Hz, 
1H), 2.43 – 2.17 (m, 4H), 2.00 – 1.92 (m, 1H), 1.70 (s, 3H), 1.54 (s, 3H), 1.18 (d, J = 7.3 Hz, 3H), 
1.06 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H) ppm. 
 
Allylic alcohol 89. Method A: A solution of propargylic alcohol 88 (0.60 mg, 1.2 µmol) in 
MeOH/H2O (1:1, 0.4 mL) was added to freshly prepared 
Zn(Cu/Ag)
[96]
 (150 mg) via syringe and the resulting grey 
suspension was heated to 50 °C for 18 h. After cooling to room 
temperature, the reaction mixture was diluted with EtOAc 
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(4 mL) and filtered through a short pad of SiO2. The filtrate was dried over Na2SO4 and concentrated 
to afforde the title compound as a white solid (0.54 mg, 91%). 
Method B: A solution of propargylic alcohol 88 (0.49 mg, 0.95µmol) in MeOH/H2O (1:2, 0.5 mL) was 
added to a refluxing solution of Rieke zinc
[97a]
 (16.7 mg, 0.256 mmol) in THF (0.3 mL) via syringe 
and the reaction mixture was stirred at reflux temperature for 14 h. After being cooled to room 
temperature, the mixture was diluted with EtOAc (4 mL) and filtered through a short pad of silica gel. 
The filtrate was washed with sat. NH4Cl solution, sat. NaHCO3 solution and brine (3 mL each), dried 
over Na2SO4 and concentrated to give the title compound as a white solid (yield 0.42 mg, 85% yield). 
1
H-NMR (600 MHz, C6D6)  = 7.16 – 7.12 (m, 2H), 7.08 – 7.04 (m, 3H), 6.63 (dd, J = 11.0 Hz, 1H), 
6.33 (dd, J = 11.3, 11.3 Hz, 1H), 6.25 (ddt, J = 14.9, 10.9, 1.5 Hz, 1H), 6.10 (d, J = 10.7 Hz, 1H), 5.86 
(dd, J = 10.3, 10.0 Hz, 1H), 5.70 (ddd, J = 14.7, 7.3, 7.2 Hz, 1H), 5.41 (d, J = 10.3 Hz, 1H), 5.41 – 
5.31 (m, 3H), 4.36 (d, J = 6.6 Hz, 1H), 4.32 (d, J = 6.6 Hz, 1H), 3.25 – 3.22 (m, 2H), 3.09 (s, 3H), 3.09 
– 3.07 (m, 1H), 2.98 – 2.91 (m, 1H), 2.65 – 2.58 (m, 1H), 2.44 (dd, J = 14.1, 13.7 Hz, 1H), 2.13 – 2.03 
(m, 2H), 1.96 – 1.83 (m, 2H), 1.69 (s, 3H), 1.36 – 1.26 (m, 1H), 1.24 (d, J = 7.3 Hz, 3H), 1.15 (s, 3H), 
1.01 (d, J = 6.7 Hz, 3H), 0.75 (d, J = 6.6 Hz, 3H) ppm; 
13
C-NMR (150 MHz, C6D6)  = 171.6, 140.2, 
136.0, 135.0, 133.2, 132.4, 130.6, 128.9 (2C), 128.7 (2C), 128.4, 127.6, 126.8, 126.4, 124.8, 124.0, 
99.5, 82.9, 65.2, 56.0, 48.0, 39.6, 39.3, 35.2, 33.6, 25.6, 22.3, 16.6, 16.5, 12.5, 11.9, 11.2 ppm; MS 
(ESI) m/z: 545.3 (M
+
+Na). HRMS (ESIpos): m/z: calcd for C33H46O5Na: 522.3345, found 522.3347. 
 
Propargylic alcohol 90. TBAF (1 M in THF, 0.259 mL, 0.259 mmol) was slowly added to a 
suspension of silyl ether 86 (74.2 mg, 0.104 mmol) and 
activated 4 Å molecular sieves in THF (1.5 mL) at 0 °C. 
After 1 h, the reaction was quenched with H2O/brine 
(2:1, 10 mL) and diluted with EtOAc (6 mL). The 
aqueous layer was extracted with EtOAc (3 x 7 mL) and the combined organic layers were dried over 
Na2SO4 and concentrated. The residue was quickly purified by flash chromatography (Florisil
®
, 
hexanes/EtOAc, 2:1 to 1:2), keeping the contact time with the Florisil
®
 as short as possible. The white 
solid (53.2 mg, 85%) thus obtained was immediately used in the next step as it was prone to 
decomposition upon storage. 
1
H NMR (400 MHz, C6D6): δ = 6.36 (dd, J = 14.9, 10.8 Hz, 1H), 6.15 (d, 
J = 10.8 Hz, 1H), 5.73 (dt, J = 15.0, 7.5 Hz, 1H), 5.53 – 5.46 (m, 3H), 5.41 – 5.35 (m, 1H), 5.08 (br t, 
J = 2.7 Hz, 1H), 4.41 (s, 2H), 3.52 (ddd, J = 10.0, 7.4, 2.8 Hz, 1H), 3.42 (dd, J = 8.6, 2.5 Hz, 1H), 
3.36 – 3.26 (m, 1H), 3.12 (s, 3H), 3.12 – 3.10 (m, 1H), 2.65 (d, J = 16.4 Hz, 1H), 2.56 (dq, J = 7.4, 
7.3 Hz, 1H), 2.30 – 2.15 (m, 6H), 2.14 – 2.02 (m, 2H), 1.93 (dd, J = 14.3, 7.7 Hz, 1H), 1.74 (s, 3H), 
1.61 (dd, J = 15.9, 9.1, 6.9, 2.2 Hz, 1H), 1.50 (ddq, J = 14.6, 7.2, 3.1 Hz, 1H), 1.41 (s, 3H), 1.33 – 
1.23 (m, 1H), 1.32 (d, J = 7.1 Hz, 3H), 1.01 (d, J = 7.0 Hz, 3H), 0.93 (d, J = 6.9 Hz, 3H), 0.91 (t, J = 
7.3 Hz, 3H), 0.67 (d, J = 6.8 Hz, 3H) ppm; IR (film):  ̃ = 3454, 2972, 2932, 1727, 1462, 1379, 1246, 
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1193, 1151, 1090, 1029, 1022, 986, 844, 759 cm
−1
; HRMS (ESIpos): m/z: calcd for C35H52O8Na: 
623.3554, found 623.3551. 
 
Isomeric propargylic alcohol 104. This diastereomer was obtained analogously from 103 (26.5 mg, 
37.1 µmol) as a white solid  (17.2 mg, 76%). 
1
H NMR 
(400 MHz, C6D6): δ = 6.31 (dd, J = 15.0, 10.9 Hz, 1H), 
6.13 (d, J = 10.9 Hz, 1H), 5.58 (dt, J = 15.0, 7.5 Hz, 
1H), 5.53 – 5.46 (m, 3H), 5.41 – 5.36 (m, 1H), 5.10 (br 
t, J = 2.5 Hz, 1H), 4.39 (s, 2H), 3.44 (ddd, J = 10.2, 7.5, 2.9 Hz, 1H), 3.41 (dd, J = 8.7, 2.7 Hz, 1H), 
3.37 – 3.27 (m, 1H), 3.10 (s, 3H), 2.95 (d, J = 2.9°Hz, 1H), 2.61 – 2.52 (m, 1H), 2.56 (d, J = 16.3 Hz, 
1H), 2.29 – 2.15 (m, 3H), 2.15 – 2.09 (m, 1H), 2.05 (d, J = 16.2 Hz, 1H), 2.09 – 2.00 (m, 2H), 1.84 
(dd, J = 14.1, 7.6 Hz, 1H), 1.71 (s, 3H), 1.51 – 1.41 (m, 2H), 1.40 (s, 3H), 1.33 (d, J = 7.1 Hz, 3H), 
1.24 (ddq, J = 14.5, 7.3, 7.2 Hz, 1H), 1.00 (d, J = 7.1 Hz, 3H), 0.93 (d, J = 6.8 Hz, 3H), 0.89 (t, 3H, J 
= 7.3 Hz), 0.58 ppm (d, 3H, J = 6.8 Hz); IR (film):  ̃ = 3457, 2970, 2934, 1728, 1455, 1377, 1246, 
1189, 1149, 1091, 1022, 987, 843, 755 cm
−1
; HRMS (ESIpos): m/z: calcd for C35H52O8Na: 623.3554, 
found 623.3553. 
 
Cyclodiene 91. A solution of propargyl alcohol 90 (48.2 mg, 80.2 µmol) in THF (0.6 mL) was added 
to a suspension of freshly prepared Zn(Cu/Ag)
[245]
 
(1.8 g) in degassed MeOH/H2O (1:1, 1.6 mL) and the 
resulting mixture was stirred for 18 h at 50 °C. After 
cooling to room temperature, the mixture was diluted 
with EtOAc (8 mL) and filtered through a short pad of Celite
®
, which was carefully rinsed with EtOAc 
(180 mL) and EtOH (20 mL). The combined filtrates were concentrated under reduced pressure to ca. 
1/10 of the original volume and then washed with brine/H2O (1:1, 15 mL). The aqueous phase was 
extracted with EtOAc (2 x 15 mL), the combined organic layers were dried over Na2SO4 and 
concentrated, and the residue was purified by flash chromatography (Florisil
®
, hexanes/EtOAc, 2:1 to 
1:1) to give the title compound as a white solid (43.1 mg, 89%). [∝]𝐷
20= −72.0 (c = 0.66, CH2Cl2); 
1
H 
NMR (600 MHz, CD2Cl2): see Table 5.1; 
13
C NMR (150 MHz, CD2Cl2): see Table 5.1; IR (film):  ̃ = 
3447, 2966, 2932, 1729, 1456, 1415, 1368, 1243, 1206, 1147, 1089, 1020, 985, 918, 863, 783, 748, 
736, 700 cm
−1
; HRMS (ESIpos): m/z: calcd for C35H54O8Na: 625.3711, found 625.3709. 
 
Isomeric bis-diene 105. This diastereomer was obtained analogously from 104 (14.0 mg, 24.1 µmol) 
as a white solid (11.7 mg, 81%). [∝]𝐷
20 = −40.1 (c = 
0.76, CH2Cl2); 
1
H NMR (500 MHz, CDCl3): δ = 6.45 
(dd, 1H, J = 11.3, 11.2 Hz), 6.40 (dd, 1H, J = 15.0, 
10.9 Hz), 6.29 (dd, 1H, J = 11.3, 11.3 Hz), 6.10 (d, 1H, 
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J = 11.0 Hz), 5.76 (ddd, 1H, J = 15.1, 7.6, 7.6 Hz), 5.57 (dd, 1H, J = 10.6, 10.3 Hz), 5.29 (d, 1H, J = 
10.7, 10.5 Hz), 5.15 – 5.10 (m, 1H), 5.09 (d, 1H, J = 10.4 Hz), 5.04 (d, 1H, J = 10.1 Hz), 4.73 (d, 1H, 
J = 6.3 Hz), 4.64 (d, 1H, J = 6.3 Hz), 3.91 (ddd, 1H, J = 10.0, 7.3, 2.9 Hz), 3.41 (s, 3H), 3.35 (d, 1H, J 
= 10.4 Hz), 3.04 – 2.94 (m, 1H), 2.90 – 2.80 (br s, 1H), 2.73 (d, 1H, J = 16.6 Hz), 2.62 – 2.54 (m, 1H), 
2.40 (d, 1H, J = 14.2, 7.9 Hz), 2.36 (d, 1H, J = 16.6 Hz), 2.35 – 2.30 (m, 3H), 2.27 – 2.18 (m, 3H), 
2.06-2.02 (m, 1H), 1.92 (s, 1H), 1.93 – 1.87 (m, 1H), 1.84 (ddq, J = 7.4, 7.4, 2.8 Hz, 1H), 1.80 (s, 3H), 
1.64 (ddq, J = 14.4, 7.2, 7.1 Hz, 1H), 1.44 (s, 3H), 1.09 (d, J = 7.1 Hz, 3H), 1.07 (d, J = 7.3 Hz, 1H), 
1.02 (d, J = 6.9 Hz, 3H), 1.01 (t, J = 7.4 Hz, 3H), 0.88 (d, J = 0.9 Hz, 3H); 
13
C NMR (100 MHz, 
CDCl3): δ = 172.4, 170.2, 137.1, 136.4, 134.1, 132.4, 131.6, 129.7, 128.3, 126.4, 124.5, 124.3, 100.0, 
89.4, 83.9, 82.9, 72.1, 65.0, 56.6, 48.1, 43.3, 43.0, 39.1, 38.7, 35.3, 33.8, 27.2, 26.4, 22.4, 16.7, 16.5, 
12.1, 11.6, 11.4, 9.2 ppm; IR (film):  ̃ = 3457, 2966, 2934, 1729, 1455, 1367, 1244, 1147, 1089, 1019, 
985, 949, 918, 863, 736 cm
−1
; HRMS (ESIpos): m/z: calcd for C35H54O8Na: 625.3711, found 
625.3716. 
 
Allylic carbamate 92. A solution of trichloroacetyl isocyanate (9.15 µL, 77.2 µmol) was added to a 
precooled solution (−78 °C) of allylic alcohol 91 
(42.3 mg, 70.2 µmol) in CH2Cl2 (3.0 mL). The 
mixture was stirred at −78 °C for 2 h, before excess 
isocyanate was quenched with MeOH (0.3 mL) at this 
temperature. After warming to ambient temperature 
and concentration under reduced pressure, the residue was dissolved in CH2Cl2 (2 mL) and the 
solution soaked on basic Al2O3. After 1.5 h, the alumina was loaded onto a short pad of Celite
®
, which 
was eluted with EtOAc/EtOH (9:1, 12 mL). The solvent was evaporated and the residue purified by 
flash chromatography (Florisil
®
, hexanes/EtOAc, 1:1 to 1:2 to 1:4) to furnish the title compound as a 
white foam (38.2 mg, 84%). [∝]𝐷
20= −66.4 (c = 0.94, CD2Cl2); 
1
H NMR (600 MHz, CDCl3): see Table 
5.2; 
13
C NMR (150 MHz, CD2Cl2): see Table 5.2; IR (film):  ̃ = 3452, 3365, 2965, 2931, 1723, 1602, 
1455, 1376, 1312, 1259, 1209, 1146, 1092, 1058, 1033, 954, 916, 863, 801, 748, 710, 679 cm
−1
; 
HRMS (ESIpos): m/z: calcd for C36H55NO9Na: 668.3780, found 668.3774.  
 
Isomeric Carbamate 106. This diastereomer was obtained analogously from 105 (9.0 mg, 15 µmol) 
as a white foam (6.1 mg, 63%). [∝]𝐷
20= −43.7 (c = 0.31, 
CH2Cl2); 
1
H NMR (600 MHz, CD2Cl2): δ = 6.69 (dd, J 
= 10.8, 10.6 Hz, 1H), 6.40 (dd, J = 15.0, 10.9 Hz, 1H), 
6.32 (dd, J = 10.8, 10.6 Hz, 1H), 6.10 (d, J = 10.8 Hz, 
1H), 5.92 (d, J = 9.2 Hz, 1H), 5.76 (ddd, J = 15.1, 7.6, 
7.6 Hz, 1H), 5.50 (dd, J = 5.5 Hz, 1H), 5.36 – 5.33 (m, 1H), 5.11 – 5.08 (m, 1H), 5.08 (d, J = 10.3 Hz, 
1H), 4.70 (d, J = 6.7 Hz, 1H), 4.58 (d, J = 6.7 Hz, 1H), 4.56 – 4.44 (br s, 2H), 3.90 (ddd, J = 10.1, 7.4, 
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2.9 Hz, 1H), 3.38 (s, 3H), 3.30 (d, J = 9.8 Hz, 1H), 3.03 – 2.95 (m, 1H), 2.73 (d, J = 16.5 Hz, 1H), 
2.54 – 2.46 (br s, 1H), 2.40 (dd, J = 14.0, 7.8 Hz, 1H), 2.36 (d, J = 16.5 Hz, 1H), 2.33 – 2.27 (m, 1H), 
2.26 – 2.15 (m, 3H), 2.05 – 1.94 (m, 2H), 1.93 – 1.91 (m, 1H), 1.89 (dq, J = 10.5, 7.1 Hz, 1H), 1.84 
(ddq, J = 7.4, 7.3, 3.1 Hz, 1H), 1.79 (s, 3H), 1.62 (ddq, J = 14.7, 7.4, 7.3 Hz, 1H), 1.26 (s, 3H), 1.13 
(d, J = 7.1 Hz, 3H), 1.09 (d, J = 6.6 Hz, 3H), 1.01 (d, J = 6.8 Hz, 3H), 1.01 (t, J = 7.3 Hz, 3H), 0.87 (d, 
J = 6.6 Hz, 3H) ppm; 
13
C NMR (150 MHz, CD2Cl2): δ = 172.3, 170.2, 156.2, 137.3, 136.8, 134.1, 
131.7, 129.7, 129.2, 128.1, 126.1, 125.1, 124.9, 98.8, 85.9, 83.7, 82.7, 72.1, 67.3, 56.2, 48.2, 43.1, 
42.9, 38.6, 38.6, 34.9, 33.8, 27.1, 22.3, 16.7, 16.7, 13.7, 12.0, 11.6, 11.3, 9.2 ppm; IR (film):  ̃ = 3441, 
3368, 2969, 2931,1729, 1603, 1376, 1208, 1147, 1059, 1035, 917, 747 cm
−1
; MS (ESI) m/z (%): 684.4 
(100); HRMS (ESIpos): m/z: calcd for C36H55NO9K: 684.3508, found 625.3514. 
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Table 5.1: Assignment of 
1
H and 
13
C NMR data of cyclodiene 91. 
 
atom n° 
1
H NMR (CD2Cl2, 600 MHz) 
13
C NMR (CD2Cl2, 150 MHz) 
 /ppm integral m COSY J (Hz)  /ppm HMBC 
1 - - - - - 172.4 2, 15 
2a 2.34 1H m 2b, 3a - 
33.7 1, 3, 5, 26 
2b 1.94 1H m 2a, 3b - 
3 2.19 2H m 2a, 2b, 4 - 22.2 1, 2, 4, 26 
4 5.12 1H m 3a, 3b, 26 - 126.3 2, 3, 6, 26 
5 - - - - - 137.01 3, 6, 7, 26, 27 
6 2.59 1H m 7, 27 - 47.9 4, 5, 7, 26, 27 
7 3.35 1H d 6 10.6 89.3 6, 9, 27, 28, 28 
8 1.66 1H m 28 - 38.9 7, 9, 10, 28 
9 5.04 1H d 10 9.8 65.0 7, 8, 11, OH1, 28 
10 5.57 1H dd 9, 11 10.8, 9.9 132.2 8, 9, 12, OH1 
11 6.29 1H dd 10, 12 11.4, 10.9 124.3 9, 12, 13, 14 
12 6.45 1H dd 11, 13 11.4, 10.7 124.4 10, 13, 14, 29 
13 5.28 1H dd 12, 14 10.7, 10.4 136.3 11, 14, 15, 29 
14 3.01 1H m 13, 15, 29 - 35.1 12, 13, 15, 29 
15 5.09 1H d 14 10.4 82.9 13, 14, 16, 17, 29, 30 
16 - - - - - 133.8 14, 15, 17, 18 
17 6.09 1H d 18 10.9 129.7 15, 16, 18, 19, 30 
18 6.38 1H dd 17, 19 11.0, 15.0 131.4 17, 20, 30 
19 5.77 1H ddd 20a, 20b 15.0, 7.5, 7.5 128.5 17, 18, 20, 21 
20a 2.41 1H dd 19, 20b 14.0, 7.2 
38.5 18, 19, 21, 22, 32 
20b 2.19 1H m 19, 20a - 
21 - - - - - 72.0 19, 20a, 20b, 22, 32 
22 1.88 1H dq 23, 33 10.0, 6.9 43.2 20, 31, 32, 
23 3.91 1H ddd 22, 24a, 24b 10.0, 7.4, 2.8 83.8 22, 24, 25 
24a 1.83 1H ddq 23, 24b, 25 7.4, 7.3, 3.0 
27.1 23, 25 
24b 1.60 1H ddq 23, 24b, 25 7.4, 7.3, 7.3 
25 1.00 3H t 24a, 24b 7.3 9.2 24 
26 1.43 3H s 4 - 11.3 4, 5, 6 
27 1.09 3H d 6 6.8 16.4 5, 7, 28 
MOM-CH2 
4.72 1H d CH2b 6.5 
99.8 7, MOM-CH3 
4.63 1H d CH2a 6.5 
MOM-CH3 3.40 3H s - - 56.6 MOM-CH2 
28 1.06 3H d 8 7.3 12.0 5, 9 
29 0.86 3H d 14 6.7 16.6 13, 14, 15 
30 1.79 3H s 17 - 12.0 15, 17 
31 1.01 3H d 22 6.9 11.5 21, 22 
32a 2.72 1H d 32b 16.5 42.8 21, 35 
32b 2.34 1H d 32a 16.6   
33 - - - - - 170.3 32a, 32b 
OHa 2.91 1H br s     
OHb 2.23 1H br s     
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Table 5.2: Assignment of 
1
H and 
13
C NMR data of the allylic carbamate 92. 
 
atom n° 
1
H NMR(CD2Cl2, 600 MHz) 
13
C NMR (CD2Cl2, 150 MHz) 
 /ppm integral m COSY J (Hz)  /ppm HMBC 
1 - - - - - 172.3 2, 15 
2a 2.27 - 2.33 1H m 2b, 3a - 
33.8 1, 4, 5, 26 
2b 1.93 - 2.02 1H m 2a, 3b - 
3 2.18 - 2.23 2H m 2a, 2b, 4 - 22.3 1 
4 5.05 - 5.11 1H m 3a, 3b, 26 - 126.1 6 
5 - - - - - 137.3 3, 26, 27 
6 2.45 - 2.55 1H m 7, 27 - 48.2 6, 26, 27 
7 3.30 1H d 6 9.9 85.9 9, 27, 28 
8 1.72 - 1.79 1H br m 30 - 38.6 30 
9 5.92 1H br d 10 9.3 67.3 7, 11, 12, 28 
10 5.50 1H br dd 9, 11 9.3, 10.0 129.2 12 
11 6.32 1H br dd 10, 12 10.1, 11.1 125.1 9, 13, 15 
12 6.68 1H br dd 11, 13 10.7, 11.0 124.9 10, 14 
13 5.29 - 5.36 1H m 12, 14 - 136.8 11, 14, 15, 29 
14 2.95 - 3.03 1H m 13, 15, 32 - 34.9 12, 13, 15, 29 
15 5.08 1H d 14 10.3 82.7 13, 14, 16, 17, 29, 30 
16 - - - - - 133.9 14, 15, 17, 18, 19, 30 
17 6.10 1H d 18 10.9 129.8 15, 16, 17, 18, 19, 30 
18 6.39 1H dd 17, 19 15.1,10.9 131.5 17, 20, 30 
19 5.77 1H ddd 18, 20a, 20b 15.1, 7.6, 7.6 128.3 17, 20, 21, 30 
20a 2.41 1H dd 19, 20b 14.0, 7.3 38.6 18, 19, 21, 22, 32 
20b 2.19 - 2.22 1H m 19, 20a -   
21 - - - - - 72.1 19, 20, 22, 314, 32 
22 1.89 1H dq 23, 34 9.9, 6.8 43.1 20, 34, 32 
23 3.91 1H ddd 22, 24a, 24b 10.1, 7.4, 2.9 83.8 22, 24, 25, 31 
24a 1.84 1H ddq 23, 24b, 25 7.4, 7.3, 2.8 
27.1 23, 25 
24b 1.62 1H ddq 23, 24b, 25 7.4, 7.3, 7.3 
25 1.00 3H t 24a, 24b 7.4 9.2 24 
26 1.43 3H br s - - 11.3 2, 6, 7 
27 1.08 3H d 6 6.6 16.7 5, 6, 7 
MOM-CH2 
4.70 1H d 28b 6.7 
98.8 MOM-CH3 
4.58 1H d 28a 6.7 
MOM-CH3 3.38 3H s - - 56.2 MOM-CH2 
28 1.13 3H d 8 7.1 13.7 8, 27 
29 0.86 3H d 14 6.6 16.6 13, 14, 15 
30 1.79 3H d 17 0.7 12.0 15, 16, 17, 19 
31 1.01 3H d 22 7.1 11.6 21, 22 
32a 2.73 1H d 32b 16.5 
42.8 21, 33 
32b 2.35 1H dd 32a 16.6, 0.3 
33 - - - - - 170.3 32a, 32b 
34 - - - - - 156.3 9 
NH2 4.51 - 4.66 2H br s - - - - 
OH 1.66 - 1.69 1H br s - - - - 
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Leiodermatolide (1). A solution of compound 33 (9.0 mg, 13.9 µmol) in CH2Cl2 (1.6 mL) was cooled 
to −90 °C (Et2O/CO2/N2 cooling bath) before a solution 
of freshly prepared Me2BBr
[238]
 (0.5 M in CH2Cl2, 
30.6 µL, 15.3 µmol) was carefully added via the cold 
wall of the flask. The mixture was allowed to reach 
−78 °C and was stirred at this temperature for 1.5 h, when 
a second aliquot of Me2BBr (0.5 M, 30.6 µL, 15.3 µmol) was introduced. After additional 1.5 h, the 
mixture was transferred via canula into a vigorously stirred mixture of sat. NaHCO3/H2O/THF (1:1:1, 
10 mL) and the flask was rinsed with THF (2 x 0.7 mL). After stirring for 10 min, the mixture was 
diluted with EtOAc (10 mL), the aqueous layer was extracted with EtOAc (3 x 10 mL), the combined 
extracts were dried over Na2SO4 and concentrated. The residue was purified by preparative thin layer 
chromatography (TLC Silica gel 60 F254 (20 x 20 cm), hexanes/EtOAc, 1:2.5) to give the title 
compound as a white solid (5.1 mg, 61%). [∝]𝐷
24 = –74.3 (c = 0.41, MeOH); 1H NMR (600 MHz, 
CD2Cl2, 4.8 mg in 0.3 mL CD2Cl2): δ = 6.53 (dd, J = 11.7, 11.3 Hz, 1H), 6.39 (dd, J = 15.3, 10.7 Hz, 
1H), 6.37 (dd, J = 11.3, 11.2, 1H), 6.10 (d, J = 10.9 Hz, 1H), 5.89 (d, J = 10.1 Hz, 1H), 5.77 (ddd, J = 
15.1, 7.6, 7.6 Hz, 1H), 5.53 (dd, J = 10.4, 10.4 Hz, 1H), 5.35 (dd, J = 10.5, 10.4°Hz, 1H), 5.09 (m, 
1H), 5.07 (d, J = 10.3 Hz, 1H), 4.84 – 4.63 (br s, 2H), 3.91 (ddd, J = 10.1, 7.4, 2.9 Hz, 1H), 3.26 (br t, 
1H), 2.97 (ddq, J = 10.1, 10.1, 6.7 Hz, 1H), 2.73 (d, J = 16.5 Hz, 1H), 2.46 (dq, J = 11.2, 5.8 Hz, 1H), 
2.42 (dd, J = 14.0, 7.3 Hz, 1H), 2.35 (dd, J = 16.6, 0.9 Hz, 1H), 2.31 (ddd, J = 16.7, 5.8, 3.0 Hz, 1H), 
2.21 (dd, J = 13.9, 8.0 Hz, 1H), 2.27 – 2.17 (m, 3H), 2.13 – 2.06 (br s, 1H), 1.99 (ddd, J = 16.7, 10.6, 
3.6 Hz, 1H), 1.89 (dq, J = 10.3, 7.0 Hz, 1H), 1.83 (ddq, J = 7.4, 7.3, 3.1 Hz, 1H), 1.79 (d, J = 0.9 Hz, 
3H), 1.74 (q, J = 7.2 Hz, 1H), 1.62 (ddq, J = 14.7, 7.4, 7.3 Hz, 1H), 1.42 (s, 3H), 1.12 (d, J = 6.7 Hz, 
3H), 1.08 (d, J = 7.3 Hz, 3H), 1.02 (d, J = .6.8 Hz, 3H), 1.01 (t, J = 7.3 Hz, 3H), 0.86 (d, J = 6.7 Hz, 
3H) ppm; 
13
C NMR (150 MHz, CD2Cl2, 4.8 mg in 0.3 mL): δ = 172.2, 170.3, 157.4, 137.6, 137.2, 
133.8, 131.5, 129.8, 128.5, 128.4, 126.2, 125.6, 124.1, 83.8, 82.5, 78.2, 72.1, 67.6, 48.5, 43.1, 42.8, 
39.3, 38.6, 35.0, 33.7, 27.1, 22.2, 16.6, 16.5, 12.5, 12.0, 11.6, 11.3, 9.2 ppm; IR (film): ̃ = 3360, 
2963, 2924, 1708, 1605, 1455, 1375, 1312, 1246, 1207, 1148, 1082, 1056, 1040, 986, 949, 915, 778, 
745 cm
−1
; MS (ESI) m/z (%): 624.4 (100); HRMS (ESIpos): m/z: calcd for C34H51NO8Na: 624.3507, 
found 624.3513. 
For an assignment of 
1
H and 
13
C NMR data, see table 5.3. 
 
Leiodermatolide isomer 2. Prepared analogously from compound 106 (3.6 mg, 5.6 µmol) as a white 
solid (0.6 mg). [∝]𝐷
24= –58 (c = 0.09, MeOH); 1H NMR 
(600 MHz, CD2Cl2): δ = see table 5.4; 
13
C NMR (150 
MHz, CD2Cl2): δ = see table 5.4; MS (ESI) m/z (%): 
624.4 (100); HRMS (ESIpos): m/z: calcd. for 
C34H51NO8Na [M
+
+Na]: 624.35069, found 624.35155. 
156 Experimental section 
 
Table 5.3:  Assignment of 
1
H and 
13
C NMR data of leiodermatolide (1), recorded with 
0.8 mg in 0.3 mL CD2Cl2. 
 
atom n° 
1
H NMR (CD2Cl2, 600 MHz) 
13
C NMR (CD2Cl2, 150 MHz) 
 /ppm Integral m COSY J (Hz)  /ppm HMBC 
1 - - - - - 172.2 2, 3, 15 
2a 2.31 1H ddd 2b, 3 16.7, n.d. 
33.7 3, 4, 26 
2b 1.99 1H ddd 2a, 3 16.7, n.d. 
3 2.20 2H m 2, 4, 26 - 22.2 2, 4, 5, 26 
4 5.09 1H ddq 3, 26 9.9, 5.5, 1.6 125.6 2, 3, 5, 6, 26 
5 - - - - - 137.2 3, 4, 6, 26, 27 
6 2.46 1H dq 7, 27 10.5, 6.7 48.5 4, 7, 25, 26, 27 
7 3.26 1H br t OH, 6, 8 9.9 78.2 6, 8, 9, 28 
8 1.74 1H qt 7, 27, 28 7.4, n.d. 39.3 7, 10, 28 
9 5.89 1H d 10 10.0 67.6 7, 28, 11 
10 5.53 1H ddt 9, 11 10.7, 10.0, 1.4 128.5 9, 11, 12, 13 
11 6.38 1H ddt 10, 12 12.0, 10.9 126.2 9, 10, 12, 13 
12 6.53 1H ddt 11, 13 11.8, 11.0, 1.0 124.4 10, 11, 13, 14 
13 5.35 1H ddt 12, 14 10.8, 10.2, 1.4 137.6 11, 12, 14, 15, 29 
14 2.98 1H tq 13, 15, 29 10.2, 6.7 35.0 12, 13, 15, 29, 30 
15 5.07 1H d 14 10.3 82.5 12, 13, 14, 17, 29, 30 
16 - - - - - 134.0 14, 15, 17, 18, 30 
17 6.10 1H dq 18, 30 10.9, 1.4 129.7 15, 16, 18, 19, 30 
18 6.40 1H ddt 17,19, 20 15.1, 10.9, 1.3 131.7 16, 17, 20, 30 
19 5.76 1H dt 18, 20 15.0, 7.6 128.2 17, 20, 30 
20a 2.41 1H dd 19, 20b 14.0, 7.5 
38.6 18, 19, 32 
20b 2.22 1H dd 19, 20a 13.8, 7.9 
21      72.1 18, 19, 20, 22, 31, 32 
22 1.89 1H dq 23, 31 10.5, 6.7 43.1 20, 21, 23, 24, 31, 32 
23 3.91 1H ddd 22, 24 10.0, 7.6, 3.1 83.8 22, 24, 25, 31 
24a 1.85 1H ddq 23, 24b, 25 14.5, 7.4, 3.1 
27.1 22, 23, 25 
24b 1.62 1H dq 23, 24a, 25 14.6, 7.4 
25 1.01 3H t 24 7.3 9.2 23, 24 
26 1.42. 3H s 3, 4 - 11.3 3, 4, 5, 6 
27 1.12 3H d 6 6.7 16.5 5, 6 
28 1.08 3H d 8 7.3 12.5 7, 8, 9 
29 0.87 3H d 14 6.7 16.6 13, 14, 15 
30 1.79 3H d 17 1.0 12.0 14, 15, 16, 17, 18, 19 
31 1.02 3H d 22 6.8 11.6 21, 22, 23, 32 
32a 2.72 1H d 32b 16.4 
42.8 21, 22, 31, 33 
32b 2.35 1H dd 32a 16.5, 1.0 
33 - - - - - 170.2 32 
34 - - - - - 157.3 9 
NH2 4.66 2H br s - - - - 
C.7-OH 2.16 1H d 7 7.9 - - 
C.21-OH 1.91 1H s - - - - 
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Table 5.4:  Assignment of 
1
H and 
13
C NMR data of leiodermatolide isomer 2; recorded 
with 0.6 mg in 0.3 mL CD2Cl2. 
 
atom n° 
1
H NMR (CD2Cl2, 600 MHz) 
13
C NMR (CD2Cl2, 150 MHz) 
 /ppm Integral m J (Hz) COSY  /ppm HMBC 
1 - - - - - 172.2 2, 3, 15 
2a 2.29 1H ddd 16.6, n.d. 2b, 3 
33.7 3, 4, 26 
2b 1.99 1H ddd 16.7, n.d. 2a, 3 
3 2.20 2H m - 2, 4, 26 22.2 2, 4, 5, 26 
4 5.09 1H ddq 8.4, 5.2, 1.4 3, 26 125.6 2, 3, 5, 6, 26 
5 - - - - - 137.3 3, 4, 6, 26, 27 
6 2.47 1H dq 10.5, 6.7 7, 27 48.5 4, 7, 25, 26, 27 
7 3.26 1H br m - OH, 6, 8 78.1 6, 8, 9, 28 
8 1.74 1H qt 7.3, n.d. 7, 27, 28 39.3 7, 10, 28 
9 5.89 1H d 10.0 10 67.6 7, 28, 11 
10 5.53 1H ddt 10.7, 10.0, 1.3 9, 11 128.5 9, 11, 12, 13 
11 6.38 1H t 11.3 10, 12 126.2 9, 10, 12, 13 
12 6.53 1H t 11.5 11, 13 124.4 10, 11, 13, 14 
13 5.35 1H ddt 10.8, 10.2, 1.4 12, 14 137.6 11, 12, 14, 15, 29 
14 2.98 1H tq 10.2, 6.7 13, 15, 29 35.0 12, 13, 15, 29, 30 
15 5.07 1H d 10.3 14 82.5 12, 13, 14, 17, 29, 30 
16 - - - - - 134.0 14, 15, 17, 18, 30 
17 6.10 1H dq 10.9, 1.4 18, 30 129.7 15, 16, 18, 19, 30 
18 6.40 1H ddt 15.0, 10.9, 1.3 17,19, 20 131.7 16, 17, 20, 30 
19 5.76 1H dt 15.1, 7.6 18, 20 128.2 17, 20, 30 
20a 2.40 1H dd 14.1, 7.8 19, 20b 
38.6 18, 19, 32 
20b 2.23 1H dd 14.2, 7.5 19, 20a 
21      72.1 18, 19, 20, 22, 31, 32 
22 1.89 1H dq 10.0, 6.8 23, 31 43.1 20, 21, 23, 24, 31, 32 
23 3.91 1H ddd 10.0, 7.6, 3.1 22, 24 83.8 22, 24, 25, 31 
24a 1.85 1H ddq 14.5, 7.4, 3.1 23, 24b, 25 
27.1 22, 23, 25 
24b 1.62 1H dq 14.6, 7.4 23, 24a, 25 
25 1.01 3H t 7.4 24 9.2 23, 24 
26 1.42. 3H s - 3, 4 11.3 3, 4, 5, 6 
27 1.12 3H d 6.7 6 16.5 5, 6 
28 1.08 3H d 7.3 8 12.5 7, 8, 9 
29 0.87 3H d 6.7 14 16.6 13, 14, 15 
30 1.79 3H d 0.7 17 12.0 14, 15, 16, 17, 18, 19 
31 1.02 3H d 6.9 22 11.6 21, 22, 23, 32 
32a 2.73 1H d 16.5 32b 
42.9 21, 22, 31, 33 
32b 2.36 1H d 16.6 32a 
33 - - - - - 170.2 32 
34 - - - - - 157.3 9 
NH2 4.67 2H br s - - - - 
C.7-OH 2.17 1H br s - 7 - - 
C.21-OH 1.91 1H s - - - - 
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5.2.5 Syntheses of analogues. 
Analogues 107, 108 and 109 were prepare by Dr. Damien Mailhol. The procedures can be 
found in the Supporting Information of the leiodermatolide full paper.
[113]
 
 
Allylic acetate 118. Acetic anhydride (2.3 µL, 25 µmol), triethylamine (4.6 µL, 33 µmol) and DMAP 
(0.2 mg, 1.7 µmol) were added successively to a ‒78 °C 
solution of alcohol 91 (10.0 mg, 16.6 µmol) in CH2Cl2, 
which was stirred for 1 h. The reaction mixture was then 
allowed to warm to 0 °C and stirred for further 18 h 
before the reaction was quenched with a mixture of 
brine and H2O (1:1, 4 mL). The aqueous layer was extracted with CH2Cl2 (3 x 4 mL) and the 
combined organic layers were dried over Na2SO4 and concentrated in vacuo. The residue was purified 
by flash chromatography (silica, hexanes/EtOAc, 3:1 to 2:1) to yield the desired mono-acetylated 
product 118 as a white solid (5.8 mg, 54% yield, ~95% purity) along with the bis-acetylated 
compound as an off-white foam (3.1 mg, 27% yield). [∝]𝐷
20 = ‒65.7 (c = 0.48, CH2Cl2). 
1
H NMR (600 
MHz, CD2Cl2): δ = 6.65 (br t, J = 12.2 Hz, 1H), 6.38 (ddt, J = 15.0, 10.7, 1.2 Hz, 1H), 6.31 (br t, J = 
10.3 Hz, 1H), 6.09 (dd, J = 10.8, 1.7 Hz, 1H), 6.03 (d, J = 10.8 Hz, 1H), 5.75 (dt, J = 15.2, 7.6 Hz, 
1H), 5.47 (br t, J = 10.0 Hz, 1H), 5.36 – 5.30 (m, 1H), 5.09 – 5.04 (m, 2H), 4.66 (d, J = 6.7 Hz, 1H), 
4.55 (d, J = 6.7 Hz, 1H), 3.90 (ddd, J = 10.3, 7.5, 3.2 Hz, 1H), 3.36 (s, 3H), 3.27 (br s, 1H), 2.97 (ddq, 
J = 10.3, 6.7, 6.6 Hz, 1H), 2.72 (d, J = 16.5 Hz, 1H), 2.52 – 2.44 (m, 1H), 2.41 (dd, J = 14.0, 7.4 Hz, 
1H), 2.34 (d, J = 16.5, 0.9 Hz, 1H), 2.32 – 2.27 (m, 1H), 2.24 – 2.17 (m, 4H), 2.00 – 1.95 (m, 2H), 
1.94 (s, 3H), 1.88 (dq, J = 9.8, 7.1 Hz, 1H), 1.84 (ddd, J = 14.7, 7.3, 3.2 Hz, 1H), 1.78 (d, J = 1.0 Hz, 
3H), 1.77 – 1.74 (m, 1H), 1.68 – 1.54 (m, 3H), 1.15 (d, J = 7.4 Hz, 3H), 1.07 (d, J = 6.8 Hz, 3H), 1.02 
– 0.99 (m, 6H), 0.86 (d, J = 6.6 Hz, 3H) ppm. 13C NMR (150 MHz, CD2Cl2): δ = 172.5, 170.4, 170.3, 
137.6, 137.2, 135.6, 134.3, 131.9, 129.9, 129.2, 128.5, 126.4, 125.0, 99.1, 86.1, 84.1, 83.0, 72.4, 66.8, 
56.5, 48.4, 43.4, 43.1, 42.3, 34.0, 27.4, 22.6, 21.6, 16.9, 16.7, 13.8, 12.3, 11.8, 11.6, 9.4 ppm; IR 
(film):  ̃ = 3480, 2967, 2930, 1732, 1457, 1369, 1243, 1208, 1148, 1091, 1036, 949, 748 cm−1; MS 
(ESI) m/z (%): 667.5 (100); HRMS (ESIpos): m/z: calcd for C37H56O9Na: 667.3817, found 667.3817. 
 
Analogue 110. A solution of allylic acetate 118 (4.8 mg, 7.4 µmol) in CH2Cl2 (0.8 mL) was cooled to 
‒90 °C (Et2O/CO2/N2 cooling bath) before a solution of 
freshly prepared Me2BBr (0.5 M in CH2Cl2, 16.4 µL, 
8.2 µmol) was carefully added via the cold wall of the 
flask. The mixture was allowed to reach ‒78 °C and was 
stirred at this temperature for 1.5 h, when a second 
aliquot of Me2BBr (0.5 M, 16.4 µL, 8.2 µmol) was introduced. The reaction mixture was stirred for 
1.5 h, when a third aliquot of Me2BBr (0.5 M, 16.4 µL, 8.2 µmol) was introduced. After an additional 
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1.5 h, the mixture was transferred via canula into a vigorously stirred mixture of sat. 
NaHCO3/H2O/THF (1:1:1, 7 mL) and the flask was rinsed with THF (2 x 0.5 mL). After stirring for 10 
min, the mixture was diluted with EtOAc (10 mL) and the aqueous layer was extracted with EtOAc (3 
x 10 mL). The combined organic extracts were dried over Na2SO4 and concentrated in vacuo. The 
residue was purified by preparative thin layer chromatography (TLC Silica gel 60 F254 (20 x 20 cm), 
hexanes/EtOAc, 1:1) to yield the title compound as an off-white solid (2.4 mg, 54% yield). 
1
H NMR 
(600 MHz, CD2Cl2): see table 5.5; 
13
C NMR (150 MHz, CD2Cl2): see table 5.5; IR (film):  ̃ = 3472, 
2956, 2924, 2854, 1733, 1459, 1371, 1259, 1246, 1207, 1149, 1100, 1015, 979 cm
−1
. MS (ESI) m/z 
(%): 593.4 (100); HRMS (ESIpos): m/z: calcd. for C34H50O7Na [M
+
+Na]: 593.3449, found 593.3455. 
 
Dioxane Analogue 119. A solution of alcohol 91 (4.0 mg, 6.66 µmol) in CH2Cl2 (0.71 mL) was 
cooled to −90 °C (Et2O/CO2/N2 cooling bath) before a 
solution of freshly prepared Me2BBr (0.5 M in CH2Cl2, 
30.6 µL, 15.3 µmol) was carefully added along the cold 
wall of the flask. The mixture was allowed to reach 
−78 °C and was stirred at this temperature for 1.5 h, when a second aliquot of Me2BBr (0.5 M, 
14.6 µL, 15.3 µmol) was introduced. This was repeated after another 1.5 h. After an additional 1.5 h, 
the mixture was transferred via canula into a vigorously stirred mixture of sat. NaHCO3/H2O/THF 
(1:1:1, 7 mL) and the flask was rinsed with THF (2 x 0.5 mL). After stirring for 10 min, the mixture 
was diluted with EtOAc (10 mL) and the aqueous layer was extracted with EtOAc (3 x 10 mL). The 
combined organic extracts were dried over Na2SO4 and concentrated. The residue was purified by 
preparative thin layer chromatography (TLC Silica gel 60 F254 (20 x 20 cm), hexanes/EtOAc, 3:2) to 
give the title compound as an off-white solid (1.1 mg, ~75% purity, 20% yield). 
1
H NMR (600 MHz, 
CD2Cl2): see table 5.6; 
13
C NMR (150 MHz, CD2Cl2): see table 5.6; IR (film): ̃ = 3469, 2963, 2924, 
2855, 1732, 1458, 1376, 1249, 1206, 1146, 1080, 1042, 1006, 898, 800, 739 cm
−1
.
 
MS (ESI) m/z (%): 
593.4 (100); HRMS (ESIpos): m/z: calcd for C34H50O7Na: 593.3449, found 593.3455. 
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Table 5.5:  Assignment of 
1
H and 
13
C NMR data of leiodermatolide analogue 110. 
 
atom n° 
1
H NMR (CD2Cl2, 600 MHz) 
13
C NMR (CD2Cl2, 150 MHz) 
 (ppm) Integral Splitting COSY J (Hz)  (ppm) HMBC 
1 – – – – – 172.4 2ab, 3, 15 
2a 2.31 1 ddd 2b, 3 16.7, 6.2, 2.8 
34.0 3, 4, (26) 
2b 1.99 1 ddd 2a, 3 16.7, 11.0, 3.2 
3 2.23 2 m 2ab, 4 – 22.5 2a(b), 4 
4 5.11 1 ddd 3ab, 26 9.4, 5.1, 1.2 126.1 2ab, 3, 6, 26 
5 – – – – – 137.4 3, 6, 26, 27 
6 2.44 1 dq 7, 27 9.0, 6.6 48.5 4, (8), 26, 27 
7 3.31 1 br d 6, OH 8.7 78.6 6, (8), 9, 27, 28 
8 1.77 1 q 28 7.3 39.4 (9), (10), 28 
9 6.02 1 d 10 10.3 67.0 (8), 11, 28, 35 
10 5.52 1 ddt 9, 11, 13 10.6, 10.3, 1.2 128.6 (8), 9, 12 
11 6.36 1 dd 10, 13 11.6, 10.8 126.3 9, 12, 13 
12 6.56 1 dd 11, 13 11.5, 11.3 124.8 10, 11, 14 
13 5.35 1 ddt 10, 12, 14 11.2, 10.1, 1.2 137.8 11, (13), 14, 15, 29 
14 2.98 1 ddq 13, 15, 29 10.1, 7.9, 6.6 35.3 12, 13, 15, 29 
15 5.08 1 d 14 10.3 82.8 (12), 14, 17, 29, 30 
16 – – – – – 134.2 14, 15, (17), 18, 30 
17 6.10 1 dq 18, 30 10.8, 1.1 129.9 15, 18, 19, 30 
18 6.40 1 ddt 17, 19, 20 14.9, 10.6, 0.8 131.9 17, 20ab, 30 
19 5.76 1 ddd 18, 20ab 15.0, 7.6, 7.5 128.4 17, 20ab, (30) 
20a 2.22 1 m 19, 20b – 
38.9 18, 19, 22, 32ab 
20b 2.41 1 dd 19, 20a 13.6, 7.4 
21 – – – – – 72.4 19, 20ab, 22, 32ab, 31 
22 1.89 1 dq 23, 31 10.0, 6.8 43.4 (23), 24ab, 31, 32ab 
23 3.91 1 ddd 22, 24a, 24b 10.1, 7.3, 3.0 84.1 22, 24ab, 25, 31 
24a 1.85 1 dqd 23, 24b, 25 14.7, 7.3, 3.2 
27.4 22, (23), 25, 31 
24b 1.63 1 dqd 23, 24a, 25 14.6, 7.4, 7.3 
25 1.02 3 t 24ab 7.4 9.42 23, 24ab, (31) 
26 1.43 3 s 4 – 11.6 4, 6 
27 1.11 3 d 6 6.7 16.6 6 
28 1.10 3 d 8 7.3 12.9 8, 9 
29 0.87 3 d 14 6.7 16.9 13, 14, 15 
30 1.80 3 d 17 1.2 12.3 15, 17 
31 1.02 3 d 22 6.5 11.9 22, (23) 
32a 2.73 1 d 32b 16.4 
43.1 20ab, 22 
32b 2.35 1 dd 32a 16.4, 1.0 
33 – – – – – 170.3 32ab 
34 – – – – – 171.5 9, 35 
35 1.98 3 s – – 21.7 – 
C7-OH 1.64 1 br s 7 – – – 
C21-OH 1.90 1 br s – – – – 
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Table 5.6:  Assignment of 
1
H and 
13
C NMR data of leiodermatolide analogue 119. 
 
atom 
n° 
1
H NMR (CD2Cl2, 600 MHz) 
13
C NMR (CD2Cl2, 150 MHz) 
 (ppm) Integral Splitting COSY J (Hz)  (ppm) HMBC 
1 - - - - - 172.4 2, 15 
2a 2.31 - 2.38 1H m 2b, 3a, 3b - 
33.8 1, 3, 5, 26 
2b 1.88 - 1.96 1H m 2a, 3a, 3b - 
3 2.18 - 2.30 2H m 2a, 2b, 4 - 22.1 1, 2, 4, 26 
4 5.12 1H dd 3a, 3b, (26) 10.2, 4.5 126.1 2, 3, 6, 26 
5 - - - - - 137.0 3, 6, 7, 26, 27 
6 2.49 1H dq 7, 27 10.9, 6.6 48.3 4, 5, 7, 26, 27 
7 3.44 1H d 6 11.0 80.4 6, 9, 27, 28, 34 
8 1.60-1.66 1H m 7, 9, 28 - 38.4 7, 9, 10, 28 
9 5.07 1H d 10 10.1 65.2 7, 8, 11, OH1, 28 
10 5.56 – 5.60 1H m 9, 11 - 131.7 8, 9, 12, OH1 
11 6.31 – 6.38 1H m 10, 12 - 123.7 9, 12, 13, 14 
12 6.46 1H dd 11, 13 11.4, 10.3 126.7 10, 13, 14, 29 
13 5.28 1H dd 12, 14 10.3, 10.2, 0.7 137.7 11, 14, 15, 29 
14 2.96 - 3.02 1H m 13, 15, 30 - 35.3 12, 13, 15, 29 
15 5.09 1H d 14 10.3 83.1 13, 14, 16, 17, 29, 30 
16 - - - - - 134.0 14, 15, 17, 18 
17 6.05 1H d 18 10.8 129.7 15, 16, 18, 19, 30 
18 6.38 – 6.42 1H m 17, 19 - 131.7 17, 20, 30 
19 5.77 1H ddd 20a, 20b 15.1, 7.5, 7.5 128.3 17, 18, 20, 21 
20a 2.41 1H dd 19, 20b 14.3, 7.9 
38.7 18, 19, 21, 22, 32 
20b 2.22 1H dd 19, 20a 14.2, 7.6 
21 - - - - - 72.1 19, 20a, 20b, 22, 32 
22 1.89 1H dq 23, 31 10.1, 7.1 43.2 20, 32, 33 
23 3.91 1H ddd 22, 24a, 24b 10.1, 7.4, 2.9 83.9 22, 24, 25 
24a 1.86 – 1.90 1H m 23, 24b, 25 - 
27.2 23, 25 
24b 1.63 1H ddq 23, 24b, 25 7.3, 7.3, 7.4 
25 1.02 3H t 24a, 24b 7.2 9.2 24 
26 1.44 3H s 4 - 11.3 4, 5, 6 
27 1.11 3H d 6 6.9 16.1 5, 7 
28 1.07 3H d 8 7.2 12.1 6, 9, (27) 
29 0.87 3H d 14 6.8 16.6 13, 14, 15 
30 1.79 3H d 17 0.6 12.2 15, 17 
31 0.98 3H d 22 6.9 11.7 21, 22 
32a 2.73 1H d 32b 16.5 
42.9 21, 33 
32b 2.35 1H d 32a 16.6 
33 - - - - - 170.1 32a, 32b 
34a 5.00 1H d 34b 6.2 
88.7 7, 9 
34b 4.80 1H d 34a 6.3 
OH 2.17 - 2.26 1H br s - - - - 
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5.2.6 2nd generation synthesis of leiodermatolide. 
The catalytic allylation/propargylation of 61 as well as the Stille couplings were carried out by Dr. 
Damien Mailhol. The corresponding procedures can be found in the leiodermatolide full paper.
[113]
 
(1E,3S,4S,5Z)-1-Iodo-2,4-dimethylnona-1,5-dien-7-yn-3-yl (6R,7S,8R,9R,E)-9-hydroxy-7-
(methoxymethoxy)-5,6,8-trimethyldodec-4-en-10-ynoate (122). A schlenck tube was charged with a 
solution of silyl ether 79 (60.0 mg, 85.9 µmol) in THF (0.6 mL) and 
the solution cooled to 0 °C. A solution of TBAF (1.0 M in THF, 
0.258 mL, 258 µmol) was added dropwise via syringe. The reaction 
mixture was allowed to warm to ambient temperature and was stirred 
for 3 h before being quenched with brine (5 mL). The aqueous phase 
was extracted with EtOAc (3 x 5 mL) and the combined organic layers were dried over Na2SO4 before 
being concentrated. The residue was purified by flash column chromatography (hexanes/EtOAc 6:1 to 
5:1) to give a colorless oil (44.2 mg, 88% yield). [∝]𝐷
20 = +97.0 (c = 1.15, CH2Cl2). 
1
H NMR (500 
MHz, C6D6): δ = 6.22 (s, 1H), 5.54 – 4.46 (m, 2H), 5.29 (d, J = 7.6 Hz, 1H), 5.09 (dd, J = 7.1, 6.7 Hz, 
1H), 5.05 (br s, 1H), 4.36 (s, 2H), 3.54 (dd, J = 7.6, 4.0 Hz, 1H), 3.33 (br s, 1H), 3.28 – 3.19 (m, 1H), 
3.05 (s, 3H), 2.25 – 2.18 (m, 3H),  2.15 (dd, J = 7.8, 6.7 Hz, 1H), 2.12 – 2.05 (m, 1H), 2.02 – 1.95 (m, 
1H), 1.80 (s, 3H), 1.60 (d, J = 1.3 Hz, 3H), 1.55 (d, J = 2.2 Hz, 3H), 1.23 (d, J = 6.9 Hz, 3H), 1.00 (d, 
J = 6.9 Hz, 3H), 0.79 (d, J = 6.8 Hz, 3H) ppm; 
13
C NMR (125 MHz, C6D6): δ = 171.6, 145.1, 142.6, 
138.7, 124.0, 111.5, 99.4, 90.8, 84.1, 81.5, 81.2, 80.3, 80.1, 76.7, 63.2, 56.2, 44.0, 42.3, 37.6, 34.3, 
23.8, 20.6, 16.8, 15.5, 13.1, 12.1, 4.2, 3.4 ppm; IR (film):  ̃ = 3480, 2967, 2918, 2864, 1736, 1454, 
1376, 1243, 1213, 1142, 1088, 1023, 980, 927, 757, 674 cm
−1
; MS (ESI) m/z (%): 607.2 (100); HRMS 
(ESIpos): m/z: calcd for C28H41O5I1Na: 607.1891, found 607.1893. 
 
(5E,7R,8S,9R,10R,13Z,15S,16S)-10-hydroxy-16-((E)-1-iodoprop-1-en-2-yl)-8-methoxymethoxy)-
6,7,9,15-tetramethyloxacyclohexadeca-5,13-dien-11-yn-2-one (123).  
Care should be taken to exclude moisture during the ring closing alkyne 
metathesis step. 
A flame-dried Schlenck tube was charged with 5 Å MS (1.2 g), sealed 
and flame-dried until a stable vacuum was obtained. Toluene (45 mL) 
and a solution of diyne 122 (45.0 mg, 77.0 µmol) in toluene (1 mL + 0.5 mL rinse) were added via 
syringe and the resulting suspension stirred for 30 min at room temperature. A solution of catalyst C1 
(12.0 mg, 11.5 µmol) in toluene (1.2 mL) was added and the reaction mixture stirred for 13 h at 
ambient temperature. After complete consumption of starting material (HPLC:50 mm Zorbax Eclipse 
Plus C18, 1.8 µm, 3mm Ø, MeOH/H2O = 90:10, 0.5 mL/min 224 bar: Rt (product) = 1.09 min; Rt 
(starting material) = 1.49 min; Rt (dimer) = 3.57 min), the reaction mixture was filtered through a pad 
of Celite
®
 and rinsed with Et2O (150 mL). After concentration under reduced pressure, the residue was 
purified by flash column chromatography (hexanes/EtOAc 6:1 to 5:1 to 4:1) to give a pale yellow oil 
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(24.8 mg, 61% yield). [∝]𝐷
20 = +86.7 (c = 0.83, CH2Cl2). 
1
H NMR (400 MHz, ): δ = 6.16 (dq, J = 1.2, 
1.0 Hz, 1H), 5.64 (dd, J = 10.5, 8.5 Hz, 1H), 5.58 (dd, J = 10.7, 0.9 Hz), 5.34 (td, J = 6.7, 1.0 Hz, 1H), 
5.27 (d, J = 5.1 Hz, 1H), 4.97 (s, 1H), 4.71 (d, J = 6.7 Hz, 1H), 4.66 (d, J = 6.7 Hz, 1H), 3.46 (dd, J = 
9.4, 2.4 Hz, 1H), 3.42 (s, 3H), 3.27 (d, J = 2.1 Hz, 1H), 2.56 (dq, J = 9.2, 6.9 Hz, 1H), 2.44 – 2.37 (m, 
2H), 2.37 – 2.30 (m, 1H), 2.28 – 2.22 (m, 1H), 1.91 (qt, J = 7.2, 2.5 Hz, 1H), 1.78 (d, J = 1.0 Hz, 3H), 
1.54 (d, J = 0.8 Hz, 3H), 1.19 (d, J = 7.2 Hz, 3H), 1.08 (d, J = 6.8 Hz, 3H), 0.94 (d, J = 6.9 Hz, 3H) 
ppm; 
13
C NMR (CDCl3, 100 MHz): δ = 171.7, 144.1, 138.2, 125.5, 111.3, 99.2, 96.1, 87.7, 80.8, 79.8, 
79.6, 63.2, 56.7, 46.7, 40.6, 38.7, 34.3, 22.7, 22.2, 17.0, 14.8, 13.3, 12.9 ppm; IR (film):  ̃ = 3481, 
2962, 2928, 2869, 1737, 1456, 1378, 1261, 1185, 1146, 1091, 1025, 929, 754 cm
−1
; MS (ESI) m/z (%): 
553.1 (100); HRMS (ESIpos): m/z: calcd for C24H35O5I1Na: 553.1421, found 553.1420. 
 
5.3 Total synthesis of mandelalide A 
5.3.1 Synthesis of acid 151. 
(4S,6S)-Nona-1,8-diene-4,6-diol (136). According to the procedure from Krische et. al.,
[151]
 a flame-
dried Young tube was charged with [Ir(cod)Cl]2 (974 mg, 1.45 mmol), (S)-
Cl,MeO-BIPHEP (1.89 g, 2.90 mmol), Cs2CO3 (3.78 g, 11.6 mmol) and 4-chloro-
3-nitrobenzoic acid (1.17 g, 5.80 mmol). 1,4-Dioxane (65 mL) and distilled allyl acetate (31.3 mL, 
290 mmol) were added, the flask was sealed, and the suspension heated to 90 °C for 30 min and 
cooled back to room temperature. A solution of 1,3-propanediol (137) (2.10 mL, 29.0 mmol) in 1,4-
dioxane (65 mL) was introduced, the flask sealed and stirring continued at 90 °C for 72 h. After 
cooling to ambient temperature, the mixture was filtered through a pad of Celite
®
 (eluent: EtOAc) and 
the filtrate was concentrated. The brown residue was purified by flash chromatography 
(hexanes/EtOAc 3:1) to give the desired diol as a pale yellow oil (3.22 g, 71% yield, >99% ee, >29:1 
d.r.). [∝]𝐷
20 = +24.5 (c = 1.0, CHCl3). 
1
H NMR (400 MHz, CDCl3): δ = 5.85 – 5.72 (m, 2H), 5.13 – 
5.09 (m, 2H), 5.09 – 5.07 (m, 2H), 4.01 – 3.91 (br s, 2H), 2.72 – 2.57 (br s, 2H), 2.27 – 2.21 (m, 4H), 
1.60 (tr, J = 5.8 Hz, 2H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 134.6, 118.0, 68.1, 42.0, 41.5 ppm. IR 
(film): ṽ = 3340, 3077, 2979, 2936, 1723, 1641, 1434, 1327, 1232, 1133, 1047, 994, 912, 871, 830 
cm
−1
. MS (EI) m/z (%) = 115 (10), 97 (74), 79 (38), 73 (19), 71 (89), 69 (52), 67 (49), 55 (19), 45 (39), 
41 (100), 39 (29), 29 (13), 27 (28). HRMS (ESIpos): m/z: calcd for C9H16O2H: 157.1228; found: 
157.1229.  
 
Bis-nitrobenzoate 138. A Schlenck tube was charged with 4-nitrobenzoyl chloride (59 mg, 
0.32 mmol), DMAP (1.6 mg, 0.013 mmol) and pyridine (52 µL, 0.64 mmol) 
before a solution of diol 136 (10. Mg, 0.064 mmol) in CH2Cl2 (0.32 mL) was 
added. The reaction mixture was stirred for 3 hours before the reaction was 
quenched by addition of sat. NH4Cl solution (5 mL). It was extracted with EtOAc 
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(3 x 5 ml) and the combined organic layers were dried over Na2SO4 and concentrated. The yellow 
residue was purified by flash chromatography (hexanes/EtOAc 5:1) to give an off-white solid 
(27.3 mg, 94%) 
1
H NMR (400 MHz, CDCl3): δ = 8.23 – 8.18 (m, 4H), 8.11 – 8.05 (m, 4H), 5.77 (ddt, 
J = 17.2, 10.1, 7.1 Hz, 2H), 5.31 (dq, J = 7.3, 6.0 Hz, 2H), 5.17 – 5.05 (m, 4H), 2.49 (ddt, J = 7.2, 6.0, 
1.2 Hz, 4H), 2.13 (dd, J = 7.1, 5.8 Hz, 2H) ppm; 
13
C NMR (100 MHz, CDCl3): δ = 164.1, 150.3, 
135.6, 132.4, 130.6, 123.5, 118.9, 71.1, 39.0, 37.4 ppm; IR (film):  ̃ = 1719, 1607, 1254, 1410, 1347, 
1319, 1268, 1117, 1102, 1014, 993, 922, 872, 836, 783, 718 cm
−1
; MS (EI) m/z (%): 413 (13), 246 (5), 
151 (8), 150 (100), 120 (9), 104 (14), 92 (4), 76 (5). HRMS (ESIpos): m/z: calcd for C23H22N2O8Na: 
477.1268, found 477.1266. 
HPLC: 250 mm Chiralpak IB (Ø 4.6 mm), n-heptane/2-propanol 85:15, 1.0 mL/min, 298 K, 4.4 MPa: 
Rt = 8.54 min (major), 10.64 min (meso), 15.44 min (minor). 
 
 
 
 
 
 
 
 
 
 
 
 
 
(2S,4R,6S)-2-Allyl-6-(iodomethyl)tetrahydro-2H-pyran-4-ol (139). NaHCO3 (4.18 g, 49.8 mmol) 
was added at 40 °C to a solution of diol 136 (3.11 g, 19.9 mmol) in MeCN 
(360 mL) and the resulting suspension was vigorously stirred for 10 min. I2 (15.2 g, 
59.7 mmol) was carefully added in three portions and the resulting brown mixture 
stirred for 15 h at 40 °C. The mixture was poured into sat. Na2S2O3-solution (200 mL) and the flask 
was rinsed with EtOAc (2 x 50 mL). After extraction of the aqueous phase with EtOAc (2 x 150 mL), 
the combined organic layers were dried over Na2SO4 and concentrated. The brown residue was 
purified by flash chromatography (hexanes/EtOAc 3:1) to yield a 5:1 mixture of diastereoisomers 
(based on 
1
H-NMR integration, solvent: C6D6) as a colorless oil (4.55 g, 81%). This mixture was 
purified by flash chromatography (SiO2 60 (15 x 40 µm), CH2Cl2/Et2O 5:1) to give the desired all-cis 
diastereomer as a colorless oil (3.54 g, 63%), which solidified upon prolonged storage at 20 °C. 
[∝]𝐷
20 = +25.7 (c = 0.37, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 5.84 (dddd, J = 16.8, 10.2, 7.5, 
6.5 Hz, 1H), 5.11 – 5.02 (m, 2H), 3.80 (m, 1H), 3.36 (m, 2H), 3.19 (dd, J = 5.8, 3.8 Hz, 2H), 2.42 – 
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2.30 (m, 1H), 2.26 – 2.12 (m, 2H), 1.90 (ddt, J = 12.5, 4.3, 2.0 Hz, 1H), 1.63 (s, 1H), 1.14 (m, 2H) 
ppm. 
13
C NMR (100 MHz, CDCl3): δ = 134.3, 117.1, 75.4, 75.0, 67.8, 40.7, 40.2, 40.1, 8.7 ppm. IR 
(film): ṽ = 3346, 2942, 2917, 2850, 1641, 1446, 1430, 1414, 1368, 1325, 1270, 1185, 1136, 1080, 
1038, 998, 916, 854 cm
−1
. MS (EI) m/z (%) = 282 (0.3), 241 (100), 223 (23), 197 (38), 73 (14), 67 
(17), 45 (15), 43 (10). HRMS (ESIpos): m/z: calcd for C9H15O2INa: 305.0009; found: 305.0009. 
 
(((2S,4R,6S)-2-Allyl-6-(iodomethyl)tetrahydro-2H-pyran-4-yl)oxy)(tert-butyl)-dimethylsilane 
(141). A solution of alcohol 139 (3.10 g, 11.0 mmol) in CH2Cl2 (38 mL) was cooled to 0 °C before 
2,6-lutidine (1.79 mL, 15.4 mmol) and TBSOTf (3.03 mL, 13.2 mmol) were added 
dropwise via syringe. The mixture was stirred for 1 h at 0 °C before the reaction 
was quenched with sat. NH4Cl solution (40 mL). After phase separation, the 
aqueous layer was extracted with EtOAc (2 x 25 mL) and the combined organic layers were washed 
with brine (50 mL), dried over Na2SO4 and concentrated. The residue was purified by flash 
chromatography (hexanes/EtOAc 29:1) to yield the desired silyl ether as a colorless oil (4.18 g, 96%). 
[∝]𝐷
20 = +15.8 (c = 1.21, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 5.90 – 5.77 (m, 1H), 5.12 – 4.97 
(m, 2H), 3.74 (dddd, J = 10.8, 10.7, 4.8, 4.7 Hz, 1H), 3.35 – 3.24 (m, 2H), 3.16 (dd, J = 5.9, 1.5 Hz, 
2H), 2.33 (dtt, J = 13.3, 6.6, 1.5 Hz, 1H), 2.18 (dddd, J = 14.4, 7.1, 5.7, 1.3 Hz, 1H), 2.00 (dddd, J = 
12.4, 4.1, 1.9, 1.8 Hz, 1H), 1.79 – 1.68 (m, 1H), 1.23 – 1.11 (m, 2H), 0.85 (s, 9H), 0.03 (s, 6H) ppm. 
1
H NMR (400 MHz, C6D6): δ = 5.92 (dddd, J = 16.7, 10.9, 8.3, 6.3 Hz, 1H), 5.09 – 4.98 (m, 2H), 3.54 
(dddd, J = 10.8, 10.7, 4.9, 4.7 Hz, 1H), 3.07 (dddd, J = 11.5, 6.7, 5.1, 1.8 Hz, 1H), 2.93 (dddd, J = 
11.2, 6.6, 4.6, 2.0 Hz, 1H), 2.85 (dd, J = 10.1, 6.7 Hz, 1H), 2.76 (dd, J = 10.1, 4.6 Hz, 1H), 2.29 (dtt, J 
= 13.2, 8.1, 6.6, 5.1 Hz, 1H), 2.08 (dddt, J = 14.0, 7.5, 5.2, 1.1 Hz, 1H), 1.74 (ddt, J = 12.3, 47, 2.0, 
1H), 1.63 (dddd, J = 12.6, 4.6, 2.0, 2.0 Hz, 1H), 1.21 (ddd, J = 12.6, 11.1, 11.1 Hz, 1H), 1.11 (ddd, J = 
12.2, 11.1, 11.0 Hz, 1H), 0.97 (s, 9H), 0.05 (s, 6H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 134.5, 
116.8, 75.4, 75.1, 68.3, 41.1, 40.7, 40.2, 25.8, 18.0, 8.9, 4.6 ppm. IR (film): ṽ = 2950, 2928, 2856, 
1642, 1471, 1462, 1383, 1251, 1126, 1087, 1068, 1005, 916, 833, 773, 669 cm
−1
. MS (EI) m/z (%) = 
340 (14), 339 (81), 271 (27), 269 (10), 172 (14), 171 (100), 141 (14), 129 (42), 101 (38), 79 (21), 75 
(37), 73 (23), 67 (11), 59 (14), 43 (25), 41 (18). HRMS (ESIpos): m/z: calcd for C15H29O2SiINa: 
419.0872; found: 419.0874. 
 
Acid 143. A solution of n-BuLi (1.58 M in hexanes, 368 µL, 0.582 mmol) was added dropwise to a 
stirred solution of diisopropylamine (85 µL, 0.61 mmol) in THF (1.1 mL) at 0 °C. 
After 5 min, the ice bath was removed and the reaction mixture allowed to warm 
to ambient temperature. After 25 min equilibration, prolinolamide R11 (43.6 mg, 
0.277 mmol) was added dropwise via syringe and the reaction was stirred for 
another 90 min. HMPA (101.3 µL, 0.582 mmol) was added and the reaction mixture recooled to 0 °C. 
A solution of alkyl iodide 141 (100 mg, 0.252 mmol) in THF (0.3 mL) was added dropwise via 
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syringe and the mixture stirred for 6 h before the reaction was quenched with water (8 mL). The 
mixture was extracted with EtOAc (3 x 6 mL) and the combined organic extracts were washed with 
brine (10 mL), dried over Na2SO4 and concentrated. The residue was purified by flash chromatography 
to yield a pale yellow oil (79.6 mg, 74%), which was immediately engaged in the next step. HRMS 
(ESIpos): m/z: calcd for C23H43N1O4Si1Na: 448.2854, found 448.2858. 
Aqueous HCl (1 N, 0.6 mL) was added to a flask containing amide 142 (27 mg, 63 µmol) and the 
resulting emulsion was heated to 100 °C for 4.5 h. The reaction mixture was cooled to 0 °C, aqueous 
NaOH solution (1 M, 1.3 mL) was added and the resulting mixture stirred for 20 min. It was then 
neutralized with conc. HCl and the aqueous phase extracted with CH2Cl2 (3 x 5 mL). The combined 
organic extracts were dried over Na2SO4 and concentrated. The desired acid 143 was obtained as a 
colorless oil and judged pure by 
1
H NMR analysis. 
1
H NMR (400 MHz, C6D6): δ = 5.99 – 5.71 (m, 
1H), 5.10 – 4.95 (m, 2H), 3.36 (tt, J = 11.1, 4.7 Hz, 1H), 3.11 – 2.93 (m, 2H), 2.68 (ddq, J = 7.0, 7.0, 
6.9 Hz, 1H), 2.26 (dtt, J = 13.3, 6.6, 1.4 Hz, 1H), 2.16 – 1.97 (m, 2H), 1.59 (dddt, J = 18.5, 12.2, 4.4, 
2.0 Hz, 2H), 1.37 – 1.22 (m, 2H), 1.10 (d, J = 7.0 Hz, 3H), 1.05 – 0.93 (m, 2H) ppm; 13C NMR (100 
MHz, C6D6): δ = 182.4, 135.1, 116.8, 75.3, 73.4, 68.0, 41.5, 40.8, 40.7, 39.7, 36.7, 17.1 ppm; MS 
(ESIneg) m/z (%): 226.9 (100 (M-H
+
)). HRMS (ESI): m/z: calcd. for C12H20O4Na [M+Na
+
]: 251.1254, 
found 251.1253. 
 
(R)-3-((2R,4R,6S)-6-Allyl-4-((tert-butyldimethylsilyl)oxy)tetrahydro-2H-pyran-2-yl)-N-((1S,2S)-
1-Hydroxy-1-phenylpropan-2-yl)-N,2-dimethylpropanamide (144). A flame-dried 3-necked round-
bottom flask equipped with a stirbar, a reflux condenser and a dropping 
funnel was charged with dry LiCl (5.13 g, 121 mmol), diisopropylamine 
(6.24 mL, 44.4 mmol) and THF (75 mL). After cooling to 78 °C, a 
solution of n-BuLi (1.50 M in hexanes, 29.0 mL, 43.5 mmol) was added 
dropwise over 20 min and the mixture was stirred for 10 min before it 
was warmed to 0 °C. After 10 min, the mixture was cooled to 78 °C and a solution of (1S,2S)-N-(2-
hydroxy-1-methyl-2-phenylethyl)-N-methylpropionic amide (R12) (4.69 g, 21.2 mmol) in THF 
(115 mL) was added over 45 min via dropping funnel. The resulting yellow suspension was stirred for 
1 h at 78 °C, for 30 min at 0 °C and for 20 min at RT before it was re-cooled to 0 °C. A solution of 
alkyl iodide 141 (4.01 g, 10.1 mmol) in THF (6 mL + 2 x 2 mL rinse) was then added dropwise over 
5 min via syringe. The mixture was warmed to 45 °C and stirred at this temperature for 48 h. After 
cooling to RT, the reaction was quenched with sat. NH4Cl solution (300 mL) and the aqueous layer 
was extracted with EtOAc (4 x 200 mL). The combined extracts were dried over Na2SO4 and 
concentrated. The residue was purified by flash chromatography (hexanes/EtOAc 2:1) to give the 
alkylated compound as a white foam that collapsed to a colorless syrup upon storage (3.83 g, 76%).[∝
]𝐷
20 = +50.7 (c = 0.96, CH2Cl2). 
1
H and 
13
C NMR spectra were complex and broadened due to the 
presence of amide bond rotamers. IR (film): ṽ = 3387, 2933, 2930, 2856, 1619, 1462, 1409, 1374, 
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1252, 1115, 1072, 913, 835, 774, 700, 673 cm
−1
. MS (EI) m/z (%) = 433 (31), 432 (97), 383 (16), 382 
(31), 325 (19), 258 (20), 257 (100), 216 (31), 193 (16), 171 (10), 148 (21), 129 (10), 119 (11), 101 
(12), 99 (19), 79 (11), 75 (22), 73 (25), 58 (39). HRMS (ESIpos): m/z: calcd for C28H47NO4SiNa: 
512.3167; found: 512.3166. 
 
(S)-3-((2R,4R,6S)-6-Allyl-4-((tert-butyldimethylsilyl)oxy)tetrahydro-2H-pyran-2-yl)-N-((1R,2R)-
1-hydroxy-1-phenylpropan-2-yl)-N,2-dimethylpropanamide (216). Prepared analogously from 
(1R,2R)-N-(2-hydroxy-1-methyl-2-phenylethyl)-N-methylpropionic 
amide (ent-R12) and alkyl iodide 141 (3.08 g, 7.77 mmol) as a sticky 
syrup (3.20 g, 84%). [∝]20
𝐷  = 24.3 (c = 0.77, CH2Cl2). 
1
H and 
13
C NMR 
spectra were complex and partially broadened due to the presence of 
amide bond rotamers. IR (film): ṽ = 3376, 2934, 2930, 2856, 1619, 1472, 1463, 1374, 1328, 1306, 
1254, 1120, 1073, 1006, 915, 857, 836, 775, 702, 671 cm
−1
. MS (EI) m/z (%) = 474 (5), 433 (28), 432 
(89), 383 (15), 382 (26), 325 (22), 258 (20), 257 (100), 222 (17), 193 (13), 148 (18), 119 (10), 99 (19), 
75 (15), 73 (17), 58 (23). HRMS (ESIpos): m/z: calcd for C28H47NO4SiNa: 512.3167; found: 512.3169. 
 
(R)-3-((2R,4R,6S)-6-Allyl-4-((tert-butyldimethylsilyl)oxy)tetrahydro-2H-pyran-2-yl)-2-methyl-
propan-1-ol (145). A solution of n-BuLi (1.60 M in hexanes, 23.1 mL, 37.0 mmol) was added over 15 
min at 78 °C to a solution of diisopropylamine (5.57 mL, 39.6 mmol) in THF 
(34 mL) and the resulting mixture was stirred at this temperature for 15 min and for 
45 min at 0 °C. Solid NH3·BH3 (90%, 1.31 g, 38.1 mmol) was then added in one 
portion and the resulting mixture stirred for 40 min at 0 °C and for 45 min at 
ambient temperature. After cooling to 0 °C, a solution of amide 144 (3.80 g, 7.62 mmol) in THF 
(34 mL) was slowly added over 10 min. After stirring for 3 h at 0 °C, the mixture was warmed to 
ambient temperature and stirring continued for 1 h before the reaction was quenched with sat. NH4Cl 
solution (200 mL). The mixture was vigorously stirred for 45 min before the phases were separated, 
the aqueous phase was extracted with EtOAc (3 x 120 mL) and the combined organic extracts were 
dried over Na2SO4 and concentrated. The residue was purified by flash chromatography 
(hexanes/EtOAc 5:1) to give the desired alcohol as a colorless oil (2.42 g, 96%). 20][ D  = +17.8 (c = 
0.83, CH2Cl2). 
1
H NMR (400 MHz, C6D6): δ = 5.85 (dddd, J = 16.0, 9.2, 6.6, 6.6 Hz, 1H), 5.07 – 5.00 
(m, 2H), 3.63 (dddd, J = 10.7, 10.4, 5.1, 5.1 Hz, 1H), 3.46 (ddd, J = 10.5, 5.2, 5.1 Hz, 1H), 3.36 (ddd, 
J = 10.4, 5.1, 5.1 Hz, 1H), 3.19 – 3.04 (m, 2H), 2.26 (dddt, J = 14.1, 7.0, 7.0, 1.2 Hz, 1H), 2.22 – 2.15 
(br t, 1H), 2.12 – 2.04 (m, 1H), 1.78 (dq, J = 12.4, 6.2 Hz, 1H), 1.75 – 1.61 (m, 2H), 1.55 (ddd, J = 
14.4, 9.6, 7.3 Hz, 1H), 1.34 – 1.21 (m, 2H), 1.09 (ddd, J = 14.4, 6.4, 2.3 Hz, 1H), 1.00 (s, 9H), 0.87 (d, 
J = 6.8 Hz, 3H), 0.09 (s, 3H), 0.08 (s, 3H) ppm. 
13
C NMR (100 MHz, C6D6): δ = 134.9, 117.2, 75.3, 
74.8, 69.1, 68.2, 43.0, 41.4, 41.2, 40.8, 34.5, 26.0, 18.2, 18.0, 4.3 ppm. IR (film): ṽ = 3395, 2926, 
2929, 2856, 1643, 1472, 1462, 1375, 1253, 1152, 1123, 1070, 975, 914, 835, 774, 671 cm
−1
. MS (EI) 
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m/z (%) = 271 (33), 201 (20), 179 (37); 171 (47), 161 (16), 159 (47), 145 (46), 131 (12), 129 (69), 127 
(12), 125 (15), 119 (15), 111 (12), 109 (65), 107 (12), 105 (22), 101 (44), 93 (18), 85 (93), 81 (28), 79 
(26), 75 (100), 73 (49), 67 (43), 59 (22), 57 (14), 55 (24), 43 (17), 41 (32). HRMS (ESIpos): m/z: calcd 
for C18H36O3SiNa: 351.2326; found: 351.2326. 
 
(S)-3-((2R,4R,6S)-6-Allyl-4-((tert-butyldimethylsilyl)oxy)tetrahydro-2H-pyran-2-yl)-2-methyl-
propan-1-ol (11-epi-145). Prepared analogously from amide 216 (3.20 g, 6.53 mmol) as a colorless 
oil (1.86 g, 87%). 20][ D  = +1.8 (c = 1.03, CH2Cl2). 
1
H NMR (400 MHz, C6D6): δ = 
5.85 (dddd, J = 17.7, 9.6, 7.0, 7.0 Hz, 1H), 5.08 – 4.99 (m, 2H), 3.65 (dddd, J = 
10.7, 10.7, 5.0, 4.8 Hz, 1H), 3.50 – 3.40 (m, 1H), 3.36 (dd, J = 10.7, 6.6 Hz, 1H), 
3.28 (dddd, J = 11.5, 8.3, 3.5, 1.9 Hz, 1H), 3.11 (dddd, J = 11.4, 7.1, 5.3, 1.9 Hz, 
1H), 2.25 (dtt, J = 14.0, 7.0, 1.4 Hz, 1H), 2.08 (dddd, J = 14.1, 8.6, 4.0, 2.6 Hz, 1H), 2.01 (br s, 1H), 
1.86 (qt, J = 6.8, 5.3 Hz, 1H), 1.77 – 1.64 (m, 2H), 1.52 (ddd, J = 13.9, 8.3, 5.4 Hz, 1H), 1.43 – 1.20 
(m, 3H), 0.99 (s, 9H), 0.86 (d, J = 6.9 Hz, 3H), 0.08 (s, 6H) ppm. 
13
C NMR (100 MHz, C6D6): δ = 
135.0, 117.0, 75.3, 73.5, 69.2, 67.5, 42.3, 41.6, 40.8, 40.0, 32.9, 26.0, 18.2, 17.6, 4.3 ppm. IR (film): 
ṽ = 3394, 2950, 2929, 2857, 1375, 1254, 1151, 1123, 1072, 1005, 914, 836, 775, 672 cm−1. MS (EI) 
m/z (%) = 271 (33), 201 (20), 179 (37); 171 (47), 161 (16), 159 (47), 145 (46), 131 (12), 129 (69), 127 
(12), 125 (15), 119 (15), 111 (12), 109 (65), 107 (12), 105 (22), 101 (44), 95 (41), 93 (18), 85 (93), 81 
(28), 79 (26), 75 (100), 73 (49), 67 (43), 59 (22), 57 (14), 55 (24), 43 (17), 41 (32). HRMS (ESIpos): 
m/z: calcd for C18H36O3SiNa: 351.2326; found: 351.2327. 
 
Methyl (E)-4-((2S,4R,6R)-4-((tert-butyldimethylsilyl)oxy)-6-((R)-3-hydroxy-2-methylpropyl)-
tetrahydro-2H-pyran-2-yl)but-2-enoate (146). Hoveyda-Grubbs 2
nd
 gen. catalyst C7 (137 mg, 
0.219 mmol) was added to a solution of the terminal alkene 145 (2.40 g, 
7.30 mmol) and methylacrylate (3.27 mmol, 36.5 mmol) in CH2Cl2 (70 mL). 
The mixture was stirred for 7.5 h at ambient temperature allowing the generated 
ethene to evaporate. After concentration, the residue (E/Z = 12:1 based on 
1
H 
NMR integration of a crude sample) was purified by flash chromatography (hexanes/EtOAc 5:1 to 
4:1) to give the title compound as a pale brown oil (2.33 g, single isomer, 83%). 20][ D  = +9.0 (c = 1.0, 
CH2Cl2). 
1
H NMR (400 MHz, C6D6): δ = 7.09 (dt, J = 15.6, 7.2 Hz, 1H), 5.90 (dt, J = 15.6, 1.5 Hz, 
1H), 3.57 (dddd, J = 10.8, 10.6, 4.9, 4.8 Hz, 1H), 3.40 (s, 3H) 3.39 – 3.29 (m, 2H), 3.09 (dddd, J = 
11.7, 9.7, 2.3, 2.3 Hz, 1H), 2.96 (dddd, J = 11.7, 7.0, 4.7, 1.9 Hz, 1H), 2.09 (dddd, J = 14.8, 7.4, 7.3, 
1.5 Hz, 1H), 1.94 (dddd, J = 8.6, 8.6, 5.1, 2.0 Hz, 1H), 1.81 – 1.70 (m, 2H), 1.67 – 1.56 (m, 2H), 1.51 
(ddd, J = 14.4, 9.6, 6.9 Hz, 1H), 1.29 – 1.12 (m, 2H), 1.07 – 1.01 (m, 1H), 0.99 (s, 9H), 0.87 (d, J = 
6.8 Hz, 3H), 0.08 (s, 3H), 0.07 (s, 3H) ppm. 
13
C NMR (100 MHz, C6D6): δ = 166.4, 145.1, 123.5, 74.6, 
74.2, 68.9, 68.1, 51.0, 42.7, 41.5, 40.7, 38.7, 34.0, 26.0, 18.2, 17.7, 4.3, 4.3 ppm. IR (film): ṽ = 
3436, 2933, 2929, 2856, 1725, 1659, 1462, 1436, 1376, 1324, 1255, 1175, 1122, 1069, 985, 855, 836, 
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775, 669 cm
−1
. MS (EI) m/z (%) = 329 (14), 237 (54), 229 (17), 203 (11), 159 (26), 137 (11), 131 (12), 
129 (20), 109 (30), 101 (23), 97 (20), 93 (21), 89 (11), 85 (100), 81 (15), 75 (46), 73 (32), 67 (18), 59 
(13), 55 (12), 41 (15). HRMS (ESIpos): m/z: calcd for C20H38O5SiNa: 409.2381; found: 409.2381. 
 
Methyl (E)-4-((2S,4R,6R)-4-((tert-butyldimethylsilyl)oxy)-6-((S)-3-hydroxy-2-methylpropyl)-
tetrahydro-2H-pyran-2-yl)but-2-enoate (11-epi-146). Prepared analogously from terminal alkene 
11-epi-145 (1.82 g, 5.63 mmol) as a colorless oil (1.99 g, 91%). [∝]𝐷
20 = 0.4 (c 
= 1.09, CH2Cl2). 
1
H NMR (400 MHz, C6D6): δ = 7.09 (dt, J = 15.7, 7.1 Hz, 1H), 
5.90 (dt, J = 15.7, 1.5 Hz, 1H), 3.59 (tt, J = 10.5, 4.7 Hz, 1H), 3.40 (m, 5H), 
3.21 (dddd, J = 11.6, 8.6, 3.4, 1.8 Hz, 1H), 2.99 (dddd, J = 11.7, 7.4, 4.4, 
2.1 Hz, 1H), 2.16 – 2.04 (m, 1H), 2.04 – 1.97 (br s, 1H), 1.93 (dddd, J = 14.9, 7.1, 4.5, 1.5 Hz, 1H), 
1.84 (tdd, J = 12.8, 7.3, 1.3 Hz, 1H), 1.67 (ddt, J = 12.6, 4.8, 1.9 Hz, 1H), 1.59 (ddt, J = 12.4, 4.8, 
1.9 Hz, 1H), 1.43 (ddd, J = 14.1, 8.3, 5.7 Hz, 1H), 1.35 (ddd, J = 14.2, 7.2, 3.9 Hz, 1H), 1.26 (ddd, J = 
11.8, 11.6, 11.1 Hz, 1H), 1.19 (ddd, J = 11.7, 11.6, 11.2 Hz, 1H), 0.98 (s, 9H), 0.87 (d, J = 6.9 Hz, 
3H), 0.06 (s, 6H) ppm. 
13
C NMR (100 MHz, C6D6): δ = 166.6, 145.5, 123.3, 74.2, 73.8, 69.0, 67.5, 
51.0, 42.2, 41.7, 40.0, 38.7, 32.9, 26.0, 18.2, 17.7, 4.3, 4.3 ppm. IR (film): ṽ = 3436, 2951, 2930, 
2857, 1726, 1660, 1463, 1436, 1376, 1330, 1256, 1175, 1154, 1122, 1072, 987, 854, 837, 776 cm
−1
. 
MS (EI) m/z (%) = 329 (14), 237 (54), 229 (17), 203 (11), 159 (26), 137 (11), 131 (12), 129 (20), 109 
(30), 101 (23), 97 (20), 93 (21), 89 (11), 85 (100), 81 (15), 75 (46), 73 (32), 67 (18), 59 (13), 55 (12), 
41 (15). HRMS (ESIpos): m/z: calcd for C20H38O5SiNa: 409.2381; found: 409.2382. 
 
(R)-Mosher Ester 218b (all 4 possible Mosher Esters were prepared analogously): Pyridine 
(10.5 µL, 129 µmol) and (S)-(+)-α-methoxy-α-
trifluoromethylphenylacetyl chloride (9.77 µL, 51.8 µmol) were 
successively added to a solution of primary alcohol 11-epi-146 
(10.0 mg, 25.9 µmol) in CH2Cl2 (300 µL). The mixture was stirred 
for 90 min before the reaction was quenched by addition of NH4Cl-
solution (3 mL). The aqueous phase was extracted with EtOAc (2 x 
3 mL), the combined extracts were washed with NaHCO3-solution, dried over Na2SO4 and 
concentrated. The residue was purified by flash chromatography (hexanes/EtOAc 15:1) to give the 
desired (R)-mosher ester as a colorless oil (14.5 mg, 93%). 
1
H NMR (400 MHz, CDCl3): δ = 7.54 – 
7.46 (m, 2H), 7.43 – 7.34 (m, 3H), 6.93 (dt, J = 15.6, 7.2 Hz, 1H), 5.84 (dt, J = 15.8, 1.4 Hz, 1H), 4.21 
(dd, J = 10.8, 5.8 Hz, 1H), 4.13 (dd, J = 10.8, 5.0 Hz, 1H), 3.70 (m, 4H), 3.52 (q, J = 1.2 Hz, 3H), 3.33 
(dddd, J = 11.6, 7.0, 5.0, 1.9 Hz, 1H), 3.25 (tdd, J = 9.2, 4.1, 2.0 Hz, 1H), 2.45 – 2.25 (m, 2H), 2.12 – 
1.99 (m, 1H), 1.75 (ddt, J = 12.5, 4.1, 1.8 Hz, 1H), 1.68 – 1.59 (m, 1H), 1.43 (ddd, J = 14.7, 8.8, 6.0 
Hz, 1H), 1.34 (ddd, J = 14.2, 7.5, 4.0 Hz, 1H), 1.14 (m, 2H), 0.94 (d, J = 6.8 Hz, 3H), 0.86 (s, 9H), 
0.04 (s, 6H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 166.8, 166.6, 145.4, 132.4, 129.6, 128.4, 127.4, 
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122.9, 74.1, 73.4, 70.5, 68.5, 55.4, 51.4, 41.8, 41.2, 39.0, 38.7, 29.4, 25.8, 18.1, 17.6, 4.5, 4.5 ppm. 
19
F NMR (282 MHz, CDCl3): δ = 71.6 ppm. MS (ESIpos) m/z (%) = 625.4 (100 (M+Na
+
)). HRMS 
(ESIpos): m/z: calcd for C30H45F3O7SiNa: 625.2779; found: 625.2774. 
 
Methyl (E)-4-((2S,4R,6R)-4-((tert-butyldimethylsilyl)oxy)-6-((R)-2-methyl-3-oxopropyl)tetra-
hydro-2H-pyran-2-yl)but-2-enoate (147). A solution of Dess-Martin periodinane (524 mg, 
1.24 mmol) in CH2Cl2 (2 mL) was cooled to 0 °C before a solution of alcohol 
146 (398 mg, 1.03 mmol) in CH2Cl2 (2 mL + 1 mL rinse) was added dropwise 
via syringe. After 5 min, the mixture was allowed to warm to ambient 
temperature and stirring was continued for 3 h. The reaction was quenched by 
addition of aq. sat. Na2S2O3 and NaHCO3 solution (1:1, 15 mL) and the aqueous phase was extracted 
with CH2Cl2 (3x 10 mL). The combined organic layers were dried over Na2SO4 and concentrated, and 
the residue was purified by flash chromatography (hexanes/EtOAc 12:1 to 9:1) to yield the desired 
aldehyde as a colorless oil (305 mg, 77%). [∝]𝐷
20 = +3.4 (c = 0.81, hexanes). 
1
H NMR (400 MHz, 
CDCl3): δ = 9.55 (d, J = 2.3 Hz, 1H), 6.91 (dd, J = 15.7, 7.3, 7.2 Hz, 1H), 5.83 (ddd, J = 15.7, 1.5, 
1.5 Hz, 1H), 3.77 – 3.68 (m, 1H), 3.71 (s, 3H), 3.39 – 3.25 (m, 2H), 2.52 (dqd, J = 7.1, 7.0, 2.4 Hz, 
1H), 2.43 – 2.24 (m, 2H), 1.93 (ddd, J = 14.3, 9.9, 7.0 Hz, 1H), 1.80 – 1.71 (m, 2H), 1.38 (ddd, J = 
14.3, 7.1, 3.0 Hz, 1H), 1.26 – 1.14 (m, 2H), 1.06 (d, J = 7.0 Hz, 3H), 0.85 (s, 9H), 0.03 (s, 6H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 204.8, 166.8, 145.2, 123.0, 74.2, 73.4, 68.4, 51.5, 43.8, 41.8, 41.1, 
38.6, 37.3, 25.8, 18.1, 13.8, 4.5 ppm. MS (EI) m/z (%) = 328 (15), 327 (60), 309 (27), 235 (20), 229 
(49), 227 (16), 203 (51), 201 (22), 199 (22), 185 (15), 183 (36), 175 (16), 157 (33), 145 (30), 129 (33), 
109 (15), 107 (23), 101 (48), 97 (29), 93 (29), 89 (22), 85 (31), 83 (25), 81 (36), 79 (15), 75 (100), 73 
(54), 59 (27), 41 (25). HRMS (ESIpos): m/z: calcd for C20H36O5SiNa: 407.2228; found: 407.2224. 
 
Methyl (E)-4-((2S,4R,6R)-4-((tert-butyldimethylsilyl)oxy)-6-((S)-2-methyl-3-oxopropyl)tetra-
hydro-2H-pyran-2-yl)but-2-enoate (11-epi-147). A slightly modified procedure had to be used: A 
solution of Dess-Martin periodinane (783 mg, 1.85 mmol) in CH2Cl2 (2 mL) 
was cooled to 0 °C and NaHCO3 (358 mg, 4.27 mmol) was added as a solid, 
followed by addition of a solution of alcohol 11-epi-146 (550 mg, 1.42 mmol) 
in CH2Cl2 (2 mL + 1 mL rinse). After 5 min, the mixture was allowed to reach 
ambient temperature and stirring was continued for 3 h. The mixture was filtered and the filtrate 
loaded onto SiO2. Purification by flash chromatography (hexanes/EtOAc 12:1 to 9:1) gave the desired 
aldehyde as a colorless oil (414 mg, 76%). [∝]𝐷
20 = +17.7 (c = 1.105, CH2Cl2). 
1
H NMR (400 MHz, 
CDCl3): δ = 9.59 (d, J = 1.4 Hz, 1H), 6.90 (dt, J = 15.7, 7.2 Hz, 1H), 5.82 (dt, J = 15.7, 1.5 Hz, 1H), 
3.71 (m, 4H), 3.39 – 3.26 (m, 2H), 2.61 – 2.48 (m, 1H), 2.41 – 2.23 (m, 2H), 1.79 (ddd, J = 14.4, 8.1, 
3.4 Hz, 1H), 1.77 – 1.70 (m, 2H), 1.65 (ddd, J = 14.0, 9.2, 4.4 Hz, 1H), 1.24 – 1.12 (m, 2H), 1.08 (d, J 
= 7.2 Hz, 3H), 0.84 (s, 9H), 0.02 (s, 6H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 204.5, 166.8, 145.2, 
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122.9, 74.1, 72.8, 68.4, 51.4, 42.8, 41.6, 41.1, 38.6, 36.9, 25.8, 18.0, 13.8, 4.5, 4.5 ppm. IR (film): ṽ 
= 2951, 2939, 2856, 1725, 1660, 1462, 1436, 1376, 1330, 1255, 1175, 1122, 1072, 853, 776 cm
−1
. MS 
(EI) m/z (%) = 328 (14), 327 (60), 309 (29), 235 (20), 229 (49), 227 (16), 203 (51), 201 (22), 199 (22), 
185 (15), 183 (36), 175 (16), 157 (33), 155 (13), 153 (15), 151 (17), 145 (30), 143 (10), 129 (33), 109 
(15), 107 (23), 101 (48), 97 (29), 93 (29), 89 (22), 85 (31), 83 (25), 81 (36), 79 (15), 75 (100), 73 (54), 
67 (17), 59 (27), 43 (17), 41 (25). HRMS (ESIpos): m/z: calcd for C20H36O5SiNa: 407.2224; found: 
407.2224. 
 
Methyl (E)-4-((2S,4R,6R)-4-((tert-butyldimethylsilyl)oxy)-6-((R,E)-4-iodo-2-methylbut-3-en-1-yl)-
tetrahydro-2H-pyran-2-yl)but-2-enoate (150). A flame-dried Schlenk tube was charged with 
CrCl2·1.7 THF (1.21 g, 4.94 mmol) which was suspended in degassed THF 
(11.5 mL). The suspension was cooled to 8 °C, before solid CHI3 (642 mg, 
1.63 mmol) was added under vigorous stirring, causing a color change from 
green-grey to brown. After 5 min, a solution of aldehyde 147 (190 mg, 
0.494 mmol) in degassed THF (1 mL + 2 x 0.5 mL rinse) was added dropwise. 
After 3 h at 8 °C, the reaction was quenched by addition of aq. serine/KHCO3 solution (1 M, pH = 8, 
25 mL) and hexanes/EtOAc (1:1, 40 mL). The mixture was allowed to warm to room temperature and 
was vigorously stirred for 30 min. After phase separation, the deep violet aqueous phase was extracted 
with hexanes/EtOAc (1:1, 3 x 40 mL) and the combined extracts were dried over Na2SO4 and 
concentrated. The residue was purified by flash chromatography (hexanes/EtOAc, 100:0 (until all 
CHI3 was removed) to 99:1 to 49:1 to 39:1 to 29:1) to yield the desired (E)-vinyl iodide as a colorless 
oil (181 mg, 72%) along with the isomeric (Z)-vinyl-iodide (18.8 mg, 8%). [∝]𝐷
20 = 29.6 (c = 1.20, 
CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 6.94 (dt, J = 15.7, 7.2 Hz, 1H), 6.43 (dd, J = 14.4, 8.0 Hz, 
1H), 5.95 (dd, J = 14.4, 1.0 Hz, 1H), 5.86 (dt, J = 15.7, 1.5 Hz, 1H), 3.76 – 3.66 (m, 1H), 3.71 (s, 3H), 
3.41 – 3.30 (m, 1H), 3.25 (dddd, J = 10.0, 8.4, 4.8, 1.8 Hz, 1H), 2.47 – 2.25 (m, 3H), 1.75 (m, 2H), 
1.62 (ddd, J = 13.8, 8.4, 6.5 Hz, 1H), 1.28 (ddd, J = 13.9, 7.0, 4.9 Hz, 1H), 1.25 – 1.09 (m, 2H), 0.97 
(d, J = 6.7 Hz, 3H), 0.86 (s, 9H), 0.03 (s, 6H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 166.9, 152.0, 
145.4, 122.8, 74.1, 73.3, 73.2, 68.6, 51.4, 41.9, 41.6, 41.3, 38.7, 37.1, 25.8, 19.1, 18.1, 4.5 ppm. IR 
(film): ṽ = 2949, 2929, 2856, 1725, 1660, 1435, 1376, 1329, 1269, 1255, 1174, 1069, 950, 836, 775, 
670 cm
−1
. MS (EI) m/z (%) = 452 (23), 451 (100), 229 (47), 197 (11), 181 (37), 169 (10), 157 (11), 
131 (34), 129 (31), 101 (19), 93 (12), 89 (13), 75 (28), 73 (21), 59 (11). HRMS (ESIpos): m/z: calcd 
for C21H37O4SiINa: 531.1398; found: 531.1402. 
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Methyl (E)-4-((2S,4R,6R)-4-((tert-butyldimethylsilyl)oxy)-6-((S,E)-4-iodo-2-methylbut-3-en-1-yl)-
tetrahydro-2H-pyran-2-yl)but-2-enoate (11-epi-150). Prepared analogously from aldehyde 11-epi-
147 (404 mg, 1.05 mmol) as a mixture of olefin isomers (384 mg, 72%, E/Z = 
10:1). An aliquot (340 mg, 0.669 mmol) was purified by preparative HPLC (2 
runs with 170 mg each, Nucleodur C18 HTec 10 µm, length: 250 mm, Ø: 
40 mm, MeOH/H2O =93:7, 75 mL/min) to give the desired (E)-isomer as a 
colorless syrup (286 mg, 84%). [∝]𝐷
20 = +92.8 (c = 1. 01, CH2Cl2). 
1
H NMR 
(400 MHz, CDCl3): δ = 6.95 (dt, J = 15.7, 7.1 Hz, 1H), 6.27 (dd, J = 14.3, 9.2 Hz, 1H), 6.00 (dd, J = 
14.3, 0.7 Hz, 1H), 5.86 (dt, J = 15.7, 1.5 Hz, 1H), 3.73 (m, 4H), 3.30 (dddd, J = 11.5, 8.2, 4.3, 1.9 Hz, 
1H), 3.18 (dddd, J = 12.0, 10.4, 3.1, 1.5 Hz, 1H), 2.49 (tdd, J = 9.2, 6.8, 3.9 Hz, 1H), 2.38 (dddd, J = 
15.3, 8.4, 7.1, 1.5 Hz, 1H), 2.29 (dddd, J = 9.1, 7.1, 3.6, 1.4 Hz, 1H), 1.80 – 1.64 (m, 2H), 1.50 (ddd, J 
= 14.2, 10.2, 4.2 Hz, 1H), 1.29 – 1.11 (m, 3H), 0.97 (d, J = 6.8 Hz, 3H), 0.85 (s, 9H), 0.03 (s, 6H) 
ppm. 
13
C NMR (100 MHz, CDCl3): δ = 166.8, 151.2, 145.9, 122.6, 74.4, 74.3, 73.2, 68.5, 51.5, 42.4, 
41.9, 41.5, 38.6, 37.4, 25.8, 20.6, 18.1, 4.5, 4.5 ppm. IR (film): ṽ = 2950, 2928, 2855, 1724, 1660, 
1435, 1375, 1253, 1219, 1175, 1156, 1126, 1067, 987, 955, 869, 834, 774, 669 cm
−1
. MS (EI) m/z (%) 
= 452 (24), 451 (100), 229 (41), 181 (22), 131 (26), 129 (20), 101 (11), 75 (14), 73 (10). HRMS 
(ESIpos): m/z: calcd for C21H37O4SiINa: 531.1398; found: 531.1393.  
 
Methyl (E)-4-((2S,4R,6R)-4-((tert-butyldimethylsilyl)oxy)-6-((R,E)-2-methylhept-3-en-5-yn-1-yl)-
tetrahydro-2H-pyran-2-yl)but-2-enoate ((E)-148). A flame-dried two-necked round-bottom flask 
equipped with a reflux condenser was charged with 1-propynylsodium 
(42.1 mg, 0.677 mmol), which was suspended in degassed THF (4 mL). 
Trimethyl borate (76.9 µL, 0.677 mmol) was added dropwise via syringe 
at rt. After stirring for 20 min, [Pd(dppf)Cl2]·CH2Cl2 (42.5 mg, 
0.0521 mmol) was added, causing the reaction mixture to turn dark red. 
Next, a solution of (E)-vinyl iodide 150 (265 mg, 0.521 mmol) in degassed THF (3 mL + 1 mL rinse) 
was added and the mixture stirred at 65 °C. After 2 h, the pale orange mixture was allowed to cool to 
ambient temperature, the reaction was quenched with sat. NH4Cl/H2O (1:1 v/v, 15 mL) and the 
aqueous phase was extracted with EtOAc (3x 20 mL). The combined organic extracts were dried over 
Na2SO4 and concentrated. The crude product was purified by flash chromatography (hexanes/EtOAc 
49:1 to 39:1 to 29:1) to give the title compound as a pale yellow oil (177 mg, 81%). [∝]𝐷
20= 30.0 (c = 
0.92, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 6.94 (dt, J = 15.7, 7.2 Hz, 1H), 5.93 (ddd, J = 15.9, 
7.9, 0.8 Hz, 1H), 5.85 (dt, J = 15.7, 1.5 Hz, 1H), 5.37 (dqd, J = 15.9, 2.2, 1.1 Hz, 1H), 3.76 – 3.66 (m, 
1H), 3.71 (s, 3H), 3.39 – 3.30 (m, 1H), 3.25 (dddd, J = 11.2, 7.4, 5.5, 1.7 Hz, 1H), 2.47 – 2.25 (m, 3H), 
1.90 (d, J = 2.2 Hz, 3H), 1.75 (dt, J = 4.8, 1.5 Hz, 1H), 1.75 (dt, J = 4.8, 1.5 Hz, 1H), 1.61 (dddd, J = 
7.1, 7.1, 7.0, 6.9 Hz, 1H), 1.28 (ddd, J = 13.6, 7.7, 5.7 Hz, 1H), 1.24 – 1.09 (m, 2H), 0.96 (d, J = 
6.7 Hz, 3H), 0.86 (s, 9H), 0.03 (s, 6H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 166.9, 148.5, 145.5, 
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122.8, 108.2, 84.4, 78.3, 74.1, 73.2, 68.6, 51.4, 42.3, 41.5, 41.3, 38.7, 33.4, 25.8, 19.6, 18.1, 4.2, 4.5, 
4.5 ppm. IR (film): ṽ = 2951, 2928, 2856, 1725, 1660, 1435, 1376, 1328, 1255, 1174, 1068, 985, 962, 
836, 775, 670 cm
−1
. MS (EI) m/z (%) = 420 (19), 364 (11), 363 (40), 313 (13), 288 (11), 229 (53), 189 
(17), 181 (37), 171 (12), 169 (13), 159 (16), 157 (14), 145 (32), 131 (24), 129 (37), 123 (10), 121 (10), 
120 (13), 119 (37), 108 (13), 105 (23), 101 (33), 97 (18), 93 (100), 91 (45), 89 (21), 81 (19), 79 (13), 
77 (41), 75( 48), 73 (46), 59 (17), 41 (14). HRMS (ESIpos): m/z: calcd for C24H40O4SiNa: 443.2588; 
found: 443.2592. 
 
Methyl (E)-4-((2S,4R,6R)-4-((tert-butyldimethylsilyl)oxy)-6-((S,E)-2-methylhept-3-en-5-yn-1-yl)-
tetrahydro-2H-pyran-2-yl)but-2-enoate (11-epi-(E)-148). Prepared analogously from vinyl iodide 
11-epi-150 (185 mg, 1.05 mmol) as a pale yellow oil (117 mg, 76%). 
[∝]𝐷
20 = +93.8 (c = 0.99, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 6.96 
(dt, J = 15.7, 7.1 Hz, 1H), 5.86 (dt, J = 15.8, 1.5 Hz, 1H), 5.79 (ddd, J = 
15.8, 9.0, 0.8 Hz, 1H), 5.41 (dqd, J = 15.9, 2.3, 0.8 Hz, 1H), 3.72 (m, 4H), 
3.38 – 3.25 (m, 1H), 3.20 (dddd, J = 11.8, 10.2, 3.0, 1.9 Hz, 1H), 2.53 – 
2.34 (m, 2H), 2.30 (tdd, J = 7.7, 4.6, 1.6 Hz, 1H), 1.91 (d, J = 2.3 Hz, 3H), 1.79 – 1.70 (m, 1H), 1.71 – 
1.63 (m, 1H), 1.53 (ddd, J = 14.0, 10.1, 4.0 Hz, 1H), 1.28 – 1.10 (m, 3H), 0.96 (d, J = 6.8 Hz, 3H), 
0.85 (s, 9H), 0.02 (s, 6H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 166.8, 148.0, 145.8, 122.7, 109.2, 
84.2, 78.4, 74.1, 73.3, 68.6, 51.4, 42.9, 42.0, 41.4, 38.6, 33.9, 25.8, 21.1, 18.1, 4.2, 4.5, 4.6 ppm. IR 
(film): ṽ = 2951, 2929, 2856, 1727, 1660, 1435, 1375, 1329, 1257, 1218, 1155, 1118, 1072, 962, 852, 
837, 776 cm
−1
. MS (EI) m/z (%) = 420 (19), 364 (11), 363 (40), 313 (13), 288 (11), 229 (53), 189 (17), 
181 (37), 171 (12), 169 (13), 159 (16), 157 (14), 145 (32), 131 (24), 129 (37), 123 (10), 121 (10), 120 
(13), 119 (37), 107 (13), 105 (23), 101 (33), 97 (18), 93 (100), 91 (45), 89 (21), 81 (19), 79 (14), 77 
(41), 75( 48), 73 (46), 59 (17), 41 (14). HRMS (ESIpos): m/z: calcd for C24H40O4SiNa: 443.2588; 
found: 443.2586. 
 
(E)-4-((2S,4R,6R)-4-((tert-Butyldimethylsilyl)oxy)-6-((R,E)-2-methylhept-3-en-5-yn-1-yl)tetra-
hydro-2H-pyran-2-yl)but-2-enoic acid (151). KOTMS (90%, 246 mg, 1.73 mmol) was added to a 
solution of methyl ester (E)-148 (145 mg, 0.345 mmol) in Et2O (7.0 mL). 
After stirring for 1h, additional KOTMS (90%, 246 mg, 1.73 mmol) was 
introduced and stirring of the yellow suspension continued for 5 h. Excess 
base was quenched with aq. HCl (0.5 M, 10 mL) and the aqueous layer was 
extracted with EtOAc (5 x 15 mL). The combined organic phases were 
dried over Na2SO4 and concentrated, and the residue purified by flash chromatography 
(hexanes/EtOAc 6:1 with 0.1% AcOH) to give the desired acid as a colorless oil (112 mg, 80%). As a 
by-product, the β,γ-olefin was isolated as a colorless oil (9.8 mg, 7%). [∝]𝐷
20 = 28.2 (c = 1.37, 
CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 13.0 – 10.4 (br s, 1H), 7.06 (dt, J = 15.7, 7.1 Hz, 1H), 5.93 
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(dd, J = 15.9, 7.8 Hz, 1H), 5.84 (dt, J = 15.7, 1.2 Hz, 1H), 5.37 (ddd, J = 15.9, 2.1, 1.1 Hz, 1H), 3.72 
(m, 1H), 3.43 – 3.31 (m, 1H), 3.31 – 3.19 (m, 1H), 2.51 – 2.28 (m, 3H), 1.90 (d, J = 2.3 Hz, 3H), 1.80 
– 1.73 (m, 2H), 1.61 (dddd, J = 7.1, 7.0, 7.0, 6.9 Hz, 1H), 1.29 (ddd, J = 13.6, 7.7, 5.7 Hz, 1H), 1.25 – 
1.08 (m, 2H), 0.97 (d, J = 6.7 Hz, 3H), 0.86 (s, 9H), 0.04 (s, 6H) ppm. 
13
C NMR (100 MHz, CDCl3): δ 
= 171.4, 148.5, 148.2, 122.4, 108.2, 84.4, 78.3, 73.9, 73.3, 68.6, 42.3, 41.5, 41.4, 38.8, 33.4, 25.8, 
19.6, 18.1, 4.2, 4.5, 4.5 ppm. IR (film): ṽ = 2928, 2926, 2855, 1698, 1654, 1462, 1443, 1376, 1282, 
1255, 1152, 1068, 960, 852, 835, 815, 774, 699, 669 cm
−1
. MS (EI) m/z (%) = 418 (5), 349 (8), 257 
(13), 237 (24), 169 (23), 160 (12), 145 (27), 131 (33), 129 (11), 121 (10), 119 (28), 107 (12), 105 (12), 
101 (24), 93 (100), 91 (37), 79 (13), 77 (37), 75 (47), 73 (32), 59 (11), 41 (11). HRMS (ESIpos): m/z: 
calcd for C23H38O4SiNa: 429.2427; found: 429.2431.  
 
(E)-4-((2S,4R,6R)-4-((tert-butyldimethylsilyl)oxy)-6-((S,E)-2-methylhept-3-en-5-yn-1-yl)tetra-
hydro-2H-pyran-2-yl)but-2-enoic acid (11-epi-151). Prepared analogously from methyl ester 11-epi-
(E)-148 (116 mg, 0.276 mmol) as a colorless oil (101 mg, 88%), along with 
the corresponding β,γ-olefin as a colorless oil (8.2 mg, 7%). [∝]𝐷
20 = +84.0 
(c = 1.02, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 13.6 – 9.40 (br s, 1H), 
7.08 (dt, J = 15.8, 7.0 Hz, 1H), 5.87 (d, J = 15.7 Hz, 1H), 5.79 (ddd, J = 
15.9, 8.9, 0.9 Hz, 1H), 5.41 (ddt, J = 16.0, 2.7, 1.9 Hz, 1H), 3.79 – 3.63 (m, 
1H), 3.34 (dddd, J = 12.6, 6.1, 4.0, 1.7 Hz, 1H), 3.22 (dddd, J = 10.9, 10.4, 2.1, 1.8 Hz, 1H), 2.53 – 
2.37 (m, 2H), 2.34 (m, 1H), 1.90 (dd, J = 2.3, 0.7 Hz, 3H), 1.81 – 1.63 (m, 2H), 1.53 (ddd, J = 14.1, 
10.0, 4.1 Hz, 1H), 1.30 – 1.10 (m, 3H), 0.96 (d, J = 6.8 Hz, 3H), 0.85 (s, 9H), 0.02 (s, 6H) ppm. 13C 
NMR (100 MHz, CDCl3): δ = 171.5, 148.3, 148.0, 122.4, 109.2, 84.3, 78.4, 74.0, 73.4, 68.5, 42.9, 
41.9, 41.5, 38.7, 33.9, 25.8, 21.1, 18.1, 4.2, 4.5, 4.6 ppm. IR (film): ṽ = 2952, 2928, 2856, 1696, 
1653, 1421, 1375, 1304, 1283, 1254, 1154, 1117, 976, 960, 924, 852, 834, 774, 739, 669 cm
−1
. MS 
(EI) m/z (%) = 418 (6), 349 (8), 257 (13), 237 (25), 169 (23), 160 (12), 145 (27), 131 (33), 129 (11), 
121 (10), 119 (28), 107 (12), 105 (11), 101 (24), 93 (100), 91 (39), 79 (13), 77 (37), 75 (49), 73 (32), 
59 (12). HRMS (ESIneg): m/z: calcd for C23H37O4Si: 405.2467; found: 405.2468. 
 
5.3.2 Synthesis of alcohol 194. 
3-(Benzyloxy)propanal (153). According to the procedure of Stahl et. al.,
[58]
 a 1 L-round-bottom flask 
was charged with 3-(benzyloxy)propanol (156) (7.20 g, 43.3 mmol) and MeCN (HPLC 
grade, 210 mL). [Cu(MeCN)4]BF4 (683 mg, 2.17 mmol) and 2,2’-bipyridine (339 mg, 
2.17 mmol) were added as solids, followed by N-methyl imidazole (346 µL, 4.34 mmol) and TEMPO 
(339 mg, 2.17 mmol). The resulting red/brown mixture was vigorously stirred open to air for 3 h until 
the reaction mixture turned dark green. After concentration at reduced pressure, the residue was 
purified by flash chromatography (hexanes/EtOAc 6:1 to 5:1 to 4:1) to give the desired aldehyde as a 
colorless oil with an unpleasant smell (6.69 g, 94%). 
1
H NMR (400 MHz, CDCl3): δ = 9.78 (t, J = 
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1.8 Hz, 1H), 7.41 – 7.22 (m, 5H), 4.52 (s, 2H), 3.80 (td, J = 6.1, 1.2 Hz, 2H), 2.68 (tt, J = 6.1, 1.6 Hz, 
2H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 201.1, 137.8, 128.4, 127.7, 127.7, 73.2, 63.8, 43.9 ppm. 
IR (film): ṽ = 3031, 2860, 2733, 1721, 1496, 1454, 1394, 1362, 1205, 1091, 1027, 899, 885, 736, 697 
cm
−1
. MS (EI) m/z (%) = 108 (79), 107 (85), 92 (17), 91 (66), 79 (100), 78 (14), 77 (56), 65 (14), 56 
(29), 55 (22), 51 (18), 39 (10), 28 (11), 27 (22), 26 (11). HRMS (ESIpos): m/z: calcd for C10H12O2H: 
165.0916; found: 165.0914. 
 
(3R,4R)-1-(Benzyloxy)-4-methylhex-5-en-3-ol (157). A solution of crotylsilane (R,R)-R17
[167]
 (1.0 M 
in CH2Cl2, 6.62 mmol, 6.62 mL) was added dropwise at 78 °C via syringe to a 
solution of aldehyde 153 (906 mg, 5.52 mmol) in CH2Cl2 (56 mL). Next, solid 
Sc(OTf)3 (136 mg, 0.276 mmol) was added and the mixture stirred for 15 min at 78 °C before it was 
allowed to reach 0 °C. Stirring was continued for 2 h. At this point, NMR analysis of an aliquot (50 
µL) confirmed full consumption of the aldehyde. The mixture was concentrated and treated with aq. 
HCl (1 M, 70 mL) and Et2O (70 mL) under vigorous stirring for 1 h. The white precipitate formed was 
filtered off and washed with Et2O (2 x 10 mL) (treatment of this solid with NaOH allowed the diamine 
ligand to be recovered after chromatographic purification in > 90%). The phases of the filtrate were 
separated and the aqueous layer extracted with Et2O (3 x 50 mL). The combined extracts were washed 
with NaHCO3 (70 mL), dried over Na2SO4, and concentrated. The residue was purified by flash 
chromatography (hexanes/EtOAc 5:1) to give the crotylated alcohol as a colorless oil (995 mg, 82% 
yield, 94% ee, 98:2 d.r.). The enantiomeric excess was determined by HPLC of the TBS ether (see 
conditions below). [∝]𝐷
20 = +16.5 (c = 1.18, CHCl3). 
1
H NMR (400 MHz, CDCl3): δ = 7.40 – 7.25 (m, 
5H), 5.77 (ddd, J = 17.7, 10.4, 7.6 Hz, 1H), 5.09 – 4.98 (m, 2H), 4.50 (s, 2H), 3.75 – 3.59 (m, 3H), 
2.80 (br s, 1H), 2.25 (m, 1H), 1.82 – 1.62 (m, 2H), 1.03 (d, J = 6.8 Hz, 3H) ppm. 13C NMR (100 MHz, 
CDCl3): δ = 141.0, 137.9, 128.4, 127.7, 127.7, 114.9, 74.5, 73.3, 69.4, 43.9, 33.5, 15.0 ppm. IR (film): 
ṽ = 3471, 3031, 2943, 2865, 1638, 1496, 1454, 1418, 1363, 1206, 1092, 1071, 1028, 997, 949, 913, 
736, 697 cm
−1
. MS (EI) m/z (%) = 220 (0.1), 165 (3), 107 (14), 92 (13), 91 (100), 79 (7), 65 (8), 55 (7). 
HRMS (ESIpos): m/z: calcd for C14H20O2Na: 243.1355; found: 243.1356.  
 
(3S,4S)-1-(Benzyloxy)-4-methylhex-5-en-3-ol (ent-157). Prepared analogously from aldehyde 153 
(1.98 g, 12.0 mmol) and crotylsilane (S,S)-R17 (1.0 M in CH2Cl2, 8.21 mmol, 
8.21 mL) as a colorless oil (2.13 g, 80% yield, 94.6% ee, 98:2 d.r.). The enantiomeric 
excess was determined by HPLC of the TBS ether (see conditions below). 
  
176 Experimental section 
 
(((3R,4R)-1-(Benzyloxy)-4-methylhex-5-en-3-yl)oxy)(tert-butyl)dimethylsilane (158). TBSOTf 
(782 µL, 3.40 mmol) and 2,6-lutidine (463 µL, 3.98 mmol) were added to a solution 
of alcohol 157 (625 mg, 2.84 mmol) in CH2Cl2 (25 mL) at 0 °C. The reaction mixture 
was stirred for 1 h at 0 °C before the reaction was quenched by addition of sat. NH4Cl 
solution (30 mL). The aqueous phase was extracted with CH2Cl2 (3 x 20 mL). The combined organic 
extracts were washed with brine (30 mL), dried over Na2SO4 and concentrated. Purification of the 
residue by flash chromatography (hexanes/EtOAc 35:1) yielded the target silyl ether as a colorless oil 
(908 mg, 96%). [∝]𝐷
20= +37.4 (c = 1.39, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.38 – 7.30 (m, 
4H), 7.30 – 7.24 (m, 1H), 5.87 (ddd, J = 17.3, 10.7, 6.8 Hz, 1H), 5.03 – 4.95 (m, 2H), 4.50 (d, J = 
11.9 Hz, 1H), 4.45 (d, J = 11.9 Hz, 1H), 3.75 – 3.69 (m, 1H), 3.55 – 3.49 (m, 2H), 2.35 – 2.25 (m, 
1H), 1.75 (dtd, J = 13.9, 7.4, 4.0 Hz, 1H), 1.65 (ddt, J = 13.9, 7.8, 6.2 Hz, 1H), 0.95 (d, J = 6.9 Hz, 
3H), 0.87 (s, 9H), 0.04 (s, 3H), 0.02 (s, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 140.8, 138.5, 
128.3, 127.6, 127.5, 114.2, 72.9, 72.9, 67.1, 43.0, 33.4, 25.9, 18.1, 14.9, −4.3, −4.6 ppm. IR (film): ṽ = 
2955, 2928, 2885, 2856, 1472, 1461, 1455, 1361, 1253, 1092, 1050, 1028, 1005, 912, 835, 774, 733, 
696 cm
−1
. MS (EI) m/z (%) = 279 (11), 173 (21), 131 (8), 91 (100), 73 (13). HRMS (ESIpos): m/z: 
calcd for C20H34O2SiNa: 357.2220; found: 357.2219. HPLC: 150 mm Chiralcel OJ-3R (Ø 4.6 mm), 
MeCN/water 70:30, 0.5 mL/min, 308 K, 9.2 MPa: Rt = 12.64 min (major syn), 14.10 min (anti), 
15.27 min (minor syn).  
  
 
(2S,3R)-5-(Benzyloxy)-3-((tert-butyldimethylsilyl)oxy)-2-methylpentanal (152). The terminal 
alkene 158 (900 mg, 2.67 mmol) was dissolved in CH2Cl2 and the resulting solution 
cooled to −78 °C. Ozone was bubbled through the solution (~30 g/Nm3) until TLC 
analysis showed complete conversion of the alkene (30 min) and the solution turned 
blue. Argon was then bubbled for 10 min through the solution, which turned colorless. 
Triphenylphosphine (842 mg, 3.21 mmol) was added as a solid and the reaction mixture was allowed 
to warm to ambient temperature and stirred for 3.5 h. The volatiles were then removed under reduced 
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pressure and the residue purified by flash chromatography (hexanes/EtOAc 29:1 to 19:1) to yield the 
desired aldehyde as a colorless liquid (823 mg, 91%) along with the benzoate as a by-product. [∝]𝐷
20 = 
+42.5 (c = 1.34, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 9.76 (d, J = 0.9 Hz, 1H), 7.37 – 7.24 (m, 
5H), 4.50 (d, J = 11.9 Hz, 1H), 4.44 (d, J = 11.9 Hz, 1H), 4.30 (ddd, J = 7.3, 5.6, 3.6 Hz, 1H), 3.56 – 
3.45 (m, 2H), 2.46 (qdd, J = 6.9, 3.7, 1.0 Hz, 1H), 1.89 – 1.69 (m, 2H), 1.04 (d, J = 7.0 Hz, 3H), 0.84 
(s, 9H), 0.05 (s, 3H), 0.02 (s, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 205.1, 138.3, 128.4, 127.6, 
73.0, 69.3, 66.6, 51.6, 34.6, 25.8, 18.0, 7.9, −4.5, −4.6 ppm. IR (film): ṽ = 2953, 2929, 2856, 1725, 
1496, 1472, 1455, 1361, 1252, 1148, 1099, 1028, 1005, 938, 834, 774, 734, 697 cm
−1
. MS (EI) m/z 
(%) = 279 (1), 187 (4), 173 (9), 145 (10), 131 (16), 115 (5), 92 (9), 91 (100), 59 (5). HRMS (ESIpos): 
m/z: calcd for C19H32O3SiNa: 359.2013; found: 357.2010. 
 
(3R,4S)-3-((tert-Butyldimethylsilyl)oxy)-4-methyl-5-oxopentyl benzoate (159). Obtained as a by-
product from the reaction described above as a colorless oil (37 mg, 4%) 
1
H NMR 
(400 MHz, CDCl3): δ = 9.76 (d, J = 1.0 Hz, 1H), 8.04 – 7.89 (m, 2H), 7.56 – 7.45 (m, 
1H), 7.44 – 7.33 (m, 2H), 4.38 (dt, J = 11.7, 6.0 Hz, 1H), 4.33 – 4.22 (m, 2H), 2.50 
(qdd, J = 7.0, 3.7, 1.0 Hz, 1H), 1.97 (dddd, J = 14.1, 7.8, 6.2, 5.1 Hz, 1H), 1.86 (ddt, J = 14.3, 7.7, 
5.7 Hz, 1H), 1.06 (d, J = 7.1 Hz, 3H), 0.82 (s, 9H), 0.03 (s, 3H), 0.00 (s, 3H) ppm. 
13
C NMR 
(100 MHz, CDCl3): δ = 204.6, 166.4, 133.0, 130.1, 129.5, 128.4, 69.2, 61.6, 51.6, 33.5, 25.7, 18.0, 8.2, 
−4.5, −4.6 ppm. IR (film): ṽ = 2954, 2911, 2876, 1455, 1414, 1363, 1238, 1091, 1004, 911, 840, 725, 
695 cm
−1
. MS (EI) m/z (%) = 293 (1), 213 (3), 201 (1), 179 (25), 172 (14), 171 (100), 141 (10), 127 
(8), 115 (32), 105 (74), 97 (41), 91 (10), 77 (25), 59 (14). HRMS (ESIpos): m/z: calcd for 
C19H30O4SiNa: 373.1806; found: 373.1807. 
 
(R)-tert-Butyl(oxiran-2-ylmethoxy)diphenylsilane (160). A solution of TBDPSCl (18.1 mL, 
69.4 mmol) in CH2Cl2 (50 mL) was added over 15 min via a dropping funnel to a 
solution of (S)-glycidol (155) (4.41 mL, 66.1 mmol) and imidazole (5.99 g, 
87.9 mmol) in CH2Cl2 (200 mL) at 0 °C. A white solid started to precipitate after 5 min and the 
reaction mixture was allowed to warm to rt. After 2 h, H2O (250 mL) was added and the aqueous 
phase extracted with CH2Cl2 (2 x 100 mL). The combined organic layers were washed with brine, 
dried over Na2SO4 and concentrated. The residue was purified by flash chromatography 
(hexanes/EtOAc 19:1 to 9:1) to give the desired silyl ether as a colorless oil (19.5 g, 94%). [∝]𝐷
20 = 
+0.9 (c = 1.41, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.75 – 7.61 (m, 4H), 7.47 – 7.32 (m, 6H), 
3.84 (dd, J = 11.8, 3.2 Hz, 1H), 3.70 (dd, J = 11.8, 4.7 Hz, 1H), 3.14 – 3.09 (m, 1H), 2.73 (dd, J = 5.2, 
4.0 Hz, 1H), 2.60 (dd, J = 5.2, 2.7 Hz, 1H), 1.05 (s, 9H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 135.6, 
135.5, 132.3, 129.7, 127.0, 64.3, 52.3, 44.4, 26.8, 19.2 ppm. IR (film): ṽ = 3071, 3049, 2998, 2930, 
2894, 2857, 1472, 1427, 1390, 1361, 1254, 1159, 1136, 1111, 1091, 1030, 980, 917, 823, 739, 700, 
690 cm
−1
. MS (EI) m/z (%) = 256 (11), 255 (53), 226 (20), 225 (100), 211 (22), 184 (16), 183 (87), 
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181 (20), 177 (46), 117 (38), 105 (13), 77 (99). HRMS (ESIpos): m/z: calcd for C19H24O2SiNa: 
335.1438; found: 335.1435. 
 
(S)-tert-Butyl(oxiran-2-ylmethoxy)diphenylsilane (ent-160). Prepared analogously from (R)-
glycidol (ent-155) (3.0 g, 40.5 mmol) as a colorless oil (12.0 g, 95%). 
 
(R)-1-((tert-Butyldiphenylsilyl)oxy)-5-(trimethylsilyl)pent-4-yn-2-ol (161). A solution of n-BuLi 
(1.65 M in hexane, 40.6 mL, 66.9 mmol) was added dropwise via dropping 
funnel over 12 min to a solution of trimethylsilylacetylene (7.17 g, 
73.0 mmol) in THF (300 mL) at −78 °C. The resulting yellow solution was stirred for 15 min at 
−78 °C, when BF3·Et2O (9.26 mL, 73.0 mmol) was added dropwise via syringe over 5 min. A solution 
of epoxide 160 (18.3 g, 58.6 mmol) in THF (15 mL) was then added dropwise via syringe over 6 min 
and the reaction mixture allowed to stir for further 90 min. The reaction was then quenched by careful 
addition of sat. NH4Cl solution (300 mL) and EtOAc (200 mL) and the mixture subsequently warmed 
to ambient temperature. After phase separation, the aqeuos phase was extracted with EtOAc (2 x 
200 mL). The combined organic extracts were dried over Na2SO4 and concentrated. Purification of the 
residue by flash chromatography (short column (~9cm), hexanes/EtOAc 14:1) yielded the desired 
alcohol as a colorless oil (21.9 g, 91%). [∝]𝐷
20 = −5.3 (c = 0.99, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): 
δ = 7.69 – 7.62 (m, 4H), 7.46 – 7.32 (m, 6H), 3.75 (ddd, J = 10.1, 4.3, 0.7 Hz, 1H), 3.91 – 3.82 (m, 
1H), 3.69 (ddd, J = 10.1, 5.9, 0.8 Hz, 1H), 2.58 – 2.42 (m, 3H), 1.06 (s, 9H), 0.10 (s, 9H) ppm. 13C 
NMR (100 MHz, CDCl3): δ = 135.5, 133.1, 129.8, 127.8, 127.7, 102.6, 87.1, 70.2, 66.4, 26.9, 24.7, 
19.3, 0.0 ppm. IR (film): ṽ = 3487, 2958, 2931, 2858, 2177, 1472, 1428, 1391, 1362, 1249, 1112, 
1188, 1112, 1030, 1008, 970, 936, 840, 823, 759, 739, 700 cm
−1
. MS (EI) m/z (%) = 353 (17), 272 
(12), 271 (45), 242 (21), 241 (100), 223 (12), 221 (9), 211 (6), 200 (13), 199 (74), 193 (13), 163 (31), 
105 (6), 73 (14). HRMS (ESIpos): m/z: calcd for C24H34O2Si2Na: 433.1990; found: 433.1987. 
 
(R)-1-((tert-Butyldiphenylsilyl)oxy)-5-(trimethylsilyl)pent-4-yn-2-ol (162). The secondary alcohol 
161 (21.8 g, 53.1 mmol) was dissolved in MeOH (200 mL) and the solution 
cooled to 15 °C. Potassium carbonate (14.6 g, 106 mmol) was added slowly and 
the reaction mixture stirred vigorously. After 1h, the reaction was quenched with sat. NH4Cl solution 
(200 mL) and the mixture extracted with EtOAc (3 x 150 mL). The combined organic extracts were 
dried over Na2SO4 and concentrated. The residue (17.5 g, 97%) thus obtained turned out to be a 8:1 
mixture of alkynes 162 and 163 as the result of 1,2-silyl migration.  
A part of the residue (16.7 g, 49.3 mmol) was dissolved in CH2Cl2 (250 mL), cooled to −78 °C, and 
treated with triethylamine (1.16 mL, 8.4 mmol), TESCl (1.24 mL, 7.4 mmol) and DMAP (30 mg, 
0.25 mmol). The mixture was stirred for 4 h at −78 °C before the reaction was quenched with sat. 
NH4Cl solution (200 mL). The aqueous phase was extracted with CH2Cl2 (2 x 200 mL) and the 
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combined organic extracts were dried over Na2SO4 and concentrated. The residue was purified by 
flash chromatography (hexanes/EtOAc 13:1 to 4:1) to yield pure secondary alcohol 162 as a colorless 
oil (12.7 g, 76%). [∝]𝐷
20 = −2.5 (c = 1.36, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.71 – 7.62 (m, 
4H), 7.46 – 7.35 (m, 6H), 3.88 (qd, J = 6.2, 4.3 Hz, 1H), 3.75 (dd, J = 10.2, 4.3 Hz, 1H), 3.69 (dd, J = 
10.2, 5.8 Hz, 1H), 2.46 m, 3H), 1.97 (t, J = 2.7 Hz, 1H), 1.07 (s, 9H) ppm. 
13
C NMR (100 MHz, 
CDCl3): δ = 135.5, 135.5, 133.0, 133.0, 129.8, 127.8, 80.3, 70.4, 70.1, 66.3, 26.8, 23.2, 19.2 ppm. IR 
(film): ṽ = 3433, 3301, 3072, 2931, 2858, 1472, 1427, 1391, 1361, 1259, 1188, 1111, 1072, 1043, 
1007, 998, 971, 936, 909, 822, 798, 739, 699 cm
−1
. MS (EI) m/z (%) = 281 (12), 242 (10), 241 (51), 
200 (18), 199 (100), 181 (12), 163 (16), 139 (12), 135 (8), 105 (8), 77 (8). HRMS (ESIpos): m/z: calcd 
for C21H26O2Si1Na: 361.1594; found: 361.1591. 
 
(R)-8,8-Diethyl-2,2-dimethyl-3,3-diphenyl-6-(prop-2-yn-1-yl)-4,7-dioxa-3,8-disiladecane (164). 
The secondary alcohol 162 (1.96 g, 5.79 mmol) was dissolved in CH2Cl2 (29 mL) 
and cooled to 0 °C. Triethylamine (0.96 mL, 6.93 mmol) and TESCl (1.08 mL, 
6.40 mmol) were added slowly via syringe, followed by DMAP (7.1 mg, 58 µmol) as a solid. The 
mixture was stirred for 3 h at 0 °C before the reaction quenched by addition of sat. NH4Cl solution 
(12 mL). After separation of the layers, the aqueous phase was further extracted with EtOAc (3 x 
7 mL). The combined organic layers were dried over Na2SO4 and concentrated. Purification of the 
residue by flash chromatography (hexanes/EtOAc 29:1) yielded the desired silyl ether as a colorless 
oil (2.28 g, 87%). [∝]𝐷
20 = +7.3 (c = 1.05, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.72 – 7.63 (m, 
4H), 7.46 – 7.31 (m, 6H), 3.91 – 3.80 (m, 1H), 3.68 – 3.56 (m, 2H), 2.60 (dddd, J = 16.7, 5.5, 2.7, 
0.8 Hz, 1H), 2.38 (dddd, J = 16.7, 5.9, 2.7, 0.8 Hz, 1H), 1.93 (t, J = 2.7 Hz, 1H), 1.04 (d, J = 0.8 Hz, 
9H), 0.90 (dd, J = 8.3, 7.5 Hz, 9H), 0.54 (q, J = 8.0 Hz, 6H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 
135.6, 135.6, 133.6, 133.4, 129.6, 127.6, 81.6, 71.4, 69.6, 66.8, 26.8, 24.4, 19.2, 6.8, 4.8 ppm. IR 
(film): ṽ = 3312, 2954, 2933, 2876, 1472, 1462, 1427, 1390, 1361, 1239, 1111, 1072, 1003, 938, 855, 
823, 807, 736, 699 cm
−1
. MS (EI) m/z (%) = 423 (19), 396 (11), 395 (30), 315 (11), 314 (30), 313 
(100), 285 (30), 243 (10), 197 (15), 183 (7), 163 (10), 143 (11), 135 (32), 87 (14). HRMS (ESIpos): 
m/z: calcd for C27H40O2Si2Na: 475.2459; found: 475.2461. 
 
(R)-1-((tert-Butyldiphenylsilyl)oxy)pent-4-yn-2-yl benzoate (165). The secondary Alcohol 162 
(1.20 g, 3.55 mmol) was dissolved in CH2Cl2 (10 mL) and the solution cooled to 
0 °C. Triethylamine (0.589 mL, 4.25 mmol) and benzoyl chloride (0.452 mL, 
3.89 mmol) were added slowly via syringe, followed by DMAP (21.7 mg, 178 µmol) as a solid. The 
mixture was stirred for 1 h at 0 °C and 3 h at ambient temperature before the reaction was quenched by 
addition of sat. NH4Cl solution (15 mL). After separation of the layers, the aqueous phase was 
extracted with CH2Cl2 (3 x 15 mL). The combined organic layers were washed with brine (15 mL), 
dried over Na2SO4 and concentrated. Purification of the residue by flash chromatography 
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(hexanes/EtOAc 9:1) yielded the desired silyl ether as a pale yellow oil (1.24 g, 79%). [∝]𝐷
20 = −11.7 
(c = 1.69, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 8.11 – 7.97 (m, 2H), 7.68 – 7.62 (m, 4H), 7.56 (t, 
J = 7.5 Hz, 1H), 7.46 – 7.25 (m, 8H), 5.36 – 5.24 (m, 1H), 3.97 (dd, J = 11.0, 4.8 Hz, 1H), 3.92 (dd, J 
= 11.0, 4.7 Hz, 1H), 2.81 (ddd, J = 16.7, 6.5, 2.3 Hz, 1H), 2.72 (ddd, J = 16.7, 5.6, 2.2 Hz, 1H), 1.96 
(t, J = 2.5 Hz, 1H), 1.04 (s, 9H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 165.8, 135.5, 133.1, 133.0, 
130.2, 129.7, 129.7, 128.3, 127.7, 127.7, 79.5, 72.6, 70.4, 63.6, 26.7, 20.6, 19.3 ppm. IR (film): ṽ = 
3305, 2958, 2931, 2858, 1718, 1602, 1588, 1472, 1451, 1427, 1391, 1361, 1315, 1266, 1176, 1108, 
1069, 1047, 1026, 997, 823, 796, 738, 701, 615 cm
−1
. MS (EI) m/z (%) = 386 (16), 385 (54), 304 (22), 
303 (88), 259 (17), 105 (100), 77 (11). HRMS (ESIpos): m/z: calcd for C28H30O3Si1Na: 465.1856; 
found: 465.1857. 
 
(R)-1-((tert-Butyldiphenylsilyl)oxy)pent-4-yn-2-yl 4-nitrobenzoate (166). The secondary Alcohol 
162 (2.00 g, 5.91 mmol) was dissolved in CH2Cl2 (20 mL) and cooled to 0 °C. 
Triethylamine (0.98 mL, 7.1 mmol) and 4-nitrobenzoyl chloride (1.21 g, 
6.50 mmol) were added slowly, followed by DMAP (36.1 mg, 296 µmol) as a solid. The mixture was 
stirred for 1.5 h at 0 °C before the reaction was quenched by addition of sat. NH4Cl solution (15 mL). 
After separation of the layers, the aqueous phase was extracted with EtOAc (3 x 10 mL). The 
combined organic layers were washed with brine (20 mL), dried over Na2SO4 and concentrated. 
Purification of the residue by flash chromatography (hexanes/EtOAc 9:1) yielded the desired silyl 
ether as a yellow oil (2.52 g, 87%). [∝]𝐷
20 = −13.3 (c = 1.01, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ 
= 8.26 (d, J = 8.5 Hz, 2H), 8.16 (d, J = 8.6 Hz, 2H), 7.66 – 7.59 (m, 4H), 7.43 – 7.27 (m, 6H), 5.36 – 
5.27 (m, 1H), 3.97 (dd, J = 11.0, 4.7 Hz, 1H), 3.93 (dd, J = 10.7, 4.2 Hz), 2.79 (ddd, J = 17.0, 6.4, 
2.6 Hz, 1H), 2.73 (ddd, J = 17.1, 6.1, 2.7 Hz, 1H), 1.03 (s, 9H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 
163.9, 150.6, 135.5, 135.5, 133.0, 132.9, 130.8, 129.8, 127.7, 127.7, 123.5, 79.0, 73.6, 70.7, 63.5, 
26.7, 20.6, 19.2 ppm. IR (film): ṽ = 3297, 3072, 2931, 2858, 1725, 1608, 1527, 1472, 1427, 1348, 
1320, 1269, 1112, 1102, 1044, 1014, 997, 873, 823, 783, 741, 718, 701 cm
−1
. MS (EI) m/z (%) = 431 
(11), 430 (35), 349 (26), 348 (100), 302 (8), 150 (30), 104 (11). HRMS (ESIpos): m/z: calcd for 
C27H40O2Si2Na: 475.2459; found: 475.2461. 
 
(5R,6R,11R)-5-(2-(Benzyloxy)ethyl)-2,2,3,3,6,15,15-heptamethyl-14,14-diphenyl-11-((triethylsilyl) 
oxy)-4,13-dioxa-3,14-disilahexadec-8-yn-7-yl acetate (167). A solution of n-BuLi (1.60 M in hexane, 
221 µL, 353 µmol) was added dropwise over 2 min to a −78 °C 
solution of terminal alkyne 164 (160 mg, 353 µmol) in THF 
(2.0 mL). After 25 min stirring at −78 °C, a solution of aldehyde 
152 (120 mg, 357 µmol) in THF (1.0 mL) was added dropwise. After 2 h, the reaction mixture was 
warmed to 0 °C and stirred for another 2 h. Acetyl chloride (25.5 µL, 0.357 mmol) was added, the 
reaction mixture allowed to warm to ambient temperature and stirred for another 2 h. The reaction was 
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quenched by addition of water (5 mL) and brine (5 mL) and the aqueous phase was extracted with 
CH2Cl2 (3 x 5 mL). The combined organic extracts were dried over Na2SO4 and concentrated. The 
residue was purified by flash chromatography to give the desired propargylic acetate as a colorless oil 
as a mixture of diastereomers (2.9:1 d.r., 104 mg, 35%). 
1
H NMR (400 MHz, C6D6, only the peaks of 
the major isomer are listed): δ = 7.86 – 7.77 (m, 4H), 7.33 – 7.23 (m, 8H), 7.23 – 7.17 (m, 2H), 7.10 
(tt, J = 7.3, 1.4 Hz, 1H), 5.90 (dt, J = 7.6, 2.0 Hz, 1H), 4.38 (dd, J = 6.2, 3.4 Hz, 1H), 4.35 – 4.27 (m, 
2H), 3.99 – 3.91 (m, 1H), 3.87 – 3.76 (m, 2H), 3.47 – 3.35 (m, 2H), 2.76 (ddd, J = 16.6, 5.6, 1.8 Hz, 
1H), 2.53 (ddd, J = 16.5, 5.9, 2.2 Hz, 1H), 2.13 (qdd, J = 7.1, 7.0, 3.3 Hz, 1H), 1.89 (q, J = 6.4 Hz, 
2H), 1.72 (s, 3H), 1.16 (s, 9H), 1.14 (d, J = 6.8 Hz, 3H), 1.01 (s, 9H), 0.97 (t, J = 8.0 Hz, 9H), 0.57 (q, 
J = 8.1 Hz, 6H), 0.23 (s, 3H), 0.13 (s, 3H) ppm. 
13
C NMR (100 MHz, C6D6, only the peaks of the 
major isomer are listed): δ = 169.1, 139.2, 136.0, 136.0, 134.0, 133.8, 130.0, 128.5, 128.1, 128.1, 
127.7, , 127.6, 83.7, 79.9, 73.1, 72.0, 70.5, 67.4, 67.0, 66.3, 43.5, 35.4, 27.1, 26.2, 25.0, 20.6, 19.5, 
18.4, 10.1, 7.1, 5.2, −4.1, −4.2 ppm. IR (film): ṽ = 2953, 2931, 2877, 2857, 1744, 1472, 1462, 1428, 
1362, 1230, 1111, 1016, 971, 940, 862, 835, 775, 737, 701 cm
−1
. MS (EI) m/z (%) = 641 (6), 639 (6), 
623 (6), 435 (9), 383 (6), 313 (21), 285 (16), 281 (12), 279 (43), 241 (10), 237 (21), 197 (11), 181 
(10), 175 (15), 174 (12), 173 (85), 171 (17), 135 (28), 131 (43), 117 (31), 115 (10), 91 (100), 87 (11). 
HRMS (ESIpos): m/z: calcd for C48H74O6Si3Na: 853.4685; found: 853.4685. 
 
((6R,11R,12R)-12-(2-(Benzyloxy)ethyl)-2,2,11,14,14,15,15-heptamethyl-3,3-diphenyl-4,13-dioxa-
3,14-disilahexadec-8-yne-6,10-diol. A solution of n-BuLi (1.60 M in hexane, 0.240 mL, 0.384 mmol) 
was added dropwise to a solution of alkyne 162 in THF (1.0 mL) at 
−78 °C. The resulting pale yellow solution was stirred for 5 min at 
−78 °C, 15 min at −30 °C and recooled to −78 °C, when aldehyde 
152 (51.5 µL, 0.148 mmol) was added dropwise via syringe. The mixture was stirred for 1.5 h at 
−78 °C before the reaction was quenched by the addition of aqueous HCl (0.1 M, 4 mL) and EtOAc 
(3 mL). After separation of the layers, the aqueous phase was extracted with EtOAc (3 x 3 mL). The 
combined organic extracts were washed with brine (5 mL), dried over Na2SO4 and concentrated. The 
residue was purified by flash chromatography (hexanes/EtoAc 5:1) to yield two inseparable 
diastereomers (48 mg, 60%, 1.4:1 mixture of diastereomers) as a colorless oil. 
1
H NMR (400 MHz, 
CDCl3, the peaks of both diastereomers are listed): δ = 7.65 (d, J = 7.1 Hz, 4H), 7.47 – 7.20 (m, 11H), 
4.54 – 4.41 (m, 2H), 4.40 – 4.24 (m, 1H), 4.14 – 4.04 (m, 1H), 3.89 – 3.81 (m, 1H), 3.74 – 3.66 (m, 
2H), 3.51 – 3.40 (m, 2H), 2.59 (br s, 1H), 2.54 – 2.42 (m, 2H), 1.96 – 1.69 (m, 3H), 1.35 – 1.24 (m, 
1H), 1.06 (s, 9H), 0.97 (d, J = 6.9 Hz, 1.7H), 0.86 (m, 10.3H), 0.13 – 0.01 (m, 6H) ppm. 13C NMR 
(100 MHz, CDCl3, the peaks of both diastereomers are listed): δ = 138.3, 135.5, 133.0, 129.8, 128.3, 
128.3, 127.8, 127.8, 127.7, 127.6, 127.5, 127.5, 83.1, 83.0, 81.8, 81.3, 72.9, 72.1, 71.5, 70.4, 70.4, 
66.8, 66.5, 65.4, 65.2, 43.9, 43.6, 41.3, 36.0, 34.6, 33.7, 32.7, 29.7, 29.0, 27.6, 26.9, 26.8, 25.8, 25.8, 
23.6, 23.6, 22.6, 20.4, 19.4, 19.2, 18.7, 18.0, 17.9, 14.3, 12.2, 11.4, 9.3, −4.3, −4.5, −4.6, −4.7 ppm. IR 
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(film): ṽ = 3413, 2953, 2929, 2885, 2856, 1471, 1462, 1427, 1389, 1361, 1252, 1111, 1027, 1005, 938, 
834, 775, 738, 699 cm
−1
. MS (ESIpos) m/z (%) = 697.5 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for 
C40H58O5Si2Na: 697.3715; found: 697.3712. 
 
(6R,11R,12R)-12-(2-(Benzyloxy)ethyl)-2,2,11,14,14,15,15-heptamethyl-3,3-diphenyl-4,13-dioxa-
3,14-disilahexadec-8-yne-6,10-diyl diacetate (168). A diastereomeric mixture of the diol described 
above (97.0 mg, 0.144 mmol) was dissolved in CH2Cl2 (0.8 mL) 
and the resulting solution cooled to 0 °C. Triethylamine (44.8 µL, 
0.323 mmol) and acetic anhydride (29.2 µL, 0.309 mmol) were 
added via syringe, followed by the addition of DMAP (1.8 mg, 14 µmol) as a solid. The mixture was 
stirred for 1 h at 0 °C before the reaction was quenched by addition of sat. NH4Cl solution (5 mL). The 
aqueous phase was then extracted with CH2Cl2 (3 x 4 mL). The combined organic extracts were dried 
over Na2SO4 and concentrated. The residue was purified by flash chromatography (hexanes/EtOAc 
14:1 to 12:1) to give the bisacetate as a colorless oil (1.5:1 mixture of diastereomers, 91.6 mg, 84%). 
[∝]𝐷
20 = +9.7 (c = 1.09, CH2Cl2). 
1
H NMR (400 MHz, CDCl3, the peaks of both diastereomers are 
listed): δ = 7.69 – 7.59 (m, 4H), 7.43 – 7.24 (m, 11H), 7.23 – 7.19 (m, 1H), 5.34 (d, J = 7.0 Hz, 0.6H, 
major isomer), 5.19 (d, J = 7.6 Hz, 0.4H, minor isomer), 5.02 – 4.93 (m, 1H), 4.50 – 4.37 (m, 2H), 
4.01 (td, J = 6.1, 3.4 Hz, 0.6H, major isomer), 3.91 (6.1 Hz, 3.1 Hz, 0.4H, minor isomer), 3.80 – 3.67 
(m, 2H), 3.49 – 3.38 (m, 2H), 2.70 – 2.48 (m, 2H), 2.03 – 1.95 (m, 6H), 1.89 – 1.69 (m, 3H), 1.01 (s, 
9H), 0.93 (dd, J = 7.0 Hz, 1.2H, minor isomer), 0.91 (d, J = 6.9 Hz, 1.8H, major isomer), 0.83 (m, 
9H), 0.03 (s, 1.8H, major isomer), 0.00 (s, 1.8H, major isomer), −0.01 (s, 1.2H, minor isomer), −0.05 
(s, 1.2H, minor isomer) ppm. 
13
C NMR (100 MHz, CDCl3, the peaks of both diastereomers are listed): 
δ = 170.1, 169.8, 169.7, 138.5, 138.4, 135.5, 135.5, 133.3, 133.2, 129.7, 128.3, 127.7, 127.7, 127.5, 
127.5, 127.5, 81.9, 81.4, 79.6, 79.2, 72.9, 72.1, 72.0, 69.9, 68.6, 67.0, 66.8, 65.9, 65.8, 63.9, 63.8, 
43.0, 41.9, 34.6, 34.5, 26.7, 25.9, 22.6, 21.0, 21.0, 21.0, 20.9, 20.8, 19.3, 18.1, 18.1, 10.1, 9.8, −4.2, 
−4.4, −4.5, −4.9 ppm. IR (film): ṽ = 2956, 2931, 2857, 1744, 1472, 1428, 1371, 1231, 1113, 1050, 
1010, 836, 776, 740, 701 cm
−1
. MS (ESIpos) m/z (%) = 781.5 (100 (M+Na)).  HRMS (ESIpos): m/z: 
calcd for C44H62O7Si2Na: 781.3926; found: 781.3921. 
 
(6R,11R,12R)-10-Acetoxy-12-(2-(benzyloxy)ethyl)-2,2,11,14,14,15,15-heptamethyl-3,3-diphenyl-
4,13-dioxa-3,14-disilahexadec-8-yn-6-yl benzoate (169). A solution of n-BuLi (1.60 M in hexane, 
0.111 mL, 0.178 mmol) was added dropwise to a solution of 
diisopropylamine (24.7 µL, 0.178 mmol) in THF (0.6 mL) at 
−78 °C. The resulting pale yellow solution was stirred for 5 min at 
−78 °C, 30 min at 0 °C and recooled to −78 °C, when a solution of alkyne 165 (85.2 mg, 0.192 mmol) 
in THF (0.4 mL) was added dropwise. The reaction mixture was stirred for another 20 min at −78 °C 
before aldehyde 152 (51.5 µL, 0.148 mmol) was added carefully. The mixture was stirred for 2 h at 
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−78 °C and 30 min at 0 °C before the reaction was quenched by the addition of sat. NH4Cl solution 
(3 mL) and EtOAc (3 mL). The aqueous phase was extracted with EtOAc (3 x 3 mL). The combined 
organic extracts were washed with brine (5 mL), dried over Na2SO4 and concentrated. The residue was 
purified by flash chromatography (hexanes/EtoAc 9:1 to 7:1 to 5:1) and yielded a mixture of two 
inseparable diastereomers as a pale yellow liquid (67 mg, 58%, 90% purity). This mixture (2.4:1 d.r., 
67.0 mg, 85.9 µmol) was dissolved in CH2Cl2 (0.6 mL) and the solution cooled to 0 °C. Triethylamine 
(13.7 µL, 98.8 µmol), acetic anhydride (8.9 µL, 95 µmol) and DMAP (1.05 mg, 8.6 µmol) were added 
successively and the mixture was stirred for 1 h at 0 °C. The reaction was then quenched by addition 
of sat. NH4Cl solution (4 mL) and the aqueous phase extracted with CH2Cl2 (3 x 4 mL). The combined 
organic extracts were dried over Na2SO4 and concentrated. Purification of the residue by flash 
chromatography (hexanes/EtOAc 19:1 to 14:1) yielded the desired propargylic acetate as a colorless 
oil (2.4:1 d.r., 42.6 mg, 60%). 
1
H NMR (400 MHz, CDCl3, the peaks of both diastereoisomers are 
listed): δ = 8.04 – 7.95 (m, 2H), 7.65 – 7.56 (m, 4H), 7.51 (dd, J = 9.2, 5.9 Hz, 1H), 7.42 – 7.20 (m, 
13H), 5.33 (d, J = 7.1 Hz, 0.8H), 5.28 – 5.15 (m, J = 10.2, 8.6, 4.7 Hz, 1.2H), 4.45 – 4.33 (m, 2H), 
3.96 (td, J = 6.2, 3.4 Hz, 0.8H), 3.92 – 3.78 (m, 2.2H), 3.43 – 3.32 (m, 2H), 2.86 – 2.64 (m, 2H), 1.93 
(s, 2.1H), 1.90 (s, 0.85H), 1.82 – 1.60 (m, 3H), 0.99 (s, 9H), 0.89 (d, J = 6.6 Hz, 0.85H), 0.87 (d, J = 
6.8 Hz, 2.1H), 0.82 – 0.78 (m, 9H), −0.02 – −0.09 (m, 6H) ppm. 13C NMR (100 MHz, CDCl3, only the 
peaks of the major isomer are listed): δ = 169.7, 165.7, 138.4, 135.5, 133.1, 133.0, 130.2, 129.7, 129.7, 
129.7, 128.3, 127.7, 127.7, 127.5, 127.5, 127.4, 81.4, 79.8, 72.9, 72.7, 69.9, 66.9, 65.8, 63.7, 43.0, 
34.5, 26.7, 25.8, 20.9, 19.2, 18.0, 9.8, −4.4, −4.6 ppm. IR (film): ṽ = 2954, 2930, 2856, 1743, 1721, 
1472, 1462, 1453, 1362, 1314, 1268, 1228, 1176, 1106, 1045, 1026, 971, 938, 835, 794, 775, 739, 700 
cm
−1
. MS (ESIpos) m/z (%) = 843.5 (100 (M+Na)).  HRMS (ESIpos): m/z: calcd for 
C49H63N1O9Si2Na: 843.4083; found: 843.4090. 
 
(6R,10R,11R,12R)-12-(2-(Benzyloxy)ethyl)-10-hydroxy-2,2,11,14,14,15,15-heptamethyl-3,3-
diphenyl-4,13-dioxa-3,14-disilahexadec-8-yn-6-yl 4-nitrobenzoate.
[246]
 A solution of n-BuLi 
(1.60 M in hexane, 0.111 mL, 0.178 mmol) was added dropwise to a 
solution of diisopropylamine (24.7 µL, 0.178 mmol) in THF 
(0.6 mL) at −78 °C. The resulting pale yellow solution was stirred 
for 5 min at −78 °C, 25 min at 0 °C and recooled to −78 °C, when a solution of alkyne 166 (93.7 mg, 
0.192 mmol) in THF (0.4 mL + 2 x 0.1 mL rinse) was introduced dropwise via syringe. The reaction 
mixture was stirred for another 20 min at −78 °C before aldehyde 152 (51.5 µL, 0.148 mmol) was 
added carefully. The mixture was stirred for 2 h at −78 °C before the reaction was quenched by the 
addition of sat. NH4Cl solution (3 mL) and EtOAc (3 mL). The aqueous phase was further extracted 
with EtOAc (3 x 3 mL). The combined organic extracts were washed with brine (5 mL), dried over 
Na2SO4 and concentrated. The residue was purified by flash chromatography (hexanes/EtoAc 8:1 to 
7:1) to yield two separable diastereomers (major: 34.5 mg, 27%; minor: 17.3 mg, 13%) as pale yellow 
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liquids. The two diastereomers were combined prior to the next step. 
1
H NMR (400 MHz, CDCl3): δ = 
8.21 (d, J = 8.6 Hz, 2H), 8.11 (d, J = 8.6 Hz, 2H), 7.64 – 7.54 (m, 4H), 7.40 – 7.24 (m, 10H), 7.21 (t, J 
= 4.8 Hz, 1H), 5.31 – 5.22 (m, 1H), 4.46 – 4.34 (m, 3H), 4.00 – 3.94 (m, 1H), 3.95 – 3.86 (m, 2H), 
3.40 (t, J = 6.3 Hz, 2H), 2.78 (dd, J = 16.8, 6.2 Hz, 1H), 2.71 (dd, J = 16.9, 6.1 Hz, 1H), 2.57 (br s, 
1H), 1.91 – 1.66 (m, 3H), 0.99 (s, 9H), 0.90 (d, J = 6.9 Hz, 3H), 0.81 (s, 9H), −0.01 (s, 6H) ppm. 13C 
NMR (100 MHz, CDCl3): δ = 163.9, 150.5, 138.3, 135.5, 135.5, 133.0, 133.0, 130.8, 129.8, 128.3, 
127.7, 127.7, 127.5, 127.5, 123.4, 83.2, 80.3, 74.0, 72.9, 72.4, 66.7, 65.3, 63.7, 43.4, 34.4, 26.7, 25.8, 
20.9, 19.2, 18.0, 9.3, −4.3, −4.6 ppm. IR (film): ṽ = 2953, 2931, 2877, 2857, 1744, 1472, 1462, 1428, 
1362, 1230, 1111, 1016, 971, 940, 862, 835, 775, 737, 701 cm
−1
. MS (ESIpos) m/z (%) = 846.5 (100 
(M+Na)). HRMS (ESIpos): m/z: calcd for C47H61N1O8Si2Na: 846.3828; found: 846.3836. 
 
(6R,10R,11R,12R)-12-(2-(Benzyloxy)ethyl)-10-hydroxy-2,2,11,14,14,15,15-heptamethyl-3,3-
diphenyl-4,13-dioxa-3,14-disilahexadec-8-yn-6-yl 4-nitrobenzoate. Obtained as the minor 
diastereomer from the reaction described above. 
1
H NMR 
(400 MHz, CDCl3): δ = 8.25 (d, J = 8.5 Hz, 2H), 8.15 (d, J = 
8.5 Hz, 2H), 7.65 – 7.57 (m, 4H), 7.40 – 7.26 (m, 11H), 5.31 (p, J = 
5.6 Hz, 1H), 4.48 (d, J = 11.8 Hz, 1H), 4.42 (d, J = 11.8 Hz, 1H), 4.27 (d, J = 9.2 Hz, 1H), 4.04 (dt, J 
= 7.9, 3.8 Hz, 1H), 3.98 – 3.88 (m, 2H), 3.56 – 3.38 (m, 3H), 2.82 (dd, J = 17.0, 6.9 Hz, 1H), 2.70 (dd, 
J = 16.8, 6.3 Hz, 1H), 1.84 – 1.70 (m, 3H), 1.01 (s, 9H), 0.84 (s, 9H), 0.81 (d, J = 7.0 Hz, 3H), 0.04 (s, 
3H), 0.03 (s, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 163.9, 150.5, 138.3, 135.6, 135.5, 133.0, 
130.8, 129.8, 128.4, 127.7, 127.7, 127.6, 127.6, 123.5, 83.3, 80.1, 73.9, 73.0, 71.8, 66.7, 65.2, 63.8, 
44.0, 32.4, 26.7, 25.8, 21.0, 19.2, 17.9, 12.5, −4.5, −4.8 ppm. IR (film): ṽ = 2954, 2931, 2878, 2857, 
1745, 1471, 1462, 1429, 1362, 1231, 1110, 1016, 972, 940, 863, 835, 776, 737, 702 cm
−1
. MS 
(ESIpos) m/z (%) = 846.5 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for C47H61N1O8Si2Na: 846.3831; 
found: 846.3836.  
 
(6R,11R,12R)-10-Acetoxy-12-(2-(benzyloxy)ethyl)-2,2,11,14,14,15,15-heptamethyl-3,3-diphenyl-
4,13-dioxa-3,14-disilahexadec-8-yn-6-yl 4-nitrobenzoate (170). A mixture of the propargylic 
alcohols described above (2.2:1 d.r., 39.0 mg, 47.4 µmol) was 
dissolved in CH2Cl2 (0.5 mL) and the solution cooled to 0 °C. 
Triethylamine (7.6 µL, 55 µmol), acetic anhydride (4.9 µL, 
52 µmol) and DMAP (0.3 mg, 2.4 µmol) were added successively and the mixture stirred for 1h at 
0 °C. The reaction was then quenched by addition of sat. NH4Cl solution (3 mL) and extracted with 
CH2Cl2 (3 x 3 mL). The combined organic extracts were dried over Na2SO4 and concentrated. 
Purification of the residue by flash chromatography (hexanes/EtOAc 9:1) yielded the desired 
propargylic acetate as a yellow oil (2.2:1 d.r., 29.5 mg, 76%). 
1
H NMR (400 MHz, CDCl3, only the 
peaks of the major isomer are listed): δ = 8.25 (dd, J = 8.7, 4.4 Hz, 2H), 8.14 (d, J = 8.5 Hz, 2H), 7.67 
Experimental section 185 
 
– 7.57 (m, 4H), 7.43 – 7.27 (m, 10H), 7.24 – 7.19 (m, 1H), 5.36 – 5.16 (m, 2H), 4.50 – 4.36 (m, 2H), 
3.95 – 3.85 (m, 2H), 3.43 (q, J = 6.9 Hz, 2H), 2.89 – 2.66 (m, 2H), 1.96 (s, 3H), 1.90 – 1.63 (m, 3H), 
1.02 (s, 9H), 0.91 (d, J = 6.8 Hz, 3H), 0.83 (s, 9H), −0.02 (s, 6H) ppm. 13C NMR (100 MHz, CDCl3, 
only the peaks of the major isomer are listed): δ = 169.7, 163.8, 150.5, 138.4, 135.5, 135.5, 133.0, 
133.0, 130.8, 129.8, 128.3, 127.8, 127.7, 127.5, 127.5, 127.5, 123.4, 80.8, 80.1, 73.7, 72.9, 69.9, 66.9, 
65.8, 63.7, 42.9, 34.5, 26.7, 25.8, 25.8, 20.9, 20.9, 19.2, 9.8, −4.4, −4.6 ppm. IR (film): ṽ = 2951, 
2930, 2857, 1737, 1733, 1608, 1529, 1472, 1428, 1349, 1271, 1231, 1113, 1103, 1015, 835, 776, 741, 
719, 702 cm
−1
. MS (ESIpos) m/z (%) = 888.45 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for 
C49H63N1O9Si2Na: 888.3934; found: 888.3936. 
 
General Procedure for Au(I)-catalyzed Meyer-Schuster rearrangement of propargylic acetate  
 
A stock solution of the catalyst was prepared as follows: A Schlenck tube is charged with Au(IPr)Cl 
(8.5 mg, 13.7 µmol) and dry AgSbF6 (3.7 mg, 13.7 µmol). THF (500 µL) was added and the resulting 
mixture stirred for 10 min. The white precipitate formed was allowed to settle and the supernatant 
used as catalyst solution (0.0274 M). 
A flame-dried Young tube was charged with a solution of propargylic acetate (1.00 equiv.) in 
THF/H2O (39:1, 22.3 µL per µmol substrate). An aliquot of the catalyst solution (0.06 equiv., 2.47 µL 
per µmol substrate) was added via syringe. The Young tube was sealed and placed in a pre-heated oil 
bath and stirred at 60 °C for 15 h. The reaction mixture was cooled to room temperature and 
concentrated. The residue was purified by flash chromatography (hexanes/EtoAc 19:1 to 14:1 to 9:1) 
to give the desired enone. 
 
(6R,11R,12R,E)-12-(2-(Benzyloxy)ethyl)-2,2,11,14,14,15,15-heptamethyl-8-oxo-3,3-diphenyl-4,13-
dioxa-3,14-disilahexadec-9-en-6-yl acetate (174). Obtained from compound 168 (10.0 mg, 
13.2 µmol) following the general procedure as a colorless oil 
(7.5 mg, 79%). [∝]𝐷
20 = +21.2 (c = 0.68, CH2Cl2). 
1
H NMR 
(400 MHz, CDCl3): δ = 7.66 – 7.60 (m, 4H), 7.43 – 7.26 (m, 11H), 
6.91 (dd, J = 16.2, 6.8 Hz, 1H), 6.06 (dd, J = 16.2, 1.4 Hz, 1H), 5.37 (td, J = 6.5, 3.4 Hz, 1H), 4.48 (d, 
J = 11.9 Hz, 1H), 4.43 (d, J = 11.9 Hz, 1H), 3.83 (dt, J = 8.3, 4.2 Hz, 1H), 3.81 – 3.71 (m, 2H), 3.49 (t, 
J = 6.4 Hz, 2H), 2.92 (dd, J = 6.5, 4.4 Hz, 2H), 2.54 – 2.43 (m, 1H), 1.95 (s, 3H), 1.75 (dtd, J = 14.3, 
7.4, 3.9 Hz, 1H), 1.05 – 0.99 (m, 12H), 0.86 (s, 9H), 0.02 (s, 6H) ppm. 13C NMR (125 MHz, CDCl3): δ 
= 196.8, 170.1, 150.1, 138.3, 135.6, 135.5, 135.4, 133.2, 130.1, 129.8, 129.7, 128.4, 127.8, 127.7, 
127.7, 127.6, 127.6, 73.0, 72.3, 70.7, 66.7, 64.5, 42.3, 40.3, 33.7, 26.8, 26.8, 25.9, 25.9, 21.0, 19.3, 
18.1, 14.1, −4.3, −4.6 ppm. IR (film): ṽ = 2955, 2930, 2857, 1742, 1673, 1627, 1472, 1462, 1428, 
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1363, 1238, 1188, 1112, 1045, 983, 939, 836, 775, 739, 701 cm
−1
. MS (ESIpos) m/z (%) = 697.5 (100 
(M+Na
+
)). HRMS (ESIpos): m/z: calcd for C42H60O6Si2Na: 739.3821; found: 739.3823. 
 
(6R,11R,12R,E)-12-(2-(benzyloxy)ethyl)-2,2,11,14,14,15,15-heptamethyl-8-oxo-3,3-diphenyl-4,13-
dioxa-3,14-disilahexadec-9-en-6-yl benzoate (175). Obtained from compound 169 (42.0 mg, 
51.2 µmol) following the general procedure as a colorless oil 
(29.2 mg, 73%). [∝]𝐷
20 = +16.4 (c = 0.97, CH2Cl2). 
1
H NMR 
(400 MHz, CDCl3): δ = 7.98 – 7.91 (m, 2H), 7.60 – 7.54 (m, 4H), 
7.39 – 7.25 (m, 10H), 7.23 – 7.18 (m, 3H), 6.90 (dd, J = 16.2, 6.8 Hz, 1H), 6.06 (dd, J = 16.1, 1.4 Hz, 
1H), 5.60 (tt, J = 6.7, 4.0 Hz, 1H), 4.43 (d, J = 11.9 Hz, 1H), 4.38 (d, J = 11.9 Hz, 1H), 3.87 (dd, J = 
4.0, 2.2 Hz, 2H), 3.78 (dt, J = 8.3, 4.3 Hz, 1H), 3.43 (t, J = 6.0 Hz, 2H), 3.08 (dd, J = 16.3, 6.4 Hz, 
1H), 3.03 (dd, J = 16.2, 6.7 Hz, 1H), 2.48 – 2.39 (m, 1H), 1.69 (dtd, J = 14.1, 7.1, 4.2 Hz, 1H), 1.54 
(ddt, J = 13.9, 8.0, 5.8 Hz, 1H), 0.98 (s, 9H), 0.95 (d, J = 6.8 Hz, 3H), 0.81 (s, 9H), −0.03 (s, 6H) ppm. 
13
C NMR (125 MHz, CDCl3): δ = 196.8, 165.6, 150.2, 138.4, 135.5, 135.4, 133.1, 132.8, 130.3, 130.1, 
129.7, 129.7, 129.7, 128.3, 128.2, 127.7, 127.6, 127.5, 73.0, 72.3, 71.4, 66.7, 64.6, 42.2, 40.4, 33.7, 
26.8, 25.8, 19.2, 18.1, 14.1, −4.4, −4.6 ppm. IR (film): ṽ = 2955, 2929, 2857, 1720, 1673, 1626, 1472, 
1452, 1428, 1361, 1314, 1270, 1176, 1110, 1026, 983, 938, 836, 775, 739, 701 cm
−1
. MS (EI) m/z (%) 
= 721 (3), 599 (8), 492 (12), 435 (4), 361 (4), 303 (11), 280 (10), 279 (45), 174 (15), 173 (100), 171 
(10), 135 (15), 131 (71), 117 (8), 105 (27), 101 (13), 91 (98), 73 (24). HRMS (ESIpos): m/z: calcd for 
C47H62O6Si2Na: 801.3977; found: 801.3976. 
 
(6R,11R,12R,E)-12-(2-(Benzyloxy)ethyl)-2,2,11,14,14,15,15-heptamethyl-8-oxo-3,3-diphenyl-4,13-
dioxa-3,14-disilahexadec-9-en-6-yl 4-nitrobenzoate (176). Obtained from compound 170 (31.0 mg, 
35.8 µmol) following the general procedure as a colorless oil 
(21.2 mg, 73%). [∝]𝐷
20 = +8.8 (c = 0.94, CH2Cl2). 
1
H NMR 
(400 MHz, CDCl3): δ = 8.23 (d, J = 8.4 Hz, 2H), 8.10 (d, J = 
8.4 Hz, 2H), 7.59 (ddt, J = 8.1, 2.7, 1.3 Hz, 4H), 7.42 – 7.25 (m, 11H), 6.95 (dd, J = 16.1, 6.8 Hz, 1H), 
6.09 (dd, J = 16.1, 1.5 Hz, 1H), 5.68 (td, J = 6.4, 3.2 Hz, 1H), 4.48 (d, J = 11.9 Hz, 1H), 4.43 (d, J = 
11.8 Hz, 1H), 3.92 (d, J = 4.0 Hz, 2H), 3.84 (dt, J = 8.3, 4.2 Hz, 1H), 3.49 (t, J = 6.5 Hz, 2H), 3.09 (d, 
J = 6.4 Hz, 2H), 2.55 – 2.44 (m, 1H), 1.75 (dtd, J = 14.3, 7.1, 4.2 Hz, 1H), 1.64 – 1.63 (m, 1H), 1.01 
(d, J = 8.0 Hz, 12H), 0.85 (s, 9H), 0.02 (s, 3H), 0.01 (s, 3H) ppm. 
13
C NMR (125 MHz, CDCl3): δ = 
196.3, 163.7, 150.5, 150.5, 138.3, 135.7, 135.5, 135.4, 133.0, 133.0, 130.7, 129.9, 129.8, 129.8, 128.4, 
127.8, 127.7, 127.7, 127.6, 127.6, 123.4, 73.0, 72.3, 72.3, 66.8, 64.5, 42.3, 40.2, 33.7, 26.8, 25.8, 19.2, 
18.1, 14.1, −4.4, −4.6 ppm. IR (film): ṽ = 2954, 2929, 2857, 1726, 1672, 1528, 1471, 1462, 1348, 
1318, 1270, 1188, 1101, 1029, 1014, 982, 939, 871, 836, 775, 737, 719, 700, 614 cm
−1
. MS (ESIpos) 
m/z (%) = 846.5 (100 (M+Na
+
)). HRMS (ESIpos): m/z: calcd for C47H61N1O8Si2Na: 846.3828; found: 
846.3824.  
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(R)-4-((tert-Butyldiphenylsilyl)oxy)-1-morpholino-3-((trimethylsilyl)oxy)butan-1-one (180).  
According to a modified protocol from Jacobsen et. al.,
[173]
 a flame-dried 
two-necked round-bottom flask was charged with Co2(CO)8 (274 mg, 
0.8 mmol). The flask was evacuated (1 x 10
−1
 mbar)
[247]
 and backfilled with 
CO (1 atm, from a balloon, 3 cycles). Dry EtOAc (15 mL) was introduced and the suspension stirred 
for 10 min, after which freshly distilled N-trimethylsilyl morpholine (2.66 mL, 15.0 mmol) and 
silylated epoxide 160 (3.12 g, 10.0 mmol) were added via syringe. The brown mixture was vigorously 
stirred under a CO atmosphere (balloon) for 15 h, before it was concentrated. The residue was quickly 
purified by flash chromatography (hexanes/EtOAc 5:1 to 4:1) to yield the desired morpholine amide as 
a colorless oil (3.70 g, 74%). [∝]𝐷
20 = +21.1 (c = 0.915, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 
7.65 (m, 4H), 7.43 – 7.34 (m, 6H), 4.25 (ddt, J = 8.5, 5.9, 4.3 Hz, 1H), 3.63 (m, 7H), 3.56 – 3.44 (m, 
3H), 2.62 (dd, J = 14.4, 4.0 Hz, 1H), 2.53 (dd, J = 14.4, 8.3 Hz, 1H), 1.04 (s, 9H), 0.02 (s, 9H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 170.1, 135.6, 135.6, 133.4, 129.7, 129.7, 127.7, 127.7, 70.7, 67.8, 
66.9, 66.7, 46.5, 41.9, 37.5, 26.8, 26.8, 19.2, 0.1 ppm. IR (film): ṽ = 2958, 2930, 2857, 1644, 1460, 
1428, 1249, 1186, 1111, 1070, 1033, 959, 840, 824, 741, 701, 612 cm
−1
. MS (EI) m/z (%) = 484 (11), 
444 (13), 443 (36), 442 (100), 364 (23), 271 (13), 230 (6), 193 (14), 135 (5), 114 (7), 73 (4). HRMS 
(ESIpos): m/z: calcd for C27H41NO4Si2Na: 522.2466; found: 522.2465. 
 
(S)-4-((tert-Butyldiphenylsilyl)oxy)-1-morpholino-3-((trimethylsilyl)oxy)butan-1-one (ent-180). 
Prepared analogously from epoxide ent-160 (3.12 g, 10.0 mmol) as a pale 
yellow oil (3.67 g, 74%). 
 
 
(R)-6-((tert-butyldiphenylsilyl)oxy)-5-hydroxyhex-1-en-3-one (179). A solution of vinylmagnesium 
chloride (1.6 M in THF, 0.65 mL, 1.03 mmol) was added dropwise over 10 min at 
−78 °C to a solution of amide 180 (246 mg, 0.492 mmol) in THF (5 mL) and the 
resulting mixture was warmed to 0 °C for 2 h. The mixture was cooled to 78 °C and slowly 
transferred via canula into a vigorously stirred aq. sat. NH4Cl solution (10 mL). The reaction flask was 
rinsed with EtOAc (2 x 5 mL), which was also transferred to the aqueous layer. The phases were 
separated and the aqueous phase was extracted with EtOAc (3 x 10 mL). The combined organic layers 
were dried over Na2SO4 and concentrated. The residue was purified by flash chromatography 
(hexanes/EtOAc 4:1) to give the desired enone as a colorless oil (74.6 mg, 41%). [∝]𝐷
20 = +20.1 (c = 
0.46, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.66 – 7.60 (m, 4H), 7.45 – 7.33 (m, 6H), 6.34 (dd, J 
= 17.8, 10.5 Hz, 1H), 6.20 (d, J = 17.6 Hz, 1H), 5.86 (d, J = 10.5 Hz, 1H), 4.22 (dd, J = 8.7, 3.3 Hz, 
1H), 3.72 – 3.58 (m, 2H), 2.91 (s, 1H), 2.78 (d, J = 6.0 Hz, 2H), 1.05 (s, 9H) ppm. 13C NMR 
(100 MHz, CDCl3): δ = 200.0, 136.8, 135.5, 135.5, 133.1, 133.1, 129.8, 129.0, 127.8, 68.3, 67.0, 42.3, 
26.9, 19.3 ppm. IR (film): ṽ = 3459, 2952, 2931, 2858, 1681, 1614, 1472, 1428, 1400, 1112, 997, 962, 
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824, 741, 702 cm
−1
. MS (ESIpos) m/z (%) = 391.1 (100 (M+Na
+
)), 759.2 (79 (2M+Na
+
)). HRMS 
(ESIpos): m/z: calcd for C22H28O3Si1Na: 391.1700; found: 391.1698. 
 
(R)-7-((tert-Butyldiphenylsilyl)oxy)-6-hydroxyhept-2-en-4-one (181). A solution of 
propenylmagnesium bromide (0.5 M in THF, 8.6 mL, 4.30 mmol) was added 
dropwise over 10 min at 0 °C to a solution of amide 180 (565 mg, 1.131 mmol) 
in THF (9 mL) and the resulting mixture was stirred at 0 °C for 2 h. The 
mixture was cooled to 78 °C and slowly transferred via canula into a vigorously stirred aq. solution 
of HCl (0.75 M, 130 mL). The reaction flask was rinsed with EtOAc (2 x 10 mL), which was also 
transferred to the aqueous acid layer. After stirring for 15 min at ambient temperature, EtOAc (20 mL) 
was added, the phases were separated and the aqueous phase extracted with EtOAc (3 x 40 mL). The 
combined organic layers were washed with brine (50 mL), dried over Na2SO4 and concentrated. The 
residue was purified by flash chromatography (hexanes/EtOAc 9:1 to 7.5:1 to 6:1) to give the desired 
enone as an inconsequential mixture of olefin isomers (E/Z = 2:1, 360 mg, 83%). 
1
H NMR (300 MHz, 
CDCl3, only the peaks assigned to the major isomer are given): δ = 7.70 – 7.57 (m, 4H), 7.47 – 7.31 
(m, 6H), 6.84 (dq, J = 15.7, 6.8 Hz, 1H), 6.11 (dq, J = 15.8, 1.6 Hz, 1H), 4.25 – 4.14 (m, 1H), 3.65 (d, 
J = 5.5 Hz, 2H), 3.02 (d, J = 4.1 Hz, 1H), 2.72 (d, J = 5.9 Hz, 2H), 1.89 (dd, J = 6.9, 1.7 Hz, 3H), 1.05 
(s, 9H) ppm. 
13
C NMR (100 MHz, CDCl3 only the peaks assigned to the major isomer are given): δ = 
199.6, 143.7, 135.5, 135.5, 133.2, 133.1, 132.3, 129.8, 127.7, 68.5, 67.0, 42.8, 26.8, 19.2, 18.3 ppm. 
IR (film): ṽ = 3462, 3071, 2930, 2587, 1680, 1663, 1628, 1472, 1428, 1362, 1188, 1112, 969, 823, 
741, 702 cm
−1
. MS (ESIpos) m/z (%) = 405.2 (100 (M+Na
+
)), 787.3 (85 ((2M+Na
+
). HRMS (ESIpos): 
m/z: calcd for C23H30O3SiNa: 405.1856; found: 405.1856. 
 
(S)-7-((tert-Butyldiphenylsilyl)oxy)-6-hydroxyhept-2-en-4-one (ent-181). Prepared analogously 
from morpholine amide ent-180 (3.67 g, 10.0 mmol) as a pale yellow oil (E/Z = 
2:1, 2.21 g, 79%). 
 
 
(((3R,4R)-1-(Benzyloxy)-4-methylhex-5-en-3-yl)oxy)triethylsilane (182). NEt3 (0.951 mL, 
6.86 mmol) and TESCl (1.05 mL, 6.29 mmol) were added via syringe at 0 °C to a 
solution of alcohol 157 (1.26 g, 5.72 mmol) in CH2Cl2 (28.6 mL). DMAP (34.9 mg, 
0.286 mmol) was then introduced and the mixture stirred for 90 min at 0 °C and for 
another 30 min at RT before the reaction was quenched with sat. NH4Cl-solution. The aqueous phase 
was extracted with CH2Cl2 (3 x 30 mL), the combined extracts were washed with brine, dried over 
Na2SO4 and concentrated. Purification of the residue by flash chromatography (hexanes/EtOAc 35:1) 
yielded the target silyl ether as a colorless oil (1.72 g, 90%). [∝]𝐷
20 = +38.6 (c = 1.13, CH2Cl2). 
1
H 
NMR (400 MHz, CDCl3): δ = 7.39 – 7.24 (m, 5H), 5.86 (ddd, J = 17.3, 10.5, 6.6 Hz, 1H), 5.03 – 4.95 
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(m, 2H), 4.50 (d, J = 11.6 Hz, 1H), 4.45 (d, J = 11.8 Hz, 1H), 3.74 (dt, J = 8.2, 4.3, 4.2 Hz, 1H), 3.53 
(t, J = 6.7 Hz, 2H), 2.35 – 2.22 (m, 1H), 1.83 – 1.70 (m, 1H), 1.70 – 1.59 (m, 1H), 0.97 (d, J = 6.8 Hz, 
3H), 0.94 (dd, J = 7.7 Hz, 9H), 0.58 (q, J = 8.0 Hz, 6H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 140.8, 
138.6, 128.3, 127.7, 127.5, 114.3, 73.2, 73.0, 67.2, 43.4, 33.7, 15.0, 7.0, 5.2 ppm. IR (film): ṽ = 2954, 
2911, 2876, 1455, 1414, 1363, 1238, 1091, 1004, 911, 840, 725, 695 cm
−1
. MS (EI) m/z (%) = 305 (8), 
279 (17), 173 (33), 159 (6), 117 (9), 115 (10), 91 (100), 87 (9), 59 (5). HRMS (ESIpos): m/z: calcd for 
C20H34O2SiNa: 357.2220; found: 357.2222. 
 
(((3S,4S)-1-(Benzyloxy)-4-methylhex-5-en-3-yl)oxy)triethylsilane (ent-182). 
Prepared analogously from alcohol ent-157 (1.70 g, 7.72 mmol) as a colorless oil 
(2.46 g, 91%). 
 
(6R,11R,12R,E)-12-(2-(Benzyloxy)ethyl)-14,14-diethyl-6-hydroxy-2,2,11-trimethyl-3,3-diphenyl-
4,13-dioxa-3,14-disilahexadec-9-en-8-one (183). A flame-dried two necked round-bottom flask 
equipped with a reflux condenser and a septum was charged with a 
solution of olefin 182 (495 mg, 1.48 mmol) in CH2Cl2 (15 mL). 
Zhan-catalyst 1B C8 (39.4 mg, 53.7 µmol) was added and the 
resulting mixture was heated to 45 °C while a solution of enone 181 (514 mg, 1.34 mmol) in CH2Cl2 
(2 mL) was added dropwise through the septum over the course of 1 h via syringe pump. After 16 h, 
the mixture was cooled to RT, another batch of Zhan-catalyst 1B C8 (19.7 mg, 26.9 µmol) was added 
and stirring continued at 45 °C. This procedure was repeated once again after additonal stirring for 
12 h. After an overall reaction time of 48 h, the mixture was concentrated and the residue purified by 
flash chromatography (hexanes/EtOAc 14:1 to 12:1 to 9:1) to yield the title compound as a pale 
orange oil (716 mg, 79%). [∝]𝐷
20 = +41.2 (c = 0.96, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.67 – 
7.60 (ddd, J = 7.9, 3.8, 1.7 Hz, 4H), 7.44 – 7.34 (m, 6H), 7.34 – 7.25 (m, 5H), 6.92 (dd, J = 16.2, 
6.8 Hz, 1H), 6.06 (dd, J = 16.2, 1.5 Hz, 1H), 4.48 (d, J = 11.9 Hz, 1H), 4.43 (d, J = 11.9 Hz, 1H), 4.25 
– 4.16 (m, 1H), 3.85 (dt, J = 8.3, 4.2 Hz, 1H), 3.64 (dd, J = 5.5, 1.5 Hz, 2H), 3.55 – 3.43 (m, 2H), 3.04 
(d, J = 3.9 Hz, 1H), 2.82 – 2.66 (m, 2H), 2.53 – 2.41 (m, 1H), 1.79 – 1.69 (m, 1H), 1.62 – 1.52 (m, 
1H), 1.05 (s, 9H), 1.01 (d, J = 6.9 Hz, 3H), 0.92 (t, J = 7.9 Hz, 9H), 0.57 (q, J = 8.0 Hz, 6H) ppm. 
13
C 
NMR (100 MHz, CDCl3): δ = 199.8, 150.5, 138.4, 135.5, 135.5, 133.2, 133.2, 130.4, 129.8, 128.3, 
127.7, 127.7, 127.6, 73.0, 72.4, 68.5, 67.1, 66.8, 42.6, 42.6, 33.9, 26.9, 19.3, 14.2, 7.0, 5.1 ppm. IR 
(film): ṽ = 3512, 3071, 2955, 2932, 2875, 1664, 1624, 1456, 1427, 1362, 1238, 1186, 1112, 1007, 823, 
739, 701 cm
−1
. MS (ESIpos) m/z (%) = 697.5 (100 (M+Na
+
)). HRMS (ESIpos): m/z: calcd for 
C40H58O5Si2Na: 697.3715; found: 697.3720. 
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(6S,11S,12S,E)-12-(2-(Benzyloxy)ethyl)-14,14-diethyl-6-hydroxy-2,2,11-trimethyl-3,3-diphenyl-
4,13-dioxa-3,14-disilahexadec-9-en-8-one (ent-183). Prepared analogously from ent-182 (2.25 g, 
6.43 mmol) and enone ent-181 (2.05 g, 5.36 mmol) as a pale yellow 
oil (2.65 g, 73%) along with recovered enone (255 mg, 12%). 
 
 
(6R,8R,11R,12R,E)-12-(2-(Benzyloxy)ethyl)-14,14-diethyl-8-hydroxy-2,2,11-trimethyl-3,3-
diphenyl-4,13-dioxa-3,14-disilahexadec-9-en-6-yl isobutyrate (184). A freshly prepared
 
solution of 
SmI2 (0.096 M in THF, 3.80 mL, 0.363 mmol) was slowly added at 
50 °C alongside the cold wall of the flask to a solution of enone 
24 (700 mg, 1.04 mmol) and freshly distilled isobutyraldehyde 
(473 µL, 5.19 mmol) in degassed THF (9.4 mL). The mixture was 
stirred for 1 h at 50 °C before it was poured into sat. aq. NaHCO3 solution (65 mL). The mixture was 
diluted with EtOAc (40 mL overall) and vigorously stirred until it reached ambient temperature. The 
phases were separated and the aqueous layer was extracted with EtOAc (3 x 40 mL). The combined 
extracts were washed with brine (60 mL), dried over Na2SO4 and concentrated. During concentration, 
a small amount of SiO2 was added and the crude product loaded on a silica gel column, from which 
the title compound was eluted with hexanes/EtOAc (12:1 to 9:1); colorless oil (598 mg, 78%). [∝]𝐷
20 = 
+27.2 (c = 1.32, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.67 – 7.61 (m, 4H), 7.44 – 7.27 (m, 11H), 
5.69 (ddd, J = 15.8, 6.9, 1.2 Hz, 1H), 5.43 (ddd, J = 15.6, 6.2, 1.3 Hz, 1H), 5.16 (ddt, J = 9.4, 5.5, 
4.1 Hz, 1H), 4.47 (d, J = 11.9 Hz, 1H), 4.43 (d, J = 11.9 Hz, 1H), 3.99 (ddd, J = 9.8, 6.3, 3.5 Hz, 1H), 
3.71 (m, 3H), 3.50 (dd, J = 7.4, 5.9 Hz, 2H), 2.73 (br s, 1H), 2.56 (hep, J = 7.0 Hz, 1H), 2.33 – 2.21 
(m, 1H), 1.77 – 1.53 (m, 4H), 1.18 (d, J = 7.2 Hz, 3H), 1.16 (d, J = 7.2 Hz, 3H), 1.02 (s, 9H), 0.95 – 
0.89 (m, 12H), 0.56 (q, J = 8.1 Hz, 6H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 178.0, 138.5, 135.6, 
135.5, 133.3, 133.3, 133.2, 131.8, 129.8, 129.7, 128.3, 127.7, 127.7, 127.5, 73.2, 73.0, 71.9, 68.3, 
67.2, 65.7, 42.0, 39.0, 34.2, 33.7, 26.7, 19.2, 19.2, 19.0, 15.3, 7.0, 5.2 ppm. IR (film): ṽ = 3502, 2956, 
2932, 2875, 1732, 1457, 1428, 1388, 1362, 1239, 1196, 1160, 1111, 1007, 975, 823, 738, 701, 612 
cm
−1
. MS (ESIpos) m/z (%) = 769.5 (100 (M+Na
+
)). HRMS (ESIpos): m/z: calcd for C44H66O6Si2Na: 
769.4290; found: 769.4291. 
 
(6S,8S,11S,12S,E)-12-(2-(Benzyloxy)ethyl)-14,14-diethyl-8-hydroxy-2,2,11-trimethyl-3,3-
diphenyl-4,13-dioxa-3,14-disilahexadec-9-en-6-yl isobutyrate 
(ent-184). Prepared analogously from-hydroxy ketone ent-183 
(2.30 g, 3.41 mmol) as a colorless oil (1.88 g, 74%). 
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(6R,8R,11R,12R,E)-12-(2-(Benzyloxy)ethyl)-8-((tert-butyldiphenylsilyl)oxy)-14,14-diethyl-2,2,11-
trimethyl-3,3-diphenyl-4,13-dioxa-3,14-disilahexadec-9-en-6-yl isobutyrate. TBDPSCl (284 µL, 
1.09 mmol) was added at 0 °C to a solution of the homoallylic 
alcohol 184 (584 mg, 0.782 mmol) and imidazole (90.5 mg, 
1.33 mmol) in CH2Cl2 (5.2 mL). After 5 min, the mixture was 
allowed to reach ambient temperature and stirring was continued 
for 17 h before the reaction was quenched with sat. NH4Cl solution (25 mL). The aqueous phase was 
extracted with CH2Cl2 (4 x 20 mL) and the combined organic extracts were dried over Na2SO4 and 
concentrated. The residue was purified by flash chromatography (hexanes/EtOAc 39:1) to afford the 
title compound as a colorless syrup (671 mg, 87%). [∝]𝐷
20 = +36.7 (c = 1.00, CH2Cl2). 
1
H NMR 
(400 MHz, CDCl3): δ = 7.67 – 7.60 (m, 8H), 7.44 – 7.25 (m, 17H), 5.34 (dd, J = 15.9, 6.8 Hz, 1H), 
5.27 (dd, J = 15.8, 5.5 Hz, 1H), 5.20 – 5.10 (m, 1H), 4.51 – 4.46 (d, J = 11.9 Hz, 1H), 4.42 (d, J = 
11.9 Hz, 1H), 4.14 (td, J = 7.5, 5.3 Hz, 1H), 3.67 – 3.53 (m, 3H), 3.49 – 3.36 (m, 2H), 2.43 (hep, J = 
7.0 Hz, 1H), 2.05 – 1.96 (m, 1H), 1.89 (ddd, J = 14.0, 7.7, 4.9 Hz, 1H), 1.77 (ddd, J = 14.1, 7.9, 
5.3 Hz, 1H), 1.62 – 1.52 (m, 1H), 1.45 – 1.34 (m, 1H), 1.10 (d, J = 6.9 Hz, 6H), 1.02 (s, 18H), 0.89 (t, 
J = 7.9 Hz, 9H), 0.73 (d, J = 6.9 Hz, 3H), 0.52 (q, J = 7.9 Hz, 6H) ppm. 
13
C NMR (100 MHz, CDCl3): 
δ = 176.1, 138.7, 136.0, 135.9, 135.6, 135.5, 134.7, 134.0, 133.5, 133.5, 133.3, 129.6, 129.6, 129.4, 
129.2, 128.3, 127.6, 127.6, 127.4, 127.2, 73.0, 72.9, 72.0, 71.4, 67.2, 65.2, 41.7, 39.8, 34.1, 33.5, 27.0, 
26.8, 19.2, 19.0, 18.9, 15.0, 7.0, 5.1 ppm. IR (film): ṽ = 2956, 2932, 2875, 2858, 1734, 1471, 1427, 
1387, 1361, 1259, 1191, 1157, 1105, 1007, 977, 822, 736, 698 cm
−1
. MS (EI) m/z (%) = 927 (2), 820 
(2), 561 (2), 509 (6), 493 (7), 469 (4), 467 (4), 377 (5), 322 (3), 319 (3), 280 (22), 279 (97), 269 (26), 
199 (16), 174 (15), 173 (100), 171 (14), 135 (22), 131 (44), 91 (57), 73 (16). HRMS (ESIpos): m/z: 
calcd for C60H84O6Si3Na: 1007.5468; found: 1007.5473. 
 
(6R,8R,11R,12R,E)-12-(2-(Benzyloxy)ethyl)-8-((tert-butyldiphenylsilyl)oxy)-14,14-diethyl-2,2,11-
trimethyl-3,3-diphenyl-4,13-dioxa-3,14-disilahexadec-9-en-6-yl isobutyrate. Prepared analogously 
fromalcohol ent-184 (1.82 g, 2.44 mmol) as a colorless oil (1.96 g, 
82%). 
 
 
 
(6R,8R)-8-((3R,4R,E)-6-(Benzyloxy)-4-hydroxy-3-methylhex-1-en-1-yl)-2,2,11,11-tetramethyl-
3,3,10,10-tetraphenyl-4,9-dioxa-3,10-disiladodecan-6-yl isobutyrate (185). Camphorsulfonic acid 
(47.7 mg, 0.205 mmol) was added at 0 °C to a solution of the tris-
silylether described above (675 mg, 0.685 mmol) in CH2Cl2/MeOH 
(2:1, 12.6 mL). The resulting mixture was stirred for 90 min before 
the reaction was carefully quenched with sat. NaHCO3 (40 mL) 
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solution. After extraction with CH2Cl2 (3 x 40 mL), the combined organic phases were washed with 
brine, dried over Na2SO4 and concentrated to give a colorless oil, which was purified by flash 
chromatography (hexanes/EtOAc 8:1) to give the title compound as a colorless oil (576 mg, 97%). 
[∝]𝐷
20 = +22.9 (c = 1.32, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.64 – 7.57 (m, 8H), 7.43 – 7.25 
(m, 18H), 5.35 (dd, J = 15.5, 7.9 Hz, 1H), 5.14 – 5.06 (m, 1H), 4.98 (dd, J = 15.5, 7.9 Hz, 1H), 4.45 (s, 
2H), 4.08 (q, J = 7.0 Hz, 1H), 3.57 (d, J = 4.8 Hz, 2H), 3.51 – 3.37 (m, 2H), 3.30 (br t, 1H), 2.51 – 
2.37 (m, 2H), 1.91 (ddd, J = 11.5, 7.4, 4.6 Hz, 2H), 1.73 (dt, J = 13.6, 6.5 Hz, 1H), 1.44 – 1.29 (m, 
3H), 1.09 (d, J = 6.9 Hz, 6H), 0.99 (d, J = 7.7 Hz, 18H), 0.79 (d, J = 6.8 Hz, 3H) ppm. 
13
C NMR 
(100 MHz, CDCl3): 176.2, 138.0, 135.9, 135.9, 135.6, 135.5, 134.6, 134.2, 133.6, 133.4, 133.4, 132.8, 
129.6, 129.6, 129.6, 129.3, 128.4, 127.7, 127.6, 127.5, 127.3, 74.0, 73.3, 72.0, 69.3, 65.2, 42.3, 39.7, 
34.1, 33.5, 26.9, 26.7, 19.2, 19.0, 19.0, 15.0 ppm. IR (film): ṽ = 3511, 2960, 2931, 2858, 1734, 1472, 
1427, 1389, 1361, 1260, 1193, 1158, 1111, 1082, 976, 822, 739, 701 cm
−1
. MS (EI) m/z (%) = 527 (5), 
467 (8), 393 (28), 363 (27), 319 (11), 271 (12), 270 (18), 269 (81), 209 (11), 200 (13), 199 (71), 197 
(19), 135 (48), 108 (21), 91 (100), 81 (11), 43 (15). HRMS (ESIpos): m/z: calcd for C54H70O6Si2Na: 
870.4711; found: 870.4715. 
 
(6R,8R)-8-((3R,4R,E)-6-(Benzyloxy)-4-hydroxy-3-methylhex-1-en-1-yl)-2,2,11,11-tetramethyl-
3,3,10,10-tetraphenyl-4,9-dioxa-3,10-disiladodecan-6-yl isobutyrate (ent-185). Prepared 
analogously from thetris-silylether described above (1.93 g, 
1.96 mmol) as a colorless oil (1.69 g, 99%). 
 
 
 
(6R,8R)-8-((2S,3R,4S,5R)-5-(2-(Benzyloxy)ethyl)-4-methyl-3-(phenylselanyl) tetrahydrofuran-2-
yl)-2,2,11,11-tetramethyl-3,3,10,10-tetraphenyl-4,9-dioxa-3,10-disiladodecan-6-yl isobutyrate  
(186). According to a modified protocol from Denmark,
[181a]
 a 
solution of alcohol 185 (574 mg, 0.659 mmol) in CH2Cl2 (10 mL) 
was prepared and cooled to 40 °C. N-(Phenylseleno)phthalimide 
(239 mg, 0.791 mmol) followed by a solution of triphenylphosphine 
sulfide (23.3 mg, 79.1 µmol) and trifluoroacetic acid (56.7 µL, 0.791 mmol) in CH2Cl2 (1 mL) were 
added via syringe over 5 min. After complete addition, the mixture was allowed to warm to 20 °C 
and stirring was continued for 3 h before the mixture was poured into a stirred emulsion of sat. aq. 
NaHCO3 solution and CH2Cl2 (1:1, 40 mL). The aqueous phase was extracted with CH2Cl2 (3 x 
15 mL), the combined organic extracts were dried over Na2SO4 and concentrated. 
1
H NMR and HPLC 
analysis of the crude mixture revealed a d.r. of 14:1. The residue was purified by flash 
chromatography (hexanes/EtOAc 100:0 to 49:1 to 29:1 to 24:1) to give the cyclized product as a 
colorless oil (560 mg, 83% yield, 14:1 d.r.). An analytically pure sample was obtained by preparative 
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HPLC (Triart C18 5 µm, 12 nm, 150x30 mm, 100% MeCN, 35 °C, 35bar, 35mL/min). [∝]𝐷
20 = +1.1 (c 
= 0.93, CH2Cl2). 
1
H NMR (600 MHz, CDCl3): δ = 7.69 – 7.66 (m, 2H), 7.64 – 7.60 (m, 6H), 7.44 – 
7.24 (m, 19H), 7.23 – 7.16 (m, 3H), 5.15 – 5.09 (m, 1H), 4.32 (s, 2H), 3.85 (ddd, J = 8.2, 5.5, 5.0 Hz, 
1H), 3.68 (ddd, J = 6.9, 6.9, 3.8 Hz, 1H), 3.63 (dd, J = 6.5, 6.5 Hz, 1H), 3.52 (dd, J = 10.9, 4.1 Hz, 
1H), 3.45 (dd, J = 10.9, 5.4 Hz, 1H), 3.14 – 3.09 (m, 2H), 2.93 (dd, J = 6.3, 3.5 Hz, 1H), 2.40 (hept, J 
= 7.0 Hz, 1H), 2.16 (ddd, J = 14.6, 9.8, 3.9 Hz, 1H), 2.07 (ddq, J = 12.4, 7.1, 3.6 Hz, 1H), 1.73 (ddd, J 
= 14.7, 7.1, 2.8 Hz, 1H), 1.49 – 1.44 (m, 2H), 1.07 (d, J = 7.0 Hz, 3H), 1.05 (d, J = 7.0 Hz, 3H), 1.01 
(s, 9H), 0.98 (s, 9H) 0.49 (d, J = 7.1 Hz, 3H) ppm. 
13
C NMR (150 MHz, CDCl3): δ = 176.0, 138.7, 
136.1, 135.8, 135.6, 135.6, 134.4, 134.4, 133.6, 133.4, 133.3, 129.6, 129.6, 129.3, 129.2, 129.1, 128.3, 
127.7, 127.7, 127.6, 127.4, 127.3, 127.1, 85.8, 72.9, 72.7, 71.6, 67.9, 65.3, 49.6, 44.6, 36.1, 34.1, 30.6, 
29.7, 27.1, 26.7, 19.7, 19.2, 19.0, 18.8, 14.9 ppm. IR (film): ṽ = 2961, 2929, 2855, 1733, 1472, 1427, 
1361, 1260, 1192, 1111, 1021, 821, 802, 738, 701 cm
−1
. MS (EI) m/z (%) = 970 (6), 969 (9), 883 (9), 
882 (13), 881 (22), 880 (8), 879 (11), 805 (11), 724 (11), 723 (11), 563 (11), 467 (10), 361 (25), 349 
(11), 319 (13), 296 (11), 295 (45), 270 (23), 269 (100), 241 (14), 239 (34), 200 (13), 199 (73), 197 
(30), 136 (12), 135 (93), 91 (84), 43 (13). HRMS (ESIpos): m/z: calcd for C60H74O6Si2SeNa: 
1049.4081; found: 1049.4072. 
 
(6R,8R)-8-((2R,3S,4S,5R)-5-(2-(Benzyloxy)ethyl)-4-methyl-3-(phenylselanyl) tetrahydrofuran-2-
yl)-2,2,11,11-tetramethyl-3,3,10,10-tetraphenyl-4,9-dioxa-3,10-disiladodecan-6-yl isobutyrate 
(187). Obtained as the minor isomer by preparative HPLC 
(conditions see above) as a colorless oil. 
1
H NMR (600 MHz, 
CDCl3): δ = 7.70 – 7.67 (m, 3H), 7.63 – 7.60 (m, 2H), 7.60 – 7.56 
(m, 4H), 7.53 – 7.49 (m, 1H), 7.40 – 7.24 (m, 17H), 7.23 – 7.14 (m, 
3H), 5.06 – 4.99 (m, 1H), 4.48 (d, J = 13.8 Hz, 2H), 4.04 (ddd, J = 7.9, 4.1, 1.4, 1H), 3.98 (ddd, J = 
8.8, 4.5, 4.5 Hz, 1H), 3.92 (dd, J = 9.9, 1.3 Hz, 1H), 3.67 (dd, J = 9.9, 6.2 Hz, 1H), 3.59 (ddd, J = 9.1, 
7.7, 5.4 Hz, 1H), 3.53 (dd, J = 11.0, 3.9 Hz, 1H), 3.50 (dd, J = 9.2, 7.2 Hz, 1H), 3.41 (dd, J = 10.9, 
5.2 Hz, 1H), 2.27 (hept, J = 7.0 Hz, 1H), 2.23 – 2.16 (m, 1H), 1.99 (ddd, J = 14.5, 9.9, 4.3 Hz, 1H), 
1.84 – 1.76 (m, 2H), 1.73 (ddd, J = 13.7, 7.3, 5.0 Hz, 1H), 1.01 (s, 9H) 1.00 (d, J = 7.0 Hz, 3H), 0.99 
(d, J = 7.0 Hz, 3H), 0.97 (s, 9H), 0.86 (d, J = 7.1 Hz, 3H) ppm. 
13
C NMR (150 MHz, CDCl3): δ = 
176.1, 138.5, 136.1, 136.0, 135.6, 135.5, 134.2, 133.5, 133.4, 133.4, 133.1, 132.5, 130.9, 130.6, 129.6, 
129.6, 129.4, 129.0, 128.8, 128.4, 127.7, 127.6, 127.6, 127.5, 127.3, 127.0, 83.3, 78.7, 73.0, 71.9, 
71.6, 68.0, 65.3, 48.1, 40.2, 34.0, 33.6, 31.9, 27.1, 26.7, 19.4, 19.2, 19.0, 18.9, 11.6 ppm. IR (film): ṽ = 
2962, 2930, 2854, 1732, 1472, 1427, 1360, 1260, 1192, 1110, 1021, 823, 799, 738, 701 cm
−1
. MS (EI) 
m/z (%) = 970 (6), 969 (9), 883 (10), 882 (14), 881 (22), 880 (8), 879 (11), 805 (11), 724 (11), 723 
(11), 563 (11), 467 (11), 361 (25), 349 (11), 319 (13), 296 (12), 295 (47), 270 (23), 269 (100), 241 
(14), 239 (34), 200 (13), 199 (73), 197 (30), 135 (93), 91 (84). HRMS (ESIpos): m/z: calcd for 
C60H74O6Si2SeNa: 1049.4081; found: 1049.4075. 
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(6S,8S)-8-((2R,3S,4R,5S)-5-(2-(Benzyloxy)ethyl)-4-methyl-3-(phenylselanyl) tetrahydrofuran-2-
yl)-2,2,11,11-tetramethyl-3,3,10,10-tetraphenyl-4,9-dioxa-3,10-disiladodecan-6-yl isobutyrate 
(ent-186). Prepared analogously fromalcohol ent-185 (1.59 g, 
1.82 mmol) as a colorless oil (1.53 g, 82%). 
 
 
 
(6R,8R)-8-((2R,4R,5R)-5-(2-(Benzyloxy)ethyl)-4-methyltetrahydrofuran-2-yl)-2,2,11,11-tetra-
methyl-3,3,10,10-tetraphenyl-4,9-dioxa-3,10-disiladodecan-6-yl isobutyrate (188). A flame-dried 
two-necked round-bottom flask equipped with a reflux condenser 
was charged with a solution of selenoether 186 (560 mg, 
0.546 mmol) in degassed toluene (22 mL). (n-Bu)3SnH (177 µL, 
0.655 mmol) was added via syringe, followed by solid AIBN 
(0.9 mg, 5.5 µmol). The resulting mixture was stirred at 80 °C for 90 min under Argon, allowing the 
generated N2 to evaporate. After cooling to room temperature, the mixture was concentrated and the 
residue purified by flash chromatography (hexanes/EtOAc 100:0 to 49:1 to 39:1 to 29:1) to yield the 
title compound as a sticky colorless syrup (440 mg, 93% yield, single diastereomer). [∝]𝐷
20 = +34.1 (c 
= 0.95, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.71 – 7.61 (m, 8H), 7.42 – 7.25 (m, 17H), 5.24 – 
5.17 (m, 1H), 4.30 (s, 2H), 3.72 – 3.63 (m, 2H), 3.61 – 3.54 (m, 3H), 3.15 – 3.03 (m, 2H), 2.36 (hep, J 
= 7.0 Hz, 1H), 2.05 (dddd, J = 13.3, 11.7, 6.7, 5.4 Hz, 1H), 1.94 (ddd, J = 12.3, 7.3, 7.2 Hz, 1H), 1.83 
(ddd, J = 14.1, 9.1, 0.2 Hz, 1H), 1.72 (ddd, J = 14.4, 7.6, 2.9 Hz, 1H), 1.51 – 1.37 (m, 2H), 1.06 – 0.99 
(m, 25H), 0.61 (d, J = 6.9 Hz, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 176.1, 138.8, 136.2, 135.9, 
135.6, 135.5, 135.0, 133.8, 133.5, 133.4, 129.6, 129.3, 129.0, 128.3, 127.7, 127.6, 127.6, 127.6, 127.4, 
127.3, 127.0, 80.8, 78.3, 73.2, 72.8, 71.3, 68.2, 63.4, 36.1, 35.6, 35.2, 34.0, 31.0, 27.2, 26.7, 19.6, 
19.3, 19.0, 18.8, 15.6 ppm. IR (film): ṽ = 2959, 2930, 2856, 1734, 1471, 1427, 1388, 1361, 1258, 
1192, 1157, 1110, 998, 937, 822, 738, 700 cm
−1
. MS (EI) m/z (%) = 814 (16), 813 (25), 726 (18), 725 
(29), 563 (14), 558 (17), 557 (37), 469 (12), 319 (12), 301 (13), 296 (13), 295 (47), 271 (11), 270 (23), 
269 (100), 241 (24), 239 (29), 200 (14), 199 (77), 197 (25), 163 (13), 136 (10), 135 (80), 91 (96). 
HRMS (ESIpos): m/z: calcd for C54H70O6Si2Na: 893.4603; found: 893.4594. 
 
(6S,8S)-8-((2S,4S,5S)-5-(2-(Benzyloxy)ethyl)-4-methyltetrahydrofuran-2-yl)-2,2,11,11-tetra-
methyl-3,3,10,10-tetraphenyl-4,9-dioxa-3,10-disiladodecan-6-yl isobutyrate (ent-188). Prepared 
analogously fromselenoether ent-186 (1.53 g, 1.49 mmol) as a 
colorless oil (1.26 g, 97%, single d.r.). 
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(6R,8R)-8-((2R,4R,5R)-5-(2-Hydroxyethyl)-4-methyltetrahydrofuran-2-yl)-2,2,11,11-tetramethyl-
3,3,10,10-tetraphenyl-4,9-dioxa-3,10-disiladodecan-6-yl isobutyrate (189). A flame-dried Schlenk 
tube was charged with Pd(OH)2/C (20 wt. %, 35.5 mg, 50.5 µmol). 
The flask was evacuated (5 x 10
−1
 mbar) and backfilled with H2 from 
a balloon (two cycles). EtOH (27 mL) was added and the suspension 
vigorously stirred for 10 min before a solution of benzyl ether 188 
(440 mg, 0.505 mmol) in EtOAc (3 mL) was introduced. After stirring for 7.5 h under a H2 
atmosphere (balloon), the mixture was filtered through a short pad of Celite
®
 that was carefully rinsed 
with EtOAc (3 x 20 mL). The combined filtrates were concentrated and the residue was purified by 
flash chromatography (hexanes/EtOAc 4:1) to yield the desired product as a white foam (345 mg, 
88%). [∝]𝐷
20 = +24.2 (c = 0.88, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.71 – 7.60 (m, 8H), 7.44 – 
7.28 (m, 12H), 5.12 (ddd, J = 9.6, 4.8, 4.9, 3.1 Hz, 1H), 3.75 – 3.66 (m, 3H), 3.58 – 3.51 (m, 2H), 3.49 
– 3.35 (m, 2H), 2.36 (hep, J = 7.0 Hz, 1H), 2.14 (dddd, J = 14.1, 14.1, 7.1, 6.9 Hz, 1H), 2.00 – 1.89 
(m, 3H), 1.88 (dd, J = 9.6, 3.0 Hz, 1H), 1.73 (ddd, J = 14.3, 7.4, 3.1 Hz, 1H), 1.50 – 1.37 (m, 1H), 1.24 
– 1.16 (m, 1H), 1.06 – 1.00 (m, 24H), 0.74 (d, J = 7.0 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ = 
176.1, 136.1, 135.8, 135.6, 135.5, 134.7, 133.5, 133.4, 133.3, 129.6, 129.6, 129.5, 129.2, 127.6, 127.6, 
127.4, 127.2, 80.9, 80.3, 72.2, 71.2, 65.3, 61.4, 35.5, 35.3, 35.2, 34.0, 32.9, 27.1, 26.7, 19.5, 19.2, 
19.0, 18.8, 15.5 ppm. IR (film): ṽ = 3487, 2960, 2930, 2857, 1735, 1472, 1428, 1388, 1259, 1193, 
1158, 1112, 998, 823, 740, 702, 610 cm
−1
. MS (EI) m/z (%) = 723 (12), 646 (10), 645 (18), 636 (13), 
635 (23), 563 (12), 558 (20), 557 (41), 437 (16), 379 (31), 319 (13), 301 (18), 295 (34), 270 (18), 269 
(82), 241 (32), 239 (32), 200 (18), 199 (97), 197 (38), 183 (12), 181 (14), 163 (14), 145 (11), 139 (12), 
137 (12), 136 (14), 135 (100), 85 (29), 71 (14), 43 (26). HRMS (ESIpos): m/z: calcd for 
C47H64O6Si2Na: 803.4134; found: 803.4135. 
 
(6S,8S)-8-((2S,4S,5S)-5-(2-Hydroxyethyl)-4-methyltetrahydrofuran-2-yl)-2,2,11,11-tetramethyl-
3,3,10,10-tetraphenyl-4,9-dioxa-3,10-disiladodecan-6-yl isobutyrate (ent-189). Prepared 
analogously frombenzyl ether ent-188 (1.25 g, 1.43 mmol) as a 
colorless oil (907 mg, 81%).  
 
 
 
(6R,8R)-2,2,11,11-Tetramethyl-8-((2R,4R,5R)-4-methyl-5-(2-oxoethyl)tetrahydrofuran-2-yl)-
3,3,10,10-tetraphenyl-4,9-dioxa-3,10-disiladodecan-6-yl isobutyrate (190). A solution of alcohol 
189 (341 mg, 0.437 mmol) in CH2Cl2 (1 mL + 2 x 0.5 mL rinse) was 
added dropwise at 0 °C to a solution of Dess-Martin periodinane 
(463 mg, 1.09 mmol) in CH2Cl2 (2.6 mL). After complete addition, the 
ice bath was removed and stirring continued at rt for 4.5 h before the 
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reaction was quenched with sat. Na2S2O3 and sat. NaHCO3 solution (1:1, 20 mL). The aqueous phase 
was extracted with CH2Cl2 (3 x 15 mL), and the combined organic extracts were dried over Na2SO4 
and concentrated. The residue was purified flash chromatography (short column, hexanes/EtOAc 19:1) 
to give the desired aldehyde as a colorless sticky syrup (310 mg, 91%). [∝]𝐷
20 = +35.2 (c = 0.57, 
CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 9.13 (t, J = 2.2 Hz, 1H), 7.70 – 7.59 (m, 8H), 7.46 – 7.25 
(m, 12H), 5.18 (dddd, J = 9.5, 4.8, 4.7, 3.0 Hz, 1H), 3.93 (ddd, J = 8.8, 6.5, 4.7 Hz, 1H), 3.75 – 3.63 
(m, 2H), 3.58 (d, J = 4.7 Hz, 2H), 2.37 (hep, J = 7.0 Hz, 1H), 2.25 – 2.19 (m, 1H), 2.16 (dd, J = 8.6, 
1.8 Hz, 1H), 2.10 (ddd, J = 16.2, 4.9, 2.5 Hz, 1H), 2.02 – 1.92 (m, 1H), 1.83 (ddd, J = 14.2, 9.5, 
2.5 Hz, 1H), 1.73 (ddd, J = 14.4, 7.6, 3.1 Hz, 1H), 1.14 – 1.09 (m, 1H), 1.05 (d, J = 7.0 Hz, 3H), 1.04 
(d, J = 7.1 Hz, 3H), 1.02 (s, 9H), 0.99 (s, 9H), 0.63 (d, J = 7.0 Hz, 3H) ppm. 
13
C NMR (100 MHz, 
CDCl3): δ = 202.1, 176.1, 136.1, 135.7, 135.6, 135.5, 134.8, 133.7, 133.4, 133.4, 129.7, 129.4, 129.1, 
127.7, 127.7, 127.3, 127.0, 81.3, 76.3, 72.9, 71.2, 65.3, 44.8, 35.8, 35.5, 35.2, 34.0, 27.1, 26.7, 19.6, 
19.3, 19.0, 18.8, 15.6 ppm. IR (film): ṽ = 2959, 2929, 2856, 1729, 1472, 1427, 1388, 1240, 1192, 
1158, 1111, 998, 822, 740, 701 cm
−1
. MS (EI) m/z (%) = 721 (7), 635 (16), 634 (42), 633 (80), 563 (7), 
377 (15), 319 (11), 295 (31), 270 (22), 269 (100), 241 (14), 239 (21), 225 (10), 200 (12), 199 (66), 197 
(29), 183 (13), 179 (15), 163 (12), 136 (10), 136 (78), 43 (19). HRMS (ESIpos): m/z: calcd for 
C47H62O6Si2Na: 801.3977; found: 801.3977. 
 
(6S,8S)-2,2,11,11-Tetramethyl-8-((2S,4S,5S)-4-methyl-5-(2-oxoethyl)tetrahydrofuran-2-yl)-
3,3,10,10-tetraphenyl-4,9-dioxa-3,10-disiladodecan-6-yl isobutyrate (ent-190). Prepared 
analogously from alcohol ent-189 (907 mg, 1.16 mmol) as a colorless 
oil (847 mg, 94%). 
 
 
 
(6R,8R)-2,2,11,11-Tetramethyl-8-((2R,4R,5R)-4-methyl-5-(prop-2-yn-1-yl)tetrahydrofuran-2-yl)-
3,3,10,10-tetraphenyl-4,9-dioxa-3,10-disiladodecan-6-yl isobutyrate (191). A flame-dried Schlenk 
tube was charged with dimethyl-1-diazo-2-oxopropylphosphonate (R18) 
(306 mg, 1.592 mmol) and THF (8 mL). The resulting solution was 
cooled to 78 °C before a freshly prepared solution of NaOMe[248] 
(0.5 M, 3.18 mL, 1.592 mmol) was added over the course of 10 min via 
syringe, causing the mixture to turn intensively yellow. After stirring for 15 min at 78 °C, a 
precooled (78 °C) solution of aldehyde 190 (310 mg, 0.398 mmol) in THF (5 mL + 2 x 1 mL rinse) 
was added slowly via canula. The reaction flask was then equipped with an Argon bubbler to allow the 
generated N2 to evaporate. The mixture was slowly warmed to 50 °C, causing a heavy gas evolution. 
After stirring for 90 min at 50 °C, the reaction was quenched by addition of sat. NH4Cl solution 
(20 mL) and H2O (4 mL) and the aqueous layer was extracted with EtOAc (4 x 30 mL). The combined 
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extracts were washed with brine (35 mL), dried over Na2SO4 and concentrated. The orange residue 
was purified by flash chromatography (hexanes/EtOAc 39:1) to yield the desired alkyne as a white 
foam that collapsed upon storage (287 mg, 93%). [∝]𝐷
20 = +19.4 (c = 1.10, CH2Cl2). 
1
H NMR 
(400 MHz, CDCl3): δ = 7.72 – 7.57 (m, 8H), 7.48 – 7.25 (m, 12H), 5.13 (dddd, J = 9.5, 4.7, 4.6, 
2.9 Hz, 1H), 3.78 – 3.64 (m, 3H), 3.57 (d, J = 4.7 Hz, 2H), 2.35 (hep, J = 7.0 Hz, 1H), 2.24 (ddd, J = 
14.0, 7.0, 7.0 Hz, 1H), 2.05 – 2.00 (m, 2H), 1.97 – 1.84 (m, 2H), 1.83 (t, J = 2.7 Hz, 1H), 1.71 (ddd, J 
= 14.5, 7.8, 3.0 Hz, 1H), 1.27 – 1.15 (m, 1H), 1.06 – 0.98 (m, 24H), 0.81 (d, J = 7.0 Hz, 3H) ppm. 13C 
NMR (100 MHz, CDCl3): δ = 176.1, 136.1, 135.9, 135.6, 135.5, 134.7, 134.0, 133.5, 133.4, 129.6, 
129.6, 129.3, 129.1, 127.7, 127.6, 127.3, 127.0, 81.6, 81.0, 79.3, 72.7, 71.2, 69.1, 65.3, 35.2, 35.1, 
34.0, 27.2, 26.7, 20.6, 19.6, 19.2, 19.0, 18.8, 14.8 ppm. IR (film): ṽ = 2960, 2930, 2857, 1735, 1472, 
1428, 1388, 1260, 1192, 1158, 1112, 1006, 822, 740, 702 cm
−1
. MS (ESIpos) m/z (%) = 797.5 (100 
(M+Na
+
)). HRMS (ESIpos): m/z: calcd for C48H62O5Si2Na: 797.4028; found: 797.4028. 
 
(6S,8S)-2,2,11,11-Tetramethyl-8-((2S,4S,5S)-4-methyl-5-(prop-2-yn-1-yl)tetrahydrofuran-2-yl)-
3,3,10,10-tetraphenyl-4,9-dioxa-3,10-disiladodecan-6-yl isobutyrate (ent-191). Prepared 
analogously fromaldehyde ent-190 (847 mg, 1.087 mmol) as a colorless 
syrup (809 mg, 96%). 
 
 
 
(6R,8R)-2,2,11,11-Tetramethyl-8-((2R,4R,5R)-4-methyl-5-(prop-2-yn-1-yl)tetrahydrofuran-2-yl)-
3,3,10,10-tetraphenyl-4,9-dioxa-3,10-disiladodecan-6-ol (194). A solution of DIBAl-H in toluene 
(1.0 M, 1.10 mL, 1.10 mmol) was added dropwise at 78 °C to a 
solution of ester 191 (285 mg, 0.368 mmol) in toluene (24 mL) and the 
resulting mixture was stirred for 30 min at this temperature. The 
mixture was then poured via canula into a stirred sat. solution of Rochelle salt (150 mL), the flask was 
rinsed with EtOAc (2 x 20 mL) and the emulsion was vigorously stirred at ambient temperature for 
4 h. The layers were separated, the aqueous phase was extracted with EtOAc (3 x 40 mL), and the 
combined organic extracts were dried over Na2SO4 and concentrated. The crude residue was purified 
by flash chromatography (hexanes/EtOAc 24:1 to 19:1) to give the title compound as a sticky 
colorless syrup (252 mg, 97%). [∝]𝐷
20 = +18.2 (c = 1.07, CHCl3). 
1
H NMR (400 MHz, CDCl3): δ = 
7.75 – 7.68 (m, 4H), 7.64 – 7.59 (m, 4H), 7.45 – 7.28 (m, 12H), 4.06 (ddd, J = 6.7, 6.6, 4.1 Hz, 1H), 
3.90 – 3.74 (m, 3H), 3.43 (d, J = 5.6 Hz, 2H), 2.60 (d, J = 3.4 Hz, 1H), 2.30 (hep, J = 7.1 Hz, 1H), 
2.13 (ddd, J = 16.7, 6.0, 2.5 Hz, 1H), 2.07 (ddd, J = 16.6, 7.6, 2.6 Hz, 1H), 1.95 (ddd, J = 12.5, 7.8, 
6.9 Hz, 1H), 1.86 (t, J = 2.7 Hz, 1H), 1.62 (ddd, J = 14.3, 9.3, 4.2 Hz, 1H), 1.56 (ddd, J = 14.4, 6.9, 
3.1 Hz, 1H), 1.30 (ddd, J = 12.5, 9.0, 7.4 Hz, 1H), 1.06 (s, 9H), 1.03 (s, 9H), 0.87 (d, J = 7.0 Hz, 3H) 
ppm. 
13
C NMR (100 MHz, CDCl3): δ = 136.1, 136.0, 135.5, 135.5, 134.2, 134.1, 133.4, 133.4, 129.7, 
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129.4, 129.4, 127.7, 127.4, 127.2, 81.6, 81.0, 79.5, 73.2, 69.3, 68.8, 68.3, 36.6, 35.2, 35.1, 27.1, 26.8, 
20.8, 19.6, 19.2, 14.8 ppm. IR (film): ṽ = 3311, 2957, 2928, 2856, 1472, 1469, 1427, 1390, 1362, 
1269, 1189, 1111, 999, 822, 739, 701 cm
−1
. MS (EI) m/z (%) = 570 (22), 569 (48), 491 (8), 417 (7), 
319 (18), 299 (10), 259 (12), 257 (14), 241 (35), 239 (19), 223 (11), 221 (35), 200 (19), 199 (100), 197 
(40), 183 (17), 181 (14), 175 (16), 163 (22), 149 (34), 139 (13), 136 (12), 135 (88), 117 (17), 93 (12), 
91 (22), 79 (12). HRMS (ESIpos): m/z: calcd for C44H56O4Si2Na: 727.3609; found: 727.3610. 
 
(6S,8S)-2,2,11,11-Tetramethyl-8-((2S,4S,5S)-4-methyl-5-(prop-2-yn-1-yl)tetrahydrofuran-2-yl)-
3,3,10,10-tetraphenyl-4,9-dioxa-3,10-disiladodecan-6-ol (ent-194). Prepared analogously fromester 
ent-191 (803 mg, 1.04 mmol) as a colorless syrup (709 mg, 97%). 
 
 
 
5.3.3 Synthesis of sugar fragment 201. 
Allyl α-L-rhamnopyranoside (196). L-Rhamnose (195) (4.0 g, 22 mmol) was dissolved in allyl 
alcohol (30 mL) and conc. H2SO4 (0.4 mL) was added. The mixture was stirred at 
100 °C for 1 h while its color changed to brown. After cooling to ambient 
temperature, solid K2CO3 (60 mg) was added and excess allyl alcohol was 
removed under reduced pressure. The residue was purified by flash 
chromatography (EtOAc) to yield the targeted compound as a highly viscous colorless oil (3.5 g, 
78%). [∝]𝐷
20 = 83.0 (c = 1.29, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 5.85 (dddd, J = 17.2, 10.3, 
6.1, 5.2 Hz, 1H), 5.25 (dq, J = 17.3, 1.6 Hz, 1H), 5.16 (dq, J = 10.4, 1.3 Hz, 1H), 4.77 (d, J = 1.5 Hz, 
1H), 4.74 – 4.56 (br s, 1H), 4.39 – 4.23 (br s, 1H), 4.30 – 4.17 (br s, 1H), 4.12 (ddt, J = 13.0, 5.3, 1.5 
Hz, 1H), 4.03 – 3.86 (m, 2H), 3.75 (dd, J = 9.5, 3.3 Hz, 1H), 3.61 (dq, J = 9.4, 6.2 Hz, 1H), 3.44 (t, J = 
9.5 Hz, 1H), 1.27 (d, J = 6.2 Hz, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 133.7, 117.5, 98.9, 72.8, 
71.7, 71.0, 68.2, 68.0, 17.5 ppm. IR (film): ṽ = 3371, 2977, 2915, 1450, 1422, 1383, 1265, 1128, 1046, 
980, 880, 835, 808, 734, 685 cm
−1
. MS (EI) m/z (%) = 131 (5), 100 (46), 87 (21), 85 (11), 83 (5), 74 
(7), 73 (18), 72 (5), 71 (63), 61 (13), 60 (96), 59 (11), 58 (46), 57 (26), 56 (6), 55 (10), 45 (18), 43 
(41), 42 (15), 41 (100), 39 (21), 31 (18), 29 (25), 27 (11). HRMS (ESIpos): m/z: calcd for C9H16O5Na: 
227.0889; found: 227.0891. 
 
Bisacetal 197. Trimethylorthoacetate (44.8 mL, 350 mmol) and 2,3-butadione (7.7 mL, 88 mmol) 
were dissolved in MeOH (200 mL) and the solution treated with pTsOH·H2O 
(1.25 g, 6.57 mmol) before the mixture was stirred at 75 °C for 24 h. After 
cooling to ambient temperature, a solution of rhamnoside 196 (3.02 g, 
14.8 mmol) in MeOH (7 mL+7 mL rinse) was added and the mixture stirred at 
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75 °C overnight. After cooling to ambient temperature, NEt3 (1.2 mL) was added to neutralize the 
medium prior to evaporation of the solvents under reduced pressure. The residue was purified by flash 
chromatography (hexanes/EtOAc 4:1) to give the desired bisacetal as a highly viscous colorless syrup 
(3.21 g, 72%). [∝]𝐷
20 = 182.6 (c = 0.99, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 5.86 (dddd, J = 
16.8, 10.3, 6.3, 5.2 Hz, 1H), 5.24 (dq, J = 17.2, 1.7 Hz, 1H), 5.15 (dq, J = 10.4, 1.4 Hz, 1H), 4.79 (d, J 
= 1.5 Hz, 1H), 4.13 (ddt, J = 12.9, 5.2, 1.5 Hz, 1H), 4.00 – 3.87 (m, 3H), 3.78 (dq, J = 9.7, 6.0 Hz, 
1H), 3.68 (t, J = 9.9 Hz, 1H), 3.22 (s, 3H), 3.19 (s, 3H), 2.46 (d, J = 2.3 Hz, 1H), 1.27 (s, 3H), 1.24 (s, 
3H), 1.22 (d, J = 6.1 Hz, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 133.8, 117.4, 100.2, 99.8, 98.9, 
69.9, 68.4, 68.2, 67.9, 66.5, 48.0, 47.6, 17.8, 17.6, 16.5 ppm. IR (film): ṽ = 3464, 2932, 2834, 1454, 
1376, 1138, 1111, 1076, 1034, 984, 929, 915, 882, 848, 734, 701, 672 cm
−1
. MS (EI) m/z (%) = 116 
(7), 113 (7), 101 (33), 85 (7), 84 (100), 83 (23), 75 (16), 73 (11), 57 (5), 55 (11), 43 (34), 41 (21), 29 
(7). HRMS (ESIpos): m/z: calcd for C15H27O7Na: 341.1571; found: 341.1571. 
 
Methylated bisacetal 198. A solution of bisacetal 197 (3.17 g, 10.4 mmol) in DMF (10 mL) was 
slowly added at 0 °C to a suspension of NaH (748 mg, 31.2 mmol) in DMF 
(60 mL). The resulting mixture was stirred for about 30 min at 0 °C until gas 
evolution had ceased. MeI (1.95 mL, 31.2 mmol) was then added dropwise, 
causing a color change to yellow. The mixture was warmed to room 
temperature overnight before the reaction was quenched with sat. NH4Cl solution (300 mL). The 
aqueous phase was extracted with EtOAc (3 x 150 mL), the combined organic extracts were washed 
with brine (200 mL), dried over Na2SO4 and concentrated. The residue was purified by flash 
chromatography (hexanes/EtOAc 3:2) to give the methylated product as pale yellow oil (2.21 g, 64%). 
[∝]𝐷
20 = 214.0 (c = 0.88, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 5.91 (m, 1H), 5.24 (dd, J = 17.3, 
1.3 Hz, 1H), 5.15 (dd, J = 10.4, 1.3 Hz, 1H), 4.82 (d, J = 1.5 Hz, 1H), 4.13 (m, 1H), 3.99 (dd, J = 9.9, 
3.0 Hz, 1H), 3.93 (m, 1H), 3.75 (dq, J = 9.8, 6.0 Hz, 1H), 3.68 (dd, J = 9.9, 9.8 Hz, 1H), 3.44 (dd, J = 
3.0, 1.5 Hz, 1H), 3.47 (s, 3H), 3.24 (s, 3H), 3.22 (s, 3H), 1.29 (s, 3H), 1.26 (s, 3H), 1.23 (d, J = 6.0 Hz, 
3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 133.9, 117.3, 99.8, 99.5, 97.1, 78.8, 68.7, 68.4, 67.9, 66.9, 
59.2, 47.9, 47.6, 17.8, 17.8, 16.6 ppm. IR (film): ṽ = 2932, 2832, 1453, 1375, 1197, 1138, 1114, 1083, 
1037, 994, 932, 882, 848, 815 cm
−1
. MS (EI) m/z (%) = 116 (9), 115 (11), 101 (25), 99 (11), 98 (100), 
97 (17), 83 (16), 75 (5), 73 (16), 71 (5), 67 (9), 55 (7), 45 (10), 43 (30), 41 (29), 39 (6), 29 (7). HRMS 
(ESIpos): m/z: calcd for C16H28O7Na: 355.1727; found: 355.1725. 
 
Allyl 2-O-methyl-α-L-rhamnopyranoside. Trifluoroacetic acid (19 mL) was added to an emulsion of 
compound 199 (2.05 g, 6.17 mmol) in H2O (1 mL) at 0 °C. The mixture turned 
slightly yellow and was allowed to stir for 7 min at this temperature. The mixture 
was diluted with CH2Cl2 (300 mL), the organic phase was dried over Na2SO4 and 
concentrated to give the diol as a pale orange oil that was used in the next step without further 
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purification (1.32 g, 98%, 95% purity). An analytically pure sample was obtained by flash 
chromatography (hexanes/EtOAc = 1:1 to 1:2). [∝]𝐷
20 = 46.3 (c = 1.00, CH2Cl2). 
1
H NMR (400 MHz, 
CDCl3): δ = 5.84 (dddd, J = 17.2, 10.4, 6.1, 5.0 Hz, 1H), 5.23 (dq, J = 17.2, 1.7 Hz, 1H), 5.14 (dq, J = 
10.4, 1.4 Hz, 1H), 4.84 (d, J = 1.6 Hz, 1H), 4.13 (ddt, J = 13.0, 5.1, 1.6 Hz, 1H), 3.92 (ddt, J = 13.0, 
6.1, 1.4 Hz, 1H), 3.75 – 3.66 (br s, 1H), 3.56 (dq, J = 9.2, 6.2 Hz, 1H), 3.50 – 3.42 (br s, 1H), 3.43 (dd, 
J = 3.8, 1.5 Hz, 1H), 3.41 (s, 3H), 3.33 (t, J = 9.5 Hz, 1H), 3.24 – 3.11 (m, 1H), 1.24 (d, J = 6.2 Hz, 
3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 133.7, 117.2, 95.4, 80.4, 73.5, 71.4, 67.9, 67.8, 58.8, 17.5 
ppm. IR (film): ṽ = 3416, 2976, 2932, 2907, 2832, 1453, 1382, 1192, 1133, 1103, 1075, 1038, 990, 
975, 926, 912, 874, 836, 807 cm
−1
. MS (EI) m/z (%) = 157 (8), 156 (16), 129 (18), 125 (7), 116 (28), 
115 (8), 114 (17), 113 (15), 103 (5), 96 (13), 87 (22), 85 (13), 83 (12), 74 (50), 45 (9), 43 (100), 41 
(20). 
 
Allyl 3,4-bis-O-acetyl-2-O-methyl-α-L-rhamnopyranoside (199). Triethylamine (2.8 mL, 21 mmol) 
and acetic anhydride (1.4 mL, 21 mmol) were successively added via syringe at 
0 °C to a solution of DMAP (152 mg, 1.2 mmol) and the crude diol described 
above (1.4 g, 6.2 mmol) in CH2Cl2 (40 mL). The ice bath was removed and 
stirring continued for 2 h at ambient temperature, before sat. NH4Cl (20 mL) was added and the 
aqueous phase extracted with EtOAc (3 x 7 mL). The combined extracts were dried over Na2SO4 and 
concentrated. The residue was purified by flash chromatography (hexanes/EtOAc 3:2) to give the 
desired bisacetate as a white crystalline solid (1.28 g, 68%). [∝]𝐷
20 = 72.3 (c = 0.98, CH2Cl2). 
1
H 
NMR (400 MHz, CDCl3): δ = 5.86 (dddd, J = 17.3, 10.4, 6.1, 5.1 Hz, 1H), 5.27 (dq, J = 17.2, 1.6 Hz, 
1H), 5.22 – 5.15 (m, 2H), 5.07 (t, J = 9.9 Hz, 1H), 4.82 (d, J = 1.8 Hz, 1H), 4.15 (ddt, J = 12.9, 5.1, 
1.5 Hz, 1H), 3.96 (ddt, J = 12.9, 6.1, 1.3 Hz, 1H), 3.78 (dq, J = 9.6, 5.2 Hz, 1H), 3.59 (dd, J = 3.3, 1.9 
Hz, 1H), 3.43 (s, 3H), 2.03 (s, 3H), 1.99 (s, 3H), 1.16 (d, J = 6.3 Hz, 3H) ppm. 
13
C NMR (100 MHz, 
CDCl3): δ = 170.3, 169.8, 133.5, 117.5, 96.4, 78.4, 71.6, 71.5, 68.1, 66.4, 59.5, 20.9, 20.7, 17.4 ppm. 
IR (film): ṽ = 2924, 1740, 1455, 1370, 1239, 1219, 1107, 1074, 1036, 1000, 976, 915, 835, 798 cm−1. 
MS (EI) m/z (%) = 157 (8), 156 (16), 129 (18), 125 (7), 116 (28), 115 (8), 114 (17), 113 (15), 103 (5), 
96 (13), 87 (22), 85 (13), 83 (12), 74 (50), 45 (9), 43 (100), 41 (20). HRMS (ESIpos): m/z: calcd for 
C14H22O7Na: 325.1258; found: 325.1255. 
 
3,4-Bis-O-acetyl-2-O-methyl-α-L-rhamnopyranose (200). SeO2 (488 mg, 4.40 mmol) was added to 
a solution of compound 199 (1.20 g, 3.97 mmol) and acetic acid (183 µL, 
3.20 mmol) in 1,4-dioxane (10 mL) and the resulting suspension was stirred at 
reflux temperature for 2 h. After cooling to room temperature, the mixture was 
neutralized with triethylamine (0.44 mL) and concentrated under reduced pressure. The residue was 
purified by flash chromatography (hexanes/EtOAc 3:2) to give the desired hemiacetal as a white solid 
(0.891 g, 86%). [∝]𝐷
20 = 42.3 (c = 0.94, CH2Cl2). 
1
H NMR (400 MHz, CDCl3, data of the major 
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anomer only): δ = 5.26 – 5.17 (m, 2H), 5.05 (t, J = 9.9 Hz, 1H), 4.04 (dq, J = 9.8, 6.2 Hz, 1H), 3.66 (d, 
J = 3.8 Hz, 1H), 3.61 (dd, J = 3.3, 1.8 Hz, 1H), 3.43 (s, 3H), 2.02 (s, 3H), 1.98 (s, 3H), 1.13 (d, J = 
6.2 Hz, 3H) ppm. 
13
C NMR (100 MHz, CDCl3, data of the major anomer only): δ = 170.4, 170.0, 92.0, 
78.6, 71.5, 71.3, 66.3, 59.5, 20.9, 20.7, 17.4 ppm. IR (film): ṽ = 3453, 2923, 2854, 1741, 1456, 1373, 
1243, 1225, 1108, 1074, 1050, 916, 797 cm
−1
. MS (EI) m/z (%) = 156 (14), 129 (34), 116 (12), 115 
(5), 114 (14), 113 (7), 87 (54), 85 (6), 83 (7), 74 (56), 45 (7), 43 (100), 29 (6). HRMS (ESIpos): m/z: 
calcd for C11H18O7Na: 285.0945; found: 285.0947. 
 
Trichloroacetimidate 201. Cl3CCN (0.934 mL, 9.31 mmol) was added dropwise to a suspension of 
hemiacetal 200 (348 mg, 0.19 mmol) and Cs2CO3 (86.7 mg, 0.039 mmol) in 
CH2Cl2 (7.0 mL). After stirring for 3 h at room temperature, the mixture was 
filtered and the filtrate was evaporated. The residue was purified by flash 
chromatography (hexanes/EtOAc 4:1) to give the desired trichloroacetimidate as 
a white solid (532 mg, 98%). [∝]𝐷
20 = 59.9 (c = 1.06, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 8.62 
(s, 1H), 6.25 (d, J = 2.0 Hz, 1H), 5.28 – 5.10 (m, 2H), 3.98 (dq, J = 9.0, 6.3 Hz, 1H), 3.80 (dd, J = 3.0, 
2.0 Hz, 1H), 3.48 (s, 3H), 2.04 (s, 3H), 2.01 (s, 3H), 1.20 (d, J = 6.3 Hz, 3H) ppm. 
13
C NMR 
(100 MHz, CDCl3): δ = 169.9, 169.3, 160.0, 94.6, 90.5, 76.1, 70.7, 70.2, 69.0, 59.2, 20.5, 20.4, 17.2 
ppm. IR (film): ṽ = 3332, 2988, 2922, 2851, 1741, 1673, 1448, 1368, 1279, 1236, 1219, 1156, 1107, 
1056, 1039, 968, 943, 926, 842, 831, 793, 734 cm
−1
. MS (EI) m/z (%) = 245 (28), 184 (19), 143 (14), 
142 (24), 129 (16), 125 (28), 116 (18), 113 (13), 87 (22), 74 (34), 43 (100). HMRS (ESIpos): m/z: 
calcd for C13H18O7NCl3Na: 428.0041; found: 428.0042. 
 
Acetal 202. 2,2-Dimethoxypropane (4.4 mL, 35.3 mmol) was added dropwise to a stirred solution of 
rhamnoside 196 (3.60 g, 17.6 mmol) and pTsOH·H2O (60.6 mg, 0.352 mmol) in 
DMF (17.6 mL) at ambient temperature. The reaction mixture was stirred for 16 h 
and used as a solution for the next step. An aliquot (0.5 mL) was removed from 
the reaction mixture and used to obtain an analytically pure sample. This aliquot 
was diluted with NH4Cl solution (3 mL) and the aqueous phase was extracted with Et2O (2 x 3 mL). 
The combined organic extracts were dried over Na2SO4 and concentrated. The residue was purified by 
flash chromatography (hexanes/EtOAc 3:1) to yield the desired compound as a colorless oil. [∝]𝐷
20 = 
−27.1 (c = 0.67, CH2Cl2). 
1
H NMR (400 MHz, C6D6): δ = 5.74 (dddd, J = 17.2, 10.4, 6.0, 5.1 Hz, 1H), 
5.15 (dq, J = 17.2, 1.7 Hz, 1H), 5.09 (s, 1H), 5.00 (dq, J = 10.4, 1.4 Hz, 1H), 4.21 – 4.12 (m, 2H), 4.02 
(ddt, J = 13.0, 5.2, 1.5 Hz, 1H), 3.81 – 3.71 (m, 2H), 3.50 (ddd, J = 9.5, 6.9, 4.2 Hz, 1H), 3.17 (d, J = 
4.2 Hz, 1H), 1.48 (s, 3H), 1.36 (d, J = 6.2 Hz, 3H), 1.23 (s, 3H) ppm. 
13
C NMR (100 MHz, C6D6): δ = 
134.4, 116.9, 109.4, 96.8, 79.3, 76.5, 74.9, 67.9, 66.2, 28.2, 26.3, 17.8 ppm. IR (film): ṽ = 3461, 2986, 
2936, 2922, 1454, 1382, 1372, 1243, 1219, 1171, 1139, 1106, 1072, 1050, 1021, 993, 919, 858, 818, 
787, 734, 668 cm
−1
. MS (EI) m/z (%) = 229 (9), 187 (8), 129 (6), 111 (5), 101 (18), 100 (100), 85 (40), 
202 Experimental section 
 
71 (31), 59 (31), 57 (10), 55 (13), 43 (29), 41 (34). HRMS (ESIpos): m/z: calcd for C12H20O5Na: 
267.1203; found: 267.1202.  
 
Acetylated Acetal 203. Pyridine (20 mL) and acetyl chloride (4.25 mL, 70.4 mmol) were added to the 
crude reaction mixture (see above) at 0 °C. The icebath was removed after 5 min 
and the reaction mixture was stirred at ambient temperature for further 24 h. The 
reaction mixture was diluted with CH2Cl2 (50 mL) and washed with aq. HCl 
(1 N, 30 mL), water (30 mL) and sat. NaHCO3 solution (30 mL). The organic 
extract was dried over Na2SO4 and concentrated. The residue was purified by flash chromatography 
(hexanes/EtOAc 21:1 to 15:1 to 9:1) to give a colorless oil (3.87 g, 73% over 2 steps). [∝]𝐷
20 = −23.0 
(c = 0.82, CH2Cl2). 
1
H NMR (400 MHz, C6D6): δ = 5.73 (dddd, J = 17.2, 10.4, 5.9, 5.1 Hz, 1H), 5.29 
(dd, J = 10.1, 7.8 Hz, 1H), 5.15 (dq, J = 17.2, 1.7 Hz, 1H), 5.10 (s, 1H), 5.00 (dq, J = 10.4, 1.4 Hz, 
1H), 4.26 – 4.16 (m, 2H), 3.98 (ddt, J = 13.1, 5.2, 1.5 Hz, 1H), 3.79 – 3.67 (m, 2H), 1.66 (s, 3H), 1.61 
(s, 3H), 1.21 (d, J = 0.8 Hz, 3H), 1.17 (d, J = 6.3 Hz, 3H) ppm. 
13
C NMR (100 MHz, C6D6): δ = 169.5, 
134.3, 116.9, 109.8, 96.8, 76.6, 76.3, 74.8, 68.0, 64.5, 28.0, 26.6, 20.5, 17.2 ppm. IR (film): ṽ = 2985, 
2938, 2925, 1742, 1455, 1373, 1219, 1176, 1139, 1122, 1082, 1045, 1027, 999, 923, 888, 857, 840, 
814, 785, 740 cm
−1
. MS (EI) m/z (%) = 271 (28), 229 (15), 169 (9), 151 (7), 142 (6), 129 (7), 113 (17), 
112 (50), 111 (17), 101 (15), 100 (89), 85 (40), 83 (26), 82 (15), 71 (10), 59 (11), 43 (100), 41 (34). 
HRMS (ESIpos): m/z: calcd for C14H22O6Na: 309.1309; found: 309.1309.  
 
Monoacetylated Diol 204. Compound 203 (2.30 g, 7.63 mmol) was dissolved in 90% AcOH (15 mL) 
and the resulting solution stirred at 110 °C for 1 h. After cooling back to ambient 
temperature, the reaction mixture was concentrated and the residue was purified 
by flash chromatography (hexanes/EtOAc 1:1) to yield the desired diol as a white 
solid (1.83 g, 97% yield). [∝]𝐷
20 = −94.1 (c = 1.46, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 5.88 
(dddd, J = 17.2, 10.4, 6.0, 5.1 Hz, 1H), 5.28 (dq, J = 17.2, 1.6 Hz, 1H), 5.19 (dq, J = 10.4, 1.4 Hz, 1H), 
4.85 (d, J = 1.7 Hz, 1H), 4.78 (t, J = 9.6 Hz, 1H), 4.16 (ddt, J = 13.0, 5.1, 1.5 Hz, 1H), 3.98 (ddt, J = 
13.0, 6.1, 1.4 Hz, 1H), 3.94 (dd, J = 3.5, 1.7 Hz, 1H), 3.88 (dd, J = 9.5, 3.5 Hz, 1H), 3.80 (ddt, J = 9.8, 
6.6, 5.9 Hz, 1H), 2.11 (s, 3H), 1.20 (d, J = 6.2 Hz, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 172.1, 
133.6, 117.5, 98.4, 75.6, 71.0, 70.3, 68.1, 65.6, 21.0, 17.4 ppm. IR (film): ṽ = 3327, 2982, 2940, 2895, 
1735, 1459, 1426, 1378, 1295, 1241, 1133, 1104, 1070, 1044, 1002, 982, 923, 834, 793, 700 cm
−1
. MS 
(EI) m/z (%) = 189 (5), 142 (5), 131 (4), 129 (5), 116 (13), 101 (25), 100 (39), 83 (4), 71 (42), 60 (26), 
43 (100), 41 (38). HRMS (ESIpos): m/z: calcd for C11H18O6Na: 269.0996; found: 269.0997.  
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Bisacetylated alcohol 205. Diol 204 (1.00 g, 4.06 mmol) and 2-aminoethyl diphenylborinate 
(91.4 mg, 0.406 mmol) were dissolved in MeCN (20 mL). Diispropylethylamine 
(0.880 mL, 5.28 mmol) and acetylchloride (0.319 mL, 5.28 mmol) were added 
dropwise at ambient temperature. The mixture was stirred for 3 hours and the 
reaction quenched by addition of H2O (20 mL). The aqueous phase was then extracted with EtOAc (3 
x 15 mL), the combined organic extracts were dried over Na2SO4 and concentrated. 
1
H NMR analysis 
of the crude mixture revealed a ratio of regioisomers of 10:1. The residue was purified by flash 
chromatography (CH2Cl2/Et2O =3:1) to give several pure fractions of the desired isomer (440 mg, 
38%) along with mixed fractions (700 mg, 59% 5:1 ratio of regioisomers). [∝]𝐷
20 = −83.0 (c = 1.51, 
CH2Cl2). 
1
H NMR (400 MHz, C6D6): δ = 5.66 (dddd, J = 17.2, 10.4, 6.0, 5.1 Hz, 1H), 5.53 (dd, J = 
10.0, 3.2 Hz, 1H), 5.49 – 5.42 (m, 1H), 5.13 (dq, J = 17.2, 1.7 Hz, 1H), 4.96 (dq, J = 10.4, 1.4 Hz, 
1H), 4.76 (d, J = 1.7 Hz, 1H), 4.06 (s, 1H), 3.97 – 3.86 (m, 2H), 3.70 (ddt, J = 13.1, 6.0, 1.4 Hz, 1H), 
2.22 (d, J = 4.5 Hz, 1H), 1.74 (s, 3H), 1.69 (s, 3H), 1.19 (d, J = 6.3 Hz, 3H) ppm. 
13
C NMR (100 MHz, 
C6D6): δ = 169.7, 169.6, 134.0, 117.1, 99.0, 72.3, 71.8, 69.9, 68.1, 66.8, 20.5, 20.4, 17.6 ppm. IR 
(film): ṽ = 3466, 2983, 2937, 1738, 1427, 1369, 1316, 1220, 1176, 1126, 1100, 1068, 1036, 984, 937, 
922, 832, 801, 699, 601 cm
−1
. MS (EI) m/z (%) = 231 (3), 171 (2), 142 (14), 115 (11), 113 (11), 102 
(15), 100 (31), 83 (12), 82 (14), 71 (17), 60 (4), 43 (100), 41 (21). HRMS (ESIpos): m/z: calcd for 
C13H20O7Na: 311.1101; found: 311.1099.  
 
 Allyl 3,4-bis-O-acetyl-2-O-methyl-α-L-rhamnopyranoside (199). Alcohol 205 (50.0 mg, 
0.173 mmol) was dissolved in CH2Cl2 (0.7 mL) and the solution cooled to 0 °C. 
Aqueous HBF4 (48%, 45.0 µL, 0.347 mmol) was added via syringe, followed by 
trimethylsilyldiazomethane (1.51 M in hexane, 0.70 mL, 1.0 mmol). The resulting 
solution was stirred for 2 hours at 0 °C, when the addition of HBF4 (48%, 45.0 µL, 0.347 mmol) and 
trimethylsilyldiazomethane (1.51 M in hexane, 0.70 mL, 1.0 mmol) was repeated. After 1h, a third 
portion of both reagents was added and the reaction mixture stirred for one more hour. It was then 
carefully quenched by addition of sat. NaHCO3 solution (10 mL) and extracted with CH2Cl2 (3 x 
10 mL). The combined organic extracts were dried over Na2SO4 and concentrated. The residue was 
purified by flash chromatography (hexanes/EtOAc 5:1) to give the methylated compound as a 
colorless oil (37.0 mg, 71%). The physical and spectroscopic data were identical with those of the 
sample obtained by the alternative route outlined above. 
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5.3.4 Fragment assembly, endgame and structure reassignment. 
Diyne 207. A flame-dried Schlenk tube was charged with a solution of alcohol 194 (224 mg, 
0.318 mmol) in CH2Cl2 (1.8 mL) and a solution of acid 151 (142 mg, 
0.350 mmol) in CH2Cl2 (0.3 mL). DMAP (194 mg, 1.59 mmol) and 
DCC (138 mg, 0.668 mmol) were introduced as solids and the 
resulting mixture was stirred at ambient temperature for 18 h. The 
white precipitate was filtered off through a short pad of Celite
®
 that 
was rinsed with CH2Cl2. The combined filtrates were concentrated and 
the residue purified by flash chromatography (hexanes/EtOAc 24:1) to 
give the diyne as a mixture of ,- and ,-olefins (1.5:1, 222 mg, 64%) as a white foam, along with 
recovered alcohol 194 (63.1 mg, 28%) as a colorless oil.  
A solution of DBU (0.5 M in MeCN, 102 µL, 0.051 mmol) was added to a solution of the just 
mentioned mixture of isomeric diynes (222 mg, 0.203 mmol) in MeCN (25 mL) and the resulting 
solution was stirred at 50 °C for 70 h. After cooling to ambient temperature, sat. NH4Cl solution 
(30 mL) containing 10 drops of 1 M HCl was added, the aqueous phase was extracted with EtOAc (4 x 
30 mL), and the combined organic extracts were dried over Na2SO4 and concentrated. The residue was 
purified by flash chromatography (hexanes/EtOAc 24:1) to yield the desired ,-olefin as a white 
foam (202 mg, 91%). [∝]𝐷
20 = 10.5 (c = 1.03, CHCl3). 
1
H NMR (400 MHz, CDCl3): δ = 7.66 – 7.57 
(m, 8H), 7.47 – 7.25 (m, 12H), 6.85 (dt, J = 15.5, 7.2 Hz, 1H), 5.90 (dd, J = 15.9, 7.9 Hz, 1H), 5.72 
(dt, J = 15.6, 1.5 Hz, 1H), 5.36 (ddd, J = 15.9, 2.0, 0.2 Hz, 1H), 5.22 – 5.11 (m, 1H), 3.79 (ddd, J = 
7.9, 6.4, 3.3 Hz, 1H), 3.76 – 3.67 (m, 3H), 3.61 (dd, J = 10.6, 4.5 Hz, 1H), 3.57 (dd, J = 10.5, 4.2 Hz, 
1H), 3.33 (ddd, J = 11.4, 5.8, 5.8 Hz, 1H), 3.26 (dd, J = 11.6, 6.2, 6.1 Hz, 1H), 2.45 – 2.19 (m, 4H), 
2.11 – 2.01 (m, 2H), 1.96 – 1.87 (m, 2H), 1.90 (d, J = 2.1 Hz, 3H), 1.83 (t, J = 2.6 Hz, 1H), 1.80 – 1.73 
(dd, J = 11.7, 3.7 Hz, 3H), 1.61 (ddd, J = 13.8, 7.4, 7.2 Hz, 1H), 1.37 – 1.27 (m, 1H), 1.23 – 1.07 (m, 
3H), 1.01 (s, 9H), 1.00 (s, 9H), 0.95 (d, J = 6.6 Hz, 3H), 0.86 (s, 9H), 0.83 (d, J = 7.0 Hz, 3H), 0.04 (s, 
3H), 0.03 (s, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 166.6, 148.4, 144.7, 136.0, 136.0, 135.9, 
135.6, 135.6, 134.6, 134.0, 133.5, 133.4, 129.6, 129.3, 129.1, 127.6, 127.6, 127.3, 127.1, 123.4, 108.3, 
84.4, 81.7, 80.9, 79.3, 78.3, 74.1, 73.2, 72.3, 69.2, 68.6, 65.2, 42.3, 41.4, 41.3, 38.8, 35.1, 35.0, 34.6, 
33.3, 27.2, 26.8, 25.8, 20.7, 19.8, 19.6, 19.2, 18.1, 3.2, 4.5, 4.5 ppm. IR (film): ṽ = 2956, 2930, 
2856, 1720, 1656, 1472, 1462, 1427, 1376, 1361, 1257, 1175, 1111, 1071, 1006, 836, 823, 776, 740, 
701 cm
−1
. MS (ESIpos) m/z (%) = 1115.7 (100 (M+Na). HRMS (ESIpos): m/z: calcd for 
C67H92O7Si3Na: 1115.6043; found: 1115.6049. 
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Diyne 11-epi-207. Prepared analogously from acid 11-epi-207 (34.9 mg, 85.8 µmol) and alcohol 194 
(55 mg, 78.0 µmol) as a white foam (1
st
 step: 216 mg, 71% yield, 2
nd
 
step: 56 mg, 92%). [∝]𝐷
20 = +32.5 (c = 0.72, CH2Cl2). 
1
H NMR 
(400 MHz, CDCl3): δ = 7.67 – 7.58 (m, 8H), 7.44 – 7.25 (m, 12H), 
6.86 (dt, J = 15.6, 7.0 Hz, 1H), 5.81 (dd, J = 15.8, 8.7 Hz, 1H), 5.73 
(dt, J = 15.6, 1.5 Hz, 1H), 5.42 (dd, J = 15.7, 2.2 Hz, 1H), 5.22 – 5.14 
(m, 1H), 3.81 (ddd, J = 7.8, 6.6, 3.1 Hz, 1H), 3.77 – 3.67 (m, 3H), 
3.64 (dd, J = 10.7, 4.8 Hz, 1H), 3.58 (dd, J = 10.7, 4.8 Hz, 1H), 3.37 – 
3.28 (m, 1H), 3.27 – 3.18 (m, 1H), 2.51 – 2.34 (m, 2H), 2.34 – 2.19 (m, 2H), 2.07 – 2.02 (m, 2H), 1.96 
– 1.88 (m, 2H), 1.86 (d, J = 2.2 Hz, 3H), 1.83 (t, J = 2.6 Hz, 1H), 1.81 – 1.67 (m, 3H), 1.54 (ddd, J = 
14.0, 9.7, 4.2 Hz, 1H), 1.26 – 1.12 (m, 4H), 1.02 (s, 9H), 1.01 (s, 9H), 0.94 (d, J = 6.7 Hz, 3H), 0.86 (s, 
9H), 0.83 (d, J = 7.1 Hz, 3H), 0.04 (s, 3H), 0.03 (s, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 166.5, 
148.0, 144.7, 136.0, 135.9, 135.9, 135.6, 135.5, 134.6, 133.9, 133.5, 133.4, 129.6, 129.3, 129.1, 127.6, 
127.6, 127.3, 127.1, 123.3, 109.2, 84.3, 81.6, 81.0, 79.3, 78.4, 74.0, 73.3, 72.3, 71.4, 69.2, 68.6, 65.2, 
42.9, 41.9, 41.3, 38.8, 35.1, 35.0, 34.7, 33.9, 27.2, 26.8, 25.8, 21.0, 20.7, 19.5, 19.2, 18.1, 14.8, 4.2, 
4.5, 4.5 ppm. IR (film): ṽ = 2956, 2930, 2856, 1721, 1472, 1462, 1428, 1361, 1258, 1112, 1075, 
1006, 836, 776, 740, 702, 612 cm
−1
. MS (ESIpos) m/z (%) = 1115.7 (100 (M+Na). HRMS (ESIpos): 
m/z: calcd for C67H92O7Si3Na: 1115.6043; found:1115.6053. 
 
Diyne 220. Prepared analogously from acid 151 (170 mg, 0,418 mmol) and alcohol ent-194 (268 mg, 
0.380 mmol) as a white foam (1
st
 step: 216 mg, 52% yield, 2
nd
 step: 
183 mg, 85%). [∝]𝐷
20 = 9.0 (c = 1.53, CH2Cl2). 
1
H NMR (400 MHz, 
CDCl3): δ = 7.67 – 7.58 (m, 8H), 7.42 – 7.24 (m, 12H), 6.86 (dt, J = 
15.6, 7.2 Hz, 1H), 5.91 (dd, J = 15.8, 8.0 Hz, 1H), 5.72 (dt, J = 15.7, 
1.4 Hz, 1H), 5.37 (ddd, J = 15.9, 2.2, 1.1 Hz, 1H), 5.16 (dtd, J = 7.9, 
4.6, 3.0 Hz, 1H), 3.82 – 3.69 (m, 4H), 3.61 (dd, J = 10.8, 4.6 Hz, 1H), 
3.58 (dd, J = 10.9, 4.5 Hz, 1H), 3.35 (ddd, J = 11.0, 5.5, 5.4 Hz, 1H), 
3.27 (ddd, J = 11.4, 5.8, 5.7 Hz, 1H), 2.46 – 2.20 (m, 4H), 2.10 – 2.01 (m, 2H), 1.97 – 1.87 (m, 5H), 
1.84 (t, J = 2.6 Hz, 1H), 1.81 – 1.67 (m, 3H), 1.69 (dd, J = 13.8, 7.2 Hz, 1H), 1.34 – 1.20 (m, 3H), 1.17 
– 1.11 (m, 1H), 1.01 (s, 9H), 1.01 (s, 9H), 0.97 (d, J = 6.8 Hz, 3H), 0.87 (s, 9H), 0.84 (d, J = 7.1 Hz, 
3H), 0.05 (s, 3H), 0.04 (s, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 165.6, 148.4, 144.7, 136.0, 
135.9, 135.6, 135.5, 135.5, 134.5, 133.8, 133.4, 133.4, 129.6, 129.3, 129.1, 127.7, 127.6, 127.6, 127.6, 
127.3, 127.1, 123.4, 108.2, 84.4, 81.6, 80.9, 79.3, 78.3, 74.1, 73.2, 72.2, 71.3, 69.2, 68.6, 65.2, 42.3, 
41.3, 41.3, 38.8, 35.1, 34.9, 34.5, 33.3, 27.2, 26.7, 25.8, 20.7, 19.8, 19.5, 19.2, 18.1, 14.8, 4.2, 4.5, 
4.5 ppm. IR (film): ṽ = 2955, 2930, 2856, 1720, 1472, 1462, 1428, 1377, 1257, 1176, 1110, 1070, 
1006, 836, 776, 739, 702, 611 cm
−1
. MS (ESIpos) m/z (%) = 1115.8 (100 (M+Na). HRMS (ESIpos): 
m/z: calcd for C67H92O7Si3Na: 1115.6043; found:1115.6052. 
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Diyne (11-epi-220). Prepared analogously from acid 11-epi-151 (89 mg, 0.219 mmol) and alcohol ent-
194 (140 mg, 0.199 mmol) as a white foam (1
st
 step: 116 mg, 53% 
yield, 2
nd
 step: 108 mg, 93%). [∝]𝐷
20 = +40.9 (c = 0.90, CH2Cl2). 
1
H 
NMR (400 MHz, CDCl3): δ = 7.66 – 7.57 (m, 8H), 7.41 – 7.25 (m, 
12H), 6.85 (dt, J = 15.6, 7.1 Hz, 1H), 5.80 (dd, J = 15.8, 8.7 Hz, 1H), 
5.72 (dt, J = 15.6, 1.2 Hz, 1H), 5.41 (dd, J = 15.8, 2.2 Hz, 1H), 5.16 
(dtd, J = 9.0, 4.6, 4.1 Hz, 1H), 3.82 – 3.75 (m, 1H), 3.76 – 3.67 (m, 
3H), 3.62 (dd, J = 10.6, 4.8 Hz, 1H), 3.57 (dd, J = 10.7, 4.7 Hz, 1H), 
3.33 (dtd, J = 11.8, 5.8, 0.7 Hz, 1H), 3.26 – 3.17 (m, 1H), 2.49 – 2.35 (m, 2H), 2.31 (ddd, J = 6.3, 6.2, 
1.3 Hz, 1H), 2.23 (dt, J = 14.2, 7.1 Hz, 1H), 2.05 (t, J = 3.0 Hz, 1H), 2.03 (dd, J = 5.0, 2.7 Hz, 1H), 
1.95 – 1.86 (m, 2H), 1.89 (d, J = 2.2 Hz, 3H), 1.84 (t, J = 2.7 Hz, 1H), 1.80 – 1.65 (m, 3H), 1.53 (ddd, 
J = 13.9, 9.7, 4.2 Hz, 1H), 1.27 – 1.21 (m, 2H), 1.21 – 1.14 (m, 2H), 1.00 (s, 9H), 0.99 (s, 9H), 0.92 (d, 
J = 6.8 Hz, 3H), 0.85 (s, 9H), 0.84 (d, J = 7.0 Hz, 3H), 0.03 (s, 3H), 0.02 (s, 3H) ppm. 
13
C NMR 
(100 MHz, CDCl3): δ = 165.6, 148.1, 144.8, 136.0, 135.9, 135.6, 135.5, 134.5, 133.8, 133.4, 133.4, 
129.7, 129.6, 129.3, 129.1, 127.6, 127.6, 127.4, 127.1, 123.3, 109.1, 84.3, 81.6, 80.9, 79.3, 78.4, 73.9, 
73.3, 72.2, 71.3, 69.2, 68.5, 65.2, 42.9, 41.9, 41.3, 38.8, 35.1, 34.9, 34.6, 33.9, 27.2, 27.1, 26.7, 26.7, 
25.8, 21.0, 20.6, 19.5, 19.2, 18.1, 14.8, 4.2, −4.5, −4.5 ppm. IR (film): ṽ = 2955, 2930, 2857, 1721, 
1472, 1462, 1428, 1361, 1257, 1155, 1112, 1071, 1006, 836, 776, 702, 610 cm
−1
. MS (ESIpos) m/z 
(%) = 1115.6 (100 (M+Na). HRMS (ESIpos): m/z: calcd for C67H92O7Si3Na: 1115.6043; 
found:1115.6047. 
 
Macrocyclic Enyne 209. A flame-dried Schlenk tube was charged with powdered 4 Å molecular 
sieves (~1.2 g) and 5 Å molecular sieves (~1.5 g). The flask was then 
evacuated and the molecular sieves were flame-dried. After reaching 
ambient temperature, a solution of diyne 207 (191 mg, 0.175 mmol) in 
toluene (85 mL) was added and the resulting suspension was stirred for 45 
min. In a separate flame-dried Schlenk tube, a solution of the molybdenum 
alkylidyne complex C1 (18.2 mg, 17.5 µmol) in toluene (2 mL) was 
prepared. This solution was added dropwise to the flask containing the 
diyne via syringe and the resulting mixture was stirred at ambient temperature for 3 h. The mixture 
was filtered through a short pad of Celite
®
 that was carefully rinsed with Et2O (100 mL). The 
combined filtrates were evaporated and the brown residue was purified by flash chromatography 
(hexanes/EtOAc 29:1 to 24:1 to 19:1) to yield the target macrocycle as a white foam (133 mg, 72%). 
[∝]𝐷
20 = 7.4 (c = 0.87, CHCl3). 
1
H NMR (400 MHz, CDCl3): δ = 7.68 – 7.60 (m, 8H), 7.45 – 7.24 (m, 
12H), 6.87 (ddd, J = 15.7, 8.2, 5.7 Hz, 1H), 5.97 (dd, J = 16.0, 7.3 Hz, 1H), 5.73 (dt, J = 15.6, 1.3 Hz, 
1H), 5.32 (dq, J = 15.9, 1.7 Hz, 1H), 5.22 – 5.15 (m, 1H), 4.09 (ddd, J = 9.6, 5.7, 2.6 Hz, 1H), 3.82 – 
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3.74 (m, 2H), 3.74 – 3.69 (m, 1H), 3.67 (dd, J = 10.3, 4.9 Hz, 1H), 3.62 (dd, J = 10.4, 5.0 Hz, 1H), 
3.27 (dddd, J = 11.2, 9.2, 2.1, 1.8 Hz, 1H), 3.22 – 3.14 (m, 1H), 2.31 (tdd, J = 9.1, 4.6, 1.5 Hz, 1H), 
2.26 – 2.12 (m, 5H), 2.10 (ddd, J = 14.2, 9.3, 2.5 Hz, 1H), 1.86 – 1.67 (m, 4H), 1.61 – 1.50 (m, 1H), 
1.35 – 1.30 (m, 2H), 1.22 – 1.11 (m, 2H), 1.03 (s, 9H), 1.01 (s, 9H), 1.00 (d, J = 6.6 Hz, 3H), 0.92 (d, J 
= 6.9 Hz, 3H), 0.87 (s, 9H), 0.04 (s, 6H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 166.8, 148.5, 144.9, 
135.9, 135.8, 135.6, 135.2, 135.0, 134.9, 133.9, 133.6, 133.0, 129.5, 129.3, 129.2, 127.9, 127.6, 127.6, 
127.4, 127.2, 123.6, 107.8, 86.8, 81.3, 81.2, 78.5, 75.6, 74.5, 71.9, 71.7, 68.6, 65.5, 43.2, 42.2, 41.8, 
38.4, 36.5, 35.1, 34.0, 33.8, 29.7, 27.2, 26.8, 25.8, 21.6, 19.6, 19.3, 18.1, 13.8, 4.5 ppm. IR (film): ṽ = 
2955, 2929, 2856, 1718, 1472, 1462, 1428, 1361, 1328, 1256, 1174, 1112, 1071, 986, 836, 823, 775, 
737, 700 cm
−1
. MS (ESIpos) m/z (%) = 1075.7 (100 (M+Na). HRMS (ESIpos): m/z: calcd for 
C64H88O7Si3Na: 1075.5730; found: 1075.5725. 
 
Macrocyclic Enyne 11-epi-209. Prepared analogously (at room temperature) from diyne 11-epi-207 
(52 mg, 47.5 µmol) as a white foam (32 mg, 64%). [∝]𝐷
20 = +54.6 (c = 
1.04, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.69 (ddd, J = 7.7, 3.3, 
1.7 Hz, 4H), 7.63 – 7.56 (m, 4H), 7.44 – 7.25 (m, 12H), 6.97 (ddd, J = 
15.4, 8.2, 7.0 Hz, 1H), 5.73 (dt, J = 15.5, 1.1 Hz, 1H), 5.60 (dd, J = 15.7, 
9.6 Hz, 1H), 5.30 (dt, J = 15.7, 1.8 Hz, 1H), 5.09 – 5.02 (m, 1H), 4.16 
(ddd, J = 8.8, 6.8, 1.8 Hz, 1H), 3.85 (ddd, J = 8.2, 5.8, 3.9 Hz, 1H), 3.80 – 
3.68 (m, 2H), 3.65 (dd, J = 11.0, 3.4 Hz, 1H), 3.47 (dd, J = 11.0, 5.4 Hz, 
1H), 3.20 – 3.08 (m, 2H), 2.63 – 2.50 (m, 1H), 2.39 – 2.17 (m, 3H), 2.13 (dd, J = 12.9, 7.9, 1H), 2.07 
(ddd, J = 16.9, 5.7, 0.2 Hz, 1H), 1.90 (ddd, J = 14.5, 7.1, 2.1 Hz, 1H), 1.80 – 1.64 (m, 4H), 1.59 – 1.51 
(m, 1H), 1.51 – 1.41 (m, 1H), 1.30 – 1.14 (m, 3H), 1.02 (s, 9H), 1.01 (m, 3H), 1.00 (s, 9H), 0.97 (d, J 
= 6.3 Hz, 3H), 0.86 (s, 9H), 0.03 (s, 6H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 165.3, 146.2, 146.0, 
135.9, 135.9, 135.6, 134.8, 134.6, 133.6, 133.6, 129.5, 129.2, 129.1, 127.6, 127.5, 127.3, 127.2, 123.3, 
110.4, 86.6, 81.6, 81.0, 78.8, 75.5, 74.1, 72.9, 72.9, 68.7, 65.8, 42.6, 42.2, 41.9, 38.6, 36.6, 35.8, 35.3, 
33.8, 27.3, 26.8, 25.8, 23.1, 21.3, 19.7, 19.3, 18.1, 13.7, 4.5, 4.6 ppm. IR (film): ṽ = 2955, 2930, 
2857, 1722, 1472, 1462, 1428, 1361, 1327, 1257, 1176, 1112, 1067, 854, 836, 823, 776, 739, 701, 608 
cm
−1
. MS (ESIpos) m/z (%) = 1075.6 (100 (M+Na). HRMS (ESIpos): m/z: calcd for C64H88O7Si3Na: 
1075.5730; found:1075.5722. 
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Macrocyclic Enyne 221. A slightly modified procedure had to be used: A flame-dried Schlenk tube 
was charged with powdered 4 Å molecular sieves (~0.7 g) and 5 Å 
molecular sieves (~0.9 g). The flask was then evacuated and the molecular 
sieves were flame-dried. After reaching ambient temperature, a solution of 
diyne 220 (90 mg, 82.3 µmol) in toluene (40 mL) was added and the 
resulting suspension was stirred for 45 min. The solution was then placed 
in a pre-heated oilbath (85 °C). In a separate flame-dried Schlenk tube, a 
solution of the molybdenum alkylidyne complex C1 (8.6 mg, 8.2 µmol) in 
toluene (2 mL) was prepared. This solution was added dropwise to the flask containing the diyne via 
syringe at 85 °C and the resulting mixture was stirred for 2 h. After cooling to room temperature, the 
mixture was filtered through a short pad of Celite
®
 that was carefully rinsed with Et2O (100 mL). The 
combined filtrates were evaporated and the brown residue was purified by flash chromatography 
(hexanes/EtOAc 29:1 to 24:1 to 19:1) to yield the targeted macrocycle as a white foam (64 mg, 74%). 
[∝]𝐷
20 = +8.5 (c = 1.31, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.68 – 7.58 (m, 8H), 7.42 – 7.25 
(m, 12H), 6.82 (ddd, J = 15.9, 5.3, 5.3 Hz, 1H), 5.87 (dd, J = 15.9, 7.8 Hz, 1H), 5.74 (dt, J = 15.9, 
1.4 Hz, 1H), 5.36 (dt, J = 15.9, 1.9 Hz, 1H), 5.13 – 5.05 (m, 1H), 4.08 (ddd, J = 9.9, 5.4, 1.1 Hz, 1H), 
3.86 (ddd, J = 8.0, 8.0, 4.2 Hz, 1H), 3.82 – 3.70 (m, 2H), 3.70 (dd, J = 10.7,4.4 Hz, 1H), 3.67 (dd, J = 
10.6, 4.0 Hz, 1H),  3.42 (dd, J = 11.0, 9.5 Hz, 1H), 3.22 (dt, J = 10.4, 5.4 Hz, 1H), 2.38 – 2.07 (m, 
7H), 1.86 – 1.67 (m, 4H),  1.52 (ddd, J = 13.8, 8.2, 5.5 Hz, 1H), 1.47 (d, J = 10.9 Hz, 1H), 1.39 (ddd, J 
= 13.9, 6.3, 4.0 Hz, 1H), 1.28 (q, J = 11.5 Hz, 1H), 1.14 (dq, J = 11.1, 10.2 Hz, 1H), 1.05 (s, 9H), 1.00 
(s, 9H), 0.99 (d, J = 7.6 Hz, 3H), 0.91 (d, J = 6.9 Hz, 3H), 0.88 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ =165.9, 147.8, 145.0, 135.9, 135.8, 135.6, 134.9, 134.7, 133.7, 133.6, 
133.4, 129.6, 129.5, 129.2, 129.2, 127.9, 127.7, 127.6, 127.4, 127.2, 122.3, 108.8, 86.2, 81.2, 80.5, 
78.6, 74.2, 73.2, 71.4, 71.2, 68.7, 65.3, 42.7, 41.9, 41.4, 37.3, 36.4, 34.5, 33.4, 33.3, 27.2, 27.1, 26.8, 
25.8, 23.2, 21.5, 19.5, 19.3, 18.1, 13.5, −4.5 ppm. IR (film): ṽ = 2956, 2930, 2856, 1720, 1472, 1462, 
1428, 1361, 1331, 1257, 1178, 1111, 1070, 937, 837, 823, 776, 739, 702, 610 cm
−1
. MS (ESIpos) m/z 
(%) = 1075.7 (100 (M+Na). HRMS (ESIpos): m/z: calcd for C64H88O7Si3Na: 1075.5730; found: 
1075.5736. 
 
Macrocyclic Enyne 11-epi-221. Prepared analogously (at room temperature) from diyne 11-epi-220 
(107 mg, 97.8 µmol) as a white foam (85.1 mg, 83%). [∝]𝐷
20 = +57.4 (c = 
0.56, CH2Cl2). 
1
H NMR (300 MHz, CDCl3): δ = 7.72 – 7.60 (m, 8H), 7.42 
– 7.25 (m, 12H), 6.85 (dt, J = 15.9, 5.2 Hz, 1H), 5.73 (dt, J = 15.8, 1.6 Hz, 
1H), 5.69 (dd, J = 15.8, 8.8 Hz, 1H), 5.56 (dt, J = 15.8, 1.7 Hz, 1H), 5.22 
– 5.13 (m, 1H), 4.24 (dd, J = 10.3, 6.0 Hz, 1H), 3.91 – 3.73 (m, 5H), 3.44 
(t, J = 10.6 Hz, 1H), 3.27 (t, J = 11.1 Hz, 1H), 2.56 – 2.33 (m, 2H), 2.29 – 
2.19 (m, 2H), 2.18 – 2.08 (m, 2H), 1.86 – 1.63 (m, 5H), 1.54 (ddd, J = 
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14.0, 11.3, 2.9 Hz, 1H), 1.34 – 1.14 (m, 4H), 1.05 (s, 9H), 1.04 (m, 3H), 1.01 (s, 9H), 0.90 (s, 9H), 
0.82 (d, J = 6.7 Hz, 3H), 0.09 (s, 3H), 0.08 (s, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 166.0, 
146.2, 145.7, 136.0, 135.8, 135.5, 135.5, 135.1, 134.0, 133.5, 133.4, 129.6, 129.5, 129.0, 128.9, 127.6, 
127.3, 127.0, 121.6, 110.1, 87.1, 82.4, 81.7, 78.2, 73.5, 72.8, 72.2, 72.0, 68.6, 65.1, 43.0, 42.1, 37.8, 
36.9, 33.9, 33.6, 33.2, 27.2, 26.8, 26.8, 25.9, 25.8, 23.0, 21.4, 19.5, 19.3, 18.1, 13.2, −4.5, −4.6 ppm. 
IR (film): ṽ = 2955, 2929, 2856, 1720, 1472, 1462, 1378, 1361, 1291, 1256, 1176, 1111, 1075, 1006, 
837, 776, 739, 702, 611 cm
−1
. MS (ESIpos) m/z (%) = 1075.8 (100 (M+Na). HRMS (ESIpos): m/z: 
calcd for C64H88O7Si3Na: m/z: 1075.5730; found:1075.5724. 
 
Macrocyclic Diene 210. In order to obtain reproducible results, all solvents used for the preparation 
of the activated Zn(Cu/Ag) and the reaction were degassed by bubbling 
Ar through the solvent for at least 20 min. 
A Young tube was evacuated, backfilled with Argon and charged with a 
mixture of MeOH/H2O (1:1, 1.8 mL). Freshly prepared Zn(Cu/Ag)
[96]
 
(1.6 g) was added, followed by a solution of enyne 209 (130 mg, 
0.123 mmol) in THF (0.5 mL + 2 x 0.2 mL rinse). The Young tube was 
sealed and placed in a preheated (45 °C) oil bath. The suspension was 
vigorously stirred at this temperature for 70 h before it was allowed to reach ambient temperature. The 
mixture was filtered through a short pad of Celite
®
 that was rinsed with EtOAc/EtOH (9:1, 75 mL). 
The combined filtrates were concentrated to 1/10 of the original volume before brine (10 mL) was 
added. The aqueous phase was extracted with EtOAc (3 x 10 mL) and the combined organic extracts 
were dried over Na2SO4 and concentrated. The residue was purified by flash chromatography 
(hexanes/EtOAc 29:1 to 24:1 to 19:1) to give the desired diene as a white foam (115 mg, 89%). [∝]𝐷
20 
= 47.9 (c = 0.70, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.64 – 7.54 (m, 8H), 7.40 – 7.22 (m, 
12H), 6.84 (ddd, J = 15.7, 8.0, 5.5 Hz, 1H), 6.19 (dd, J = 15.4, 10.8 Hz, 1H), 5.88 (t, J = 10.8 Hz, 1H), 
5.76 (dt, J = 15.7, 1.4 Hz, 1H), 5.55 (dd, J = 15.4, 6.8 Hz, 1H), 5.18 – 5.08 (m, 2H), 3.99 (ddd, J = 8.8, 
6.0, 2.3 Hz, 1H), 3.73 (td, J = 7.9, 6.3 Hz, 1H), 3.66 (dt, J = 10.0, 4.8 Hz, 1H), 3.64 – 3.59 (m, 2H), 
3.56 (dt, J = 7.0, 5.7 Hz, 1H), 3.28 – 3.14 (m, 2H), 2.43 – 2.33 (m, 1H), 2.32 – 2.24 (m, 1H), 2.20 
(ddd, J = 16.0, 8.2, 2.7 Hz, 1H), 2.14 – 1.95 (m, 3H), 1.90 (dt, J = 15.7, 7.5 Hz, 1H), 1.85 – 1.77 (m, 
2H), 1.75 – 1.64 (m, 3H), 1.34 (ddd, J = 12.7, 7.3, 5.2 Hz, 1H), 1.29 – 1.25 (m, 1H), 1.23 – 1.17 (m, 
2H), 1.17 – 1.07 (m, 1H), 0.99 (s, 9H), 0.97 (s, 9H), 0.94 (d, J = 6. 7 Hz, 3H), 0.83 (s, 9H), 0.76 (d, J = 
7.1 Hz, 3H), 0.00 (s, 6H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 165.8, 145.0, 140.2, 136.0, 136.0, 
135.6, 135.6, 134.7, 133.9, 133.5, 133.5, 129.6, 129.5, 129.4, 127.6, 127.6, 127.4, 127.2, 126.4, 124.3, 
123.3, 81.4, 80.1, 74.2, 73.4, 72.0, 71.6, 68.7, 65.4, 43.1, 41.9, 41.9, 38.5, 35.4, 34.4, 34.3, 32.1, 30.0, 
27.2, 26.8, 25.8, 20.7, 19.5, 19.3, 18.1, 15.4, 4.5 ppm. IR (film): ṽ = 2956, 2930, 2857, 1721, 1654, 
1472, 1462, 1428, 1375, 1257, 1175, 1112, 1073, 1006, 836, 823, 775, 739, 702 cm
−1
. MS (ESIpos) 
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m/z (%) = 1077.6 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for C64H90O7Si3Na: 1077.5887; found: 
1075.5884. 
 
Macrocyclic Diene 11-epi-210. Prepared analogously from enyne 11-epi-209 (31.0 mg, 29.4 µmol) as 
a white foam (26.8 mg, 86%). [∝]𝐷
20 = +15.2 (c = 1.22, CH2Cl2). 
1
H NMR 
(400 MHz, CDCl3): δ = 7.66 – 7.53 (m, 8H), 7.42 – 7.20 (m, 12H), 7.09 
(ddd, J = 15.1, 10.3, 4.3 Hz, 1H), 6.21 (dd, J = 14.9, 11.1 Hz, 1H), 5.89 
(tt, J = 10.9, 1.9 Hz, 1H), 5.74 (dd, J = 15.6, 1.6 Hz, 1H), 5.25 (dd, J = 
14.9, 9.7 Hz, 1H), 5.12 – 5.02 (m, 2H), 3.92 – 3.82 (m, 2H), 3.77 – 3.65 
(m, 2H), 3.41 (dd, J = 11.2, 3.3 Hz, 1H), 3.34 (dd, J = 11.2, 5.3 Hz, 1H), 
3.18 – 3.04 (m, 2H), 2.71 – 2.59 (m, 1H), 2.40 (tdd, J = 9.6, 4.6, 1.9 Hz, 
1H), 2.26 – 2.11 (m, 4H), 2.03 (dt, J = 15.1, 7.4 Hz, 1H), 1.93 (dt, J = 14.6, 5.9 Hz, 1H), 1.85 – 1.72 
(m, 2H), 1.66 (dd, J = 12.5, 4.7 Hz, 1H), 1.56 (ddd, J = 14.0, 10.6, 2.9 Hz, 2H), 1.49 – 1.38 (m, 1H), 
1.25 – 1.12 (m, 4H), 1.01 (s, 9H), 0.99 (d, J = 6.8 Hz, 3H), 0.97 (s, 9H), 0.85 (s, 9H), 0.79 (d, J = 
7.0 Hz, 3H), 0.02 (s, 3H), 0.02 (s, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 165.2, 145.7, 139.8, 
135.9, 135.8, 135.7, 135.6, 134.1, 133.9, 133.7, 133.4, 129.6, 129.5, 127.6, 127.5, 127.5, 127.4, 125.9, 
125.6, 122.8, 81.3, 80.7, 75.1, 73.0, 72.3, 72.0, 68.5, 65.1, 43.5, 42.3, 42.1, 39.3, 35.6, 34.6, 34.6, 
33.9, 29.4, 27.1, 26.7, 25.8, 22.1, 19.4, 19.2, 18.1, 15.1, −4.5, −4.5 ppm. IR (film): ṽ = 2957, 2928, 
2856, 1724, 1427, 1257, 1157, 1113, 1076, 833, 822, 778, 741, 703, 557 cm
−1
. MS (ESIpos) m/z (%) = 
1077.6 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for C64H90O7Si3Na: 1077.5887; found: 1077.5884. 
 
Macrocyclic Diene 222. Prepared analogously from enyne 221 (26.3 mg, 25.0 µmol) as a white foam 
(24.1 mg, 91%).  [∝]𝐷
20 = +13.2 (c = 1.21, CH2Cl2). 
1
H NMR (400 MHz, 
CDCl3): δ = 7.67 – 7.58 (m, 8H), 7.42 – 7.25 (m, 12H), 6.88 (ddd, J = 
15.7, 7.6, 6.2 Hz, 1H), 6.21 (dd, J = 15.0, 11.0 Hz, 1H), 5.93 (t, J = 
10.7 Hz, 1H), 5.83 (dt, J = 15.7, 1.2 Hz, 1H), 5.20 (dd, J = 15.2, 8.1 Hz, 
1H), 5.24 – 5.13 (m, 2H), 4.01 (ddd, J = 8.6, 5.6, 3.0 Hz, 1H), 3.80 – 3.66 
(m, 2H), 3.64 – 3.57 (m, 2H), 3.54 (dd, J = 10.8, 4.9 Hz, 1H), 3.40 – 3.32 
(m, 1H), 3.31 – 3.23 (m, 1H), 2.40 (dd, J = 13.2, 7.2 Hz, 1H), 2.36 – 2.29 
(m, 1H), 2.20 – 2.08 (m, 2H), 1.99 (dt, J = 13.9, 7.2 Hz, 1H), 1.93 (dt, J = 14.6, 5.9 Hz, 1H), 1.91 
(ddd, J = 14.5, 8.4, 3.0 Hz, 1H), 1.85 – 1.69 (m, 4H), 1.36 (dt, J = 12.8, 7.6 Hz, 1H), 1.34 – 1.25 (m, 
2H), 1.23 – 1.13 (m, 2H), 1.00 (s, 18H), 0.95 (d, J = 6.8 Hz, 3H), 0.89 (d, J = 7.3 Hz, 3H) 0.87 (s, 9H), 
0.05 (s, 6H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 165.7, 145.2, 140.1, 136.0, 135.9, 135.6, 135.6, 
134.7, 134.0, 133.5, 133.4, 129.9, 129.5, 129.3, 127.6, 127.3, 127.3, 126.8, 124.3, 123.3, 81.2, 80.1, 
73.8, 73.2, 72.7, 71.6, 68.8, 65.5, 43.0, 41.9, 41.8, 38.5, 35.7, 34.4, 34.1, 33.3, 30.2, 27.2, 26.7, 25.8, 
20.2, 19.5, 19.2, 18.1, 15.2, −4.5 ppm. IR (film): ṽ = 2956, 2929, 2857, 1722, 1428, 1293, 1258, 1177, 
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1107, 741, 702 cm
−1
. MS (ESIpos) m/z (%) = 1077.7 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for 
C64H90O7Si3Na: 1077.5887; found: 1077.5896. 
 
Macrocyclic Diene 11-epi-222. Prepared analogously from enyne 11-epi-221 (71.0 mg, 67.4 µmol) as 
a white foam (59.2 mg, 83%). [∝]𝐷
20 = +79.1 (c = 1.05, CH2Cl2). 
1
H NMR 
(400 MHz, CDCl3): δ = 7.66 – 7.57 (m, 8H), 7.42 – 7.25 (m, 12H), 6.84 
(ddd, J = 15.8, 7.2, 5.6 Hz, 1H), 6.26 (dd, J = 15.2, 10.9 Hz, 1H), 5.98 (t, 
J = 10.9 Hz, 1H), 5.72 (dt, J = 15.7, 1.4 Hz, 1H), 5.36 (dd, J = 15.1, 
8.6 Hz, 1H), 5.22 (td, J = 10.0, 6.3 Hz, 1H), 5.02 – 4.94 (m, 1H), 4.10 
(ddd, J = 8.8, 4.9, 2.3 Hz, 1H), 3.82 (td, J = 7.8, 4.8 Hz, 1H), 3.76 – 3.61 
(m, 4H), 3.28 (ddt, J = 10.9, 9.6, 1.6 Hz, 1H), 3.21 (t, J = 10.9 Hz, 1H), 
2.59 – 2.47 (m, 1H), 2.45 – 2.16 (m, 5H), 2.09 (dtd, J = 14.7, 5.4, 1.1 Hz, 1H), 1.90 (dt, J = 13.0, 
7.8 Hz, 1H), 1.82 – 1.72 (m, 2H), 1.69 – 1.62 (m, 1H), 1.59 – 1.48 (m, 2H), 1.28 – 1.13 (m, 3H), 1.03 
(s, 9H), 1.01 (s, 9H), 0.99 (d, J = 7.0 Hz, 3H), 0.88 (s, 9H) 0.82 (d, J = 7.0 Hz, 3H), 0.06 (s, 3H), 0.05 
(s, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 165.7, 145.0, 141.2, 135.9, 135.9, 135.6, 135.5, 134.3, 
133.6, 133.4, 133.3, 130.0, 129.6, 129.5, 129.4, 129.4, 127.6, 127.6, 127.5, 127.4, 126.8, 125.5, 122.9, 
81.3, 79.7, 73.8, 73.2, 72.4, 70.8, 68.5, 65.4, 44.2, 42.4, 42.3, 39.0, 35.7, 33.3, 33.3, 33.1, 30.8, 27.1, 
26.7, 25.8, 22.9, 19.4, 19.2, 18.1, 15.3, −4.5 ppm. IR (film): ṽ = 2955, 2931, 2857, 1718, 1472, 1462, 
1428, 1257, 1177, 1155, 1112, 1076, 1005, 836, 776, 737, 702 cm
−1
. MS (ESIpos) m/z (%) = 1077.7 
(100 (M+Na)). HRMS (ESIpos): m/z: calcd for C64H90O7Si3Na: 1077.5887; found: 1077.5878. 
 
Alcohol 211. pTsOH·H2O (6.2 mg, 32.6 µmol) was added to a solution of silyl ether 210 (114 mg, 
0.109 mmol) in CH2Cl2/MeOH (2:1, 12 mL) and the mixture was stirred 
for 5 h. The reaction was quenched by addition of sat. NaHCO3 solution 
(12 mL) and the aqueous layer was extracted with CH2Cl2 (3 x 8 mL). The 
combined extracts were dried over Na2SO4 and concentrated, and the 
residue was purified by flash chromatography (hexanes/EtOAc 2:1) to 
yield the desired alcohol as a white foam (92 mg, 90%). [∝]𝐷
20 = 42.5 (c 
= 0.89, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.70 – 7.58 (m, 8H), 
7.43 – 7.25 (m, 12H), 6.87 (ddd, J = 15.8, 7.9, 5.7 Hz, 1H), 6.23 (ddt, J = 15.6, 10.8, 1.2 Hz, 1H), 5.92 
(t, J = 10.8 Hz, 1H), 5.80 (dt, J = 15.8, 1.4 Hz, 1H), 5.59 (dd, J = 15.4, 6.9 Hz, 1H), 5.23 – 5.12 (m, 
2H), 4.03 (ddd, J = 8.8, 6.0, 2.3 Hz, 1H), 3.83 – 3.71 (m, 2H), 3.71 – 3.56 (m, 3H), 3.35 – 3.21 (m, 
2H), 2.46 – 2.30 (m, 2H), 2.27 (tdd, J = 7.5, 3.0, 1.3 Hz, 1H), 2.18 – 2.05 (m, 2H), 2.03 (ddd, J = 14.5, 
10.1, 0.1 Hz, 1H), 1.99 – 1.81 (m, 5H), 1.76 (ddd, J = 14.0, 8.2, 6.0 Hz, 1H), 1.52 – 1.44 (br s, 1H), 
1.38 (ddd, J = 12.8, 7.3, 5.4 Hz, 1H), 1.33 (ddd, J = 13.5, 8.1, 4.8 Hz, 1H), 1.22 (ddd, J = 11.5, 10.9, 
10.6 Hz, 1H), 1.13 (ddd, J = 11.6, 11.3, 1.09 Hz, 1H), 1.03 (s, 9H), 1.01 (s, 9H), 0.98 (d, J = 6.7 Hz, 
3H), 0.80 (d, J = 7.0 Hz, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 165.7, 143.7, 140.0, 136.0, 
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136.0, 135.6, 135.6, 134.6, 133.9, 133.5, 130.0, 129.6, 129.6, 129.4, 129.2, 127.6, 127.6, 127.4, 127.2, 
126.4, 124.4, 123.3, 81.4, 80.1, 74.2, 73.4, 72.1, 71.6, 68.1, 65.4, 42.9, 41.4, 41.3, 38.4, 35.4, 34.5, 
34.3, 32.1, 30.0, 27.2, 26.8, 20.9, 19.5, 15.4 ppm. IR (film): ṽ = 3454, 2957, 2930, 2857, 1720, 1654, 
1472, 1427, 1361, 1265, 1176, 1112, 1006, 822, 739, 702 cm
−1
. MS (ESIpos) m/z (%) = 963.6 (100 
(M+Na). HRMS (ESIpos): m/z: calcd for C58H76O7Si2Na: 963.5022; found: 963.5028. 
 
Alcohol 11-epi-211. Prepared analogously from silyl ether 11-epi-210 (24.2 mg, 22.9 µmol) as a white 
foam (19.3 mg, 89%). [∝]𝐷
20 = +28.4 (c = 0.96, CH2Cl2). 
1
H NMR 
(400 MHz, CDCl3): δ = 7.66 – 7.53 (m, 8H), 7.42 – 7.20 (m, 12H), 7.07 
(ddd, J = 15.1, 10.2, 4.4 Hz, 1H), 6.20 (dd, J = 14.9, 11.0 Hz, 1H), 5.87 
(tt, J = 10.9, 1.9 Hz, 1H), 5.75 (dd, J = 15.6, 1.7 Hz, 1H), 5.24 (dd, J = 
14.9, 9.7 Hz, 1H), 5.11 – 5.01 (m, 2H), 3.93 – 3.83 (m, 2H), 3.79 – 3.68 
(m, 2H), 3.41 (dd, J = 11.1, 3.5 Hz, 1H), 3.35 (dd, J = 11.2, 5.3 Hz, 1H), 
3.21 – 3.07 (m, 2H), 2.64 (tt, J = 9.5, 3.4 Hz, 1H), 2.42 (tdd, J = 9.6, 4.7, 
1.9 Hz, 1H), 2.27 – 2.10 (m, 4H), 2.02 (dd, J = 8.0, 7.7, 7.4 Hz, 1H), 1.96 – 1.86 (m, 2H), 1.84 – 1.75 
(m, 2H), 1.63 – 1.52 (m, 2H), 1.42 (ddd, J = 13.6, 7.2, 3.5 Hz, 1H), 1.23 – 1.11 (m, 3H), 1.01 (s, 9H), 
0.99 (d, J = 6.8 Hz, 3H), 0.97 (s, 9H), 0.78 (d, J = 7.0 Hz, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 
165.2, 145.4, 139.6, 135.9, 135.8, 135.7, 135.6, 134.1, 133.9, 133.6, 133.5, 129.6, 129.5, 127.6, 127.5, 
127.5, 127.4, 126.0, 125.7, 122.9, 81.3, 80.8, 75.0, 73.1, 72.4, 72.1, 68.0, 65.2, 43.4, 41.7, 41.6, 39.2, 
35.6, 34.6, 34.6, 34.0, 29.5, 27.1, 26.7, 20.1, 19.4, 19.2, 15.1 ppm. IR (film): ṽ = 3414, 2957, 2930, 
2857, 1722, 1655, 1472, 1428, 1361, 1326, 1262, 1177, 1111, 990, 822, 739, 702, 610 cm
−1
. MS 
(ESIpos) m/z (%) = 963.6 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for C58H76O7Si2Na: 963.5022; 
found: 963.5017. 
 
Secondary alcohol 223. Prepared analogously from silyl ether 222 (24.1 mg, 22.8 µmol) as a white 
foam (18.4 mg, 86%). [∝]𝐷
20 = +13.8 (c = 0.92, CH2Cl2). 
1
H NMR 
(400 MHz, CDCl3): δ = 7.66 – 7.57 (m, 8H), 7.43 – 7.23 (m, 12H), 6.87 
(ddd, J = 15.7, 7.3, 6.3 Hz, 1H), 6.25 (dd, J = 15.1, 10.9 Hz, 1H), 5.93 (t, 
J = 10.9 Hz, 1H), 5.83 (dt, J = 15.7, 1.0 Hz, 1H), 5.53 (dd, J = 15.1, 
8.0 Hz, 1H), 5.25 – 5.13 (m, 2H), 4.02 (ddd, J = 8.8, 5.6, 3.1 Hz, 1H), 
3.79 (ddt, J = 10.7, 10.2, 5.1 Hz, 1H), 3.70 (ddd, J = 7.7, 7.6, 5.7 Hz, 1H), 
3.64 – 3.58 (m, 2H), 3.54 (dd, J = 10.9, 4.9 Hz, 1H), 3.43 – 3.35 (m, 1H), 
3.30 (dddd, J = 10.6, 8.9, 3.7, 1.7 Hz, 1H), 2.45 – 2.29 (m, 3H), 2.21 – 2.09 (m, 2H), 2.01 (dt, J = 
13.9, 6.8 Hz, 1H),  1.97 – 1.81 (m, 4H), 1.75 (ddd, J = 14.5, 9.0, 3.4 Hz, 1H), 1.64 (ddd, J = 13.9, 8.6, 
5.4 Hz, 1H), 1.60 – 1.47 (br d, 1H), 1.43 – 1.30 (m, 2H), 1.23 – 1.08 (m, 2H), 1.00 (s, 9H), 1.00 (s, 
9H),  0.95 (d, J = 6.8 Hz, 3H), 0.89 (d, J = 7.1 Hz, 3H) ppm. 
13
C NMR (100 MHz, CDCl3): δ = 165.6, 
144.9, 140.0, 136.0, 135.9, 135.6, 135.6, 134.6, 134.0, 133.4, 129.9, 129.5, 129.4, 127.6, 127.3, 127.3, 
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126.8, 124.3, 123.4, 81.2, 80.0, 73.7, 73.2, 72.5, 71.6, 68.1, 65.4, 43.0, 41.3, 41.3, 38.4, 35.6, 34.3, 
34.0, 33.1, 30.2, 27.2, 26.7, 20.2, 19.5, 19.2, 15.2 ppm. IR (film): ṽ = 3422, 2957, 2931, 2857, 1719, 
1656, 1472, 1428, 1362, 1265, 1177, 1111, 982, 823, 740, 702, 611 cm
−1
. MS (ESIpos) m/z (%) = 
963.6 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for C58H76O7Si2Na: 963.5022; found: 963.5021. 
 
Alcohol 11-epi-223. Prepared analogously from silyl ether 11-epi-222 (23.1 mg, 21.9 µmol) as a white 
foam (18.5 mg, 90%). [∝]𝐷
20 = +100.5 (c = 0.92, CH2Cl2). 
1
H NMR 
(400 MHz, CDCl3): δ = 7.67 – 7.55 (m, 8H), 7.42 – 7.23 (m, 12H), 6.82 
(ddd, J = 15.8, 7.2, 5.4 Hz, 1H), 6.25 (dd, J = 15.2, 10.9 Hz, 1H), 5.96 (t, 
J = 10.9 Hz, 1H), 5.71 (dt, J = 15.7, 1.4 Hz, 1H), 5.34 (dd, J = 15.1, 
8.5 Hz, 1H), 5.22 (td, J = 10.2, 6.1 Hz, 1H), 5.02 – 4.95 (m, 1H), 4.10 
(ddd, J = 8.9, 4.8, 2.3 Hz, 1H), 3.80 (td, J = 7.8, 4.8 Hz, 1H), 3.77 – 3.70 
(m, 2H), 3.70 – 3.62 (m, 2H), 3.31 (ddt, J = 11.3, 9.5, 2.0 Hz, 1H), 3.24 (t, 
J = 10.7 Hz, 1H), 2.57 – 2.47 (m, 1H), 2.42 (dddd, J = 16.4, 9.5, 5.4, 1.7 Hz, 1H), 2.38 – 2.16 (m, 4H), 
2.08 (dt, J = 14.9, 5.2 Hz, 1H), 1.95 – 1.85 (m, 2H), 1.82 – 1.73 (m, 2H), 1.60 – 1.50 (m, 2H), 1.25 – 
1.12 (m, 4H), 1.03 (s, 9H), 1.00 (s, 9H),  0.98 (d, J = 7.2 Hz, 3H), 0.82 (d, J = 6.8 Hz, 3H) ppm. 
13
C 
NMR (100 MHz, CDCl3): δ = 165.7, 144.7, 141.0, 135.9, 135.9, 135.5, 135.5, 134.2, 133.5, 133.4, 
133.3, 130.0, 129.6, 129.5, 129.4, 129.4, 127.6, 127.5, 127.4, 126.9, 125.6, 123.0, 81.3, 79.6, 73.6, 
73.2, 72.3, 70.6, 67.9, 65.4, 44.2, 41.8, 41.7, 38.9, 35.6, 33.3, 33.2, 33.0, 30.8, 27.1, 26.7, 22.9, 19.4, 
19.2, 15.4 ppm. IR (film): ṽ = 3456, 2957, 2931, 2857, 1714, 1472, 1462, 1428, 1362, 1268, 1180, 
1110, 1089, 1048, 999, 908, 822, 731, 701, 610 cm
−1
. MS (ESIpos) m/z (%) = 963.6 (100 (M+Na)). 
HRMS (ESIpos): m/z: calcd for C58H76O7Si2Na: 963.5022; found: 963.5024. 
 
Glycoside 212. A Schlenk tube was charged with powdered 4 Å MS (400 mg) and flame-dried in 
vacuo. After reaching RT, the molecular sieves were suspended in 
CH2Cl2 (10 mL) and a solution of alcohol 211 (87.0 mg, 92.4 µmol) in 
CH2Cl2 (1.6 mL) was introduced. Rhamnosyl donor 201 (56.3 mg, 
139 µmol) was added as a solid and the resulting suspension was 
stirred for 45 min at ambient temperature before it was cooled to 
50 °C. A solution of TESOTf (0.1 M, 277 µL, 27.7 µmol) was added 
dropwise via syringe over 1 min. After stirring for 30 min at 50 °C, 
the reaction was quenched with NEt3 (0.1 mL), the mixture was filtered 
through a pad of Celite
®
 and the filtrate was evaporated. The crude 
residue was purified by flash chromatography (hexanes/EtOAc 3:1) to yield the desired glycoside as a 
white foam (97.0 mg, 88% yield, 16:1 d.r.). [∝]𝐷
20 = 61.5 (c = 0.82, CHCl3). 
1
H NMR (600 MHz, 
CDCl3): δ = 7.70 – 7.55 (m, 8H), 7.43 – 7.24 (m, 12H), 6.85 (ddd, J = 15.8, 8.1, 5.5 Hz, 1H), 6.23 (dd, 
J = 15.4, 10.8 Hz, 1H), 5.91 (t, J = 10.8 Hz, 1H), 5.80 (dt, J = 15.7, 1.1 Hz, 1H), 5.58 (dd, J = 15.4, 
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6.8 Hz, 1H), 5.23 – 5.14 (m, 3H), 5.08 (t, J = 9.9 Hz, 1H), 4.95 (d, J = 1.9 Hz, 1H), 4.02 (ddd, J = 8.8, 
6.1, 2.4 Hz, 1H), 3.82 (dq, J = 9.7, 6.3 Hz, 1H), 3.79 – 3.70 (m, 2H), 3.65 (dd, J = 10.7, 4.5 Hz, 2H), 
3.60 (q, J = 6.4 Hz, 1H), 3.54 (dd, J = 3.3, 1.8 Hz, 1H), 3.45 (s, 3H), 3.32 – 3.23 (m, 2H), 2.44 – 2.37 
(m, 1H), 2.37 – 2.31 (m, 1H), 2.25 (ddd, J = 15.3, 8.1, 2.6 Hz, 1H), 2.14 – 2.06 (m, 2H), 2.05 (s, 3H), 
2.03 – 1.99 (m, 1H), 2.00 (s, 3H), 1.98 – 1.90 (m, 2H), 1.90 – 1.81 (m, 3H), 1.75 (ddd, J = 14.1, 8.5, 
6.0 Hz, 1H), 1.37 (ddd, J = 12.7, 7.3, 5.1 Hz, 1H), 1.34 – 1.28 (m, 2H), 1.27 – 1.26 (m, 1H), 1.17 (d, J 
= 6.3 Hz, 3H), 1.02 (s, 9H), 1.00 (s, 9H), 0.98 (d, J = 6.7 Hz, 3H), 0.79 (d, J = 7.1 Hz, 3H) ppm. 
13
C 
NMR (150 MHz, CDCl3): δ = 170.3, 169.9, 165.7, 144.5, 140.0, 136.0, 136.0, 135.6, 135.6, 135.6, 
134.6, 133.9, 133.5, 130.0, 129.6, 129.6, 129.4, 129.2, 127.6, 127.6, 127.4, 127.2, 126.5, 124.4, 123.5, 
95.4, 81.4, 80.1, 78.8, 74.1, 73.4, 73.2, 72.1, 71.7, 71.6, 71.6, 66.7, 65.4, 59.6, 43.0, 39.1, 38.5, 37.6, 
35.4, 34.5, 34.3, 32.1, 29.9, 29.7, 27.2, 26.8, 21.0, 20.8, 19.5, 19.3, 17.5, 15.3 ppm. IR (film): ṽ = 
2958, 2929, 2857, 1745, 1720, 1654, 1472, 1361, 1427, 1365, 1241, 1223, 1177, 1107, 1074, 1040, 
998, 822, 803, 755, 702 cm
−1
. MS (ESIpos) m/z (%) = 1207.6 (100 (M+Na)). HRMS (ESIpos): m/z: 
calcd for C69H92O13Si2Na: 1207.5969; found: 107.5976. 
 
Glycoside 11-epi-212. Prepared analogously from 11-epi-211 (24.2 mg, 22.9 µmol) as a white foam 
(20.6 mg, 87% yield, single diastereomer). [∝]𝐷
20 = 17.4 (c = 0.87, 
CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.67 – 7.52 (m, 8H), 7.43 – 
7.24 (m, 11H), 7.23 – 7.20 (m, 1H), 7.05 (ddd, J = 15.2, 10.3, 4.4 Hz, 
1H), 6.19 (dd, J = 14.9, 11.0 Hz, 1H), 5.87 (t, J = 11.0 Hz, 1H), 5.74 
(dd, J = 15.6, 1.1 Hz, 1H), 5.24 (dd, J = 15.0 Hz, 9.7 Hz, 1H), 5.18 (dd, 
J = 10.1, 3.2 Hz, 1H), 5.12 – 5.00 (m, 3H), 4.91 (d, J = 1.9 Hz, 1H), 
3.92 – 3.83 (m, 2H), 3.80 (dq, J = 9.5, 6.2 Hz, 1H), 3.77 – 3.66 (m, 
2H), 3.52 (dd, J = 3.18, 1.98 Hz, 1H), 3.43 (s, 3H), 3.40 (dd, J = 11.1, 
3.5 Hz, 1H), 3.35 (dd, J = 11.2, 5.1 Hz, 1H), 3.21 – 3.06 (m, 2H), 2.69 
– 2.56 (m, 1H), 2.43 (dddd, J = 14.1, 9.3, 4.3, 1.5 Hz, 1H), 2.25 – 2.17 (m, 2H), 2.17 – 2.10 (m, 2H), 
2.04 (s, 3H), 2.01 (s, 3H), 1.96 – 1.87 (m, 2H), 1.83 – 1.74 (m, 2H), 1.56 (dd, J = 14.0, 2.8 Hz, 1H), 
1.45 – 1.37 (m, 1H), 1.31 (q, J = 11.7 Hz, 2H), 1.23 – 1.16 (m, 2H), 1.15 (d, J = 6.2 Hz, 3H), 1.00 (s, 
9H), 0.98 (d, J = 6.6 Hz, 3H), 0.96 (s, 9H), 0.78 (d, J = 7.0 Hz, 3H) ppm. 
13
C NMR (100 MHz, 
CDCl3): δ = 170.3, 169.9, 165.2, 145.3, 139.5, 135.9, 135.8, 135.6, 135.6, 134.1, 133.9, 133.6, 133.4, 
129.6, 129.5, 129.5, 127.6, 127.5, 127.5, 127.4, 126.0, 125.7, 123.0, 95.4, 81.3, 80.8, 78.8, 75.0, 73.1, 
73.1, 72.4, 72.1, 71.6, 71.6, 66.6, 65.1, 59.6, 43.4, 39.3, 39.3, 37.9, 35.6, 34.6, 33.9, 29.4, 27.0, 26.7, 
22.0, 21.0, 20.8, 19.4, 19.2, 17.4, 15.1 ppm. IR (film): ṽ = 2956, 2930, 2857, 1725, 1428, 1365, 1327, 
1243, 1223, 1178, 1110, 1042, 912, 824, 736, 703, 611 cm
−1
. MS (ESIpos) m/z (%) = 1207.6 (100 
(M+Na)). HRMS (ESIpos): m/z: calcd for C69H92O13Si2Na: 1207.5969; found: 1207.5966. 
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Glycoside 223a. Prepared analogously from 223 (18.4 mg, 19.5 µmol) as a white foam (20.5 mg, 94% 
purity, 83% yield, single diastereomer). [∝]𝐷
20 = 10.2 (c = 0.97, 
CH2Cl2). 
1
H NMR (300 MHz, CDCl3): δ = 7.68 – 7.54 (m, 8H), 7.43 – 
7.21 (m, 12H), 6.86 (dt, J = 15.6, 6.9 Hz, 1H), 6.24 (dd, J = 15.1, 
11.0 Hz, 1H), 5.93 (t, J = 10.9 Hz, 1H), 5.82 (dt, J = 15.8, 1.2 Hz, 1H), 
5.52 (dd, J = 15.1 Hz, 8.0 Hz, 1H), 5.26 – 5.13 (m, 3H), 5.08 (t, J = 
9.8 Hz, 1H), 4.96 (d, J = 1.5 Hz, 1H), 4.00 (ddd, J = 8.4, 5.3, 3.2 Hz, 
1H), 3.88 – 3.66 (m, 3H), 3.65 – 3.50 (m, 4H), 3.46 (s, 3H), 3.43 – 3.25 
(m, 2H), 2.46 – 2.29 (m, 3H), 2.21 – 2.09 (m, 2H), 2.09 – 2.03 (m, 1H), 
2.05 (s, 3H), 2.01 (s, 3H), 1.99 – 1.90 (m, 2H), 1.84 (dd, J = 7.2, 
5.4 Hz, 1H), 1.74 (ddd, J = 14.5, 9.0, 3.6 Hz, 1H), 1.64 (ddd, J = 13.9, 8.4, 5.4 Hz, 1H), 1.47 – 1.15 
(m, 5H), 1.17 (d, J = 6.2 Hz, 3H), 1.00 (s, 18H), 0.95 (d, J = 6.7 Hz, 3H), 0.89 (d, J = 7.0 Hz, 3H) 
ppm. 
13
C NMR (100 MHz, CDCl3): δ = 170.3, 169.9, 165.6, 144.8, 140.0, 136.0, 135.9, 135.6, 135.5, 
134.6, 134.0, 133.5, 133.4, 129.8, 129.5, 129.4, 127.6, 127.3, 126.9, 124.3, 123.5, 95.3, 81.2, 80.0, 
78.8, 73.6, 73.3, 73.2, 72.6, 71.7, 71.6, 71.5, 66.6, 65.4, 59.6, 42.9, 39.1, 38.5, 37.4, 35.6, 34.4, 34.1, 
33.2, 30.2, 27.1, 26.7, 21.0, 20.8, 20.2, 19.5, 19.2, 17.4, 15.2 ppm. IR (film): ṽ = 2957, 2930, 2857, 
1725, 1472, 1461, 1428, 1365, 1242, 1224, 1110, 1043, 999, 913, 823, 736, 703, 611 cm
−1
. MS 
(ESIpos) m/z (%) = 1207.6 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for C69H92O13Si2Na: 
1207.5969; found: 1207.5963. 
 
Glycoside 11-epi-223a. Prepared analogously from 11-epi-223 (18.6 mg, 19.8 µmol) as a white foam 
(19.9 mg, 94% purity, 80% yield, single diastereomer). [∝]𝐷
20 = +41.2 
(c = 0.95, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.65 – 7.56 (m, 
8H), 7.42 – 7.22 (m, 12H), 6.86 (ddd, J = 15.7, 7.1, 5.6 Hz, 1H), 6.24 
(dd, J = 15.2, 10.9 Hz, 1H), 5.96 (t, J = 10.9 Hz, 1H), 5.70 (dt, J = 
15.7, 1.4 Hz, 1H), 5.34 (dd, J = 15.2 Hz, 8.6 Hz, 1H), 5.26 – 5.19 (m, 
1H), 5.20 (dd, J = 10.0, 3.2 Hz, 1H), 5.08 (t, J = 9.9 Hz, 1H), 5.00 – 
4.93 (m, 1H), 4.97 (d, J = 1.7 Hz, 1H), 4.08 (ddd, J = 8.8, 4.7, 2.5 Hz, 
1H), 3.86 – 3.77 (m, 2H), 3.76 – 3.61 (m, 4H), 3.55 (dd, J = 3.2, 
1.9 Hz, 1H), 3.46 (s, 3H), 3.33 – 3.18 (m, 2H), 2.56 – 2.46 (m, 1H), 
2.41 (dddd, J = 16.5, 9.5, 5.6, 1.7 Hz, 1H), 2.37 – 2.17 (m, 4H), 2.06 (s, 3H), 2.02 (s, 3H), 1.99 – 1.94 
(m, 1H), 1.90 (dt, J = 13.0, 7.9 Hz, 1H), 1.84 – 1.78 (m, 1H), 1.75 (ddd, J = 14.5, 8.9, 2.2 Hz, 1H), 
1.58 – 1.49 (m, 2H), 1.34 – 1.26 (m, 1H), 1.27 – 1.20 (m, 2H), 1.20 – 1.15 (m, 1H), 1.17 (d, J = 
6.3 Hz, 3H), 1.02 (s, 9H), 1.00 (s, 9H), 0.98 (d, J = 7.3 Hz, 3H), 0.81 (d, J = 6.9 Hz, 3H) ppm. 
13
C 
NMR (100 MHz, CDCl3): δ = 170.4, 169.9, 165.7, 144.5, 141.0, 135.9, 135.9, 135.5, 135.5, 134.2, 
133.5, 133.4, 133.3, 130.0, 129.6, 129.5, 129.4, 127.6, 127.5, 127.4, 126.9, 125.6, 123.0, 95.4, 81.3, 
79.6, 78.8, 73.6, 73.3, 73.2, 72.4, 71.6, 70.7, 66.6, 65.4, 59.6, 44.2, 39.7, 39.0, 37.9, 35.6, 33.3, 33.2, 
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33.0, 30.8, 27.1, 26.7, 22.9, 21.0, 20.8, 19.4, 19.2, 17.4, 15.4 ppm. IR (film): ṽ = 2955, 2929, 2857, 
1722, 1461, 1428, 1356, 1330, 1242, 1223, 1179, 1110, 1076, 1041, 999, 823, 739, 703, 611 cm
−1
. MS 
(ESIpos) m/z (%) = 1207.7 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for C69H92O13Si2Na: 
1207.5969; found: 1207.5967. 
 
Diol 213. Dry K2CO3 (28.3 mg, 205 µmol) was added to a solution of compound 212 (96.9 mg, 
81.8 µmol) in MeOH (11 mL) at 0 °C. The mixture was stirred at this 
temperature for 2 h before a second portion of K2CO3 (22.6 mg, 
164 µmol) was introduced. After an additonal 2 h at 0 °C, the reaction 
was quenched with NH4Cl solution (15 mL) and the mixture allowed to 
reach ambient temperature. The aqueous phase was extracted with 
EtOAc (4 x 15 mL) and the combined organic extracts were dried over 
Na2SO4 and concentrated. The residue was purified by flash 
chromatography (hexanes/EtOAc 2:3) to give the desired product as a 
white foam (72.3 mg, 80%). [∝]𝐷
20 = 53.1 (c = 0.57, CHCl3). 
1
H NMR 
(600 MHz, CDCl3): δ = 7.66 – 7.59 (m, 8H), 7.41 – 7.25 (m, 12H), 6.86 (ddd, J = 15.8, 8.2, 5.6 Hz, 
1H), 6.22 (ddt, J = 15.5, 10.8, 1.2 Hz, 1H), 5.91 (t, J = 10.8 Hz, 1H), 5.80 (dt, J = 15.7, 1.4 Hz, 1H), 
5.59 (dd, J = 15.4, 6.8 Hz, 1H), 5.21 – 5.09 (m, 2H), 5.02 (d, J = 1.5 Hz, 1H), 4.02 (ddd, J = 8.9, 6.2, 
2.3 Hz, 1H), 3.80 – 3.72 (m, 2H), 3.69 (td, J = 9.6, 3.7 Hz, 1H), 3.69 – 3.65 (m, 2H), 3.64 – 3.58 (m, 
2H), 3.45 (s, 3H), 3.40 (dd, J = 3.8, 1.5 Hz, 1H), 3.36 (dd, J = 9.6, 9.4 Hz, 1H), 3.35 – 3.25 (m, 2H), 
2.45 – 2.39 (m, 1H), 2.38 – 2.31 (m, 2H), 2.31 – 2.23 (m, 2H), 2.13 – 2.06 (m, 2H), 2.02 (ddd, J = 
14.9, 10.1, 2.5 Hz, 1H), 1.97 – 1.90 (m, 2H), 1.90 – 1.82 (m, 3H), 1.75 (ddd, J = 14.0, 8.4, 5.9 Hz, 
1H), 1.37 (ddd, J = 12.8, 7.4, 5.3 Hz, 1H), 1.32 (ddd, J = 13.7, 8.0, 4.2 Hz, 1H), 1.28 (d, J = 6.2 Hz, 
3H), 1.24 – 1.17 (m, 2H), 1.03 (s, 9H), 1.00 (s, 9H), 0.98 (d, J = 6.7 Hz, 3H), 0.79 (d, J = 7.0 Hz, 3H) 
ppm. 
13
C NMR (150 MHz, CDCl3): δ = 165.7, 144.5, 140.0, 136.0, 136.0, 135.6, 135.6, 135.5, 134.6, 
134.0, 133.5, 130.0, 129.6, 129.6, 129.3, 129.2, 127.6, 127.6, 127.4, 127.2, 126.5, 124.4, 123.5, 93.9, 
81.4, 80.6, 80.1, 74.0, 74.0, 73.5, 72.7, 72.1, 71.7, 71.4, 67.9, 65.4, 58.9, 43.0, 39.1, 38.5, 37.5, 35.4, 
34.5, 34.4, 29.9, 27.2, 26.8, 20.8, 19.5, 19.3, 17.5, 15.4 ppm. IR (film): ṽ = 3411, 2958, 2930, 2857, 
1719, 1656, 1462, 1428, 1360, 1327, 1263, 1176, 1111, 1076, 1045, 823, 740, 702 cm
−1
. MS (ESIpos) 
m/z (%) = 1123.7 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for C65H88O11Si2Na: 1123.5757; found: 
1123.5748. 
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Diol 11-epi-213. Prepared analogously from compound 11-epi-212 (20.0 mg, 16.9 µmol) as a white 
foam (16.4 mg, 88%). [∝]𝐷
20 = 5.9 (c = 0.67, CH2Cl2). 
1
H NMR 
(600 MHz, CDCl3): δ = 7.65 – 7.53 (m, 8H), 7.42 – 7.24 (m, 10H), 7.24 
– 7.19 (m, 2H), 7.05 (ddd, J = 15.5, 10.3, 4.3 Hz, 1H), 6.20 (dd, J = 
15.0, 11.0 Hz, 1H), 5.88 (tt, J = 11.0, 1.9 Hz, 1H), 5.77 – 5.71 (m, 1H), 
5.25 (dd, J = 14.9, 9.7 Hz, 1H), 5.11 – 5.00 (m, 2H), 4.97 (d, J = 
1.4 Hz, 1H), 3.91 – 3.83 (m, 2H), 3.76 – 3.69 (m, 2H), 3.67 (dd, J = 9.4, 
3.8 Hz, 1H), 3.61 (dq, J = 9.4, 6.2 Hz, 1H), 3.42 (s, 3H), 3.40 – 3.33 (m, 
3H), 3.32 (t, J = 9.3 Hz, 1H), 3.17 (tt, J = 11.3, 1.9 Hz, 1H), 3.11 (tdd, J 
= 11.2, 3.3, 1.8 Hz, 1H), 2.70 – 2.57 (m, 1H), 2.43 (dddd, J = 14.4, 9.2, 
4.3, 1.9 Hz, 1H), 2.36 – 2.28 (br s, 1H), 2.23 – 2.17 (m, 2H), 2.18 – 2.11 (m, 2H), 2.03 (dt, J = 13.1, 
7.6 Hz, 1H), 1.97 – 1.88 (m, 2H), 1.83 – 1.75 (m, 2H), 1.56 (ddd, J = 14.1, 11.1, 3.1 Hz, 1H), 1.41 
(ddd, J = 13.6, 7.7, 5.9 Hz, 1H), 1.31 – 1.22 (m, 2H), 1.26 (d, J = 6.1 Hz, 3H), 1.22 – 1.10 (m, 2H), 
1.00 (s, 9H), 0.99 (d, J = 6.5 Hz, 3H), 0.97 (s, 9H), 0.78 (d, J = 7.0 Hz, 3H) ppm. 
13
C NMR (150 MHz, 
CDCl3): δ = 165.2, 145.3, 139.6, 135.9, 135.8, 135.7, 135.6, 134.1, 133.9, 133.6, 133.4, 129.6, 129.5, 
129.5, 129.5, 127.6, 127.5, 127.5, 127.4, 126.0, 125.7, 123.0, 93.9, 81.3, 80.7, 80.6, 74.9, 74.0, 73.1, 
72.6, 72.4, 72.1, 71.4, 67.8, 65.1, 58.8, 43.4, 39.3, 37.9, 35.6, 34.6, 34.6, 33.9, 29.4, 27.0, 26.7, 22.0, 
19.4, 19.2, 17.5, 15.2 ppm. IR (film): ṽ = 3426, 2956, 2929, 2857, 1722, 1461, 1428, 1390, 1361, 
1326, 1261, 1178, 1108, 1077, 1043, 909, 822, 734, 702, 611 cm
−1
. MS (ESIpos) m/z (%) = 1123.6 
(100 (M+Na)). HRMS (ESIpos): m/z: calcd for C65H88O11Si2Na: 1123.5757; found: 1123.5754. 
 
Diol 223b. Prepared analogously from compound 223a (20.5 mg, 16.3 µmol) as a white foam 
(17.3 mg, 96%). [∝]𝐷
20 = 2.2 (c = 0.80, CH2Cl2). 
1
H NMR (600 MHz, 
CDCl3): δ = 7.65 – 7.57 (m, 8H), 7.42 – 7.24 (m, 12H), 6.86 (ddd, J = 
15.7, 7.2, 6.6 Hz, 1H), 6.24 (dd, J = 15.2, 10.9 Hz, 1H), 5.93 (tt, J = 
10.9, 1.4 Hz, 1H), 5.82 (dt, J = 15.7, 1.3 Hz, 1H), 5.53 (dd, J = 15.2, 
8.0 Hz, 1H), 5.21 (dt, J = 10.0, 8.1 Hz, 1H), 5.16 (ddt, J = 8.2, 4.3, 
4.1 Hz, 1H), 5.02 (d, J = 1.1 Hz, 1H), 4.00 (ddd, J = 8.8, 5.5, 3.3 Hz, 
1H), 3.77 (tt, J = 10.8, 4.9 Hz, 1H), 3.70 (td, J = 7.8, 5.6 Hz, 1H), 3.70 – 
3.65 (m, 1H), 3.63 (dd, J = 9.5, 6.3 Hz, 1H), 3.61 (t, J = 6.2 Hz, 1H), 
3.62 – 3.58 (m, 1H), 3.53 (dd, J = 10.8, 4.9 Hz, 1H), 3.46 (s, 3H), 3.41 – 
3.36 (m, 1H), 3.39 (dd, J = 3.9, 1.4 Hz, 1H), 3.34 (t, J = 9.4 Hz, 1H), 3.34 – 3.28 (m, 1H), 2.43 – 2.36 
(m, 1H), 2.36 – 2.25 (m, 4H), 2.18 – 2.10 (m, 2H), 2.02 (ddt, J = 14.0, 6.9, 1.2 Hz, 1H), 1.99 – 1.95 
(m, 1H), 1.93 (ddd, J = 14.5, 8.5, 3.3 Hz, 1H), 1.88 – 1.81 (m, 2H), 1.74 (ddd, J = 14.5, 8.9, 3.4 Hz, 
1H), 1.63 (ddd, J = 14.0, 8.5, 5.5 Hz, 1H), 1.39 (dt, J = 12.7, 7.5 Hz, 1H), 1.33 (ddd, J = 13.7, 7.9, 
3.9 Hz, 1H), 1.28 (d, J = 6.2 Hz, 3H), 1.26 – 1.22 (m, 2H), 1.00 (s, 9H), 0.99 (s, 9H), 0.95 (d, J = 
6.8 Hz, 3H), 0.89 (d, J = 7.1 Hz, 3H) ppm. 
13
C NMR (150 MHz, CDCl3): δ = 165.6, 144.7, 140.0, 
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136.0, 135.9, 135.6, 135.6, 134.6, 134.0, 133.6, 133.4, 129.9, 129.5, 129.4, 129.3, 127.6, 127.6, 127.3, 
127.3, 126.8, 124.4, 123.6, 93.9, 81.3, 80.6, 80.1, 74.0, 73.7, 73.3, 72.9, 72.6, 71.7, 71.4, 67.9, 65.5, 
58.9, 43.0, 39.2, 38.5, 37.4, 35.7, 34.4, 34.1, 33.2, 30.3, 27.2, 26.7, 20.3, 19.5, 19.2, 17.5, 15.2 ppm. 
IR (film): ṽ = 3436, 2957, 2929, 2856, 1719, 1461, 1428, 1373, 1265, 1242, 1178, 1106, 1078, 1044, 
985, 822, 739, 702, 609 cm
−1
. MS (ESIpos) m/z (%) = 1123.6 (100 (M+Na)). HRMS (ESIpos): m/z: 
calcd for C65H88O11Si2Na: 1123.5757; found: 1123.5760. 
 
Diol 11-epi-223b. Prepared analogously from compound 11-epi-223a (19.1 mg, 15.1 µmol) as a white 
foam (15.4 mg, 92%). [∝]𝐷
20 = +50.6 (c = 0.77, CH2Cl2). 
1
H NMR 
(600 MHz, CDCl3): δ = 7.64 – 7.57 (m, 8H), 7.41 – 7.24 (m, 12H), 6.81 
(ddd, J = 15.8, 7.2, 5.6 Hz, 1H), 6.25 (dd, J = 15.1, 10.7 Hz, 1H), 5.97 
(tt, J = 10.9, 1.3 Hz, 1H), 5.71 (dt, J = 15.8, 1.6 Hz, 1H), 5.34 (dd, J = 
15.1, 8.6 Hz, 1H), 5.21 (td, J = 10.1, 6.2 Hz, 1H), 5.03 (d, J = 1.1 Hz, 
1H), 4.99 – 4.94 (m, 1H), 4.09 (ddd, J = 8.8, 4.8, 2.4 Hz, 1H), 3.81 (td, J 
= 7.9, 4.8 Hz, 1H), 3.76 – 3.60 (m, 6H), 3.47 (s, 3H), 3.40 (dd, J = 3.8, 
1.4 Hz, 1H), 3.34 (t, J = 9.4 Hz, 1H), 3.29 (ddt, J = 11.2, 9.5, 1.9 Hz, 
1H), 3.24 (tt, J = 10.9, 1.5 Hz, 1H), 2.56 – 2.46 (m, 1H), 2.41 (dddd, J = 
16.4, 9.4, 5.6, 1.7 Hz, 1H), 2.36 – 2.17 (m, 6H), 2.09 (dddd, J = 14.8, 5.5, 5.4, 0.7 Hz, 1H), 1.96 (ddt, 
J = 12.3, 3.9, 2.0 Hz, 1H), 1.90 (dt, J = 13.0, 7.9 Hz, 1H), 1.80 (ddt, J = 12.6, 4.1, 1.9 Hz, 1H), 1.75 
(ddd, J = 14.5, 8.9, 2.4 Hz, 1H), 1.57 – 1.50 (m, 2H), 1.28 – 1.23 (m, 1H), 1.28 (d, J = 6.2 Hz, 3H), 
1.21 – 1.12 (m, 2H), 1.02 (s, 9H), 1.00 (s, 9H), 0.98 (d, J = 7.1 Hz, 3H), 0.83 (d, J = 6.8 Hz, 3H) ppm. 
13
C NMR (150 MHz, CDCl3): δ = 165.7, 144.5, 140.9, 135.9, 135.9, 135.6, 135.5, 134.3, 133.6, 133.5, 
133.3, 130.0, 129.6, 129.5, 129.4, 129.4, 127.6, 127.5, 127.4, 126.9, 125.7, 123.1, 94.1, 81.3, 80.6, 
79.7, 74.1, 73.7, 73.2, 72.9, 72.4, 71.5, 70.8, 67.9, 65.5, 58.8, 44.1, 39.7, 39.1, 38.0, 35.6, 33.4, 33.3, 
33.1, 30.8, 27.1, 26.8, 22.9, 19.4, 19.2, 17.5, 15.4 ppm. IR (film): ṽ = 3428, 2957, 2931, 2857, 1717, 
1462, 1428, 1361, 1267, 1179, 1111, 1079, 1045, 998, 910, 823, 736, 703, 611 cm
−1
. MS (ESIpos) m/z 
(%) = 1123.7 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for C65H88O11Si2Na: 1123.5757; found: 
1123.5760. 
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Putative mandelalide A (124). A Teflon vial was charged with diol 213 (42.0 mg, 38.1 µmol) and 
THF (2.5 mL). The solution was cooled to 0 °C before pyridine (2.5 mL) 
and HF·pyridine (2.5 mL) were slowly added via an Eppendorf pipette. 
After stirring for 5 min at 0 °C, the ice bath was removed and stirring 
continued at ambient temperature for 46 h. The mixture was diluted with 
EtOAc (10 mL) and carefully poured into NaHCO3 solution (30 mL). The 
aqueous phase was extracted with EtOAc/EtOH (9:1, 4 x 15 mL). The 
combined organic extracts were washed with NH4Cl solution (20 mL), 
dried over Na2SO4 and concentrated. The residue was purified by flash 
chromatography (CH2Cl2/MeOH 97:3 to 96:4 to 95:5 to 96:4) to give the 
desired compound as a white amorphous solid (19.1 mg, 80%). [∝]𝐷
23 = 29 (c = 0.25, MeOH). 1H 
NMR (600 MHz, CDCl3): see table 5.7; 
13
C NMR (150 MHz, CDCl3): see table 5.7; IR (film): ṽ = 
3414, 2955, 2924, 2854, 1714, 1653, 1457, 1374, 1323, 1277, 1228, 1179, 1106, 1071, 1043, 988, 
955, 911, 814, 732 cm
−1
. MS (ESIpos) m/z (%) = 647.4 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for 
C33H52O11Na: 647.3402; found: 647.3406.  
 
Ring-expanded mandelalide A isomer (215). Obtained as a by-product from the reaction described 
above. [∝]𝐷
23 = +10 (c = 0.21, MeOH). 
1
H NMR (600 MHz, CDCl3):  = 7.04 
(ddd, J = 15.8, 7.3, 6.6 Hz, 1H), 6.35 (ddt, J = 15.3, 10.9, 1.3 Hz, 1H), 6.08 (t, 
J = 10.9 Hz, 1H), 5.91 (dt, J = 15.8, 1.4 Hz, 1H), 5.73 (dd, J = 15.3, 6.5 Hz, 
1H), 5.36 (dt, J = 10.5, 8.1 Hz, 1H), 5.01 (d, J = 1.4 Hz, 1H), 4.16 (dd, J = 
11.1, 5.6 Hz, 1H), 4.14 (dd, J = 11.2, 5.0 Hz, 1H), 4.10 – 4.04 (m, 2H), 3.81 – 
3.74 (m, 2H), 3.68 (dd, J = 9.5, 3.8 Hz, 1H), 3.66 (br s, 1H), 3.62 (dq, J = 9.3, 
6.2 Hz, 1H), 3.45 (s, 3H), 3.39 (dd, J = 3.8, 1.5 Hz, 1H), 3.37 – 3.29 (m, 3H), 
2.97 (br s, 1H), 2.64 – 2.48 (m, 2H), 2.47 – 2.38 (m, 2H), 2.38 – 2.32 (m, 2H), 
2.32 – 2.23 (m, 3H), 1.99 (ddt, J = 12.2, 4.4, 1.7 Hz, 1H), 1.94 (ddd, J = 12.1, 7.2, 6.1 Hz, 1H), 1.86 
(ddt, J = 12.5, 4.5, 1.7 Hz, 1H), 1.71 (ddd, J = 14.4, 8.9, 3.2 Hz, 1H), 1.67 – 1.56 (m, 1H), 1.64 (ddd, J 
= 14.1, 10.2, 4.7 Hz, 1H), 1.59 (ddd, J = 14.4, 8.6, 3.5 Hz, 1H),  1.52 – 1.44 (m, 1H), 1.27 – 1.26 (m, 
4H), 1.19 (td, J = 11.6, 11.5 Hz, 1H), 1.04 (d, J = 7.0 Hz, 3H), 1.01 (d, J = 6.6 Hz, 3H) ppm. 
13
C NMR 
(150 MHz, CDCl3):  = 166.4, 146.0, 142.0, 130.9, 126.4, 123.1, 122.8, 94.0, 81.4, 80.8, 80.6, 74.2, 
74.0, 73.3, 72.7, 71.4, 71.1, 68.1, 68.0, 67.9, 58.9, 42.8, 39.3, 38.1, 37.5, 37.2, 36.9, 35.6, 32.7, 30.4, 
18.0, 17.5, 14.5 ppm. IR (film): ṽ = 3427, 2924, 1714, 1653, 1454, 1373, 1323, 1275, 1179, 1106, 
1043, 988, 734 cm
−1
. MS (ESIpos) m/z (%) = 647.3 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for 
C33H52O11Na: 647.3402; found: 647.3404.  
 
220 Experimental section 
 
11-epi-Isomer of putative mandelalide A 11-epi-124. Prepared analogously from diol 11-epi-213 
(10.0 mg, 9.08 µmol) as a white amorphous solid (4.8 mg, 85%). [∝]𝐷
23 = 
25.8 (c = 0.41, MeOH). 1H NMR (600 MHz, CDCl3): see table 5.8. 
13
C 
NMR (150 MHz, CDCl3): see table 5.8. IR (film): ṽ = 3411, 2924, 2854, 
1716, 1654, 1457, 1373, 1246, 1178, 1107, 1045, 992, 812, 733 cm
−1
. MS 
(ESIpos) m/z (%) = 647.4 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for 
C33H52O11Na: 647.3402; found: 647.3402. 
 
 
 
Reassigned mandelalide A (219). Prepared analogously from diol 223b (14.0 mg, 12.7 µmol) as a 
white amorphous solid (5.6 mg, 71%). [∝]𝐷
23 = 40.1 (c = 0.27, MeOH). 1H 
NMR (600 MHz, CDCl3): see table 5.9. 
13
C NMR (150 MHz, CDCl3): see 
table 5.9. IR (film): ṽ = 3404, 2958, 2922, 1716, 1657, 1454, 1372, 1318, 
1262, 1221, 1181, 1105, 1042, 985, 813, 734 cm
−1
. MS (ESIpos) m/z (%) = 
647.5 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for C35H52O11Na: 
647.3402; found: 647.3401. 
 
 
 
11-epi-Isomer of actual mandelalide A 11-epi-219. Prepared analogously from diol 11-epi-223b 
(15.0 mg, 13.6 µmol) as a white amorphous solid (5.8 mg, 68%). [∝]𝐷
23 = 
18.8 (c = 0.47, CH2Cl2). 
1
H NMR (600 MHz, CDCl3): see table 5.10. 
13
C 
NMR (150 MHz, CDCl3): see table 5.10. IR (film): ṽ = 3424, 2921, 1713, 
1655, 1454, 1369, 1329, 1262, 1181, 1132, 1105, 1044, 990, 813 cm
−1
. MS 
(ESIpos) m/z (%) = 647.37 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for 
C35H52O11Na: 647.3402; found: 647.3402. 
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Table 5.7: 
1
H & 
13
C NMR data of putative Mandelalide A (124) (4.2 mg in 0.45 mL CDCl3). 
 
atom 
n° 
1
H NMR (CDCl3, 600 MHz) 
13
C NMR (CDCl3, 150 
MHz)  /ppm m J /Hz COSY NOESY  /ppm HMBC 
1 - - - - - 167.3 - 
2 5.92 dt 15.6, 1.5 3, (4ab) 3, 4(a)b, (25) 123.1 1, (3), 4 
3 7.02 ddd 15.5, 8.6, 5.5 2, 4a(b) 2, 4a(b), (6a) 146.3 1, 2, 4, 5 
4a 2.34 ddd 15.2, 6.5, 5.6, 1.8 (3), 4b, 5 (2), 3, 4b, 5 
38.5 
2, 3, 5, 6 
4b 2.46 dddd 15.2, 8.6, 3.7, 1.2 3, 4a, (5) 2, 3, 4a, 5, 25 2, 3, 5, (6) 
5 3.42 m - 4a(b), 6a (3), 4ab, 6b, 7, 9 73.4 3, (4), 7, 9 
6a 1.26 m - 5, 6b, 7 - 
36.7 
5, 7, 8 
6b 1.94 ddt 12.0, 4.6, 1.9 6a, 7 (5), 6a, 7, 1' 6, 8 
7 3.77 m - 6ab, 8ab 5, 6b, 8b, 9, 1' 72.8 6, 8, (1') 
8a 1.22 m - 7, 8b, 9 - 
39.3 
- 
8b 1.84 dddd 12.5, 4.2, 1.9, 1.9 7, 8a, (9) 7, 8a, 9 6, 7, 9 
9 3.33 m - 8a(b), 10ab 5, 7, 8b, 10b, 25 73.1 (5), (7), 8, 10 
10a 1.27 m - 9, 10b, 11 - 
42.9 
- 
10b 1.69 ddd 14.1, 9.1, 5.1 9, 10a, (11) 9, 10a 8, 9, 11, 12, 25 
11 2.44 m - 10a(b), 12, 25 9, 10a, 12, 13, 25 32.8 9, 10, 12, 13, 25 
12 5.61 dd 15.2, 7.6 11, 13 (10ab), 11, 13, 14, 25 140.9 10, 11, 14, (15), 25 
13 6.22 ddt 15.2, 10.8, 1.0 12, 14 11, 12, 14, 16ab, 25 123.8 11, 14, 15 
14 6.01 tt 10.8, 1.8 13, 15 12, 13, 15 130.5 12, 13, 16 
15 5.27 ddd 10.8, 8.3, 7.5 14, 16ab 14, 16ab, 17, (26) 126.5 13, 16, 17 
16a 2.14 dddd 14.8, 6.8, 5.1, 1.9 15, 16b, 17 13, (15), 16a, (17), (26) 
31.2 
14, 15, 17, 18 
16b 2.29 dtd 14.8, 8.5, 1.6 15, 16a, 17 13, 15, 16b, 17, 26 (13), 14, 15, 17, 18 
17 4.03 ddd 8.6, 7.2, 4.9 16ab, 18 15, 16a(b), 18, (20), (26) 81.3 15, 19, 20, 26 
18 2.43 m - 17, 19a(b), 26 17, 19ab, 20, 26 37.1 16, 17, 19, (20), 26 
19a 1.28 m - 18, 19b, 20 (18), 19b, 21, 26 
36.0 
- 
19b 2.04 dt 12.3, 6.7 (18), 19a, 20 18, 19a, 20, (26) 17, 18, (20), 21, 26 
20 3.71 ddd 8.4, 8.2, 6.7 19ab, 21 17, 18, 19b, 21, 22a(b) 82.7 (18), 19, 21, 22 
21 3.45 m - 20, 22(a)b 19a, 20, 22b, 23, 25, 26 73.4 (19), 20, 22, 23 
22a 1.54 ddd 14.4, 10.5, 2.5 21, 22b, (23) 20, 21, 22b, 23, 24ab 
34.1 
20, 23, 24 
22b 1.77 ddd 14.4, 10.8, 2.0 (21), 22a, 23 (19b), 21, 22a, 23, (24a) (20), 23, 24 
23 5.24 m - 22(a)b, 24ab 21, 22a(b), 24ab 72.5 (22), (1) 
24a 3.65 m - 23, 24b (22ab), 23, 24b 
65.7 
22, 23 
24b 3.78 dd 12.1, 3.3 23, 24a 21, 23, 24a 22, (23) 
25 1.00 d 6.7 11 2, 9, (10b), 11, 12, 13, 21 20.1 10, 11, 12 
26 0.98 d 7.0 18 16a(b), (17), 18, (21) 14.7 17, 18, 19 
1' 5.02 d 1.5 2' 6b, 7, 2', 7' 94.0 7, 2', 3', 5' 
2' 3.40 dd 3.8, 1.5 1', 3' 1', 7', 3' 80.9 3', 4', 7' 
3' 3.69 m - 2', 4' (2'), 5' 71.7 (2'), 4' 
4' 3.34 t 9.4 3', 5' 6', 7' 74.2 3', 5' 
5' 3.63 dd 9.4, 6.1 4', 6' (2'), 3', 6' 68.2 (1'), 3', 4', (6') 
6' 1.28 d 6.3 5' 4', 5', 7' 17.7 (1'), 4', 5' 
7' 3.46 s - - 1', 6' 59.2 2' 
OHa 2.56-2.33 - - 21  - 21,22 
OHb 2.56-2.33 - -   -  
OHc 2.44-2.34 - - 3'  - 3' 
OHd 2.78-2.64 br s - 4'  - 4' 
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Table 5.8: 
1
H & 
13
C NMR data of 11-epi-Isomer of putative mandelalide A (11-epi-124) (4.1 mg in 
0.25 mL CDCl3). 
atom 
n° 
1
H NMR (CDCl3, 600 MHz) 
13
C NMR (CDCl3, 150 MHz) 
 /ppm m J /Hz COSY NOESY  /ppm HMBC 
1 - - - - - 166.8 - 
2 5.92 dt 15.6, 1.1 3, (4a) 3, 4b 123.6 1, 3, 4, (5) 
3 7.09 ddd 15.6, 8.2, 6.7 2, 4ab 2, 4ab, 5, 11, 13, (21) 146.1 1, 2, 4, 5 
4a 2.31 dddd 14.3, 8.2, 2.7, 0.8 3, 4b, (5) 2, 3, 4b, 5, (6a) 
39.5 
2, 3, 5, (6) 
4b 2.39 m - 3, 4a, 5 2, 3, 4b, 6a 2, 3, 5, 6 
5 3.26 dddd 11.2, 10.5, 3.0, 2.1 4a, 4b, 6a(b) 4a, 6b, 7, 9 74.0 (3), (4), (9) 
6a 1.15 ddd 11.8, 11.7, 11.6 5, 6b, 7 4b, 6b, 8a 
38.2 
5, 7, 8 
6b 1.98 ddt 12.2, 4.7, 1.9 5, 6a, 7 4a, 5, 6a, 7, 1' (5), 7, 8 
7 3.76 m - 6a(b), 8a(b) 5, 6b, 8b, 9, 1' 72.7 8, (9), 1' 
8a 1.27 m - 7, 8b, 9 6a, 8b 
39.2 
6, 7, 9, 10 
8b 1.75 ddt 12.4, 4.7, 1.9, 1.7 7, 8a, (9) 7, 8a, 9, 10a 6, 7, 9 
9 3.16 tt 11.1, 1.5 8a, 10(a)b 5, 7, 8b, 10a 73.2 5, 7, 10, 11 
10a 1.14 m - (9), 10b, 11 8b, 9, 10b, (12), (25) 
43.5 
(5), 7, 8, 11, 12, 25 
10b 1.52 ddd 13.9, 11.0, 2.8 9, (11), 10a (8a), 10a, 11, 25 9, 11, 12, 25 
11 2.48 m - 10a, 12, 25 9, 10b, (12), 13, 25 34.1 9, 10, 12, 13, (25) 
12 5.32 dd 14.9, 9.7 11, 13 (9), 10a, (11), 13, 14, 25 141.3 10, 11, 14, 25 
13 6.10 dd 14.9, 11.0 12, 14 (3), 11, 12, 16(a)b, (21) 124.9 11, 14, 15 
14 6.00 ddt 11.0, 10.9, 1.5 (10ab), 13, 15 12, 15, 16b 130.6 12, 13, 16 
15 5.20 m - 14, 16ab 13, 14, 16ab, 17, 26 126.2 13, 16, 17 
16a 2.08 ddd 14.6, 5.9, 1.9 15, 16b, 17 13, 15, 16b, 17, 21, 26 
31.0 
(13), 14, 15, 17, 18 
16b 2.25 dddd 14.7, 9.0, 7.5, 1.4 (14), 15, 16a, 17 13, 15, 16a, 17, 19a, 26 14, 15, 17, 18 
17 3.99 dt 7.3, 6.2 18, 16ab 16ab, 18, 20, (26) 81.8 15, 19, 20, 26 
18 2.46 m - 17, 19ab, 26 (15), 17, 19(a)b, 20, 26 36.9 16, 17, 20, 26 
19a 1.26 m - 18, 19b, 20 (18), 19b, 26 
36.4 
18, (20), 21, 26 
19b 2.09 ddd 12.3, 7.1, 7.1 (18), 19a, 20 18, 19a, 20, 21 18, 20, 21, 26 
20 3.74 m - 19ab, 21 17, 18, 19(a)b, 21, (22b) 82.1 17, 19, 21, 22 
21 3.46 dddd 9.1, 7.6, 2.8, 1.6 20, 22ab, OHa (3), 19a, 20, 22ab, 23, OHa 73.3 20, 22, 23 
22a 1.55 ddd 14.7, 9.2, 2.1 21, 22b, (23) 21, 22b, 24ab 
34.7 
20, 21, 24 
22b 1.88 dddt 14.4, 11.5, 1.4 21, 22a, 23 19a(b), 21, 22a, 24ab 20, 23, 24 
23 5.23 dddd 11.2, 5.3, 2.8, 2.7 22(a)b, 24ab 21, 22ab, 24ab 73.9 (1), 22 
24a 3.65 m - 23, 24b 22ab, 23, 24b 
65.7 
22, 23 
24b 3.79 m - 23, 24a 22a(b), 23, 24a 22, 23 
25 0.98 d 6.8 11 10ab, 11, 12 22.0 10, 11, 12 
26 0.98 d 7.0 18 16a(b), (15), (17), 18 14.9 17, 18, 19 
1' 4.99 d 1.2 2' 2', 7', 6b, 7 94.1 2', 3', 5', 7 
2' 3.38 dd 3.8, 1.5 1', 3' 1', 3', 7' 80.9 3', 4', 7' 
3' 3.68 td 9.7, 3.8 2', 4', OHc 2', 5', OHc, OHd 71.6 1', 4' 
4' 3.33 td 9.5, 1.9 3', 5', OHd 5', 6', OHc, OHd 74.2 3', 5', 6', 7' 
5' 3.61 dq 9.4, 6.2 4', 6' 3', 4', 6' 68.2 1', 3', 4', 6' 
6' 1.26 d 6.2 5' 4', 5', 7' 17.7 4', 5' 
7' 3.44 s - 
 
2', 6', OH3 59.1 2' 
OHa 2.74-2.72 br s - 21  - 21,22 
OHb 2.40-2.36 m - 
 
 - 
 
OHc 2.42-2.35 m - 3'  - 3' 
OHd 2.48-2.44 m - 4'  - 4' 
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Table 5.9: 
1
H & 
13
C NMR data of synthetic mandelalide A (219) (4.6 mg in 0.25 mL CDCl3).
  
 
atom 
n° 
1
H NMR (CDCl3, 600 MHz) 
13
C NMR (CDCl3, 150 
MHz)  /ppm m J /Hz COSY NOESY  
/ppm 
HMBC 
1 - - - - - 167.4 - 
2 6.01 dt 15.5, 0.8 3, 4a 3, 4ab, (5) 123.1 1, 3, 4, (5) 
3 6.96 ddd 15.3, 10.4, 4.9 2, 4ab 2, 4ab, 5, 25 147.1 1, 2, 4, 5 
4a 2.36 m - 3, 4b, (5) 2, 3, 5, 6a, 12, 13, 25 
38.8 
2, 3, 5, (6) 
4b 2.39 ddd 13.9, 10.8, 10.7 3, 4a, 5  2, 3, 5, (6) 
5 3.37 m - 4a, 4b, 6ab 3, 4ab, 6b, 7 73.9 3, 4, 9 
6a 1.20 m - 5, 6b, 7 6b, 8a, 10b 
37.6 
4, 5, 7, 8 
6b 2.02 dddd 12.1, 5.6, 2.3, 1.6 5, 6a, 7, (8b) 4b, (5), 6a, (12) (5), 7, 8, 2‘ 
7 3.82 dddd 11.3, 10.6, 4.8, 4.5 6ab, 8ab 5, 6b, 8b, 9, 1‘ 73.1 8, (9), 1' 
8a 1.22 m - 7, 8b, 9 8b, 10b, (12), 25 
39.7 
6, 7, 9, 10 
8b 1.87 dddt 13.2, 7.8, 5.3, 1.9 6b, 7, 8a, 9 7, 8a, 9, 10a, 1‘ 6, 7, 9 
9 3.31 tt 10.7, 2.1 8ab, 10ab 7, 8b, 10a, 25 72.5 5, 7 
10a 1.21 m - 9, 10b, 11 10b, (11), 12, 25 
43.1 
8, 11, 12, 25 
10b 1.52 ddd 14.1, 11.1, 3.3 9, 10a, (11) 10a, 11, (12) 8, 9, 11, 12, 25 
11 2.37 m - 10a, 12, 25 10ab, 12, 13, 14, 25 34.2 9, 10, 12, 13, 25 
12 5.44 dd 14.9, 9.9 11, 13 (10a), 11, 14, 25 141.5 10, 11, 14, 25 
13 6.27 dd 14.8, 11.1 12, 14 11, 16b, 21, (25) 123.9 10, 11, 14, 15 
14 6.05 dd 10.9, 10.9 13, 15 12, 15 131.3 12, 13, 16, 17 
15 5.28 dt 10.8, 5.6 14, 16ab 14, 16ab, 17 126.9 13, 16, 17 
16a 1.88 m - 15, 16b, 17 15, 16b, 17, 26 
31.1 
14, 15, 17, 18 
16b 2.25 m m 15, 16a, 17 13, (15), 16a, 19a, 21, 26 14, 15, 17, 18 
17 3.98 ddd 10.9, 8.5, 1.7 16ab, 18 15, 16a, 18, 20 81.0 15, (18), 19, 20 
18 2.52 dddq 12.3, 7.0, 7.0, 6.9 17, 19ab, 26 14, 17, 19b, 20, 26 37.4 16, 17, (20), 26 
19a 1.17 ddd 12.2, 12.1, 10.2 18, 19b, 20 16b, 19b, 21, 22b, 26 
36.8 
18, (20), 21, 26 
19b 2.01 ddd 11.8, 7.1, 6.0 18, 19a, 20 19a, 22b, 20 17, 18, 21, (26) 
20 3.63 m - 19ab, 21 17, 18, 19b, 22a 83.2 (17), (19), 21, 22 
21 3.42 ddd 11.2, 8.9, 1.8 20, 22ab, (OHa) 13, 18, 19a, 22b, 23 73.1 19, 20, 22, (23) 
22a 1.46 ddd 14.2, 11.3, 1.9 21, 22b, 23 20, 22b, 23, 24b 
34.1 
20, 21 
22b 1.76 ddt 12.8, 12.6, 1.5 21, 22a, 23 (19ab), 20, 21, 22a, (23) 21, 24 
23 5.23 dddd 11.6, 5.1, 3.1, 2.0 22ab, 24ab (16b, 18), 22ab, 21, 24ab 72.3 1, 22 
24a 3.61 m - 23, 24b 22a(b), 23, 24b 
66.1 
22, 23 
24b 3.79 m - 23, 24a 22a, 23, 24 22, 23 
25 0.85 d 6.6 11 9, 10a, 11, 12 18.3 10, 11, 12 
26 1.02 d 7.0 18 16a, (17), 18, 19a(b) 14.5 17, 18, 19 
1' 5.02 d 1.1 2' 6b, 7, 8b, 2‘, 7‘ 94.2 2', 3', 5', 7 
2' 3.40 dd 3.9, 1.5 1', 3' 1‘, 3‘ 80.8 3', 4', 7' 
3' 3.68 td 9.8, 3.7 2', 4', OHc (1‘), 2‘, (4‘), OHd 71.7 4' 
4' 3.34 dd 10.5, 9.3 3', 5' 3‘, (5‘), 6‘ 74.3 2‘, 3', 5', 6' 
5' 3.62 dd 9.9, 5.9 4', 6' (4‘), 6‘ 68.1 1', 3', 4', 6' 
6' 1.26 d 6.3 5' 4‘, 5‘ 17.7 4', 5' 
7' 3.45 s - - 1‘ 59.1 2' 
OHa 2.69 br s - 21  - 21,22 
OHb 2.31 br s - 24ab  - (24) 
OHc 2.35 m - 3'  - 3', 4’ 
OHd 2.53 br s - 4'  - 2‘, 5‘ 
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Table 5.10: 
1
H & 
13
C NMR data of 11-epi-isomer of actual mandelalide A 11-epi-219 (4.1 mg in 
0.25 mL CDCl3). 
atom 
n° 
1
H NMR (CDCl3, 600 MHz) 
13
C NMR (CDCl3, 150 MHz) 
 /ppm m J/Hz COSY  /ppm HMBC 
1 - - - - 167.4 - 
2 5.93 dd 15.5, 0.7 3, (4a) 123.4 1, 3, 4, 5 
3 6.98 ddd 15.3, 8.1, 7.0 2, 4a 146.8 1, 2, 4, 5 
4a 2.31 m - 3, 4b, 5 
39.5 
2, 3, 5, 6 
4b 2.42 ddd 14.1, 6.3, 3.2 3, 4a, 5 2, 3, 5, 6 
5 3.30 m - 4ab, 6a(b) 74.2 (3), 4, 6, 7, (9) 
6a 1.17 dt 11.5, 11.4 5, 6b, 7 
37.5 
5, 7, 8 
6b 2.00 m - (5), 6a, 7 7, 8, 2’ 
7 3.75 m - 6ab, 8ab 73.1 8, 1’ 
8a 1.23 m - 7, 8b, 9 
39.5 
6, 7, 9, 10 
8b 1.82 m - 7, 8a, 9 6, 7, 9, 10 
9 3.27 tt 9.9, 2.1 8a, 10ab 72.9 8, 10, 11 
10a 1.37 ddd 14.1, 8.7, 2.7 9, 10b, 11 
43.0 
8, 11, 12, (25) 
10b 1.49 ddd 14.3, 9.4, 5.1 9, 10a, 11 8, 11, 12, 25 
11 2.45 m - 10ab, 12, 25 33.5 10, 12, 13, 25 
12 5.60 dd 15.2, 7.7 11, 13 141.0 10, 11, 14, 25 
13 6.20 dd 15.2, 10.7 12, 14 124.7 11, 14, (15) 
14 6.00 dd 10.8, 10.8 13, 15 130.5 12, 13, 16 
15 5.28 td 10.5, 7.7 14, 16ab 126.8 13, 16, 17 
16a 2.21 m - (14), 15, 16b, 17 
31.5 
14, 15, 17, 18 
16b 2.20 m - 15, 16a, 17 14, 15, 17, 18 
17 4.01 q 6.7 16ab, 18 80.9 15, (18), 19, 20, 26 
18 2.44 m - 17, 19a(b), 26 37.5 17, 19, 26 
19a 1.28 m - 18, 19b, 20 
35.8 
17, 18, 21, 26 
19b 2.00 m - 19a 18, 20, 21, 26 
20 3.73 ddd 9.3, 6.9, 6.9 19ab, 21 82.5 19, 21, 22 
21 3.76 m - 20, 22ab 73.1 19, 22 
22a 1.53 m - 21, 22b, 23 
33.8 
21, 24 
22b 1.83 ddd 14.1, 11.0, 2.8 21, 22a, 23 19, 20, 23 
23 5.17 ddd 10.2,  8.1, 1.9 22ab, 24ab 72.2 19, 21, 22 
24a 3.67 m - 23, 24b 
65.6 
22, 23 
24b 3.78 m - 23, 24a 22, 23 
25 1.00 d 6.9 11 21.4 10, 11, 12 
26 0.98 d 6.9 18 14.7 17, 18, 19 
1' 5.00 d 1.3 2‘ 94.3 7, 2‘, 3‘, 5‘ 
2' 3.38 dd 3.6, 1.3 1‘, 3‘ 80.8 3‘, 4‘, 7‘ 
3' 3.69 m - 2‘, 4‘ 71.7 4‘ 
4' 3.33 dd 9.4, 9.4 3‘, 5‘ 74.4 3‘, 5‘, 6‘, 7‘ 
5' 3.61 m - 4‘, 6‘ 68.1 3‘, 4‘, 6‘ 
6' 1.26 d 6.2 4‘, 5‘ 17.8 5‘ 
7' 3.45 d 0.6 - 59.1 2‘ 
OHa not assigned 
OHb not assigned 
OHc not assigned 
OHd not assigned 
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5.3.5 Synthesis of 2,3-epi-mandelalide C. 
1-((tert-Butyldiphenylsilyl)oxy)tridecan-2-ol (230). A flame-dried Schlenck flask was charged with 
a solution of n-decylmagnesium bromide (1 M in Et2O, 22 mL, 22 mmol), which 
was cooled to −15 °C. Copper cyanide (36 mg, 0.40 mmol) was, followed by a 
solution of (R)-tert-butyl(oxiran-2-ylmethoxy)diphenylsilane (160) (6.25 g, 20.0 mmol) in THF 
(17 mL) via dropping funnel. After stirring for 30 min, the reaction mixture was quenched by pouring 
into sat. NH4Cl solution (100 mL). The aqueous phase was extracted with EtOAc (3 x 50 mL) and the 
combined organic layers were dried over NaSO4 and concentrated. The pale yellow residue (8.9 g, 
98%) was used in the next step without further purification. 
1
H NMR (300 MHz, CDCl3): δ = 7.62 – 
7.56 (m, 4H), 7.37 – 7.26 (m, 6H), 3.68 – 3.52 (m, 2H), 3.41 (dd, J = 9.9, 7.3 Hz, 1H), 2.18 (br s, 1H), 
1.37 – 1.27 (m, 2H), 1.22 – 1.13 (m, 18H), 0.99 (s, 9H), 0.83 – 0.78 (t, J = 6.8 Hz, 3H) ppm. 13C NMR 
(75 MHz, CDCl3): δ = 135.6, 135.5, 133.3, 133.3, 129.8, 127.7, 72.0, 68.1, 32.8, 31.9, 29.7, 29.6, 29.6, 
29.6, 29.5, 29.3, 26.9, 25.5, 22.7, 19.3, 14.1 ppm. IR (film): ṽ = 3470, 2924, 2854, 1754, 1463, 1428, 
1361, 1263, 1189, 1110, 1031, 1007, 938, 882, 823, 739, 700, 638, 613 cm
−1
. MS (EI) m/z (%) = 397 
(15), 229 (12), 200 (18), 199 (100), 139 (49), 111 (6), 97 (8) 69 (5). HRMS (ESIpos): m/z: calcd for 
C29H46O2Si1Na: 477.3159; found: 477.3158. 
 
(R)-1-((tert-Butyldiphenylsilyl)oxy)tridecan-2-yl (E)-but-2-enoate (231). (E)-Crotonic acid (3.06 g, 
35.6 mmol), DMAP (7.25 g, 59.3 g) and N,N’-dicyclohexylcarbodiimide (8.98 g, 
43.5 mmol) were added successively to a stirred solution of crude alcohol 230 
(8.02 g, 19.8 mmol) in CH2Cl2 (100 mL) at ambient temperature. After 17 h, the 
reaction mixture was filtered through a pad of Celite
®
, which was rinsed with CH2Cl2 (2 x 10 mL). 
The filtrate was concentrated and the residue purified by flash chromatography (hexanes/EtOAc 15:1) 
to give the desired ester as a colorless oil (8.32 g, 81% yield). [∝]𝐷
20 = +12.4 (c = 0.89, CH2Cl2). 
1
H 
NMR (400 MHz, CDCl3): δ = 7.72 – 7.58 (m, 4H), 7.45 – 7.31 (m, 6H), 6.94 (dq, J = 15.5, 6.9 Hz, 
1H), 5.83 (dq, J = 15.5, 1.7 Hz, 1H), 5.03 (ddd, J = 10.1, 7.4, 5.1 Hz, 1H), 3.70 (dd, J = 10.9, 5.4 Hz, 
1H), 1.87 (dd, J = 6.9, 1.7 Hz, 3H), 1.64 – 1.54 (m, 2H), 1.26 (s, 18H), 1.02 (s, 9H), 0.89 – 0.84 (m, 
3H) ppm. 13C NMR (100 MHz, CDCl3): δ = 166.1, 144.3, 135.6, 135.6, 133.5, 129.6, 127.6, 127.6, 
127.6, 123.0, 74.1, 65.0, 34.9, 31.9, 30.5, 29.6, 29.6, 29.5, 29.5, 29.5, 29.3, 26.7, 25.4, 25.2, 24.7, 
22.7, 19.2, 18.0, 14.1 ppm. IR (film): ṽ = 2925, 2854, 2118, 1720, 1660, 1446, 1428, 1360, 1293, 
1262, 1181, 1112, 1046, 1005, 969, 823, 802, 739, 700, 614 cm
−1
. MS (EI) m/z (%) = 465 (14), 268 
(22), 267 (100), 207 (25), 199 (16), 135 (5), 69 (19). HRMS (ESIpos): m/z: calcd for C33H50O3Si1Na: 
545.3421; found: 545.3419. 
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(R)-1-Hydroxytridecan-2-yl (E)-but-2-enoate (232). Silyl ether 231 (5.01 g, 9.56 mmol) was 
dissolved in THF (50 mL) and the solution cooled to 0 °C. Acetic acid (1.92 mL, 
33.5 mmol) and a solution of TBAF (1 M in THF, 28.7 mL, 28.7 mmol) were added 
slowly. After 5 min stirring at 0 °C, the ice bath was removed and the mixture was 
allowed to warm to ambient temperature. After 3.5 h, it was diluted with EtOAc (20 mL), poured into 
sat. NaHCO3 solution (40 mL) and the aqueous phase was extracted with EtOAc (3 x 40 mL). The 
combined organic phases were dried over Na2SO4 and concentrated. The residue was purified by flash 
chromatography (hexanes/EtOAc 8:1 to 6:1 to 4:1 to give the desired primary alcohol as a colorless oil 
(2.42 g, 89% yield). [∝]𝐷
20 = +9.8 (c = 0.64, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.00 (dq, J = 
15.5, 6.9 Hz, 1H), 5.87 (dq, J = 15.5, 1.7 Hz, 1H), 4.95 (dtd, J = 7.4, 6.2, 3.2 Hz, 1H), 3.73 (dd, J = 
12.0, 3.2 Hz, 1H), 3.64 (dd, J = 12.1, 6.3 Hz, 1H), 2.07 (br s, 1H), 1.89 (dd, J = 6.9, 1.7 Hz, 3H), 1.65 
– 1.54 (m, 2H), 1.31 – 1.22 (m, 18H), 0.87 (t, J = 7.0 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ = 
166.9, 145.3, 122.6, 75.5, 65.0, 31.9, 30.6, 29.6, 29.5, 29.4, 29.3, 25.3, 22.7, 18.0, 14.1 ppm. IR (film): 
ṽ = 3428, 2955, 2923, 2854, 1719, 1658, 1465, 1444, 1377, 1308, 1292, 1265, 1182, 1101, 1057, 
1002, 968, 919, 838, 722, 688 cm
−1
. MS (EI) m/z (%) = 285 (1), 142 (9), 100 (8), 87 (12), 69 (100), 55 
(6), 41 (12). HRMS (ESIpos): m/z: calcd for C17H32O3Na: 307.2244; found: 307.2244. 
 
(R)-1-Oxotridecan-2-yl (E)-but-2-enoate (233). Dess-Martin periodinane (4.65 g, 11.0 mmol) and 
NaHCO3 (2.13 g, 25.3 mmol) were added successively to a solution of primary 
alcohol 232 (1.20 g, 4.22 mmol) in CH2Cl2 (60 mL) at 0 °C. The icebath was 
removed after 5 min and the white suspension was stirred vigorously at ambient 
temperature for 4 h. The reaction was then poured into a sat. solution of NaHCO3/Na2S2O3 (1:1, 
100 mL) and the aqueous phase was extracted with CH2Cl2 (3 x 75 mL). The combined organic 
extracts were dried over Na2SO4 and concentrated. The residue was purified by flash chromatography 
(10 cm SiO2, hexanes/EtOAc 19:1 to 15:1 to 12:1 to 9:1) to give the product as a colorless liquid 
(661 mg, 55% yield). [∝]𝐷
20 = +31.0 (c = 0.64, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 9.51 (d, J = 
0.9 Hz, 1H), 7.06 (dq, J = 15.5, 6.9 Hz, 1H), 5.92 (dq, J = 15.5, 1.7 Hz, 1H), 4.99 (ddd, J = 8.3, 4.8, 
0.9 Hz, 1H), 1.90 (dd, J = 6.9, 1.7 Hz, 3H), 1.86 – 1.78 (m, 1H), 1.76 – 1.67 (m, 1H), 1.43 – 1.35 (m, 
2H), 1.28 – 1.20 (m, 16H), 0.87 – 0.82 (t, J = 6.9 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ = 
198.8, 165.9, 146.5, 121.6, 78.1, 31.9, 29.6, 29.5, 29.3, 29.3, 29.2, 28.8, 24.9, 22.7, 18.1, 14.1 ppm. IR 
(film): ṽ = 2923, 2854, 1721, 1657, 1465, 1444, 1377, 1292, 1258, 1175, 1102, 968, 837, 722, 688 
cm
−1
. MS (ESIpos) m/z (%) = 337.3 (100 (M+MeOH+Na)). HRMS (ESIpos): m/z: calcd for 
C17H30O3Na: 305.2087; found: 305.2085. 
 
Morita-Baylis-Hillman product (E)-(234).A flame-dried Young tube was charged with a solution of 
aldehyde 233 (150 mg, 0.531 mmol) in DMF (5 mL). Methyldiphenylphosphine 
(29.6 µL, 0.159 mmol) was added via syringe and the Young tube was sealed. It was 
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placed in a preheated oil-bath at 120 °C and the reaction mixture was stirred at this temperature for 
22 h. After cooling to rt, it was poured into NH4Cl (15 mL) and the aqueous phase was extracted with 
Et2O (3 x 5 mL). The combined organic extracts were washed with brine (25 mL), dried over Na2SO4 
and concentrated. The residue was purified by flash chromatography (hexanes/EtOAc 4:1 to 3:1 to 
2:1) to give the Baylis-Hillman alcohol (E)-234 as a white solid (82 mg, 55% yield, 16:1 d.r. at C.3) 
along with the minor isomer (Z)-234 (see below). [∝]𝐷
20 = +4.9 (c = 1.21, CH2Cl2). 
1
H NMR 
(400 MHz, CDCl3, data is given only for the major diastereomer): δ = 6.95 (qd, J = 7.2, 1.9 Hz, 1H), 
4.53 (br s, 1H), 4.28 (ddd, J = 8.1, 6.0, 2.3 Hz, 1H), 2.78 (br s, 1H), 1.98 (dd, J = 7.3, 1.0 Hz, 3H), 
1.59 – 1.44 (m, 2H), 1.43 – 1.30 (m, 2H), 1.25 – 1.15 (m, 16H), 0.84 – 0.78 (t, J = 7.0 Hz, 3H) ppm. 
13
C NMR (100 MHz, CDCl3, data is given only for the major diastereomer): δ = 169.8, 143.4, 130.5, 
86.5, 70.8, 34.0, 31.9, 29.6, 29.6, 29.5, 29.4, 29.3, 29.3, 24.7, 22.7, 15.4, 14.1 ppm. IR (film): ṽ = 
3420, 2922, 2853, 1734, 1680, 1465, 1440, 1377, 1332, 1215, 1143, 1207, 980, 814, 722, 610 cm
−1
. 
MS (EI) m/z (%) = 282 (1), 99 (6), 98 (100), 70 (22), 69 (6). HRMS (ESIpos): m/z: calcd for 
C17H30O3Na: 305.2087; found: 305.2086. 
 
Morita-Baylis-Hillman product (Z)-(234). Obtained as the minor isomer as a mixture of 
diastereomers at C.3 (18.2 mg, 12% yield, 18:1 d.r.). [∝]𝐷
20 = +8.0 (c = 0.98, 
CH2Cl2). 
1
H NMR (400 MHz, CDCl3, data is given only for the major 
diastereomer): δ = 6.61 (qd, J = 7.3, 1.7 Hz, 1H), 4.37 (br s, 1H), 4.19 (ddd, J = 7.8, 
5.7, 3.7 Hz, 1H), 2.55 (br s, 1H), 2.26 – 2.16 (dd, J = 7.4, 1.6 Hz, 3H), 1.66 – 1.55 (m, 2H), 1.50 – 
1.36 (m, 2H), 1.23 (m, 16H), 0.88 – 0.82 (t, J = 6.9 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3, data is 
given only for the major diastereomer): δ = 168.6, 144.0, 129.8, 85.1, 74.1, 33.7, 31.9, 29.6, 29.6, 
29.5, 29.5, 29.4, 29.3, 29.3, 24.9, 22.7, 14.3, 14.1 ppm. IR (film): ṽ = 3429, 2922, 2853, 1735, 1677, 
1465, 1439, 1378, 1353, 1207, 1123, 1075, 1038, 970, 865, 816, 722, 663 cm
−1
. MS (EI) m/z (%) = 
282 (1), 99 (6), 98 (100), 70 (22), 69 (6). HRMS (ESIpos): m/z: calcd for C17H30O3Na: 305.2087; 
found: 305.2085. 
 
2-Oxotridecyl (E)-but-2-enoate (235). DBU (5.3 µL, 35 µmol) was added to a solution of aldehyde 
233 (20.0 mg, 70.8 µmol) in CH3CN (0.7 mL) at 0 °C. After stirring at 0 °C for 1 h, 
the reaction mixture was stirred for 12 h at rt. The reaction was then quenched by 
addition of sat. NH4Cl solution (3 mL) and the aqueous phase was extracted with 
EtOAc (3 x 3 mL). The combined organic extracts were washed with brine, dried over Na2SO4 and 
concentrated. The crude residue was purified by flash chromatography to yield the rearranged ketone 
as a colorless oil (16.1 mg, 80%). 
1
H NMR (400 MHz, CDCl3): δ = 7.05 (dq, J = 15.6, 6.9 Hz, 1H), 
5.91 (dq, J = 15.5, 1.7 Hz, 1H), 4.67 (s, 2H), 2.39 (t, J = 7.3 Hz, 2H), 1.89 (dd, J = 6.9, 1.8 Hz, 3H), 
1.85 – 1.70 (m, 2H), 1.64 – 1.53 (m, 2H), 1.28 – 1.20 (m, 14H), 0.85 (t, J = 6.8 Hz, 3H) ppm. 13C 
NMR (100 MHz, CDCl3): δ = 204.4, 165.6, 146.4, 121.6, 67.8, 38.8, 31.9, 29.6, 29.4, 29.3, 29.2, 28.8, 
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24.9, 22.7, 18.1, 14.1 ppm. IR (film): ṽ = 2953, 2922, 2853, 1722, 1656, 1468, 1444, 1377, 1294, 
1258, 1175, 1101, 969, 720 cm
−1
. MS (ESIpos) m/z (%) = 305.2 (100 (M+Na
+
)). HRMS (ESIpos): 
m/z: calcd for C17H30O3Na: 305.2087; found: 305.2084. 
 
(R)-1-Bromotridecan-2-yl (E)-but-2-enoate (237). Alcohol 232 (362 mg, 1.27 mmol) was dissolved 
in CH2Cl2 (6.4 mL) and the resulting solution cooled to 0 °C. Triphenylphosphine 
(401 mg, 1.53 mmol) and CBr4 (464 mg, 1.40 mmol) were added as solids at 0 °C. 
The ice bath was removed and the orange solution allowed to warm to ambient 
temperature and stirred for further 30 min. Hexane (14 mL) was added and the suspension filtered 
through Celite
®
 (10 mL rinse with hexanes). The filtrate was washed with aq. H2O2 solution (5%, 
10 mL) and the aqueous washings were extracted with hexanes/EtOAc (9:1, 2 x 10 mL). The 
combined organic fractions were dried over Na2SO4 and concentrated. The brown residue was purified 
by flash chromatography (hexanes/EtOAc 29:1 to 24:1) to give the desired alkyl bromide as a 
colorless oil (273 mg, 62% yield). [∝]𝐷
20 = +11.7 (c = 0.76, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 
6.99 (dq, J = 15.5, 6.9 Hz, 1H), 5.84 (dq, J = 15.5, 1.7 Hz, 1H), 5.02 (tt, J = 6.5, 4.9 Hz, 1H), 3.50 (dd, 
J = 10.8, 4.6 Hz, 1H), 3.43 (dd, J = 10.8, 5.2 Hz, 1H), 1.87 (dd, J = 6.9, 1.7 Hz, 3H), 1.71 – 1.63 (m, 
2H), 1.29 – 1.20 (m, 18H), 0.85 (t, J = 6.8 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ = 165.8, 
145.4, 122.4, 72.0, 34.4, 32.5, 31.9, 29.6, 29.5, 29.4, 29.4, 29.3, 29.3, 25.0, 22.7, 18.0, 14.1 ppm. IR 
(film): ṽ = 2922, 2853, 1721, 1658, 1465, 1443, 1293, 1259, 1172, 1101, 1017, 968, 837 cm−1. MS 
(EI) m/z (%) = 349 (0.3), 347 (0.3), 267 (1), 180 (4), 111 (5), 97 (9), 87 (39), 69 (100), 41 (25). HRMS 
(ESIpos): m/z: calcd for C17H31O2BrNa: 369.1400; found: 369.1396. 
 
(R)-1-Hydroxytridecan-2-yl (Z)-2-bromobut-2-enoate (239). Alcohol 232 (117 mg, 0.411 mmol) 
was dissolved in CH2Cl2 (1.5 mL) and the resulting solution cooled to 0 °C. 
Bromine (31.6 µL, 0.617 mmol) was added dropwise via syringe. After 45 min at 
0 °C, TLC analysis indicated full consumption of the s.m. and all volatiles were 
removed under vacuum. The residue was redissolved in Et2O (2 mL), before 
triethylamine (68.8 µL, 0.494 mmol) was added at ambient temperature. After stirring for 38 h, the 
white precipitate formed was filtered off. The filtrate was concentrated and purified by flash 
chromatography (hexanes/EtOAc 12:1 to 9:1 to 7:1) to give the title compound  as a pale-yellow oil 
(86 mg, 58% yield). Due to the unstable nature (1,2-Acyl shift), it was immediately engaged in the 
next step. 
1
H NMR (400 MHz, CDCl3): δ = 7.38 (q, J = 6.8 Hz, 1H), 4.97 (dtd, J = 7.5, 6.0, 3.3 Hz, 
1H), 3.79 – 3.71 (m, 1H), 3.66 (dd, J = 12.2, 6.1 Hz, 1H), 2.05 – 1.89 (br s, 1H), 1.93 (d, J = 6.8 Hz, 
3H), 1.70 – 1.55 (m, 2H), 1.36 – 1.18 (m, 18H), 0.88 – 0.82 (t, J = 6.7 Hz, 3H) ppm. IR (film): ṽ = 
3428, 2923, 2853, 1715, 1630, 1465, 1376, 1335, 1249, 1227, 1108, 1036, 953, 845, 739 cm
−1
. MS 
(ESIpos) m/z (%) = 467.1 (100 (M+Na)).  HRMS (ESIpos): m/z: calcd for C17H31O3BrNa: 465.9611; 
found: 465.0611. 
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(R)-1-Oxotridecan-2-yl (Z)-2-bromobut-2-enoate (240). Dess-Martin periodinane (298 mg, 
0.702 mmol) and NaHCO3 (157 mg, 1.88 mmol) were added to a solution of 
primary alcohol 239 (85.1 mg, 0.234 mmol) in CH2Cl2 (2.4 mL) at 0 °C. After 
5 min, the ice bath was removed and the white suspension allowed to warm to 
ambient temperature under vigorous stirring. After 100 min, the reaction mixture 
was poured into sat. Na2S2O3/NaHCO3 solution (1:1, 8 mL) and the aqueous phase was extracted with 
CH2Cl2 (3 x 6 mL). The combined organic extracts were dried over Na2SO4 and concentrated. The 
residue was purified by flash chromatography (hexanes/EtOAc 9:1) to give a colorless oil (43 mg, 
51% yield, 90% purity). [∝]𝐷
20 = +20.0 (c = 0.89, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 9.51 (d, J 
= 0.8 Hz, 1H), 7.47 (q, J = 6.9 Hz, 1H), 5.05 (dd, J = 8.2, 4.7 Hz, 1H), 1.96 (d, J = 6.8 Hz, 3H), 1.90 – 
1.74 (m, 2H), 1.47 – 1.39 (m, J = 7.6 Hz, 2H), 1.26 (m, 16H), 0.86 – 0.82 (t, J = 6.7 Hz, 3H) ppm. 13C 
NMR (100 MHz, CDCl3): δ = 197.8, 162.0, 143.0, 116.4, 79.9, 31.9, 29.6, 29.4, 29.3, 29.3, 29.2, 28.6, 
24.8, 22.7, 18.0, 14.1 ppm. IR (film): ṽ = 2923, 2853, 1726, 1629, 1465, 1376, 1245, 1107, 1074, 
1035, 944, 839, 775, 737 cm
−1
. MS (EI) m/z (%) = 361 (1), 363 (1), 331 (0.5), 183 (8), 167 (16), 165 
(11), 149 (100), 137 (99), 119 (9), 98 (36), 83 (7), 69 (10), 68 (9), 57 (12, 55 (14), 43 (19), 41 (14), 39 
(12). HRMS (ESIpos): m/z: calcd for C17H29O3BrNa: 383.1192; found: 383.1192. 
 
(3R,4R,5R)-3,4-Dihydroxy-3-((S)-1-hydroxyethyl)-5-undecyldihydrofuran-2(3H)-one (245). A 
flame-dried Schlenck tube was charged with a solution of alcohol (E)-234 
(16.0 mg, 56.7 µmol) in CH2Cl2 (3.0 mL) and the solution cooled to −78 °C. 
TMEDA (9.8 µL, 65 µmol) was added via syringe and the resulting solution was 
stirred for 5 min. A solution of OsO4 (0.6 m in CH2Cl2, 104 µL, 62.3 µmol) was then added dropwise 
via syringe over the course of 4 min. After 20 min stirring at −78 °C, the cooling bath was removed 
and the reaction mixture concentrated by applying an Ar flow and finally dried under high vacuum. 
The residue was redissolved in THF (0.7 mL) and the solution treated with sat. NaHSO3
[249]
 (0.7 mL) 
for 36 h under vigorous stirring. The biphasic mixture was then diluted with sat. NH4Cl solution and 
extracted with EtOAc (3 x 4 mL). The combined organic extracts were dried over Na2SO4 and 
concentrated. The residue was purified by flash chromatography (hexanes/EtOAc 3:2) to give the 
desired triol as a white solid (13.2 mg, 74%). [∝]𝐷
20 = +36.8 (c = 0.58, DMSO). 
1
H NMR (400 MHz, 
[D6]-DMSO): δ = 5.46 (d, J = 6.8 Hz, 1H), 5.39 (s, 1H), 4.94 (d, J = 4.7 Hz, 1H), 4.03 (td, J = 7.8, 
4.4 Hz, 1H), 3.96 (t, J = 7.1 Hz, 1H), 3.67 (qd, J = 6.4, 4.7 Hz, 1H), 1.70 (dtd, J = 9.5, 7.4, 6.4, 4.5 Hz, 
1H), 1.60 – 1.51 (m, 1H), 1.46 – 1.33 (m, 2H), 1.27 (d, J = 6.6 Hz, 3H), 1.31 – 1.21 (m, 16H), 0.85 (t, 
J = 6.8 Hz, 3H) ppm. 
13
C NMR (100 MHz, [D6]-DMSO): δ = 174.1, 81.4, 75.9, 72.4, 67.1, 32.3, 31.3, 
29.1, 29.1, 29.0, 29.0, 28.9, 28.8, 25.0, 22.1, 16.7, 14.0 ppm. IR (film): ṽ = 3400, 2955, 2922, 2853, 
1762, 1465, 1377, 1345, 1270, 1212, 1108, 1078, 1001, 967, 895, 798, 746, 721, 700 cm
−1
. MS 
(ESIpos) m/z (%) = 339.3 (100 (M+Na)), 655.2 (45 (2M+Na)). HRMS (ESIpos): m/z: calcd for 
C17H32O5Na: 339.2142; found: 339.2142. 
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Primary Alcohol 11-epi-247. Ammoniumfluoride (52.6 mg, 1.42 mmol) was added to a solution of 
diene 210 (14.0 mg, 0.133 mmol) in hexafluroisopropanol (1.4 mL) and the 
resulting solution stirred for 72 h at ambient temperature. The reaction mixture 
was then poured into sat. NaHCO3 solution (6 mL) and the aqueous phase was 
extracted with CH2Cl2 (5 x 5 mL). The combined organic extracts were dried 
over Na2SO4 and concentrated. The residue was purified by flash 
chromatography to yield the title compound as a colorless oil (6.9 mg, 64%). 
[∝]𝐷
20 = +49.7 (c = 0.68, CH2Cl2). 
1
H NMR (600 MHz, CDCl3): δ = 7.65 – 
7.61 (m, 4H), 7.40 – 7.37 (m, 2H), 7.36 – 7.31 (m, 4H), 6.93 (ddd, J = 15.6, 7.8, 6.0 Hz, 1H), 6.22 (dd, 
J = 15.0, 10.9 Hz, 1H), 5.93 (tt, J = 10.8, 1.5 Hz, 1H), 5.71 (dt, J = 15.7, 1.5 Hz, 1H), 5.33 (dd, J = 
15.0, 8.9 Hz, 1H), 5.18 (dt, J = 10.8, 7.4 Hz, 1H), 4.55 (ddt, J = 9.2, 6.0, 3.1 Hz, 1H), 4.02 (ddd, J = 
7.3, 4.8, 3.5 Hz, 1H), 3.90 (ddd, J = 9.1, 6.7, 4.7 Hz, 1H), 3.78 (td, J = 7.2, 5.9 Hz, 1H), 3.70 (tt, J = 
10.7, 4.8 Hz, 1H), 3.57 (d, J = 12.3 Hz, 1H), 3.47 – 3.41 (m, 1H), 3.20 (tdd, J = 11.4, 9.7, 2.1 Hz, 1H), 
3.16 (tt, J = 11.2, 1.5 Hz, 1H), 2.59 – 2.50 (m, 1H), 2.41 (br t, 1H), 2.36 (ddd, J = 15.6, 9.6, 6.0, 
1.6 Hz, 1H), 2.32 – 2.27 (dt, J = 14.9, 7.4 Hz, 1H), 2.26 – 2.15 (m, 4H), 1.97 (dt, J = 12.6, 7.0 Hz, 
1H), 1.76 (ddt, J = 12.4, 4.2, 1.8 Hz, 1H), 1.67 – 1.63 (m, 1H), 1.62 (ddd, J = 14.6, 7.3, 3.9 Hz, 1H), 
1.56 – 1.52 (m, 2H), 1.22 – 1.13 (m, 3H), 1.02 (s, 9H), 0.97 (d, J = 7.0 Hz, 3H), 0.97 (d, J = 6.9 Hz, 
3H), 0.86 (s, 9H), 0.03 (s, 3H), 0.03 (s, 3H) ppm. 
13
C NMR (150 MHz, CDCl3): δ = 166.9, 146.5, 
140.4, 135.9, 135.9, 133.9, 133.8, 129.7, 129.7, 129.6, 127.6, 127.6, 126.4, 125.6, 122.4, 81.2, 80.3, 
75.6, 74.2, 73.1, 71.1, 68.5, 65.3, 43.7, 42.2, 42.1, 39.1, 35.9, 33.4, 33.4, 33.2, 30.9, 27.0, 25.8, 22.4, 
19.4, 18.1, 14.9, −4.5, −4.5 ppm. IR (film): ṽ = 3470, 2954, 2929, 2856, 1716, 1656, 1472, 1462, 
1428, 1374, 1255, 1177, 1156, 1112, 1074, 967, 849, 837, 776, 739, 703, 610 cm
−1
. MS (ESIpos) m/z 
(%) = 839.6 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for C48H72O7Si2Na: 839.4709; found: 
839.4701. 
 
Aldehyde 11-epi-227. Sodium bicarbonate (4.8 mg, 56 µmol) and Dess-Martin periodinane (9.0 mg, 
21 µmol) were added successively to a solution of alcohol 11-epi-247 (5.8 mg, 
7.1 µmol) in CH2Cl2 (1.4 mL) at 0 °C and the resulting suspension was 
vigorously stirred. After 5 min, the ice bath was removed and the reaction 
mixture was allowed to reach ambient temperature. After 90 min, the reaction 
mixture was poured into aq. NaHCO3/Na2S2O3 (1:1, 5 mL) and the aqueous 
phase was extracted with CH2Cl2 (3 x 5 mL). The combined organic extracts 
were dried over Na2SO4 and concentrated. The residue was quickly purified by 
flash chromatography (short column < 8cm length, hexanes/EtOAc 12:1) keeping the contact time 
with silica gel as short as possible to give the rather unstable aldehyde as a colorless oil. (3.0 mg, 
52%). [∝]𝐷
20 = +58 (c = 0.28, CH2Cl2). 
1
H NMR (600 MHz, C6D6): δ = 9.34 (d, J = 0.7 Hz, 1H), 7.85 – 
7.74 (m, 4H), 7.30 – 7.21 (m, 7H), 6.58 (dd, J =14.6, 11.3 Hz, 1H), 6.07 (tt, J = 11.0, 2.2 Hz, 1H), 
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5.76 (dt, J = 15.7, 0.8 Hz, 1H), 5.30 (dd, J = 15.0, 9.3 Hz, 1H), 5.12 (dt, J = 10.8, 7.2 Hz, 1H), 4.59 
(ddd, J = 10.8, 3.1, 1.5 Hz, 1H), 4.30 (ddt, J = 7.7, 4.7, 2.3 Hz, 1H), 3.69 (ddd, J = 8.7, 6.9, 4.7 Hz, 
1H), 3.56 (ddd, J = 15.7, 10.5, 5.0 Hz, 1H), 3.15 (t, J = 11.0 Hz, 1H), 2.83 (tt, J = 10.6, 1.7 Hz, 1H), 
2.79 – 2.72 (m, 1H), 2.42 (ddd, J = 14.9, 11.0, 2.2 Hz, 1H), 2.34 (dddd, J = 16.7, 8.0, 4.9, 1.8 Hz, 1H), 
2.30 – 2.24 (m, 1H), 2.19 – 2.14 (m, 1H), 2.12 (dddd, J = 15.1, 10.3, 5.0, 1.9 Hz, 1H), 1.98 (dq, J = 
8.5, 7.0 Hz, 1H), 1.80 (dt, J = 12.8, 7.0 Hz, 1H), 1.73 (dddd, J = 15.3, 9.0, 2.4, 1.1 Hz, 1H), 1.63 (dd, J 
= 12.6, 5.0 Hz, 1H), 1.56 – 1.49 (m, 2H), 1.41 – 1.38 (m, 1H), 1.33 – 1.25 (m, 4H), 1.17 (s, 9H), 1.02 
(s, 9H), 0.90 (d, J = 6.8 Hz, 3H), 0.77 (d, J = 7.0 Hz, 3H), 0.09 (s, 6H) ppm. 
13
C NMR (150 MHz, 
C6D6): δ = 197.3, 165.7, 147.6, 140.5, 136.3, 136.3, 134.3, 134.2, 130.1, 130.0, 130.0, 126.6, 126.2, 
121.8, 81.1, 80.5, 78.5, 73.9, 73.0, 71.6, 68.8, 44.1, 42.7, 42.6, 39.4, 36.4, 34.1, 33.7, 31.9, 31.3, 30.2, 
27.3, 26.0, 22.3, 19.6, 18.2, 14.7, −4.3, −4.3 ppm. IR (film): ṽ = 2954, 2928, 2856, 1722, 1654, 1471, 
1462, 1428, 1345, 1257, 1170, 1111, 1081, 1006, 989, 869, 837, 776, 739, 703, 610 cm
−1
. MS 
(ESIpos) m/z (%) = 837.5 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for C48H70O7Si2Na: 837.4552; 
found: 837.4558. 
 
Alcohol 247. Ammonium fluoride (328 mg, 8.86 mmol) was added as a solid to a stirred solution of 
diene 210 (85.0 mg, 80.5 µmol) in hexafluoroisopropanol (8.5 mL) at 5 °C. 
The reaction mixture was allowed to warm to 15 °C after 12 h and stirred at 
this temperature for further 36 h. The reaction was then quenched by pouring it 
into sat. NH4Cl solution (25 mL). The aqueous phase was extracted with 
CH2Cl2 (1 x 15 mL) and EtOAc (3 x 15 mL) and the combined organic 
extracts were dried over Na2SO4 and concentrated. The residue was purified by 
flash chromatography (hexanes/EtOAc 6:1) to give the desired primary alcohol 
as a white foam (43.0 mg, 65% yield). [∝]𝐷
20 = +11.8 (c = 0.96, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): 
δ = 7.69 – 7.61 (m, 4H), 7.42 – 7.29 (m, 6H), 6.91 (dt, J = 15.7, 6.9 Hz, 1H), 6.23 (dd, J = 15.1, 
10.9 Hz, 1H), 5.94 (t, J = 10.9 Hz, 1H), 5.85 (dt, J = 15.6, 1.2 Hz, 1H), 5.50 (dd, J = 15.0, 8.5 Hz, 1H), 
5.20 (dt, J = 10.4, 7.8 Hz, 1H), 4.96 (ddd, J = 12.4, 6.3, 3.1 Hz, 1H), 4.04 (ddd, J = 7.9, 5.6, 4.3 Hz, 
1H), 3.81 (dd, J = 7.7, 5.8 Hz, 1H), 3.74 (ddd, J = 10.7, 5.8, 4.9 Hz, 1H), 3.69 (dd, J = 6.7, 6.6 Hz, 
1H), 3.51 (dd, J = 12.2, 2.7 Hz, 1H), 3.41 – 3.30 (m, 2H), 3.29 – 3.21 (m, 1H), 2.45 – 2.36 (m, 1H), 
2.36 – 2.30 (m, 2H), 2.28 – 2.14 (m, 2H), 2.06 (dt, J = 13.8, 6.9 Hz, 1H), 1.93 (dt, J = 13.0, 7.7 Hz, 
1H), 1.90 – 1.81 (m, 2H), 1.78 (ddt, J = 12.4, 4.3, 1.9 Hz, 1H), 1.69 (ddt, J = 12.6, 4.2, 1.7 Hz, 1H), 
1.64 – 1.54 (m, 2H), 1.41 (ddd, J = 12.7, 8.3, 6.6 Hz, 1H), 1.32 – 1.27 (m, 1H), 1.21 – 1.16 (m, 2H), 
1.01 (s, 9H), 0.94 (d, J = 6.6 Hz, 3H), 0.88 (d, J = 7.1 Hz, 3H), 0.86 (s, 9H), 0.04 (s, 6H) ppm. 
13
C 
NMR (100 MHz, CDCl3): δ = 166.8, 146.5, 140.4, 136.0, 134.3, 134.0, 130.0, 129.6, 129.6, 127.6, 
127.5, 127.5, 126.4, 124.1, 122.7, 81.2, 80.1, 73.7, 73.6, 73.2, 72.1, 68.8, 65.5, 42.8, 41.9, 41.7, 38.5, 
35.3, 34.4, 33.9, 33.6, 30.1, 27.1, 25.8, 20.1, 19.5, 18.1, 15.2, −4.5 ppm. IR (film): ṽ = 3466, 2955, 
2929, 2856, 1718, 1656, 1472, 1462, 1428, 1374, 1319, 1256, 1177, 1155, 1107, 1069, 961, 836, 775, 
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740, 703, 609 cm
−1
. MS (ESIpos) m/z (%) = 839.6 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for 
C48H72O7Si2Na: 839.4709; found: 839.4703. 
 
Aldehyde 227. Dess-Martin periodinane (46.8 mg, 0.110 mmol) and NaHCO3 (25.3 mg, 0.301 mmol) 
were added as solids to a solution of alcohol 247 (41.0 mg, 50.2 µmol) in 
CH2Cl2 (9.6 mL) at 0 °C. The ice bath was removed 5 min after the addition and 
the reaction mixture allowed to warm to ambient temperature while stirring 
vigorously. After 2.5 h, the reaction mixture was quenched by pouring it into 
sat. NaHCO3/Na2S2O5 solution (1:1, 15 mL) and the aqueous phase was 
extracted with CH2Cl2 (4 x 12 mL). The combined organic extracts were dried 
over Na2SO4 and concentrated. The residue was purified by flash 
chromatography (8 cm SiO2, hexanes/EtOAc 9:1) keeping the contact time with silica gel as short as 
possible to yield the desired aldehyde as a white foam (34.3 mg, 84% yield). [∝]𝐷
20 = +15.6 (c = 0.98, 
CH2Cl2). 
1
H NMR (400 MHz, C6D6): δ = 9.22 (s, 1H), 7.88 – 7.81 (m, 4H), 7.29 – 7.22 (m, 6H), 7.09 
(ddd, J = 15.3, 8.7, 6.2 Hz, 1H), 6.50 (dd, J = 15.0, 11.0 Hz, 1H), 6.11 (t, J = 10.8 Hz, 1H), 5.99 (dd, J 
= 15.7, 1.0 Hz, 1H), 5.54 (dd, J = 15.1, 8.3 Hz, 1H), 5.46 (dd, J = 9.9, 3.6 Hz, 1H), 5.19 (dt, J = 10.7, 
7.7 Hz, 1H), 4.22 (ddd, J = 9.4, 6.3, 3.1 Hz, 1H), 3.82 (dt, J = 8.9, 6.7 Hz, 1H), 3.65 – 3.55 (m, 2H), 
3.14 (td, J = 9.8, 1.6 Hz, 1H), 2.88 (td, J = 10.0, 0.8 Hz, 1H), 2.67 – 2.55 (m, 1H), 2.11 (dt, J = 15.3, 
7.6 Hz, 1H), 1.99 (dt, J = 15.0, 8.8 Hz, 1H), 1.92 – 1.75 (m, 5H), 1.73 – 1.62 (m, 2H), 1.56 – 1.46 (m, 
2H), 1.21 (s, 9H), 1.19 – 1.12 (m, 4H), 1.04 – 0.99 (m, 12H), 0.70 – 0.65 (d, J = 6.9 Hz, 3H), 0.09 (s, 
6H). ppm. 
13
C NMR (100 MHz, C6D6): δ = 197.3, 165.6, 147.1, 140.3, 136.5, 136.4, 135.0, 134.5, 
130.4, 129.9, 129.9, 127.9, 127.9, 126.9, 125.2, 122.7, 81.2, 81.0, 76.1, 73.7, 73.5, 72.8, 69.0, 43.5, 
42.4, 42.0, 38.6, 36.3, 35.2, 33.7, 32.6, 30.7, 27.5, 26.0, 20.1, 19.9, 18.2, 14.7, −4.3 ppm. IR (film): ṽ = 
2955, 2928, 2956, 1722, 1655, 1471, 1462, 1428, 1257, 1171, 1106, 1052, 1005, 982, 941, 836, 775, 
738, 702, 609 cm
−1
. MS (ESIpos) m/z (%) = 837.5 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for 
C48H70O7Si2Na: 837.4552; found: 837.4550. 
 
Alcohol 220a. Ammonium fluoride (54.2 mg, 1.46 mmol) was added to a solution of diyne 220 
(16.0 mg, 0.146 mmol) in 1,1,1,3,3,3-hexafluro-2-propanol (1.5 mL) and 
the resulting solution stirred for 40 h at ambient temperature. The reaction 
mixture was then poured into sat. aq. NaHCO3 solution and the aqueous 
phase was extracted with CH2Cl2 (4 x 5 mL). The combined organic 
extracts were dried over Na2SO4 and concentrated. The residue was 
purified by flash chromatography (hexanes/EtOAc 15:1 to 9:1 to 7:1 5:1) 
to yield the title compound as a white foam (8.8 mg, 70%). [∝]𝐷
20 = −16.4 
(c = 0.86, CH2Cl2). 
1
H NMR (400 MHz, CDCl3): δ = 7.68 – 7.61 (m, 4H), 7.40 – 7.35 (m, 2H), 7.35 – 
7.28 (m, 4H), 6.87 (dt, J = 15.6, 7.2 Hz, 1H), 5.92 (dd, J = 15.9, 7.9 Hz, 1H), 5.71 (dt, J = 15.7, 
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1.2 Hz, 1H), 5.36 (ddq, J = 15.9, 2.6, 1.3 Hz, 1H), 4.98 (ddt, J = 8.4, 4.7, 4.3 Hz, 1H), 3.84 (ddd, J = 
7.1, 6.1, 3.9 Hz, 1H), 3.82 – 3.74 (m, 2H), 3.70 (tt, J = 10.6, 4.9 Hz, 1H), 3.58 (dd, J = 12.1, 3.3 Hz, 
1H), 3.47 (dd, J = 12.3, 5.7 Hz, 1H), 3.33 (dddd, J = 11.4, 6.6, 5.2, 1.2 Hz, 1H), 3.25 (dd, J = 11.2, 
7.2, 5.8, 1.4 Hz, 1H), 2.44 – 2.24 (m, 4H), 2.18 – 2.04 (m, 3H), 2.01 – 1.89 (m, 2H), 1.90 (d, J = 
2.2 Hz, 3H), 1.87 (t, J = 2.6 Hz, 1H), 1.80 – 1.71 (m, 2H), 1.69 – 1.57 (m, 2H), 1.32 (ddd, J = 12.4, 
8.4, 7.9 Hz, 1H), 1.35 – 1.26 (ddd, J = 13.4, 7.0, 6.4 Hz, 1H), 1.23 – 1.07 (m, 2H), 1.00 (s, 9H), 0.96 
(d, J = 6.5 Hz, 3H), 0.86 (d, J = 7.0 Hz, 3H), 0.86 (s, 9H), 0.04 (s, 6H) ppm. 
13
C NMR (100 MHz, 
CDCl3): δ = 166.6, 148.5, 145.9, 136.0, 135.9, 134.1, 133.9, 129.5, 129.4, 127.5, 127.3, 122.9, 108.2, 
84.5, 81.7, 81.0, 79.3, 78.3, 74.0, 73.3, 73.1, 71.8, 69.3, 68.6, 65.3, 42.3, 41.4, 41.3, 38.8, 35.2, 34.8, 
34.4, 33.4, 27.1, 25.8, 20.9, 19.8, 19.5, 18.1, 14.7, 4.2, −4.5, −4.5 ppm. IR (film): ṽ = 3466, 2954, 
2929, 2856, 1718, 1656, 1472, 1462, 1428, 1377, 1256, 1219, 1177, 1109, 1069, 1005, 837, 776, 739, 
703, 611 cm
−1
. MS (ESIpos) m/z (%) = 877.6 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for 
C51H74O7Si2Na: 877.4865; found: 877.4860. 
 
Aldehyde 249. Dess-Martin periodinane (9.8 mg, 23 µmol) and NaHCO3 (5.2 mg, 62 µmol) were 
added as solids to a stirred solution of alcohol 220a (6.6 mg, 7.7 µmol) in 
CH2Cl2 (2.4 mL) at room temperature. The resulting white suspension was 
stirred vigorously for 2.5 h. The reaction mixture was then poured into sat. 
NaHCO3/Na2S2O5 solution (1:1, 6 mL) and the aqueous phase was extracted 
with CH2Cl2 (4 x 5 mL). The combined organic extracts were dried over 
Na2SO4 and concentrated. The residue was purified by flash chromatography 
(8 cm SiO2, hexanes/EtOAc 12:1), keeping the contact time with silica gel 
as short as possible, to give the rather unstable aldehyde as a colorless oil (5.5 mg, 84% yield). [∝]𝐷
20 = 
−11.7 (c = 0.48, CH2Cl2). 
1
H NMR (600 MHz, CDCl3): δ = 9.39 (d, J = 0.8 Hz, 1H), 7.65 – 7.60 (m, 
4H), 7.39 – 7.35 (m, 2H), 7.33 – 7.29 (m, 4H), 6.91 (dt, J = 15.7, 7.1 Hz, 1H), 5.91 (ddd, J = 15.9, 8.0, 
0.8 Hz, 1H), 5.74 (dt, J = 15.7, 1.5 Hz, 1H), 5.36 (dqd, J = 15.9, 2.3, 1.1 Hz, 1H), 5.03 (dd, J = 9.9, 
3.6 Hz, 1H), 3.93 (ddd, J = 8.3, 6.0, 3.4 Hz, 1H), 3.82 – 3.77 (m, 2H), 3.73 (tt, J = 10.8, 4.7 Hz, 1H), 
3.36 (dddd, J = 11.8, 7.0, 5.0, 1.8 Hz, 1H), 3.26 (dddd, J = 11.2, 7.3, 5.7, 1.6 Hz, 1H), 2.41 (dtd, J = 
14.2, 7.1, 1.6 Hz, 1H), 2.38 – 2.26 (m, 3H), 2.12 – 2.08 (m, 2H), 1.96 (dt, J = 12.8, 7.4 Hz, 1H), 1.92 – 
1.89 (m, 1H), 1.90 (d, J = 2.2 Hz, 3H), 1.87 (t, J = 2.7 Hz, 1H), 1.80 – 1.73 (m, 2H), 1.62 (dt, J = 14.3, 
7.1 Hz, 1H), 1.34 – 1.27 (m, 2H), 1.22 – 1.17 (m, 2H), 1.16 – 1.10 (m, 1H), 1.01 (s, 9H), 0.96 (d, J = 
6.7 Hz, 3H), 0.87 (d, J = 7.1 Hz, 1H), 0.86 (s, 9H), 0.04 (s, 6H) ppm. 13C NMR (150 MHz, CDCl3): δ 
= 198.3, 165.5, 148.4, 147.0, 135.9, 133.8, 133.5, 129.6, 129.5, 127.6, 127.3, 121.9, 108.2, 84.4, 81.5, 
80.6, 79.4, 78.3, 75.5, 73.9, 73.3, 71.0, 69.5, 68.6, 42.3, 41.4, 41.4, 38.9, 35.2, 34.7, 33.4, 31.8, 27.1, 
25.8, 20.9, 19.7, 19.5, 14.7, 4.2, −4.5, −4.5.ppm. IR (film): ṽ = 2955, 2929, 2856, 1725, 1655, 1472, 
1462, 1428, 1376, 1258, 1171, 1110, 1060, 1006, 962, 837, 776, 740, 703, 611 cm
−1
. MS (ESIpos) m/z 
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(%) = 875.5 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for C51H72O7Si2Na: 875.4711; found: 
875.4709. 
 
Baylis-Hillman alcohol 250. A flame-dried Young tube was charged with a solution of aldehyde 249 
(1.2 mg, 1.41 µmol) in DMF (30 µL) followed by a solution of 
dimethylphenylphosphine (0.05 M in DMF, 8.4 µL, 0.42 µmol). The 
Young tube was sealed and place in a preheated oil bath (90 °C). The 
reaction mixture was stirred at this temperature for 8 h before being 
cooled to room temperature. It was then poured into sat. NH4Cl solution 
(3 mL) and the aqueous phase was extracted with Et2O (3 x 2 mL). The 
combined organic layers were dried over Na2SO4 and concentrated. The 
residue was purified by flash chromatography (hexanes/EtOAc 9.1 to 8:1 to 7:1 to 6:1 to 5:1) to give 
alcohol 250 as a white amorphous solid (0.45 mg, 38% yield, 6:1 E/Z, ~90% pure). 
1
H NMR 
(600 MHz, C6D6): δ = see table 5.11. 
13
C NMR (150 MHz, C6D6): δ = see table 5.11. IR (film): ṽ = 
3461, 2956, 2931, 2855, 1724, 1658, 1472, 1463, 1428, 1376, 1256, 1172, 1111, 1060, 1005, 960, 
835, 778, 742, 706 cm
−1
. MS (ESIpos) m/z (%) = 875.5 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for 
C51H72O7Si2Na: 875.4711; found: 875.4707. 
 
Baylis-Hillman alcohol ((24R)-226, major isomer). A flame-dried Young-tube was charged with a 
solution of aldehyde 227 (34.3 mg, 42.1 µmol) in DMF (1.1 mL). A solution  
of dimethylphenylphosphine (0.2 M in DMF, 63.1 µL, 12.6 µmol) was added 
via syringe, the Young tube was sealed, placed in a preheated oil bath (90 °C) 
and the reaction mixture was stirred for 60 h at this temperature. After 
cooling to ambient temperature, the reaction mixture was poured into sat. 
NH4Cl solution (10 mL) and the aqueous phase was extracted with Et2O (3 x 
4 mL). The combined organic extracts were dried over Na2SO4 and 
concentrated. The pale yellow residue was purified by flash chromatography (hexanes/EtoAc 12:1 to 
9:1 to 8:1 to 7:1) to yield alcohol (24R)-226 (11.7 mg, 34% yield) along with its isomer (24S)-226 (see 
below) and elimination product 251 (see below). [∝]𝐷
20 = +47 (c = 0.28, CH2Cl2). 
1
H NMR (400 MHz, 
CDCl3): see table 5.12. 
13
C NMR (100 MHz, CDCl3): see table 5.12. IR (film): ṽ = 3426, 2955, 2930, 
2894, 2857, 1760, 1744, 1683, 1462, 1428, 1376, 1362, 1331, 1252, 1195, 1111, 1077, 1029, 1006, 
945, 856, 836, 775, 739, 704 cm
−1
. MS (ESIpos) m/z (%) = 837.5 (100 (M+Na)). HRMS (ESIpos): 
calcd for C48H70O7Si2Na: m/z: 837.4552; found: 837.4549. 
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Table 5.11: Assignment of the 
1
H & 
13
C NMR data for the anti-Baylis-Hillman alcohol 250.* 
 
atom 
n° 
1
H NMR (C6D6, 600 MHz) 
13
C NMR (C6D6,  
150 MHz)  /ppm
 
 /ppm m J/Hz COSY NOESY 
1 - - - - - 168.2 
2 - - - - - 134.3 
3 6.95 ddd 9.8, 7.1, 2.0 4ab, 24 4a(b) 139.8 
4a 2.33 ddd 14.0, 9.8, 4.0 3, 4b, 5 4b, 5, 24 
34.9 
4b 1.95 m - 3, 4a, 5 4a, 5 
5 2.95 dtd 11.5, 6.5, 1.4 4ab, 6ab 4ab, 6b, 7, 9 73.7 
6a 1.53 m - 5, 6b, 7 6b 
40.3 
6b 1.28 m - 5, 6a, 7 5, 6a, 7 
7 3.50 dddd 10.5, 10.3, 5.0, 4.9 6ab, 8ab 5, 6b, 8b, 9 68.9 
8a 1.60 ddt 12.9, 4.4, 2.1 7, 8b, 9 8b 
41.1 
8b 0.97 m - 7, 8a, 9 7, 8a, 9, 11 
9 3.09 dtd 11.2, 6.7, 1.2 8ab, 10ab 5, 7, 8b, 10a, (11), 25 74.2 
10a 1.47 t 11.3 9, 10b, 11 9, 10b, 12 
42.0 
10b 1.08 m - 9, 10a, 11 10a, (25) 
11 2.16 m - 10ab, 12 8b, (9), 10a(b), (12), 13, 25 33.8 
12 5.96 dd 15.8, 8.3 11, 13 10a, (11), 25 147.9 
13 5.52 dqd 15.9, 2.2, 0.9 (11), 12, 14‘‘ 11, (25) 109.6 
14 - - - - - 78.9 
14‘ - - - - - 84.9 
14‘‘ 1.63 d 2.3 13 - 3.9 
15‘ 1.70 t 2.7 16ab - 70.0 
15 - - - - - 81.7 
16a 2.03 ddd 16.7, 5.6, 2.7 16b, 17 16b, 17, 18 
21.1 
16b 1.93 m - 16a, 17 16a, 17 
17 3.64 ddd 7.8, 7.1, 5.6 16ab, 18 16ab, 18 79.7 
18 1.93 m - 17, 19a, 26 17, 19a, 26 35.6 
19a 1.53 m - 18, 19b, 20 18, 19b, 20, 21 
35.5 
19b 1.06 m - 19a 19a, (22b), 26 
20 3.68 dt 8.9, 6.7 19a, 21 19ab, 21, 22b, (23, (26) 81.7 
21 4.18 ddd 7.2, 7.0, 4.2 20, 22ab 19a, 20, 22b, 23, 24 72.8 
22a 1.71 m - 21, 22b, 23 20, 22b, 23 
39.1 
22b 1.71 m - 21, 22a, 23 20, 22a, 23 
23 4.82 ddd 9.0, 5.0, 2.4 22ab, 24 (20), 21, 22b, 24 82.3 
24 4.34 dd 2.4, 2.1 23, OH 4ab, (21), 22b, 23 70.9 
25 0.78 d 6.6 11 9, 10a(b), 11, 12, (13) 20.0 
26 0.66 d 7.0 18 18, 19, (20) 14.6 
OH 3.35 br s - 23 24 - 
 
* The signals of the TBS & TBDPS group are not listed and appear as follows: 1H NMR (600 MHz, 
C6D6): δ = 7.93 – 7.88 (m, 4H), 7.30 – 7.22 (m, 6H), 1.23 (s, 9H), 0.99 (s, 9H), 0.07 (s, 3H), 0.06 (s, 
3H) ppm. 
13
C NMR (150 MHz, C6D6): δ = 136.5, 134.8, 134.5, 129.9, 129.7, 127.9, 27.5, 26.0, −4.4  
ppm. 
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Table 5.12: Assignment of the 
1
H & 
13
C NMR data for the anti-Baylis-Hillman alcohol (24R)-226.* 
 
atom 
n° 
1
H (CDCl3, 600 MHz) 
13
C (CDCl3, 150 MHz) 
 /ppm m J /Hz COSY NOESY  /ppm HMBC 
1 - - - - - 168.7 - 
2 - - - - - 132.8 - 
3 6.85 ddd 9.7, 7.0, 2.1 4ab 4ab, 5, 6a, (24), (25) 142.3 1, (5), 24 
4a 2.63 ddd 14.0, 9.7, 8.3 3, 4b, (5) 3, 4b, 5, (6a), 24 
35.0 
2, 3, 5 
4b 2.39 ddd 14.0, 7.1, 2.4 3, 4a, 5 3, 4a, 5, 24 2, 5, 6 
5 3.45 dddd 11.1, 8.5, 2.0, 1.7 4(a)b, 6a 3, 4ab, 6b, 7, 9 74.3 (3), 4, 5 
6a 1.29 m - 5, 6b, 7 3, (4a), 6b, 8a 
40.7 
5, 7 
6b 1.83 ddt 12.5, 4.7, 1.7 6a, 7 5, 6a, 7 7, 8 
7 3.75 m - 6ab, 8ab 5, 6b, 8b, 9, 25 68.6 6,8 
8a 1.16 m - 7, 8b, 9 6a, 8b 
41.8 
7, 9, 10 
8b 1.68 ddt 12.7, 4.7, 1.7 7, 8a, (9) 7, 8a, 9 6, 7 
9 3.29 tt 10.9, 2.0 8a(b), 10b 5, 7, 8b, 10b, 11, 25 73.1 7, 11 
10a 1.19 m - 10b, 11 9, 10b, 11, 12 
43.7 
8, 12 
10b 1.47 m - 9, 10a 10a, 11, 12, 13 9 
11 2.31 m - 10ab, 12, 25 9, 10a, 13, 24, 25, OH 32.8 12 
12 5.45 dd 15.1, 8.3 11, 13 10ab, (11), 12, 13, 25 141.0 11, 14, 25 
13 6.34 dd 15.2, 10.9 12, 14 10a, 11, 16a, (17), (24), 25 125.0 11 
14 5.93 dd 10.8, 10.8 13, 15 12, 15 130.5 16 
15 5.28 dt 10.2, 6.6 14, 16ab 14, 16ab, 17, (26) 127.0 13, 17 
16a 2.00 dddd 14.5, 6.6, 3.1, 0.5 15, 16b, 17 13, 15, 16b, 17, 23, 26 
30.4 
14, 15, 17 
16b 2.36 m - 15, 16a, 17 15, 17, 16a, 26 14, 15 
17 3.72 ddd 8.7, 7.3, 3.0 16ab, 18 (13), 15, 16ab, 18, 20, 25 81.5 15 
18 2.46 ddq 7.4, 7.3, 7.3 17, 19ab, 26 17, 19a, 20, 26 35.4 19, (20), 26 
19a 1.48 m - 18, 19b, 20 18, 19b, 20 
33.7 
17, 18, (20), 26 
19b 1.92 ddd 12.9, 7.7, 7.0 18, 19a, 20 19a, 21, 22a, 23 18, 20, (21), 26 
20 3.83 ddd 9.3, 6.6, 4.9 19ab, 21 17, 18, 19a, 21 80.0 (18), 22 
21 4.34 m - 20, 22ab 19b, 20, 22a 69.0 19, 23 
22a 1.74 ddd 14.2, 7.5, 5.9 21, 22b, 23 19b, 21, 22b, 23, 24 
36.0 
20, 21 23, 24 
22b 1.93 ddd 14.4, 8.2, 6.0 21, 22a, 23 22a (21), 23, 24 
23 4.54 ddd 8.7, 5.9, 3.5 22ab, 24 16a, 19b, 22a, 24, 25, OH 82.0 (1) 
24 4.33 ddd - 23, OH (3), 4ab, 11, (13), 22a, 23 71.0  
25 0.86 d 6.4 11 (3), 7, 9, 11, 12, (13) 18.6 10, 11 
26 0.95 d 7.1 18 16ab, 17, 18, 19b, 22, 23 15.7 17, 18, 19 
OH 2.84 br d 4.4 23 11, 23, 24 - - 
 
*The signals of the TBS & TBDPS group are not listed and appear as follows: 
1
H NMR (600 MHz, 
CDCl3): δ = 7.68 – 7.63 (m, 4H), 7.42 – 7.31 (m, 6H), 1.04 (s, 9H), 0.85 (s, 9H), 0.04 (s, 3H), 0.03 (s, 
3H) ppm. 
13
C NMR (150 MHz, CDCl3): δ = 136.0, 133.8, 133.7, 129.7, 129.7, 127.6, 127.6, 127.5, 
27.1, 25.8, 19.5, 18.1, −4.5, −4.6 ppm 
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Baylis-Hillman alcohol ((24S)-226, minor isomer). Obtained from the reaction described above as 
the minor isomer (6.4 mg, 19% yield). [∝]𝐷
20 = +46.1 (c = 0.67, CH2Cl2). 
1
H 
NMR (600 MHz, C6D6): δ = see table 5.13. 
13
C NMR (150 MHz, CDCl3): δ = 
see table 5.13. IR (film): ṽ = 3417, 2955, 2928, 2856, 2856, 1760, 1742, 
1682, 1462, 1428, 1376, 1252, 1194, 1110, 1075, 1006, 945, 856, 836, 775, 
739, 703 cm
−1
. MS (ESIpos) m/z (%) = 837.5 (100 (M+Na)). HRMS 
(ESIpos): m/z: calcd for C48H70O7Si2Na: 837.4552; found: 837.4551. 
 
 
Elimination product 251. Obtained from the reaction described above as an unpolar by-product 
(1.6 mg, 5% yield). [∝]𝐷
20 = +27.8 (c = 0.34, CH2Cl2). 
1
H NMR (400 MHz, 
CDCl3): δ = 7.67 – 7.61 (m, 4H), 7.40 – 7.30 (m, 6H), 6.40 (dd, J = 10.6, 
6.5 Hz, 1H), 6.16 (dd, J = 15.0, 11.1 Hz, 1H), 5.99 (t, J = 11.0 Hz, 1H), 5.91 (s, 
1H), 5.48 (dd, J = 15.0, 8.4 Hz, 1H), 5.31 (td, J = 10.1, 6.4 Hz, 1H), 4.30 (ddd, 
J = 8.3, 5.6, 4.4 Hz, 1H), 3.74 – 3.66 (m, 3H), 3.17 – 3.06 (m, 2H), 2.89 (dd, J 
= 14.8, 5.6 Hz, 1H), 2.54 (dd, J = 14.8, 8.2 Hz, 1H), 2.44 (ddd, J = 13.0, 10.7, 
7.8 Hz, 1H), 2.33 – 2.23 (m, 4H), 2.12 – 2.06 (m, 1H), 1.93 (ddd, J = 12.4, 7.6, 
6.2 Hz, 1H), 1.83 (ddt, J = 12.4, 4.7, 1.6 Hz, 1H), 1.68 (ddt, J = 12.5, 4.6, 1.6 Hz, 1H), 1.58 (dt, J = 
12.4, 9.5 Hz, 1H), 1.47 (ddd, J = 13.8, 9.9, 6.2 Hz, 1H), 1.26 (dd, J = 6.6, 2.7 Hz, 1H), 1.21 – 1.13 (m, 
2H), 1.01 (s, 9H), 0.99 (d, J = 7.0 Hz, 3H), 0.86 (s, 9H), 0.80 (d, J = 6.7 Hz, 3H), 0.03 (s, 3H), 0.03 (s, 
3H) ppm. 
13
C NMR (150 MHz, CDCl3): δ = 168.1, 156.9, 141.5, 135.9, 135.9, 133.8, 133.7, 133.6, 
130.9, 130.4, 129.7, 129.6, 127.6, 127.5, 126.5, 123.3, 103.6, 81.6, 79.7, 74.4, 73.5, 69.6, 68.7, 42.3, 
42.1, 41.5, 36.5, 35.6, 34.4, 33.7, 32.3, 29.9, 27.0, 25.8, 19.6, 19.4, 18.1, 15.5, −4.5, −4.5 ppm. IR 
(film): ṽ = 2955, 2928, 2856, 1782, 1655, 1471, 1462, 1428, 1376, 1324, 1254, 1151, 1105, 1081, 
1006, 927, 867, 837, 823, 776, 740, 703 cm
−1
. MS (EI) m/z (%) = 796 (14), 741 (16), 740 (34), 739 
(58), 711 (29), 607 (22), 540 (38), 483 (17), 408 (51), 295 (38), 239 (25), 217 (26), 199 (63), 197 (44), 
135 (100), 131 (18), 93 (20), 73 (32). HRMS (ESIpos): m/z: calcd for C48H68O6Si2Na: 819.4447; 
found: 819.4443. 
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Table 5.13: Assignment of the 
1
H & 
13
C NMR data for the syn-Baylis-Hillman alcohol (24S)-226.*
 
 
atom 
n° 
1
H (CDCl3, 600 MHz) 
13
C (CDCl3, 150 MHz) 
 /ppm m J /Hz COSY NOESY  /ppm HMBC 
1 - - - - - 168.7 - 
2 - - - - - 134.8 - 
3 6.79 ddd 11.3, 6.0, 1.6 4ab 4ab, 5 140.0 1, 24 
4a 2.46 m - 3, 4b, (5) 3, 5, 23, OH 
36.7 
2, 3, 5 
4b 2.46 m - 3, 4a, 5 3, 5, 23, OH 2, 3, 5 
5 3.38 dddd 11.3, 11.3, 3.5, 1.8 4(a)b, 6a 3, 4ab, 6b, 7, 9 72.8 4, 7 
6a 1.31 ddd 11.9, 11.7, 11.2 5, 6b, 7 6b 
41.9 
4, 5, 7 
6b 1.91 m - 6a, 7 5, 6b, 7 7, 8 
7 3.79 dddd 10.6, 10.6, 4.8, 4.8 6ab, 8ab 5, 6b, 8b, 9 68.3 - 
8a 1.24 ddd 12.5, 11.4, 11.3 7, 8b, 9 8b 
41.9 
7, 9, 10 
8b 1.69 ddt 12.8, 4.8, 1.7 7, 8a, (9) 7, 8a, 9, 10b 7 
9 3.29 tt 11.2, 2.0 8a(b), 10b 5, 7, 8b, 10b, 25 73.7 7 
10a 1.53 m - 10b, 11 (11), (25) 
43.5 
25 
10b 1.15 ddd 14.2, 12.4, 1.1 9, 10a 9, 10b, 25 11, (12), 25 
11 2.39 m - 10b, 12, 25 13, 25, OH 31.3 25 
12 5.39 dd 15.2, 7.6 11, 13 (13), 14, 25 141.2 11, (13), (17) 
13 6.35 dd 15.2, 10.9 12, 14 11, (12, 14), 16a, (OH) 125.1 11, 14, 15 
14 5.92 dd 10.9, 10.9 13, 15 12, (13), 15 130.3 11, 12, (13) 
15 5.17 td 10.9, 5.1 14, 16ab 14, 16b, 17 127.6 11, 13, 17 
16a 2.33 m - 15, 16b, 17 13, 16b 
31.2 
14, 15, 17 
16b 1.92 dddd 14.6, 11.1, 2.3, 2.2 15, 16a, 17 16a, 17, 26 14, 15, 17 
17 3.85 m - 16ab, 18 15, 16, 18 81.5 15, 19, (20), 26 
18 2.24 ddq 10.8, 7.4, 7.1 17, 19b, 26 17, 19b, 20, 26 35.7 17, 19, 26 
19a 1.86 ddd 12.6, 6.4, 6.3 19b, 20 18, 19b, 20 
33.2 
17, 18, 21 
19b 1.51 m - 18, 19a, 20 19a, 26 18, 20, 21, 26 
20 3.88 m - 19ab, 21 19a, 21 80.0 21, 22 
21 4.49 ddd 11.6, 4.8, 1.9 20, 22b 20, 22b 69.6 19, 20, 22 
22a 2.35 m - 22b, 23 21, 22b 
29.7 
23 
22b 1.81 dd 13.2, 0.5 21, 22a 22a, 23, 24 20, 21 
23 4.51 ddd 12.4, 5.3, 1.6 22a, 24 22b, 24 78.5 20, 21, 22, 24 
24 4.72 dd 5.3, 1.3 (23), OH 4ab, 23, OH 65.8 1, (2, 3), 23 
25 0.80 d 6.6 11 9, 10b, 11, 12 18.1 10, 11, 12 
26 0.98 d 7.0 18 16b, 18 15.2 17, 18, 19 
OH 4.23 s - (23) 4ab, 11, (13), 24 - 23, 24 
 
*The signals of the TBS & TBDPS group are not listed and appear as follows: 
1
H NMR (500 MHz, 
CDCl3): δ = 7.67 – 7.61 (m, 4H), 7.41 – 7.30 (m, 6H), 1.03 (s, 9H), 0.86 (s, 9H), 0.04 (s, 3H), 0.03 (s, 
3H) ppm. 
13
C NMR (125 MHz, CDCl3): δ = 135.9, 135.9 133.9, 133.9, 129.7, 129.7, 127.5, 27.2, 27.1, 
25.8, 19.7, 18.0, −4.5, −4.6 ppm. 
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Triol 252. A flame-dried Schlenck tube was charged with a solution of alcohol (24R)-226 (10.0 mg, 
12.3 µmol) in CH2Cl2 (1.3 mL) and the solution was cooled to −78 °C. A 
solution of TMEDA (0.2 m in CH2Cl2, 70.5 µL, 14.1 µmol) was introduced 
and the reaction mixture stirred at −78 °C for 5 min. A solution of osmium 
tetroxide (0.12 M in CH2Cl2, 103 µL, 12.4 µmol) was added dropwise via 
syringe through a septum over 3 min. After stirring at −78 °C for 20 min, the 
mixture was allowed to warm to rt, the volatiles were removed by first 
applying an Ar flow and the residue was dried under high vacuum. The residue 
was redissolved in THF (0.6 mL) and the solution treated with aq. sat. NaHSO3 solution (0.6 mL) for 
23 h under vigorous stirring. The resulting emulsion was diluted with EtOAc/NaCl solution (1:1, 
6 mL) and the layers were separated. The aqueous phase was extracted with EtoAc (3 x 4 mL). The 
combined organic extracts were dried over Na2SO4 and concentrated. The pale red residue was 
purified by flash chromatography (hexanes/EtOAc 5:1) to afford the triol as a white foam (6.8 mg, 
65%). [∝]𝐷
20 = +13.6 (c = 0.59, CH2Cl2). 
1
H NMR (600 MHz, CDCl3): δ = 7.67 – 7.61 (m, 4H), 7.42 – 
7.38 (m, 2H), 7.36 – 7.32 (m, 4H), 6.16 (ddt, J = 15.2, 10.8, 1.1 Hz, 1H), 5.92 (tt, J = 10.9, 1.7 Hz, 
1H), 5.55 (dd, J = 15.2, 8.0 Hz, 1H), 5.25 (td, J = 9.8, 5.4 Hz, 1H), 4.35 (ddd, J = 8.5, 4.8, 3.4 Hz, 
1H), 4.25 (ddd, J = 10.5, 7.7, 2.9 Hz, 1H), 3.94 – 3.87 (m, 2H), 3.84 (td, J = 8.0, 4.7 Hz, 1H), 3.75 
(ddd, J = 10.7, 6.0, 4.7 Hz, 1H), 3.72 (br s, 1H), 3.59 (dd, J = 8.9, 8.0 Hz, 1H), 3.50 (d, J = 2.9 Hz, 
1H), 3.46 (ddt, J = 11.3, 10.5, 1.9 Hz, 1H), 3.32 (ddt, J = 11.9, 9.9, 2.3 Hz, 1H), 2.78 (d, J = 9.3 Hz, 
1H), 2.37 – 2.26 (m, 3H), 2.06 (dtd, J = 15.4, 5.1, 1.9 Hz, 1H), 2.01 (ddd, J = 14.5, 8.9, 2.9 Hz, 1H), 
2.01 – 1.92 (m, 2H), 1.85 (ddd, J = 14.2, 10.4, 3.4 Hz, 1H), 1.77 (ddt, J = 12.5, 4.2, 1.7 Hz, 1H), 1.70 
(ddd, J = 12.5, 4.5, 2.0 Hz, 1H), 1.57 – 1.48 (m, 3H), 1.29 (ddd, J = 13.9, 10.0, 2.5 Hz, 1H), 1.25 – 
1.18 (m, 2H), 1.05 (s, 9H), 0.98 (d, J = 7.0 Hz, 3H), 0.93 (d, J = 6.7 Hz, 3H), 0.85 (s, 9H), 0.03 (s, 6H) 
ppm. 
13
C NMR (150 MHz, CDCl3): δ = 175.8, 140.7, 135.9, 133.7, 133.6, 129.8, 129.8, 127.6, 126.7, 
123.9, 80.9, 80.2, 79.9, 74.4, 74.1, 73.2, 72.9, 71.3, 69.1, 68.6, 44.0, 42.2, 41.7, 36.4, 35.8, 34.7, 33.6, 
33.1, 31.0, 27.1, 25.8, 19.5, 19.3, 18.1, 14.9, −4.5, −4.5 ppm. IR (film): ṽ = 3477, 2956, 2930, 2857, 
1763, 1472, 1462, 1428, 1376, 1362, 1255, 11943, 1111, 1078, 1031, 1006, 981, 922, 857, 837, 776, 
739, 703, 611 cm
−1
. MS (ESIpos) m/z (%) = 871.59 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for 
C48H72O9Si2Na: 871.4607; found: 871.4607. 
 
2,3,24-epi-Deacylmandelalide D (253). A teflon vial was charged with a solution of triol 252 (5.0 mg, 
5.9 µmol) in THF (0.5 mL) and pyridine (0.5 mL) and the mixture cooled to 
0 °C. HF·pyr (500 µL) was then added slowly via an Eppendorf pipette. After 
stirring 5 min at 0 °C, the reaction mixture was allowed to warm to ambient 
temperature and stirred for further 24 h. The reaction was then quenched by 
pouring it into pH 7.2 buffer (NaH2PO4/Na2HPO4, 5 mL) and the buffered 
aqueous phase was extracted with EtOAc/EtOH (9:1, 4 x 6 mL). The 
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combined organic extracts were dried over Na2SO4 and concentrated. The residue was purified by 
flash chromatography (CH2Cl2/MeOH 93:7 to 92:8 to 91:9 to 90:10) to yield the desired pentaol as a 
white solid (2.1 mg, 72% yield).  [∝]𝐷
27 = −2.0 (c = 0.34, MeOH). 1H NMR (600 MHz, CD3OD): see 
table 5.14. 
13
C NMR (150 MHz, CD3OD): δ = see table 5.14. IR (film): ṽ = 3379, 2957, 2924, 2873, 
2856, 1763, 1650, 1455, 1375, 1261, 1375, 1214, 1109, 1063, 1036, 998, 948, 883, 732 cm
−1
. MS 
(ESIpos) m/z (%) = 519.20 (100 (M+Na)), 1016.37 (32 (2M+Na)). HRMS (ESIpos): m/z: calcd for 
C26H40O9Na: 519.2565; found: 519.2564. 
 
Triol 254. A flame-dried Schlenck tube was charged with a solution of alcohol (24S)-226 (6.0 mg, 
7.4 µmol) in CH2Cl2 (1.0 mL) and the resulting mixture cooled to −78 °C. A 
solution of TMEDA (0.2 m in CH2Cl2, 42.3 µL, 8.5 µmol) was introduced and 
the reaction mixture stirred 5 min at −78 °C. A solution of osmium tetroxide 
(0.12 M in CH2Cl2, 61.3 µL, 7.4 µmol) was added dropwise via syringe 
through a septum over 3 min. After stirring at −78 °C for 20 min, the cooling 
bath was removed and the volatiles were removed by first applying an Ar flow. 
The residue was finally dried under high vacuum before it was redissolved in 
THF (0.4 mL) and the solution treated with aq. sat. NaHSO3 (0.4 mL) for 23 h under vigorous stirring. 
The resulting emulsion was diluted with EtOAc/NaCl solution (1:1, 6 mL) and the layers were 
separated. The aqueous phase was further extracted with EtoAc (3 x 4 mL). The combined organic 
extracts were dried over Na2SO4 and concentrated. The pale red residue was purified by flash 
chromatography (hexanes/EtOAc 7:1 to 6:1) to afford the triol as a white foam (4.9 mg, 78%). [∝]𝐷
20 = 
+30.2 (c = 0.42, CH2Cl2). 
1
H NMR (600 MHz, CDCl3): δ = 7.67 – 7.61 (m, 4H), 7.41 – 7.37 (m, 2H), 
7.36 – 7.32 (m, 4H), 6.30 (ddt, J = 15.3, 10.9, 1.2 Hz, 1H), 5.87 (ddt, J = 13.0, 10.7, 1.9 Hz, 1H), 5.43 
(dd, J = 15.2, 7.7 Hz, 1H), 5.16 (td, J = 9.6, 4.5 Hz, 1H), 4.87 (ddt, J = 11.2, 3.3, 1.6 Hz, 1H), 4.34 
(ddd, J = 10.8, 4.8, 2.2 Hz, 1H), 4.26 (dt, J = 5.1, 2.1 Hz, 1H), 4.08 (t, J = 1.6 Hz, 1H), 4.01 (dd, J = 
3.3, 1.8 Hz, 1H), 4.00 – 3.92 (m, 2H), 3.78 (tt, J = 10.7, 4.7 Hz, 1H), 3.55 (tt, J = 11.3, 2.2 Hz, 1H), 
3.48 (br s, 1H), 3.43 – 3.38 (m, 1H), 3.21 (br s, 1H), 2.43 – 2.30 (m, 4H), 2.18 (dddd, J = 16.3, 6.8, 
4.7, 2.3 Hz, 1H), 1.90 – 1.83 (m, 2H), 1.79 (ddt, J = 15.8, 11.5, 1.6 Hz, 1H), 1.73 – 1.67 (m, 2H), 1.67 
– 1.62 (m, 1H), 1.59 (dd, J = 10.1, 2.5 Hz, 1H), 1.57 – 1.54 (m, 1H), 1.27 – 1.24 (m, 1H), 1.20 (dd, J = 
4.0, 1.8 Hz, 1H), 1.17 (dd, J = 13.4, 2.0 Hz, 1H), 1.05 (s, 9H), 0.98 (d, J = 6.9 Hz, 3H), 0.94 (d, J = 
6.6 Hz, 3H), 0.86 (s, 9H), 0.04 (s, 6H) ppm. 
13
C NMR (150 MHz, CDCl3): δ = 177.5, 140.2, 135.9, 
135.9, 133.9, 133.4, 129.7, 129.7, 129.0, 127.6, 127.5, 127.1, 125.1, 81.5, 80.1, 79.1, 78.7, 74.9, 74.4, 
74.1, 69.7, 68.2, 68.2, 44.1, 42.1, 41.9, 38.9, 36.5, 32.5, 32.5, 32.4, 29.5, 27.1, 25.8, 19.6, 19.4, 18.1, 
14.4, −4.6, −4.6 ppm. IR (film): ṽ = 3374, 2956, 2929, 2856, 1759, 1471, 1461, 1427, 1375, 1362, 
1332, 1259, 1203, 1107, 1069, 979, 856, 836, 801, 775, 737, 702 cm
−1
. MS (ESIpos) m/z (%) = 871.6 
(100 (M+Na)). HRMS (ESIpos): m/z: calcd for C48H72O9Si2Na: 871.4607; found: 871.4606. 
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Table 5.14: 
1
H and 
13
C NMR data of 2,3,24-epi-deacylmandelalide D (253). 
 
atom 
n° 
1
H NMR (CD3OD, 600 MHz) 
13
C NMR (CD3OD,  
600 MHz)  /ppm
 
 /ppm m J /Hz COSY NOESY 
1 - -   - 177.9 
2 - -   - 76.9 
3 3.92 m - 4ab, 5 - 73.3 
4a 1.74 ddd 14.9, 8.5, 2.3 3, 4b, 5 4b, 5, 6a 
38.0 
4b 1.96 m - 3, 4a, 5 3, 4a 
5 3.58 dddd 11.4, 10.0, 1.9, 1.8 4ab, 6ab 3, 4a, 6b, 7, 9 74.2 
6a 1.19 dt 12.0, 11.3 5, 6b, 7 6b 
42.3 
6b 1.89 ddt 12.1, 4.2, 1.8 5, 6a, 7 (4a), 6a, 5, 7 
7 3.78 dddd 11.0, 10.9, 4.8, 4.6 6ab, 8ab 5, 6b, 8b, 9 68.8 
8a 1.11 dt 12.1, 11.3 7, 8b, 9 8b, (10a) 
42.9 
8b 1.88 m - 7, 8a, 9 7, 8a, 9, (10b) 
9 3.41 ddt 11.1, 10.1, 2.1 8ab, 10ab 5, 7, 8b, 10a, (11), 25 74.2 
10a 1.35 ddd 13.7, 10.7, 2.9 10b, 11 (8a), 10b, (11) 
45.3 
10b 1.54 ddd 13.8, 10.1, 3.8 10a, 11 8b, 9, 10a, 25  
11 2.52 m - 10ab, 12, 25 (9), (10b), 12, 13, 25 34.9 
12 5.55 dd 15.2, 8.3 11, 13 3, (11), 14, 25 141.9 
13 6.44 ddt 15.1, 10.8, 0.9 12, 14 (10a), 11, 16b, (17), 25 126.2 
14 5.98 tq 10.8, 0.7 13, 15 12, 15 131.6 
15 5.33 m - 14, 16ab 14, 16a, 17, (26) 127.9 
16a 2.16 dddd 15.1, 6.2, 4.3, 1.6 15, 16b, 17 15, 16b, 17, 26 
31.8 
16b 2.38 m - 15, 16a, 17 13, 16a, 17 
17 3.91 m - - - 82.8* 
18 2.40 m - 17, 19ab, 26 17, 19b, 26 37.9 
19a 1.51 td 12.4, 9.0 18, 19b, 20 19b, 20, (22ab), (26) 
35.1 
19b 2.05 ddd 12.4, 7.2, 6.3 18, 19a, 20 17, 18, 19a, 20 
20 3.90 m - - - 83.0* 
21 3.91 m - - - 75.3** 
22a 1.95 m - 21, 22b, 23 21, 22b, 23 
36.3 
22b 1.96 m - 21, 22a, 23 21, 22a 
23 4.48 ddd 8.3, 6.0, 4.4 22ab, 24 22ab, 24 82.9 
24 3.90 m - - - 69.9** 
25 0.99 d 6.8 11 9, 10b, 11, 12 19.8 
26 1.03 d 7.1 18 16ab, 19a 15.3 
OH not observed due to H/D exchange with CD3OD 
 
*,**: Due to overlap in the spectra, these signals could not be assigned and appear arbitrary. 
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2,3-epi-Deacylmandelalide D (255). A teflon vial was charged with a solution of triol 254 (1.0 mg, 
1.2 µmol) in THF (0.1 mL) and the mixture cooled to 0 °C. Pyridine 
(100 µL) and HF·pyr (100 µL) were added slowly via an Eppendorf pipette. 
After stirring for 5 min at 0 °C, the reaction mixture was allowed to warm to 
ambient temperature and stirred for further 41 h. The reaction was then 
quenched by pouring the mixture into pH 7.2 buffer (NaH2PO4/Na2HPO4, 
5 mL) and the buffered aqueous phase was extracted with EtOAc/EtOH (9:1, 
4 x 6 mL). The combined organic extracts were dried over Na2SO4 and 
concentrated. The residue was purified by flash chromatography (CH2Cl2/MeOH 93:7 to 92:8 to 91:9) 
to yield the desired pentaol as a white solid (0.5 mg, 86% yield).  [∝]𝐷
27 = +14 (c = 0.16, MeOH). 
1
H 
NMR (600 MHz, CD3OD): see table 5.15. 
13
C NMR (150 MHz, CD3OD): see table 5.15. IR (film): ṽ = 
3357, 2956, 2922, 2853, 1758, 1665, 1632, 1609, 1510, 1458, 1408, 1376, 1249, 1205, 1102, 1086, 
1046, 979, 707 cm
−1
. MS (ESIpos) m/z (%) = 519.3 (100 (M+Na)), 1016.37 (32 (2M+Na)). HRMS 
(ESIpos): m/z: calcd for C26H40O9Na: 519.2565; found: 519.2563. 
 
Monobutyrate (2R,3S)-256. Triol 254 (2.0 mg, 2.4 µmol) was dissolved in CH2Cl2 (0.2 mL) and the 
resulting solution cooled to 0 °C. Pyridine (4.8 µL, 59 µmol) was added 
via syringe followed by a solution of n-butyric anhydride (0.6 M in 
CH2Cl2, 8.6 µL, 5.2 µmol) and DMAP (1 crystal, ~0.1 mg). The ice bath 
was removed after 10 min and the reaction mixture was stirred for another 
2 h at ambient temperature. The reaction was quenched by addition of sat. 
NH4Cl solution (5 mL) and the aqueous phase was extracted with EtOAc 
(4 x 4 mL). The combined organic extracts were dried over Na2SO4 and 
concentrated. The residue was purified by flash chromatography (hexanes/EtOAc 12:1 to 9:1) to give 
the monobutyrate as a white amorphous solid (1.5 mg, 69% yield). [∝]𝐷
20 = +26.2 (c = 0.31, CH2Cl2). 
1
H NMR (600 MHz, CDCl3): δ = 7.66 – 7.61 (m, 4H), 7.40 – 7.36 (m, 2H), 7.35 – 7.31 (m, 4H), 6.30 
(ddt, J = 15.2, 10.8, 1.1 Hz, 1H), 5.89 (t, J = 10.8 Hz, 1H), 5.48 (dd, J = 15.2, 7.3 Hz, 1H), 5.42 (dd, J 
= 4.7, 2.8 Hz, 1H), 5.15 (td, J = 9.8, 4.7 Hz, 1H), 4.87 (br d, J = 10.7 Hz, 1H), 4.38 (br s, 1H), 4.35 
(ddd, J =10.5, 4.7, 2.6 Hz, 1H), 4.00 (dd, J = 3.2, 2.2 Hz, 1H), 3.93 – 3.87 (m, 2H), 3.78 (tt, J = 10.4, 
4.7 Hz, 1H), 3.70 (tt, J = 11.3, 1.7 Hz, 1H), 3.49 (dd, J = 11.6, 9.7 Hz, 1H), 2.89 (s, 1H), 2.53 – 2.45 
(m, 1H), 2.41 (ddd, J = 16.0, 8.4, 6.8 Hz, 1H), 2.36 – 2.26 (m, 4H), 2.12 (dtd, J = 15.8, 5.1, 2.1 Hz, 
1H), 2.02 (ddd, J = 16.3, 11.2, 2.8 Hz, 1H), 1.84 (dt, J = 12.6, 6.4 Hz, 1H), 1.78 (dt, J = 12.7, 2.6 Hz, 
1H), 1.72 – 1.69 (m, 2H), 1.68 – 1.65 (m, 2H), 1.61 (ddd, J = 13.4, 10.0, 2.9 Hz, 1H), 1.55 (m, 1H), 
1.28 – 1.24 (m, 1H), 1.22 – 1.18 (m, 1H), 1.20 – 1.12 (m, 2H), 1.04 (s, 9H), 0.98 (d, J = 6.7 Hz, 3H), 
0.96 (d, J = 7.1 Hz, 3H), 0.96 (t, J = 7.4 Hz, 3H), 0.85 (s, 9H), 0.03 (s, 6H) ppm. 
13
C NMR (150 MHz, 
CDCl3): δ = 173.1, 172.8, 140.6, 135.9, 135.9, 134.0, 133.6, 129.7, 129.6, 129.4, 127.6, 127.5, 127.1, 
124.9, 81.5, 80.2, 78.8, 77.4, 75.2, 74.2, 73.7, 69.7, 69.3, 68.1, 43.9, 42.1, 41.8, 39.2, 36.3, 36.1, 32.6, 
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32.1, 32.1, 29.7, 29.5, 27.1, 25.8, 19.6, 19.2, 18.2, 18.1, 14.7, 13.7, −4.5, −4.6 ppm. IR (film): ṽ = 
3380, 2956, 2928, 2856, 1782, 1743, 1462, 1428, 1376, 1362, 1257, 1177, 1110, 1070, 979, 858, 836, 
776, 704 cm
−1
. MS (ESIpos) m/z (%) = 941.6 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for 
C52H78O10Si2Na: 941.5026; found: 941.5022. 
 
Table 5.15: 
1
H and 
13
C NMR data of 2,3-epi-deacylmandelalide D (255). 
 
atom 
n° 
1
H NMR (CD3OD, 600 MHz) 
13
C NMR (CD3OD, 600 MHz) 
 /ppm m J /Hz COSY NOESY  /ppm HMBC 
1 - -  - - 178.9 - 
2 - -  - - 80.1 - 
3 4.34 dd 6.6, 2.0 4ab 4b, 5, 11, (24) 69.5 1, 4, 5 
4a 1.70 ddd 15.3, 6.6, 2.0 3, 4b, 5 (3), 4b, (5) 
40.4 
3 
4b 1.90 ddd 15.4, 10.8, 2.0 3, 4a, 5 3, 4a, 24 2, 5 
5 3.64 tt 11.0, 1.8 4ab, 6ab 3, 4a, 6b, 7, 9 75.2 (4), 7 
6a 1.17 m - 5, 6b, 7 6b 
42.5 
4, 7, 8, (9) 
6b 1.94 ddt 12.3, 4.4, 1.9 5, 6a, 7 5, 6a, 7 7, 8 
7 3.81 tt 11.0, 4.7 6ab, 8ab 5, 6b, 8b, 9 68.6 - 
8a 1.15 td 11.6, 11.2 7, 8b, 9 8b, (10b) 
42.7 
6, 7, 9, 10 
8b 1.85 m - 7, 8a, 9 7, 8a, 9 6, 7 
9 3.50 ddt 11.2, 10.2, 1.8 8ab, 10ab 5, 7, 8b (10a), (11), 25 74.8 7 
10a 1.28 m - 9, 10b, 11 (8b), (9), 10b, 25 
45.2 
11, 25 
10b 1.58 ddd 13.8, 10.3, 2.8 9, 10a, 11 (8a), (11), 10a 9, 25 
11 2.58 m - 10ab, 12, 25 3, 10b, 13, 25 34.0 (13) 
12 5.53 dd 15.1, 7.8 11, 13 (11), 14, 25 141.9 10, 11, 14, 25 
13 6.40 ddt 15.2, 11.1, 0.6 12, 14 11, 16b 126.2 11, 14, 15 
14 5.93 tt 10.9, 1.6 13, 15, (16ab) 12, 15 130.8 12, 13, 16 
15 5.23 td 9.8, 5.3 14, 16ab 13, 16a, 17, 26 128.0 13, (16) 
16a 2.27 dtd 15.8, 5.8, 2.1 15, 16b, 17 (13), (15), 16a, (17), 26 
33.1 
14, 15, 17, 18 
16b 2.42 dddd 15.7, 9.1, 6.4, 1.6 15, 16a, 17 13, 16b, (17) 14, 15, 17 , (18) 
17 4.01 td 7.1, 6.2 16ab, 18 15, (16b), 18 83.4 15, 19, 20 
18 2.47 dqd 7.1, 7.0, 3.9 17, 19ab, 26 17 ,19a, 26 38.4 16, 17, 19, 26 
19a 1.62 m - 18, 19b, 20 17, 18, 19b, 20 
34.1 
17, 18, 20, 21, 26 
19b 2.00 dt 12.6, 6.6 18, 19a, 20 19a, (22b), 26 17, 18, 20, 26 
20 4.04 ddd 9.6, 6.3, 4.1 19ab, 21 17, 18, 19a, 21 83.0 22 
21 3.95 ddd 11.0, 4.1, 2.2 20, 22ab 20, 22a, 23 69.3 19 
22a 2.22 ddd 14.7, 8.7, 2.2 21, 22b, 23 21, 22b, (23) 
31.5 
23, 24 
22b 1.85 m - 21, 22a, 23 22a, 23 21 
23 4.95 ddd 8.7, 4.9, 3.6 22ab, 24 21, 22ab, 24 80.8 (1) 
24 4.14 d 3.6 23 (3), 4b, 23 77.1 1, 2, 23 
25 1.00 d 6.7 11 9, 10a, 11, 12 20.0 10, 11, 12 
26 1.04 d 7.0 18 (15), 16(a)b, 18, 19b 14.9 17, 18, 19 
OH not observed due to H/D exchange with CD3OD 
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2,3-epi-Mandelalide C (257). A teflon vial was charged with a solution of mono-butyrate 256 
(1.5 mg, 1.6 µmol) in THF (0.15 mL). Pyridine (0.15 mL) was added 
and the reaction mixture was cooled to 0 °C. HF·pyr (0.15 mL) was 
added carefully and the ice bath was removed 5 min after the addition.  
The reaction mixture was stirred for 25 h before the reaction was 
quenched with EtOAc (3 mL) and pH 7.2 buffer (NaH2PO4/Na2HPO4, 
5 mL). The aqueous phase was extracted with EtOAc/EtOH (9:1, 3 x 
4 mL), the combined organic extracts were dried over Na2SO4 and 
concentrated. The residue was purified by flash chromatography (CH2Cl2/MeOH 97:3 to 96:4 to 95:5) 
to give a white amorphous solid (0.72 mg, 78% yield). [∝]𝐷
20 = −19 (c = 0.14, CH2Cl2). 
1
H NMR 
(600 MHz, CDCl3): see table 5.16. 
13
C NMR (150 MHz, CDCl3): see table 5.16. IR (film): ṽ = 3377, 
2961, 2930, 2875, 1775, 1737, 1455, 1413, 1367, 1329, 1262, 1179, 1102, 1057, 979, 947, 733 cm
−1
. 
MS (ESIpos) m/z (%) = 589.4 (100 (M+Na)). HRMS (ESIpos): m/z: calcd for C30H46O10Na: 589.2983; 
found: 589.2978. 
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Table 5.16: 
1
H and 
13
C NMR data for 2,3-epi-mandelalide C (257). 
 
atom 
n° 
1
H NMR (CDCl3, 600 MHz) 
13
C NMR (CDCl3,  
150 MHz)  /ppm
 
 /ppm m J /Hz COSY NOESY 
1 - - - - - 172.5 
2 - - - - - 78.3 
3 5.51 dd 4.8, 4.8 4ab 4a, 5, 11, (24), 28a OHd 69.3 
4a 1.73 ddd 16.2, 4.6, 1.6 3, 4b, 5 3, 4b, 5, 6b 
38.6 
4b 2.11 m - 3, 4a, 5 4a, (6b) 
5 3.74 dddd 11.0, 11.0, 1.9, 1.7 4ab, 6ab 6b, 7, 9 73.5 
6a 1.23 ddd 12.3, 11.7, 11.6 5, 6b, 7 - 
41.2 
6b 1.93 m - 6a 4a(b), 5, 7 
7 3.85 dddd 11.0, 11.0, 4.8, 4.8 6ab, 8ab 5, 6b, 8b, 9 67.5 
8a 1.33 ddd 12.6, 11.3, 11.3 7, 8b, 9 - 
40.8 
8b 1.94 m - 8a 7, 9 
9 3.50 m - 8ab, 10ab 5, 7, 8b, 10ab, 12, (25) 74.5 
10a 1.33 ddd 14.0, 9.9, 4.0 9, 10b, 11 (8a), 9, 10b, (11), 25 
42.6 
10b 1.71 m - 9, 10a, 11 8b, 9, 10a, 11, 12, 24, 25, OHd 
11 2.46 m - 10ab, 12, 13 9, 10a, 11, 12, 13, (24), OHd 30.6 
12 5.72 dd 15.5, 5.2 11, 13 9, (10ab), 11, 14, 25 140.6 
13 6.26 dddd 15.6, 10.7, 1.2, 1.1 11, 12, 14 10a, 11, 16a, 21, 25, OHc 123.3 
14 6.06 dd 10.7, 10.7 13, 15, 16ab 12, 15 130.9 
15 5.31 ddd 11.0, 5.0, 5.0 14, 16ab 14, 16b, 17 127.3 
16a 1.98 ddt 14.0, 4.7, 2.1 14, 15, 16b, 17 15, 16b, 17, 18, 26 
30.4 
16b 2.39 m - 14, 15, 16a, 17 13, 16a, 21 
17 3.95 ddd 10.6, 7.2, 1.9 16ab, 18 16b, 18, 26 81.7 
18 2.41 m - 17, 19ab, 26 17, 19a, 20, 26 36.5 
19a 1.54 m - 18, 19b, 20 18, 19b, 22b, 26 
35.7 
19b 2.10 m - 18, 19a, 20 18, 19a, 20, (21), 26 
20 3.80 ddd 8.5, 7.3, 3.6 19ab, 21 9, 17, 18, 19a, 22a 81.1 
21 3.46 m - 20, 22ab, OHc 13, 16a, (19a), 20, 23, 24 70.6 
22a 1.93 m - 21, 22b, 23 - 
31.7 
22b 2.24 ddd 14.1, 11.3, 11.3 21, 22a, 23 20, 22a, 23, 24, OHc, OHd 
23 4.74 ddd 11.3, 4.3, 3.2 22ab, 24 21, 24 80.0 
24 4.21 dd 3.1, 2.1 23, OHd (3), 4a, 5, 23, OHa, OHc, OHd 74.3 
25 1.05 d 7.0 11 9, 10(a)b, 11, 12, 13 20.2 
26 1.02 d 6.8 18 16a, 17, 18, 19ab 14.8 
27 - - - - - 172.9 
28a 2.42 ddd 15.9, 8.2, 6.8 28b, 29ab 28b, 30 
36.0 
28b 2.33 ddd 16.0, 8.1, 6.9 28a, 29ab 28a, 30 
29 1.68 m - 28ab, 30 - 18.2 
30 0.94 t 7.4 29 28ab 13.7 
OHa 3.42 br s - - OH d - 
OHb 1.56 m - - - - 
OHc 2.87 d 6.6 21 13, 24 - 
OHd 4.81 d 2.1 (23), 24 3, 4b, 5, 10b, 11, 22a, 24 - 
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(E)-3-((Z)-Hept-4-en-1-ylidene)dihydrofuran-2(3H)-one ((E)-261). LiHMDS (475 mg, 2.83 mmol) 
was dissolved in THF (6 mL) and the solution cooled to −78 °C before a solution 
of -butyrolactone (259) (200 µL, 2.60 mmol) in THF (2.4 mL) was introduced 
via canula. The resulting yellow mixture was stirred for 30 min at −78 °C before 
a solution of cis-4-heptenal (260) (313 µL, 2.37 mmol) in THF (3.8 mL) was added via canula. The 
reaction mixture was allowed to stir for 1 h at −78 °C, when triethylamine (494 µL, 3.54 mmol) and 
methanesulfonyl chloride (0.238 mL, 3.07 mmol) were added via syringe. The reaction mixture was 
allowed to warm to ambient temperature and stirred for further 2 h. It was then cooled to 0 °C and 
DBU (530 µL, 3.54 mmol) was added via syringe. The cooling bath was removed after 5 min and the 
reaction mixture stirred for another 1 h at ambient temperature. The reaction was quenched by pouring 
the mixture into sat. NaHCO3 solution (20 mL). After dilution with Et2O (15 mL), the organic phase 
was washed with sat. NaHCO3 solution (15 mL) and the combined aqueous washings were re-
extracted with Et2O (2 x 20 mL). The combined organic extracts were dried over Na2SO4 and 
concentrated. The residue was purified by flash chromatography (pentane/Et2O 4:1 to 3.5:1 to 3:1) to 
yield the major (E)-isomer (246 mg, 58%) as a pale yellow oil along with the minor (Z)-isomer 
(40 mg, 9%).
1
H NMR (400 MHz, CDCl3): δ = 6.71 (ttd, J = 7.4, 2.9, 0.9 Hz, 1H), 5.44 – 5.36 (m, 1H), 
5.27 (dtt, J = 10.6, 7.1, 1.6 Hz, 1H), 4.37 – 4.32 (m, 2H), 2.84 (tdd, J = 7.4, 3.0, 1.5 Hz, 2H), 2.26 – 
2.15 (m, 4H), 2.06 – 1.95 (m, 2H), 0.93 (td, J = 7.5, 0.6 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ 
= 171.2, 140.2, 133.3, 126.9, 125.5, 65.3, 30.4, 25.6, 25.1, 20.5, 14.2 ppm. IR (film): ṽ = 3005, 2963, 
2932, 2873, 1746, 1679, 1440, 1378, 1352, 1306, 1282, 1217, 1197, 1177, 1139, 1028, 961, 868, 719, 
614 cm
−1
. MS (EI) m/z (%) = 112 (100), 91 (4), 83 (11), 79 (6), 77 (5), 69 (21), 67 (22), 41 (32). 
HRMS (ESIpos): m/z: calcd for C11H16O2Na: 203.1042; found: 203.1042. 
 
(Z)-3-((Z)-Hept-4-en-1-ylidene)dihydrofuran-2(3H)-one ((Z)-261). Obtained as the minor isomer 
from the reaction described above. 
1
H NMR (400 MHz, CDCl3): δ = 6.20 (tt, J = 
7.7, 2.4 Hz, 1H), 5.43 – 5.35 (m, 1H), 5.34 – 5.26 (m, 1H), 4.28 (t, J = 7.4 Hz, 
2H), 2.88 (tq, J = 7.4, 2.1 Hz, 2H), 2.75 (qt, J = 7.5, 2.0 Hz, 2H), 2.15 (qd, J = 
7.3, 1.4 Hz, 2H), 2.05 – 1.96 (m, 2H), 0.93 (t, J = 7.5 Hz, 3H) ppm. 13C NMR (100 MHz, CDCl3): δ = 
170.1, 143.4, 132.7, 127.5, 123.7, 65.3, 29.1, 27.4, 26.5, 20.5, 14.2 ppm. IR (film): ṽ = 3005, 2963, 
2931, 2872, 1747, 1671, 1443, 1374, 1221, 1168, 1126, 1077, 1025, 958, 867, 866, 798, 756, 717 
cm
−1
. MS (EI) m/z (%) = 180 (6), 151 (8), 125 (5), 123 (9), 113 (7), 112 (100), 95 (10), 91 (15), 83 
(15), 79 (20), 77 (11), 69 (16), 67 (37), 53 (14), 41 (34), 39 (13). HRMS (ESIpos): m/z: calcd for 
C11H16O2Na: 203.1042; found: 203.1043. 
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Diol 262. A solution of diene (E)-261 (10.0 mg, 55.5 µmol) was dissolved in CH2Cl2 (1.1 mL) and 
cooled to −78 °C. TMEDA (9.6 µL, 63.8 µmol) was added via syringe and the 
reaction mixture was equilibrated at −78 °C for 5 min. A solution of OsO4 (0.6 M 
in CH2Cl2, 105 µL, 62.7 µmol) was then added dropwise until no more SM was 
detected by TLC analysis (after every three drops (~8-10 µL), the reaction mixture was controlled by 
TLC). Upon complete consumption of the s.m., all volatiles were removed under reduced pressure and 
the composition of the residue controlled by 
1
H NMR analysis (see below). The residue was 
redissolved in THF (0.7 mL) and treated with sat. NaHSO3 (0.7 mL) under vigorous stirring for 16 h. 
For work up, brine (5 mL) was added and the aqueous phase was extracted with EtOAc (3 x 5 mL). 
The combined organic extracts were dried over Na2SO4 and concentrated. The residue was purified by 
flash chromatography (hexanes/EtOAc 3:2 to 1:1) to yield the desired diol as a colorless oil (8.5 mg, 
72% yield). 
1
H NMR (400 MHz, CDCl3): δ = 5.46 – 5.37 (m, 1H), 5.28 (dddt, J = 10.9, 8.2, 6.8, 
1.5 Hz, 1H), 4.44 (td, J = 8.8, 6.8 Hz, 1H), 4.32 (ddd, J = 9.0, 8.1, 3.4 Hz, 1H), 3.74 (dd, J = 10.6, 2.3 
Hz, 1H), 3.45 (br s, 1H), 3.38 (br s, 1H), 2.29 – 2.13 (m, 4H), 2.09 – 1.98 (m, 2H), 1.68 (dddd, J = 
13.9, 10.6, 7.8, 5.4 Hz, 1H), 1.34 (dtd, J = 13.9, 8.2, 2.3 Hz, 1H), 0.94 (t, J = 7.5 Hz, 3H) ppm. 
13
C 
NMR (100 MHz, CDCl3): δ = 178.7, 133.1, 127.6, 75.1, 72.9, 66.3, 32.0, 29.6, 23.0, 20.5, 14.3 ppm. 
IR (film): ṽ = 3446, 3004, 2962, 2932, 2873, 1758, 1455, 1381, 1307, 1202, 1155, 1119, 1082, 1023, 
984, 953, 690 cm
−1
. MS (EI) m/z (%) = 196 (2), 178 (7), 123 (10), 115 (36), 109 (13), 102 (100), 95 
(45), 83 (23), 67 (62), 56 (64), 55 (51), 41 (52). HRMS (ESIpos): m/z: calcd for C13H20O7Na: 
237.1097; found: 237.1097. 
Four compounds were contained in the crude product, they were assigned to the following compounds 
on the basis of 
1
H NMR and ESI-MS. 
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6 List of abbreviations 
Ac acetyl 
acac acetylacetonate 
AIBN azobisisobutyronitrile 
aq. aqueous 
Ar aryl 
BBN 9-Borabicyclo(3.3.1)nonane 
Bn benzyl 
br broad 
Bu butyl 
Bz benzoyl 
calcd calculated 
cm centimeter 
cod cyclooctadienyl 
CSA camphorsulfonic acid 
Cy cyclohexyl 
d.r. diastereomeric ratio 
DABCO 1,4-diazabicyclo[2.2.2]octane 
DBU 1,8-diazabicyclo[5.4.0]undec-7-ene 
DCC dicyclohexylcarbodiimide 
DCE 1,2-dichloroethane 
dd doublet 
DIBAl-H diisobutylalumnium hydride 
DMA dimethylacetamide 
DMAP N,N-dimethyl 4-aminopyridine 
DMF dimethylformamide 
DMP Dess-Martin Periodinane 
DMPU 1,3-Dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone 
DMS dimethyl sulfide 
DMSO dimethylsulfoxide 
EDCI 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EDTA ethylenediaminetetraacetic acid 
ee enantiomeric excess 
ent enantiomeric 
epi epimeric 
Et ethyl 
g gram 
GI50 growth inhibition of 50% 
h hour 
hep heptet 
HFIP hexafluoroisopropanol 
HMPA hexamethylphosphoramide 
HPLC high pressure liquid chromatography 
i iso (branched) 
IC50 half maximal inhibitory concentration 
IR infrared spectroscopy 
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KHMDS potassium hexamethyldisilazide 
l liter 
l.l.s. longest linear sequence 
LDA lithium diisopropylamide 
LiHMDS lithium hexamethyldisilazide 
M molar (mol/L) 
m multiplet 
MBH Morita Baylis-Hillman 
Me methyl 
Mes mesityl 
mg miligram 
MIDA N-methyliminodiacetic acid 
min minute 
mL mililiter 
MOM methoxy methyl 
mp. melting point 
Ms methanesulfonyl 
MTBE tert-butylmethylether 
n normal (linear) 
n normal (mol/kg) 
µg microgram 
µL microliter 
NaHMDS sodium hexamethyldisilazide 
n.d. not determined 
NHC N-heterocyclic carbene 
NMI N-Methylimidazole 
NMR nuclear magnetic resonance 
4-NO2-Bz 4-nitrobenzoyl 
NOE nuclear overhauser effect 
NOESY nuclear overhauser effect spectroscopy 
N-PSP N-(phenylseleno)phthalimide 
PCC pyridinium chlorochromate 
Ph phenyl 
pin pinacol 
PG Protecting group 
PMB para-methoxybenzyl 
Pr propyl 
q quartet 
quant quantitative 
r.r. regioisomeric ratio 
rac racemic 
RCAM ring closing alkyne metathesis 
RCM  ring closing (olefin) metathesis 
ROESY rotating frame nuclear overhauser effect spectroscopy 
rt room temperature 
s singlet 
s.m. starting material 
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sat. saturated 
t triplet 
TASF tris(dimethylamino)sulfonium difluorotrimethylsilicate 
TBAF tetra-n-butylammonium fluoride 
TBDPS tert-butyldiphenylsilyl 
TBS dimethyltert-butylsilyl 
TC thiophene-2-carboxylate 
TEMPO (2,2,6,6-tetramethyl-piperidin-1-yl)oxyl 
TES triethylsilyl 
Tf trifluoromethanesulfonyl 
TFA trifluoroacetic acid 
THF Tetrahydrofuran 
TLC thin layer chromatography 
TMS trimethylsilyl 
Tol ortho-tolyl 
Ts toluenesulfonyl 
w/o with or without 
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[249] Obtained from Sigma Aldrich as an unspecified mixture of NaHSO3 and Na2S2O5. On this 
model system, use of sat. aq. Na2S2O5 gave comparable results. It is presumed, that NaHSO3 is 
formed from Na2S2O5 upon contact with water. 
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8. Appendix 
8.1 Crystallographic data 
Compound epi-70 
C8
C6
C7
C5 C4
O2
O3
C3
C9
C11
C1
C10
C2
O1
 
Identification code (intern)  7700 
Empirical formula  C11 H18 O3 
Color  colourless 
Formula weight  198.25  g · mol-1 
Temperature  100 K 
Wavelength  1.54178 Å 
Crystal system  MONOCLINIC 
Space group  P21,  (no. 4) 
Unit cell dimensions a = 9.1535(5) Å = 90°. 
 b = 5.5655(3) Å = 103.613(2)°. 
 c = 11.1241(6) Å  = 90°. 
Volume 550.78(5) Å3 
Z 2 
Density (calculated) 1.195  Mg · m-3 
Absorption coefficient 0.695 mm-1 
F(000) 216 e 
Crystal size 0.30 x 0.11 x 0.07 mm3 
 range for data collection 4.09 to 67.00°. 
Index ranges -10 ≤ h ≤ 10, -6 ≤ k ≤ 6, -13 ≤ l ≤ 13 
Reflections collected 12661 
Independent reflections 1825 [Rint = 0.0418] 
Reflections with I>2(I) 1780 
Completeness to  = 67.00° 99.6 % 
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Absorption correction Gaussian 
Max. and min. transmission 0.96 and 0.86 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1825 / 1 / 138 
Goodness-of-fit on F2 1.096 
Final R indices [I>2(I)] R1 = 0.0269 wR
2 = 0.0648 
R indices (all data) R1 = 0.0276 wR
2 = 0.0655 
Absolute structure parameter 0.01(17) 
Largest diff. peak and hole 0.116 and -0.158 e · Å-3 
 
 
Compound ent-70 
C9
C11
C6
C8 C3
C7
C10
C2
O2
C1
O1
C4
C5
O3
 
Identification code (intern) 7868 
Empirical formula  C11 H18 O3 
Color  colourless 
Formula weight  198.25  g · mol-1 
Temperature  100 K 
Wavelength  1.54184 Å 
Crystal system  MONOCLINIC 
Space group  P21,  (no. 4) 
Unit cell dimensions a = 7.1017(4) Å = 90°. 
 b = 10.4344(5) Å = 113.6280(10)°. 
 c = 8.2612(4) Å  = 90°. 
Volume 560.85(5) Å3 
Z 2 
Density (calculated) 1.174  Mg · m-3 
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Absorption coefficient 0.682 mm-1 
F(000) 216 e 
Crystal size 0.64 x 0.05 x 0.04 mm3 
 range for data collection 5.85 to 66.96°. 
Index ranges -8 ≤ h ≤ 8, -12≤ k ≤ 11, -9 ≤ l ≤ 9 
Reflections collected 12794 
Independent reflections 1858 [Rint = 0.0464] 
Reflections with I>2(I) 1831 
Completeness to  = 66.96° 99.1 % 
Absorption correction Gaussian 
Max. and min. transmission 0.98 and 0.80 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 1858 / 1 / 131 
Goodness-of-fit on F2 1.038 
Final R indices [I>2(I)] R1 = 0.0307 wR
2 = 0.0833 
R indices (all data) R1 = 0.0311 wR
2 = 0.0836 
Absolute structure parameter -0.10(17) 
Extinction coefficient 0.0086(19) 
Largest diff. peak and hole 0.169 and -0.165 e · Å-3 
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8.2 Comparison of synthetic and natural leiodermatolide 
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Table 8.1: Comparison of the 
1
H NMR shifts (600 MHz, CD2Cl2) of natural leiotermatolide (Lit.)
[31]
 
and the synthetic samples 1 and 2. For this comparison, the spectra of the synthetic samples 
were calibrated on CD2Cl2 δH5.29 ppm; if the spectra are calibrated on CD2Cl2 δH5.32 
ppm, all shifts systematically deviate by −0.3 ppm. 
 
atom 
n° 
 (Lit.) 
/ppm 
 (synthetic 1)  
/ppm 
 (Lit-1) 
 (synthetic 2) 
/ppm 
 (Lit-1) 
1 - - 
 
- 
 
2a 2.28 2.28 0.00 2.26 0.02 
2b 1.97 1.96 0.01 1.96 0.01 
3 2.18 2.17 0.01 2.17 0.01 
4 5.07 5.06 0.01 5.06 0.01 
5 - - - - - 
6 2.44 2.43 0.01 2.44 0.00 
7 3.24 3.23 0.01 3.23 0.01 
8 1.72 1.71 0.01 1.71 0.01 
9 5.86 5.86 0.00 5.86 0.00 
10 5.5 5.5 0.00 5.5 0.00 
11 6.35 6.35 0.00 6.35 0.00 
12 6.51 6.5 0.01 6.5 0.01 
13 5.33 5.32 0.01 5.32 0.01 
14 2.95 2.95 0.00 2.95 0.00 
15 5.04 5.04 0.00 5.04 0.00 
16 - - - - - 
17 6.07 6.07 0.00 6.07 0.00 
18 6.36 6.37 -0.01 6.37 -0.01 
19 5.73 5.73 0.00 5.73 0.00 
20a 2.39 2.38 0.01 2.37 0.02 
20b 2.19 2.19 0 2.2 -0.01 
21 - - - - - 
22 1.86 1.86 0 1.86 0.00 
23 3.89 3.88 0.01 3.88 0.01 
24a 1.82 1.82 0.00 1.82 0.00 
24b 1.61 1.59 0.02 1.59 0.02 
25 0.98 0.98 0.00 0.98 0.00 
26 1.39 - - - - 
27 1.09 1.09 0.00 1.09 0.00 
28 1.05 1.05 0.00 1.05 0.00 
29 0.84 0.84 0.00 0.84 0.00 
30 1.76 1.76 0.00 1.76 0.00 
31 0.99 0.99 0.00 0.99 0.00 
32a 2.7 2.69 0.01 2.7 0.00 
32b 2.33 2.32 0.01 2.33 0.00 
33 - - - - - 
34 - - - - - 
NH2 4.62 4.63 -0.01 4.64 -0.02 
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Table 8.2: Comparison of the 
13
C NMR shifts (150 MHz, CD2Cl2) of natural leiotermatolide (Lit.)
[31]
 
and the synthetic samples 1 and 2. For this particular comparison, the spectra of the 
synthetic samples were calibrated on the well resolved signal C.13 (137.869 ppm); if the 
spectra are calibrated on CD2Cl2 δC53.8 ppm, all shifts systematically deviate by +0.25 
ppm. 
 
atom 
n° 
 (Lit.) 
/ppm 
 (synthetic 1) 
/ppm 
 (Lit-1) 
 (synthetic 2) 
/ppm 
 (Lit-1) 
1 172.4 172.4 0.0 172.4 0.0 
2 34.0 34.0 0.0 34.0 0.0 
3 22.5 22.5 0.0 22.4 0.1 
4 125.9 125.9 0.0 125.8 0.1 
5 137.5 137.5 0.0 137.5 0.0 
6 48.7 48.8 −0.1 48.7 0.0 
7 78.4 78.4 0.0 78.4 0.0 
8 39.6 39.5 0.1 39.5 0.1 
9 68.0 67.9 0.1 67.9 0.1 
10 128.8 128.7 0.1 128.7 0.1 
11 126.4 126.4 0.0 126.4 0.0 
12 124.7 124.6 0.1 124.6 0.1 
13 137.9 137.9 0.0 137.9 0.0 
14 35.3 35.2 −0.1 35.2 0.0 
15 82.8 82.8 0.0 82.7 0.1 
16 134.2 134.1 0.1 134.2 0.1 
17 130.0 130.0 0.0 129.9 0.1 
18 131.8 131.8 0.0 131.9 −0.1 
19 128.5 128.6 −0.1 128.7 −0.2 
20 38.9 38.8 0.1 38.8 0.1 
21 72.3 72.3 0.0 72.3 0.0 
22 43.4 43.4 0.0 43.3 0.0 
23 84.1 84.1 0.0 84.0 0.1 
24 27.4 27.4 0.0 27.3 0.1 
25 9.4 9.4 0.0 9.4 0.0 
26 11.5 11.5 0.0 11.5 0.0 
27 16.8 16.8 0.0 16.7 0.1 
28 12.7 12.7 0.0 12.7 0.0 
29 16.8 16.8 0.0 16.8 0.0 
30 12.2 12.2 0.0 12.2 0.0 
31 11.8 11.8 0.0 11.8 0.0 
32 43.1 43.0 0.1 43.1 0.0 
33 170.4 170.5 −0.1 170.4 0.0 
34 157.6 157.6 0.0 157.5 0.1 
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8.3 Comparison of synthetic isomers and natural mandelalide A 
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Table 8.3: Comparison of the
 1
H NMR chemical shifts of 124 (600 MHz, CDCl3) and 11-epi-124 with 
the data of the  natural product (Lit.
[141]
; 700 MHz, CDCl3). 
 
atom n°  (Lit.) /ppm (124) /ppm  (124Lit.) 
(11-epi-124) 
/ppm 
 (11-epi-
1Lit) 
1 - - - - - 
2 6.01 5.92 -0.09 5.92 -0.09 
3 6.97 7.02 0.05 7.09 0.12 
4a 2.36 2.34 -0.02 2.31 -0.05 
4b 2.39 2.46 0.07 2.39 0.00 
5 3.36 3.42 0.06 3.26 -0.10 
6a 1.20 1.26 0.06 1.15 -0.05 
6b 2.02 1.94 -0.08 1.98 -0.04 
7 3.82 3.77 -0.05 3.76 -0.06 
8a 1.22 1.22 0.00 1.27 0.05 
8b 1.87 1.84 -0.03 1.75 -0.12 
9 3.32 3.33 0.01 3.16 -0.16 
10a 1.21 1.27 0.06 1.14 -0.07 
10b 1.51 1.69 0.18 1.52 0.01 
11 2.37 2.44 0.07 2.48 0.11 
12 5.45 5.61 0.16 5.32 -0.13 
13 6.28 6.22 -0.06 6.10 -0.18 
14 6.05 6.01 -0.04 6.00 -0.05 
15 5.28 5.27 -0.01 5.20 -0.08 
16a 1.88 2.14 0.26 2.08 0.20 
16b 2.28 2.29 0.01 2.25 -0.03 
17 3.98 4.03 0.05 3.99 0.01 
18 2.52 2.43 -0.09 2.46 -0.06 
19a 1.17 1.28 0.11 1.26 0.09 
19b 2.01 2.04 0.03 2.09 0.08 
20 3.63 3.71 0.08 3.74 0.11 
21 3.42 3.45 0.03 3.46 0.04 
22a 1.46 1.54 0.08 1.55 0.09 
22b 1.76 1.77 0.01 1.88 0.12 
23 5.23 5.24 0.01 5.23 0.00 
24a 3.61 3.65 0.04 3.65 0.04 
24b 3.81 3.78 -0.03 3.79 -0.02 
25 0.85 1.00 0.15 0.98 0.13 
26 1.03 0.98 -0.05 0.98 -0.05 
1' 5.02 5.02 0.00 4.99 -0.03 
2' 3.40 3.40 0.00 3.38 -0.02 
3' 3.68 3.69 0.01 3.68 0.00 
4' 3.34 3.34 0.00 3.33 -0.01 
5' 3.62 3.63 0.01 3.61 -0.01 
6' 1.27 1.28 0.01 1.26 -0.01 
7' 3.45 3.46 0.01 3.44 -0.01 
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Table 8.4: Comparison of the
 13
C NMR chemical shifts of 124 and 11-epi-124 (150 MHz, CDCl3)with 
the data of the  natural product (Lit.
[141]
; 175 MHz, CDCl3). 
 
atom n°  (Lit.) /ppm (124) /ppm  (124Lit.) 
(11-epi-124) 
/ppm 
 (11-epi-
124Lit) 
1 167.5 167.3 -0.2 166.8 -0.7 
2 123.1 123.1 0.0 123.6 0.5 
3 147.1 146.3 -0.8 146.1 -1.0 
4 38.8 38.5 -0.3 39.5 0.7 
5 73.9 73.4 -0.5 73.9 0.0 
6 37.6 36.7 -0.9 38.2 0.6 
7 73.1 72.8 -0.3 72.7 -0.4 
8 39.7 39.3 -0.4 39.2 -0.5 
9 72.5 73.1 0.6 73.2 0.7 
10 43.1 42.9 -0.2 43.5 0.4 
11 34.2 32.8 -1.4 34.1 -0.1 
12 141.5 140.9 -0.6 141.3 -0.2 
13 123.9 123.8 -0.1 124.9 1.0 
14 131.3 130.5 -0.8 130.6 -0.7 
15 126.9 126.5 -0.4 126.2 -0.7 
16 31.1 31.2 0.1 31.0 -0.1 
17 81.0 81.3 0.3 81.8 0.8 
18 37.4 37.1 -0.3 36.9 -0.5 
19 36.8 36.0 -0.8 36.4 -0.4 
20 83.2 82.7 -0.5 82.1 -1.1 
21 73.0 73.4 0.4 73.3 0.3 
22 34.1 34.1 0.0 34.7 0.6 
23 72.3 72.5 0.2 74.0 1.7 
24 66.1 65.7 -0.4 65.7 -0.4 
25 18.3 20.1 1.8 22.0 3.7 
26 14.5 14.7 0.2 14.9 0.4 
1' 94.2 94.0 -0.2 94.1 -0.1 
2' 80.8 80.9 0.1 80.9 0.1 
3' 71.7 71.7 0.0 71.6 -0.1 
4' 74.3 74.2 -0.1 74.2 -0.1 
5' 68.1 68.2 0.1 68.2 0.1 
6' 17.7 17.7 0.0 17.7 0.0 
7' 59.1 59.2 0.1 59.1 0.0 
 
Appendix 271 
 
 
 
272 Appendix 
 
 
  
Appendix 273 
 
Table 8.5: Comparison of the
 1
H NMR chemical shifts of 219 and 11-epi-219 (600 MHz, CDCl3) with 
the data of the  natural product (Lit.
[141]
; 700 MHz, CDCl3).
 
 
atom n°  (Lit.) /ppm (219) /ppm  (219Lit.) 
(11-epi-219) 
/ppm 
 (11-epi-
219Lit.) 
1 - - - - - 
2 6.01 6.01 0.00 5.93 -0.08 
3 6.97 6.96 -0.01 6.98 0.01 
4a 2.36 2.36 0.00 2.31 -0.05 
4b 2.39 2.39 0.00 2.42 0.03 
5 3.36 3.37 0.01 3.3 -0.06 
6a 1.20 1.20 0.00 1.17 -0.03 
6b 2.02 2.02 0.00 2.00 -0.02 
7 3.82 3.82 0.00 3.75 -0.07 
8a 1.22 1.22 0.00 1.23 0.01 
8b 1.87 1.87 0.00 1.82 -0.05 
9 3.32 3.31 -0.01 3.27 -0.05 
10a 1.21 1.21 0.00 1.37 0.16 
10b 1.51 1.52 0.01 1.49 -0.02 
11 2.37 2.37 0.00 2.45 0.08 
12 5.45 5.44 -0.01 5.6 0.15 
13 6.28 6.27 -0.01 6.2 -0.08 
14 6.05 6.05 0.00 6.00 -0.05 
15 5.28 5.28 0.00 5.28 0.00 
16a 1.88 1.88 0.00 2.21 0.33 
16b 2.28 2.25 -0.03 2.2 -0.08 
17 3.98 3.98 0.00 4.01 0.03 
18 2.52 2.52 0.00 2.44 -0.08 
19a 1.17 1.17 0.00 1.28 0.11 
19b 2.01 2.01 0.00 2.00 -0.01 
20 3.63 3.63 0.00 3.73 0.10 
21 3.42 3.42 0.00 3.76 0.34 
22a 1.46 1.46 0.00 1.53 0.07 
22b 1.76 1.76 0.00 1.83 0.07 
23 5.23 5.23 0.00 5.17 -0.06 
24a 3.61 3.61 0.00 3.67 0.06 
24b 3.81 3.79 -0.02 3.78 -0.03 
25 0.85 0.85 0.00 1.00 0.15 
26 1.03 1.02 -0.01 0.98 -0.05 
1' 5.02 5.02 0.00 5.00 -0.02 
2' 3.40 3.40 0.00 3.38 -0.02 
3' 3.68 3.68 0.00 3.69 0.01 
4' 3.34 3.34 0.00 3.33 -0.01 
5' 3.62 3.62 0.00 3.61 -0.01 
6' 1.27 1.26 -0.01 1.26 -0.01 
7' 3.45 3.45 0.00 3.45 0.00 
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Table 8.6: Comparison of the
 13
C NMR chemical shifts of 219 and 11-epi-219 (150 MHz, CDCl3) with 
the data of the  natural product (Lit.
[141]
; 175 MHz, CDCl3).
 
 
atom n°  (Lit.) /ppm (219) /ppm  (219Lit.) 
(11-epi-219) 
/ppm 
 (11-epi-
219Lit.) 
1 167.5 167.4 -0.1 167.4 -0.1 
2 123.1 123.1 0.0 123.4 0.3 
3 147.1 147.1 0.0 146.8 -0.3 
4 38.8 38.8 0.0 39.5 0.7 
5 73.9 73.9 0.0 74.2 0.3 
6 37.6 37.6 0.0 37.5 -0.1 
7 73.1 73.1 0.0 73.1 0.0 
8 39.7 39.7 0.0 39.5 -0.2 
9 72.5 72.5 0.0 72.9 0.4 
10 43.1 43.1 0.0 43 -0.1 
11 34.2 34.2 0.0 33.5 -0.7 
12 141.5 141.5 0.0 141 -0.5 
13 123.9 123.9 0.0 124.7 0.8 
14 131.3 131.3 0.0 130.5 -0.8 
15 126.9 126.9 0.0 126.8 -0.1 
16 31.1 31.1 0.0 31.5 0.4 
17 81.0 81 0.0 80.9 -0.1 
18 37.4 37.4 -0.1 37.5 0.1 
19 36.8 36.8 0.0 35.8 -1.0 
20 83.2 83.2 0.0 82.5 -0.7 
21 73.0 73.1 -0.1 73.1 0.1 
22 34.1 34.1 0.0 33.8 -0.3 
23 72.3 72.3 0.0 72.2 -0.1 
24 66.1 66.1 0.0 65.6 -0.5 
25 18.3 18.3 0.0 21.4 3.1 
26 14.5 14.5 0.0 14.7 0.2 
1' 94.2 94.2 0.0 94.3 0.1 
2' 80.8 80.8 0.0 80.8 0.0 
3' 71.7 71.7 0.0 71.7 0.0 
4' 74.3 74.3 0.0 74.4 0.1 
5' 68.1 68.1 0.0 68.1 0.0 
6' 17.7 17.7 0.0 17.8 0.1 
7' 59.1 59.1 0.0 59.1 0.0 
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8.4 Comparison of synthetic 2,3-epi-mandelalide C with the natural product. 
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Table 8.7: Comparison of 
1
H and 
13
C NMR chemical shifts of 257 (
1
H: 600 MHz, 
13
C: 150 MHz 
CDCl3) with the data of the  natural product (Lit.
[141]
; 
1
H: 600 MHz, 
13
C: 175 MHz, CDCl3). 
 
 1H NMR 
13
C NMR 
atom n° (Lit.) /ppm (257) /ppm  (257-Lit.) (Lit.) /ppm (257) /ppm  (257-Lit.) 
1 - - - 174.7 172.5 2.2 
2 - - - 82.0 78.3 3.7 
3 5.51 5.51 0.00 68.3 69.3 -1.0 
4a 1.65 1.73 -0.08 
36.4 38.6 -2.2 
4b 2.14 2.11 0.03 
5 3.25 3.74 -0.49 72.3 73.5 -1.2 
6a 1.11 1.23 -0.12 
41.2 41.2 0.0 
6b 1.86 1.93 -0.07 
7 3.76 3.85 -0.09 68.3 67.5 0.8 
8a 1.13 1.33 -0.20 
41.8 40.8 1.0 
8b 1.83 1.94 -0.11 
9 3.37 3.50 -0.13 72.3 74.5 -2.2 
10a 1.19 1.33 -0.14 
42.1 42.6 -0.5 
10b 1.57 1.71 -0.14 
11 2.49 2.46 0.03 34.0 30.6 3.4 
12 5.5 5.72 -0.22 142.2 140.6 1.6 
13 6.39 6.26 0.13 123.2 123.3 -0.1 
14 6.1 6.06 0.04 131.1 130.9 0.2 
15 5.28 5.31 -0.03 127.1 127.3 -0.2 
16a 1.9 1.98 -0.08 
30.7 30.4 0.3 
16b 2.3 2.39 -0.09 
17 3.95 3.95 0 81.6 81.7 -0.1 
18 2.53 2.41 0.12 38.3 36.5 1.8 
19a 1.33 1.54 -0.21 
35.7 35.7 0.0 
19b 2.1 2.10 0 
20 3.82 3.80 0.02 82.4 81.1 1.3 
21 3.73 3.46 0.27 74.4 70.6 3.8 
22a 1.59 1.93 -0.34 
32.1 31.7 0.4 
22b 1.82 2.24 -0.42 
23 5.01 4.74 0.27 78.9 80.0 -1.1 
24 3.98 4.21 -0.23 72.2 74.3 -2.1 
25 1.06 1.05 0.01 18.4 20.2 -1.8 
26 1.03 1.02 0.01 14.2 14.8 -0.6 
27 - - - 173.4 172.9 0.5 
28a 2.34 2.42 -0.08 
36.3 36.0 0.3 
28b 2.34 2.33 0.01 
29 1.65 1.68 -0.03 18.7 18.2 0.5 
30 0.94 0.94 0.00 13.9 13.7 0.2 
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8.5 Comparison of synthetic deacylmandelalide D isomers 253 and 255 with 
the natural product. 
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Table 8.8: Comparison of 
1
H NMR chemical shifts of 253 and 255 (600 MHz, CD3OD) with the data 
of the  natural product (Lit.
[141]
; 700 MHz, CD3OD). 
 
atom n°  (Lit.) /ppm (255) /ppm  (255Lit.) (253) /ppm  (253Lit.) 
1 - - - - - 
2 - - - - - 
3 4.06 4.34 −0.28 3.92 0.14 
4a 1.56 1.70 −0.14 1.74 −0.18 
4b 2.02 1.90 0.12 1.96 0.06 
5 3.39 3.64 −0.25 3.58 −0.19 
6a 1.11 1.17 −0.06 1.19 −0.08 
6b 1.88 1.94 −0.06 1.89 −0.01 
7 3.76 3.81 −0.05 3.78 −0.02 
8a 1.08 1.15 −0.07 1.11 −0.03 
8b 1.83 1.85 −0.02 1.88 −0.05 
9 3.39 3.50 −0.11 3.41 −0.02 
10a 1.23 1.28 −0.05 1.35 −0.12 
10b 1.49 1.58 −0.09 1.54 −0.05 
11 2.49 2.58 −0.09 2.52 −0.03 
12 5.51 5.53 −0.02 5.55 −0.04 
13 6.42 6.4 0.02 6.44 −0.02 
14 6.1 5.93 0.17 5.98 0.12 
15 5.3 5.23 0.07 5.33 −0.03 
16a 1.94 2.27 −0.33 2.16 −0.22 
16b 2.38 2.42 −0.04 2.38 0.00 
17 3.98 4.01 −0.03 3.91 0.07 
18 2.52 2.47 0.05 2.40 0.12 
19a 1.37 1.62 −0.25 1.51 −0.14 
19b 2.14 2.00 0.14 2.05 0.09 
20 3.84 4.04 −0.20 3.90 −0.06 
21 3.75 3.95 −0.20 3.91 −0.16 
22a 1.52 1.85 −0.33 1.95 −0.43 
22b 1.81 2.22 −0.41 1.96 −0.15 
23 4.81 4.95 −0.14 4.48 0.33 
24a 4.32 4.14 0.18 3.90 0.42 
24b 1.01 1.00 0.01 0.99 0.02 
25 1.08 1.04 0.04 1.03 0.05 
26 4.06 4.34 −0.28 3.92 0.14 
 
  
Appendix 281 
 
Table 8.9: Comparison of 
13
C NMR chemical shifts of 253 and 255 (150 MHz, CD3OD) with the data 
of the  natural product (Lit.
[141]
; 175 MHz, CD3OD). 
 
atom n°  (Lit.) /ppm (255) /ppm  (255Lit.) (253) /ppm  (253Lit.) 
1 176.3 178.9 −2.6 177.9 0.2 
2 82.4 80.1 2.3 76.9 5.5 
3 66.6 69.5 −2.9 73.3 −6.7 
4 37.4 40.4 −3.0 38.0 −0.6 
5 72.3 75.2 −2.9 74.2 −1.9 
6 40.3 42.5 −2.2 42.3 −2.0 
7 67.1 68.6 −1.5 68.8 −1.7 
8 40.7 42.7 −2.0 42.9 −2.2 
9 71.1 74.8 −3.7 74.2 −3.1 
10 41.2 45.2 −4.0 45.3 −4.1 
11 33.5 34.0 −0.5 34.9 −1.4 
12 140.7 141.9 −1.2 141.9 −1.2 
13 122.8 126.2 −3.4 126.2 −3.4 
14 130.0 130.8 −0.8 131.6 −1.6 
15 126.3 128.0 −1.7 127.9 −1.6 
16 31.2 33.1 −1.9 31.8 −0.6 
17 81.0 83.4 −2.4 82.8 −1.8 
18 37.6 38.4 −0.8 37.9 −0.3 
19 34.7 34.1 0.6 35.1 −0.4 
20 82.2 83.0 −0.8 83.0 −0.8 
21 73.9 69.3 4.6 75.3 −1.4 
22 32.0 31.5 0.5 36.3 −4.3 
23 78.3 80.8 −2.5 82.9 −4.6 
24 71.7 77.1 −5.4 69.9 1.8 
25 17.0 20.0 −3.0 19.8 −2.8 
26 12.3 14.9 −2.6 15.3 −3.0 
 
